@ARTICLE{noauthor_undated-ix,

}

@ARTICLE{Ribas2016-on,
  title    = "Association of Pembrolizumab With Tumor Response and Survival
              Among Patients With Advanced Melanoma",
  author   = "Ribas, Antoni and Hamid, Omid and Daud, Adil and Hodi, F Stephen
              and Wolchok, Jedd D and Kefford, Richard and Joshua, Anthony M
              and Patnaik, Amita and Hwu, Wen-Jen and Weber, Jeffrey S and
              Gangadhar, Tara C and Hersey, Peter and Dronca, Roxana and
              Joseph, Richard W and Zarour, Hassane and Chmielowski, Bartosz
              and Lawrence, Donald P and Algazi, Alain and Rizvi, Naiyer A and
              Hoffner, Brianna and Mateus, Christine and Gergich, Kevin and
              Lindia, Jill A and Giannotti, Maxine and Li, Xiaoyun Nicole and
              Ebbinghaus, Scot and Kang, S Peter and Robert, Caroline",
  abstract = "IMPORTANCE: The programmed death 1 (PD-1) pathway limits immune
              responses to melanoma and can be blocked with the humanized
              anti-PD-1 monoclonal antibody pembrolizumab. OBJECTIVE: To
              characterize the association of pembrolizumab with tumor response
              and overall survival among patients with advanced melanoma.
              DESIGN, SETTINGS, AND PARTICIPANTS: Open-label, multicohort,
              phase 1b clinical trials (enrollment, December 2011-September
              2013). Median duration of follow-up was 21 months. The study was
              performed in academic medical centers in Australia, Canada,
              France, and the United States. Eligible patients were aged 18
              years and older and had advanced or metastatic melanoma. Data
              were pooled from 655 enrolled patients (135 from a nonrandomized
              cohort [n = 87 ipilimumab naive; n = 48 ipilimumab treated] and
              520 from randomized cohorts [n = 226 ipilimumab naive; n = 294
              ipilimumab treated]). Cutoff dates were April 18, 2014, for
              safety analyses and October 18, 2014, for efficacy analyses.
              EXPOSURES: Pembrolizumab 10 mg/kg every 2 weeks, 10 mg/kg every 3
              weeks, or 2 mg/kg every 3 weeks continued until disease
              progression, intolerable toxicity, or investigator decision. MAIN
              OUTCOMES AND MEASURES: The primary end point was confirmed
              objective response rate (best overall response of complete
              response or partial response) in patients with measurable disease
              at baseline per independent central review. Secondary end points
              included toxicity, duration of response, progression-free
              survival, and overall survival. RESULTS: Among the 655 patients
              (median [range] age, 61 [18-94] years; 405 [62\%] men), 581 had
              measurable disease at baseline. An objective response was
              reported in 194 of 581 patients (33\% [95\% CI, 30\%-37\%]) and
              in 60 of 133 treatment-naive patients (45\% [95\% CI, 36\% to
              54\%]). Overall, 74\% (152/205) of responses were ongoing at the
              time of data cutoff; 44\% (90/205) of patients had response
              duration for at least 1 year and 79\% (162/205) had response
              duration for at least 6 months. Twelve-month progression-free
              survival rates were 35\% (95\% CI, 31\%-39\%) in the total
              population and 52\% (95\% CI, 43\%-60\%) among treatment-naive
              patients. Median overall survival in the total population was 23
              months (95\% CI, 20-29) with a 12-month survival rate of 66\%
              (95\% CI, 62\%-69\%) and a 24-month survival rate of 49\% (95\%
              CI, 44\%-53\%). In treatment-naive patients, median overall
              survival was 31 months (95\% CI, 24 to not reached) with a
              12-month survival rate of 73\% (95\% CI, 65\%-79\%) and a
              24-month survival rate of 60\% (95\% CI, 51\%-68\%). Ninety-two
              of 655 patients (14\%) experienced at least 1 treatment-related
              grade 3 or 4 adverse event (AE) and 27 of 655 (4\%) patients
              discontinued treatment because of a treatment-related AE.
              Treatment-related serious AEs were reported in 59 patients (9\%).
              There were no drug-related deaths. CONCLUSIONS AND RELEVANCE:
              Among patients with advanced melanoma, pembrolizumab
              administration was associated with an overall objective response
              rate of 33\%, 12-month progression-free survival rate of 35\%,
              and median overall survival of 23 months; grade 3 or 4
              treatment-related AEs occurred in 14\%. TRIAL REGISTRATION:
              clinicaltrials.gov Identifier: NCT01295827.",
  journal  = "JAMA",
  volume   =  315,
  number   =  15,
  pages    = "1600--1609",
  month    =  apr,
  year     =  2016,
  language = "en"
}

@ARTICLE{Sit1996-wr,
  title    = "Sequestration of mitotic (M-phase) chromosomes in autophagosomes:
              mitotic programmed cell death in human Chang liver cells induced
              by an {OH*} burst from vanadyl(4)",
  author   = "Sit, K H and Paramanantham, R and Bay, B H and Chan, H L and
              Wong, K P and Thong, P and Watt, F",
  abstract = "BACKGROUND: Fragmentation of genomic DNA in apoptosis/programmed
              cell death (PCD) is a characteristic hallmark in which both 2N
              and 4N DNA from G1, S, and G2/M cell cycle phases were seen
              degraded to the sub-2N Ao level in PCD such as from serum
              deprivation, glucocorticoid treatment, and gamma-radiation.
              However M-phase (mitotic) cells are said to perish only via
              non-programmed or necrotic cell death unless they were allowed to
              complete cytokinesis and re-enter interphase. The morphological
              criteria of PCD refer only to interphase cells with intact
              nuclear membranes, none seems applied to mitotic cells. We show
              here autophagic sequestration of mitotic chromosomes in a typical
              PCD response where G1, S, and G2/M DNA were replaced by a sub-2N
              Ao peak, suggesting that mitotic cells may yet have the option of
              PCD or suicide. Autophagy is absent in necrosis. METHODS: Mitotic
              human Chang liver cells in normal monolayer culture were compared
              with apoptotic counterparts initiated by a burst of hydroxyl free
              radicals (OH*) generated from vanadium internalized by an NH4Cl
              prepulse containing vanadyl(4) ions. Total (free and bound)
              vanadium uptake was quantitated by elemental spectral analysis of
              single cells using a) Particle-Induced X-ray Emission (PIXE)
              profiling, and b) Scanning Transmission Ion Microscopy (STIM) in
              the nuclear microscope. The Coulter EPICS PROFILE II flow
              cytometer was used for a) the cell cycle analysis using propidium
              iodide-DNA binding, b) intracellular pH (pHi) evaluation in the
              acidification-and-recovery cycle, using ratiometric
              2',7'-bis(2-carboxyethyl)-5 (and-6)-carboxyfluorescein (BCECF)
              fluorescence quantitation. Transmission electron microscopy
              examined the morphological changes. Vanadyl(4)- generated
              hydroxyl free radicals (OH*) were evaluated by measuring
              OH*-benzoic adduct fluorescence at 304/413 nm using the SPEX
              Fluoromax photon counting spectrofluorometer. RESULTS: Nuclear
              microscopy showed that a 30 min acidification prepulse containing
              4mM vanadyl(4) ions, V(4), had increased the total (free and
              bound) vanadium concentration of human Chang liver cells from
              normal ultratrace levels to 56,992 ppm of dry wt (1.1174 Eq per
              kg dry wt). After the prepulse, cells realkalinized in DMEM
              growth medium, recovering to the physiological pHi level in 30
              min. At the physiological pH 7 level, V(4) generated a burst of
              OH* free radicals in the order of 15,000 folds above the prepulse
              (pH 4.5) level. In these conditions, spectrofluorometric
              evaluation showed loss of DNA intercalation with propidium iodide
              (PI-DNA binding) indicating DNA degradation. Cell-by-cell
              evaluation of the PI-DNA binding by flow cytometry showed
              abolition of G1, S, and G2/M phases and their replacement by a
              sub-2N Ao peak of fragmented DNA, emulating serum deprivation PCD
              in these cells. Immediately upon initiating an OH* burst
              ultrastructural profiles showed mitotic chromosomes (M-phase
              chromatin) being surrounded by rough endoplasmic reticulum (RER)
              and small vesicles, indicating their sequestration in
              autophagosomes. Autophagy was also seen to be a prominent feature
              in serum deprivation PCD. CONCLUSION: Sequestration of mitotic
              chromosomes by autophagosomes in a typical PCD response showed a
              well-defined morphological pathway for direct degradation of
              M-phase chromatin without first completing cytokinesis. Mitotic
              cells could commit suicide via autophagy directed at its own
              chromatin. Autophagic sequestration of chromatin in PCD is novel.",
  journal  = "Anat. Rec.",
  volume   =  245,
  number   =  1,
  pages    = "1--8",
  month    =  may,
  year     =  1996,
  language = "en"
}

@ARTICLE{Cooper2002-ez,
  title     = "{4--1BB} ({CD137}) controls the clonal expansion and survival of
               {CD8} {T} cells in vivo but does not contribute to the
               development of cytotoxicity",
  author    = "Cooper, David and Bansal-Pakala, Pratima and Croft, Michael",
  abstract  = "Abstract 4?1BB is expressed on activated T cells. We analyzed
               the role of 4?1BB during the CD8 T cell response of OT-I
               TCR-transgenic T cells to ovalbumin. In vitro, blocking 4?1BB
               during peptide presentation reduced proliferation of naive CD8 T
               cells, but did not affect the generation of CTL. Using an in
               vivo adoptive transfer model, clonal expansion of CD8 T cells to
               whole protein in adjuvant was significantly reduced when 4?1BB
               was blocked, with 50?70\% fewer CD8 T cells accumulating. This
               was due to a reduction in T cell division and to enhanced
               apoptosis of CD8 T cellsthat had undergone many divisions. T
               cells generated in the absence of 4?1BB were impaired in their
               ability to secrete IFN-? whereas CTL activity of the T cells
               that survived was unaffected. These findings demonstrate that
               4?1BB contributes to clonal expansion, survival, and development
               of Tc1 cells when protein antigen is encountered by primary CD8
               T cells in an inflammatory environment in vivo.",
  journal   = "Eur. J. Immunol.",
  publisher = "John Wiley \& Sons, Ltd",
  volume    =  32,
  number    =  2,
  pages     = "521--529",
  month     =  feb,
  year      =  2002,
  keywords  = "4--1BB; Costimulatory molecule; Clonal expansion; Cytotoxicity"
}

@ARTICLE{Babich2017-bn,
  title    = "Radiocarbon Production by Thunderstorms",
  author   = "Babich, L P",
  abstract = "In view of the neutron flux enhancements observed in
              thunderstorms, a contribution of thunderstorm neutrons to
              atmospheric radiocarbon (isotope C614) production is analyzed in
              connection with the archaeometry. Herein, estimates of neutron
              fluence per lightning electromagnetic pulse in regions with
              severe thunderstorm activity, at which a local rate of the C614
              production is comparable to the observed rates, are shown to be
              consistent with the measured magnitudes of thunderstorm neutron
              fluence. At present, available observations of atmospheric
              neutron and parent gamma ray flashes correlated with
              thunderstorms do not allow making final conclusions about
              thunderstorm contributions to C614 production. For this, numerous
              studies of high-energy phenomena in thunderstorms are required,
              especially in the tropical belt where the thunderstorm activity
              is especially severe and where the C614 production by galactic
              cosmic rays is almost independent of the solar activity
              disturbing the Earth's magnetic field shielding the Earth from
              cosmic rays.",
  journal  = "Geophys. Res. Lett.",
  volume   =  44,
  number   =  21,
  pages    = "2017GL075131",
  month    =  nov,
  year     =  2017,
  keywords = "radiocarbon; neutrons; thunderstorm; 1150 Cosmogenic-nuclide
              exposure dating; 3304 Atmospheric electricity; 3324 Lightning"
}

@ARTICLE{DiNardo2015-do,
  title    = "Characteristics, clinical outcome, and prognostic significance of
              {IDH} mutations in {AML}",
  author   = "DiNardo, Courtney D and Ravandi, Farhad and Agresta, Sam and
              Konopleva, Marina and Takahashi, Koichi and Kadia, Tapan and
              Routbort, Mark and Patel, Keyur P and {Mark Brandt} and Pierce,
              Sherry and Garcia-Manero, Guillermo and Cortes, Jorge and
              Kantarjian, Hagop",
  abstract = "The pathophysiology of IDH mutations in tumorigenesis is
              increasingly described, yet the prognostic significance of IDH1
              and IDH2 mutations in AML remains controversial. The primary
              objective of this study was to define the natural history and
              prognosis of patients with AML and IDH1 or IDH2 mutations and
              provide historical survival expectations. A total of 826 patients
              treated from 2010 to 2014 at a single institution were evaluated,
              including 167 patients (20\%) with AML and IDH1 or IDH2
              mutations. Median age was 62 years (range 18-92). There were 59
              IDH1-R132, 83 IDH2-R140, and 23 IDH2-R172 mutations.
              Clinicopathologic characteristics associated with IDH-mutations
              included older age, less frequent therapy-related status, and
              increased incidence of intermediate-risk cytogenetics, FLT3-ITD
              mutations, and NPM1 mutations. Remission rates (CR/CRi) by AML
              treatment status were: induction, 68\%; Salvage-1 (S1), 42\%; and
              Salvage-2 and beyond (S2+), 27\%. No difference in response was
              identified by IDH mutation status. Similarly, overall survival
              (OS) was not dependent on IDH status within any cohort. The
              median OS was 15.4 months in induction, 8.7 months in S1, and 4.8
              months in S2+. This analysis defines the clinical outcome
              associated with IDH-mutations in both the front-line and salvage
              AML treatment settings, and confirms that response rate and OS
              for both IDH-mutated and IDH wild-type AML patients is
              comparable. This provides contemporary data to be used for
              comparison with results of novel investigational (e.g., selective
              IDH inhibitor) strategies.",
  journal  = "Am. J. Hematol.",
  volume   =  90,
  number   =  8,
  pages    = "732--736",
  month    =  aug,
  year     =  2015,
  language = "en"
}

@ARTICLE{Chen2012-kk,
  title    = "Whole chromosome aneuploidy: big mutations drive adaptation by
              phenotypic leap",
  author   = "Chen, Guangbo and Rubinstein, Boris and Li, Rong",
  abstract = "Despite its widespread existence, the adaptive role of aneuploidy
              (the abnormal state of having an unequal number of different
              chromosomes) has been a subject of debate. Cellular aneuploidy
              has been associated with enhanced resistance to stress, whereas
              on the organismal level it is detrimental to multicellular
              species. Certain aneuploid karyotypes are deleterious for
              specific environments, but karyotype diversity in a population
              potentiates adaptive evolution. To reconcile these paradoxical
              observations, this review distinguishes the role of aneuploidy in
              cellular versus organismal evolution. Further, it proposes a
              population genetics perspective to examine the behavior of
              aneuploidy on a populational versus individual level. By altering
              the copy number of a significant portion of the genome,
              aneuploidy introduces large phenotypic leaps that enable small
              cell populations to explore a wide phenotypic landscape, from
              which adaptive traits can be selected. The production of
              chromosome number variation can be further increased by stress-
              or mutation-induced chromosomal instability, fueling rapid
              cellular adaptation.",
  journal  = "Bioessays",
  volume   =  34,
  number   =  10,
  pages    = "893--900",
  month    =  oct,
  year     =  2012,
  language = "en"
}

@ARTICLE{Milo2013-cc,
  title    = "What is the total number of protein molecules per cell volume? A
              call to rethink some published values",
  author   = "Milo, Ron",
  abstract = "Novel methods such as mass-spectrometry enable a view of the
              proteomes of cells in unprecedented detail. Recently, these
              efforts have culminated in quantitative measurements of the
              number of copies per cell for most expressed proteins in
              organisms ranging from bacteria to mammalian cells. Here, we
              estimate the expected total number of proteins per unit of cell
              volume using known parameters related to the composition of cells
              such as the fraction of cell mass that is protein, and the
              average protein length. Using simple arguments, we estimate a
              range of 2-4 million proteins per cubic micron (i.e. 1 fL) in
              bacteria, yeast, and mammalian cells. Interestingly, we find that
              measured values that are reported for fission yeast and mammalian
              cells are often about 3-10 times lower. We discuss this apparent
              discrepancy and how to use the estimate as benchmark to
              recalibrate proteome-wide quantitative censuses or to revisit
              assumptions about cell composition.",
  journal  = "Bioessays",
  volume   =  35,
  number   =  12,
  pages    = "1050--1055",
  month    =  dec,
  year     =  2013,
  keywords = "cell biology by the numbers; mass spectrometry; protein
              abundance; protein copy numbers; proteins per cell; proteomic
              calibration; quantitative proteomics",
  language = "en"
}

@ARTICLE{Yuraszeck2017-iy,
  title    = "Translation and Clinical Development of Bispecific T-cell
              Engaging Antibodies for Cancer Treatment",
  author   = "Yuraszeck, T and Kasichayanula, S and Benjamin, J E",
  abstract = "Bispecific T-cell Engagers (BiTE\textregistered{}) antibody
              constructs enable a polyclonal T-cell response to cell-surface
              tumor-associated antigens, bypassing the narrow specificities of
              T-cell receptors and the need for antigen presentation through
              the major histocompatibility complex pathways. Blinatumomab, a
              CD19xCD3 BiTE\textregistered{} antibody construct, received
              accelerated approval for the treatment of relapsed/refractory
              Philadelphia chromosome negative acute lymphoblastic leukemia.
              Herein we review the pharmacology, safety, and efficacy observed
              in studies of blinatumomab and other BiTE\textregistered{}
              antibody constructs. Quantitative systems pharmacology is
              envisioned as a means to optimize dosing decisions for trials in
              which BiTE\textregistered{} antibody constructs are administered
              as monotherapy or in combination with other immunotherapies.",
  journal  = "Clin. Pharmacol. Ther.",
  volume   =  101,
  number   =  5,
  pages    = "634--645",
  month    =  may,
  year     =  2017,
  language = "en"
}

@ARTICLE{Zagury1975-if,
  title    = "Isolation and characterization of individual functionally
              reactive cytotoxic {T} lymphocytes: conjugation, killing and
              recycling at the single cell level",
  author   = "Zagury, D and Bernard, Jacky and Thierness, Noelle and Feldman, M
              and Berke, G",
  abstract = "Abstract Isolation and characterization of individual
              functionally reactive cytotoxic T lymphocytes have been achieved.
              Peritoneal exudate cytotoxic lymphocytes were obtained from
              BALB/c mice injected with EL4 tumor cells. Lymphocyte tumor cell
              conjugation was promoted by centrifugation. Individual conjugates
              comprised of one lymphocyte bound to one tumor cell were isolated
              with a micropipette. The ultrastructure of isolated killer
              lymphocytes and the lysis of conjugated target cells were
              analyzed. The cytotoxic lymphocytes are small cells with an
              indented nucleus which is poor in peripheral chromatin and rich
              in rough nuclear sap. The cytoplasm contains one-membrane-bound
              lysosome-like granules and clusters of ribosomes, but no rough
              endoplasmatic reticulum. The Golgi apparatus is well developed.
              Direct evidence obtained at the single cell level shows that a
              single effector lymphocyte is required and sufficient for the
              destruction of a single target cell and that killer cells which
              have been responsible for the lysis of a given target cell can
              lyse a second and even a third time.",
  journal  = "Eur. J. Immunol.",
  volume   =  5,
  number   =  12,
  pages    = "818--822",
  month    =  dec,
  year     =  1975
}

@ARTICLE{Isaaz1995-wc,
  title    = "Serial killing by cytotoxic {T} lymphocytes: {T} cell receptor
              triggers degranulation, re-filling of the lytic granules and
              secretion of lytic proteins via a non-granule pathway",
  author   = "Isaaz, S and Baetz, K and Olsen, K and Podack, E and Griffiths, G
              M",
  abstract = "CD8+ cytotoxic T lymphocyte (CTL) clones begin to synthesize the
              lytic proteins granzyme A, granzyme B and perforin after
              stimulation with allogeneic target cells. The lytic proteins are
              stored in the secretory granules which are released after
              cross-linking of the T cell receptor (TcR) upon target cell
              recognition. During lytic granule biogenesis granzyme A protein
              synthesis can be detected between 2 and 10 days after allogeneic
              stimulation of the CTL. Although granzyme A is stored in the
              lytic granules over this period, the majority of granzyme A
              synthesized is secreted directly from the CTL. TcR triggering of
              degranulation also results in new synthesis of the lytic
              proteins, which can be inhibited by cycloheximide (CHX). Some of
              the newly synthesized lytic proteins can be stored in the cell
              and refill the granules. But up to one third of granzymes A and B
              can be secreted directly from the CTL via the constitutive
              secretory pathway as shown by granzyme A enzymatic activity and
              immunoblots of secreted granzyme B, where one third of the
              protein fails to acquire the granule targeting signal. Perforin
              is also secreted via the constitutive pathway, both from the
              natural killer cell line, YT, and from CTL clones after TcR
              cross-linking. Constitutive secretion of the lytic proteins can
              be blocked by both CHX and brefeldin A (BFA). While BFA does not
              affect the directional killing of recognized targets, it
              abrogates bystander killing, indicating that bystander killing
              arises from newly synthesized lytic proteins delivered via a
              non-granule route. These results demonstrate that the
              perforin/granzyme-mediated lytic pathway can be maintained while
              CTL kill multiple targets. We show that CTL not only re-fill
              their granules during killing, but also secrete lytic proteins
              via a non-granule-mediated pathway.",
  journal  = "Eur. J. Immunol.",
  volume   =  25,
  number   =  4,
  pages    = "1071--1079",
  month    =  apr,
  year     =  1995,
  language = "en"
}

@ARTICLE{Blohm2006-ex,
  title    = "Solid tumors ``melt'' from the inside after successful {CD8} {T}
              cell attack",
  author   = "Blohm, Ulrike and Potthoff, Dan and van der Kogel, Albert J and
              Pircher, Hanspeter",
  abstract = "Adoptive transfer of tumor-specific T cells represents a
              promising approach for cancer immunotherapy. Here, we visualized
              the anti-tumor response of CD8 T cells from P14 TCR-transgenic
              mice specific for the model antigen GP33 by immunohistology. P14
              T cells, adoptively transferred into tumor-bearing hosts, induced
              regression of established 3LL-A9(GP33) and MCA102(GP33) tumors
              that express GP33 as a tumor-associated model antigen.
              Strikingly, the visible effects of P14 T cell attack, such as the
              destruction of the tumor vasculature and accumulation of
              granulocytes, were predominantly detected inside the tumor mass.
              In regressing tumors, P14 T cells were found in the intact rim
              zone but not in central areas that were infiltrated with
              granulocytes and lacked CD31(+) endothelial cells. The rim of P14
              T cell-treated tumors showed an increase in vascular density and
              decrease in hypoxia compared to untreated tumors. Hypoxic areas
              of tumors are known to exhibit decreased sensitivity to radiation
              therapy or chemotherapy. Thus, our data also imply that adoptive
              transfer of tumor-specific CD8 T cells might synergize with
              radiation therapy or chemotherapy in the elimination of solid
              tumors in vivo.",
  journal  = "Eur. J. Immunol.",
  volume   =  36,
  number   =  2,
  pages    = "468--477",
  month    =  feb,
  year     =  2006,
  language = "en"
}

@ARTICLE{Briesemeister2011-wq,
  title    = "Tumor rejection by local interferon gamma induction in
              established tumors is associated with blood vessel destruction
              and necrosis",
  author   = "Briesemeister, Dana and Sommermeyer, Daniel and Loddenkemper,
              Christoph and Loew, Rainer and Uckert, Wolfgang and Blankenstein,
              Thomas and Kammertoens, Thomas",
  abstract = "It has been shown that injecting a suspension of
              IFN-$\gamma$-secreting tumor cells results in their rejection.
              This effect has been attributed to IFN-$\gamma$ preventing tumor
              stroma formation but not to a direct effect on the cancer cells.
              However, it is not known, which influence IFN-$\gamma$ has on
              tumors with an established stroma. To address this question, the
              plasmacytoma cell line J558L was transduced with a vector
              allowing doxycycline-inducible IFN-$\gamma$ gene expression.
              After the injection of the tumor cells into mice, IFN-$\gamma$
              was induced at different time points. Tumors did not grow when
              inducing IFN-$\gamma$ immediately after tumor cell inoculation,
              while approximately half of the tumors were rejected when
              IFN-$\gamma$ was induced in early established tumors within 2
              weeks. Induction of IFN-$\gamma$ 2-3 weeks after tumor cell
              inoculation was less efficient (0-17\% rejection). IFN-$\gamma$
              induction in established tumors led to a reduction of CD146(+)
              endothelial cells and massive necrosis. Together, we show that
              vascularized tumors can be rejected by local IFN-$\gamma$
              expression, but that rejection of established tumors was less
              efficient over time. This suggests that transplanted tumors
              became less susceptible to local IFN-$\gamma$ treatment the
              better they are established.",
  journal  = "Int. J. Cancer",
  volume   =  128,
  number   =  2,
  pages    = "371--378",
  month    =  jan,
  year     =  2011,
  language = "en"
}

@ARTICLE{Hosoi2014-np,
  title    = "Adoptive cytotoxic {T} lymphocyte therapy triggers a
              counter-regulatory immunosuppressive mechanism via recruitment of
              myeloid-derived suppressor cells",
  author   = "Hosoi, Akihiro and Matsushita, Hirokazu and Shimizu, Kanako and
              Fujii, Shin-Ichiro and Ueha, Satoshi and Abe, Jun and Kurachi,
              Makoto and Maekawa, Ryuji and Matsushima, Kouji and Kakimi,
              Kazuhiro",
  abstract = "Complex interactions among multiple cell types contribute to the
              immunosuppressive milieu of the tumor microenvironment. Using a
              murine model of adoptive T-cell immunotherapy (ACT) for B16
              melanoma, we investigated the impact of tumor infiltrating cells
              on this complex regulatory network in the tumor. Transgenic
              pmel-1-specific cytotoxic T lymphocytes (CTLs) were injected
              intravenously into tumor-bearing mice and could be detected in
              the tumor as early as on day 1, peaking on day 3. They produced
              IFN-$\gamma$, exerted anti-tumor activity and inhibited tumor
              growth. However, CTL infiltration into the tumor was accompanied
              by the accumulation of large numbers of cells, the majority of
              which were CD11b(+) Gr1(+) myeloid-derived suppressor cells
              (MDSCs). Notably, CD11b(+) Gr1(int) Ly6G(-) Ly6C(+) monocytic
              MDSCs outnumbered the CTLs by day 5. They produced nitric oxide,
              arginase I and reactive oxygen species, and inhibited the
              proliferation of antigen-specific CD8(+) T cells. The anti-tumor
              activity of the adoptively-transferred CTLs and the accumulation
              of MDSCs both depended on IFN-$\gamma$ production on recognition
              of tumor antigens by the former. In CCR2(-/-) mice, monocytic
              MDSCs did not accumulate in the tumor, and inhibition of tumor
              growth by ACT was improved. Thus, ACT triggered
              counter-regulatory immunosuppressive mechanism via recruitment of
              MDSCs. Our results suggest that strategies to regulate the
              treatment-induced recruitment of these MDSCs would improve the
              efficacy of immunotherapy.",
  journal  = "Int. J. Cancer",
  volume   =  134,
  number   =  8,
  pages    = "1810--1822",
  month    =  apr,
  year     =  2014,
  keywords = "CTL; MDSC; adoptive transfer; immunotherapy;B16F10\_specific",
  language = "en"
}

@ARTICLE{Movafagh2015-ma,
  title    = "Regulation of hypoxia-inducible factor-1a by reactive oxygen
              species: new developments in an old debate",
  author   = "Movafagh, Shahrzad and Crook, Sean and Vo, Kim",
  abstract = "Hypoxia-Inducible Factor-1 (HIF-1) has been largely studied for
              its role in cell survival in hypoxic conditions. The regulation
              of HIF-1 is a complex process and involves a number of molecules
              and pathways. Among these mechanisms a direct regulatory role of
              reactive oxygen species (ROS) on HIF-1 alpha subunit has received
              a great deal of attention and the existing body of literature
              includes many contradictory findings. Other intermediates such as
              nitric oxide (NO), specific microRNAs (miR), and transcriptional
              and post-translational modification have also been implicated as
              players in ROS mediated HIF-1a regulation. The focus of this
              review is to present the past conflicting evidence along with
              more recent findings in order to relate various aspects of this
              complex process. Aside from the direct role of ROS on HIF-1a
              regulation under hypoxia and normoxia, we analyzed the effect of
              different sources and concentrations of NO and the interplay
              between superoxide (SO) and NO in this process. We also present
              findings on transcriptional and translational regulation of
              HIF-1a via ROS and the interplay with microRNAs in this process.
              This review further provides insight on ERK and PI3K/AKT
              signaling as a common mechanism relating several pathways of ROS
              mediated HIF-1a regulation. Ultimately further research and
              discovery regarding HIF-1 regulation by oxidative stress is
              warranted for better understanding of disease development and
              potential therapeutics for pathologies such as cancer,
              inflammatory diseases, and ischemia-reperfusion injury.",
  journal  = "J. Cell. Biochem.",
  volume   =  116,
  number   =  5,
  pages    = "696--703",
  month    =  may,
  year     =  2015,
  keywords = "ERK; HIF-1; HYPOXIA; MICRORNA; NITRIC OXIDE; PI3K/AKT; SUPEROXIDE",
  language = "en"
}

@ARTICLE{Ravid2002-tv,
  title    = "Roads to polyploidy: the megakaryocyte example",
  author   = "Ravid, Katya and Lu, Jun and Zimmet, Jeffrey M and Jones, Matthew
              R",
  abstract = "Polyploidy, recognized by multiple copies of the haploid
              chromosome number, has been described in plants, insects, and in
              mammalian cells such as, the platelet precursors, the
              megakaryocytes. Several of these cell types reach high ploidy via
              a different cell cycle. Megakaryocytes undergo an endomitotic
              cell cycle, which consists of an S phase interrupted by a gap,
              during which the cells enter mitosis but skip anaphase B and
              cytokinesis. Here, we review the mechanisms that lead to this
              cell cycle and to polyploidy in megakaryocytes, while also
              comparing them to those described for other systems in which high
              ploidy is achieved. Overall, polyploidy is associated with an
              orchestrated change in expression of several genes, of which,
              some may be a result of high ploidy and hence a determinant of a
              new cell physiology, while others are inducers of
              polyploidization. Future studies will aim to further explore
              these two groups of genes.",
  journal  = "J. Cell. Physiol.",
  volume   =  190,
  number   =  1,
  pages    = "7--20",
  month    =  jan,
  year     =  2002,
  language = "en"
}

@ARTICLE{Bartholomew1976-eu,
  title    = "Effect of serum on the growth of Balb oT3 {A31} mouse fibroblasts
              and an {SV40-transformed} derivative",
  author   = "Bartholomew, J C and Yokota, H and Ross, P",
  abstract = "The effect of serum on the growth properties of non-transformed
              Balb 3T3 A31 and SV40-transformed Balb 3T3 A31 was studied. The
              concentration of serum in the growth medium of non-transformed
              cells had little effect on the initial population doubling time,
              but did regulate the cell density at which the population became
              quiescent in G1. The doubling time of transformed cells, however,
              was increased significantly as the concentration of serum was
              decreased below 4\%. This effect on the growth of transformed
              cells was seen at serum concentrations so low that
              non-transformed cells did not complete one population doubling.
              Flow microfluorometric analysis of these populations indicated
              that the primary effect of different serum concentrations on the
              non-transformed cells was to modulate the average residence time
              in G1, whereas, all the cell cycle phases of the transformed
              cells were affected by serum. At saturation densities, the
              non-transformed cells became quiescent in G1, but the transformed
              cells still traversed the cell cycle and their saturation density
              appeared to be a balance between cell production and cell death
              occurring primarily in the G1 phase of the cell cycle.",
  journal  = "J. Cell. Physiol.",
  volume   =  88,
  number   =  3,
  pages    = "277--286",
  month    =  jul,
  year     =  1976,
  language = "en"
}

@ARTICLE{Roh2012-fj,
  title    = "Tumorigenic polyploid cells contain elevated {ROS} and {ARE}
              selectively targeted by antioxidant treatment",
  author   = "Roh, Meejeon and van der Meer, Riet and Abdulkadir, Sarki A",
  abstract = "Polyploidy has been linked to tumorigenicity mainly due to the
              chromosomal aberrations. Elevated reactive oxygen species (ROS)
              generation, on the other hand, has also been associated with
              oncogenic transformation in most cancer cells. However, a
              possible link between ploidy and ROS is largely unexplored. Here
              we have examined the role of ROS in the tumorigenicity of
              polyploid cells. We show that polyploid prostate and mammary
              epithelial cells contain higher levels of ROS due to their higher
              mitochondrial contents. ROS levels and mitochondrial mass are
              also higher in dihydrocytochalasin B (DCB)-induced polyploid
              cells, suggesting that higher levels of ROS observed in polyploid
              cell can occur due to cytokinesis failure. Interestingly,
              polyploid cells were more sensitive to the inhibitory effect of
              the antioxidant, N-Acetyl-L-cysteine (NAC), than control diploid
              cells. Treatment of polyploid/diploid cells with NAC led to the
              selective elimination of polyploid cells over time and abrogated
              the tumorigenicity of polyploid cells. This effect was partially
              mediated via the Akt signaling pathway. We next explored a
              possible role for ROS in promoting chromosomal instability by
              analyzing the effects of ROS on the mitotic stage of the cell
              cycle. Enhancing ROS levels by treating cells with hydrogen
              peroxide delayed not only entry into and but also exit from
              mitosis. Furthermore, increasing ROS levels significantly
              increased taxol resistance. Our results indicated that increased
              ROS in polyploid cells can contribute to tumorigenicity and
              highlight the therapeutic potential of antioxidants by
              selectively targeting the tumorigenic polyploid cells and by
              reversing taxol resistance.",
  journal  = "J. Cell. Physiol.",
  volume   =  227,
  number   =  2,
  pages    = "801--812",
  month    =  feb,
  year     =  2012,
  language = "en"
}

@ARTICLE{Salmaninejad2019-uq,
  title    = "{PD-1/PD-L1} pathway: Basic biology and role in cancer
              immunotherapy",
  author   = "Salmaninejad, Arash and Valilou, Saeed Farajzadeh and Shabgah,
              Arezoo Gowhari and Aslani, Saeed and Alimardani, Malihe and
              Pasdar, Alireza and Sahebkar, Amirhossein",
  abstract = "Over the course of past few years, cancer immunotherapy has been
              accompanied with promising results. However, preliminary
              investigations with respect to immunotherapy concentrated mostly
              on targeting the immune checkpoints, nowadays, emerge as the most
              efficient strategy to raise beneficial antitumor immune
              responses. Programmed cell death protein 1 (PD-1) plays an
              important role in subsiding immune responses and promoting
              self-tolerance through suppressing the activity of T cells and
              promoting differentiation of regulatory T cells. PD-1 is
              considered as an immune checkpoint and protects against
              autoimmune responses through both induction of apoptosis in
              antigen-specific T cells and inhibiting apoptosis in regulatory T
              cells. Several clinical trials exerting PD-1 monoclonal
              antibodies as well as other immune-checkpoint blockades have had
              prosperous outcomes and opened new horizons in tumor
              immunotherapy. Nonetheless, a bulk of patients have failed to
              respond to these newly emerging immune-based approach and the
              survival rate was not satisfying. Additional strategies,
              especially combination therapies, has been initiated and been
              further promising. Attempts to identify novel and well-suited
              predictive biomarkers are also sensed. In this review, the
              promotion of cancer immunotherapy targeting PD-1 immunoinhibitory
              pathway is discussed.",
  journal  = "J. Cell. Physiol.",
  volume   =  234,
  number   =  10,
  pages    = "16824--16837",
  month    =  aug,
  year     =  2019,
  keywords = "PD-1; PD-L-1; cancer therapy; immune checkpoint; monoclonal
              antibody",
  language = "en"
}

@ARTICLE{Linder2013-nf,
  title    = "A marching cubes based failure surface propagation concept for
              three-dimensional finite elements with non-planar embedded strong
              discontinuities of higher-order kinematics: A {MARCHING}
              {CUBES-BASED} {FAILURE} {SURFACE} {PROPAGATION} {CONCEPT}",
  author   = "Linder, Christian and Zhang, Xiaoxuan",
  abstract = "SUMMARYThis paper presents an advanced failure surface
              propagation concept based on the marching cubes algorithm
              initially proposed in the field of computer graphics and applies
              it to the embedded finite element method. When modeling
              three-dimensional (3D) solids at failure, the propagation of the
              failure surface representing a crack or shear band should not
              exhibit a strong sensitivity to the details of the finite element
              discretization. This results in the need for a propagation of the
              discrete failure zone through the individual finite elements,
              which is possible for finite elements with embedded strong
              discontinuities. Whereas for two-dimensional calculations the
              failure zone propagation location is easily predicted by the
              maximal principal stress direction, more advanced strategies are
              needed to achieve a smooth failure surface in 3D simulations. An
              example for such method is the global tracking algorithm, which
              predicts the crack path by a scalar level set function computed
              on the basis of the solution of a simplified heat conduction like
              problem. Its prediction may though lead to various scenarios on
              how the failure surface may propagate through the individual
              finite elements. In particular, for a hexahedral eight-node
              finite element, 256 such cases exist. To capture all those
              possibilities, the marching cubes algorithm is combined with the
              global tracking algorithm and the finite elements with embedded
              strong discontinuities in this work. In addition, because many of
              the possible cases result in non-planar failure surfaces within a
              single finite element and because the local quantities used to
              describe the kinematics of the embedded strong discontinuities
              are physically meaningful in a strict sense only for planar
              failure surfaces, a remedy for such scenarios is proposed.
              Various 3D failure propagation simulations outline the
              performance of the proposed concept. Copyright ? 2013 John Wiley
              \& Sons, Ltd.",
  journal  = "Int. J. Numer. Meth. Engng",
  volume   =  96,
  number   =  6,
  pages    = "339--372",
  month    =  nov,
  year     =  2013
}

@ARTICLE{Morris2018-xq,
  title    = "The molecular details of cytokine signaling via the {JAK/STAT}
              pathway",
  author   = "Morris, Rhiannon and Kershaw, Nadia J and Babon, Jeffrey J",
  abstract = "More than 50 cytokines signal via the JAK/STAT pathway to
              orchestrate hematopoiesis, induce inflammation and control the
              immune response. Cytokines are secreted glycoproteins that act as
              intercellular messengers, inducing proliferation,
              differentiation, growth, or apoptosis of their target cells. They
              act by binding to specific receptors on the surface of target
              cells and switching on a phosphotyrosine-based intracellular
              signaling cascade initiated by kinases then propagated and
              effected by SH2 domain-containing transcription factors. As
              cytokine signaling is proliferative and often inflammatory, it is
              tightly regulated in terms of both amplitude and duration. Here
              we review molecular details of the cytokine-induced signaling
              cascade and describe the architectures of the proteins involved,
              including the receptors, kinases, and transcription factors that
              initiate and propagate signaling and the regulatory proteins that
              control it.",
  journal  = "Protein Sci.",
  volume   =  27,
  number   =  12,
  pages    = "1984--2009",
  month    =  dec,
  year     =  2018,
  keywords = "Cytokine Signaling; JAK/STAT; SOCS; cytokine; cytokine receptor;
              hematopoiesis",
  language = "en"
}

@ARTICLE{Stein2010-by,
  title    = "Targeting tumor metabolism with 2-deoxyglucose in patients with
              castrate-resistant prostate cancer and advanced malignancies",
  author   = "Stein, Mark and Lin, Hongxia and Jeyamohan, Chandrika and
              Dvorzhinski, Dmitri and Gounder, Murugesan and Bray, Kevin and
              Eddy, Simantini and Goodin, Susan and White, Eileen and Dipaola,
              Robert S",
  abstract = "BACKGROUND: A profound difference between cancer and normal
              tissues is the preferential utilization of glycolysis by cancer
              cells. To translate this paradigm in the clinic, we completed a
              phase I study of 2-deoxyglucose (2DG), and assessed 2DG uptake
              with fluorodeoxyglucose (FDG) positron emission tomography (PET)
              and the autophagy substrate p62 as a marker of 2DG resistance.
              METHODS: Patients received 2DG orally on days 1-14 of a 21-day
              cycle in cohorts of three in a dose-escalating manner.
              Correlative assessments included PET scans at baseline and day 2
              and p62 protein in peripheral blood mononuclear cells as a
              potential marker of 2DG resistance. RESULTS: The dose of 45 mg/kg
              was defined as the recommended phase II dose, secondary to
              dose-limiting toxicity of grade 3 asymptomatic QTc prolongation
              at a dose of 60 mg/kg. PK evaluation of 2DG revealed linear
              pharmacokinetics with C(max) 45 microg/ml (277 microM), 73.7
              microg/ml (449 microM), and 122 microg/ml (744 microM) in dose
              levels 30, 45, and 60 mg/kg, respectively. Five of eight patients
              assessed with FDG-PET scanning demonstrated decreased FDG uptake
              by day 2 of therapy, suggesting competition of 2DG with FDG. Five
              of six patients assessed for p62 had a decrease in p62 at 24 hr.
              CONCLUSIONS: These data support the safety of 2DG, defined 2DG
              PK, demonstrated the effect of 2DG on FDG-PET imaging, and
              demonstrated the feasibility of assessment of p62 as an
              autophagic resistance marker. These data support future studies
              of 2DG alone or in combination with approaches to abrogate
              autophagy.",
  journal  = "Prostate",
  volume   =  70,
  number   =  13,
  pages    = "1388--1394",
  month    =  sep,
  year     =  2010,
  language = "en"
}

@ARTICLE{Aalen1993-ic,
  title    = "Further results on the non-parametric linear regression model in
              survival analysis",
  author   = "Aalen, O O",
  abstract = "This paper gives further developments of a non-parametric linear
              regression model in survival analysis. Three subjects are
              studied. First, martingale residuals, originally developed for
              the Cox model, are introduced for our linear model. Their theory
              is developed and they are shown to be useful for judging goodness
              of fit. The second focus of the paper is on the use of bootstrap
              replications to judge which features of the cumulative regression
              plots are likely to reflect real phenomena and not merely random
              variation. In particular, this is applied to judging whether the
              effect of a covariate disappears over time, a problem for which
              no formal test exists. The third subject is density type, or
              kernel, estimation of the regression functions themselves. This
              might give more direct information than the cumulative plots. The
              approaches are illustrated by data from a clinical trial of
              carcinoma of the oropharynx, and by survival times of grafts in
              renal patients.",
  journal  = "Stat. Med.",
  volume   =  12,
  number   =  17,
  pages    = "1569--1588",
  month    =  sep,
  year     =  1993,
  language = "en"
}

@ARTICLE{Oshima2001-op,
  title    = "Involvement of {TRAIL/TRAIL-R} interaction in {IFN-alpha-induced}
              apoptosis of Daudi {B} lymphoma cells",
  author   = "Oshima, K and Yanase, N and Ibukiyama, C and Yamashina, A and
              Kayagaki, N and Yagita, H and Mizuguchi, J",
  abstract = "Interferon-alpha (IFN-alpha) exerts the anti-tumour effect on
              various tumours at least partly through induction of apoptosis.
              Apoptosis is induced by members of the tumour necrosis factor
              (TNF) family, including Fas (CD95) and TNF-related
              apoptosis-inducing ligand (TRAIL). In the present study, we
              examined whether the TRAIL/TRAIL-R system is involved in
              IFN-alpha-induced apoptosis using Daudi B lymphoma cells.
              IFN-alpha upregulated the expression of TRAIL within 12 h, as
              assessed by flow cytometry and RT-PCR, and the level increased
              with time until 72 h. The levels of both TRAIL-R1 and TRAIL-R2,
              low in Daudi cells, were enhanced by IFN-alpha. The enhanced
              TRAIL-R1/-R2 appeared to function as a death-inducing molecule
              since IFN-alpha-stimulated cells were more susceptible to
              TRAIL-induced cell death. The IFN-alpha-stimulated Daudi cells or
              their derived culture supernatants displayed cytotoxicity against
              TRAIL-sensitive, but not resistant lines. Moreover, the
              IFN-alpha-induced reduction in mitochondrial membrane potential
              preceding the induction of apoptosis was substantially prevented
              by neutralizing anti-TRAIL monoclonal antibody. Taken together,
              IFN-alpha-induced apoptosis appears to be mediated by the
              autocrine and/or paracrine loop involving TRAIL/TRAIL-R.",
  journal  = "Cytokine",
  volume   =  14,
  number   =  4,
  pages    = "193--201",
  month    =  may,
  year     =  2001,
  language = "en"
}

@ARTICLE{Badie2000-uk,
  title    = "Interferon-gamma induces apoptosis and augments the expression of
              Fas and Fas ligand by microglia in vitro",
  author   = "Badie, B and Schartner, J and Vorpahl, J and Preston, K",
  abstract = "Activation of microglia by interferon-gamma (IFN-gamma) has been
              implicated in a number of central nervous system (CNS)
              inflammatory disease processes. Because IFN-gamma has also been
              shown to play a role in programmed cell death, we investigated
              its cytotoxicity and its effect on the Fas apoptotic pathway in
              microglia. Flow cytometry was used to quantify the
              IFN-gamma-mediated apoptotic response and Fas and Fas ligand
              (FasL) expression in two well-characterized murine microglia cell
              lines (BV-2 and N9). Nuclear fragmentation, suggestive of
              apoptosis, was noted within 24 h of incubation of microglia with
              IFN-gamma (10 U/ml). After a 72-h incubation, almost every BV-2
              and N9 microglia, but not GL261 glioma cells, underwent cell
              death and detached from the culture plates. This cytotoxicity
              occurred even at low IFN-gamma concentrations (1 U/ml) and was
              inhibited by BAF, a pan-caspase inhibitor. Incubation of BV-2 and
              N9 microglia, but not GL261 glioma cells, with IFN-gamma also
              potentiated the expression of Fas and FasL in a similar
              dose-response and time-course manner, as seen for the apoptotic
              response. Whereas Fas expression increased by 100\% in both
              microglia cells, FasL upregulation was more pronounced and
              increased by as much as 200\% in the N9 cells. These findings
              suggest that in addition to its role as a microglia activator,
              IFN-gamma may also induce apoptosis of microglia, possibly
              through simultaneous upregulation of Fas and FasL.
              Interferon-gamma modulation of the Fas pathway and apoptosis in
              microglia may be important in the pathogenesis of inflammatory
              CNS disease processes.",
  journal  = "Exp. Neurol.",
  volume   =  162,
  number   =  2,
  pages    = "290--296",
  month    =  apr,
  year     =  2000,
  language = "en"
}

@INCOLLECTION{Poleszczuk2016-vh,
  title     = "{Agent-Based} Modeling of Cancer Stem Cell Driven Solid Tumor
               Growth",
  booktitle = "Stem Cell Heterogeneity: Methods and Protocols",
  author    = "Poleszczuk, Jan and Macklin, Paul and Enderling, Heiko",
  editor    = "Turksen, Kursad",
  abstract  = "Computational modeling of tumor growth has become an invaluable
               tool to simulate complex cell--cell interactions and emerging
               population-level dynamics. Agent-based models are commonly used
               to describe the behavior and interaction of individual cells in
               different environments. Behavioral rules can be informed and
               calibrated by in vitro assays, and emerging population-level
               dynamics may be validated with both in vitro and in vivo
               experiments. Here, we describe the design and implementation of
               a lattice-based agent-based model of cancer stem cell driven
               tumor growth.",
  publisher = "Springer New York",
  pages     = "335--346",
  year      =  2016,
  address   = "New York, NY"
}

@INCOLLECTION{Golstein1977-jc,
  title     = "Mechanism of {T-Cell-Mediated} Cytolysis: The Lethal Hit Stage",
  booktitle = "Contemporary Topics in Immunobiology: {T} Cells",
  author    = "Golstein, Pierre and Smith, Evan T",
  editor    = "Stutman, Osias",
  abstract  = "The existence of cell-mediated cell-destruction systems in
               higher organisms (extensively reviewed by Perlmann and Holm,
               1969, and Cerottini and Brunner, 1974) raises two basic
               questions, namely: (1) Why; i.e., what is the selective
               advantage for the reproductive multicellular individual of
               possessing cytotoxic devices? (2) How; i.e., by which
               mechanism(s) is a cell able to destroy another cell? This
               chapter deals exclusively with the latter question, delineated
               as follows:First, only model cytotoxicity experiments done in
               vitro will be described or discussed, irrespective of whether
               similar cytotoxic phenomena occur or do not occur in vivo.
               Cell-mediated cytotoxicity will thus be considered here, not
               from a utilitarian immunologic point of view, but as a problem
               of cell physiology studied under test-tube conditions.",
  publisher = "Springer US",
  pages     = "273--300",
  year      =  1977,
  address   = "Boston, MA",
  keywords  = "Direct Killing (Perf/Gzym/FAS)"
}

@ARTICLE{Chen2018-di,
  title    = "Profiling Tumor Infiltrating Immune Cells with {CIBERSORT}",
  author   = "Chen, Binbin and Khodadoust, Michael S and Liu, Chih Long and
              Newman, Aaron M and Alizadeh, Ash A",
  abstract = "Tumor infiltrating leukocytes (TILs) are an integral component of
              the tumor microenvironment and have been found to correlate with
              prognosis and response to therapy. Methods to enumerate immune
              subsets such as immunohistochemistry or flow cytometry suffer
              from limitations in phenotypic markers and can be challenging to
              practically implement and standardize. An alternative approach is
              to acquire aggregative high dimensional data from cellular
              mixtures and to subsequently infer the cellular components
              computationally. We recently described CIBERSORT, a versatile
              computational method for quantifying cell fractions from bulk
              tissue gene expression profiles (GEPs). Combining support vector
              regression with prior knowledge of expression profiles from
              purified leukocyte subsets, CIBERSORT can accurately estimate the
              immune composition of a tumor biopsy. In this chapter, we provide
              a primer on the CIBERSORT method and illustrate its use for
              characterizing TILs in tumor samples profiled by microarray or
              RNA-Seq.",
  journal  = "Methods Mol. Biol.",
  volume   =  1711,
  pages    = "243--259",
  year     =  2018,
  keywords = "Cancer immunology; Deconvolution; Gene expression; Microarray;
              RNA-Seq; Support vector regression (SVR); TCGA; Tumor
              heterogeneity; Tumor infiltrating leukocytes (TILs); Tumor
              microenvironment",
  language = "en"
}

@ARTICLE{Macken1985-wc,
  title    = "Some stochastic models in immunology",
  author   = "Macken, Catherinf A and Perelson, Alan S",
  abstract = "Conditional probability arguments and the theory of
              continuous-time Markov chains are used to develop models for the
              kinetics of a cell-mediated cytotoxic reaction. While the models
              are conceptually simple, when fitted to data, they lead to
              surprising insights into the mechanisms of the immune response.
              Based on examples and discussion, we demonstrate the potential
              for creative and relevant application of mathematics within the
              rapidly developing field of immunology.",
  journal  = "Acta Appl. Math.",
  volume   =  4,
  number   =  2,
  pages    = "157--200",
  month    =  sep,
  year     =  1985
}

@ARTICLE{Buttgereit1992-kr,
  title    = "{ConA} induced changes in energy metabolism of rat thymocytes",
  author   = "Buttgereit, F and Brand, M D and M{\"u}ller, M",
  abstract = "The influence of ConA on the energy metabolism of quiescent rat
              thymocytes was investigated by measuring the effects of
              inhibitors of protein synthesis, proteolysis, RNA/DNA synthesis,
              Na+K(+)-ATPase, Ca(2+)-ATPase and mitochondrial ATP synthesis on
              respiration. Only about 50\% of the coupled oxygen consumption of
              quiescent thymocytes could be assigned to specific processes
              using two different media. Under these conditions the oxygen is
              mainly used to drive mitochondrial proton leak and to provide ATP
              for protein synthesis and cation transport, whereas oxygen
              consumption to provide ATP for RNA/DNA synthesis and
              ATP-dependent proteolysis was not measurable. The mitogen ConA
              produced a persistent increase in oxygen consumption by about
              30\% within seconds. After stimulation more than 80\% of
              respiration could be assigned to specific processes. The major
              oxygen consuming processes of ConA-stimulated thymocytes are
              mitochondrial proton leak, protein synthesis and Na+K(+)-ATPase
              with about 20\% each of total oxygen consumption, while
              Ca(2+)-ATPase and RNA/DNA synthesis contribute about 10\% each.
              Quiescent thymocytes resemble resting hepatocytes in that most of
              the oxygen consumption remains unexplained. In contrast, the
              pattern of energy metabolism in stimulated thymocytes is similar
              to that described for Ehrlich Ascites tumour cells and
              splenocytes, which may also be in an activated state. Most of the
              oxygen consumption is accounted for, so the unexplained
              process(es) in unstimulated cells shut(s) off on stimulation.",
  journal  = "Biosci. Rep.",
  volume   =  12,
  number   =  5,
  pages    = "381--386",
  month    =  oct,
  year     =  1992,
  language = "en"
}

@ARTICLE{Kuznetsov1994-ak,
  title     = "Nonlinear dynamics of immunogenic tumors: parameter estimation
               and global bifurcation analysis",
  author    = "Kuznetsov, V A and Makalkin, I A and Taylor, M A and Perelson, A
               S",
  abstract  = "We present a mathematical model of the cytotoxic T lymphocyte
               response to the growth of an immunogenic tumor. The model
               exhibits a number of phenomena that are seen in vivo, including
               immunostimulation of tumor growth, ``sneaking through'' of the
               tumor, and formation of a tumor ``dormant state''. The model is
               used to describe the kinetics of growth and regression of the
               B-lymphoma BCL1 in the spleen of mice. By comparing the model
               with experimental data, numerical estimates of parameters
               describing processes that cannot be measured in vivo are
               derived. Local and global bifurcations are calculated for
               realistic values of the parameters. For a large set of
               parameters we predict that the course of tumor growth and its
               clinical manifestation have a recurrent profile with a 3- to
               4-month cycle, similar to patterns seen in certain leukemias.",
  journal   = "Bull. Math. Biol.",
  publisher = "Elsevier",
  volume    =  56,
  number    =  2,
  pages     = "295--321",
  month     =  mar,
  year      =  1994,
  language  = "en"
}

@ARTICLE{Kronik2008-ob,
  title     = "Improving alloreactive {CTL} immunotherapy for malignant gliomas
               using a simulation model of their interactive dynamics",
  author    = "Kronik, Natalie and Kogan, Yuri and Vainstein, Vladimir and
               Agur, Zvia",
  abstract  = "Glioblastoma (GBM), a highly aggressive (WHO grade IV) primary
               brain tumor, is refractory to traditional treatments, such as
               surgery, radiation or chemotherapy. This study aims at aiding in
               the design of more efficacious GBM therapies. We constructed a
               mathematical model for glioma and the immune system
               interactions, that may ensue upon direct intra-tumoral
               administration of ex vivo activated alloreactive
               cytotoxic-T-lymphocytes (aCTL). Our model encompasses
               considerations of the interactive dynamics of aCTL, tumor cells,
               major histocompatibility complex (MHC) class I and MHC class II
               molecules, as well as cytokines, such as TGF-beta and IFN-gamma,
               which dampen or increase the pro-inflammatory environment,
               respectively. Computer simulations were used for model
               verification and for retrieving putative treatment scenarios.
               The mathematical model successfully retrieved clinical trial
               results of efficacious aCTL immunotherapy for recurrent
               anaplastic oligodendroglioma and anaplastic astrocytoma (WHO
               grade III). It predicted that cellular adoptive immunotherapy
               failed in GBM because the administered dose was 20-fold lower
               than required for therapeutic efficacy. Model analysis suggests
               that GBM may be eradicated by new dose-intensive strategies,
               e.g., 3 x 10(8) aCTL every 4 days for small tumor burden, or 2 x
               10(9) aCTL, infused every 5 days for larger tumor burden.
               Further analysis pinpoints crucial bio-markers relating to tumor
               growth rate, tumor size, and tumor sensitivity to the immune
               system, whose estimation enables regimen personalization. We
               propose that adoptive cellular immunotherapy was prematurely
               abandoned. It may prove efficacious for GBM, if dose intensity
               is augmented, as prescribed by the mathematical model.
               Re-initiation of clinical trials, using calculated
               individualized regimens for grade III-IV malignant glioma, is
               suggested.",
  journal   = "Cancer Immunol. Immunother.",
  publisher = "Springer",
  volume    =  57,
  number    =  3,
  pages     = "425--439",
  month     =  mar,
  year      =  2008,
  language  = "en"
}

@ARTICLE{Hegde2017-lu,
  title    = "Current status of chimeric antigen receptor engineered {T}
              cell-based and immune checkpoint blockade-based cancer
              immunotherapies",
  author   = "Hegde, Upendra P and Mukherji, Bijay",
  abstract = "Adoptive cell therapies with chimeric antigen receptor (CAR)
              engineered T cells (CAR-T) and immune checkpoint inhibition
              (ICI)-based cancer immunotherapies have lately shown remarkable
              success in certain tumor types. CAR-T cell-based therapies
              targeting CD19 can now induce durable remissions as well as
              prolong disease-free survival of patients with CD19 positive
              treatment refractory B cell malignancies and ICI-based therapies
              with humanized monoclonal antibodies against the T cell
              inhibitory receptors CTLA-4 and PD-1 as well as against the PD-1
              ligand, PD-L1, can now achieve durable remissions as well as
              prolongation of life of a sizeable fraction of patients with
              melanoma and Hodgkin's lymphoma and non-small cell cancers. Most
              importantly, these immuno-therapeutic treatment modalities have
              raised the possibility of achieving long-term ``containment'' as
              well as ``cures'' for certain types of cancer. While this
              represents major advances in cancer immunotherapy, both
              modalities come with considerable toxicities, including
              fatalities. Although more work will be needed to bring CAR-T
              cell-based therapies to the bedside for most major cancers and a
              good deal more will be needed to make ICI-alone or in combination
              with other treatment modalities-work more consistently and across
              most major cancers, these two treatment modalities stand out as
              superb examples of successful translation of bench research to
              the bedside as well as represent real progress in the field of
              cancer immunotherapy.",
  journal  = "Cancer Immunol. Immunother.",
  volume   =  66,
  number   =  9,
  pages    = "1113--1121",
  month    =  sep,
  year     =  2017,
  keywords = "CAR-T cells; ICI; Immunotherapy; Tumor",
  language = "en"
}

@ARTICLE{Zhu2019-py,
  title    = "Apoptosis of tumor-infiltrating {T} lymphocytes: a new immune
              checkpoint mechanism",
  author   = "Zhu, Jingjing and Petit, Pierre-Florent and Van den Eynde, Benoit
              J",
  abstract = "Immunotherapy based on checkpoint inhibitors is providing
              substantial clinical benefit, but only to a minority of cancer
              patients. The current priority is to understand why the majority
              of patients fail to respond. Besides T-cell dysfunction, T-cell
              apoptosis was reported in several recent studies as a relevant
              mechanism of tumoral immune resistance. Several death receptors
              (Fas, DR3, DR4, DR5, TNFR1) can trigger apoptosis when activated
              by their respective ligands. In this review, we discuss the
              immunomodulatory role of the main death receptors and how these
              are shaping the tumor microenvironment, with a focus on Fas and
              its ligand. Fas-mediated apoptosis of T cells has long been known
              as a mechanism allowing the contraction of T-cell responses to
              prevent immunopathology, a phenomenon known as activation-induced
              cell death, which is triggered by induction of Fas ligand (FasL)
              expression on T cells themselves and qualifies as an immune
              checkpoint mechanism. Recent evidence indicates that other cells
              in the tumor microenvironment can express FasL and trigger
              apoptosis of tumor-infiltrating lymphocytes (TIL), including
              endothelial cells and myeloid-derived suppressor cells. The
              resulting disappearance of TIL prevents anti-tumor immunity and
              may in fact contribute to the absence of TIL that is typical of
              ``cold'' tumors that fail to respond to immunotherapy.
              Interfering with the Fas-FasL pathway in the tumor
              microenvironment has the potential to increase the efficacy of
              cancer immunotherapy.",
  journal  = "Cancer Immunol. Immunother.",
  volume   =  68,
  number   =  5,
  pages    = "835--847",
  month    =  may,
  year     =  2019,
  keywords = "Cancer immunotherapy; Death receptors; Fas ligand; MDSC; PIVAC
              17; TIL apoptosis",
  language = "en"
}

@ARTICLE{Raez2013-sw,
  title    = "A phase {I} dose-escalation trial of 2-deoxy-D-glucose alone or
              combined with docetaxel in patients with advanced solid tumors",
  author   = "Raez, Luis E and Papadopoulos, Kyriakos and Ricart, Alejandro D
              and Chiorean, E Gabriella and Dipaola, Robert S and Stein, Mark N
              and Rocha Lima, Caio M and Schlesselman, James J and Tolba,
              Khaled and Langmuir, Virginia K and Kroll, Stewart and Jung,
              Donald T and Kurtoglu, Metin and Rosenblatt, Joseph and Lampidis,
              Theodore J",
  abstract = "PURPOSE: This phase I trial was initiated to evaluate the safety,
              pharmacokinetics (PK) and maximum tolerated dose (MTD) of the
              glycolytic inhibitor, 2-deoxy-D-glucose (2DG) in combination with
              docetaxel, in patients with advanced solid tumors. METHODS: A
              modified accelerated titration design was used. 2DG was
              administered orally once daily for 7 days every other week
              starting at a dose of 2 mg/kg and docetaxel was administered
              intravenously at 30 mg/m(2) for 3 of every 4 weeks beginning on
              day 1 of week 2. Following the completion of dose escalation,
              cohorts of patients were then treated with 2DG for 21 days or
              every day of each 4-week cycle for up to 12 cycles. RESULTS:
              Thirty-four patients were enrolled: 21 on every other week, 6 on
              a 21 of 28-day cycle and 7 on the continuous 2DG dosing schedule.
              There were no dose-limiting toxicities which met the MTD
              criteria. The most common adverse events were fatigue, sweating,
              dizziness and nausea mimicking the hypoglycemic symptoms expected
              from 2DG administration. Therefore, 63 mg/kg was selected as the
              clinically tolerable dose. The most significant adverse effects
              noted at 63-88 mg/kg doses were reversible hyperglycemia (100
              \%), gastrointestinal bleeding (6 \%) and reversible grade 3 QTc
              prolongation (22 \%). Eleven patients (32 \%) had stable disease,
              1 patient (3 \%) partial response and 22 patients (66 \%)
              progressive disease as their best response. There was no PK
              interaction between 2DG and docetaxel. CONCLUSION: The
              recommended dose of 2DG in combination with weekly docetaxel is
              63 mg/kg/day with tolerable adverse effects.",
  journal  = "Cancer Chemother. Pharmacol.",
  volume   =  71,
  number   =  2,
  pages    = "523--530",
  month    =  feb,
  year     =  2013,
  language = "en"
}

@ARTICLE{Stephanou2018-kg,
  title    = "Systems Biology, Systems Medicine, Systems Pharmacology: The What
              and The Why",
  author   = "St{\'e}phanou, Ang{\'e}lique and Fanchon, Eric and Innominato,
              Pasquale F and Ballesta, Annabelle",
  abstract = "Systems biology is today such a widespread discipline that it
              becomes difficult to propose a clear definition of what it really
              is. For some, it remains restricted to the genomic field. For
              many, it designates the integrated approach or the corpus of
              computational methods employed to handle the vast amount of
              biological or medical data and investigate the complexity of the
              living. Although defining systems biology might be difficult, on
              the other hand its purpose is clear: systems biology, with its
              emerging subfields systems medicine and systems pharmacology,
              clearly aims at making sense of complex observations/experimental
              and clinical datasets to improve our understanding of diseases
              and their treatments without putting aside the context in which
              they appear and develop. In this short review, we aim to
              specifically focus on these new subfields with the new
              theoretical tools and approaches that were developed in the
              context of cancer. Systems pharmacology and medicine now give
              hope for major improvements in cancer therapy, making
              personalized medicine closer to reality. As we will see, the
              current challenge is to be able to improve the clinical practice
              according to the paradigm shift of systems sciences.",
  journal  = "Acta Biotheor.",
  volume   =  66,
  number   =  4,
  pages    = "345--365",
  month    =  dec,
  year     =  2018,
  keywords = "Big data; Drug development; Multi-scale approach; Personalized
              medicine; Precision medicine",
  language = "en"
}

@ARTICLE{Zhao2020-nr,
  title    = "Heterogeneity and chimerism of endothelial cells revealed by
              single-cell transcriptome in orthotopic liver tumors",
  author   = "Zhao, Qi and Molina-Portela, Maria Del Pilar and Parveen, Asma
              and Adler, Alexander and Adler, Christina and E, Hock and Wang,
              Wei and Ni, Min and Wei, Yi and Atwal, Gurinder and Mohrs, Markus
              and Thurston, Gavin and Eichten, Alexandra",
  abstract = "The liver is a common host organ for cancer, either through
              lesions that arise in liver epithelial cells [e.g.,
              hepatocellular carcinoma (HCC)] or as a site of metastasis by
              tumors arising in other organs (e.g., colorectal cancer).
              However, the changes that occur in liver stromal cells in
              response to cancer have not been fully characterized, nor has it
              been determined whether the different sources of liver cancer
              induce distinct stromal changes. Here, we performed single-cell
              profiling of liver stromal cells from mouse models of induced
              spontaneous liver cancer or implanted colorectal liver
              metastases, with a focus on tumor endothelial cells (ECs). While
              ECs in liver tissue adjacent to cancerous lesions (so-called
              adjacent normal) corresponded to liver zonation phenotypes, their
              transcriptomes were also clearly altered by the presence of a
              tumor. In comparison, tumor EC transcriptomes show stronger
              similarities to venous than sinusoidal ECs. Further, tumor ECs,
              independent of tumor origin, formed distinct clusters displaying
              conserved ``tip-like'' or ``stalk-like'' characteristics, similar
              to ECs from subcutaneous tumors. However, they also carried
              liver-specific signatures found in normal liver ECs, suggesting
              an influence of the host organ on tumor ECs. Our results document
              gene expression signatures in ECs in liver cancer and show that
              the host organ, and not the site of tumor origin (liver versus
              colorectal), is a primary determinant of EC phenotype. In
              addition, primarily in tumors, we further defined a cluster of
              chimeric cells that expressed both myeloid and endothelial cell
              markers and might play a role in tumor angiogenesis.",
  journal  = "Angiogenesis",
  month    =  may,
  year     =  2020,
  keywords = "Adjacent normal tissue; Endothelial cell heterogeneity; Kupffer
              cells; Liver tumor endothelial cells; Single cell transcriptome",
  language = "en"
}

@ARTICLE{Hermel2017-sy,
  title    = "Erratum to: Combining forces: the promise and peril of
              synergistic immune checkpoint blockade and targeted therapy in
              metastatic melanoma",
  author   = "Hermel, David J and Ott, Patrick A",
  journal  = "Cancer Metastasis Rev.",
  volume   =  36,
  number   =  1,
  pages    = "51",
  month    =  mar,
  year     =  2017,
  language = "en"
}

@ARTICLE{Kindler2009-ak,
  title    = "A phase {II} multicenter study of L-alanosine, a potent inhibitor
              of adenine biosynthesis, in patients with {MTAP-deficient} cancer",
  author   = "Kindler, Hedy Lee and Burris, 3rd, Howard A and Sandler, Alan B
              and Oliff, Ira Anton",
  abstract = "OBJECTIVE: Methylthioadenosine phosphorylase (MTAP)-deficient
              tumors are dependent on the de novo purine synthesis pathway.
              These cancers are potential targets for selective chemotherapy
              with inhibitors of de novo adenine synthesis such as L-alanosine
              [L-2-amino-3-(N-hydroxy-N-nitrosamino) propionic acid]. This
              phase II study was designed to evaluate the efficacy and safety
              of L-alanosine in patients with MTAP-deficient solid tumors.
              METHODS: Patients with mesothelioma, non-small cell lung cancer
              (NSCLC), soft tissue sarcoma, osteosarcoma, or pancreatic cancer
              whose tumors were MTAP deficient by immunohistochemistry were
              eligible. Patients received L-alanosine at a starting dose of 80
              mg/m(2) by continuous intravenous infusion daily for 5 days every
              21 days. Computed tomography scans or magnetic resonance imaging
              were performed every 3 cycles. RESULTS: 65 patients (16
              mesothelioma, 13 NSCLC, 15 soft tissue sarcoma, 7 osteosarcoma,
              14 pancreatic cancer) were enrolled at 19 centers; 55 were
              evaluable for response. There were no objective responses; 24\%
              had s disease, including 2 patients with mesothelioma who had
              prolonged stable disease lasting 7.5 and 15.2 months,
              respectively. Grade 3/4 toxicities included mucositis 11\%,
              fatigue 6\%, nausea 3\%, and renal failure 1.5\%. CONCLUSION: At
              this dose and schedule, L-alanosine was ineffective in patients
              with advanced MTAP-deficient tumors.",
  journal  = "Invest. New Drugs",
  volume   =  27,
  number   =  1,
  pages    = "75--81",
  month    =  feb,
  year     =  2009,
  language = "en"
}

@ARTICLE{Ott2013-tr,
  title    = "Phase {I/II} study of pegylated arginine deiminase ({ADI-PEG} 20)
              in patients with advanced melanoma",
  author   = "Ott, Patrick A and Carvajal, Richard D and Pandit-Taskar, Neeta
              and Jungbluth, Achim A and Hoffman, Eric W and Wu, Bor-Wen and
              Bomalaski, John S and Venhaus, Ralph and Pan, Linda and Old,
              Lloyd J and Pavlick, Anna C and Wolchok, Jedd D",
  abstract = "Background Arginine deiminase (ADI) is an enzyme that degrades
              arginine, an amino acid that is important for growth and
              development of normal and neoplastic cells. Melanoma cells are
              auxotrophic for arginine, because they lack
              argininosuccinatesynthetase (ASS), a key enzyme required for the
              synthesis of arginine. Patients and methods Patients with
              advanced melanoma were treated with 40, 80 or 160 IU/m(2) ADI-PEG
              20 i.m. weekly. Primary endpoints were toxicity and tumor
              response, secondary endpoints included metabolic response by
              (18)FDG-PET, pharmacodynamic (PD) effects upon circulating
              arginine levels, and argininosuccinate synthetase tumor
              expression by immunohistochemistry. Results 31 previously treated
              patients were enrolled. The main toxicities were grade 1 and 2
              adverse events including injection site pain, rash, and fatigue.
              No objective responses were seen. Nine patients achieved stable
              disease (SD), with 2 of these durable for >6 months. Four of the
              9 patients with SD had uveal melanoma. PD analysis showed
              complete plasma arginine depletion in 30/31 patients by day 8.
              Mean plasma levels of ADI-PEG 20 correlated inversely with
              ADI-PEG 20 antibody levels. Immunohistochemical ASS expression
              analysis in tumor tissue was negative in 24 patients, whereas 5
              patients had <5 \% cells positive. Conclusions ADI-PEG 20 is well
              tolerated in advanced melanoma patients and leads to consistent,
              but transient, arginine depletion. Although no RECIST responses
              were observed, the encouraging rate of SD in uveal melanoma
              patients indicates that it may be worthwhile to evaluate ADI-PEG
              20 in this melanoma subgroup.",
  journal  = "Invest. New Drugs",
  volume   =  31,
  number   =  2,
  pages    = "425--434",
  month    =  apr,
  year     =  2013,
  language = "en"
}

@ARTICLE{Yang2014-yu,
  title    = "Different drought-stress responses in photosynthesis and reactive
              oxygen metabolism between autotetraploid and diploid rice",
  author   = "Yang, P-M and Huang, Q-C and Qin, G-Y and Zhao, S-P and Zhou, J-G",
  abstract = "Photosynthetic light curve, chlorophyll (Chl) content, Chl
              fluorescence parameters, malondialdehyde (MDA) content,
              phosphoenolpyruvate carboxylase (PEPC) activity and reactive
              oxygen metabolism were studied under drought stress in two
              autotetraploid rice lines and corresponding diploid rice lines.
              Net photosynthetic rate decreased dramatically, especially under
              severe drought stress and under high photosynthetic active
              radiation in diploid rice, while it declined less under the same
              conditions in autotetraploid lines. Compared with the
              corresponding diploid lines, the Chl content, maximum
              photochemical efficiency of photosystem (PS) II, and actual
              photochemical efficiency of PSII were reduced less in
              autotetraploid lines. PEPC activities were higher in
              autotetraploid rice lines. PEPC could alleviate inhibition of
              photosynthesis caused by drought stress. The chromosome-doubling
              enhanced rice photoinhibition tolerance under drought stress. The
              lower MDA content and superoxide anion production rate was found
              in the autotetraploid rice indicating low peroxidation level of
              cell membranes. At the same time, the superoxide dismutase (SOD),
              peroxidase (POD), and catalase (CAT) activities were higher in
              autotetraploid rice lines. SOD, POD, and CAT could effectively
              diminish the reactive oxygen species and reduced the membrane
              lipid peroxidation.",
  journal  = "Photosynthetica",
  volume   =  52,
  number   =  2,
  pages    = "193--202",
  month    =  jun,
  year     =  2014
}

@ARTICLE{Fischer2021-zd,
  title    = "A robust and efficient algorithm to find profile likelihood
              confidence intervals",
  author   = "Fischer, Samuel M and Lewis, Mark A",
  abstract = "Profile likelihood confidence intervals are a robust alternative
              to Wald's method if the asymptotic properties of the maximum
              likelihood estimator are not met. However, the constrained
              optimization problem defining profile likelihood confidence
              intervals can be difficult to solve in these situations, because
              the likelihood function may exhibit unfavorable properties. As a
              result, existing methods may be inefficient and yield misleading
              results. In this paper, we address this problem by computing
              profile likelihood confidence intervals via a trust-region
              approach, where steps computed based on local approximations are
              constrained to regions where these approximations are
              sufficiently precise. As our algorithm also accounts for
              numerical issues arising if the likelihood function is strongly
              non-linear or parameters are not estimable, the method is
              applicable in many scenarios where earlier approaches are shown
              to be unreliable. To demonstrate its potential in applications,
              we apply our algorithm to benchmark problems and compare it with
              6 existing approaches to compute profile likelihood confidence
              intervals. Our algorithm consistently achieved higher success
              rates than any competitor while also being among the quickest
              methods. As our algorithm can be applied to compute both
              confidence intervals of parameters and model predictions, it is
              useful in a wide range of scenarios.",
  journal  = "Stat. Comput.",
  volume   =  31,
  number   =  4,
  pages    = "38",
  month    =  may,
  year     =  2021
}

@ARTICLE{Feng2016-rp,
  title    = "Chimeric antigen receptor-modified {T} cells for the
              immunotherapy of patients with {EGFR-expressing} advanced
              relapsed/refractory non-small cell lung cancer",
  author   = "Feng, Kaichao and Guo, Yelei and Dai, Hanren and Wang, Yao and
              Li, Xiang and Jia, Hejin and Han, Weidong",
  abstract = "The successes achieved by chimeric antigen receptor-modified T
              (CAR-T) cells in hematological malignancies raised the
              possibility of their use in non-small lung cancer (NSCLC). In
              this phase I clinical study (NCT01869166), patients with
              epidermal growth factor receptor (EGFR)-positive (>50\%
              expression), relapsed/refractory NSCLC received escalating doses
              of EGFR-targeted CAR-T cell infusions. The EGFR-targeted CAR-T
              cells were generated from peripheral blood after a 10 to 13-day
              in vitro expansion. Serum cytokines in peripheral blood and copy
              numbers of CAR-EGFR transgene in peripheral blood and in tissue
              biopsy were monitored periodically. Clinical responses were
              evaluated with RECIST1.1 and immune- related response criteria,
              and adverse events were graded with CTCAE 4.0. The EGFR-targeted
              CAR-T cell infusions were well-tolerated without severe toxicity.
              Of 11 evaluable patients, two patients obtained partial response
              and five had stable disease for two to eight months. The median
              dose of transfused CAR(+) T cells was 0.97$\times$10(7) cells
              kg(-1) (interquartile range (IQR), 0.45 to 1.09$\times$10(7)
              cells kg(-1)). Pathological eradication of EGFR positive tumor
              cells after EGFR-targeted CAR-T cell treatment can be observed in
              tumor biopsies, along with the CAR-EGFR gene detected in
              tumor-infiltrating T cells in all four biopsied patients. The
              EGFR-targeted CAR-T cell therapy is safe and feasible for
              EGFR-positive advanced relapsed/refractory NSCLC.",
  journal  = "Sci. China Life Sci.",
  volume   =  59,
  number   =  5,
  pages    = "468--479",
  month    =  may,
  year     =  2016,
  keywords = "chimeric antigen receptor; epidermal growth factor receptor;
              immunotherapy; non-small cell lung cancer; relapsed/refractory",
  language = "en"
}

@ARTICLE{Mendoza-Juez2012-sm,
  title    = "A mathematical model for the glucose-lactate metabolism of in
              vitro cancer cells",
  author   = "Mendoza-Juez, Berta and Mart{\'\i}nez-Gonz{\'a}lez, Alicia and
              Calvo, Gabriel F and P{\'e}rez-Garc{\'\i}a, V{\'\i}ctor M",
  abstract = "We propose a mathematical model of tumor cell nutrient uptake
              governed by the presence of two key biomolecular fuels: glucose
              and lactate. The model allows us to describe, in a remarkably
              simple way, different in vitro scenarios previously reported in
              experiments of tumor cell metabolism using distinct energy
              sources. The predictions of our model show good agreement with
              all the examined tumor cell lines (cervix, colon, and glioma) and
              provide a first step toward the development of more comprehensive
              frameworks accounting for in vivo cancer dynamics under complex
              spatial heterogeneities.",
  journal  = "Bull. Math. Biol.",
  volume   =  74,
  number   =  5,
  pages    = "1125--1142",
  month    =  may,
  year     =  2012,
  language = "en"
}

@ARTICLE{Talkington2015-vp,
  title    = "Estimating Tumor Growth Rates In Vivo",
  author   = "Talkington, Anne and Durrett, Rick",
  abstract = "In this paper, we develop methods for inferring tumor growth
              rates from the observation of tumor volumes at two time points.
              We fit power law, exponential, Gompertz, and Spratt's generalized
              logistic model to five data sets. Though the data sets are small
              and there are biases due to the way the samples were ascertained,
              there is a clear sign of exponential growth for the breast and
              liver cancers, and a 2/3's power law (surface growth) for the two
              neurological cancers.",
  journal  = "Bull. Math. Biol.",
  volume   =  77,
  number   =  10,
  pages    = "1934--1954",
  month    =  oct,
  year     =  2015,
  language = "en"
}

@ARTICLE{Machineni2017-ah,
  title    = "Influence of Nutrient Availability and Quorum Sensing on the
              Formation of Metabolically Inactive Microcolonies Within
              Structurally Heterogeneous Bacterial Biofilms: An
              {Individual-Based} {3D} Cellular Automata Model",
  author   = "Machineni, Lakshmi and Rajapantul, Anil and Nandamuri, Vandana
              and Pawar, Parag D",
  abstract = "The resistance of bacterial biofilms to antibiotic treatment has
              been attributed to the emergence of structurally heterogeneous
              microenvironments containing metabolically inactive cell
              populations. In this study, we use a three-dimensional
              individual-based cellular automata model to investigate the
              influence of nutrient availability and quorum sensing on
              microbial heterogeneity in growing biofilms. Mature biofilms
              exhibited at least three structurally distinct strata: a
              high-volume, homogeneous region sandwiched between two compact
              sections of high heterogeneity. Cell death occurred
              preferentially in layers in close proximity to the substratum,
              resulting in increased heterogeneity in this section of the
              biofilm; the thickness and heterogeneity of this lowermost layer
              increased with time, ultimately leading to sloughing. The model
              predicted the formation of metabolically dormant cellular
              microniches embedded within faster-growing cell clusters.
              Biofilms utilizing quorum sensing were more heterogeneous
              compared to their non-quorum sensing counterparts, and resisted
              sloughing, featuring a cell-devoid layer of EPS atop the
              substratum upon which the remainder of the biofilm developed.
              Overall, our study provides a computational framework to analyze
              metabolic diversity and heterogeneity of biofilm-associated
              microorganisms and may pave the way toward gaining further
              insights into the biophysical mechanisms of antibiotic
              resistance.",
  journal  = "Bull. Math. Biol.",
  volume   =  79,
  number   =  3,
  pages    = "594--618",
  month    =  mar,
  year     =  2017,
  keywords = "Autoinducer; Biofilms; Extracellular polymeric substances;
              Heterogeneity; Metabolic diversity; Quorum sensing",
  language = "en"
}

@ARTICLE{Talkington2018-zw,
  title    = "Ordinary Differential Equation Models for Adoptive Immunotherapy",
  author   = "Talkington, Anne and Dantoin, Claudia and Durrett, Rick",
  abstract = "Modified T cells that have been engineered to recognize the CD19
              surface marker have recently been shown to be very successful at
              treating acute lymphocytic leukemias. Here, we explore four
              previous approaches that have used ordinary differential
              equations to model this type of therapy, compare their
              properties, and modify the models to address their deficiencies.
              Although the four models treat the workings of the immune system
              in slightly different ways, they all predict that adoptive
              immunotherapy can be successful to move a patient from the large
              tumor fixed point to an equilibrium with little or no tumor.",
  journal  = "Bull. Math. Biol.",
  volume   =  80,
  number   =  5,
  pages    = "1059--1083",
  month    =  may,
  year     =  2018,
  keywords = "Acute lymphoblastic leukemia; Chimeric antigen receptor T cells;
              ODE models; Saturating response; Stability analysis",
  language = "en"
}

@ARTICLE{Gillespie1976-fh,
  title    = "A general method for numerically simulating the stochastic time
              evolution of coupled chemical reactions",
  author   = "Gillespie, Daniel T",
  abstract = "An exact method is presented for numerically calculating, within
              the framework of the stochastic formulation of chemical kinetics,
              the time evolution of any spatially homogeneous mixture of
              molecular species which interreact through a specified set of
              coupled chemical reaction channels. The method is a compact,
              computer-oriented, Monte Carlo simulation procedure. It should be
              particularly useful for modeling the transient behavior of
              well-mixed gas-phase systems in which many molecular species
              participate in many highly coupled chemical reactions. For
              ``ordinary'' chemical systems in which fluctuations and
              correlations play no significant role, the method stands as an
              alternative to the traditional procedure of numerically solving
              the deterministic reaction rate equations. For nonlinear systems
              near chemical instabilities, where fluctuations and correlations
              may invalidate the deterministic equations, the method
              constitutes an efficient way of numerically examining the
              predictions of the stochastic master equation. Although fully
              equivalent to the spatially homogeneous master equation, the
              numerical simulation algorithm presented here is more directly
              based on a newly defined entity called ``the reaction probability
              density function.'' The purpose of this article is to describe
              the mechanics of the simulation algorithm, and to establish in a
              rigorous, a priori manner its physical and mathematical validity;
              numerical applications to specific chemical systems will be
              presented in subsequent publications.",
  journal  = "J. Comput. Phys.",
  volume   =  22,
  number   =  4,
  pages    = "403--434",
  month    =  dec,
  year     =  1976
}

@ARTICLE{Merrill1982-qr,
  title    = "Foundations of the use of an enzyme-kinetic analogy in
              cell-mediated cytotoxicity",
  author   = "Merrill, Stephen J",
  abstract = "A mathematical model of the 51Cr-release microcytotoxicity assay
              is utilized to find conditions under which the kinetics of this
              assay resemble the kinetics of a classical enzyme-substrate
              reaction. Assuming a steady-state approximation, that
              ``bystander'' effector cells do not bind markedly better than the
              cytotoxic effector cells, and that the programming of the target
              cells for lysis is irreversible, it is shown that the velocity of
              label release is v = vmaxTT/(K12+TT), where both Vmax and K12 are
              linear functions of the effector-cell population and TT is the
              initial target-cell population. Moreover, the expressions for K12
              and Vmax are expressed in terms of natural kinetic parameters of
              the process and attributes of the noncytotoxic bystanders.",
  journal  = "Math. Biosci.",
  volume   =  62,
  number   =  2,
  pages    = "219--235",
  month    =  dec,
  year     =  1982
}

@ARTICLE{Mosmann1996-og,
  title    = "The expanding universe of T-cell subsets: Th1, Th2 and more",
  author   = "Mosmann, T R and Sad, S",
  abstract = "Since their discovery nearly ten years ago, T helper 1 (Th1) and
              Th2 subsets have been implicated in the regulation of many immune
              responses. In this article, Tim Mosmann and Subash Sad discuss
              the increasing number of T-cell subsets defined by cytokine
              patterns; the differentiation pathways of CD4+ and CD8+ T cells;
              the contribution of other cell types to these patterns; and the
              cytokine interactions during infection and pregnancy.",
  journal  = "Immunol. Today",
  volume   =  17,
  number   =  3,
  pages    = "138--146",
  month    =  mar,
  year     =  1996,
  language = "en"
}

@ARTICLE{Dighe1994-se,
  title    = "Enhanced in vivo growth and resistance to rejection of tumor
              cells expressing dominant negative {IFN$\gamma$} receptors",
  author   = "Dighe, Anand S and Richards, Elizabeth and Old, Lloyd J and
              Schreiber, Robert D",
  abstract = "Using a neutralizing monoclonal antibody specific for murine IFNy
              we show that endogenously produced IFN$\gamma$ plays an obligate
              role in mediating LPS-induced rejection of the Meth A
              fibrosarcoma tumor in syngeneic BALE/c mice. To examine the
              cellular targets of IFN$\gamma$ action, we generated
              IFN$\gamma$-insensitive tumor cells by stably overexpressing in
              Meth A a truncated dominant negative form of the murine
              IFN$\gamma$ receptor a chain. When implanted in BALB/c mice,
              IFN$\gamma$-insensitive Meth A cells displayed enhanced
              tumorigenicity compared with control Meth A cells and were not
              rejected when tumor-bearing mice were treated with concentrations
              of LPS that eliminated control tumors. In Meth A immune mice,
              IFN$\gamma$-sensitive Meth A did not establish tumors while
              IFN$\gamma$-insensitive tumors grew in a progressive manner. In
              addition, the IFN$\gamma$-insensitive tumor cells were unable to
              elicit strong protective immunity to subsequent wild-type tumor
              challenge. These results show that IFN$\gamma$ has direct effects
              on tumor cell immunogenicity and thus plays an important role in
              promoting tumor cell recognition and elimination.",
  journal  = "Immunity",
  volume   =  1,
  number   =  6,
  pages    = "447--456",
  month    =  sep,
  year     =  1994
}

% The entry below contains non-ASCII chars that could not be converted
% to a LaTeX equivalent.
@INCOLLECTION{Schoenborn2007-eu,
  title     = "Regulation of {Interferon$\gamma$} During Innate and Adaptive
               Immune Responses",
  booktitle = "Advances in Immunology",
  author    = "Schoenborn, Jamie R and Wilson, Christopher B",
  abstract  = "Interferon$\gamma$ (IFN$\gamma$) is crucial for immunity
               against intracellular pathogens and for tumor control. However,
               aberrant IFN$\gamma$ expression has been associated with a
               number of autoinflammatory and autoimmune diseases. This
               cytokine is produced predominantly by natural killer (NK) and
               natural killer T (NKT) cells as part of the innate immune
               response, and by Th1 CD4 and CD8 cytotoxic T lymphocyte (CTL)
               effector T cells once antigenspecific immunity develops.
               Herein, we briefly review the functions of IFN$\gamma$, the
               cells that produce it, the cell extrinsic signals that induce
               its production and influence the differentiation of na{\"\i}ve T
               cells into IFN$\gamma$producing effector T cells, and the
               signaling pathways and transcription factors that facilitate,
               induce, or repress production of this cytokine. We then review
               and discuss recent insights regarding the molecular regulation
               of IFN$\gamma$, focusing on work that has led to the
               identification and characterization of distal regulatory
               elements and epigenetic modifications with the IFN$\gamma$
               locus (Ifng) that govern its expression. The epigenetic
               modifications and threedimensional structure of the Ifng locus
               in naive CD4 T cells, and the modifications they undergo as
               these cells differentiate into effector T cells, suggest a model
               whereby the chromatin architecture of Ifng is poised to
               facilitate either rapid opening or silencing during Th1 or Th2
               differentiation, respectively.",
  publisher = "Academic Press",
  volume    =  96,
  pages     = "41--101",
  month     =  jan,
  year      =  2007
}

@INCOLLECTION{Perlmann1969-jp,
  title     = "Cytotoxic Effects of Lymphoid Cells in Vitro",
  booktitle = "Advances in Immunology",
  author    = "Perlmann, Peter and Holm, G{\"o}ran",
  editor    = "Dixon, F J and Kunkel, Henry G",
  abstract  = "Publisher Summary This chapter discusses the cytotoxic effects
               of lymphoid cells in vitro. The chapter discusses the complex
               problem of different types of cytotoxic effects of lymphoid
               cells. These outstanding workers in the field have managed to
               present a cohesive picture of the various effects on the target
               cells. The role of ``nonspecific'' factors is particularly well
               clarified. The interrelationships among contact lysis, release
               of pharmacologically active substances, and the terminal
               components of the complement system are given in the chapter for
               special consideration. In an in vitro model, it is shown that
               lymphoid cells from sensitized donors destroy tissue culture
               cells carrying the antigen to which the cell donor is
               sensitized. This type of cytolytic reactions is encountered in a
               great variety of immune situations, comprising all those
               mentioned in the chapter. The cell that initiates in vitro
               cytotoxic reaction is assumed to be the sensitized lymphocyte,
               equipped with its own recognition sites for antigen on the cells
               that are destroyed. Although this may be true in many
               situations, it now seems clear that ``normal'' lymphoid cells
               can become cytotoxic to other cells by a variety of pathways.
               The study of the various pathways by which lymphoid cells can
               become cytotoxic has been helpful for the understanding of
               effector role of these cells in cell-destructive reactions in
               general.",
  publisher = "Academic Press",
  volume    =  11,
  pages     = "117--193",
  month     =  jan,
  year      =  1969
}

% The entry below contains non-ASCII chars that could not be converted
% to a LaTeX equivalent.
@INCOLLECTION{Massey2006-pq,
  title     = "{ChaperoneMediated} Autophagy in Aging and Disease",
  booktitle = "Current Topics in Developmental Biology",
  author    = "Massey, Ashish C and Zhang, Cong and Cuervo, Ana Maria",
  abstract  = "Different mechanisms target intracellular components for their
               degradation into lysosomes through what is known as autophagy.
               In mammals, three main forms of autophagy have been described:
               macroautophagy, microautophagy, and chaperonemediated autophagy
               (CMA). CMA is the only autophagic pathway that allows selective
               degradation of soluble proteins in lysosomes. In contrast to the
               other mammalian forms of autophagy, CMA does not require vesicle
               formation or major changes in the lysosomal membrane. Instead,
               substrate proteins directly cross the lysosomal membrane to
               reach the lumen, where they are rapidly degraded. The substrate
               proteins are targeted to the lysosomal membrane by recognition
               of a targeting motif (a KFERQlike motif), by a chaperone
               complex, consisting of hsc70 and its cochaperones, in the
               cytoplasm. Once at the lysosomal membrane, the protein interacts
               with a lysosomal receptor for this pathway, lysosomal associated
               membrane protein type 2A (LAMP2A), and it is translocated
               across the membrane into the lysosomal lumen assisted by a
               lysosome resident chaperone. These two
               characteristics---selectivity and direct substrate
               translocation---determine the particular role of CMA in
               different physiological and pathological conditions. In this
               chapter, we cover current findings on the molecular mechanisms
               for CMA and the possible pathophysiological relevance of this
               selective lysosomal degradation.",
  publisher = "Academic Press",
  volume    =  73,
  pages     = "205--235",
  month     =  jan,
  year      =  2006
}

% The entry below contains non-ASCII chars that could not be converted
% to a LaTeX equivalent.
@ARTICLE{Lee2015-rq,
  title    = "{T} cells expressing {CD19} chimeric antigen receptors for acute
              lymphoblastic leukaemia in children and young adults: a phase 1
              dose-escalation trial",
  author   = "Lee, Daniel W and Kochenderfer, James N and Stetler-Stevenson,
              Maryalice and Cui, Yongzhi K and Delbrook, Cindy and Feldman,
              Steven A and Fry, Terry J and Orentas, Rimas and Sabatino,
              Marianna and Shah, Nirali N and Steinberg, Seth M and Stroncek,
              Dave and Tschernia, Nick and Yuan, Constance and Zhang, Hua and
              Zhang, Ling and Rosenberg, Steven A and Wayne, Alan S and
              Mackall, Crystal L",
  abstract = "BACKGROUND: Chimeric antigen receptor (CAR) modified T cells
              targeting CD19 have shown activity in case series of patients
              with acute and chronic lymphocytic leukaemia and B-cell
              lymphomas, but feasibility, toxicity, and response rates of
              consecutively enrolled patients treated with a consistent regimen
              and assessed on an intention-to-treat basis have not been
              reported. We aimed to define feasibility, toxicity, maximum
              tolerated dose, response rate, and biological correlates of
              response in children and young adults with refractory B-cell
              malignancies treated with CD19-CAR T cells. METHODS: This phase
              1, dose-escalation trial consecutively enrolled children and
              young adults (aged 1-30 years) with relapsed or refractory acute
              lymphoblastic leukaemia or non-Hodgkin lymphoma. Autologous T
              cells were engineered via an 11-day manufacturing process to
              express a CD19-CAR incorporating an anti-CD19 single-chain
              variable fragment plus TCR zeta and CD28 signalling domains. All
              patients received fludarabine and cyclophosphamide before a
              single infusion of CD19-CAR T cells. Using a standard 3 + 3
              design to establish the maximum tolerated dose, patients received
              either 1 $\times$ 10(6) CAR-transduced T cells per kg (dose 1), 3
              $\times$ 10(6) CAR-transduced T cells per kg (dose 2), or the
              entire CAR T-cell product if sufficient numbers of cells to meet
              the assigned dose were not generated. After the dose-escalation
              phase, an expansion cohort was treated at the maximum tolerated
              dose. The trial is registered with ClinicalTrials.gov, number
              NCT01593696. FINDINGS: Between July 2, 2012, and June 20, 2014,
              21 patients (including eight who had previously undergone
              allogeneic haematopoietic stem-cell transplantation) were
              enrolled and infused with CD19-CAR T cells. 19 received the
              prescribed dose of CD19-CAR T cells, whereas the assigned dose
              concentration could not be generated for two patients (90\%
              feasible). All patients enrolled were assessed for response. The
              maximum tolerated dose was defined as 1 $\times$ 10(6) CD19-CAR T
              cells per kg. All toxicities were fully reversible, with the most
              severe being grade 4 cytokine release syndrome that occurred in
              three (14\%) of 21 patients (95\% CI 30-363). The most common
              non-haematological grade 3 adverse events were fever (nine [43\%]
              of 21 patients), hypokalaemia (nine [43\%] of 21 patients), fever
              and neutropenia (eight [38\%] of 21 patients), and cytokine
              release syndrome (three [14\%) of 21 patients). INTERPRETATION:
              CD19-CAR T cell therapy is feasible, safe, and mediates potent
              anti-leukaemic activity in children and young adults with
              chemotherapy-resistant B-precursor acute lymphoblastic leukaemia.
              All toxicities were reversible and prolonged B-cell aplasia did
              not occur. FUNDING: National Institutes of Health Intramural
              funds and St Baldrick's Foundation.",
  journal  = "Lancet",
  volume   =  385,
  number   =  9967,
  pages    = "517--528",
  month    =  feb,
  year     =  2015,
  language = "en"
}

% The entry below contains non-ASCII chars that could not be converted
% to a LaTeX equivalent.
@ARTICLE{Pages2018-lc,
  title    = "International validation of the consensus Immunoscore for the
              classification of colon cancer: a prognostic and accuracy study",
  author   = "Pag{\`e}s, Franck and Mlecnik, Bernhard and Marliot, Florence and
              Bindea, Gabriela and Ou, Fang-Shu and Bifulco, Carlo and Lugli,
              Alessandro and Zlobec, Inti and Rau, Tilman T and Berger, Martin
              D and Nagtegaal, Iris D and Vink-B{\"o}rger, Elisa and Hartmann,
              Arndt and Geppert, Carol and Kolwelter, Julie and Merkel, Susanne
              and Gr{\"u}tzmann, Robert and Van den Eynde, Marc and
              Jouret-Mourin, Anne and Kartheuser, Alex and L{\'e}onard, Daniel
              and Remue, Christophe and Wang, Julia Y and Bavi, Prashant and
              Roehrl, Michael H A and Ohashi, Pamela S and Nguyen, Linh T and
              Han, Seongjun and MacGregor, Heather L and Hafezi-Bakhtiari, Sara
              and Wouters, Bradly G and Masucci, Giuseppe V and Andersson,
              Emilia K and Zavadova, Eva and Vocka, Michal and Spacek, Jan and
              Petruzelka, Lubos and Konopasek, Bohuslav and Dundr, Pavel and
              Skalova, Helena and Nemejcova, Kristyna and Botti, Gerardo and
              Tatangelo, Fabiana and Delrio, Paolo and Ciliberto, Gennaro and
              Maio, Michele and Laghi, Luigi and Grizzi, Fabio and Fredriksen,
              Tessa and Buttard, B{\'e}n{\'e}dicte and Angelova, Mihaela and
              Vasaturo, Angela and Maby, Pauline and Church, Sarah E and
              Angell, Helen K and Lafontaine, Lucie and Bruni, Daniela and El
              Sissy, Carine and Haicheur, Nacilla and Kirilovsky, Amos and
              Berger, Anne and Lagorce, Christine and Meyers, Jeffrey P and
              Paustian, Christopher and Feng, Zipei and Ballesteros-Merino,
              Carmen and Dijkstra, Jeroen and van de Water, Carlijn and van
              Lent-van Vliet, Shannon and Knijn, Nikki and Muin{\u a},
              Ana-Maria and Scripcariu, Dragos-Viorel and Popivanova, Boryana
              and Xu, Mingli and Fujita, Tomonobu and Hazama, Shoichi and
              Suzuki, Nobuaki and Nagano, Hiroaki and Okuno, Kiyotaka and
              Torigoe, Toshihiko and Sato, Noriyuki and Furuhata, Tomohisa and
              Takemasa, Ichiro and Itoh, Kyogo and Patel, Prabhu S and Vora,
              Hemangini H and Shah, Birva and Patel, Jayendrakumar B and
              Rajvik, Kruti N and Pandya, Shashank J and Shukla, Shilin N and
              Wang, Yili and Zhang, Guanjun and Kawakami, Yutaka and Marincola,
              Francesco M and Ascierto, Paolo A and Sargent, Daniel J and Fox,
              Bernard A and Galon, J{\'e}r{\^o}me",
  abstract = "BACKGROUND: The estimation of risk of recurrence for patients
              with colon carcinoma must be improved. A robust immune score
              quantification is needed to introduce immune parameters into
              cancer classification. The aim of the study was to assess the
              prognostic value of total tumour-infiltrating T-cell counts and
              cytotoxic tumour-infiltrating T-cells counts with the consensus
              Immunoscore assay in patients with stage I-III colon cancer.
              METHODS: An international consortium of 14 centres in 13
              countries, led by the Society for Immunotherapy of Cancer,
              assessed the Immunoscore assay in patients with TNM stage I-III
              colon cancer. Patients were randomly assigned to a training set,
              an internal validation set, or an external validation set.
              Paraffin sections of the colon tumour and invasive margin from
              each patient were processed by immunohistochemistry, and the
              densities of CD3+ and cytotoxic CD8+ T cells in the tumour and in
              the invasive margin were quantified by digital pathology. An
              Immunoscore for each patient was derived from the mean of four
              density percentiles. The primary endpoint was to evaluate the
              prognostic value of the Immunoscore for time to recurrence,
              defined as time from surgery to disease recurrence. Stratified
              multivariable Cox models were used to assess the associations
              between Immunoscore and outcomes, adjusting for potential
              confounders. Harrell's C-statistics was used to assess model
              performance. FINDINGS: Tissue samples from 3539 patients were
              processed, and samples from 2681 patients were included in the
              analyses after quality controls (700 patients in the training
              set, 636 patients in the internal validation set, and 1345
              patients in the external validation set). The Immunoscore assay
              showed a high level of reproducibility between observers and
              centres (r=097 for colon tumour; r=097 for invasive margin;
              p<00001). In the training set, patients with a high Immunoscore
              had the lowest risk of recurrence at 5 years (14 [8\%] patients
              with a high Immunoscore vs 65 (19\%) patients with an
              intermediate Immunoscore vs 51 (32\%) patients with a low
              Immunoscore; hazard ratio [HR] for high vs low Immunoscore 020,
              95\% CI 010-038; p<00001). The findings were confirmed in the
              two validation sets (n=1981). In the stratified Cox multivariable
              analysis, the Immunoscore association with time to recurrence was
              independent of patient age, sex, T stage, N stage, microsatellite
              instability, and existing prognostic factors (p<00001). Of 1434
              patients with stage II cancer, the difference in risk of
              recurrence at 5 years was significant (HR for high vs low
              Immunoscore 033, 95\% CI 021-052; p<00001), including in Cox
              multivariable analysis (p<00001). Immunoscore had the highest
              relative contribution to the risk of all clinical parameters,
              including the American Joint Committee on Cancer and Union for
              International Cancer Control TNM classification system.
              INTERPRETATION: The Immunoscore provides a reliable estimate of
              the risk of recurrence in patients with colon cancer. These
              results support the implementation of the consensus Immunoscore
              as a new component of a TNM-Immune classification of cancer.
              FUNDING: French National Institute of Health and Medical
              Research, the LabEx Immuno-oncology, the Transcan ERAnet
              Immunoscore European project, Association pour la Recherche
              contre le Cancer, CARPEM, AP-HP, Institut National du Cancer,
              Italian Association for Cancer Research, national grants and the
              Society for Immunotherapy of Cancer.",
  journal  = "Lancet",
  volume   =  391,
  number   =  10135,
  pages    = "2128--2139",
  month    =  may,
  year     =  2018,
  language = "en"
}

@ARTICLE{Li1998-am,
  title    = "An iterative algorithm for minimum cross entropy thresholding",
  author   = "Li, C H and Tam, P K S",
  abstract = "A fast iterative method is derived for minimum cross entropy
              thresholding using a one-point iteration scheme. Simulations
              performed using synthetic generated histograms and a real image
              show the speed advantage and the accuracy of the iterated
              version.",
  journal  = "Pattern Recognit. Lett.",
  volume   =  19,
  number   =  8,
  pages    = "771--776",
  month    =  jun,
  year     =  1998
}

@ARTICLE{Ouchi2003-ia,
  title    = "Improving the realism of the cellular Potts model in simulations
              of biological cells",
  author   = "Ouchi, Noriyuki Bob and Glazier, James A and Rieu, Jean-Paul and
              Upadhyaya, Arpita and Sawada, Yasuji",
  abstract = "Because the extended or cellular large-Q Potts model (CPM)
              captures effectively the global features of tissue rearrangement
              experiments, including cell sorting and tissue engulfment, it has
              become a common technique for cell level simulation of tissues.
              However, it omits three key elements of real cells, their fixed
              membrane area, their attractive binding and the dissipation of
              making and breaking membrane contacts. In this paper, we modify
              the Hamiltonian to use negative surface energies, constrained
              surface area and a spin flip energy threshold to improve the
              correspondence to reality. We find that the new model correctly
              predicts several dynamical behaviors of cells which the original
              CPM does not, including the hierarchy of diffusion constants.",
  journal  = "Physica A: Statistical Mechanics and its Applications",
  volume   =  329,
  number   =  3,
  pages    = "451--458",
  month    =  nov,
  year     =  2003,
  keywords = "Potts model; Diffusion; Cell motion"
}

@ARTICLE{Gusev2000-bj,
  title    = "A stochastic model of chromosome segregation errors with
              reference to cancer cells",
  author   = "Gusev, Y and Kagansky, V and Dooley, W C",
  abstract = "A majority of tumor cells have an abnormal number of chromosomes,
              and this number varies even among the cells of clonal origin.
              Recent publications suggest that the acquisition of chromosome
              numerical abnormalities is an early event in a carcinogenesis
              pathway. Chromosomal instability may also play an important role
              in tumor progression. However, the mechanisms that result in
              abnormal number of chromosomes are poorly understood. One of the
              possible sources of chromosomal instability is a failure of
              chromosomes to segregate to the proper cells during cell
              division. We now propose a stochastic model that describes the
              evolution of chromosome number in a population of dividing cells
              as a result of such chromosome segregation errors (CSE). Assuming
              the independence of life cycles for all chromosomes within a
              cell, our model describes a process of evolution of cell
              karyotypes as a random branching walk in a K-dimensional
              nonnegative integer space (K = 23 for human cells). The
              conditions of cell death define K absorption boundaries for this
              random walk. Our basic model of human cells has all absorption
              boundaries set to zero. In the model, we have introduced a single
              parameter, a probability of segregation errors, which reflects an
              average rate of segregation errors per cell division. Using this
              model, we have examined the possible impact of CSE on chromosome
              numerical changes in cell populations. The model was implemented
              in a C++ program based on a discrete event simulation algorithm.
              Using computer simulation experiments, we have tested the
              sensitivity of our model to the initial conditions and parameter
              values. We have examined the effects of CSE on survival of cells
              and clones as well as on the dynamics of population growth and
              chromosome number distributions. Our modeling results suggest
              that the long-term dynamics of cell population growth depends
              upon the rate of segregation errors. The fraction of clones
              surviving was estimated as a function of the probability of CSE,
              and critical values for the probability of CSE were approximated
              which separates qualitatively different patterns of model
              behavior. The model suggests a theoretical limit for the rate of
              CSE that would allow a diploid population to survive without a
              complete loss of any chromosome type. It also suggests a minimal
              interval of probability of CSE values for which 100\% survival of
              clones is possible. Our modeling results allow comparisons to be",
  journal  = "Math. Comput. Model.",
  volume   =  32,
  number   =  1,
  pages    = "97--111",
  month    =  jul,
  year     =  2000,
  keywords = "Chromosomes; Chromosomal instability; Cancer; Random branching
              walk; Stochastic models"
}

@ARTICLE{Gusev2001-qc,
  title    = "Long-term dynamics of chromosomal instability in cancer: A
              transition probability model",
  author   = "Gusev, Y and Kagansky, V and Dooley, W C",
  abstract = "A stochastic model of chromosomal instability has been previously
              developed which has included one adjustable parameter---the
              probability of a segregation error. Using computer simulations,
              we have previously analyzed this model and were able to reproduce
              a short-term dynamics of chromosome copy number distributions in
              clones of cancer cells. In a short run, segregation errors
              provide a continuous production of deviant cells with increasing
              variation of cell karyotypes, which depends upon the rate of
              segregation errors. In the long-term observations, many tumors
              and cancer cell lines have been observed to maintain a stable,
              although abnormal, distribution of chromosome number for hundreds
              of cell generations. This phenomenon of ``stability within
              instability'' presents an interesting paradox, which could be
              addressed mathematically. However, this would require modeling of
              long term growth of tumor cell clones for hundreds of
              generations, which has far exceeded capabilities of modern
              computer systems. In this study, we have analyzed asymptotic
              behavior of our model using a semianalytical approach. A
              transition probability matrix was derived analytically and
              implemented in a recursive algorithm for computational
              experiments. Using this transition probability model, the
              expected frequencies of chromosome copy number have been
              calculated under various initial and boundary conditions. We have
              also tested several alternative models, which describe various
              mechanisms of errors in segregation of chromosomes, and found
              conditions for stabilization of distribution of chromosomes copy
              numbers over a large number of cell generations. Stable clonal
              frequencies were estimated which are independent of initial
              conditions, i.e., chromosome copy numbers in the initiator cells.
              These stable distributions were, however, dependent on the model
              assumptions regarding particular mechanism of errors in
              segregation of chromosomes. Thus, our modeling results have
              suggested a possible connection between the form of stable
              distribution of chromosome numbers in tumors and the underlying
              mechanism of errors in segregation of chromosomes. This new
              analytical approach allows us to overcome technical impairments
              and limitations of computer simulation, and, for the first time,
              provides mathematical insight into long-term evolution of
              chromosome numerical changes in human tumors.",
  journal  = "Math. Comput. Model.",
  volume   =  33,
  number   =  12,
  pages    = "1253--1273",
  month    =  jun,
  year     =  2001
}

@ARTICLE{Gibney2016-jq,
  title    = "Predictive biomarkers for checkpoint inhibitor-based
              immunotherapy",
  author   = "Gibney, Geoffrey T and Weiner, Louis M and Atkins, Michael B",
  abstract = "The clinical development of checkpoint inhibitor-based
              immunotherapy has ushered in an exciting era of anticancer
              therapy. Durable responses can be seen in patients with melanoma
              and other malignancies. Although monotherapy with PD-1 or PD-L1
              agents are typically well tolerated, the risk of immune-related
              adverse events increases with combination regimens. The
              development of predictive biomarkers is needed to optimise
              patient benefit, minimise risk of toxicities, and guide
              combination approaches. The greatest focus has been on
              tumour-cell PD-L1 expression. Although PD-L1 positivity enriches
              for populations with clinical benefit, PD-L1 testing alone is
              insufficient for patient selection in most malignancies. In this
              Review, we discuss the status of PD-L1 testing and explore
              emerging data on new biomarker strategies with
              tumour-infiltrating lymphocytes, mutational burden, immune gene
              signatures, and multiplex immunohistochemistry. Future
              development of an effective predictive biomarker for checkpoint
              inhibitor-based immunotherapy will integrate multiple approaches
              for optimal characterisation of the immune tumour
              microenvironment.",
  journal  = "Lancet Oncol.",
  volume   =  17,
  number   =  12,
  pages    = "e542--e551",
  month    =  dec,
  year     =  2016,
  language = "en"
}

@ARTICLE{Chandran2017-ev,
  title    = "Treatment of metastatic uveal melanoma with adoptive transfer of
              tumour-infiltrating lymphocytes: a single-centre, two-stage,
              single-arm, phase 2 study",
  author   = "Chandran, Smita S and Somerville, Robert P T and Yang, James C
              and Sherry, Richard M and Klebanoff, Christopher A and Goff,
              Stephanie L and Wunderlich, John R and Danforth, David N and
              Zlott, Daniel and Paria, Biman C and Sabesan, Arvind C and
              Srivastava, Abhishek K and Xi, Liqiang and Pham, Trinh H and
              Raffeld, Mark and White, Donald E and Toomey, Mary Ann and
              Rosenberg, Steven A and Kammula, Udai S",
  abstract = "BACKGROUND: Uveal melanoma is a rare tumour with no established
              treatments once metastases develop. Although a variety of
              immune-based therapies have shown efficacy in metastatic
              cutaneous melanoma, their use in ocular variants has been
              disappointing. Recently, adoptive T-cell therapy has shown
              salvage responses in multiple refractory solid tumours. Thus, we
              sought to determine if adoptive transfer of autologous
              tumour-infiltrating lymphocytes (TILs) could mediate regression
              of metastatic uveal melanoma. METHODS: In this ongoing
              single-centre, two-stage, phase 2, single-arm trial, patients
              (aged $\geq$16 years) with histologically confirmed metastatic
              ocular melanoma were enrolled. Key eligibility criteria were an
              Eastern Cooperative Oncology Group performance status of 0 or 1,
              progressive metastatic disease, and adequate haematological,
              renal, and hepatic function. Metastasectomies were done to
              procure tumour tissue to generate autologous TIL cultures, which
              then underwent large scale ex-vivo expansion. Patients were
              treated with lymphodepleting conditioning chemotherapy
              (intravenous cyclophosphamide [60 mg/kg] daily for 2 days
              followed by fludarabine [25 mg/m2] daily for 5 days, followed by
              a single intravenous infusion of autologous TILs and high-dose
              interleukin-2 [720 000 IU/kg] every 8 h). The primary endpoint
              was objective tumour response in evaluable patients per protocol
              using Response to Evaluation Criteria in Solid Tumors, version
              1.0. An interim analysis of this trial is reported here. The
              trial is registered at ClinicalTrials.gov, number NCT01814046.
              FINDINGS: From the completed first stage and ongoing expansion
              stage of this trial, a total of 21 consecutive patients with
              metastatic uveal melanoma were enrolled between June 7, 2013, and
              Sept 9, 2016, and received TIL therapy. Seven (35\%, 95\% CI
              16-59) of 20 evaluable patients had objective tumour regression.
              Among the responders, six patients achieved a partial response,
              two of which are ongoing and have not reached maximum response.
              One patient achieved complete response of numerous hepatic
              metastases, currently ongoing at 21 months post therapy. Three of
              the responders were refractory to previous immune checkpoint
              blockade. Common grade 3 or worse toxic effects were related to
              the lymphodepleting chemotherapy regimen and included
              lymphopenia, neutropenia, and thrombocytopenia (21 [100\%]
              patients for each toxicity); anaemia (14 [67\%] patients); and
              infection (six [29\%] patients). There was one treatment-related
              death secondary to sepsis-induced multiorgan failure.
              INTERPRETATION: To our knowledge, this is the first report
              describing adoptive transfer of autologous TILs to mediate
              objective tumour regression in patients with metastatic uveal
              melanoma. These initial results challenge the belief that
              metastatic uveal melanoma is immunotherapy resistant and support
              the further investigation of immune-based therapies for this
              cancer. Refinement of this T-cell therapy is crucial to improve
              the frequency of clinical responses and the general applicability
              of this treatment modality. FUNDING: Intramural Research Program
              of the National Institutes of Health, National Cancer Institute,
              Center for Cancer Research.",
  journal  = "Lancet Oncol.",
  volume   =  18,
  number   =  6,
  pages    = "792--802",
  month    =  jun,
  year     =  2017,
  language = "en"
}

@ARTICLE{Masoud2015-by,
  title    = "{HIF-1$\alpha$} pathway: role, regulation and intervention for
              cancer therapy",
  author   = "Masoud, Georgina N and Li, Wei",
  abstract = "Hypoxia-inducible factor-1 (HIF-1) has been recognized as an
              important cancer drug target. Many recent studies have provided
              convincing evidences of strong correlation between elevated
              levels of HIF-1 and tumor metastasis, angiogenesis, poor patient
              prognosis as well as tumor resistance therapy. It was found that
              hypoxia (low O2 levels) is a common character in many types of
              solid tumors. As an adaptive response to hypoxic stress, hypoxic
              tumor cells activate several survival pathways to carry out their
              essential biological processes in different ways compared with
              normal cells. Recent advances in cancer biology at the cellular
              and molecular levels highlighted the HIF-1$\alpha$ pathway as a
              crucial survival pathway for which novel strategies of cancer
              therapy could be developed. However, targeting the HIF-1$\alpha$
              pathway has been a challenging but promising progresses have been
              made in the past twenty years. This review summarizes the role
              and regulation of the HIF-1$\alpha$ in cancer, and recent
              therapeutic approaches targeting this important pathway.",
  journal  = "Acta Pharm Sin B",
  volume   =  5,
  number   =  5,
  pages    = "378--389",
  month    =  sep,
  year     =  2015,
  keywords = "4E-BP1, eukaryotic translation initiation factor 4E (eIF-4E)
              binding protein p70 S6 kinase (S6K); ADM, adrenomedullin; AKt,
              protein kinase B; ARD-1, arrest-defective-1; ARNT, aryl
              hydrocarbon nuclear translocator; AhR, aryl hydrocarbon receptor;
              C-MYC, myelocytomatosis virus oncogene cellular homolog; C-TAD,
              COOH-terminal TAD; CAC, circulating angiogenic cells; CPTs,
              camptothecins; Cancer drug discovery and development; ChIP,
              chromatin immunoprecipitation; CoCl2, cobalt chloride; DFO,
              deferoxamine; EGF, epidermal growth factor; ELISA, enzyme-linked
              immunosorbent assay; EMSA, electrophoretic mobility shift assay;
              EPO, erythropoietin; ERK, extracellular signal-regulated kinase;
              FIH-1, factor inhibiting HIF-1; GA, geldanamycin; GAs,
              geldanamycins; GLUT1, glucose transporter 1; GLUT3, glucose
              transporter 3; GLUTs, glucose transporters; HDAC, histone
              deacetylase; HIF-1$\alpha$; HIF-1$\alpha$ inhibitors;
              HIF-1$\alpha$, hypoxia-inducible factor-1$\alpha$; HK1,
              hexokinase 1; HK2, hexokinase 2; HPH, HIF-1 prolyl hydroxylases;
              HRE, hypoxia response elements; HTS, high throughput screens;
              Hsp90, heat shock protein 90; ID2, DNA-binding protein inhibitor;
              IGF-BP2, IGF-factor-binding protein 2; IGF-BP3,
              IGF-factor-binding protein 3; IGF2, insulin-like growth factor 2;
              IPAS, inhibitory PAS; K, lysine residue; LDHA, lactate
              dehydrogenase; LEP, leptin; LRP1, LDL-receptor-related protein 1;
              Luc, luciferase; MAPK, mitogen-activated protein kinases; MEK,
              MAPK/ERK kinase; MNK, MAP kinase interacting kinase; MTs,
              microtubules; Mdm2, mouse double minute 2 homolog; N, asparagine
              residue; N-TAD, NH2-terminal TAD; NOS, nitric oxide synthase;
              ODDD, oxygen dependent degradation domain; P, proline residue;
              PAS, Per and Sim; PCAF, p300/CBP associated factor; PHDs,
              prolyl-4-hydroxylases; PI3K, phosphatidyl
              inositol-4,5-bisphosphate-3-kinase; PKM, pyruvate kinase M; RCC,
              renal cell carcinoma; RT-PCR, reverse transcription polymerase
              chain reaction; Raf, rapidly accelerated fibrosarcoma; Ras, rat
              sarcoma; SIRT 1, Sirtuin 1; TAD, transactivation domains;
              TGF-$\alpha$, transforming growth factor $\alpha$; TGF-$\beta$3,
              transforming growth factor beta3; TPT, topotecan; Top I,
              topoisomerase I; VEGF, vascular endothelial growth factor; bHLH,
              basic-helix-loop-helix; eIF-4E, eukaryotic translation initiation
              factor 4E; mTOR, mammalian target of rapamycin; pVHL, von
              Hippel-Lindau protein",
  language = "en"
}

@ARTICLE{Bhat2016-ls,
  title    = "Syntaxin 8 is required for efficient lytic granule trafficking in
              cytotoxic {T} lymphocytes",
  author   = "Bhat, Shruthi S and Friedmann, Kim S and Kn{\"o}rck, Arne and
              Hoxha, Cora and Leidinger, Petra and Backes, Christina and Meese,
              Eckart and Keller, Andreas and Rettig, Jens and Hoth, Markus and
              Qu, Bin and Schwarz, Eva C",
  abstract = "Cytotoxic T lymphocytes (CTL) eliminate pathogen-infected and
              cancerous cells mainly by polarized secretion of lytic granules
              (LG, containing cytotoxic molecules like perforin and granzymes)
              at the immunological synapse (IS). Members of the SNARE (soluble
              N-ethylmaleimide-sensitive factor attachment protein receptor)
              family are involved in trafficking (generation, transport and
              fusion) of vesicles at the IS. Syntaxin 8 (Stx8) is expressed in
              LG and colocalizes with the T cell receptor (TCR) upon IS
              formation. Here, we report the significance of Stx8 for human CTL
              cytotoxicity. We found that Stx8 mostly localized in late,
              recycling endosomal and lysosomal compartments with little
              expression in early endosomal compartments. Down-regulation of
              Stx8 by siRNA resulted in reduced cytotoxicity. We found that
              following perforin release of the pre-existing pool upon target
              cell contact, Stx8 down-regulated CTL regenerate perforin pools
              less efficiently and thus release less perforin compared to
              control CTL. CD107a degranulation, real-time and end-point
              population cytotoxicity assays, and high resolution microscopy
              support our conclusion that Stx8 is required for proper and
              timely sorting and trafficking of cytotoxic molecules to
              functional LG through the endosomal pathway in human CTL.",
  journal  = "Biochim. Biophys. Acta",
  volume   =  1863,
  number   = "7 Pt A",
  pages    = "1653--1664",
  month    =  jul,
  year     =  2016,
  keywords = "CTL; Exocytosis; Human CD8 T cell; Killing; Lytic granule; SNARE;
              Syntaxin 8 (Stx8)",
  language = "en"
}

@ARTICLE{Hornberg2006-mr,
  title    = "Cancer: a Systems Biology disease",
  author   = "Hornberg, Jorrit J and Bruggeman, Frank J and Westerhoff, Hans V
              and Lankelma, Jan",
  abstract = "Cancer research has focused on the identification of molecular
              differences between cancerous and healthy cells. The emerging
              picture is overwhelmingly complex. Molecules out of many parallel
              signal transduction pathways are involved. Their activities
              appear to be controlled by multiple factors. The action of
              regulatory circuits, cross-talk between pathways and the
              non-linear reaction kinetics of biochemical processes complicate
              the understanding and prediction of the outcome of intracellular
              signaling. In addition, interactions between tumor and other cell
              types give rise to a complex supra-cellular communication
              network. If cancer is such a complex system, how can one ever
              predict the effect of a mutation in a particular gene on a
              functionality of the entire system? And, how should one go about
              identifying drug targets? Here, we argue that one aspect is to
              recognize, where the essence resides, i.e. recognize cancer as a
              Systems Biology disease. Then, more cancer biologists could
              become systems biologists aiming to provide answers to some of
              the above systemic questions. To this aim, they should integrate
              the available knowledge stemming from quantitative experimental
              results through mathematical models. Models that have contributed
              to the understanding of complex biological systems are discussed.
              We show that the architecture of a signaling network is important
              for determining the site at which an oncologist should intervene.
              Finally, we discuss the possibility of applying network-based
              drug design to cancer treatment and how rationalized therapies,
              such as the application of kinase inhibitors, may benefit from
              Systems Biology.",
  journal  = "Biosystems.",
  volume   =  83,
  number   = "2-3",
  pages    = "81--90",
  month    =  feb,
  year     =  2006,
  language = "en"
}

@ARTICLE{Liu2019-gb,
  title    = "Immunotherapy in acute myeloid leukemia and myelodysplastic
              syndromes: The dawn of a new era?",
  author   = "Liu, Yuxin and Bewersdorf, Jan Philipp and Stahl, Maximilian and
              Zeidan, Amer M",
  abstract = "Immunotherapy has revolutionized therapy in both solid and liquid
              malignancies. The ability to cure acute myeloid leukemia (AML)
              and myelodysplastic syndromes (MDS) with an allogeneic
              hematopoietic stem cell transplant (HSCT) is proof of concept for
              the application of immunotherapy in AML and MDS. However, outside
              of HSCT, only the anti-CD33 antibody drug conjugate gemtuzumab
              ozogamicin is currently approved as an antibody-targeted therapy
              for AML. Several avenues of immunotherapeutic drugs are currently
              in different stages of clinical development. Here, we review
              recent advances in antibody-based therapy, immune checkpoint
              inhibitors, vaccines and adoptive cell-based therapy for patients
              with AML and MDS. First, we discuss different antibody
              constructs. Immune checkpoint inhibitors targeting cytotoxic
              T-lymphocyte-associated protein 4 (CTLA-4), programmed cell death
              protein-1 (PD-1) and CD47 as well as peptide, dendritic cell and
              dendritic/AML cell-based vaccines are reviewed next. Lastly,
              adoptive cell-based therapy including chimeric antigen receptor
              (CAR)-T cell and NK cell therapy is discussed.",
  journal  = "Blood Rev.",
  volume   =  34,
  pages    = "67--83",
  month    =  mar,
  year     =  2019,
  keywords = "Acute myelogenous leukemia; adoptive cell therapy; antibody;
              immunotherapy; myelodysplastic syndrome; vaccine",
  language = "en"
}

@ARTICLE{Gadhamsetty2014-wf,
  title    = "A general functional response of cytotoxic {T}
              lymphocyte-mediated killing of target cells",
  author   = "Gadhamsetty, Saikrishna and Mar{\'e}e, Athanasius F M and
              Beltman, Joost B and de Boer, Rob J",
  abstract = "Cytotoxic T lymphocytes (CTLs) kill virus-infected cells and
              tumor cells, and play a critical role in immune protection. Our
              knowledge of how the CTL killing efficiency varies with CTL and
              target cell numbers is limited. Here, we simulate a region of
              lymphoid tissue using a cellular Potts model to characterize the
              functional response of CTL killing of target cells, and find that
              the total killing rate saturates both with the CTL and the target
              cell densities. The relative saturation in CTL and target cell
              densities is determined by whether a CTL can kill multiple target
              cells at the same time, and whether a target cell can be killed
              by many CTLs together. We find that all the studied regimes can
              be well described by a double-saturation (DS) function with two
              different saturation constants. We show that this DS model can be
              mechanistically derived for the cases where target cells are
              killed by a single CTL. For the other cases, a biological
              interpretation of the parameters is still possible. Our results
              imply that this DS function can be used as a tool to predict the
              cellular interactions in cytotoxicity data.",
  journal  = "Biophys. J.",
  volume   =  106,
  number   =  8,
  pages    = "1780--1791",
  month    =  apr,
  year     =  2014,
  language = "en"
}

@ARTICLE{Gadhamsetty2017-qi,
  title    = "A Sigmoid Functional Response Emerges When Cytotoxic {T}
              Lymphocytes Start Killing Fresh Target Cells",
  author   = "Gadhamsetty, Saikrishna and Mar{\'e}e, Athanasius F M and
              Beltman, Joost B and de Boer, Rob J",
  abstract = "Cytotoxic T lymphocyte (CTL)-mediated killing involves the
              formation of a synapse with a target cell, followed by delivery
              of perforin and granzymes. Previously, we derived a general
              functional response for CTL killing while considering that CTLs
              form stable synapses (i.e., single-stage) and that the number of
              conjugates remains at steady state. However, the killing of
              target cells sometimes requires multiple engagements (i.e.,
              multistage). To study how multistage killing and a lack of steady
              state influence the functional response, we here analyze a set of
              differential equations as well as simulations employing the
              cellular Potts model, in both cases describing CTLs that kill
              target cells. We find that at steady state the total killing rate
              (i.e., the number of target cells killed by all CTLs) is well
              described by the previously derived double saturation function.
              Compared to single-stage killing, the total killing rate during
              multistage killing saturates at higher CTL and target cell
              densities. Importantly, when the killing is measured before the
              steady state is approached, a qualitatively different functional
              response emerges for two reasons: First, the killing signal of
              each CTL gets diluted over several targets and because this
              dilution effect is strongest at high target cell densities; this
              can result in a peak in the dependence of the total killing rate
              on the target cell density. Second, the total killing rate
              exhibits a sigmoid dependence on the CTL density when killing is
              a multistage process, because it takes typically more than one
              CTL to kill a target. In conclusion, a sigmoid dependence of the
              killing rate on the CTLs during initial phases of killing may be
              indicative of a multistage killing process. Observation of a
              sigmoid functional response may thus arise from a dilution effect
              and is not necessarily due to cooperative behavior of the CTLs.",
  journal  = "Biophys. J.",
  volume   =  112,
  number   =  6,
  pages    = "1221--1235",
  month    =  mar,
  year     =  2017,
  language = "en"
}

@ARTICLE{Zaytseva2012-ue,
  title    = "{mTOR} inhibitors in cancer therapy",
  author   = "Zaytseva, Yekaterina Y and Valentino, Joseph D and Gulhati, Pat
              and Evers, B Mark",
  abstract = "The mammalian target of rapamycin (mTOR) plays a key role in
              regulation of cellular metabolism, growth, and proliferation. The
              frequent hyperactivation of mTOR signaling makes it an attractive
              target for therapeutic intervention and has driven the
              development of a number of mTOR inhibitors. Encouraging data from
              preclinical studies have resulted in initiation of multiple
              clinical trials. Furthermore, combinational strategies are being
              studied in an effort to overcome resistance and enhance efficacy.
              Although additional studies are required to determine their
              specific role in the clinical setting, mTOR inhibitors remain a
              promising therapeutic option for the treatment of cancer.",
  journal  = "Cancer Lett.",
  volume   =  319,
  number   =  1,
  pages    = "1--7",
  month    =  jun,
  year     =  2012,
  language = "en"
}

@ARTICLE{Robinson2020-qy,
  title    = "Dysregulation of de novo nucleotide biosynthetic pathway enzymes
              in cancer and targeting opportunities",
  author   = "Robinson, Alyncia D and Eich, Marie-Lisa and Varambally,
              Sooryanarayana",
  abstract = "Cancer is a disease of uncontrolled cell growth and a major cause
              of death worldwide. Many molecular events characterize tumor
              initiation and progression. Global gene expression analyses using
              next-generation sequencing, proteomics and metabolomics show
              genomic, epigenetic, and metabolite concentration changes in
              various tumors. Molecular alterations identified include multiple
              cancer-driving mutations, gene fusions, amplifications,
              deletions, and post-translational modifications. Data integration
              from many high-throughput platforms unraveled dysregulation in
              many metabolic pathways in cancer. Since cancer cells are
              fast-growing, their metabolic needs are enhanced, hence the
              requirement for de novo synthesis of essential metabolites. One
              critical requirement of fast-growing cells and a historically
              important pathway in cancer is the nucleotide biosynthetic
              pathway and its enzymes are valuable targets for small molecule
              inhibition. Purines and pyrimidines are building blocks of DNA
              synthesis and due to their excessive growth, cancer cells
              extensively utilize de novo pathways for nucleotide biosynthesis.
              Methotrexate, one of the early chemotherapeutic agents, targets
              dihydrofolate reductase of the folate metabolic pathway that is
              involved in nucleotide biosynthesis. In this review, we discuss
              the nucleotide biosynthetic pathways in cancer and targeting
              opportunities.",
  journal  = "Cancer Lett.",
  volume   =  470,
  pages    = "134--140",
  month    =  feb,
  year     =  2020,
  keywords = "Energetics; Folate; One carbon metabolism; Purine; Pyrimidine",
  language = "en"
}

@ARTICLE{Masuyama2019-rg,
  title    = "{DNA} barcodes evolve for high-resolution cell lineage tracing",
  author   = "Masuyama, Nanami and Mori, Hideto and Yachie, Nozomu",
  abstract = "Mammalian development involves continuous dynamic processes in
              which cells propagate, differentiate, orchestrate, and decease to
              produce high-order functions. Although accurate cell lineage
              information can provide a strong foundation to understand such
              complex processes, the cell lineages involved in development of
              the whole mammalian body remain largely unclear, except for in
              early embryogenesis, which is observable under a microscope. With
              CRISPR genome editing, the concept of 'evolving DNA barcodes' has
              rapidly emerged for large-scale, high-resolution cell lineage
              tracing, where cell-embedded DNA barcodes continuously accumulate
              random mutations that are inherited from mother to daughter
              cells. Similar to evolutionary tree reconstruction using species'
              DNA sequences, cell lineages can be reconstructed using shared
              mutation patterns in the DNA barcodes identified using massively
              parallel sequencing. The dramatic developments of single-cell and
              imaging technologies have enabled analyses of the molecular and
              spatial architecture of heterogeneous cells. The evolving DNA
              barcodes can also consolidate this information on a reconstructed
              cell lineage tree and accelerate our understanding of
              multicellular organisms.",
  journal  = "Curr. Opin. Chem. Biol.",
  volume   =  52,
  pages    = "63--71",
  month    =  oct,
  year     =  2019,
  language = "en"
}

@ARTICLE{Zheng2016-al,
  title    = "Comprehensive {Pan-Genomic} Characterization of Adrenocortical
              Carcinoma",
  author   = "Zheng, Siyuan and Cherniack, Andrew D and Dewal, Ninad and
              Moffitt, Richard A and Danilova, Ludmila and Murray, Bradley A
              and Lerario, Antonio M and Else, Tobias and Knijnenburg, Theo A
              and Ciriello, Giovanni and Kim, Seungchan and Assie, Guillaume
              and Morozova, Olena and Akbani, Rehan and Shih, Juliann and
              Hoadley, Katherine A and Choueiri, Toni K and Waldmann, Jens and
              Mete, Ozgur and Robertson, A Gordon and Wu, Hsin-Ta and Raphael,
              Benjamin J and Shao, Lina and Meyerson, Matthew and Demeure,
              Michael J and Beuschlein, Felix and Gill, Anthony J and Sidhu,
              Stan B and Almeida, Madson Q and Fragoso, Maria C B V and Cope,
              Leslie M and Kebebew, Electron and Habra, Mouhammed A and
              Whitsett, Timothy G and Bussey, Kimberly J and Rainey, William E
              and Asa, Sylvia L and Bertherat, J{\'e}r{\^o}me and Fassnacht,
              Martin and Wheeler, David A and {Cancer Genome Atlas Research
              Network} and Hammer, Gary D and Giordano, Thomas J and Verhaak,
              Roel G W",
  abstract = "We describe a comprehensive genomic characterization of
              adrenocortical carcinoma (ACC). Using this dataset, we expand the
              catalogue of known ACC driver genes to include PRKAR1A, RPL22,
              TERF2, CCNE1, and NF1. Genome wide DNA copy-number analysis
              revealed frequent occurrence of massive DNA loss followed by
              whole-genome doubling (WGD), which was associated with aggressive
              clinical course, suggesting WGD is a hallmark of disease
              progression. Corroborating this hypothesis were increased TERT
              expression, decreased telomere length, and activation of
              cell-cycle programs. Integrated subtype analysis identified three
              ACC subtypes with distinct clinical outcome and molecular
              alterations which could be captured by a 68-CpG probe
              DNA-methylation signature, proposing a strategy for clinical
              stratification of patients based on molecular markers.",
  journal  = "Cancer Cell",
  volume   =  29,
  number   =  5,
  pages    = "723--736",
  month    =  may,
  year     =  2016,
  language = "en"
}

@ARTICLE{Palazon2017-vx,
  title    = "An {HIF-1$\alpha$/VEGF-A} Axis in Cytotoxic {T} Cells Regulates
              Tumor Progression",
  author   = "Palazon, Asis and Tyrakis, Petros A and Macias, David and Veli{\c
              c}a, Pedro and Rundqvist, Helene and Fitzpatrick, Susan and
              Vojnovic, Nikola and Phan, Anthony T and Loman, Niklas and
              Hedenfalk, Ingrid and Hatschek, Thomas and L{\"o}vrot, John and
              Foukakis, Theodoros and Goldrath, Ananda W and Bergh, Jonas and
              Johnson, Randall S",
  abstract = "Cytotoxic T cells infiltrating tumors are thought to utilize HIF
              transcription factors during adaptation to the hypoxic tumor
              microenvironment. Deletion analyses of the two key HIF isoforms
              found that HIF-1$\alpha$, but not HIF-2$\alpha$, was essential
              for the effector state in CD8+ T cells. Furthermore, loss of
              HIF-1$\alpha$ in CD8+ T cells reduced tumor infiltration and
              tumor cell killing, and altered tumor vascularization. Deletion
              of VEGF-A, an HIF target gene, in CD8+ T cells accelerated
              tumorigenesis while also altering vascularization. Analyses of
              human breast cancer showed inverse correlations between VEGF-A
              expression and CD8+ T cell infiltration, and a link between T
              cell infiltration and vascularization. These data demonstrate
              that the HIF-1$\alpha$/VEGF-A axis is an essential aspect of
              tumor immunity.",
  journal  = "Cancer Cell",
  volume   =  32,
  number   =  5,
  pages    = "669--683.e5",
  month    =  nov,
  year     =  2017,
  keywords = "HIF transcription factors; VEGF; angiogenesis; cytotoxic T cells;
              hypoxia; immunotherapy",
  language = "en"
}

@ARTICLE{Taylor2018-ep,
  title    = "Genomic and Functional Approaches to Understanding Cancer
              Aneuploidy",
  author   = "Taylor, Alison M and Shih, Juliann and Ha, Gavin and Gao, Galen F
              and Zhang, Xiaoyang and Berger, Ashton C and Schumacher, Steven E
              and Wang, Chen and Hu, Hai and Liu, Jianfang and Lazar, Alexander
              J and {Cancer Genome Atlas Research Network} and Cherniack,
              Andrew D and Beroukhim, Rameen and Meyerson, Matthew",
  abstract = "Aneuploidy, whole chromosome or chromosome arm imbalance, is a
              near-universal characteristic of human cancers. In 10,522 cancer
              genomes from The Cancer Genome Atlas, aneuploidy was correlated
              with TP53 mutation, somatic mutation rate, and expression of
              proliferation genes. Aneuploidy was anti-correlated with
              expression of immune signaling genes, due to decreased leukocyte
              infiltrates in high-aneuploidy samples. Chromosome arm-level
              alterations show cancer-specific patterns, including loss of
              chromosome arm 3p in squamous cancers. We applied genome
              engineering to delete 3p in lung cells, causing decreased
              proliferation rescued in part by chromosome 3 duplication. This
              study defines genomic and phenotypic correlates of cancer
              aneuploidy and provides an experimental approach to study
              chromosome arm aneuploidy.",
  journal  = "Cancer Cell",
  volume   =  33,
  number   =  4,
  pages    = "676--689.e3",
  month    =  apr,
  year     =  2018,
  keywords = "aneuploidy; cancer genomics; genome engineering; lung squamous
              cell carcinoma",
  language = "en"
}

@ARTICLE{Thommen2018-gz,
  title    = "{T} Cell Dysfunction in Cancer",
  author   = "Thommen, Daniela S and Schumacher, Ton N",
  abstract = "Therapeutic reinvigoration of tumor-specific T cells has greatly
              improved clinical outcome in cancer. Nevertheless, many patients
              still do not achieve durable benefit. Recent evidence from
              studies in murine and human cancer suggest that intratumoral T
              cells display a broad spectrum of (dys-)functional states, shaped
              by the multifaceted suppressive signals that occur within the
              tumor microenvironment. Here we discuss the current understanding
              of T cell dysfunction in cancer, the value of novel technologies
              to dissect such dysfunction at the single cell level, and how our
              emerging understanding of T cell dysfunction may be utilized to
              develop personalized strategies to restore antitumor immunity.",
  journal  = "Cancer Cell",
  volume   =  33,
  number   =  4,
  pages    = "547--562",
  month    =  apr,
  year     =  2018,
  keywords = "PD-1; T cell exhaustion; cancer; cancer immunotherapy; single
              cell technologies; tumor microenvironment",
  language = "en"
}

@ARTICLE{Hellmann2018-vc,
  title    = "Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and
              in Combination with Ipilimumab in {Small-Cell} Lung Cancer",
  author   = "Hellmann, Matthew D and Callahan, Margaret K and Awad, Mark M and
              Calvo, Emiliano and Ascierto, Paolo A and Atmaca, Akin and Rizvi,
              Naiyer A and Hirsch, Fred R and Selvaggi, Giovanni and
              Szustakowski, Joseph D and Sasson, Ariella and Golhar, Ryan and
              Vitazka, Patrik and Chang, Han and Geese, William J and Antonia,
              Scott J",
  abstract = "Durable responses and encouraging survival have been demonstrated
              with immune checkpoint inhibitors in small-cell lung cancer
              (SCLC), but predictive markers are unknown. We used whole exome
              sequencing to evaluate the impact of tumor mutational burden on
              efficacy of nivolumab monotherapy or combined with ipilimumab in
              patients with SCLC from the nonrandomized or randomized cohorts
              of CheckMate 032. Patients received nivolumab (3 mg/kg every 2
              weeks) or nivolumab plus ipilimumab (1 mg/kg plus 3 mg/kg every 3
              weeks for four cycles, followed by nivolumab 3 mg/kg every 2
              weeks). Efficacy of nivolumab $\pm$ ipilimumab was enhanced in
              patients with high tumor mutational burden. Nivolumab plus
              ipilimumab appeared to provide a greater clinical benefit than
              nivolumab monotherapy in the high tumor mutational burden
              tertile.",
  journal  = "Cancer Cell",
  volume   =  33,
  number   =  5,
  pages    = "853--861.e4",
  month    =  may,
  year     =  2018,
  keywords = "CTLA-4; PD-1; biomarkers; clinical trial; immunotherapy;
              ipilimumab; nivolumab; small cell lung cancer; tumor mutation
              burden",
  language = "en"
}

@ARTICLE{Grasso2020-ex,
  title    = "Conserved {Interferon-$\gamma$} Signaling Drives Clinical
              Response to Immune Checkpoint Blockade Therapy in Melanoma",
  author   = "Grasso, Catherine S and Tsoi, Jennifer and Onyshchenko, Mykola
              and Abril-Rodriguez, Gabriel and Ross-Macdonald, Petra and
              Wind-Rotolo, Megan and Champhekar, Ameya and Medina, Egmidio and
              Torrejon, Davis Y and Shin, Daniel Sanghoon and Tran, Phuong and
              Kim, Yeon Joo and Puig-Saus, Cristina and Campbell, Katie and
              Vega-Crespo, Agustin and Quist, Michael and Martignier,
              Christophe and Luke, Jason J and Wolchok, Jedd D and Johnson,
              Douglas B and Chmielowski, Bartosz and Hodi, F Stephen and
              Bhatia, Shailender and Sharfman, William and Urba, Walter J and
              Slingluff, Jr, Craig L and Diab, Adi and Haanen, John B A G and
              Algarra, Salvador Martin and Pardoll, Drew M and Anagnostou,
              Valsamo and Topalian, Suzanne L and Velculescu, Victor E and
              Speiser, Daniel E and Kalbasi, Anusha and Ribas, Antoni",
  abstract = "We analyze the transcriptome of baseline and on-therapy tumor
              biopsies from 101 patients with advanced melanoma treated with
              nivolumab (anti-PD-1) alone or combined with ipilimumab
              (anti-CTLA-4). We find that T cell infiltration and
              interferon-$\gamma$ (IFN-$\gamma$) signaling signatures
              correspond most highly with clinical response to therapy, with a
              reciprocal decrease in cell-cycle and WNT signaling pathways in
              responding biopsies. We model the interaction in 58 human cell
              lines, where IFN-$\gamma$ in vitro exposure leads to a conserved
              transcriptome response unless cells have IFN-$\gamma$ receptor
              alterations. This conserved IFN-$\gamma$ transcriptome response
              in melanoma cells serves to amplify the antitumor immune
              response. Therefore, the magnitude of the antitumor T cell
              response and the corresponding downstream IFN-$\gamma$ signaling
              are the main drivers of clinical response or resistance to immune
              checkpoint blockade therapy.",
  journal  = "Cancer Cell",
  month    =  sep,
  year     =  2020,
  keywords = "RNA-seq; anti-CTLA-4; anti-PD-1; biopsies; clinical trial; immune
              checkpoint blockade; immune exclusion; interferon-$\gamma$;
              resistance; response; transcriptomics",
  language = "en"
}

@ARTICLE{Thomas2005-mw,
  title    = "{TGF-beta} directly targets cytotoxic {T} cell functions during
              tumor evasion of immune surveillance",
  author   = "Thomas, Dori A and Massagu{\'e}, Joan",
  abstract = "Tumors escape from immune surveillance by producing the
              immunosuppressive cytokine TGF-beta. However, the mechanism by
              which TGF-beta inhibits T cell-mediated tumor clearance in vivo
              is unknown. We demonstrate that TGF-beta acts on cytotoxic T
              lymphocytes (CTLs) to specifically inhibit the expression of five
              cytolytic gene products-namely, perforin, granzyme A, granzyme B,
              Fas ligand, and interferon gamma-which are collectively
              responsible for CTL-mediated tumor cytotoxicity. Repression of
              granzyme B and interferon-gamma involves binding of
              TGF-beta-activated Smad and ATF1 transcription factors to their
              promoter regions, indicating direct and selective regulation by
              the TGF-beta/Smad pathway. Neutralization of systemic TGF-beta in
              mice enables tumor clearance with restoration of cytotoxic gene
              expression in antigen-specific CTLs in vivo. We suggest that
              TGF-beta suppresses CTL function in vivo through an anticytotoxic
              program of transcriptional repression.",
  journal  = "Cancer Cell",
  volume   =  8,
  number   =  5,
  pages    = "369--380",
  month    =  nov,
  year     =  2005,
  language = "en"
}

@ARTICLE{Figueroa2010-bc,
  title    = "Leukemic {IDH1} and {IDH2} mutations result in a hypermethylation
              phenotype, disrupt {TET2} function, and impair hematopoietic
              differentiation",
  author   = "Figueroa, Maria E and Abdel-Wahab, Omar and Lu, Chao and Ward,
              Patrick S and Patel, Jay and Shih, Alan and Li, Yushan and
              Bhagwat, Neha and Vasanthakumar, Aparna and Fernandez, Hugo F and
              Tallman, Martin S and Sun, Zhuoxin and Wolniak, Kristy and
              Peeters, Justine K and Liu, Wei and Choe, Sung E and Fantin,
              Valeria R and Paietta, Elisabeth and L{\"o}wenberg, Bob and
              Licht, Jonathan D and Godley, Lucy A and Delwel, Ruud and Valk,
              Peter J M and Thompson, Craig B and Levine, Ross L and Melnick,
              Ari",
  abstract = "Cancer-associated IDH mutations are characterized by neomorphic
              enzyme activity and resultant 2-hydroxyglutarate (2HG)
              production. Mutational and epigenetic profiling of a large acute
              myeloid leukemia (AML) patient cohort revealed that IDH1/2-mutant
              AMLs display global DNA hypermethylation and a specific
              hypermethylation signature. Furthermore, expression of
              2HG-producing IDH alleles in cells induced global DNA
              hypermethylation. In the AML cohort, IDH1/2 mutations were
              mutually exclusive with mutations in the
              $\alpha$-ketoglutarate-dependent enzyme TET2, and TET2
              loss-of-function mutations were associated with similar
              epigenetic defects as IDH1/2 mutants. Consistent with these
              genetic and epigenetic data, expression of IDH mutants impaired
              TET2 catalytic function in cells. Finally, either expression of
              mutant IDH1/2 or Tet2 depletion impaired hematopoietic
              differentiation and increased stem/progenitor cell marker
              expression, suggesting a shared proleukemogenic effect.",
  journal  = "Cancer Cell",
  volume   =  18,
  number   =  6,
  pages    = "553--567",
  month    =  dec,
  year     =  2010,
  language = "en"
}

@ARTICLE{Cooper2006-uw,
  title    = "The evolution of adaptive immune systems",
  author   = "Cooper, Max D and Alder, Matthew N",
  abstract = "A clonally diverse anticipatory repertoire in which each
              lymphocyte bears a unique antigen receptor is the central feature
              of the adaptive immune system that evolved in our vertebrate
              ancestors. The survival advantage gained through adding this type
              of adaptive immune system to a pre-existing innate immune system
              led to the evolution of alternative ways for lymphocytes to
              generate diverse antigen receptors for use in recognizing and
              repelling pathogen invaders. All jawed vertebrates assemble their
              antigen-receptor genes through recombinatorial rearrangement of
              different immunoglobulin or T cell receptor gene segments. The
              surviving jawless vertebrates, lampreys and hagfish, instead
              solved the receptor diversification problem by the
              recombinatorial assembly of leucine-rich-repeat genetic modules
              to encode variable lymphocyte receptors. The convergent evolution
              of these remarkably different adaptive immune systems involved
              innovative genetic modification of innate-immune-system
              components.",
  journal  = "Cell",
  volume   =  124,
  number   =  4,
  pages    = "815--822",
  month    =  feb,
  year     =  2006,
  language = "en"
}

@ARTICLE{Anderson2006-ui,
  title    = "Tumor morphology and phenotypic evolution driven by selective
              pressure from the microenvironment",
  author   = "Anderson, Alexander R A and Weaver, Alissa M and Cummings, Peter
              T and Quaranta, Vito",
  abstract = "Emergence of invasive behavior in cancer is life-threatening, yet
              ill-defined due to its multifactorial nature. We present a
              multiscale mathematical model of cancer invasion, which considers
              cellular and microenvironmental factors simultaneously and
              interactively. Unexpectedly, the model simulations predict that
              harsh tumor microenvironment conditions (e.g., hypoxia,
              heterogenous extracellular matrix) exert a dramatic selective
              force on the tumor, which grows as an invasive mass with
              fingering margins, dominated by a few clones with aggressive
              traits. In contrast, mild microenvironment conditions (e.g.,
              normoxia, homogeneous matrix) allow clones with similar
              aggressive traits to coexist with less aggressive phenotypes in a
              heterogeneous tumor mass with smooth, noninvasive margins. Thus,
              the genetic make-up of a cancer cell may realize its invasive
              potential through a clonal evolution process driven by definable
              microenvironmental selective forces. Our mathematical model
              provides a theoretical/experimental framework to quantitatively
              characterize this selective pressure for invasion and test ways
              to eliminate it.",
  journal  = "Cell",
  volume   =  127,
  number   =  5,
  pages    = "905--915",
  month    =  dec,
  year     =  2006,
  language = "en"
}

@ARTICLE{Martinvalet2008-mz,
  title    = "Granzyme A cleaves a mitochondrial complex {I} protein to
              initiate caspase-independent cell death",
  author   = "Martinvalet, Denis and Dykxhoorn, Derek M and Ferrini, Roger and
              Lieberman, Judy",
  abstract = "The killer lymphocyte protease granzyme A (GzmA) triggers
              caspase-independent target cell death with morphological features
              of apoptosis. We previously showed that GzmA acts directly on
              mitochondria to generate reactive oxygen species (ROS) and
              disrupt the transmembrane potential (DeltaPsi(m)) but does not
              permeabilize the mitochondrial outer membrane. Mitochondrial
              damage is critical to GzmA-induced cell death since cells treated
              with superoxide scavengers are resistant to GzmA. Here we find
              that GzmA accesses the mitochondrial matrix to cleave the complex
              I protein NDUFS3, an iron-sulfur subunit of the NADH:ubiquinone
              oxidoreductase complex I, after Lys56 to interfere with NADH
              oxidation and generate superoxide anions. Target cells expressing
              a cleavage site mutant of NDUFS3 are resistant to GzmA-mediated
              cell death but remain sensitive to GzmB.",
  journal  = "Cell",
  volume   =  133,
  number   =  4,
  pages    = "681--692",
  month    =  may,
  year     =  2008,
  language = "en"
}

@ARTICLE{Torres2010-tm,
  title    = "Identification of aneuploidy-tolerating mutations",
  author   = "Torres, Eduardo M and Dephoure, Noah and Panneerselvam, Amudha
              and Tucker, Cheryl M and Whittaker, Charles A and Gygi, Steven P
              and Dunham, Maitreya J and Amon, Angelika",
  abstract = "Aneuploidy causes a proliferative disadvantage in all normal
              cells analyzed to date, yet this condition is associated with a
              disease characterized by unabated proliferative potential,
              cancer. The mechanisms that allow cancer cells to tolerate the
              adverse effects of aneuploidy are not known. To probe this
              question, we identified aneuploid yeast strains with improved
              proliferative abilities. Their molecular characterization
              revealed strain-specific genetic alterations as well as mutations
              shared between different aneuploid strains. Among the latter, a
              loss-of-function mutation in the gene encoding the
              deubiquitinating enzyme Ubp6 improves growth rates in four
              different aneuploid yeast strains by attenuating the changes in
              intracellular protein composition caused by aneuploidy. Our
              results demonstrate the existence of aneuploidy-tolerating
              mutations that improve the fitness of multiple different
              aneuploidies and highlight the importance of
              ubiquitin-proteasomal degradation in suppressing the adverse
              effects of aneuploidy.",
  journal  = "Cell",
  volume   =  143,
  number   =  1,
  pages    = "71--83",
  month    =  oct,
  year     =  2010,
  language = "en"
}

@ARTICLE{Tang2011-cn,
  title    = "Identification of aneuploidy-selective antiproliferation
              compounds",
  author   = "Tang, Yun-Chi and Williams, Bret R and Siegel, Jake J and Amon,
              Angelika",
  abstract = "Aneuploidy, an incorrect chromosome number, is a hallmark of
              cancer. Compounds that cause lethality in aneuploid, but not
              euploid, cells could therefore provide new cancer therapies. We
              have identified the energy stress-inducing agent AICAR, the
              protein folding inhibitor 17-AAG, and the autophagy inhibitor
              chloroquine as exhibiting this property. AICAR induces
              p53-mediated apoptosis in primary mouse embryonic fibroblasts
              (MEFs) trisomic for chromosome 1, 13, 16, or 19. AICAR and
              17-AAG, especially when combined, also show efficacy against
              aneuploid human cancer cell lines. Our results suggest that
              compounds that interfere with pathways that are essential for the
              survival of aneuploid cells could serve as a new treatment
              strategy against a broad spectrum of human tumors.",
  journal  = "Cell",
  volume   =  144,
  number   =  4,
  pages    = "499--512",
  month    =  feb,
  year     =  2011,
  language = "en"
}

@ARTICLE{Spencer2011-bv,
  title    = "Measuring and modeling apoptosis in single cells",
  author   = "Spencer, Sabrina L and Sorger, Peter K",
  abstract = "Cell death plays an essential role in the development of tissues
              and organisms, the etiology of disease, and the responses of
              cells to therapeutic drugs. Here we review progress made over the
              last decade in using mathematical models and quantitative, often
              single-cell, data to study apoptosis. We discuss the delay that
              follows exposure of cells to prodeath stimuli, control of
              mitochondrial outer membrane permeabilization, switch-like
              activation of effector caspases, and variability in the timing
              and probability of death from one cell to the next. Finally, we
              discuss challenges facing the fields of biochemical modeling and
              systems pharmacology.",
  journal  = "Cell",
  volume   =  144,
  number   =  6,
  pages    = "926--939",
  month    =  mar,
  year     =  2011,
  language = "en"
}

@ARTICLE{Tang2013-ki,
  title    = "Gene copy-number alterations: a cost-benefit analysis",
  author   = "Tang, Yun-Chi and Amon, Angelika",
  abstract = "Changes in DNA copy number, whether confined to specific genes or
              affecting whole chromosomes, have been identified as causes of
              diseases and developmental abnormalities and as sources of
              adaptive potential. Here, we discuss the costs and benefits of
              DNA copy-number alterations. Changes in DNA copy number are
              largely detrimental. Amplifications or deletions of specific
              genes can elicit discrete defects. Large-scale changes in DNA
              copy number can also cause detrimental phenotypes that are due to
              the cumulative effects of copy-number alterations of many genes
              simultaneously. On the other hand, studies in microorganisms show
              that DNA copy-number alterations can be beneficial, increasing
              survival under selective pressure. As DNA copy-number alterations
              underlie many human diseases, we will end with a discussion of
              gene copy-number changes as therapeutic targets.",
  journal  = "Cell",
  volume   =  152,
  number   =  3,
  pages    = "394--405",
  month    =  jan,
  year     =  2013,
  language = "en"
}

@ARTICLE{Davoli2013-kp,
  title    = "Cumulative haploinsufficiency and triplosensitivity drive
              aneuploidy patterns and shape the cancer genome",
  author   = "Davoli, Teresa and Xu, Andrew Wei and Mengwasser, Kristen E and
              Sack, Laura M and Yoon, John C and Park, Peter J and Elledge,
              Stephen J",
  abstract = "Aneuploidy has been recognized as a hallmark of cancer for more
              than 100 years, yet no general theory to explain the recurring
              patterns of aneuploidy in cancer has emerged. Here, we develop
              Tumor Suppressor and Oncogene (TUSON) Explorer, a computational
              method that analyzes the patterns of mutational signatures in
              tumors and predicts the likelihood that any individual gene
              functions as a tumor suppressor (TSG) or oncogene (OG). By
              analyzing >8,200 tumor-normal pairs, we provide statistical
              evidence suggesting that many more genes possess cancer driver
              properties than anticipated, forming a continuum of oncogenic
              potential. Integrating our driver predictions with information on
              somatic copy number alterations, we find that the distribution
              and potency of TSGs (STOP genes), OGs, and essential genes (GO
              genes) on chromosomes can predict the complex patterns of
              aneuploidy and copy number variation characteristic of cancer
              genomes. We propose that the cancer genome is shaped through a
              process of cumulative haploinsufficiency and triplosensitivity.",
  journal  = "Cell",
  volume   =  155,
  number   =  4,
  pages    = "948--962",
  month    =  nov,
  year     =  2013,
  language = "en"
}

@ARTICLE{Steinert2015-do,
  title    = "Quantifying Memory {CD8} {T} Cells Reveals Regionalization of
              Immunosurveillance",
  author   = "Steinert, Elizabeth M and Schenkel, Jason M and Fraser, Kathryn A
              and Beura, Lalit K and Manlove, Luke S and Igy{\'a}rt{\'o},
              Botond Z and Southern, Peter J and Masopust, David",
  abstract = "Memory CD8 T cells protect against intracellular pathogens by
              scanning host cell surfaces; thus, infection detection rates
              depend on memory cell number and distribution. Population
              analyses rely on cell isolation from whole organs, and
              interpretation is predicated on presumptions of near complete
              cell recovery. Paradigmatically, memory is parsed into central,
              effector, and resident subsets, ostensibly defined by
              immunosurveillance patterns but in practice identified by
              phenotypic markers. Because isolation methods ultimately inform
              models of memory T cell differentiation, protection, and vaccine
              translation, we tested their validity via parabiosis and
              quantitative immunofluorescence microscopy of a mouse memory CD8
              T cell population. We report three major findings: lymphocyte
              isolation fails to recover most cells and biases against certain
              subsets, residents greatly outnumber recirculating cells within
              non-lymphoid tissues, and memory subset homing to inflammation
              does not conform to previously hypothesized migration patterns.
              These results indicate that most host cells are surveyed for
              reinfection by segregated residents rather than by recirculating
              cells that migrate throughout the blood and body.",
  journal  = "Cell",
  volume   =  161,
  number   =  4,
  pages    = "737--749",
  month    =  may,
  year     =  2015,
  language = "en"
}

@ARTICLE{Birsoy2015-pc,
  title    = "An Essential Role of the Mitochondrial Electron Transport Chain
              in Cell Proliferation Is to Enable Aspartate Synthesis",
  author   = "Birsoy, K{\i}van{\c c} and Wang, Tim and Chen, Walter W and
              Freinkman, Elizaveta and Abu-Remaileh, Monther and Sabatini,
              David M",
  abstract = "The mitochondrial electron transport chain (ETC) enables many
              metabolic processes, but why its inhibition suppresses cell
              proliferation is unclear. It is also not well understood why
              pyruvate supplementation allows cells lacking ETC function to
              proliferate. We used a CRISPR-based genetic screen to identify
              genes whose loss sensitizes human cells to phenformin, a complex
              I inhibitor. The screen yielded GOT1, the cytosolic aspartate
              aminotransferase, loss of which kills cells upon ETC inhibition.
              GOT1 normally consumes aspartate to transfer electrons into
              mitochondria, but, upon ETC inhibition, it reverses to generate
              aspartate in the cytosol, which partially compensates for the
              loss of mitochondrial aspartate synthesis. Pyruvate stimulates
              aspartate synthesis in a GOT1-dependent fashion, which is
              required for pyruvate to rescue proliferation of cells with ETC
              dysfunction. Aspartate supplementation or overexpression of an
              aspartate transporter allows cells without ETC activity to
              proliferate. Thus, enabling aspartate synthesis is an essential
              role of the ETC in cell proliferation.",
  journal  = "Cell",
  volume   =  162,
  number   =  3,
  pages    = "540--551",
  month    =  jul,
  year     =  2015,
  language = "en"
}

@ARTICLE{Sullivan2015-bl,
  title    = "Supporting Aspartate Biosynthesis Is an Essential Function of
              Respiration in Proliferating Cells",
  author   = "Sullivan, Lucas B and Gui, Dan Y and Hosios, Aaron M and Bush,
              Lauren N and Freinkman, Elizaveta and Vander Heiden, Matthew G",
  abstract = "Mitochondrial respiration is important for cell proliferation;
              however, the specific metabolic requirements fulfilled by
              respiration to support proliferation have not been defined. Here,
              we show that a major role of respiration in proliferating cells
              is to provide electron acceptors for aspartate synthesis. This
              finding is consistent with the observation that cells lacking a
              functional respiratory chain are auxotrophic for pyruvate, which
              serves as an exogenous electron acceptor. Further, the pyruvate
              requirement can be fulfilled with an alternative electron
              acceptor, alpha-ketobutyrate, which provides cells neither carbon
              nor ATP. Alpha-ketobutyrate restores proliferation when
              respiration is inhibited, suggesting that an alternative electron
              acceptor can substitute for respiration to support proliferation.
              We find that electron acceptors are limiting for producing
              aspartate, and supplying aspartate enables proliferation of
              respiration deficient cells in the absence of exogenous electron
              acceptors. Together, these data argue a major function of
              respiration in proliferating cells is to support aspartate
              synthesis.",
  journal  = "Cell",
  volume   =  162,
  number   =  3,
  pages    = "552--563",
  month    =  jul,
  year     =  2015,
  language = "en"
}

@ARTICLE{Kleffel2015-gs,
  title    = "Melanoma {Cell-Intrinsic} {PD-1} Receptor Functions Promote Tumor
              Growth",
  author   = "Kleffel, Sonja and Posch, Christian and Barthel, Steven R and
              Mueller, Hansgeorg and Schlapbach, Christoph and Guenova,
              Emmanuella and Elco, Christopher P and Lee, Nayoung and Juneja,
              Vikram R and Zhan, Qian and Lian, Christine G and Thomi, Rahel
              and Hoetzenecker, Wolfram and Cozzio, Antonio and Dummer,
              Reinhard and Mihm, Jr, Martin C and Flaherty, Keith T and Frank,
              Markus H and Murphy, George F and Sharpe, Arlene H and Kupper,
              Thomas S and Schatton, Tobias",
  abstract = "Therapeutic antibodies targeting programmed cell death 1 (PD-1)
              activate tumor-specific immunity and have shown remarkable
              efficacy in the treatment of melanoma. Yet, little is known about
              tumor cell-intrinsic PD-1 pathway effects. Here, we show that
              murine and human melanomas contain PD-1-expressing cancer
              subpopulations and demonstrate that melanoma cell-intrinsic PD-1
              promotes tumorigenesis, even in mice lacking adaptive immunity.
              PD-1 inhibition on melanoma cells by RNAi, blocking antibodies,
              or mutagenesis of melanoma-PD-1 signaling motifs suppresses tumor
              growth in immunocompetent, immunocompromised, and PD-1-deficient
              tumor graft recipient mice. Conversely, melanoma-specific PD-1
              overexpression enhances tumorigenicity, as does engagement of
              melanoma-PD-1 by its ligand, PD-L1, whereas melanoma-PD-L1
              inhibition or knockout of host-PD-L1 attenuate growth of
              PD-1-positive melanomas. Mechanistically, the melanoma-PD-1
              receptor modulates downstream effectors of mTOR signaling. Our
              results identify melanoma cell-intrinsic functions of the
              PD-1:PD-L1 axis in tumor growth and suggest that blocking
              melanoma-PD-1 might contribute to the striking clinical efficacy
              of anti-PD-1 therapy.",
  journal  = "Cell",
  volume   =  162,
  number   =  6,
  pages    = "1242--1256",
  month    =  sep,
  year     =  2015,
  keywords = "Melanoma; PD-1; PD-L1; S6 ribosomal protein; antibody; blockade;
              immune checkpoint; mTOR signaling; p-S6; programmed cell death-1;
              therapy",
  language = "en"
}

@ARTICLE{Basu2016-uy,
  title    = "Cytotoxic {T} Cells Use Mechanical Force to Potentiate Target
              Cell Killing",
  author   = "Basu, Roshni and Whitlock, Benjamin M and Husson, Julien and Le
              Floc'h, Audrey and Jin, Weiyang and Oyler-Yaniv, Alon and
              Dotiwala, Farokh and Giannone, Gregory and Hivroz, Claire and
              Biais, Nicolas and Lieberman, Judy and Kam, Lance C and Huse,
              Morgan",
  abstract = "The immunological synapse formed between a cytotoxic T lymphocyte
              (CTL) and an infected or transformed target cell is a physically
              active structure capable of exerting mechanical force. Here, we
              investigated whether synaptic forces promote the destruction of
              target cells. CTLs kill by secreting toxic proteases and the pore
              forming protein perforin into the synapse. Biophysical
              experiments revealed a striking correlation between the magnitude
              of force exertion across the synapse and the speed of perforin
              pore formation on the target cell, implying that force
              potentiates cytotoxicity by enhancing perforin activity.
              Consistent with this interpretation, we found that increasing
              target cell tension augmented pore formation by perforin and
              killing by CTLs. Our data also indicate that CTLs coordinate
              perforin release and force exertion in space and time. These
              results reveal an unappreciated physical dimension to lymphocyte
              function and demonstrate that cells use mechanical forces to
              control the activity of outgoing chemical signals.",
  journal  = "Cell",
  volume   =  165,
  number   =  1,
  pages    = "100--110",
  month    =  mar,
  year     =  2016,
  language = "en"
}

@ARTICLE{Hugo2016-tn,
  title    = "Genomic and Transcriptomic Features of Response to {Anti-PD-1}
              Therapy in Metastatic Melanoma",
  author   = "Hugo, Willy and Zaretsky, Jesse M and Sun, Lu and Song, Chunying
              and Moreno, Blanca Homet and Hu-Lieskovan, Siwen and Berent-Maoz,
              Beata and Pang, Jia and Chmielowski, Bartosz and Cherry, Grace
              and Seja, Elizabeth and Lomeli, Shirley and Kong, Xiangju and
              Kelley, Mark C and Sosman, Jeffrey A and Johnson, Douglas B and
              Ribas, Antoni and Lo, Roger S",
  abstract = "PD-1 immune checkpoint blockade provides significant clinical
              benefits for melanoma patients. We analyzed the somatic mutanomes
              and transcriptomes of pretreatment melanoma biopsies to identify
              factors that may influence innate sensitivity or resistance to
              anti-PD-1 therapy. We find that overall high mutational loads
              associate with improved survival, and tumors from responding
              patients are enriched for mutations in the DNA repair gene BRCA2.
              Innately resistant tumors display a transcriptional signature
              (referred to as the IPRES, or innate anti-PD-1 resistance),
              indicating concurrent up-expression of genes involved in the
              regulation of mesenchymal transition, cell adhesion,
              extracellular matrix remodeling, angiogenesis, and wound healing.
              Notably, mitogen-activated protein kinase (MAPK)-targeted therapy
              (MAPK inhibitor) induces similar signatures in melanoma,
              suggesting that a non-genomic form of MAPK inhibitor resistance
              mediates cross-resistance to anti-PD-1 therapy. Validation of the
              IPRES in other independent tumor cohorts defines a transcriptomic
              subset across distinct types of advanced cancer. These findings
              suggest that attenuating the biological processes that underlie
              IPRES may improve anti-PD-1 response in melanoma and other cancer
              types.",
  journal  = "Cell",
  volume   =  165,
  number   =  1,
  pages    = "35--44",
  month    =  mar,
  year     =  2016,
  language = "en"
}

@ARTICLE{Liu2016-ls,
  title    = "On the Dependency of Cellular Protein Levels on {mRNA} Abundance",
  author   = "Liu, Yansheng and Beyer, Andreas and Aebersold, Ruedi",
  abstract = "The question of how genomic information is expressed to determine
              phenotypes is of central importance for basic and translational
              life science research and has been studied by transcriptomic and
              proteomic profiling. Here, we review the relationship between
              protein and mRNA levels under various scenarios, such as steady
              state, long-term state changes, and short-term adaptation,
              demonstrating the complexity of gene expression regulation,
              especially during dynamic transitions. The spatial and temporal
              variations of mRNAs, as well as the local availability of
              resources for protein biosynthesis, strongly influence the
              relationship between protein levels and their coding transcripts.
              We further discuss the buffering of mRNA fluctuations at the
              level of protein concentrations. We conclude that transcript
              levels by themselves are not sufficient to predict protein levels
              in many scenarios and to thus explain genotype-phenotype
              relationships and that high-quality data quantifying different
              levels of gene expression are indispensable for the complete
              understanding of biological processes.",
  journal  = "Cell",
  volume   =  165,
  number   =  3,
  pages    = "535--550",
  month    =  apr,
  year     =  2016,
  language = "en"
}

@ARTICLE{Buck2016-cl,
  title    = "Mitochondrial Dynamics Controls {T} Cell Fate through Metabolic
              Programming",
  author   = "Buck, Michael D and O'Sullivan, David and Klein Geltink, Ramon I
              and Curtis, Jonathan D and Chang, Chih-Hao and Sanin, David E and
              Qiu, Jing and Kretz, Oliver and Braas, Daniel and van der Windt,
              Gerritje J W and Chen, Qiongyu and Huang, Stanley Ching-Cheng and
              O'Neill, Christina M and Edelson, Brian T and Pearce, Edward J
              and Sesaki, Hiromi and Huber, Tobias B and Rambold, Angelika S
              and Pearce, Erika L",
  abstract = "Activated effector T (TE) cells augment anabolic pathways of
              metabolism, such as aerobic glycolysis, while memory T (TM) cells
              engage catabolic pathways, like fatty acid oxidation (FAO).
              However, signals that drive these differences remain unclear.
              Mitochondria are metabolic organelles that actively transform
              their ultrastructure. Therefore, we questioned whether
              mitochondrial dynamics controls T cell metabolism. We show that
              TE cells have punctate mitochondria, while TM cells maintain
              fused networks. The fusion protein Opa1 is required for TM, but
              not TE cells after infection, and enforcing fusion in TE cells
              imposes TM cell characteristics and enhances antitumor function.
              Our data suggest that, by altering cristae morphology, fusion in
              TM cells configures electron transport chain (ETC) complex
              associations favoring oxidative phosphorylation (OXPHOS) and FAO,
              while fission in TE cells leads to cristae expansion, reducing
              ETC efficiency and promoting aerobic glycolysis. Thus,
              mitochondrial remodeling is a signaling mechanism that instructs
              T cell metabolic programming.",
  journal  = "Cell",
  volume   =  166,
  number   =  1,
  pages    = "63--76",
  month    =  jun,
  year     =  2016,
  language = "en"
}

@ARTICLE{Singer2016-sd,
  title    = "A Distinct Gene Module for Dysfunction Uncoupled from Activation
              in {Tumor-Infiltrating} {T} Cells",
  author   = "Singer, Meromit and Wang, Chao and Cong, Le and Marjanovic,
              Nemanja D and Kowalczyk, Monika S and Zhang, Huiyuan and Nyman,
              Jackson and Sakuishi, Kaori and Kurtulus, Sema and Gennert, David
              and Xia, Junrong and Kwon, John Y H and Nevin, James and Herbst,
              Rebecca H and Yanai, Itai and Rozenblatt-Rosen, Orit and Kuchroo,
              Vijay K and Regev, Aviv and Anderson, Ana C",
  abstract = "Reversing the dysfunctional T cell state that arises in cancer
              and chronic viral infections is the focus of therapeutic
              interventions; however, current therapies are effective in only
              some patients and some tumor types. To gain a deeper molecular
              understanding of the dysfunctional T cell state, we analyzed
              population and single-cell RNA profiles of CD8(+)
              tumor-infiltrating lymphocytes (TILs) and used genetic
              perturbations to identify a distinct gene module for T cell
              dysfunction that can be uncoupled from T cell activation. This
              distinct dysfunction module is downstream of intracellular
              metallothioneins that regulate zinc metabolism and can be
              identified at single-cell resolution. We further identify Gata-3,
              a zinc-finger transcription factor in the dysfunctional module,
              as a regulator of dysfunction, and we use CRISPR-Cas9 genome
              editing to show that it drives a dysfunctional phenotype in
              CD8(+) TILs. Our results open novel avenues for targeting
              dysfunctional T cell states while leaving activation programs
              intact.",
  journal  = "Cell",
  volume   =  166,
  number   =  6,
  pages    = "1500--1511.e9",
  month    =  sep,
  year     =  2016,
  keywords = "CD8; CRISPR/Cas9; Gata-3; T cell; TILs; cancer; dysfunction;
              exhaustion; metallothioneins; single-cell; tumor; zinc",
  language = "en"
}

@ARTICLE{Gao2016-vv,
  title    = "Loss of {IFN-$\gamma$} Pathway Genes in Tumor Cells as a
              Mechanism of Resistance to {Anti-CTLA-4} Therapy",
  author   = "Gao, Jianjun and Shi, Lewis Zhichang and Zhao, Hao and Chen,
              Jianfeng and Xiong, Liangwen and He, Qiuming and Chen, Tenghui
              and Roszik, Jason and Bernatchez, Chantale and Woodman, Scott E
              and Chen, Pei-Ling and Hwu, Patrick and Allison, James P and
              Futreal, Andrew and Wargo, Jennifer A and Sharma, Padmanee",
  abstract = "Antibody blockade of the inhibitory CTLA-4 pathway has led to
              clinical benefit in a subset of patients with metastatic
              melanoma. Anti-CTLA-4 enhances T cell responses, including
              production of IFN-$\gamma$, which is a critical cytokine for host
              immune responses. However, the role of IFN-$\gamma$ signaling in
              tumor cells in the setting of anti-CTLA-4 therapy remains
              unknown. Here, we demonstrate that patients identified as
              non-responders to anti-CTLA-4 (ipilimumab) have tumors with
              genomic defects in IFN-$\gamma$ pathway genes. Furthermore, mice
              bearing melanoma tumors with knockdown of IFN-$\gamma$ receptor 1
              (IFNGR1) have impaired tumor rejection upon anti-CTLA-4 therapy.
              These data highlight that loss of the IFN-$\gamma$ signaling
              pathway is associated with primary resistance to anti-CTLA-4
              therapy. Our findings demonstrate the importance of tumor genomic
              data, especially IFN-$\gamma$ related genes, as prognostic
              information for patients selected to receive treatment with
              immune checkpoint therapy.",
  journal  = "Cell",
  volume   =  167,
  number   =  2,
  pages    = "397--404.e9",
  month    =  oct,
  year     =  2016,
  keywords = "IFN-$\gamma$ signaling; Melanoma; anti-CTLA-4; copy-number
              alteration; ipilimumab; primary resistance",
  language = "en"
}

@ARTICLE{Benci2016-ep,
  title    = "Tumor Interferon Signaling Regulates a Multigenic Resistance
              Program to Immune Checkpoint Blockade",
  author   = "Benci, Joseph L and Xu, Bihui and Qiu, Yu and Wu, Tony J and
              Dada, Hannah and Twyman-Saint Victor, Christina and Cucolo, Lisa
              and Lee, David S M and Pauken, Kristen E and Huang, Alexander C
              and Gangadhar, Tara C and Amaravadi, Ravi K and Schuchter, Lynn M
              and Feldman, Michael D and Ishwaran, Hemant and Vonderheide,
              Robert H and Maity, Amit and Wherry, E John and Minn, Andy J",
  abstract = "Therapeutic blocking of the PD1 pathway results in significant
              tumor responses, but resistance is common. We demonstrate that
              prolonged interferon signaling orchestrates PDL1-dependent and
              PDL1-independent resistance to immune checkpoint blockade (ICB)
              and to combinations such as radiation plus anti-CTLA4. Persistent
              type II interferon signaling allows tumors to acquire
              STAT1-related epigenomic changes and augments expression of
              interferon-stimulated genes and ligands for multiple T cell
              inhibitory receptors. Both type I and II interferons maintain
              this resistance program. Crippling the program genetically or
              pharmacologically interferes with multiple inhibitory pathways
              and expands distinct T cell populations with improved function
              despite expressing markers of severe exhaustion. Consequently,
              tumors resistant to multi-agent ICB are rendered responsive to
              ICB monotherapy. Finally, we observe that biomarkers for
              interferon-driven resistance associate with clinical progression
              after anti-PD1 therapy. Thus, the duration of tumor interferon
              signaling augments adaptive resistance and inhibition of the
              interferon response bypasses requirements for combinatorial ICB
              therapies.",
  journal  = "Cell",
  volume   =  167,
  number   =  6,
  pages    = "1540--1554.e12",
  month    =  dec,
  year     =  2016,
  language = "en"
}

@ARTICLE{Vander_Heiden2017-bs,
  title    = "Understanding the Intersections between Metabolism and Cancer
              Biology",
  author   = "Vander Heiden, Matthew G and DeBerardinis, Ralph J",
  abstract = "Transformed cells adapt metabolism to support tumor initiation
              and progression. Specific metabolic activities can participate
              directly in the process of transformation or support the
              biological processes that enable tumor growth. Exploiting cancer
              metabolism for clinical benefit requires defining the pathways
              that are limiting for cancer progression and understanding the
              context specificity of metabolic preferences and liabilities in
              malignant cells. Progress toward answering these questions is
              providing new insight into cancer biology and can guide the more
              effective targeting of metabolism to help patients.",
  journal  = "Cell",
  volume   =  168,
  number   =  4,
  pages    = "657--669",
  month    =  feb,
  year     =  2017,
  language = "en"
}

@ARTICLE{Kim2018-bw,
  title    = "Chemoresistance Evolution in {Triple-Negative} Breast Cancer
              Delineated by {Single-Cell} Sequencing",
  author   = "Kim, Charissa and Gao, Ruli and Sei, Emi and Brandt, Rachel and
              Hartman, Johan and Hatschek, Thomas and Crosetto, Nicola and
              Foukakis, Theodoros and Navin, Nicholas E",
  abstract = "Triple-negative breast cancer (TNBC) is an aggressive subtype
              that frequently develops resistance to chemotherapy. An
              unresolved question is whether resistance is caused by the
              selection of rare pre-existing clones or alternatively through
              the acquisition of new genomic aberrations. To investigate this
              question, we applied single-cell DNA and RNA sequencing in
              addition to bulk exome sequencing to profile longitudinal samples
              from 20 TNBC patients during neoadjuvant chemotherapy (NAC).
              Deep-exome sequencing identified 10 patients in which NAC led to
              clonal extinction and 10 patients in which clones persisted after
              treatment. In 8 patients, we performed a more detailed study
              using single-cell DNA sequencing to analyze 900 cells and
              single-cell RNA sequencing to analyze 6,862 cells. Our data
              showed that resistant genotypes were pre-existing and adaptively
              selected by NAC, while transcriptional profiles were acquired by
              reprogramming in response to chemotherapy in TNBC patients.",
  journal  = "Cell",
  volume   =  173,
  number   =  4,
  pages    = "879--893.e13",
  month    =  may,
  year     =  2018,
  keywords = "breast cancer genomics; cancer aneuploidy; chemotherapy;
              copy-number evolution; intratumor heterogeneity; single-cell
              sequencing; therapy resistance; triple-negative breast cancer;
              tumor evolution",
  language = "en"
}

@ARTICLE{Bakhoum2018-ai,
  title    = "The Multifaceted Role of Chromosomal Instability in Cancer and
              Its Microenvironment",
  author   = "Bakhoum, Samuel F and Cantley, Lewis C",
  abstract = "Chromosomal instability (CIN) is a hallmark of human cancer, and
              it is associated with poor prognosis, metastasis, and therapeutic
              resistance. CIN results from errors in chromosome segregation
              during mitosis, leading to structural and numerical chromosomal
              abnormalities. In addition to generating genomic heterogeneity
              that acts as a substrate for natural selection, CIN promotes
              inflammatory signaling by introducing double-stranded DNA into
              the cytosol, engaging the cGAS-STING anti-viral pathway. These
              multipronged effects distinguish CIN as a central driver of tumor
              evolution and as a genomic source for the crosstalk between the
              tumor and its microenvironment, in the course of immune editing
              and evasion.",
  journal  = "Cell",
  volume   =  174,
  number   =  6,
  pages    = "1347--1360",
  month    =  sep,
  year     =  2018,
  language = "en"
}

@ARTICLE{Li2019-cm,
  title    = "Dysfunctional {CD8} {T} Cells Form a Proliferative, Dynamically
              Regulated Compartment within Human Melanoma",
  author   = "Li, Hanjie and van der Leun, Anne M and Yofe, Ido and Lubling,
              Yaniv and Gelbard-Solodkin, Dikla and van Akkooi, Alexander C J
              and van den Braber, Marlous and Rozeman, Elisa A and Haanen, John
              B A G and Blank, Christian U and Horlings, Hugo M and David, Eyal
              and Baran, Yael and Bercovich, Akhiad and Lifshitz, Aviezer and
              Schumacher, Ton N and Tanay, Amos and Amit, Ido",
  abstract = "Tumor immune cell compositions play a major role in response to
              immunotherapy, but the heterogeneity and dynamics of immune
              infiltrates in human cancer lesions remain poorly characterized.
              Here, we identify conserved intratumoral CD4 and CD8 T cell
              behaviors in scRNA-seq data from 25 melanoma patients. We
              discover a large population of CD8 T cells showing continuous
              progression from an early effector ``transitional'' into a
              dysfunctional T cell state. CD8 T cells that express a complete
              cytotoxic gene set are rare, and TCR sharing data suggest their
              independence from the transitional and dysfunctional cell states.
              Notably, we demonstrate that dysfunctional T cells are the major
              intratumoral proliferating immune cell compartment and that the
              intensity of the dysfunctional signature is associated with tumor
              reactivity. Our data demonstrate that CD8 T cells previously
              defined as exhausted are in fact a highly proliferating, clonal,
              and dynamically differentiating cell population within the human
              tumor microenvironment.",
  journal  = "Cell",
  volume   =  176,
  number   =  4,
  pages    = "775--789.e18",
  month    =  feb,
  year     =  2019,
  keywords = "T cell dysfunction; immune checkpoints; immunology;
              immunotherapy; melanoma; single-cell RNA-seq; tumor immunology;
              tumor microenvironment; tumor reactivity",
  language = "en"
}

@ARTICLE{Nguyen2022-dg,
  title    = "Genomic characterization of metastatic patterns from prospective
              clinical sequencing of 25,000 patients",
  author   = "Nguyen, Bastien and Fong, Christopher and Luthra, Anisha and
              Smith, Shaleigh A and DiNatale, Renzo G and Nandakumar, Subhiksha
              and Walch, Henry and Chatila, Walid K and Madupuri, Ramyasree and
              Kundra, Ritika and Bielski, Craig M and Mastrogiacomo, Brooke and
              Donoghue, Mark T A and Boire, Adrienne and Chandarlapaty, Sarat
              and Ganesh, Karuna and Harding, James J and Iacobuzio-Donahue,
              Christine A and Razavi, Pedram and Reznik, Ed and Rudin, Charles
              M and Zamarin, Dmitriy and Abida, Wassim and Abou-Alfa, Ghassan K
              and Aghajanian, Carol and Cercek, Andrea and Chi, Ping and
              Feldman, Darren and Ho, Alan L and Iyer, Gopakumar and Janjigian,
              Yelena Y and Morris, Michael and Motzer, Robert J and O'Reilly,
              Eileen M and Postow, Michael A and Raj, Nitya P and Riely,
              Gregory J and Robson, Mark E and Rosenberg, Jonathan E and
              Safonov, Anton and Shoushtari, Alexander N and Tap, William and
              Teo, Min Yuen and Varghese, Anna M and Voss, Martin and Yaeger,
              Rona and Zauderer, Marjorie G and Abu-Rustum, Nadeem and
              Garcia-Aguilar, Julio and Bochner, Bernard and Hakimi, Abraham
              and Jarnagin, William R and Jones, David R and Molena, Daniela
              and Morris, Luc and Rios-Doria, Eric and Russo, Paul and Singer,
              Samuel and Strong, Vivian E and Chakravarty, Debyani and
              Ellenson, Lora H and Gopalan, Anuradha and Reis-Filho, Jorge S
              and Weigelt, Britta and Ladanyi, Marc and Gonen, Mithat and Shah,
              Sohrab P and Massague, Joan and Gao, Jianjiong and Zehir, Ahmet
              and Berger, Michael F and Solit, David B and Bakhoum, Samuel F
              and Sanchez-Vega, Francisco and Schultz, Nikolaus",
  abstract = "Metastatic progression is the main cause of death in cancer
              patients, whereas the underlying genomic mechanisms driving
              metastasis remain largely unknown. Here, we assembled MSK-MET, a
              pan-cancer cohort of over 25,000 patients with metastatic
              diseases. By analyzing genomic and clinical data from this
              cohort, we identified associations between genomic alterations
              and patterns of metastatic dissemination across 50 tumor types.
              We found that chromosomal instability is strongly correlated with
              metastatic burden in some tumor types, including prostate
              adenocarcinoma, lung adenocarcinoma, and HR+/HER2+ breast ductal
              carcinoma, but not in others, including colorectal cancer and
              high-grade serous ovarian cancer, where copy-number alteration
              patterns may be established early in tumor development. We also
              identified somatic alterations associated with metastatic burden
              and specific target organs. Our data offer a valuable resource
              for the investigation of the biological basis for metastatic
              spread and highlight the complex role of chromosomal instability
              in cancer progression.",
  journal  = "Cell",
  volume   =  185,
  number   =  3,
  pages    = "563--575.e11",
  month    =  feb,
  year     =  2022,
  keywords = "DNA sequencing; cancer; clinical sequencing; genomics;
              metastasis; molecular profiling; mutations; next-generation
              sequencing; organotropism; pan-cancer",
  language = "en"
}

@ARTICLE{Fustin2012-pq,
  title    = "Rhythmic nucleotide synthesis in the liver: temporal segregation
              of metabolites",
  author   = "Fustin, Jean-Michel and Doi, Masao and Yamada, Hiroyuki and
              Komatsu, Rie and Shimba, Shigeki and Okamura, Hitoshi",
  abstract = "The synthesis of nucleotides in the body is centrally controlled
              by the liver, via salvage or de novo synthesis. We reveal a
              pervasive circadian influence on hepatic nucleotide metabolism,
              from rhythmic gene expression of rate-limiting enzymes to
              oscillating nucleotide metabolome in wild-type (WT) mice. Genetic
              disruption of the hepatic clock leads to aberrant expression of
              these enzymes, together with anomalous nucleotide rhythms, such
              as constant low levels of ATP with an excess in uric acid, the
              degradation product of purines. These results clearly demonstrate
              that the hepatic circadian clock orchestrates nucleotide
              synthesis and degradation. This circadian metabolome timetable,
              obtained using state-of-the-art capillary electrophoresis
              time-of-flight mass spectrometry, will guide further
              investigations in nucleotide metabolism-related disorders.",
  journal  = "Cell Rep.",
  volume   =  1,
  number   =  4,
  pages    = "341--349",
  month    =  apr,
  year     =  2012,
  language = "en"
}

@ARTICLE{Labuschagne2014-we,
  title    = "Serine, but not glycine, supports one-carbon metabolism and
              proliferation of cancer cells",
  author   = "Labuschagne, Christiaan F and van den Broek, Niels J F and
              Mackay, Gillian M and Vousden, Karen H and Maddocks, Oliver D K",
  abstract = "Previous work has shown that some cancer cells are highly
              dependent on serine/glycine uptake for proliferation. Although
              serine and glycine can be interconverted and either might be used
              for nucleotide synthesis and one-carbon metabolism, we show that
              exogenous glycine cannot replace serine to support cancer cell
              proliferation. Cancer cells selectively consumed exogenous
              serine, which was converted to intracellular glycine and
              one-carbon units for building nucleotides. Restriction of
              exogenous glycine or depletion of the glycine cleavage system did
              not impede proliferation. In the absence of serine, uptake of
              exogenous glycine was unable to support nucleotide synthesis.
              Indeed, higher concentrations of glycine inhibited proliferation.
              Under these conditions, glycine was converted to serine, a
              reaction that would deplete the one-carbon pool. Providing
              one-carbon units by adding formate rescued nucleotide synthesis
              and growth of glycine-fed cells. We conclude that nucleotide
              synthesis and cancer cell proliferation are supported by
              serine--rather than glycine--consumption.",
  journal  = "Cell Rep.",
  volume   =  7,
  number   =  4,
  pages    = "1248--1258",
  month    =  may,
  year     =  2014,
  language = "en"
}

@ARTICLE{Vasconcelos2015-mm,
  title    = "Individual Human Cytotoxic {T} Lymphocytes Exhibit Intraclonal
              Heterogeneity during Sustained Killing",
  author   = "Vasconcelos, Zilton and M{\"u}ller, Sabina and Guipouy, Delphine
              and Yu, Wong and Christophe, Claire and Gadat, S{\'e}bastien and
              Valitutti, Salvatore and Dupr{\'e}, Lo{\"\i}c",
  abstract = "The killing of antigen-bearing cells by clonal populations of
              cytotoxic T lymphocytes (CTLs) is thought to be a rapid
              phenomenon executed uniformly by individual CTLs. We combined
              bulk and single-CTL killing assays over a prolonged time period
              to provide the killing statistics of clonal human CTLs against an
              excess of target cells. Our data reveal efficiency in sustained
              killing at the population level, which relied on a highly
              heterogeneous multiple killing performance at the individual
              level. Although intraclonal functional heterogeneity was a stable
              trait in clonal populations, it was reset in the progeny of
              individual CTLs. In-depth mathematical analysis of individual CTL
              killing data revealed a substantial proportion of high-rate
              killer CTLs with burst killing activity. Importantly, such
              activity was delayed and required activation with strong
              antigenic stimulation. Our study implies that functional
              heterogeneity allows CTL populations to calibrate prolonged
              cytotoxic activity to the size of target cell populations.",
  journal  = "Cell Rep.",
  volume   =  11,
  number   =  9,
  pages    = "1474--1485",
  month    =  jun,
  year     =  2015,
  language = "en"
}

@ARTICLE{Laughney2015-qk,
  title    = "Dynamics of Tumor Heterogeneity Derived from Clonal Karyotypic
              Evolution",
  author   = "Laughney, Ashley M and Elizalde, Sergi and Genovese, Giulio and
              Bakhoum, Samuel F",
  abstract = "Numerical chromosomal instability is a ubiquitous feature of
              human neoplasms. Due to experimental limitations, fundamental
              characteristics of karyotypic changes in cancer are poorly
              understood. Using an experimentally inspired stochastic model,
              based on the potency and chromosomal distribution of oncogenes
              and tumor suppressor genes, we show that cancer cells have
              evolved to exist within a narrow range of chromosome
              missegregation rates that optimizes phenotypic heterogeneity and
              clonal survival. Departure from this range reduces clonal fitness
              and limits subclonal diversity. Mapping of the aneuploid fitness
              landscape reveals a highly favorable, commonly observed,
              near-triploid state onto which evolving diploid- and
              tetraploid-derived populations spontaneously converge, albeit at
              a much lower fitness cost for the latter. Finally, by analyzing
              1,368 chromosomal translocation events in five human cancers, we
              find that karyotypic evolution also shapes chromosomal
              translocation patterns by selecting for more oncogenic derivative
              chromosomes. Thus, chromosomal instability can generate the
              heterogeneity required for Darwinian tumor evolution.",
  journal  = "Cell Rep.",
  volume   =  12,
  number   =  5,
  pages    = "809--820",
  month    =  aug,
  year     =  2015,
  language = "en"
}

@ARTICLE{Kafri2016-fg,
  title    = "The Cost of Protein Production",
  author   = "Kafri, Moshe and Metzl-Raz, Eyal and Jona, Ghil and Barkai, Naama",
  abstract = "The economy of protein production is central to cell physiology,
              being intimately linked with cell division rate and cell size.
              Attempts to model cellular physiology are limited by the scarcity
              of experimental data defining the molecular processes limiting
              protein expression. Here, we distinguish the relative
              contribution of gene transcription and protein translation to the
              slower proliferation of budding yeast producing excess levels of
              unneeded proteins. In contrast to widely held assumptions,
              rapidly growing cells are not universally limited by ribosome
              content. Rather, transcription dominates cost under some
              conditions (e.g., low phosphate), translation in others (e.g.,
              low nitrogen), and both in other conditions (e.g., rich media).
              Furthermore, cells adapted to enforced protein production by
              becoming larger and increasing their endogenous protein levels,
              suggesting limited competition for common resources. We propose
              that rapidly growing cells do not exhaust their resources to
              maximize growth but maintain sufficient reserves to accommodate
              changing requirements.",
  journal  = "Cell Rep.",
  volume   =  14,
  number   =  1,
  pages    = "22--31",
  month    =  jan,
  year     =  2016,
  keywords = "budding yeast; fitness cost; protein burden; protein synthesis",
  language = "en"
}

@ARTICLE{Charoentong2017-lo,
  title    = "Pan-cancer Immunogenomic Analyses Reveal
              {Genotype-Immunophenotype} Relationships and Predictors of
              Response to Checkpoint Blockade",
  author   = "Charoentong, Pornpimol and Finotello, Francesca and Angelova,
              Mihaela and Mayer, Clemens and Efremova, Mirjana and Rieder,
              Dietmar and Hackl, Hubert and Trajanoski, Zlatko",
  abstract = "The Cancer Genome Atlas revealed the genomic landscapes of human
              cancers. In parallel, immunotherapy is transforming the treatment
              of advanced cancers. Unfortunately, the majority of patients do
              not respond to immunotherapy, making the identification of
              predictive markers and the mechanisms of resistance an area of
              intense research. To increase our understanding of tumor-immune
              cell interactions, we characterized the intratumoral immune
              landscapes and the cancer antigenomes from 20 solid cancers and
              created The Cancer Immunome Atlas (https://tcia.at/). Cellular
              characterization of the immune infiltrates showed that tumor
              genotypes determine immunophenotypes and tumor escape mechanisms.
              Using machine learning, we identified determinants of tumor
              immunogenicity and developed a scoring scheme for the
              quantification termed immunophenoscore. The immunophenoscore was
              a superior predictor of response to anti-cytotoxic T lymphocyte
              antigen-4 (CTLA-4) and anti-programmed cell death protein 1
              (anti-PD-1) antibodies in two independent validation cohorts. Our
              findings and this resource may help inform cancer immunotherapy
              and facilitate the development of precision immuno-oncology.",
  journal  = "Cell Rep.",
  volume   =  18,
  number   =  1,
  pages    = "248--262",
  month    =  jan,
  year     =  2017,
  keywords = "cancer-germline antigens; neoantigens; predictive marker;
              tumor-infiltrating lymphocytes",
  language = "en"
}

@ARTICLE{Garcia-Diaz2017-ig,
  title    = "Interferon Receptor Signaling Pathways Regulating {PD-L1} and
              {PD-L2} Expression",
  author   = "Garcia-Diaz, Angel and Shin, Daniel Sanghoon and Moreno, Blanca
              Homet and Saco, Justin and Escuin-Ordinas, Helena and Rodriguez,
              Gabriel Abril and Zaretsky, Jesse M and Sun, Lu and Hugo, Willy
              and Wang, Xiaoyan and Parisi, Giulia and Saus, Cristina Puig and
              Torrejon, Davis Y and Graeber, Thomas G and Comin-Anduix, Begonya
              and Hu-Lieskovan, Siwen and Damoiseaux, Robert and Lo, Roger S
              and Ribas, Antoni",
  abstract = "PD-L1 and PD-L2 are ligands for the PD-1 immune inhibiting
              checkpoint that can be induced in tumors by interferon exposure,
              leading to immune evasion. This process is important for
              immunotherapy based on PD-1 blockade. We examined the specific
              molecules involved in interferon-induced signaling that regulates
              PD-L1 and PD-L2 expression in melanoma cells. These studies
              revealed that the
              interferon-gamma-JAK1/JAK2-STAT1/STAT2/STAT3-IRF1 axis primarily
              regulates PD-L1 expression, with IRF1 binding to its promoter.
              PD-L2 responded equally to interferon beta and gamma and is
              regulated through both IRF1 and STAT3, which bind to the PD-L2
              promoter. Analysis of biopsy specimens from patients with
              melanoma confirmed interferon signature enrichment and
              upregulation of gene targets for STAT1/STAT2/STAT3 and IRF1 in
              anti-PD-1-responding tumors. Therefore, these studies map the
              signaling pathway of interferon-gamma-inducible PD-1 ligand
              expression.",
  journal  = "Cell Rep.",
  volume   =  19,
  number   =  6,
  pages    = "1189--1201",
  month    =  may,
  year     =  2017,
  keywords = "IRF1; JAK-STATs; PD-1; PD-L1; PD-L2; immunotherapy; interferon
              receptor signaling pathways; melanoma",
  language = "en"
}

@ARTICLE{Wang2020-ip,
  title    = "{SCOPE}: A Normalization and {Copy-Number} Estimation Method for
              {Single-Cell} {DNA} Sequencing",
  author   = "Wang, Rujin and Lin, Dan-Yu and Jiang, Yuchao",
  abstract = "Whole-genome single-cell DNA sequencing (scDNA-seq) enables
              characterization of copy-number profiles at the cellular level.
              We propose SCOPE, a normalization and copy-number estimation
              method for the noisy scDNA-seq data. SCOPE's main features
              include the following: (1) a Poisson latent factor model for
              normalization, which borrows information across cells and regions
              to estimate bias, using in silico identified negative control
              cells; (2) an expectation-maximization algorithm embedded in the
              normalization step, which accounts for the aberrant copy-number
              changes and allows direct ploidy estimation without the need for
              post hoc adjustment; and (3) a cross-sample segmentation
              procedure to identify breakpoints that are shared across cells
              with the same genetic background. We evaluate SCOPE on a diverse
              set of scDNA-seq data in cancer genomics and show that SCOPE
              offers accurate copy-number estimates and successfully
              reconstructs subclonal structure. A record of this paper's
              transparent peer review process is included in the Supplemental
              Information.",
  journal  = "Cell Syst",
  volume   =  10,
  number   =  5,
  pages    = "445--452.e6",
  month    =  may,
  year     =  2020,
  keywords = "cancer genomics; copy number aberration; copy number variation;
              normalization; single-cell DNA sequencing; tumor heterogeneity",
  language = "en"
}

@ARTICLE{Luengo2017-zt,
  title    = "Targeting Metabolism for Cancer Therapy",
  author   = "Luengo, Alba and Gui, Dan Y and Vander Heiden, Matthew G",
  abstract = "Metabolic reprogramming contributes to tumor development and
              introduces metabolic liabilities that can be exploited to treat
              cancer. Chemotherapies targeting metabolism have been effective
              cancer treatments for decades, and the success of these therapies
              demonstrates that a therapeutic window exists to target malignant
              metabolism. New insights into the differential metabolic
              dependencies of tumors have provided novel therapeutic strategies
              to exploit altered metabolism, some of which are being evaluated
              in preclinical models or clinical trials. Here, we review our
              current understanding of cancer metabolism and discuss how this
              might guide treatments targeting the metabolic requirements of
              tumor cells.",
  journal  = "Cell Chem Biol",
  volume   =  24,
  number   =  9,
  pages    = "1161--1180",
  month    =  sep,
  year     =  2017,
  keywords = "cancer metabolism; cell metabolism; chemotherapy",
  language = "en"
}

@ARTICLE{Mahoney2015-qh,
  title    = "The Next {Immune-Checkpoint} Inhibitors: {PD-1/PD-L1} Blockade in
              Melanoma",
  author   = "Mahoney, Kathleen M and Freeman, Gordon J and McDermott, David F",
  abstract = "PURPOSE: Blocking the interaction between the programmed cell
              death (PD)-1 protein and one of its ligands, PD-L1, has been
              reported to have impressive antitumor responses. Therapeutics
              targeting this pathway are currently in clinical trials.
              Pembrolizumab and nivolumab are the first of this anti-PD-1
              pathway family of checkpoint inhibitors to gain accelerated
              approval from the US Food and Drug Administration (FDA) for the
              treatment of ipilimumab-refractory melanoma. Nivolumab has been
              associated with improved overall survival compared with
              dacarbazine in patients with previously untreated wild-type
              serine/threonine-protein kinase B-raf proto-oncogene BRAF
              melanoma. Although the most mature data are in the treatment of
              melanoma, the FDA has granted approval of nivolumab for squamous
              cell lung cancer and the breakthrough therapy designation to
              immune- checkpoint inhibitors for use in other cancers:
              nivolumab, an anti-PD-1 monoclonal antibody, for Hodgkin
              lymphoma, and MPDL-3280A, an anti-PD-L1 monoclonal antibody, for
              bladder cancer and non-small cell lung cancer. Here we review the
              literature on PD-1 and PD-L1 blockade and focus on the reported
              clinical studies that have included patients with melanoma.
              METHODS: PubMed was searched to identify relevant clinical
              studies of PD-1/PD-L1-targeted therapies in melanoma. A review of
              data from the current trials on clinicaltrial.gov was
              incorporated, as well as data presented in abstracts at the 2014
              annual meeting of the American Society of Clinical Oncology,
              given the limited number of published clinical trials on this
              topic. FINDINGS: The anti-PD-1 and anti-PD-L1 agents have been
              reported to have impressive antitumor effects in several
              malignancies, including melanoma. The greatest clinical activity
              in unselected patients has been seen in melanoma. Tumor
              expression of PD-L1 is a suggestive, but inadequate, biomarker
              predictive of response to immune-checkpoint blockade. However,
              tumors expressing little or no PD-L1 are less likely to respond
              to PD-1 pathway blockade. Combination checkpoint blockade with
              PD-1 plus cytotoxic T-lymphocyte antigen (CTLA)-4 blockade
              appears to improve response rates in patients who are less likely
              to respond to single-checkpoint blockade. Toxicity with PD-1
              blocking agents is less than the toxicity with previous
              immunotherapies (eg, interleukin 2, CTLA-4 blockade). Certain
              adverse events can be severe and potentially life threatening,
              but most can be prevented or reversed with close monitoring and
              appropriate management. IMPLICATIONS: This family of
              immune-checkpoint inhibitors benefits not only patients with
              metastatic melanoma but also those with historically less
              responsive tumor types. Although a subset of patients responds to
              single-agent blockade, the initial trial of checkpoint-inhibitor
              combinations has reported a potential to improve response rates.
              Combination therapies appear to be a means of increasing response
              rates, albeit with increased immune-related adverse events. As
              these treatments become available to patients, education
              regarding the recognition and management of immune-related
              effects of immune-checkpoint blockade will be essential for
              maximizing clinical benefit.",
  journal  = "Clin. Ther.",
  volume   =  37,
  number   =  4,
  pages    = "764--782",
  month    =  apr,
  year     =  2015,
  keywords = "MPDL3280A; PD-1; PD-L1; melanoma; nivolumab; pembrolizumab;
              pidilizumab; programmed cell death 1",
  language = "en"
}

@ARTICLE{Le2012-hn,
  title    = "Glucose-independent glutamine metabolism via {TCA} cycling for
              proliferation and survival in {B} cells",
  author   = "Le, Anne and Lane, Andrew N and Hamaker, Max and Bose, Sminu and
              Gouw, Arvin and Barbi, Joseph and Tsukamoto, Takashi and Rojas,
              Camilio J and Slusher, Barbara S and Zhang, Haixia and Zimmerman,
              Lisa J and Liebler, Daniel C and Slebos, Robbert J C and
              Lorkiewicz, Pawel K and Higashi, Richard M and Fan, Teresa W M
              and Dang, Chi V",
  abstract = "Because MYC plays a causal role in many human cancers, including
              those with hypoxic and nutrient-poor tumor microenvironments, we
              have determined the metabolic responses of a MYC-inducible human
              Burkitt lymphoma model P493 cell line to aerobic and hypoxic
              conditions, and to glucose deprivation, using stable
              isotope-resolved metabolomics. Using [U-(13)C]-glucose as the
              tracer, both glucose consumption and lactate production were
              increased by MYC expression and hypoxia. Using
              [U-(13)C,(15)N]-glutamine as the tracer, glutamine import and
              metabolism through the TCA cycle persisted under hypoxia, and
              glutamine contributed significantly to citrate carbons. Under
              glucose deprivation, glutamine-derived fumarate, malate, and
              citrate were significantly increased. Their (13)C-labeling
              patterns demonstrate an alternative energy-generating
              glutaminolysis pathway involving a glucose-independent TCA cycle.
              The essential role of glutamine metabolism in cell survival and
              proliferation under hypoxia and glucose deficiency makes them
              susceptible to the glutaminase inhibitor BPTES and hence could be
              targeted for cancer therapy.",
  journal  = "Cell Metab.",
  volume   =  15,
  number   =  1,
  pages    = "110--121",
  month    =  jan,
  year     =  2012,
  language = "en"
}

@ARTICLE{Yuneva2012-ex,
  title    = "The metabolic profile of tumors depends on both the responsible
              genetic lesion and tissue type",
  author   = "Yuneva, Mariia O and Fan, Teresa W M and Allen, Thaddeus D and
              Higashi, Richard M and Ferraris, Dana V and Tsukamoto, Takashi
              and Mat{\'e}s, Jos{\'e} M and Alonso, Francisco J and Wang,
              Chunmei and Seo, Youngho and Chen, Xin and Bishop, J Michael",
  abstract = "The altered metabolism of tumors has been considered a target for
              anticancer therapy. However, the relationship between distinct
              tumor-initiating lesions and anomalies of tumor metabolism in
              vivo has not been addressed. We report that MYC-induced mouse
              liver tumors significantly increase both glucose and glutamine
              catabolism, whereas MET-induced liver tumors use glucose to
              produce glutamine. Increased glutamine catabolism in MYC-induced
              liver tumors is associated with decreased levels of glutamine
              synthetase (Glul) and the switch from Gls2 to Gls1 glutaminase.
              In contrast to liver tumors, MYC-induced lung tumors display
              increased expression of both Glul and Gls1 and accumulate
              glutamine. We also show that inhibition of Gls1 kills cells that
              overexpress MYC and catabolize glutamine. Our results suggest
              that the metabolic profiles of tumors are likely to depend on
              both the genotype and tissue of origin and have implications
              regarding the design of therapies targeting tumor metabolism.",
  journal  = "Cell Metab.",
  volume   =  15,
  number   =  2,
  pages    = "157--170",
  month    =  feb,
  year     =  2012,
  language = "en"
}

@ARTICLE{Crespo2013-ke,
  title    = "{T} cell anergy, exhaustion, senescence, and stemness in the
              tumor microenvironment",
  author   = "Crespo, Joel and Sun, Haoyu and Welling, Theodore H and Tian,
              Zhigang and Zou, Weiping",
  abstract = "Human tumors progress despite the presence of tumor associated
              antigen (TAA)-specific T cells. Many different molecular and
              cellular mechanisms contribute to the failure of T cells to
              eradicate the tumor. These include immune suppressive networks
              that impair ongoing T cell function and enable tumor escape.
              Recent studies have started to reveal the nature of effector T
              cells in the tumor microenvironment. In this article we discuss T
              cell anergy, exhaustion, senescence, and stemness, and review the
              phenotype of dysfunctional T cell subsets and the underlying
              molecular mechanisms in the tumor microenvironments. We suggest
              that targeting T cell dysfunctional mechanisms and
              introducing/promoting T cell stemness are important approaches to
              treat patients with cancer.",
  journal  = "Curr. Opin. Immunol.",
  volume   =  25,
  number   =  2,
  pages    = "214--221",
  month    =  apr,
  year     =  2013,
  language = "en"
}

@ARTICLE{Wieland2021-xb,
  title    = "On structural and practical identifiability",
  author   = "Wieland, Franz-Georg and Hauber, Adrian L and Rosenblatt, Marcus
              and T{\"o}nsing, Christian and Timmer, Jens",
  abstract = "We discuss issues of structural and practical identifiability of
              partially observed differential equations, which are often
              applied in systems biology. The development of mathematical
              methods to investigate structural nonidentifiability has a long
              tradition. Computationally efficient methods to detect and cure
              it have been developed recently. Practical nonidentifiability, on
              the other hand, has not been investigated at the same
              conceptually clear level. We argue that practical identifiability
              is more challenging than structural identifiability when it comes
              to modeling experimental data. We discuss that the classical
              approach based on the Fisher information matrix has severe
              shortcomings. As an alternative, we propose using the profile
              likelihood, which is a powerful approach to detect and resolve
              practical nonidentifiability.",
  journal  = "Current Opinion in Systems Biology",
  volume   =  25,
  pages    = "60--69",
  month    =  mar,
  year     =  2021,
  keywords = "Identifiability; Structural identifiability; Practical
              identifiability; Profile likelihood; Fisher information matrix;
              Nonlinear dynamics; ODE models; Experimental design; Model
              reduction; Observability"
}

@ARTICLE{Ghaffari2010-uh,
  title     = "Optimal therapeutic protocols in cancer immunotherapy",
  author    = "Ghaffari, A and Naserifar, N",
  abstract  = "Using one of the well known mathematical models for
               immunotherapy of tumor-immune interactions, in this paper an
               algorithm is developed to optimize the immunotherapy in cancer
               treatment. The optimal control strategy is defined to maximize
               the effector cells and interleukin-2 concentration, while
               minimizing the tumor cells. The performance index is developed
               to stop the growth of tumor cells even at the end of the
               treatment. The maximum principle approach is the optimal control
               strategy in this paper. Analyzing the results and comparing them
               with very recent researches, it is shown that the amount of
               tumor cells with the proposed control algorithm is less then the
               others, both during and after the completion of the treatment.",
  journal   = "Comput. Biol. Med.",
  publisher = "Elsevier",
  volume    =  40,
  number    =  3,
  pages     = "261--270",
  month     =  mar,
  year      =  2010,
  language  = "en"
}

@ARTICLE{Al-Saleh2007-sg,
  title    = "Finite mixture of gamma distributions: A conjugate prior",
  author   = "Al-Saleh, Jamal A and Agarwal, Satish K",
  abstract = "A finite mixture of gamma distributions [Finite mixture of
              certain distributions. Comm. Statist. Theory Methods 31(12),
              2123--2137] is used as a conjugate prior, which gives a nice form
              of posterior distribution. This class of conjugate priors offers
              a more flexible class of priors than the class of gamma prior
              distributions. The usefulness of a mixture gamma-type prior and
              the posterior of uncertain parameters $\lambda$ for the Poisson
              distribution are illustrated by using Markov Chain Monte Carlo
              (MCMC), Gibbs sampling approach, on hierarchical models. Using
              the generalized hypergeometric function, the method to
              approximate maximum likelihood estimators for the parameters of
              Agarwal and Al-Saleh [Generalized gamma type distribution and its
              hazard rate function. Comm. Statist. Theory Methods 30(2),
              309--318] generalized gamma-type distribution is also suggested.",
  journal  = "Comput. Stat. Data Anal.",
  volume   =  51,
  number   =  9,
  pages    = "4369--4378",
  month    =  may,
  year     =  2007,
  keywords = "Bayesian analysis; Conjugate prior; Generalized hypergeometric
              function; Gibbs sampling; Hierarchical models; Kobayashi's
              gamma-type function; Markov Chain Monte Carlo; Maximum likelihood
              estimation; Mixture gamma distributions"
}

@ARTICLE{Al-Saleh2007-eb,
  title   = "Finite mixture of gamma distributions: A conjugate prior",
  author  = "Al-Saleh, Jamal A and Agarwal, Satish K",
  journal = "Comput. Stat. Data Anal.",
  volume  =  51,
  pages   = "4369--4378",
  year    =  2007
}

@ARTICLE{Cao2012-dp,
  title    = "Unfolded protein response",
  author   = "Cao, Stewart Siyan and Kaufman, Randal J",
  journal  = "Curr. Biol.",
  volume   =  22,
  number   =  16,
  pages    = "R622--6",
  month    =  aug,
  year     =  2012,
  language = "en"
}

@ARTICLE{Carisey2018-pr,
  title    = "Nanoscale Dynamism of Actin Enables Secretory Function in
              Cytolytic Cells",
  author   = "Carisey, Alexandre F and Mace, Emily M and Saeed, Mezida B and
              Davis, Daniel M and Orange, Jordan S",
  abstract = "Natural killer (NK) cells are innate immune effectors that lyse
              virally infected and tumorigenic cells through the formation of
              an immunological synapse. Actin remodeling at the lytic
              immunological synapse is a critical requirement for multiple
              facets of cytotoxic function. Activating receptor and integrin
              signaling leads to the regulated turnover and remodeling of
              actin, which is required for adhesion, sustained receptor
              signaling, and ultimately exocytosis. NK cells undergo lytic
              granule exocytosis in hypodense regions of a pervasive actin
              network. Although these requirements have been well demonstrated,
              neither the dynamic regulation of synaptic actin nor its specific
              function, however, has been determined at a nanoscale level.
              Here, live-cell super-resolution microscopy demonstrates
              nanoscale filamentous actin dynamism in NK cell lytic granule
              secretion. Following cell spreading, the overall content of the
              branched actin network at an immune synapse is stable over time
              and contains branched actin fibers and discrete actin foci.
              Similar actin architecture is generated in cytolytic T cells,
              although the timescale differs from that of NK cells. Individual
              filament displacement leads to stochastic clearance formation and
              disappearance, which are independent of lytic granule
              positioning. Actin dynamism is dependent upon branched network
              formation mediated by Arp2/3 and contractility generated by
              myosin IIA. Importantly, the use of small-molecule inhibitors
              demonstrates that actin dynamism is ultimately needed for granule
              secretion. Thus, we describe a requirement for nanoscale actin
              fiber rearrangement in generating the complex actin architecture
              that enables lytic granule secretion.",
  journal  = "Curr. Biol.",
  volume   =  28,
  number   =  4,
  pages    = "489--502.e9",
  month    =  feb,
  year     =  2018,
  keywords = "actin cytoskeleton; cytotoxicity; degranulation; immune synapse;
              natural killer cell; super-resolution microscopy",
  language = "en"
}

@ARTICLE{Mehta2018-mf,
  title    = "{TNF} activity and {T} cells",
  author   = "Mehta, Amit K and Gracias, Donald T and Croft, Michael",
  abstract = "TNF (tumor necrosis factor) is both a pro-inflammatory and
              anti-inflammatory cytokine that is central to the development of
              autoimmune disease, cancer, and protection against infectious
              pathogens. As well as a myriad other activities, TNF can be a
              product of T cells and can act on T cells. Here we review old and
              new data on the importance of TNF produced by T cells and how TNF
              signaling via TNFR2 may directly impact alternate aspects of T
              cell biology. TNF can promote the activation and proliferation of
              na{\"\i}ve and effector T cells, but also can induce apoptosis of
              highly activated effector T cells, further determining the size
              of the pathogenic or protective conventional T cell pool.
              Moreover, TNF can have divergent effects on regulatory T cells.
              It can both downregulate their suppressive capacity, but also
              contribute in other instances to their development or
              accumulation. Biologics that block TNF or stimulate TNFR2
              therefore have the potential to strongly modulate the balance
              between effector T cells and Treg cells which could impact
              disease in both positive and negative manners.",
  journal  = "Cytokine",
  volume   =  101,
  pages    = "14--18",
  month    =  jan,
  year     =  2018,
  keywords = "T cells; TNF; TNFR1; TNFR2; Treg",
  language = "en"
}

@ARTICLE{Spencer2019-uw,
  title    = "Insights into the dynamics of memory, effector and apoptotic
              cytotoxic {T} lymphocytes in channel catfish, Ictalurus punctatus",
  author   = "Spencer, David A and Quiniou, Sylvie M A and Crider, Jonathan and
              Musungu, Bryan and Bengten, Eva and Wilson, Melanie",
  abstract = "In this study, we used the channel catfish model clonal TS32.15
              alloantigen-specific cytotoxic T cell (CTL) line to examine the
              dynamics of memory CTL expansion and senescence in teleosts.
              Although TS32.15 has been routinely cultured to study catfish CTL
              responses and killing mechanisms, little is known about the
              dynamics of the CTLs in these cultures. Here we show that this
              cell line consists of small non-cytotoxic T cells and larger
              granular effector T cells and that their ratios vary with time
              after stimulation. Small CTLs, when exposed to their irradiated
              targets, replicate and differentiate to morphologically distinct
              cytotoxic effectors, which do not replicate. After lysing target
              cells, or with prolonged absence of stimulation, the effector
              cells transition to a non-cytolytic senescent stage or become
              apoptotic. In addition, we demonstrate that natural IgM in
              catfish serum binds lipids, including PIP2, on early apoptotic
              CTLs, and that these IgM+ CTL can be cleared by catfish head
              kidney-derived macrophages.",
  journal  = "Dev. Comp. Immunol.",
  volume   =  92,
  pages    = "116--128",
  month    =  mar,
  year     =  2019,
  keywords = "Effector T cells; Lipid binding; Memory T cells; Natural IgM;
              Phosphatidylinositol bisphosphate; Teleosts",
  language = "en"
}

@ARTICLE{Scott2004-ky,
  title    = "Role and regulation of starvation-induced autophagy in the
              Drosophila fat body",
  author   = "Scott, Ryan C and Schuldiner, Oren and Neufeld, Thomas P",
  abstract = "In response to starvation, eukaryotic cells recover nutrients
              through autophagy, a lysosomal-mediated process of cytoplasmic
              degradation. Autophagy is known to be inhibited by TOR signaling,
              but the mechanisms of autophagy regulation and its role in
              TOR-mediated cell growth are unclear. Here, we show that
              signaling through TOR and its upstream regulators PI3K and Rheb
              is necessary and sufficient to suppress starvation-induced
              autophagy in the Drosophila fat body. In contrast, TOR's
              downstream effector S6K promotes rather than suppresses
              autophagy, suggesting S6K downregulation may limit autophagy
              during extended starvation. Despite the catabolic potential of
              autophagy, disruption of conserved components of the autophagic
              machinery, including ATG1 and ATG5, does not restore growth to
              TOR mutant cells. Instead, inhibition of autophagy enhances TOR
              mutant phenotypes, including reduced cell size, growth rate, and
              survival. Thus, in cells lacking TOR, autophagy plays a
              protective role that is dominant over its potential role as a
              growth suppressor.",
  journal  = "Dev. Cell",
  volume   =  7,
  number   =  2,
  pages    = "167--178",
  month    =  aug,
  year     =  2004,
  language = "en"
}

@ARTICLE{Hosios2016-jc,
  title    = "Amino Acids Rather than Glucose Account for the Majority of Cell
              Mass in Proliferating Mammalian Cells",
  author   = "Hosios, Aaron M and Hecht, Vivian C and Danai, Laura V and
              Johnson, Marc O and Rathmell, Jeffrey C and Steinhauser, Matthew
              L and Manalis, Scott R and Vander Heiden, Matthew G",
  abstract = "Cells must duplicate their mass in order to proliferate. Glucose
              and glutamine are the major nutrients consumed by proliferating
              mammalian cells, but the extent to which these and other
              nutrients contribute to cell mass is unknown. We quantified the
              fraction of cell mass derived from different nutrients and found
              that the majority of carbon mass in cells is derived from other
              amino acids, which are consumed at much lower rates than glucose
              and glutamine. While glucose carbon has diverse fates, glutamine
              contributes most to protein, suggesting that glutamine's ability
              to replenish tricarboxylic acid cycle intermediates (anaplerosis)
              is primarily used for amino acid biosynthesis. These findings
              demonstrate that rates of nutrient consumption are indirectly
              associated with mass accumulation and suggest that high rates of
              glucose and glutamine consumption support rapid cell
              proliferation beyond providing carbon for biosynthesis.",
  journal  = "Dev. Cell",
  volume   =  36,
  number   =  5,
  pages    = "540--549",
  month    =  mar,
  year     =  2016,
  language = "en"
}

@ARTICLE{Santaguida2017-ak,
  title    = "Chromosome Mis-segregation Generates {Cell-Cycle-Arrested} Cells
              with Complex Karyotypes that Are Eliminated by the Immune System",
  author   = "Santaguida, Stefano and Richardson, Amelia and Iyer, Divya
              Ramalingam and M'Saad, Ons and Zasadil, Lauren and Knouse,
              Kristin A and Wong, Yao Liang and Rhind, Nicholas and Desai,
              Arshad and Amon, Angelika",
  abstract = "Aneuploidy, a state of karyotype imbalance, is a hallmark of
              cancer. Changes in chromosome copy number have been proposed to
              drive disease by modulating the dosage of cancer driver genes and
              by promoting cancer genome evolution. Given the potential of
              cells with abnormal karyotypes to become cancerous, do pathways
              that limit the prevalence of such cells exist? By investigating
              the immediate consequences of aneuploidy on cell physiology, we
              identified mechanisms that eliminate aneuploid cells. We find
              that chromosome mis-segregation leads to further genomic
              instability that ultimately causes cell-cycle arrest. We further
              show that cells with complex karyotypes exhibit features of
              senescence and produce pro-inflammatory signals that promote
              their clearance by the immune system. We propose that cells with
              abnormal karyotypes generate a signal for their own elimination
              that may serve as a means for cancer cell immunosurveillance.",
  journal  = "Dev. Cell",
  volume   =  41,
  number   =  6,
  pages    = "638--651.e5",
  month    =  jun,
  year     =  2017,
  keywords = "aneuploidy; cancer; genome instability; immune system; senescence",
  language = "en"
}

@ARTICLE{Zhu2018-sa,
  title    = "Cellular Stress Associated with Aneuploidy",
  author   = "Zhu, Jin and Tsai, Hung-Ji and Gordon, Molly R and Li, Rong",
  abstract = "Aneuploidy, chromosome stoichiometry that deviates from exact
              multiples of the haploid compliment of an organism, exists in
              eukaryotic microbes, several normal human tissues, and the
              majority of solid tumors. Here, we review the current
              understanding about the cellular stress states that may result
              from aneuploidy. The topics of aneuploidy-induced proteotoxic,
              metabolic, replication, and mitotic stress are assessed in the
              context of the gene dosage imbalance observed in aneuploid cells.
              We also highlight emerging findings related to the downstream
              effects of aneuploidy-induced cellular stress on the immune
              surveillance against aneuploid cells.",
  journal  = "Dev. Cell",
  volume   =  44,
  number   =  4,
  pages    = "420--431",
  month    =  feb,
  year     =  2018,
  keywords = "aneuploidy; metabolic stress; mitotic stress; proteotoxic stress;
              replication stress",
  language = "en"
}

@ARTICLE{Ippolito2021-yx,
  title    = "Gene copy-number changes and chromosomal instability induced by
              aneuploidy confer resistance to chemotherapy",
  author   = "Ippolito, Marica Rosaria and Martis, Valentino and Martin, Sara
              and Tijhuis, Andr{\'e}a E and Hong, Christy and Wardenaar,
              Ren{\'e} and Dumont, Marie and Zerbib, Johanna and Spierings,
              Diana C J and Fachinetti, Daniele and Ben-David, Uri and Foijer,
              Floris and Santaguida, Stefano",
  abstract = "Mitotic errors lead to aneuploidy, a condition of karyotype
              imbalance, frequently found in cancer cells. Alterations in
              chromosome copy number induce a wide variety of cellular
              stresses, including genome instability. Here, we show that cancer
              cells might exploit aneuploidy-induced genome instability and the
              resulting gene copy-number changes to survive under conditions of
              selective pressure, such as chemotherapy. Resistance to
              chemotherapeutic drugs was dictated by the acquisition of
              recurrent karyotypes, indicating that gene dosage might play a
              role in driving chemoresistance. Thus, our study establishes a
              causal link between aneuploidy-driven changes in gene copy number
              and chemoresistance and might explain why some chemotherapies
              fail to succeed.",
  journal  = "Dev. Cell",
  volume   =  56,
  number   =  17,
  pages    = "2440--2454.e6",
  month    =  sep,
  year     =  2021,
  keywords = "aneuploidy; cancer; chemotherapy; drug resistance; genome
              instability",
  language = "en"
}

@ARTICLE{Lukow2021-ld,
  title    = "Chromosomal instability accelerates the evolution of resistance
              to anti-cancer therapies",
  author   = "Lukow, Devon A and Sausville, Erin L and Suri, Pavit and
              Chunduri, Narendra Kumar and Wieland, Angela and Leu, Justin and
              Smith, Joan C and Girish, Vishruth and Kumar, Ankith A and
              Kendall, Jude and Wang, Zihua and Storchova, Zuzana and Sheltzer,
              Jason M",
  abstract = "Aneuploidy is a ubiquitous feature of human tumors, but the
              acquisition of aneuploidy typically antagonizes cellular fitness.
              To investigate how aneuploidy could contribute to tumor growth,
              we triggered periods of chromosomal instability (CIN) in human
              cells and then exposed them to different culture environments. We
              discovered that transient CIN reproducibly accelerates the
              acquisition of resistance to anti-cancer therapies. Single-cell
              sequencing revealed that these resistant populations develop
              recurrent aneuploidies, and independently deriving one
              chromosome-loss event that was frequently observed in
              paclitaxel-resistant cells was sufficient to decrease paclitaxel
              sensitivity. Finally, we demonstrated that intrinsic levels of
              CIN correlate with poor responses to numerous therapies in human
              tumors. Our results show that, although CIN generally decreases
              cancer cell fitness, it also provides phenotypic plasticity to
              cancer cells that can allow them to adapt to diverse stressful
              environments. Moreover, our findings suggest that aneuploidy may
              function as an under-explored cause of therapy failure.",
  journal  = "Dev. Cell",
  volume   =  56,
  number   =  17,
  pages    = "2427--2439.e4",
  month    =  sep,
  year     =  2021,
  keywords = "CIN; aneuploidy; cancer; drug resistance; evolution",
  language = "en"
}

@ARTICLE{Lukey2017-uw,
  title    = "Targeting amino acid metabolism for cancer therapy",
  author   = "Lukey, Michael J and Katt, William P and Cerione, Richard A",
  abstract = "To support sustained biomass accumulation, tumor cells undergo
              metabolic reprogramming. Nutrient transporters and metabolic
              enzymes are regulated by the same oncogenic signals that drive
              cell-cycle progression. Some of the earliest cancer therapies
              used antimetabolites to disrupt tumor metabolism, and there is
              now renewed interest in developing drugs that target metabolic
              dependencies. Many cancers exhibit increased demand for specific
              amino acids, and become dependent on either an exogenous supply
              or upregulated de novo synthesis. Strategies to exploit such
              'metabolic addictions' include depleting amino acids in blood
              serum, blocking uptake by transporters and inhibiting
              biosynthetic or catabolic enzymes. Recent findings highlight the
              importance of using appropriate model systems and identifying
              target patient groups as potential therapies advance into the
              clinic.",
  journal  = "Drug Discov. Today",
  volume   =  22,
  number   =  5,
  pages    = "796--804",
  month    =  may,
  year     =  2017,
  language = "en"
}

@ARTICLE{Denisenko2016-fx,
  title    = "Mitotic catastrophe and cancer drug resistance: A link that must
              to be broken",
  author   = "Denisenko, Tatiana V and Sorokina, Irina V and Gogvadze, Vladimir
              and Zhivotovsky, Boris",
  abstract = "An increased tendency of genomic alterations during the life
              cycle of cells leads to genomic instability, which is a major
              driving force for tumorigenesis. A considerable fraction of tumor
              cells are tetraploid or aneuploid, which renders them
              intrinsically susceptible to mitotic aberrations, and hence, are
              particularly sensitive to the induction of mitotic catastrophe.
              Resistance to cell death is also closely linked to genomic
              instability, as it enables malignant cells to expand even in a
              stressful environment. Currently it is known that cells can die
              via multiple mechanisms. Mitotic catastrophe represents a step
              preceding apoptosis or necrosis, depending on the expression
              and/or proper function of several proteins. Mitotic catastrophe
              was proposed to be an onco-suppressive mechanism and the evasion
              of mitotic catastrophe constitutes one of the gateways to cancer
              development. Thus, stimulation of mitotic catastrophe appears to
              be a promising strategy in cancer treatment. Indeed, several
              chemotherapeutic drugs are currently used at concentrations that
              induce apoptosis irrespective of the cell cycle phase, yet are
              very efficient at triggering mitotic catastrophe at lower doses,
              significantly limiting side effects. In the present review we
              summarize current data concerning the role of mitotic catastrophe
              in cancer drug resistance and discuss novel strategies to break
              this link.",
  journal  = "Drug Resist. Updat.",
  volume   =  24,
  pages    = "1--12",
  month    =  jan,
  year     =  2016,
  keywords = "Cancer; Drug resistance; Genomic instability; Mitotic catastrophe",
  language = "en"
}

% The entry below contains non-ASCII chars that could not be converted
% to a LaTeX equivalent.
@ARTICLE{Sarmento-Ribeiro2019-yi,
  title    = "The emergence of drug resistance to targeted cancer therapies:
              Clinical evidence",
  author   = "Sarmento-Ribeiro, Ana Bela and Scorilas, Andreas and Gon{\c
              c}alves, Ana Cristina and Efferth, Thomas and Trougakos, Ioannis
              P",
  abstract = "For many decades classical anti-tumor therapies included
              chemotherapy, radiation and surgery; however, in the last two
              decades, following the identification of the genomic drivers and
              main hallmarks of cancer, the introduction of therapies that
              target specific tumor-promoting oncogenic or non-oncogenic
              pathways, has revolutionized cancer therapeutics. Despite the
              significant progress in cancer therapy, clinical oncologists are
              often facing the primary impediment of anticancer drug
              resistance, as many cancer patients display either intrinsic
              chemoresistance from the very beginning of the therapy or after
              initial responses and upon repeated drug treatment cycles,
              acquired drug resistance develops and thus relapse emerges,
              resulting in increased mortality. Our attempts to understand the
              molecular basis underlying these drug resistance phenotypes in
              pre-clinical models and patient specimens revealed the extreme
              plasticity and adaptive pathways employed by tumor cells, being
              under sustained stress and extensive genomic/proteomic
              instability due to the applied therapeutic regimens. Subsequent
              efforts have yielded more effective inhibitors and combinatorial
              approaches (e.g. the use of specific pharmacologic inhibitors
              with immunotherapy) that exhibit synergistic effects against
              tumor cells, hence enhancing therapeutic indices. Furthermore,
              new advanced methodologies that allow for the early detection of
              genetic/epigenetic alterations that lead to drug chemoresistance
              and prospective validation of biomarkers which identify patients
              that will benet from certain drug classes, have started to
              improve the clinical outcome. This review discusses emerging
              principles of drug resistance to cancer therapies targeting a
              wide array of oncogenic kinases, along with hedgehog pathway and
              the proteasome and apoptotic inducers, as well as epigenetic and
              metabolic modulators. We further discuss mechanisms of resistance
              to monoclonal antibodies, immunomodulators and immune checkpoint
              inhibitors, potential biomarkers of drug response/drug
              resistance, along with possible new therapeutic avenues for the
              clinicians to combat devastating drug resistant malignancies. It
              is foreseen that these topics will be major areas of focused
              multidisciplinary translational research in the years to come.",
  journal  = "Drug Resist. Updat.",
  volume   =  47,
  pages    = "100646",
  month    =  dec,
  year     =  2019,
  keywords = "Apoptosis; Autophagy; Epigenetic modulator; Hedgehog inhibitor;
              Immunotherapeutic agents; Kinase inhibitor; Metabolic modulator;
              Proteasome inhibitors",
  language = "en"
}

@ARTICLE{Eisenhauer2009-pz,
  title    = "New response evaluation criteria in solid tumours: revised
              {RECIST} guideline (version 1.1)",
  author   = "Eisenhauer, E A and Therasse, P and Bogaerts, J and Schwartz, L H
              and Sargent, D and Ford, R and Dancey, J and Arbuck, S and
              Gwyther, S and Mooney, M and Rubinstein, L and Shankar, L and
              Dodd, L and Kaplan, R and Lacombe, D and Verweij, J",
  abstract = "BACKGROUND: Assessment of the change in tumour burden is an
              important feature of the clinical evaluation of cancer
              therapeutics: both tumour shrinkage (objective response) and
              disease progression are useful endpoints in clinical trials.
              Since RECIST was published in 2000, many investigators,
              cooperative groups, industry and government authorities have
              adopted these criteria in the assessment of treatment outcomes.
              However, a number of questions and issues have arisen which have
              led to the development of a revised RECIST guideline (version
              1.1). Evidence for changes, summarised in separate papers in this
              special issue, has come from assessment of a large data warehouse
              (>6500 patients), simulation studies and literature reviews.
              HIGHLIGHTS OF REVISED RECIST 1.1: Major changes include: Number
              of lesions to be assessed: based on evidence from numerous trial
              databases merged into a data warehouse for analysis purposes, the
              number of lesions required to assess tumour burden for response
              determination has been reduced from a maximum of 10 to a maximum
              of five total (and from five to two per organ, maximum).
              Assessment of pathological lymph nodes is now incorporated: nodes
              with a short axis of 15 mm are considered measurable and
              assessable as target lesions. The short axis measurement should
              be included in the sum of lesions in calculation of tumour
              response. Nodes that shrink to <10mm short axis are considered
              normal. Confirmation of response is required for trials with
              response primary endpoint but is no longer required in randomised
              studies since the control arm serves as appropriate means of
              interpretation of data. Disease progression is clarified in
              several aspects: in addition to the previous definition of
              progression in target disease of 20\% increase in sum, a 5mm
              absolute increase is now required as well to guard against over
              calling PD when the total sum is very small. Furthermore, there
              is guidance offered on what constitutes 'unequivocal progression'
              of non-measurable/non-target disease, a source of confusion in
              the original RECIST guideline. Finally, a section on detection of
              new lesions, including the interpretation of FDG-PET scan
              assessment is included. Imaging guidance: the revised RECIST
              includes a new imaging appendix with updated recommendations on
              the optimal anatomical assessment of lesions. FUTURE WORK: A key
              question considered by the RECIST Working Group in developing
              RECIST 1.1 was whether it was appropriate to move from anatomic
              unidimensional assessment of tumour burden to either volumetric
              anatomical assessment or to functional assessment with PET or
              MRI. It was concluded that, at present, there is not sufficient
              standardisation or evidence to abandon anatomical assessment of
              tumour burden. The only exception to this is in the use of
              FDG-PET imaging as an adjunct to determination of progression. As
              is detailed in the final paper in this special issue, the use of
              these promising newer approaches requires appropriate clinical
              validation studies.",
  journal  = "Eur. J. Cancer",
  volume   =  45,
  number   =  2,
  pages    = "228--247",
  month    =  jan,
  year     =  2009,
  language = "en"
}

@ARTICLE{Raica2009-rk,
  title    = "Angiogenesis in pre-malignant conditions",
  author   = "Raica, Marius and Cimpean, Anca Maria and Ribatti, Domenico",
  abstract = "Angiogenesis is an essential process involved in the normal
              growth and differentiation. In its defective and excessive form,
              angiogenesis is a crucial event in the progression of many human
              diseases. Excessive angiogenesis was largely investigated in
              psoriasis, arthritis, diabetic retinopathy and malignant tumours.
              Soon after the discovery of angiogenic factors and their
              inhibitors, the angiogenesis jumped from the experimental studies
              to clinical application. Tumour-associated angiogenesis is
              nowadays considered as a priority in oncology based on numerous
              evidences that showed a significant reduction in tumour growth
              following anti-angiogenic therapy. However, few data are
              available on pre-malignant conditions. First evidences on
              angiogenesis in pre-malignant lesions came from the evaluation of
              microvessel density (MVD). MVD was found to be significantly
              increased in a relatively large spectrum of pre-malignant
              squamous cell lesions, such as in the oral mucosa, skin, uterine
              cervix, vulva and anal canal. For many of them, a correlation was
              found between MVD and the expression of vascular endothelial
              growth factor (VEGF). Based on these data, it was suggested that
              tumour angiogenesis is not necessarily a characteristic of
              invasive tumour, but may be an early event during tumourigenesis.
              Additional evidences came from pre-malignant lesions of glandular
              epithelia, in which the angiogenic switch was demonstrated by the
              immunohistochemical expression of VEGF in gastric metaplasia and
              dysplasia, in atypical adenoma of the colon, atypical hyperplasia
              and carcinoma in situ of the breast and others. Actually, there
              are convincing evidences for an active angiogenesis in many cases
              with pre-malignant conditions, and this supports a more accurate
              evaluation of different chemopreventive agents.",
  journal  = "Eur. J. Cancer",
  volume   =  45,
  number   =  11,
  pages    = "1924--1934",
  month    =  jul,
  year     =  2009,
  language = "en"
}

@ARTICLE{Makkouk2016-kr,
  title    = "Rationale for {anti-CD137} cancer immunotherapy",
  author   = "Makkouk, Amani and Chester, Cariad and Kohrt, Holbrook E",
  abstract = "The consideration of the complex interplay between the tumour
              microenvironment (TME) and the immune response is the key for
              designing effective immunotherapies. Therapeutic strategies that
              harness co-stimulatory receptors have recently gained momentum in
              the clinic. One such strategy with promising clinical
              applications is the targeting of CD137, a member of the tumour
              necrosis factor receptor superfamily. Its expression on both
              innate and adaptive immune cells, coupled with its unique ability
              to potentiate antitumour responses through modulating the TME and
              to ameliorate autoimmune responses, has established it as an
              appealing target. In this review, we will discuss the various
              CD137-targeted immunotherapeutics that have reached clinical
              development, with a focus on recent advances and novel modalities
              such as CD137 chimeric antigen receptors and CD137 bispecific
              antibodies. We will also highlight the effect of CD137 targeting
              on the TME and discuss the importance of probing TME changes for
              predicting and testing the efficacy of CD137-mediated
              immunotherapy.",
  journal  = "Eur. J. Cancer",
  volume   =  54,
  pages    = "112--119",
  month    =  feb,
  year     =  2016,
  keywords = "Bispecific antibodies; CAR; CD137; Cancer immunotherapy;
              Cytotoxic T cells; Monoclonal antibodies; Natural killer cells;
              Tumour microenvironment",
  language = "en"
}

@ARTICLE{Chen2017-ft,
  title    = "Activation of {CD137} signaling accelerates vascular
              calcification in vivo and vitro",
  author   = "Chen, Yao and Bangash, Abdul Basit and Song, Juan and Zhong, Wei
              and Wang, Cuiping and Shao, Chen and Wang, Zhongqun and Yan,
              Jinchuan",
  abstract = "OBJECTIVES: Vascular calcification is a characteristic feature of
              atherosclerosis and is considered as an independent predictor of
              cardiovascular risk. CD137 signaling has previously shown to be
              involved in atherosclerosis. However, the possible role of CD137
              signaling in regulation of vascular calcification has not been
              reported. In the present study, we investigated the effect of
              CD137 signaling on vascular calcification in ApoE-/- mice and in
              vascular smooth muscle cells (VSMCs) of mice. METHODS: Calcium
              deposition and muscle fibers in vivo or vitro were identified by
              von-Kossa and Masson's trichrome staining respectively. Alkaline
              phosphatase (ALP) activity was measured by the ALP assay Kit. The
              presence of bone morphogenic protein 2 (BMP2) and runt-related
              transcription factor 2 (Runx2) was detected by real-time PCR,
              Western blot and immunofluorescence in vitro or vivo. RESULTS:
              Our data shows that activation of CD137 signaling by
              intraperitoneal injection of agonist-CD137 antibody increased the
              areas of vascular calcification. Activation of CD137 signaling
              also increased the expression of BMP2 and Runx2 in the
              atherosclerotic plaques. In vitro, activation of CD137 signaling
              also aggravated VSMC calcification, while blocking CD137
              signaling could alleviate agonist-CD137 induced VSMC
              calcification. In addition, the levels of calcium, BMP2 and
              Runx2, indicators of calcification, were all significantly
              elevated in agonist-CD137 group in VSMCs. CONCLUSION: Our data
              revealed a previously unrecognized role of CD137 signaling in
              vascular calcification in vivo and vitro and provides a novel
              target for prevention and treatment of atherosclerosis in the
              future.",
  journal  = "Int. J. Cardiol.",
  volume   =  230,
  pages    = "198--203",
  month    =  mar,
  year     =  2017,
  keywords = "CD137; Calcification; Osteogenic; TNFRSF; VSMC",
  language = "en"
}

@ARTICLE{Isogawa2005-te,
  title    = "Oscillating {CD8(+}) {T} cell effector functions after antigen
              recognition in the liver",
  author   = "Isogawa, Masanori and Furuichi, Yoshihiro and Chisari, Francis V",
  abstract = "When hepatitis B virus (HBV)-specific CD8(+) cytotoxic T
              lymphocytes (CTLs) are adoptively transferred into HBV transgenic
              mice, they enter the liver, recognize antigen, secrete interferon
              gamma (IFNgamma), inhibit viral replication, and kill their
              target cells, causing hepatitis. In the current study, we
              examined the impact of antigen recognition on the evolution of
              the activation phenotype, antiviral effector functions, expansion
              and contraction kinetics, and compartmentalization of the
              transferred CTLs. The results reveal that noncytolytic and
              cytolytic effector functions and expansion-contraction kinetics
              of the CTLs are regulated asynchronously and in an oscillatory
              manner as a consequence of antigen recognition in the liver and
              in association with PD-1 upregulation. We suggest that such
              oscillations maximize viral clearance and minimize tissue injury
              during HBV infection and that poor coordination of these events
              could lead to viral persistence and chronic liver disease.",
  journal  = "Immunity",
  volume   =  23,
  number   =  1,
  pages    = "53--63",
  month    =  jul,
  year     =  2005,
  language = "en"
}

@ARTICLE{Keefe2005-ul,
  title    = "Perforin triggers a plasma membrane-repair response that
              facilitates {CTL} induction of apoptosis",
  author   = "Keefe, Dennis and Shi, Lianfa and Feske, Stefan and Massol,
              Ramiro and Navarro, Francisco and Kirchhausen, Tomas and
              Lieberman, Judy",
  abstract = "Perforin delivers granzymes to induce target-cell apoptosis. At
              high concentrations, perforin multimerizes in the plasma membrane
              to form pores. However, whether granzymes enter target cells via
              membrane pores is uncertain. Here we find that perforin at
              physiologically relevant concentrations and during cell-mediated
              lysis creates pores in the target-cell membrane, transiently
              allowing Ca(2+) and small dyes into the cell. The Ca(2+) flux
              triggers a wounded membrane-repair response in which internal
              vesicles, including lysosomes and endosomes, donate their
              membranes to reseal the damaged membrane. Perforin also triggers
              the rapid endocytosis of granzymes into large EEA-1-staining
              vesicles. The restoration of target-cell membrane integrity by
              triggering the repair response is necessary for target cells
              subjected to cytotoxic T lymphocyte attack to avoid necrosis and
              undergo the slower process of programmed cell death. Thus, the
              target cell actively participates in determining its own fate
              during cell-mediated death.",
  journal  = "Immunity",
  volume   =  23,
  number   =  3,
  pages    = "249--262",
  month    =  sep,
  year     =  2005,
  keywords = "Direct Killing (Perf/Gzym/FAS)",
  language = "en"
}

@ARTICLE{Chang2011-ja,
  title    = "Asymmetric proteasome segregation as a mechanism for unequal
              partitioning of the transcription factor T-bet during {T}
              lymphocyte division",
  author   = "Chang, John T and Ciocca, Maria L and Kinjyo, Ichiko and
              Palanivel, Vikram R and McClurkin, Courtney E and Dejong, Caitlin
              S and Mooney, Erin C and Kim, Jiyeon S and Steinel, Natalie C and
              Oliaro, Jane and Yin, Catherine C and Florea, Bogdan I and
              Overkleeft, Herman S and Berg, Leslie J and Russell, Sarah M and
              Koretzky, Gary A and Jordan, Martha S and Reiner, Steven L",
  abstract = "Polarized segregation of proteins in T cells is thought to play a
              role in diverse cellular functions including signal transduction,
              migration, and directed secretion of cytokines. Persistence of
              this polarization can result in asymmetric segregation of
              fate-determining proteins during cell division, which may enable
              a T cell to generate diverse progeny. Here, we provide evidence
              that a lineage-determining transcription factor, T-bet, underwent
              asymmetric organization in activated T cells preparing to divide
              and that it was unequally partitioned into the two daughter
              cells. This unequal acquisition of T-bet appeared to result from
              its asymmetric destruction during mitosis by virtue of
              concomitant asymmetric segregation of the proteasome. These
              results suggest a mechanism by which a cell may unequally
              localize cellular activities during division, thereby imparting
              disparity in the abundance of cell fate regulators in the
              daughter cells.",
  journal  = "Immunity",
  volume   =  34,
  number   =  4,
  pages    = "492--504",
  month    =  apr,
  year     =  2011,
  language = "en"
}

@ARTICLE{Zhang2011-qm,
  title    = "{CD8(+}) {T} cells: foot soldiers of the immune system",
  author   = "Zhang, Nu and Bevan, Michael J",
  abstract = "Resting naive CD8(+) T cells have an astounding capacity to react
              to pathogens by massive expansion and differentiation into
              cytotoxic effector cells that migrate to all corners of the body
              to clear the infection. The initial interaction with
              antigen-presenting cells in the central lymphoid organs drives an
              orchestrated program of differentiation aimed at producing
              sufficient numbers of effectors to get the job done without
              resulting in clonal exhaustion. Interactions with
              antigen-presenting cells and other immune cells continue at the
              site of infection to regulate further on-site expansion and
              differentiation, all with the goal of protecting the host with
              minimal bystander tissue damage. Here we review recent advances
              in CD8(+) T cell recognition of antigen in lymphoid as well as in
              nonlymphoid tissues in the periphery, and how CD8(+) T cell
              expansion and differentiation are controlled in these contexts.",
  journal  = "Immunity",
  volume   =  35,
  number   =  2,
  pages    = "161--168",
  month    =  aug,
  year     =  2011,
  language = "en"
}

@ARTICLE{Chen2013-ee,
  title    = "Oncology meets immunology: the cancer-immunity cycle",
  author   = "Chen, Daniel S and Mellman, Ira",
  abstract = "The genetic and cellular alterations that define cancer provide
              the immune system with the means to generate T cell responses
              that recognize and eradicate cancer cells. However, elimination
              of cancer by T cells is only one step in the Cancer-Immunity
              Cycle, which manages the delicate balance between the recognition
              of nonself and the prevention of autoimmunity. Identification of
              cancer cell T cell inhibitory signals, including PD-L1, has
              prompted the development of a new class of cancer immunotherapy
              that specifically hinders immune effector inhibition,
              reinvigorating and potentially expanding preexisting anticancer
              immune responses. The presence of suppressive factors in the
              tumor microenvironment may explain the limited activity observed
              with previous immune-based therapies and why these therapies may
              be more effective in combination with agents that target other
              steps of the cycle. Emerging clinical data suggest that cancer
              immunotherapy is likely to become a key part of the clinical
              management of cancer.",
  journal  = "Immunity",
  volume   =  39,
  number   =  1,
  pages    = "1--10",
  month    =  jul,
  year     =  2013,
  language = "en"
}

@ARTICLE{Ritter2015-oq,
  title    = "Actin depletion initiates events leading to granule secretion at
              the immunological synapse",
  author   = "Ritter, Alex T and Asano, Yukako and Stinchcombe, Jane C and
              Dieckmann, N M G and Chen, Bi-Chang and Gawden-Bone, C and van
              Engelenburg, Schuyler and Legant, Wesley and Gao, Liang and
              Davidson, Michael W and Betzig, Eric and Lippincott-Schwartz,
              Jennifer and Griffiths, Gillian M",
  abstract = "Cytotoxic T lymphocytes (CTLs) use polarized secretion to rapidly
              destroy virally infected and tumor cells. To understand the
              temporal relationships between key events leading to secretion,
              we used high-resolution 4D imaging. CTLs approached targets with
              actin-rich projections at the leading edge, creating an initially
              actin-enriched contact with rearward-flowing actin. Within 1 min,
              cortical actin reduced across the synapse, T cell receptors
              (TCRs) clustered centrally to form the central supramolecular
              activation cluster (cSMAC), and centrosome polarization began.
              Granules clustered around the moving centrosome within 2.5 min
              and reached the synapse after 6 min. TCR-bearing intracellular
              vesicles were delivered to the cSMAC as the centrosome docked. We
              found that the centrosome and granules were delivered to an area
              of membrane with reduced cortical actin density and phospholipid
              PIP2. These data resolve the temporal order of events during
              synapse maturation in 4D and reveal a critical role for actin
              depletion in regulating secretion.",
  journal  = "Immunity",
  volume   =  42,
  number   =  5,
  pages    = "864--876",
  month    =  may,
  year     =  2015,
  language = "en"
}

@ARTICLE{Pfirschke2016-kb,
  title    = "Immunogenic Chemotherapy Sensitizes Tumors to Checkpoint Blockade
              Therapy",
  author   = "Pfirschke, Christina and Engblom, Camilla and Rickelt, Steffen
              and Cortez-Retamozo, Virna and Garris, Christopher and Pucci,
              Ferdinando and Yamazaki, Takahiro and Poirier-Colame, Vichnou and
              Newton, Andita and Redouane, Younes and Lin, Yi-Jang and
              Wojtkiewicz, Gregory and Iwamoto, Yoshiko and Mino-Kenudson, Mari
              and Huynh, Tiffany G and Hynes, Richard O and Freeman, Gordon J
              and Kroemer, Guido and Zitvogel, Laurence and Weissleder, Ralph
              and Pittet, Mikael J",
  abstract = "Checkpoint blockade immunotherapies can be extraordinarily
              effective, but might benefit only the minority of patients whose
              tumors are pre-infiltrated by T cells. Here, using lung
              adenocarcinoma mouse models, including genetic models, we show
              that autochthonous tumors that lacked T cell infiltration and
              resisted current treatment options could be successfully
              sensitized to host antitumor T cell immunity when appropriately
              selected immunogenic drugs (e.g., oxaliplatin combined with
              cyclophosphamide for treatment against tumors expressing
              oncogenic Kras and lacking Trp53) were used. The antitumor
              response was triggered by direct drug actions on tumor cells,
              relied on innate immune sensing through toll-like receptor 4
              signaling, and ultimately depended on CD8(+) T cell antitumor
              immunity. Furthermore, instigating tumor infiltration by T cells
              sensitized tumors to checkpoint inhibition and controlled cancer
              durably. These findings indicate that the proportion of cancers
              responding to checkpoint therapy can be feasibly and
              substantially expanded by combining checkpoint blockade with
              immunogenic drugs.",
  journal  = "Immunity",
  volume   =  44,
  number   =  2,
  pages    = "343--354",
  month    =  feb,
  year     =  2016,
  language = "en"
}

@ARTICLE{Halle2016-ti,
  title    = "In Vivo Killing Capacity of Cytotoxic {T} Cells Is Limited and
              Involves Dynamic Interactions and {T} Cell Cooperativity",
  author   = "Halle, Stephan and Keyser, Kirsten Anja and Stahl, Felix Rolf and
              Busche, Andreas and Marquardt, Anja and Zheng, Xiang and Galla,
              Melanie and Heissmeyer, Vigo and Heller, Katrin and Boelter,
              Jasmin and Wagner, Karen and Bischoff, Yvonne and Martens, Rieke
              and Braun, Asolina and Werth, Kathrin and Uvarovskii, Alexey and
              Kempf, Harald and Meyer-Hermann, Michael and Arens, Ramon and
              Kremer, Melanie and Sutter, Gerd and Messerle, Martin and
              F{\"o}rster, Reinhold",
  abstract = "According to in vitro assays, T cells are thought to kill rapidly
              and efficiently, but the efficacy and dynamics of cytotoxic T
              lymphocyte (CTL)-mediated killing of virus-infected cells in vivo
              remains elusive. We used two-photon microscopy to quantify
              CTL-mediated killing in mice infected with herpesviruses or
              poxviruses. On average, one CTL killed 2-16 virus-infected cells
              per day as determined by real-time imaging and by mathematical
              modeling. In contrast, upon virus-induced MHC class I
              downmodulation, CTLs failed to destroy their targets. During
              killing, CTLs remained migratory and formed motile kinapses
              rather than static synapses with targets. Viruses encoding the
              calcium sensor GCaMP6s revealed strong heterogeneity in
              individual CTL functional capacity. Furthermore, the probability
              of death of infected cells increased for those contacted by more
              than two CTLs, indicative of CTL cooperation. Thus, direct
              visualization of CTLs during killing of virus-infected cells
              reveals crucial parameters of CD8(+) T cell immunity.",
  journal  = "Immunity",
  volume   =  44,
  number   =  2,
  pages    = "233--245",
  month    =  feb,
  year     =  2016,
  language = "en"
}

@ARTICLE{Mlecnik2016-qs,
  title    = "Integrative Analyses of Colorectal Cancer Show Immunoscore Is a
              Stronger Predictor of Patient Survival Than Microsatellite
              Instability",
  author   = "Mlecnik, Bernhard and Bindea, Gabriela and Angell, Helen K and
              Maby, Pauline and Angelova, Mihaela and Tougeron, David and
              Church, Sarah E and Lafontaine, Lucie and Fischer, Maria and
              Fredriksen, Tessa and Sasso, Maristella and Bilocq, Am{\'e}lie M
              and Kirilovsky, Amos and Obenauf, Anna C and Hamieh, Mohamad and
              Berger, Anne and Bruneval, Patrick and Tuech, Jean-Jacques and
              Sabourin, Jean-Christophe and Le Pessot, Florence and Mauillon,
              Jacques and Rafii, Arash and Laurent-Puig, Pierre and Speicher,
              Michael R and Trajanoski, Zlatko and Michel, Pierre and
              Sesbo{\"u}e, Richard and Frebourg, Thierry and Pag{\`e}s, Franck
              and Valge-Archer, Viia and Latouche, Jean-Baptiste and Galon,
              J{\'e}r{\^o}me",
  abstract = "Microsatellite instability in colorectal cancer predicts
              favorable outcomes. However, the mechanistic relationship between
              microsatellite instability, tumor-infiltrating immune cells,
              Immunoscore, and their impact on patient survival remains to be
              elucidated. We found significant differences in mutational
              patterns, chromosomal instability, and gene expression that
              correlated with patient microsatellite instability status. A
              prominent immune gene expression was observed in
              microsatellite-instable (MSI) tumors, as well as in a subgroup of
              microsatellite-stable (MSS) tumors. MSI tumors had increased
              frameshift mutations, showed genetic evidence of immunoediting,
              had higher densities of Th1, effector-memory T cells, in situ
              proliferating T cells, and inhibitory PD1-PDL1 cells, had high
              Immunoscores, and were infiltrated with mutation-specific
              cytotoxic T cells. Multivariate analysis revealed that
              Immunoscore was superior to microsatellite instability in
              predicting patients' disease-specific recurrence and survival.
              These findings indicate that assessment of the immune status via
              Immunoscore provides a potent indicator of tumor recurrence
              beyond microsatellite-instability staging that could be an
              important guide for immunotherapy strategies.",
  journal  = "Immunity",
  volume   =  44,
  number   =  3,
  pages    = "698--711",
  month    =  mar,
  year     =  2016,
  language = "en"
}

@ARTICLE{Esensten2016-vj,
  title    = "{CD28} Costimulation: From Mechanism to Therapy",
  author   = "Esensten, Jonathan H and Helou, Ynes A and Chopra, Gaurav and
              Weiss, Arthur and Bluestone, Jeffrey A",
  abstract = "Ligation of the CD28 receptor on T cells provides a critical
              second signal alongside T cell receptor (TCR) ligation for naive
              T cell activation. Here, we discuss the expression, structure,
              and biochemistry of CD28 and its ligands. CD28 signals play a key
              role in many T cell processes, including cytoskeletal remodeling,
              production of cytokines, survival, and differentiation. CD28
              ligation leads to unique epigenetic, transcriptional, and
              post-translational changes in T cells that cannot be
              recapitulated by TCR ligation alone. We discuss the function of
              CD28 and its ligands in both effector and regulatory T cells.
              CD28 is critical for regulatory T cell survival and the
              maintenance of immune homeostasis. We outline the roles that CD28
              and its family members play in human disease and we review the
              clinical efficacy of drugs that block CD28 ligands. Despite the
              centrality of CD28 and its family members and ligands to immune
              function, many aspects of CD28 biology remain unclear.
              Translation of a basic understanding of CD28 function into
              immunomodulatory therapeutics has been uneven, with both
              successes and failures. Such real-world results might stem from
              multiple factors, including complex receptor-ligand interactions
              among CD28 family members, differences between the mouse and
              human CD28 families, and cell-type specific roles of CD28 family
              members.",
  journal  = "Immunity",
  volume   =  44,
  number   =  5,
  pages    = "973--988",
  month    =  may,
  year     =  2016,
  language = "en"
}

@ARTICLE{Oyler-Yaniv2017-dx,
  title    = "A Tunable {Diffusion-Consumption} Mechanism of Cytokine
              Propagation Enables Plasticity in {Cell-to-Cell} Communication in
              the Immune System",
  author   = "Oyler-Yaniv, Alon and Oyler-Yaniv, Jennifer and Whitlock,
              Benjamin M and Liu, Zhiduo and Germain, Ronald N and Huse, Morgan
              and Altan-Bonnet, Gr{\'e}goire and Krichevsky, Oleg",
  abstract = "Immune cells communicate by exchanging cytokines to achieve a
              context-appropriate response, but the distances over which such
              communication happens are not known. Here, we used theoretical
              considerations and experimental models of immune responses in
              vitro and in vivo to quantify the spatial extent of cytokine
              communications in dense tissues. We established that competition
              between cytokine diffusion and consumption generated spatial
              niches of high cytokine concentrations with sharp boundaries. The
              size of these self-assembled niches scaled with the density of
              cytokine-consuming cells, a parameter that gets tuned during
              immune responses. In vivo, we measured interactions on length
              scales of 80-120 $\mu$m, which resulted in a high degree of
              cell-to-cell variance in cytokine exposure. Such heterogeneous
              distributions of cytokines were a source of non-genetic
              cell-to-cell variability that is often overlooked in single-cell
              studies. Our findings thus provide a basis for understanding
              variability in the patterning of immune responses by diffusible
              factors.",
  journal  = "Immunity",
  volume   =  46,
  number   =  4,
  pages    = "609--620",
  month    =  apr,
  year     =  2017,
  keywords = "Cell-to-cell communications; Cell-to-cell variability; Cytokine
              niches; Cytokines; Diffusion/Consumption; Interleukin-2;
              Quantitative Immunology; STAT5; Theoretical Modeling",
  language = "en"
}

@ARTICLE{Dyck2018-zw,
  title    = "New Job for {NK} Cells: Architects of the Tumor Microenvironment",
  author   = "Dyck, Lydia and Lynch, Lydia",
  abstract = "NK cells control tumor growth directly through targeted cytotoxic
              granule release or cytokine secretion and indirectly by
              orchestrating anti-tumor immune responses. In this issue of
              Immunity, Glasner et al. (2018) now reveal a new role for NK
              cells in preventing metastatic spread through controlling tumor
              architecture.",
  journal  = "Immunity",
  volume   =  48,
  number   =  1,
  pages    = "9--11",
  month    =  jan,
  year     =  2018,
  language = "en"
}

@ARTICLE{Garris2018-rd,
  title    = "Successful {Anti-PD-1} Cancer Immunotherapy Requires {T}
              {Cell-Dendritic} Cell Crosstalk Involving the Cytokines
              {IFN-$\gamma$} and {IL-12}",
  author   = "Garris, Christopher S and Arlauckas, Sean P and Kohler, Rainer H
              and Trefny, Marcel P and Garren, Seth and Piot, C{\'e}cile and
              Engblom, Camilla and Pfirschke, Christina and Siwicki, Marie and
              Gungabeesoon, Jeremy and Freeman, Gordon J and Warren, Sarah E
              and Ong, Sufey and Browning, Erica and Twitty, Christopher G and
              Pierce, Robert H and Le, Mai H and Algazi, Alain P and Daud, Adil
              I and Pai, Sara I and Zippelius, Alfred and Weissleder, Ralph and
              Pittet, Mikael J",
  abstract = "Anti-PD-1 immune checkpoint blockers can induce sustained
              clinical responses in cancer but how they function in vivo
              remains incompletely understood. Here, we combined intravital
              real-time imaging with single-cell RNA sequencing analysis and
              mouse models to uncover anti-PD-1 pharmacodynamics directly
              within tumors. We showed that effective antitumor responses
              required a subset of tumor-infiltrating dendritic cells (DCs),
              which produced interleukin 12 (IL-12). These DCs did not bind
              anti-PD-1 but produced IL-12 upon sensing interferon $\gamma$
              (IFN-$\gamma$) that was released from neighboring T cells. In
              turn, DC-derived IL-12 stimulated antitumor T cell immunity.
              These findings suggest that full-fledged activation of antitumor
              T cells by anti-PD-1 is not direct, but rather involves T cell:DC
              crosstalk and is licensed by IFN-$\gamma$ and IL-12. Furthermore,
              we found that activating the non-canonical NF-$\kappa$B
              transcription factor pathway amplified IL-12-producing DCs and
              sensitized tumors to anti-PD-1 treatment, suggesting a
              therapeutic strategy to improve responses to checkpoint blockade.",
  journal  = "Immunity",
  volume   =  49,
  number   =  6,
  pages    = "1148--1161.e7",
  month    =  dec,
  year     =  2018,
  keywords = "IFN-$\gamma$; IL-12; anti-PD-1; cancer; checkpoint; dendritic
              cell; immunotherapy; non-canonical NF-$\kappa$B",
  language = "en"
}

@ARTICLE{Pai2019-da,
  title    = "Clonal Deletion of {Tumor-Specific} {T} Cells by
              {Interferon-$\gamma$} Confers Therapeutic Resistance to
              Combination Immune Checkpoint Blockade",
  author   = "Pai, Chien-Chun Steven and Huang, John T and Lu, Xiaoqing and
              Simons, Donald M and Park, Chanhyuk and Chang, Anthony and
              Tamaki, Whitney and Liu, Eric and Roybal, Kole T and Seagal, Jane
              and Chen, Mingyi and Hagihara, Katsunobu and Wei, Xiao X and
              DuPage, Michel and Kwek, Serena S and Oh, David Y and Daud, Adil
              and Tsai, Katy K and Wu, Clint and Zhang, Li and Fasso, Marcella
              and Sachidanandam, Ravi and Jayaprakash, Anitha and Lin, Ingrid
              and Casbon, Amy-Jo and Kinsbury, Gillian A and Fong, Lawrence",
  abstract = "Resistance to checkpoint-blockade treatments is a challenge in
              the clinic. We found that although treatment with combined
              anti-CTLA-4 and anti-PD-1 improved control of established tumors,
              this combination compromised anti-tumor immunity in the low tumor
              burden (LTB) state in pre-clinical models as well as in melanoma
              patients. Activated tumor-specific T cells expressed higher
              amounts of interferon-$\gamma$ (IFN-$\gamma$) receptor and were
              more susceptible to apoptosis than naive T cells. Combination
              treatment induced deletion of tumor-specific T cells and altered
              the T cell repertoire landscape, skewing the distribution of T
              cells toward lower-frequency clonotypes. Additionally,
              combination therapy induced higher IFN-$\gamma$ production in the
              LTB state than in the high tumor burden (HTB) state on a per-cell
              basis, reflecting a less exhausted immune status in the LTB
              state. Thus, elevated IFN-$\gamma$ secretion in the LTB state
              contributes to the development of an immune-intrinsic mechanism
              of resistance to combination checkpoint blockade, highlighting
              the importance of achieving the optimal magnitude of immune
              stimulation for successful combination immunotherapy strategies.",
  journal  = "Immunity",
  month    =  feb,
  year     =  2019,
  keywords = "IFN-$\gamma$; activation-induced cell death; anti-CTLA-4;
              anti-PD-1; cancer; immunotherapy",
  language = "en"
}

@ARTICLE{Takeda2019-lb,
  title    = "{Single-Cell} Survey of Human Lymphatics Unveils Marked
              Endothelial Cell Heterogeneity and Mechanisms of Homing for
              Neutrophils",
  author   = "Takeda, Akira and Hollm{\'e}n, Maija and Dermadi, Denis and Pan,
              Junliang and Brulois, Kevin Francis and Kaukonen, Riina and
              L{\"o}nnberg, Tapio and Bostr{\"o}m, Pia and Koskivuo, Ilkka and
              Irjala, Heikki and Miyasaka, Masayuki and Salmi, Marko and
              Butcher, Eugene C and Jalkanen, Sirpa",
  abstract = "Lymphatic vessels form a critical component in the regulation of
              human health and disease. While their functional significance is
              increasingly being recognized, the comprehensive heterogeneity of
              lymphatics remains uncharacterized. Here, we report the profiling
              of 33,000 lymphatic endothelial cells (LECs) in human lymph nodes
              (LNs) by single-cell RNA sequencing. Unbiased clustering revealed
              six major types of human LECs. LECs lining the subcapsular sinus
              (SCS) of LNs abundantly expressed neutrophil chemoattractants,
              whereas LECs lining the medullary sinus (MS) expressed a C-type
              lectin CD209. Binding of a carbohydrate Lewis X (CD15) to CD209
              mediated neutrophil binding to the MS. The neutrophil-selective
              homing by MS LECs may retain neutrophils in the LN medulla and
              allow lymph-borne pathogens to clear, preventing their spread
              through LNs in humans. Our study provides a comprehensive
              characterization of LEC heterogeneity and unveils a previously
              undefined role for medullary LECs in human immunity.",
  journal  = "Immunity",
  volume   =  51,
  number   =  3,
  pages    = "561--572.e5",
  month    =  sep,
  year     =  2019,
  keywords = "cell adhesion; heterogeneity; human immunity; leukocyte
              trafficking; lymph nodes; lymphatic endothelial cells; lymphatic
              vessels; lymphatics; neutrophils; single-cell RNA-seq",
  language = "en"
}

@ARTICLE{Zenke2020-pg,
  title    = "Quorum Regulation via Nested Antagonistic Feedback Circuits
              Mediated by the Receptors {CD28} and {CTLA-4} Confers Robustness
              to {T} Cell Population Dynamics",
  author   = "Zenke, Simon and Palm, Margriet M and Braun, Julia and Gavrilov,
              Alina and Meiser, Philippa and B{\"o}ttcher, Jan P and
              Beyersdorf, Niklas and Ehl, Stephan and Gerard, Audrey and
              L{\"a}mmermann, Tim and Schumacher, Ton N and Beltman, Joost B
              and Rohr, Jan C",
  abstract = "T cell responses upon infection display a remarkably reproducible
              pattern of expansion, contraction, and memory formation. If the
              robustness of this pattern builds entirely on signals derived
              from other cell types or if activated T cells themselves
              contribute to the orchestration of these population dynamics-akin
              to bacterial quorum regulation-is unclear. Here, we examined this
              question using time-lapse microscopy, genetic perturbation,
              bioinformatic predictions, and mathematical modeling. We found
              that ICAM-1-mediated cell clustering enabled CD8+ T cells to
              collectively regulate the balance between proliferation and
              apoptosis. Mechanistically, T cell expressed CD80 and CD86
              interacted with the receptors CD28 and CTLA-4 on neighboring T
              cells; these interactions fed two nested antagonistic feedback
              circuits that regulated interleukin 2 production in a manner
              dependent on T cell density as confirmed by in vivo modulation of
              this network. Thus, CD8+ T cell-population-intrinsic mechanisms
              regulate cellular behavior, thereby promoting robustness of
              population dynamics.",
  journal  = "Immunity",
  volume   =  52,
  number   =  2,
  pages    = "313--327.e7",
  month    =  feb,
  year     =  2020,
  keywords = "CD28; CD80; CTLA-4; IL-2; T lymphocyte; feedback; population
              dynamics; quorum regulation; robustness",
  language = "en"
}

@ARTICLE{Pauken2015-ts,
  title    = "Overcoming {T} cell exhaustion in infection and cancer",
  author   = "Pauken, Kristen E and Wherry, E John",
  abstract = "Inhibitors of the Programmed Cell Death 1: Programmed Cell Death
              1 ligand 1 (PD-1:PD-L1) pathway, a central regulator of T cell
              exhaustion, have been recently shown to be effective for
              treatment of different cancers. However, clinical responses are
              mixed, highlighting the need to better understand the mechanisms
              of action of PD-1:PD-L1, the role of this pathway in immunity to
              different tumors, and the molecular and cellular effects of PD-1
              blockade. Here, we review the molecular regulation of T cell
              exhaustion, placing recent findings on PD-1 blockade therapies in
              cancer in the context of the broader understanding of the roles
              of the PD-1:PD-L1 pathway in T cell exhaustion during chronic
              infection. We discuss the current understanding of the mechanisms
              involved in reversing T cell exhaustion, and outline critical
              areas of focus for future research, both basic and clinical.",
  journal  = "Trends Immunol.",
  volume   =  36,
  number   =  4,
  pages    = "265--276",
  month    =  apr,
  year     =  2015,
  keywords = "PD-1; PD-L1; T cell exhaustion; cancer; chronic infection;
              immunotherapy",
  language = "en"
}

@ARTICLE{Halle2017-vg,
  title    = "Mechanisms and Dynamics of {T} {Cell-Mediated} Cytotoxicity In
              Vivo",
  author   = "Halle, Stephan and Halle, Olga and F{\"o}rster, Reinhold",
  abstract = "Cytotoxic T lymphocytes (CTLs) are critical in the elimination of
              infected or malignant cells and are emerging as a major
              therapeutic target. How CTLs recognize and kill harmful cells has
              been characterized in vitro but little is known about these
              processes in the living organism. Here we review recent insights
              into CTL-mediated killing with an emphasis on in vivo CTL
              biology. Specifically, we focus on the possible rate-limiting
              steps determining the efficiency of CTL-mediated killing. We also
              highlight the need for cell-based datasets that permit the
              quantification of CTL dynamics, including CTL location,
              migration, and killing rates. A better understanding of these
              factors is required to predict protective CD8 T cell immunity in
              vivo and to design optimized vaccination protocols.",
  journal  = "Trends Immunol.",
  volume   =  38,
  number   =  6,
  pages    = "432--443",
  month    =  jun,
  year     =  2017,
  keywords = "cell migration; cellular immunity; chemokines; cytotoxic T cells;
              immunological synapses; immunotherapy; two-photon imaging",
  language = "en"
}

@ARTICLE{Beltman2009-od,
  title    = "Towards estimating the true duration of dendritic cell
              interactions with {T} cells",
  author   = "Beltman, Joost B and Henrickson, Sarah E and von Andrian, Ulrich
              H and de Boer, Rob J and Mar{\'e}e, Athanasius F M",
  abstract = "To initiate an adaptive immune response, T cells need to interact
              with dendritic cells (DCs), and the duration of these
              interactions plays an important role. In vitro and in vivo
              experiments have generally tried to estimate the required period
              of opportunity for T cell stimulation rather than the duration of
              individual T cell-DC interactions. Since the application of
              multi-photon microscopy (MPM) to living lymphoid tissues, the
              interactions between immune cells, as well as the duration
              thereof, can directly be observed in vivo. Indeed, long-lasting
              interactions between T cells and DCs were shown to be important
              for the onset of immune responses. However, because MPM imaging
              is typically restricted to experiments lasting 1 h, and because T
              cell-DC conjugates frequently move into and out of the imaged
              volume, it is difficult to estimate the true duration of
              interactions from MPM contact data. Here, we present a method to
              properly make such an estimate of (the average of) the
              distribution of contact durations. We validate the method by
              applying it to spatially explicit computer simulations where the
              true distribution of contact duration is known. Finally, we apply
              our analysis to a large experimental data set of T-DC contacts,
              and predict an average contact time of about three hours.
              However, we identify a mismatch between the experimental data and
              the model predictions, and investigate possible causes of the
              mismatch, including minor tissue drift during imaging
              experiments. We discuss in detail how future experiments can be
              optimized such that MPM contact data will be minimally affected
              by these factors.",
  journal  = "J. Immunol. Methods",
  volume   =  347,
  number   = "1-2",
  pages    = "54--69",
  month    =  aug,
  year     =  2009,
  language = "en"
}

@ARTICLE{Moore2004-zw,
  title     = "A mathematical model for chronic myelogenous leukemia ({CML})
               and {T} cell interaction",
  author    = "Moore, Helen and Li, Natasha K",
  abstract  = "In this paper, we propose and analyse a mathematical model for
               chronic myelogenous leukemia (CML), a cancer of the blood. We
               model the interaction between naive T cells, effector T cells,
               and CML cancer cells in the body, using a system of ordinary
               differential equations which gives rates of change of the three
               cell populations. One of the difficulties in modeling CML is the
               scarcity of experimental data which can be used to estimate
               parameters values. To compensate for the resulting
               uncertainties, we use Latin hypercube sampling (LHS) on large
               ranges of possible parameter values in our analysis. A major
               goal of this work is the determination of parameters which play
               a critical role in remission or clearance of the cancer in the
               model. Our analysis examines 12 parameters, and identifies two
               of these, the growth and death rates of CML, as critical to the
               outcome of the system. Our results indicate that the most
               promising research avenues for treatments of CML should be those
               that affect these two significant parameters (CML growth and
               death rates), while altering the other parameters should have
               little effect on the outcome.",
  journal   = "J. Theor. Biol.",
  publisher = "Elsevier",
  volume    =  227,
  number    =  4,
  pages     = "513--523",
  month     =  apr,
  year      =  2004,
  language  = "en"
}

@ARTICLE{De_Pillis2006-cl,
  title    = "Mixed immunotherapy and chemotherapy of tumors: modeling,
              applications and biological interpretations",
  author   = "de Pillis, L G and Gu, W and Radunskaya, A E",
  abstract = "We develop and analyze a mathematical model, in the form of a
              system of ordinary differential equations (ODEs), governing
              cancer growth on a cell population level with combination immune,
              vaccine and chemotherapy treatments. We characterize the ODE
              system dynamics by locating equilibrium points, determining
              stability properties, performing a bifurcation analysis, and
              identifying basins of attraction. These system characteristics
              are useful not only to gain a broad understanding of the specific
              system dynamics, but also to help guide the development of
              combination therapies. Numerical simulations of mixed
              chemo-immuno and vaccine therapy using both mouse and human
              parameters are presented. We illustrate situations for which
              neither chemotherapy nor immunotherapy alone are sufficient to
              control tumor growth, but in combination the therapies are able
              to eliminate the entire tumor.",
  journal  = "J. Theor. Biol.",
  volume   =  238,
  number   =  4,
  pages    = "841--862",
  month    =  feb,
  year     =  2006,
  language = "en"
}

@ARTICLE{Gerlee2007-re,
  title    = "An evolutionary hybrid cellular automaton model of solid tumour
              growth",
  author   = "Gerlee, P and Anderson, A R A",
  abstract = "We propose a cellular automaton model of solid tumour growth, in
              which each cell is equipped with a micro-environment response
              network. This network is modelled using a feed-forward artificial
              neural network, that takes environmental variables as an input
              and from these determines the cellular behaviour as the output.
              The response of the network is determined by connection weights
              and thresholds in the network, which are subject to mutations
              when the cells divide. As both available space and nutrients are
              limited resources for the tumour, this gives rise to clonal
              evolution where only the fittest cells survive. Using this
              approach we have investigated the impact of the tissue oxygen
              concentration on the growth and evolutionary dynamics of the
              tumour. The results show that the oxygen concentration affects
              the selection pressure, cell population diversity and morphology
              of the tumour. A low oxygen concentration in the tissue gives
              rise to a tumour with a fingered morphology that contains
              aggressive phenotypes with a small apoptotic potential, while a
              high oxygen concentration in the tissue gives rise to a tumour
              with a round morphology containing less evolved phenotypes. The
              tissue oxygen concentration thus affects the tumour at both the
              morphological level and on the phenotype level.",
  journal  = "J. Theor. Biol.",
  volume   =  246,
  number   =  4,
  pages    = "583--603",
  month    =  jun,
  year     =  2007,
  language = "en"
}

@ARTICLE{Robertson-Tessi2012-hb,
  title    = "A mathematical model of tumor-immune interactions",
  author   = "Robertson-Tessi, Mark and El-Kareh, Ardith and Goriely, Alain",
  abstract = "A mathematical model of the interactions between a growing tumor
              and the immune system is presented. The equations and parameters
              of the model are based on experimental and clinical results from
              published studies. The model includes the primary cell
              populations involved in effector T-cell mediated tumor killing:
              regulatory T cells, helper T cells, and dendritic cells. A key
              feature is the inclusion of multiple mechanisms of
              immunosuppression through the main cytokines and growth factors
              mediating the interactions between the cell populations.
              Decreased access of effector cells to the tumor interior with
              increasing tumor size is accounted for. The model is applied to
              tumors with different growth rates and antigenicities to gauge
              the relative importance of various immunosuppressive mechanisms.
              The most important factors leading to tumor escape are
              TGF-$\beta$-induced immunosuppression, conversion of helper T
              cells into regulatory T cells, and the limitation of immune cell
              access to the full tumor at large tumor sizes. The results
              suggest that for a given tumor growth rate, there is an optimal
              antigenicity maximizing the response of the immune system.
              Further increases in antigenicity result in increased
              immunosuppression, and therefore a decrease in tumor killing
              rate. This result may have implications for immunotherapies which
              modulate the effective antigenicity. Simulation of dendritic cell
              therapy with the model suggests that for some tumors, there is an
              optimal dose of transfused dendritic cells.",
  journal  = "J. Theor. Biol.",
  volume   =  294,
  pages    = "56--73",
  month    =  feb,
  year     =  2012,
  language = "en"
}

@ARTICLE{Levin2016-gl,
  title    = "A spatial model of the efficiency of {T} cell search in the
              influenza-infected lung",
  author   = "Levin, Drew and Forrest, Stephanie and Banerjee, Soumya and Clay,
              Candice and Cannon, Judy and Moses, Melanie and Koster, Frederick",
  abstract = "Emerging strains of influenza, such as avian H5N1 and 2009
              pandemic H1N1, are more virulent than seasonal H1N1 influenza,
              yet the underlying mechanisms for these differences are not well
              understood. Subtle differences in how a given strain interacts
              with the immune system are likely a key factor in determining
              virulence. One aspect of the interaction is the ability of T
              cells to locate the foci of the infection in time to prevent
              uncontrolled expansion. Here, we develop an agent based spatial
              model to focus on T cell migration from lymph nodes through the
              vascular system to sites of infection. We use our model to
              investigate whether different strains of influenza modulate this
              process. We calibrate the model using viral and chemokine
              secretion rates we measure in vitro together with values taken
              from literature. The spatial nature of the model reveals unique
              challenges for T cell recruitment that are not apparent in
              standard differential equation models. In this model comparing
              three influenza viruses, plaque expansion is governed primarily
              by the replication rate of the virus strain, and the efficiency
              of the T cell search-and-kill is limited by the density of
              infected epithelial cells in each plaque. Thus for each virus
              there is a different threshold of T cell search time above which
              recruited T cells are unable to control further expansion. Future
              models could use this relationship to more accurately predict
              control of the infection.",
  journal  = "J. Theor. Biol.",
  volume   =  398,
  pages    = "52--63",
  month    =  jun,
  year     =  2016,
  keywords = "Agent-based model; Computational biology; Immunology; Systems
              biology; Virology",
  language = "en"
}

@ARTICLE{DAmato2007-sq,
  title    = "Chemotherapy resistance and oncogene expression in non-small cell
              lung cancer",
  author   = "d'Amato, Thomas A and Landreneau, Rodney J and Ricketts, William
              and Huang, Weidong and Parker, Ricardo and Mechetner, Eugene and
              Yu, Ing-Ru and Luketich, James D",
  abstract = "OBJECTIVES: Empiric chemotherapy for patients with non-small cell
              lung cancer who have undergone resection is recommended without
              knowledge of the tumor's specific biologic characteristics, and
              many patients may not benefit. In vitro chemotherapy resistance
              is associated with clinical unresponsiveness in some tumors, and
              in lung cancer, chemotherapy resistance is prevalent.
              Multiple-agent chemotherapy resistance and association of
              chemotherapy resistance with molecular markers are described.
              METHODS: Chemotherapy resistance to doublets--carboplatin and
              paclitaxel, cisplatin and navelbline, cisplatin and docetaxel,
              and cisplatin and gemcitabine--was analyzed in 4571 non-small
              cell lung cancer tumors with the extreme drug resistance assay.
              Chemotherapy resistance is defined as follows: extreme drug
              resistance, 1 SD above the median chemotherapy resistance;
              intermediate drug resistance, between the median and extreme drug
              resistances; and low drug resistance, 1 SD below the median.
              Chemotherapy resistance was compared with DNA ploidy measured by
              flow cytometry, and markers p53 and epithelial growth factor
              receptor were assayed by immunohistochemistry. RESULTS: Tumors
              with extreme or intermediate drug resistance were noted in 30\%
              to carboplatin-paclitaxel, in 24\% to cisplatin-navelbline, in
              42\% to cisplatin-gemcitabine, and in 27\% to
              cisplatin-docetaxel. Extreme or intermediate drug resistance to
              at least one drug occurred in 74\% to carboplatin-paclitaxel, in
              68\% to cisplatin-navelbline, in 88\% to cisplatin-gemcitabine,
              and in 68\% to cisplatin-docetaxel. More intermediate plus
              extreme chemotherapy resistances occurred in aneuploid tumors to
              etoposide (53\% vs 36\%, P = .0002) and topotecan (48\% vs 36\%,
              P = .0094), with less intermediate or extreme chemotherapy
              resistance to gemcitabine (88\% vs 81\%, P = .0345). p53-Positive
              tumors had more intermediate or extreme resistance to etoposide
              (57\% vs 44\%, P = .0009) and doxorubicin (73\% vs. 58\%, P =
              .0324) and less intermediate or extreme resistance to cisplatin
              (44\% vs 54\%, P = .0125), to carboplatin (47\% vs 57\%, P =
              .0129), to taxol (47\% vs 57\%, P = .0056), and to gemcitabine
              (78\% vs 87\%, P = .0108). Fewer epithelial growth factor
              receptor-positive tumors were extremely drug resistant to
              cisplatin (13\% vs 26\%, P = .0074) and carboplatin (13\% v.
              30\%, P = .0008). CONCLUSIONS: Multi-drug chemotherapy resistance
              in non-small cell lung cancer tumor cultures is common, and
              associations between molecular markers and in vitro chemotherapy
              resistance are noted. Clinical validation through integration of
              such testing into clinical trials seems warranted.",
  journal  = "J. Thorac. Cardiovasc. Surg.",
  volume   =  133,
  number   =  2,
  pages    = "352--363",
  month    =  feb,
  year     =  2007,
  language = "en"
}

@ARTICLE{Choi2009-qd,
  title    = "Chromosomal instability is a risk factor for poor prognosis of
              adenocarcinoma of the lung: Fluorescence in situ hybridization
              analysis of paraffin-embedded tissue from Korean patients",
  author   = "Choi, Chang-Min and Seo, Kwang Won and Jang, Se Jin and Oh,
              Yeon-Mok and Shim, Tae-Sun and Kim, Woo Sung and Lee, Dong-Soon
              and Lee, Sang-Do",
  abstract = "BACKGROUND: In this study, we sought to evaluate the prognostic
              importance of chromosomal instability (CIN) in adenocarcinoma
              (AC) of the lung. The relationship between CIN detected by
              fluorescence in situ hybridization (FISH) and survival in AC
              patients was examined. METHODS: Sixty-three surgical specimens of
              lung AC were analyzed. To identify tumors with CIN, p16 and
              multi-target DNA FISH assays for c-myc, chromosome 6, EGFR, and
              chromosome 5 (LAVysion, Vysis) were performed on nuclei extracted
              from paraffin-embedded tumor tissues. Survival rates were
              compared in terms of sex, age, histology, T factor, N factor,
              CIN, and smoking status. A sample was classified as CIN-positive
              if at least three of the five chromosomes were positive. RESULTS:
              Out of the 63 specimens, 32 (39.7\%) were CIN-positive. The
              5-year overall disease-free survival rate was 58.7\% as a whole,
              46.9\% for CIN-positive patients and 71.0\% for the CIN-negative
              patients [hazard ratio (HR), 2.34; 95\% confidence interval (CI),
              1.04-5.26; p = 0.04]. The 5-year overall survival rate was
              81.0\%, 68.7\% for CIN-positive patients and 93.5\% for the
              CIN-negative patients (HR, 5.64; 95\% CI, 1.23-25.70; p = 0.026).
              In multivariate analysis after adjusting for pathologic nodal
              staging, tumor staging, sex, age, and smoking history, compared
              with the CIN-negative patients, the CIN-positive status remained
              significantly associated with decreased overall survival (HR,
              8.48; 95\% CI, 1.66-43.42; p = 0.010). CONCLUSIONS: CIN can be
              effectively detected in primary AC of lung using FISH analysis.
              CIN is associated with poor prognosis for AC, and may thus be
              utilized as an independent prognostic factor for the disease.",
  journal  = "Lung Cancer",
  volume   =  64,
  number   =  1,
  pages    = "66--70",
  month    =  apr,
  year     =  2009,
  language = "en"
}

@ARTICLE{Hug2013-qx,
  title    = "High-dimensional Bayesian parameter estimation: case study for a
              model of {JAK2/STAT5} signaling",
  author   = "Hug, S and Raue, A and Hasenauer, J and Bachmann, J and
              Klingm{\"u}ller, U and Timmer, J and Theis, F J",
  abstract = "In this work we present results of a detailed Bayesian parameter
              estimation for an analysis of ordinary differential equation
              models. These depend on many unknown parameters that have to be
              inferred from experimental data. The statistical inference in a
              high-dimensional parameter space is however conceptually and
              computationally challenging. To ensure rigorous assessment of
              model and prediction uncertainties we take advantage of both a
              profile posterior approach and Markov chain Monte Carlo sampling.
              We analyzed a dynamical model of the JAK2/STAT5 signal
              transduction pathway that contains more than one hundred
              parameters. Using the profile posterior we found that the
              corresponding posterior distribution is bimodal. To guarantee
              efficient mixing in the presence of multimodal posterior
              distributions we applied a multi-chain sampling approach. The
              Bayesian parameter estimation enables the assessment of
              prediction uncertainties and the design of additional experiments
              that enhance the explanatory power of the model. This study
              represents a proof of principle that detailed statistical
              analysis for quantitative dynamical modeling used in systems
              biology is feasible also in high-dimensional parameter spaces.",
  journal  = "Math. Biosci.",
  volume   =  246,
  number   =  2,
  pages    = "293--304",
  month    =  dec,
  year     =  2013,
  keywords = "Bayesian inference; Cellular signal transduction pathways;
              Ordinary differential equation models; Parameter estimation;
              Profile likelihood",
  language = "en"
}

@ARTICLE{Frascoli2014-dy,
  title    = "A dynamical model of tumour immunotherapy",
  author   = "Frascoli, Federico and Kim, Peter S and Hughes, Barry D and
              Landman, Kerry A",
  abstract = "A coupled ordinary differential equation model of tumour-immune
              dynamics is presented and analysed. The model accounts for
              biological and clinical factors which regulate the interaction
              rates of cytotoxic T lymphocytes on the surface of the tumour
              mass. A phase plane analysis demonstrates that competition
              between tumour cells and lymphocytes can result in tumour
              eradication, perpetual oscillations, or unbounded solutions. To
              investigate the dependence of the dynamic behaviour on model
              parameters, the equations are solved analytically and conditions
              for unbounded versus bounded solutions are discussed. An analytic
              characterisation of the basin of attraction for oscillatory
              orbits is given. It is also shown that the tumour shape,
              characterised by a surface area to volume scaling factor,
              influences the size of the basin, with significant consequences
              for therapy design. The findings reveal that the tumour volume
              must surpass a threshold size that depends on lymphocyte
              parameters for the cancer to be completely eliminated. A
              semi-analytic procedure to calculate oscillation periods and
              determine their sensitivity to model parameters is also
              presented. Numerical results show that the period of oscillations
              exhibits notable nonlinear dependence on biologically relevant
              conditions.",
  journal  = "Math. Biosci.",
  volume   =  253,
  pages    = "50--62",
  month    =  jul,
  year     =  2014,
  keywords = "Cancer; Dynamical systems; Finite-time tumour elimination;
              Immunotherapy; Ordinary differential equations",
  language = "en"
}

@ARTICLE{Qomlaqi2017-mr,
  title    = "An extended mathematical model of tumor growth and its
              interaction with the immune system, to be used for developing an
              optimized immunotherapy treatment protocol",
  author   = "Qomlaqi, Milad and Bahrami, Fariba and Ajami, Maryam and Hajati,
              Jamshid",
  abstract = "BACKGROUND: Chemotherapy is usually known as the main modality
              for cancer treatment. Nevertheless, most of chronic cancers could
              not be treated with chemotherapy alone. Immunotherapy is a new
              modality for cancer treatment that is effective for early stages
              of cancer and it has fewer side effects compared to chemotherapy,
              specifically for those types of cancer that are resistant to it.
              METHOD: This work presents an extended mathematical model to
              depict interactions between cancerous and adaptive immune system
              in mouse. We called the model an extended model, because we
              embedded all those compartments that have important roles in
              response to tumor in one model. The model includes tumor cells,
              natural killers, na{\"\i}ve and mature cytotoxic T cells,
              na{\"\i}ve and mature helper T cells, regulatory T cells,
              dendritic cells and interleukin 2 cytokine. Whole cycle of cell
              division program of immune cells is also considered in the model.
              We also optimized protocol of immunotherapy with DC vaccine based
              on the proposed mathematical model. RESULT: Simulation results of
              the proposed model are in conformity with the experimental data
              recorded from mouse in immunology department of Tehran University
              of Medical Science as well as what has been explained in the
              literature. Our results explain dynamics of the immune cells from
              the first day of cancer growth and progression. Simulation result
              shows that reducing intervals between immunotherapy injections,
              efficacy of the treatment will be increased because CD8+ cells
              are boosted more rapidly. Optimized protocol for immunotherapy
              suggests that if the effect of DC vaccines on increasing number
              of anti-tumor immune cells be just before the maximum number of
              CD8+ cells, the effect of treatment will be maximized.",
  journal  = "Math. Biosci.",
  volume   =  292,
  pages    = "1--9",
  month    =  oct,
  year     =  2017,
  keywords = "Cancer; Immune system; Immunotherapy; Mathematical model;
              Optimization; Tumor",
  language = "en"
}

@ARTICLE{Hartl2014-gn,
  title    = "What can we learn from fitness landscapes?",
  author   = "Hartl, Daniel L",
  abstract = "A combinatorially complete data set consists of studies of all
              possible combinations of a set of mutant sites in a gene or
              mutant alleles in a genome. Among the most robust conclusions
              from these studies is that epistasis between beneficial mutations
              often shows a pattern of diminishing returns, in which favorable
              mutations are less fit when combined than would be expected.
              Another robust inference is that the number of adaptive
              evolutionary paths is often limited to a relatively small
              fraction of the theoretical possibilities, owing largely to sign
              epistasis requiring evolutionary steps that would entail a
              decrease in fitness. Here we summarize these and other results
              while also examining issues that remain unresolved and future
              directions that seem promising.",
  journal  = "Curr. Opin. Microbiol.",
  volume   =  21,
  pages    = "51--57",
  month    =  oct,
  year     =  2014,
  language = "en"
}

% The entry below contains non-ASCII chars that could not be converted
% to a LaTeX equivalent.
@ARTICLE{Frumkin2017-ry,
  title    = "Gene Architectures that Minimize Cost of Gene Expression",
  author   = "Frumkin, Idan and Schirman, Dvir and Rotman, Aviv and Li, Fangfei
              and Zahavi, Liron and Mordret, Ernest and Asraf, Omer and Wu,
              Song and Levy, Sasha F and Pilpel, Yitzhak",
  abstract = "Gene expression burdens cells by consuming resources and energy.
              While numerous studies have investigated regulation of expression
              level, little is known about gene design elements that govern
              expression costs. Here, we ask how cells minimize production
              costs while maintaining a given protein expression level and
              whether there are gene architectures that optimize this process.
              We measured fitness of 14,000 E. coli strains, each expressing a
              reporter gene with a unique 5' architecture. By comparing
              cost-effective and ineffective architectures, we found that cost
              per protein molecule could be minimized by lowering transcription
              levels, regulating translation speeds, and utilizing amino acids
              that are cheap to synthesize and that are less hydrophobic. We
              then examined natural E. coli genes and found that highly
              expressed genes have evolved more forcefully to minimize costs
              associated with their expression. Our study thus elucidates gene
              design elements that improve the economy of protein expression in
              natural and heterologous systems.",
  journal  = "Mol. Cell",
  volume   =  65,
  number   =  1,
  pages    = "142--153",
  month    =  jan,
  year     =  2017,
  keywords = "expression cost; gene expression; genome evolution; optimal gene
              architecture; synthetic biology; synthetic library; systems
              biology; translation efficiency",
  language = "en"
}

@ARTICLE{Urao2016-sc,
  title    = "{MicroCT} angiography detects vascular formation and regression
              in skin wound healing",
  author   = "Urao, Norifumi and Okonkwo, Uzoagu A and Fang, Milie M and
              Zhuang, Zhen W and Koh, Timothy J and DiPietro, Luisa A",
  abstract = "Properly regulated angiogenesis and arteriogenesis are essential
              for effective wound healing. Tissue injury induces robust new
              vessel formation and subsequent vessel maturation, which involves
              vessel regression and remodeling. Although formation of
              functional vasculature is essential for healing, alterations in
              vascular structure over the time course of skin wound healing are
              not well understood. Here, using high-resolution ex vivo X-ray
              micro-computed tomography (microCT), we describe the vascular
              network during healing of skin excisional wounds with highly
              detailed three-dimensional (3D) reconstructed images and
              associated quantitative analysis. We found that relative vessel
              volume, surface area and branching number are significantly
              decreased in wounds from day 7 to days 14 and 21. Segmentation
              and skeletonization analysis of selected branches from
              high-resolution images as small as 2.5$\mu$m voxel size show that
              branching orders are decreased in the wound vessels during
              healing. In histological analysis, we found that the contrast
              agent fills mainly arterioles, but not small capillaries nor
              large veins. In summary, high-resolution microCT revealed dynamic
              alterations of vessel structures during wound healing. This
              technique may be useful as a key tool in the study of the
              formation and regression of wound vessels.",
  journal  = "Microvasc. Res.",
  volume   =  106,
  pages    = "57--66",
  month    =  jul,
  year     =  2016,
  keywords = "Angiogenesis; Angiography; Micro-computed tomography;
              Three-dimensional; Wound healing",
  language = "en"
}

@ARTICLE{Longo2016-nf,
  title    = "Why do we need theories?",
  author   = "Longo, Giuseppe and Soto, Ana M",
  abstract = "Theories organize knowledge and construct objectivity by framing
              observations and experiments. The elaboration of theoretical
              principles is examined in the light of the rich interactions
              between physics and mathematics. These two disciplines share
              common principles of construction of concepts and of the proper
              objects of inquiry. Theory construction in physics relies on
              mathematical symmetries that preserve the key invariants observed
              and proposed by such theory; these invariants buttress the idea
              that the objects of physics are generic and thus interchangeable
              and they move along specific trajectories which are uniquely
              determined, in classical and relativistic physics. In contrast to
              physics, biology is a historical science that centers on the
              changes that organisms experience while undergoing ontogenesis
              and phylogenesis. Biological objects, namely organisms, are not
              generic but specific; they are individuals. The incessant changes
              they undergo represent the breaking of symmetries, and thus the
              opposite of symmetry conservation, a central component of
              physical theories. This instability corresponds to the changes of
              the environment and the phenotypes. Inspired by Galileo's
              principle of inertia, the ``default state'' of inert matter, we
              propose a ``default state'' for biological dynamics following
              Darwin's first principle, ``descent with modification'' that we
              transform into ``proliferation with variation and motility'' as a
              property that spans life, including cells in an organism. These
              dissimilarities between theories of the inert and of biology also
              apply to causality: biological causality is to be understood in
              relation to the distinctive role that constraints assume in this
              discipline. Consequently, the notion of cause will be reframed in
              a context where constraints to activity are seen as the core
              component of biological analyses. Finally, we assert that the
              radical materiality of life rules out distinctions such as
              ``software vs. hardware.''",
  journal  = "Prog. Biophys. Mol. Biol.",
  volume   =  122,
  number   =  1,
  pages    = "4--10",
  month    =  oct,
  year     =  2016,
  keywords = "Biological organization; Default state; Mathematical symmetries;
              Phase space",
  language = "en"
}

@ARTICLE{Li2017-sl,
  title    = "Experimental animal modeling for immuno-oncology",
  author   = "Li, Qi-Xiang and Feuer, Gerold and Ouyang, Xuesong and An, Xiaoyu",
  abstract = "Immuno-oncology (I/O) research has intensified significantly in
              recent years due to the breakthrough development and the
              regulatory approval of several immune checkpoint inhibitors,
              leading to the rapid expansion of the new discovery of novel I/O
              therapies, new checkpoint inhibitors and beyond. However, many
              I/O questions remain unanswered, including why only certain
              subsets of patients respond to these treatments, who the
              responders would be, and how to expand patient response (the
              conversion of non-responders or maximizing response in partial
              responders). All of these require relevant I/O experimental
              systems, particularly relevant preclinical animal models.
              Compared to other oncology drug discovery, e.g. cytotoxic and
              targeted drugs, a lack of relevant animal models is a major
              obstacle in I/O drug discovery, and an urgent and unmet need.
              Despite the obvious importance, and the fact that much I/O
              research has been performed using many different animal models,
              there are few comprehensive and introductory reviews on this
              topic. This article attempts to review the efforts in development
              of a variety of such models, as well as their applications and
              limitations for readers new to the field, particularly those in
              the pharmaceutical industry.",
  journal  = "Pharmacol. Ther.",
  volume   =  173,
  pages    = "34--46",
  month    =  may,
  year     =  2017,
  keywords = "GEMM; Homograft; Humanization; Murine and human immunity;
              Syngeneic; Xenograft",
  language = "en"
}

@ARTICLE{Nachtomy2007-kt,
  title    = "Gene expression and the concept of the phenotype",
  author   = "Nachtomy, Ohad and Shavit, Ayelet and Yakhini, Zohar",
  abstract = "While the definition of the 'genotype' has undergone dramatic
              changes in the transition from classical to molecular genetics,
              the definition of the 'phenotype' has remained for a long time
              within the classical framework. In addition, while the notion of
              the genotype has received significant attention from philosophers
              of biology, the notion of the phenotype has not. Recent
              developments in the technology of measuring gene-expression
              levels have made it possible to conceive of phenotypic traits in
              terms of levels of gene expression. We demonstrate that not only
              has this become possible but it has also become an actual
              practice. This suggests a significant change in our conception of
              the phenotype: as in the case of the 'genotype', phenotypes can
              now be conceived in quantitative and measurable terms on a
              comprehensive molecular level. We discuss in what sense gene
              expression profiles can be regarded as phenotypic traits and
              whether these traits are better described as a novel concept of
              phenotype or as an extension of the classical concept. We argue
              for an extension of the classical concept and call for an
              examination of the type of extension involved.",
  journal  = "Stud. Hist. Philos. Biol. Biomed. Sci.",
  volume   =  38,
  number   =  1,
  pages    = "238--254",
  month    =  mar,
  year     =  2007,
  language = "en"
}

@ARTICLE{Butler2021-dd,
  title    = "Amino Acid Depletion Therapies: Starving Cancer Cells to Death",
  author   = "Butler, Miriam and van der Meer, Laurens T and van Leeuwen, Frank
              N",
  abstract = "Targeting tumor cell metabolism is an attractive form of therapy,
              as it may enhance treatment response in therapy resistant cancers
              as well as mitigate treatment-related toxicities by reducing the
              need for genotoxic agents. To meet their increased demand for
              biomass accumulation and energy production and to maintain redox
              homeostasis, tumor cells undergo profound changes in their
              metabolism. In addition to the diversion of glucose metabolism,
              this is achieved by upregulation of amino acid metabolism.
              Interfering with amino acid availability can be selectively
              lethal to tumor cells and has proven to be a cancer specific
              Achilles' heel. Here we review the biology behind such cancer
              specific amino acid dependencies and discuss how these
              vulnerabilities can be exploited to improve cancer therapies.",
  journal  = "Trends Endocrinol. Metab.",
  volume   =  32,
  number   =  6,
  pages    = "367--381",
  month    =  jun,
  year     =  2021,
  keywords = "amino acid depletion therapy; amino acid metabolism; cancer;
              tumor metabolism",
  language = "en"
}

@ARTICLE{Vashi2021-iv,
  title    = "The Evolution of {STING} Signaling and Its Involvement in Cancer",
  author   = "Vashi, Nimi and Bakhoum, Samuel F",
  abstract = "The cyclic GMP-AMP synthase (cGAS)-stimulator of interferon genes
              (STING) pathway has been primarily characterized as an
              inflammatory mechanism in higher eukaryotes in response to
              cytosolic double-stranded DNA (dsDNA). Since its initial
              discovery, detailed mechanisms delineating the dynamic
              subcellular localization of its different components and
              downstream signaling have been uncovered, leading to attempts to
              harness its proinflammatory properties for therapeutic benefit in
              cancer. Emerging evidence, however, indicates that a crucial
              primordial function of STING is to promote autophagy, and that
              downstream interferon (IFN) signaling emerged recently in its
              evolutionary history. Furthermore, studies suggest that this
              pathway is a crucial regulator of cellular metabolism that
              potentially couples inflammation to nutrient availability. We
              focus on the evolutionarily conserved functions of STING, and we
              discuss how a broader understanding of this pathway can help us
              to better appreciate its potential role in cancer and harness it
              for therapeutic benefit.",
  journal  = "Trends Biochem. Sci.",
  volume   =  46,
  number   =  6,
  pages    = "446--460",
  month    =  jun,
  year     =  2021,
  keywords = "autophagy; inflammation; membrane trafficking; metabolism;
              metastasis; non-canonical NF-$\kappa$B",
  language = "en"
}

@ARTICLE{Geigl2008-az,
  title    = "Defining `chromosomal instability'",
  author   = "Geigl, Jochen B and Obenauf, Anna C and Schwarzbraun, Thomas and
              Speicher, Michael R",
  abstract = "Most scientists agree that the majority of human solid malignant
              tumors are characterized by chromosomal instability (CIN)
              involving gain or loss of whole chromosomes or fractions of
              chromosomes. CIN is thought to be an early event during
              tumorigenesis and might therefore be involved in tumor
              initiation. Despite its frequent occurrence in tumors and its
              potential importance in tumor evolution, CIN is poorly defined
              and is used inconsistently and imprecisely. Here, we provide
              criteria to define CIN and argue that few experimental approaches
              are capable of assessing the presence of CIN. Accurate assessment
              of CIN is crucial to elucidate whether CIN is a driving force for
              tumorigenesis and whether a chromosomally unstable genome is
              necessary for tumor progression.",
  journal  = "Trends Genet.",
  volume   =  24,
  number   =  2,
  pages    = "64--69",
  month    =  feb,
  year     =  2008
}

@ARTICLE{Veitia2008-gz,
  title    = "Cellular reactions to gene dosage imbalance: genomic,
              transcriptomic and proteomic effects",
  author   = "Veitia, Reiner A and Bottani, Samuel and Birchler, James A",
  abstract = "There is increasing evidence suggesting that stoichiometric
              imbalances in macromolecular complexes and in
              signaling/transcriptional networks are a source of
              dosage-dependent phenotypes. Such alterations can result from
              total or partial aneuploidy, gene copy number variants or
              regulatory alterations. Thus, some gene balance is required to
              ensure a normal function. This balance also dictates which genes
              are preferentially over- or underretained after single gene,
              segmental or whole genome duplications. Here, we review the
              mechanisms leading to dosage effects and compensation at the
              transcriptional and translational levels. Moreover, we propose
              that the involvement of a protein in a complex can affect its
              stability: formation of complexes might mask degradation signals
              in the monomers leading to their preferential degradation when in
              excess, alleviating dosage imbalances.",
  journal  = "Trends Genet.",
  volume   =  24,
  number   =  8,
  pages    = "390--397",
  month    =  aug,
  year     =  2008,
  language = "en"
}

@ARTICLE{Bragg2009-xq,
  title    = "Protein material costs: single atoms can make an evolutionary
              difference",
  author   = "Bragg, Jason G and Wagner, Andreas",
  abstract = "The process of gene expression has material costs caused by the
              quantities of carbon, nitrogen, sulfur and phosphorus that are
              needed to make mRNAs and proteins. When any such chemical element
              is ecologically limiting, mutations increasing these costs can
              reduce growth. Here, we ask if such mutations are `visible' to
              natural selection in the yeast Saccharomyces cerevisiae. We find
              that mutations causing small increases in expression and even
              single amino acid replacements can be subject to natural
              selection on the basis of their material costs.",
  journal  = "Trends Genet.",
  volume   =  25,
  number   =  1,
  pages    = "5--8",
  month    =  jan,
  year     =  2009
}

@ARTICLE{Bragg2009-re,
  title    = "Protein material costs: single atoms can make an evolutionary
              difference",
  author   = "Bragg, Jason G and Wagner, Andreas",
  abstract = "The process of gene expression has material costs caused by the
              quantities of carbon, nitrogen, sulfur and phosphorus that are
              needed to make mRNAs and proteins. When any such chemical element
              is ecologically limiting, mutations increasing these costs can
              reduce growth. Here, we ask if such mutations are 'visible' to
              natural selection in the yeast Saccharomyces cerevisiae. We find
              that mutations causing small increases in expression and even
              single amino acid replacements can be subject to natural
              selection on the basis of their material costs.",
  journal  = "Trends Genet.",
  volume   =  25,
  number   =  1,
  pages    = "5--8",
  month    =  jan,
  year     =  2009,
  language = "en"
}

@ARTICLE{Sheltzer2011-sf,
  title    = "The aneuploidy paradox: costs and benefits of an incorrect
              karyotype",
  author   = "Sheltzer, Jason M and Amon, Angelika",
  abstract = "Aneuploidy has a paradoxical effect on cell proliferation. In all
              normal cells analyzed to date, aneuploidy has been found to
              decrease the rate of cell proliferation. Yet, aneuploidy is also
              a hallmark of cancer, a disease of enhanced proliferative
              capacity, and aneuploid cells are frequently recovered following
              the experimental evolution of microorganisms. Thus, in certain
              contexts, aneuploidy might also have growth-advantageous
              properties. New models of aneuploidy and chromosomal instability
              have shed light on the diverse effects that karyotypic imbalances
              have on cellular phenotypes, and suggest novel ways of
              understanding the role of aneuploidy in development and disease.",
  journal  = "Trends Genet.",
  volume   =  27,
  number   =  11,
  pages    = "446--453",
  month    =  nov,
  year     =  2011,
  language = "en"
}

@ARTICLE{Lukow2022-lf,
  title    = "Chromosomal instability and aneuploidy as causes of cancer drug
              resistance",
  author   = "Lukow, Devon A and Sheltzer, Jason M",
  abstract = "High levels of aneuploidy and chromosomal instability (CIN) are
              correlated with poor patient outcomes, though the mechanism(s)
              underlying this relationship have not been established. Recent
              evidence has demonstrated that chromosome copy number changes can
              function as point mutation-independent sources of drug resistance
              in cancer, which may partially explain this clinical association.
              CIN generates intratumoral heterogeneity in the form of gene
              dosage alterations, upon which the selective pressures induced by
              drug treatments can act. Thus, although CIN and aneuploidy impair
              cell fitness under most conditions, CIN can augment cellular
              adaptability, establishing CIN as a bet-hedging mechanism in
              tumor evolution. CIN may also endow cancers with unique
              vulnerabilities, which could be exploited therapeutically to
              achieve better patient outcomes.",
  journal  = "Trends Cancer Res.",
  volume   =  8,
  number   =  1,
  pages    = "43--53",
  month    =  jan,
  year     =  2022,
  keywords = "aneuploidy; chromosomal instability; drug resistance; tumor
              evolution",
  language = "en"
}

@ARTICLE{Keeley2011-gx,
  title    = "Chemokines as mediators of tumor angiogenesis and
              neovascularization",
  author   = "Keeley, Ellen C and Mehrad, Borna and Strieter, Robert M",
  abstract = "Chemokines are a superfamily of structurally homologous
              heparin-binding proteins that influence tumor growth and
              metastasis. Several members of the CXC and CC chemokine families
              are potent inducers of neovascularization, whereas a subset of
              the CXC chemokines are potent inhibitors. In this paper, we
              review the current literature regarding the role of chemokines as
              mediators of tumor angiogenesis and neovascularization.",
  journal  = "Exp. Cell Res.",
  volume   =  317,
  number   =  5,
  pages    = "685--690",
  month    =  mar,
  year     =  2011,
  language = "en"
}

@ARTICLE{Mazouzi2014-fk,
  title    = "{DNA} replication stress: causes, resolution and disease",
  author   = "Mazouzi, Abdelghani and Velimezi, Georgia and Loizou, Joanna I",
  abstract = "DNA replication is a fundamental process of the cell that ensures
              accurate duplication of the genetic information and subsequent
              transfer to daughter cells. Various pertubations, originating
              from endogenous or exogenous sources, can interfere with proper
              progression and completion of the replication process, thus
              threatening genome integrity. Coordinated regulation of
              replication and the DNA damage response is therefore fundamental
              to counteract these challenges and ensure accurate synthesis of
              the genetic material under conditions of replication stress. In
              this review, we summarize the main sources of replication stress
              and the DNA damage signaling pathways that are activated in order
              to preserve genome integrity during DNA replication. We also
              discuss the association of replication stress and DNA damage in
              human disease and future perspectives in the field.",
  journal  = "Exp. Cell Res.",
  volume   =  329,
  number   =  1,
  pages    = "85--93",
  month    =  nov,
  year     =  2014,
  keywords = "Chromosome fragile sites; DNA damage signaling; DNA replication;
              Genome stability; Replication stress",
  language = "en"
}

@ARTICLE{Picard2018-lt,
  title    = "An energetic view of stress: Focus on mitochondria",
  author   = "Picard, Martin and McEwen, Bruce S and Epel, Elissa S and Sandi,
              Carmen",
  abstract = "Energy is required to sustain life and enable stress adaptation.
              At the cellular level, energy is largely derived from
              mitochondria - unique multifunctional organelles with their own
              genome. Four main elements connect mitochondria to stress: (1)
              Energy is required at the molecular, (epi)genetic, cellular,
              organellar, and systemic levels to sustain components of stress
              responses; (2) Glucocorticoids and other steroid hormones are
              produced and metabolized by mitochondria; (3) Reciprocally,
              mitochondria respond to neuroendocrine and metabolic stress
              mediators; and (4) Experimentally manipulating mitochondrial
              functions alters physiological and behavioral responses to
              psychological stress. Thus, mitochondria are endocrine organelles
              that provide both the energy and signals that enable and direct
              stress adaptation. Neural circuits regulating social behavior -
              as well as psychopathological processes - are also influenced by
              mitochondrial energetics. An integrative view of stress as an
              energy-driven process opens new opportunities to study mechanisms
              of adaptation and regulation across the lifespan.",
  journal  = "Front. Neuroendocrinol.",
  volume   =  49,
  pages    = "72--85",
  month    =  apr,
  year     =  2018,
  keywords = "ATP; Brain; CORT; Chronic stress; HPA axis; Mitochondrial
              signaling; Mitochondrion; Mitokine; Stress pathophysiology; mtDNA",
  language = "en"
}

@ARTICLE{Le_Poole2002-jc,
  title    = "Interferon-gamma reduces melanosomal antigen expression and
              recognition of melanoma cells by cytotoxic {T} cells",
  author   = "Le Poole, I Caroline and Riker, Adam I and Quevedo, M Eugenia and
              Stennett, Lawrence S and Wang, Ena and Marincola, Francesco M and
              Kast, W Martin and Robinson, June K and Nickoloff, Brian J",
  abstract = "In malignant melanoma, tumor-infiltrating lymphocytes are
              frequently reactive with melanosomal antigens. Achieving complete
              remissions by peptide therapy is frequently hampered by
              metastases evading immune recognition. The tumor microenvironment
              seems to favor reduced expression of target antigens by melanoma
              cells. Among candidate factors, interferon-gamma (IFN-gamma)
              (10(2) to 10(3) U/ml) suppressed expression of antigens MART-1,
              TRP-1, and gp100 by M14 melanoma cells as shown by
              immunohistology and fluorescence-activated cell sorting analysis,
              reducing MART-1 expression by >65\%. Northern blot analysis
              revealed that reduced expression was regulated at the
              transcriptional level, demonstrating a 79\% reduction in MART-1
              transcript abundance after 32 hours of IFN-gamma treatment. To
              evaluate consequences of IFN-gamma exposure for immune
              recognition, MART-1-responsive T cells were reacted with
              pretreated HLA-matched melanoma cells. Cytotoxicity was reduced
              up to 78\% by IFN-gamma pretreatment, and was restored by
              addition of MART-1 peptide AAGIGILTV for 2 hours. Examination of
              melanoma lesions by quantitative reverse transcriptase-polymerase
              chain reaction revealed up to 188-fold more abundant IFN-gamma
              transcripts when compared to control skin. Laser capture
              microdissection and immunohistology localized most
              IFN-gamma-producing T cells to the tumor stroma. Reduced MART-1
              expression was frequently observed in adjacent tumor cells.
              Consequently, IFN-gamma may enhance inflammatory responses yet
              hamper effective recognition of melanoma cells.",
  journal  = "Am. J. Pathol.",
  volume   =  160,
  number   =  2,
  pages    = "521--528",
  month    =  feb,
  year     =  2002,
  language = "en"
}

@ARTICLE{Efferth2003-vq,
  title    = "Identification of gene expression profiles predicting tumor cell
              response to L-alanosine",
  author   = "Efferth, Thomas and Gebhart, Erich and Ross, Douglas D and
              Sauerbrey, Axel",
  abstract = "The methylthioadenosine phosphorylase (MTAP) gene gained
              considerable interest as therapeutic target for tumors with the
              9p21 deletion. This gene maps to 9p21 and loss of this
              chromosomal region in tumors offers an unique opportunity for
              chemoselective treatment, since MTAP is an important salvage
              enzyme for the formation of adenine that is needed for DNA
              synthesis. L-Alanosine, an antibiotic from Streptomyces
              alanosinicus, blocks the common de novo purine biosynthesis
              pathway and, thereby, inhibits tumor cells with MTAP deficiency.
              Normal cells escape the detrimental effects of L-alanosine due to
              their proficiency in the MTAP salvage pathway. The present
              analysis was undertaken to gain insights into the molecular
              architecture of tumor cells that determines the response to
              L-alanosine apart from the MTAP gene. Analysis of cell doubling
              times and IC(50) values for L-alanosine showed that slowly
              growing cell lines were more resistant to L-alanosine than
              rapidly growing ones. Mining the database of the National Cancer
              Institute (N.C.I.), for the mRNA expression of 9706 genes in 60
              cell lines by means of Kendall's tau-test, false discovery rate
              calculation, and hierarchical cluster analysis pointed to 11
              genes or expressed sequence tags whose mRNA expression correlated
              with the IC(50) values for L-alanosine. Furthermore, we tested
              L-alanosine for cross-resistance in multidrug-resistant cell
              lines which overexpress selectively either the
              P-glycoprotein/MDR1 (CEM/ADR5000), MRP1 (HL-60/AR), or BCRP
              (MDA-MB-231-BCRP) genes. None of the multidrug-resistant cell
              lines was cross-resistant to L-alanosine indicating that
              L-alanosine may be suitable to treat multidrug-resistant,
              refractory tumors in the clinic. Finally, the IC(50) values for
              L-alanosine of the 60 cell lines were correlated to the p53
              mutational status and expression of p53 downstream genes. We
              found that p53 mutated cell lines were more resistant to
              L-alanosine than p53 wild type cell lines.",
  journal  = "Biochem. Pharmacol.",
  volume   =  66,
  number   =  4,
  pages    = "613--621",
  month    =  aug,
  year     =  2003,
  language = "en"
}

@ARTICLE{Hanahan1996-jm,
  title    = "Patterns and emerging mechanisms of the angiogenic switch during
              tumorigenesis",
  author   = "Hanahan, D and Folkman, J",
  journal  = "Cell",
  volume   =  86,
  number   =  3,
  pages    = "353--364",
  month    =  aug,
  year     =  1996,
  language = "en"
}

@ARTICLE{Keast1970-th,
  title    = "Immunosurveillance and cancer",
  author   = "Keast, D",
  journal  = "Lancet",
  volume   =  2,
  number   =  7675,
  pages    = "710--712",
  month    =  oct,
  year     =  1970,
  language = "en"
}

@ARTICLE{Moseley2000-nx,
  title    = "Stress proteins and the immune response",
  author   = "Moseley, P",
  abstract = "The heat shock or stress response is one of the most highly
              conserved adaptive responses in nature. In single cell organisms,
              the stress response confers tolerance to a variety of stresses
              including hyperthermia, hyperoxia, hypoxia, and other
              perturbations, which alter protein synthesis. This tolerance
              phenomenon is also extremely important in the multicellular
              organism, resulting in not only thermal tolerance, but also
              resistance to stresses of the whole organism such as
              ischemia-reperfusion injury. Moreover, recent data indicates that
              these stress proteins have the ability to modulate the cellular
              immune response. Although the terms heat shock proteins (HSPs)
              and stress proteins are often used interchangeably, the term
              stress proteins includes the HSPs, the glucose-regulated proteins
              (GRPs) and ubiquitin. The stress proteins may be grouped by
              molecular weight ranging from the large 110 kDa HSP110 to
              ubiquitin at 8 kDa. These proteins serve as cellular chaperones,
              participating in protein synthesis and transport through the
              various cellular compartments. Because these proteins have unique
              cellular localizations, the chaperone function of the stress
              proteins often involves a transfer of peptides between stress
              proteins as the peptide is moved between cellular compartments.
              For example, HSP70 is a cytosolic and nuclear chaperone, which is
              critical for the transfer of cellular peptides in the
              mitochondrion through a hand-off that involves mitochondrial
              HSP60 at the inner mitochondrial membrane. Similarly, cytosolic
              proteins are transferred from HSP70 to gp96 as they move into the
              endoplasmic reticulum. The central role of the stress proteins in
              the transfer of peptides through the cell may be responsible for
              the recently recognized importance of the stress proteins in the
              modulation of the immune system [Feder, M.E., Hofmann, G.E.,
              1999. Heat-shock proteins, molecular chaperones, and the stress
              response: evolutionary and ecological physiology. Annu. Rev.
              Physiol. 61, 243-282.]. This importance in immune regulation is
              best addressed using Matzinger's model of the immune response -
              The Danger Theory of Immunity [Matzinger, P., Fuchs, E.J., 1996.
              Beyond self and non-self: immunity is a conversation, not a war.
              J. NIH Res. 8, 35-39.]. Matzinger suggests that an immune system
              model based on the differentiation between ``self and non-self''
              does not easily account for the changes that occur in the
              organism with growth and development. Why, for example does an
              organism not self-destruct when the immune system encounters the
              myriad of new peptides generated at puberty? Instead, she
              proposes a model of immune function based on the ability to
              detect and address dangers. This model states that the basic
              function of all cells of the organism is appropriately timed
              death ``from natural causes''. This type of cell death, or
              apoptosis, generates no stress signals. If, on the other hand, a
              cell is ``murdered'' by an infectious agent or dies an untimely
              death due to necrosis or ischemia, the cell undergoes a stress
              response with the liberation of stress protein-peptide complexes
              into the extracellular environment upon cell lysis. Not only do
              they serve as a ``danger signal'' to alert the immune system to
              the death of a cell under stress, but their role as protein
              carriers allows the immune effector cells to survey the peptides
              released by this stressed cell and to activate against new or
              unrecognized peptides carried by the stress protein. Matzinger
              bases the Danger Theory of Immunity on three ``Laws of
              Lymphotics''. These laws state that: (1) resting T lymphocytes
              require both antigen stimulation by an antigen-presenting cell
              (APC) and co-stimulation with a danger signal to become
              activated; (2) the co-stimulatory signal must be received through
              the APC; and (3) T cells receiving only antigen stimulation
              without the co-stimulatory signal undergo apoptosis. The Danger
              Theory gives a simple model for both tolerance and activation.
              (ABSTRACT TRUNCATED)",
  journal  = "Immunopharmacology",
  volume   =  48,
  number   =  3,
  pages    = "299--302",
  month    =  jul,
  year     =  2000,
  language = "en"
}

@ARTICLE{Rasnick2002-zj,
  title    = "Aneuploidy theory explains tumor formation, the absence of immune
              surveillance, and the failure of chemotherapy",
  author   = "Rasnick, David",
  abstract = "The autocatalyzed progression of aneuploidy accounts for all
              cancer-specific phenotypes, the Hayflick limit of cultured cells,
              carcinogen-induced tumors in mice, the age distribution of human
              cancer, and multidrug-resistance. Here aneuploidy theory
              addresses tumor formation. The logistic equation, phi(n)(+1) =
              rphi(n) (1 - phi(n)), models the autocatalyzed progression of
              aneuploidy in vivo and in vitro. The variable phi(n)(+1) is the
              average aneuploid fraction of a population of cells at the n+1
              cell division and is determined by the value at the nth cell
              division. The value r is the growth control parameter. The
              logistic equation was used to compute the probability
              distribution for values of phi after numerous divisions of
              aneuploid cells. The autocatalyzed progression of aneuploidy
              follows the laws of deterministic chaos, which means that certain
              values of phi are more probable than others. The probability map
              of the logistic equation shows that: 1) an aneuploid fraction of
              at least 0.30 is necessary to sustain a population of cancer
              cells; and 2) the most likely aneuploid fraction after many
              population doublings is 0.70, which is equivalent to a
              DNA(index)=1.7, the point of maximum disorder of the genome that
              still sustains life. Aneuploidy theory also explains the lack of
              immune surveillance and the failure of chemotherapy.",
  journal  = "Cancer Genet. Cytogenet.",
  volume   =  136,
  number   =  1,
  pages    = "66--72",
  month    =  jul,
  year     =  2002,
  language = "en"
}

@ARTICLE{Shen2003-hj,
  title    = "Resistance to the anti-proliferative activity of recombinant
              arginine deiminase in cell culture correlates with the endogenous
              enzyme, argininosuccinate synthetase",
  author   = "Shen, Li-Jiuan and Lin, Wen-Chun and Beloussow, Karin and Shen,
              Wei-Chiang",
  abstract = "Recombinant mycoplasma enzyme, arginine deiminase (rADI), has
              been proposed as a possible cancer treatment via arginine
              depletion. However, many cell lines are resistant to
              rADI-treatment, even though most require arginine for
              proliferation. We compared eight different cell lines for
              sensitivity in cell proliferation to the effect of either rADI or
              arginine deprivation. The activity of argininosuccinate
              synthetase (AS), the rate-limiting enzyme for converting
              citrulline to arginine, was also measured. Our results indicate
              that resistance to rADI-treatment may correlate with cellular AS
              activity, either constitutive or inducible, allowing cell
              survival by conversion of the product of the rADI reaction, i.e.
              citrulline to arginine.",
  journal  = "Cancer Lett.",
  volume   =  191,
  number   =  2,
  pages    = "165--170",
  month    =  mar,
  year     =  2003,
  language = "en"
}

@ARTICLE{Kowaltowski1999-nd,
  title    = "Mitochondrial damage induced by conditions of oxidative stress",
  author   = "Kowaltowski, A J and Vercesi, A E",
  abstract = "Up to 2\% of the oxygen consumed by the mitochondrial respiratory
              chain undergoes one electron reduction, typically by the
              semiquinone form of coenzyme Q, to generate the superoxide
              radical, and subsequently other reactive oxygen species such as
              hydrogen peroxide and the hydroxyl radical. Under conditions in
              which mitochondrial generation of reactive oxygen species is
              increased (such as in the presence of Ca2+ ions or when the
              mitochondrial antioxidant defense mechanisms are compromised),
              these reactive oxygen species may lead to irreversible damage of
              mitochondrial DNA, membrane lipids and proteins, resulting in
              mitochondrial dysfunction and ultimately cell death. The nature
              of this damage and the cellular conditions in which it occurs are
              discussed in this review article.",
  journal  = "Free Radic. Biol. Med.",
  volume   =  26,
  number   = "3-4",
  pages    = "463--471",
  month    =  feb,
  year     =  1999,
  language = "en"
}

@ARTICLE{Warner1999-kc,
  title    = "The economics of ribosome biosynthesis in yeast",
  author   = "Warner, J R",
  abstract = "In a rapidly growing yeast cell, 60\% of total transcription is
              devoted to ribosomal RNA, and 50\% of RNA polymerase II
              transcription and 90\% of mRNA splicing are devoted to ribosomal
              proteins (RPs). Coordinate regulation of the approximately 150
              rRNA genes and 137 RP genes that make such prodigious use of
              resources is essential for the economy of the cell. This is
              entrusted to a number of signal transduction pathways that can
              abruptly induce or silence the ribosomal genes, leading to major
              implications for the expression of other genes as well.",
  journal  = "Trends Biochem. Sci.",
  volume   =  24,
  number   =  11,
  pages    = "437--440",
  month    =  nov,
  year     =  1999,
  language = "en"
}

@ARTICLE{Livingston1970-pv,
  title    = "Glutamine antagonists in chemotherapy",
  author   = "Livingston, R B and Venditti, J M and Cooney, D A and Carter, S K",
  journal  = "Adv. Pharmacol. Chemother.",
  volume   =  8,
  pages    = "57--120",
  year     =  1970,
  language = "en"
}

@ARTICLE{Princiotta2003-lc,
  title    = "Quantitating protein synthesis, degradation, and endogenous
              antigen processing",
  author   = "Princiotta, Michael F and Finzi, Diana and Qian, Shu-Bing and
              Gibbs, James and Schuchmann, Sebastian and Buttgereit, Frank and
              Bennink, Jack R and Yewdell, Jonathan W",
  abstract = "Using L929 cells, we quantitated the macroeconomics of protein
              synthesis and degradation and the microeconomics of producing MHC
              class I associated peptides from viral translation products. To
              maintain a content of 2.6 x 10(9) proteins, each cell's 6 x 10(6)
              ribosomes produce 4 x 10(6) proteins min(-1). Each of the cell's
              8 x 10(5) proteasomes degrades 2.5 substrates min(-1), creating
              one MHC class I-peptide complex for each 500-3000 viral
              translation products degraded. The efficiency of complex
              formation is similar in dendritic cells and macrophages, which
              play a critical role in activating T cells in vivo. Proteasomes
              create antigenic peptides at different efficiencies from two
              distinct substrate pools: rapidly degraded newly synthesized
              proteins that clearly represent defective ribosomal products
              (DRiPs) and a less rapidly degraded pool in which DRiPs may also
              predominate.",
  journal  = "Immunity",
  volume   =  18,
  number   =  3,
  pages    = "343--354",
  month    =  mar,
  year     =  2003,
  language = "en"
}

@ARTICLE{Dmitrieva2001-if,
  title    = "Cell cycle delay and apoptosis in response to osmotic stress",
  author   = "Dmitrieva, N I and Michea, L F and Rocha, G M and Burg, M B",
  abstract = "As part of the urinary concentrating mechanism, renal inner
              medulla cells may be exposed to extremely variable NaCl and urea
              concentrations that can reach very high levels. A number of
              studies, reviewed herein, aim to understand how such osmotic
              stress affects the cells and what protective mechanisms might
              exist. The majority of these studies are done on inner medullary
              epithelial cells that grow continuously in tissue culture
              (mIMCD3). Cells grown at 300 mosmol/kg survive increase to 500
              mosmol/kg by adding NaCl or urea, but only after a growth arrest
              of approximately 24 h. At a higher osmolality (650-700 mosmol/kg)
              most cells die within hours by apoptosis. The cells both in vitro
              and in vivo adapt to high osmolality by a number of mechanisms,
              including accumulation of variety of organic osmolytes and
              induction of heat shock proteins. The cell cycle delay results
              from blocks at the G1 and G2/M checkpoints and slowing during S.
              After adding NaCl, but not urea, the amount and transcriptional
              activity of p53 (the tumor suppressor protein) increases. The p53
              is phosphorylated on ser-15 and is transcriptionally active at
              500 mosmol/kg (associated with cell survival), but not at 700
              mosmol/kg (associated with apoptosis). Reduction of p53
              expression by p53 antisense oligonucleotide increases sensitivity
              of renal cells in culture to hyperosmotic stress caused by NaCl.
              The possible mechanisms of the protection action of p53 against
              hypertonic stress are discussed.",
  journal  = "Comp. Biochem. Physiol. A Mol. Integr. Physiol.",
  volume   =  130,
  number   =  3,
  pages    = "411--420",
  month    =  oct,
  year     =  2001,
  language = "en"
}

@ARTICLE{Lindsten2000-al,
  title    = "The combined functions of proapoptotic Bcl-2 family members bak
              and bax are essential for normal development of multiple tissues",
  author   = "Lindsten, T and Ross, A J and King, A and Zong, W X and Rathmell,
              J C and Shiels, H A and Ulrich, E and Waymire, K G and Mahar, P
              and Frauwirth, K and Chen, Y and Wei, M and Eng, V M and Adelman,
              D M and Simon, M C and Ma, A and Golden, J A and Evan, G and
              Korsmeyer, S J and MacGregor, G R and Thompson, C B",
  abstract = "Proapoptotic Bcl-2 family members have been proposed to play a
              central role in regulating apoptosis. However, mice lacking bax
              display limited phenotypic abnormalities. As presented here,
              bak(-/-) mice were found to be developmentally normal and
              reproductively fit and failed to develop any age-related
              disorders. However, when Bak-deficient mice were mated to
              Bax-deficient mice to create mice lacking both genes, the
              majority of bax(-/-)bak(-/-) animals died perinatally with fewer
              than 10\% surviving into adulthood. bax(-/-)bak(-/-) mice
              displayed multiple developmental defects, including persistence
              of interdigital webs, an imperforate vaginal canal, and
              accumulation of excess cells within both the central nervous and
              hematopoietic systems. Thus, Bax and Bak have overlapping roles
              in the regulation of apoptosis during mammalian development and
              tissue homeostasis.",
  journal  = "Mol. Cell",
  volume   =  6,
  number   =  6,
  pages    = "1389--1399",
  month    =  dec,
  year     =  2000,
  language = "en"
}

@ARTICLE{Cambridge2011-tc,
  title    = "Systems-wide proteomic analysis in mammalian cells reveals
              conserved, functional protein turnover",
  author   = "Cambridge, Sidney B and Gnad, Florian and Nguyen, Chuong and
              Bermejo, Justo Lorenzo and Kr{\"u}ger, Marcus and Mann, Matthias",
  abstract = "The turnover of each protein in the mammalian proteome is a
              functionally important characteristic. Here, we employed
              high-resolution mass spectrometry to quantify protein dynamics in
              nondividing mammalian cells. The ratio of externally supplied
              versus endogenous amino acids to de novo protein synthesis was
              about 17:1. Using subsaturating SILAC labeling, we obtained
              accurate turnover rates of 4106 proteins in HeLa and 3528
              proteins in C2C12 cells. Comparison of these human and mouse cell
              lines revealed a highly significant turnover correlation of
              protein orthologs and thus high species conservation.
              Functionally, we observed statistically significant trends for
              the turnover of phosphoproteins and gene ontology categories that
              showed extensive covariation between mouse and human. Likewise,
              the members of some protein complexes, such as the proteasome,
              have highly similar turnover rates. The high species conservation
              and the low complex variances thus imply great regulatory
              fine-tuning of protein turnover.",
  journal  = "J. Proteome Res.",
  volume   =  10,
  number   =  12,
  pages    = "5275--5284",
  month    =  dec,
  year     =  2011,
  language = "en"
}

@ARTICLE{Neale1997-wn,
  title    = "The use of likelihood-based confidence intervals in genetic
              models",
  author   = "Neale, M C and Miller, M B",
  abstract = "This article describes the computation and relative merits of
              likelihood-based confidence intervals, compared to other measures
              of error in parameter estimates. Likelihood-based confidence
              intervals have the advantage of being asymmetric, which is often
              the case with structural equation models for genetically
              informative studies. We show how the package Mx provides
              confidence intervals for parameters and functions of parameters
              in the context of a simple additive genetic, common, and specific
              environment threshold model for binary data. Previously published
              contingency tables for major depression in adult female twins are
              used for illustration. The support for the model shows a marked
              skew as the additive genetic parameter is systematically varied
              from zero to one. The impact of allowing different prevalence
              rates in MZ vs. DZ twins is explored by fitting a model with
              separate threshold parameters and comparing the confidence
              intervals. Despite the improvement in fit of the different
              prevalence model, the confidence intervals on all parameters
              broaden, owing to their covariance.",
  journal  = "Behav. Genet.",
  volume   =  27,
  number   =  2,
  pages    = "113--120",
  month    =  mar,
  year     =  1997,
  language = "en"
}

@ARTICLE{Pantelouris1968-lx,
  title    = "Absence of thymus in a mouse mutant",
  author   = "Pantelouris, E M",
  journal  = "Nature",
  volume   =  217,
  number   =  5126,
  pages    = "370--371",
  month    =  jan,
  year     =  1968,
  language = "en"
}

@ARTICLE{Shankaran2001-td,
  title    = "{IFNgamma} and lymphocytes prevent primary tumour development and
              shape tumour immunogenicity",
  author   = "Shankaran, V and Ikeda, H and Bruce, A T and White, J M and
              Swanson, P E and Old, L J and Schreiber, R D",
  abstract = "Lymphocytes were originally thought to form the basis of a
              'cancer immunosurveillance' process that protects immunocompetent
              hosts against primary tumour development, but this idea was
              largely abandoned when no differences in primary tumour
              development were found between athymic nude mice and syngeneic
              wild-type mice. However, subsequent observations that nude mice
              do not completely lack functional T cells and that two components
              of the immune system-IFNgamma and perforin-help to prevent tumour
              formation in mice have led to renewed interest in a
              tumour-suppressor role for the immune response. Here we show that
              lymphocytes and IFNgamma collaborate to protect against
              development of carcinogen-induced sarcomas and spontaneous
              epithelial carcinomas and also to select for tumour cells with
              reduced immunogenicity. The immune response thus functions as an
              effective extrinsic tumour-suppressor system. However, this
              process also leads to the immunoselection of tumour cells that
              are more capable of surviving in an immunocompetent host, which
              explains the apparent paradox of tumour formation in
              immunologically intact individuals.",
  journal  = "Nature",
  volume   =  410,
  number   =  6832,
  pages    = "1107--1111",
  month    =  apr,
  year     =  2001,
  language = "en"
}

@ARTICLE{Kagi1994-zu,
  title    = "Cytotoxicity mediated by {T} cells and natural killer cells is
              greatly impaired in perforin-deficient mice",
  author   = "K{\"a}gi, D and Ledermann, B and B{\"u}rki, K and Seiler, P and
              Odermatt, B and Olsen, K J and Podack, E R and Zinkernagel, R M
              and Hengartner, H",
  abstract = "Perforin-deficient mice have been generated by homologous
              recombination to determine whether the effects of CD8+ cytolytic
              T cells and natural killer cells are mediated by pore formation
              involving perforin. These mice are viable and fertile and have
              normal numbers of CD8+ T cells and natural killer cells which do
              not lyse virus-infected or allogeneic fibroblasts or natural
              killer target cells in vitro. The mice fail to clear lymphocytic
              choriomeningitis virus and they eliminate fibrosarcoma tumour
              cells with reduced efficiency. Perforin is therefore a key
              effector molecule for T-cell- and natural killer-cell-mediated
              cytolysis.",
  journal  = "Nature",
  volume   =  369,
  number   =  6475,
  pages    = "31--37",
  month    =  may,
  year     =  1994,
  keywords = "Direct Killing (Perf/Gzym/FAS)",
  language = "en"
}

@MISC{Gatenby2009-ug,
  title        = "A change of strategy in the war on cancer",
  booktitle    = "Nature Publishing Group {UK}",
  author       = "Gatenby, Robert A",
  abstract     = "Patients and politicians anxiously await and increasingly
                  demand a 'cure' for cancer. But trying to control the disease
                  may prove a better plan than striving to cure it, says Robert
                  A. Gatenby.",
  month        =  may,
  year         =  2009,
  howpublished = "\url{http://dx.doi.org/10.1038/459508a}",
  note         = "Accessed: 2023-5-16",
  language     = "en"
}

@ARTICLE{Hendriks2000-fr,
  title    = "{CD27} is required for generation and long-term maintenance of
              {T} cell immunity",
  author   = "Hendriks, J and Gravestein, L A and Tesselaar, K and van Lier, R
              A and Schumacher, T N and Borst, J",
  abstract = "The Traf-linked tumor necrosis factor receptor family member CD27
              is known as a T cell costimulatory molecule. We generated CD27-/-
              mice and found that CD27 makes essential contributions to mature
              CD4+ and CD8+ T cell function: CD27 supported antigen-specific
              expansion (but not effector cell maturation) of na{\"\i}ve T
              cells, independent of the cell cycle-promoting activities of CD28
              and interleukin 2. Primary CD4+ and CD8+ T cell responses to
              influenza virus were impaired in CD27-/- mice. Effects of
              deleting the gene encoding CD27 were most profound on T cell
              memory, reflected by delayed response kinetics and reduction of
              CD8+ virus-specific T cell numbers to the level seen in the
              primary response. This demonstrates the requirement for a
              costimulatory receptor in the generation of T cell memory.",
  journal  = "Nat. Immunol.",
  volume   =  1,
  number   =  5,
  pages    = "433--440",
  month    =  nov,
  year     =  2000,
  language = "en"
}

@ARTICLE{Hewitt1976-bs,
  title    = "A critique of the evidence for active host defence against
              cancer, based on personal studies of 27 murine tumours of
              spontaneous origin",
  author   = "Hewitt, H B and Blake, E R and Walder, A S",
  abstract = "Extensive experience with isotransplants of 27 different tumours
              (leukaemias, sarcomata, carcinomata), all of strictly spontaneous
              origin in laboratory bred mice of low cancer strains CBA/Ht and
              WHT/Ht, has revealed no evidence of tumour immunogenicity. Of
              approximately 20,000 maintenance transplants, none failed and
              none regressed; of almost 10,000 carefully observed tumours
              arising from small or minimal inocula of tumour cells, none
              spontaneously regressed. The number of injected viable tumour
              cells required to give a 50\% probability of successful
              transplantation (the TD50) ranged from approximately 1 cell to
              greater than 10,000 cells among the 27 tumours; high TD50 values,
              which were dramatically reduced by various procedures having no
              immunological significance, did not signify active ``resistance''
              of the hosts. In the case of all of 7 randomly selected tumours,
              prior ``immunization'' of recipients with homologous lethally
              irradiated cells increased their tumour receptivity. Several
              experiments using various tumours failed to give evidence that
              immunity could be non-specifically induced or that a massive
              preponderance of lymphocytes from specifically sensitized mice
              could inhibit tumour transplantation or growth in vivo; no trace
              of ``resistance'' to tumour was adopted by isogeneic recipients
              of lymphocytes from regional nodes of tumour bearers. A limited
              review of the recent literature on tumour immunity shows that
              practically all the animal data presented in support of a general
              theory of tumour immunogenicity or to provide a basis for active
              clinical immunotherapy have been obtained from transplanted
              tumour systems which entail artefactual immunity associated with
              viral or chemical induction of the tumours or their allogeneic
              transplantation. It is suggested that isotransplants of
              spontaneously arising tumours are the only appropriate models of
              human cancer and that any genuine rapport between the animal
              laboratory and the clinic requires their exclusive use.",
  journal  = "Br. J. Cancer",
  volume   =  33,
  number   =  3,
  pages    = "241--259",
  month    =  mar,
  year     =  1976,
  language = "en"
}

@ARTICLE{Feun2012-ob,
  title    = "Negative argininosuccinate synthetase expression in melanoma
              tumours may predict clinical benefit from arginine-depleting
              therapy with pegylated arginine deiminase",
  author   = "Feun, L G and Marini, A and Walker, G and Elgart, G and Moffat, F
              and Rodgers, S E and Wu, C J and You, M and Wangpaichitr, M and
              Kuo, M T and Sisson, W and Jungbluth, A A and Bomalaski, J and
              Savaraj, N",
  abstract = "BACKGROUND: Arginine-depleting therapy with pegylated arginine
              deiminase (ADI-PEG20) was reported to have activity in advanced
              melanoma in early phase I-II trial, and clinical trials are
              currently underway in other cancers. However, the optimal patient
              population who benefit from this treatment is unknown. METHODS:
              Advanced melanoma patients with accessible tumours had biopsy
              performed before the start of treatment with ADI-PEG20 and at the
              time of progression or relapse when amenable to determine whether
              argininosuccinate synthetase (ASS) expression in tumour was
              predictive of response to ADI-PEG20. RESULTS: Twenty-seven of
              thirty-eight patients treated had melanoma tumours assessable for
              ASS staining before treatment. Clinical benefit rate (CBR) and
              longer time to progression were associated with negative
              expression of tumour ASS. Only 1 of 10 patients with ASS-positive
              tumours (ASS+) had stable disease, whereas 4 of 17 (24\%) had
              partial response and 5 had stable disease, when ASS expression
              was negative (ASS-), giving CBR rates of 52.9 vs 10\%, P=0.041.
              Two responding patients with negative ASS expression before
              therapy had rebiopsy after tumour progression and the ASS
              expression became positive. The survival of ASS- patients
              receiving at least four doses at 320 IU m(-2) was significantly
              better than the ASS+ group at 26.5 vs 8.5 months, P=0.024.
              CONCLUSION: ADI-PEG20 is safe and the drug is only efficacious in
              melanoma patients whose tumour has negative ASS expression.
              Argininosuccinate synthetase tumour positivity is associated with
              drug resistance and tumour progression.",
  journal  = "Br. J. Cancer",
  volume   =  106,
  number   =  9,
  pages    = "1481--1485",
  month    =  apr,
  year     =  2012,
  language = "en"
}

@ARTICLE{Vakifahmetoglu2008-gb,
  title    = "Death through a tragedy: mitotic catastrophe",
  author   = "Vakifahmetoglu, H and Olsson, M and Zhivotovsky, B",
  abstract = "Mitotic catastrophe (MC) has long been considered as a mode of
              cell death that results from premature or inappropriate entry of
              cells into mitosis and can be caused by chemical or physical
              stresses. Whereas it initially was depicted as the main form of
              cell death induced by ionizing radiation, it is today known to be
              triggered also by treatment with agents influencing the stability
              of microtubule, various anticancer drugs and mitotic failure
              caused by defective cell cycle checkpoints. Although various
              descriptions explaining MC exist, there is still no general
              accepted definition of this phenomenon. Here, we present
              evidences indicating that death-associated MC is not a separate
              mode of cell death, rather a process ('prestage') preceding cell
              death, which can occur through necrosis or apoptosis. The final
              outcome of MC depends on the molecular profile of the cell.",
  journal  = "Cell Death Differ.",
  volume   =  15,
  number   =  7,
  pages    = "1153--1162",
  month    =  jul,
  year     =  2008,
  language = "en"
}

@ARTICLE{Cullen2010-pm,
  title    = "Granzymes in cancer and immunity",
  author   = "Cullen, S P and Brunet, M and Martin, S J",
  abstract = "Cytotoxic T lymphocytes (CTLs) and natural killer (NK) cells are
              indispensable factors in the body's ongoing defence against viral
              infection and tumor development. CTL/NK cells recognize and kill
              infected or aberrant target cells by two major pathways: either
              through introduction of a battery of proteases - called granzymes
              - to the target cell cytosol, or through TNF
              superfamily-dependent killing. During granzyme-dependent killing,
              target cell death is quick and efficient and is mediated by
              multiple granzymes, acting via redundant cell death pathways.
              Although granzyme-mediated cell death has been intensively
              studied, recent work has also hinted at an alternative,
              proinflammatory role for these enzymes. Thus, in addition to
              their well-established role as intracellular effectors of target
              cell death, recent data suggest that granzymes may have an
              extracellular role in the propagation of immune signals. In this
              study, we discuss the role of granzymes as central factors in
              antitumor immunity, as well possible roles for these proteases as
              instigators of inflammation.",
  journal  = "Cell Death Differ.",
  volume   =  17,
  number   =  4,
  pages    = "616--623",
  month    =  apr,
  year     =  2010,
  language = "en"
}

@ARTICLE{Ju2009-tg,
  title    = "Blockade of Tim-3 pathway ameliorates interferon-gamma production
              from hepatic {CD8+} {T} cells in a mouse model of hepatitis {B}
              virus infection",
  author   = "Ju, Ying and Hou, Nan and Zhang, Xiao Ning and Zhao, Di and Liu,
              Ying and Wang, Jin Jin and Luan, Fang and Shi, Wei and Zhu, Fa
              Liang and Sun, Wen Sheng and Zhang, Li Ning and Gao, Cheng Jiang
              and Gao, Li Fen and Liang, Xiao Hong and Ma, Chun Hong",
  abstract = "T cell immunoglobulin- and mucin-domain-containing molecule-3
              (Tim-3) has been reported to participate in the pathogenesis of
              inflammatory diseases. However, whether Tim-3 is involved in
              hepatitis B virus (HBV) infection remains unknown. Here, we
              studied the expression and function of Tim-3 in a
              hydrodynamics-based mouse model of HBV infection. A significant
              increase of Tim-3 expression on hepatic T lymphocytes, especially
              on CD8+ T cells, was demonstrated in HBV model mice from day 7 to
              day 18. After Tim-3 knockdown by specific shRNAs, significantly
              increased IFN-gamma production from hepatic CD8+ T cells in HBV
              model mice was observed. Very interestingly, we found Tim-3
              expression on CD8+ T cells was higher in HBV model mice with
              higher serum anti-HBs production. Moreover, Tim-3 knockdown
              influenced anti-HBs production in vivo. Collectively, our data
              suggested that Tim-3 might act as a potent regulator of antiviral
              T-cell responses in HBV infection.",
  journal  = "Cell. Mol. Immunol.",
  volume   =  6,
  number   =  1,
  pages    = "35--43",
  month    =  feb,
  year     =  2009,
  language = "en"
}

@ARTICLE{Xin_Yu2019-uv,
  title    = "The global pipeline of cell therapies for cancer",
  author   = "Xin Yu, Jia and Hubbard-Lucey, Vanessa M and Tang, Jun",
  journal  = "Nat. Rev. Drug Discov.",
  volume   =  18,
  number   =  11,
  pages    = "821--822",
  month    =  oct,
  year     =  2019,
  language = "en"
}

@ARTICLE{Xin_Yu2019-lg,
  title    = "Immuno-oncology drug development goes global",
  author   = "Xin Yu, Jia and Hubbard-Lucey, Vanessa M and Tang, Jun",
  journal  = "Nat. Rev. Drug Discov.",
  volume   =  18,
  number   =  12,
  pages    = "899--900",
  month    =  nov,
  year     =  2019,
  language = "en"
}

@ARTICLE{Upadhaya2020-fw,
  title    = "Immuno-oncology drug development forges on despite {COVID-19}",
  author   = "Upadhaya, Samik and Hubbard-Lucey, Vanessa M and Yu, Jia Xin",
  journal  = "Nat. Rev. Drug Discov.",
  volume   =  19,
  number   =  11,
  pages    = "751--752",
  month    =  nov,
  year     =  2020,
  language = "en"
}

@ARTICLE{Amrhein2019-qg,
  title    = "Scientists rise up against statistical significance",
  author   = "Amrhein, Valentin and Greenland, Sander and McShane, Blake",
  journal  = "Nature",
  volume   =  567,
  number   =  7748,
  pages    = "305--307",
  month    =  mar,
  year     =  2019,
  keywords = "Research data; Research management",
  language = "en"
}

@ARTICLE{Holland2012-oi,
  title    = "Losing balance: the origin and impact of aneuploidy in cancer",
  author   = "Holland, Andrew J and Cleveland, Don W",
  abstract = "Most solid human tumours are aneuploid, that is, they contain an
              abnormal number of chromosomes. Paradoxically, however,
              aneuploidy has been reported to induce a stress response that
              suppresses cellular proliferation in vitro. Here, we review the
              progress in our understanding of the causes and effects of
              aneuploidy in cancer and discuss how, in specific contexts,
              aneuploidy can provide a growth advantage and facilitate cellular
              transformation. We also explore the emerging possibilities for
              targeting the cause or consequences of aneuploidy
              therapeutically.",
  journal  = "EMBO Rep.",
  volume   =  13,
  number   =  6,
  pages    = "501--514",
  month    =  jun,
  year     =  2012,
  language = "en"
}

@ARTICLE{McGranahan2012-qr,
  title    = "Cancer chromosomal instability: therapeutic and diagnostic
              challenges",
  author   = "McGranahan, Nicholas and Burrell, Rebecca A and Endesfelder,
              David and Novelli, Marco R and Swanton, Charles",
  abstract = "Chromosomal instability (CIN)-which is a high rate of loss or
              gain of whole or parts of chromosomes-is a characteristic of most
              human cancers and a cause of tumour aneuploidy and intra-tumour
              heterogeneity. CIN is associated with poor patient outcome and
              drug resistance, which could be mediated by evolutionary
              adaptation fostered by intra-tumour heterogeneity. In this
              review, we discuss the clinical consequences of CIN and the
              challenges inherent to its measurement in tumour specimens. The
              relationship between CIN and prognosis supports assessment of CIN
              status in the clinical setting and suggests that stratifying
              tumours according to levels of CIN could facilitate clinical risk
              assessment.",
  journal  = "EMBO Rep.",
  volume   =  13,
  number   =  6,
  pages    = "528--538",
  month    =  jun,
  year     =  2012,
  language = "en"
}

@ARTICLE{Viard-Leveugle2013-cc,
  title    = "{TNF-$\alpha$} and {IFN-$\gamma$} are potential inducers of
              Fas-mediated keratinocyte apoptosis through activation of
              inducible nitric oxide synthase in toxic epidermal necrolysis",
  author   = "Viard-Leveugle, Isabelle and Gaide, Olivier and Jankovic, Dragana
              and Feldmeyer, Laurence and Kerl, Katrin and Pickard, Chris and
              Roques, St{\'e}phanie and Friedmann, Peter S and Contassot,
              Emmanuel and French, Lars E",
  abstract = "Toxic epidermal necrolysis (TEN) is a severe immune-mediated
              adverse cutaneous drug eruption characterized by rapid and
              extensive epithelial cell death in the epidermis and mucosae. The
              molecular events leading to this often fatal condition are only
              partially understood, but evidence suggests a dual mechanism
              implicating a ``drug''-specific immune response on one side and
              the onset of target cell death by proapoptotic molecules
              including FasL on the other side. Herein, we describe a potential
              molecular bridge between these two events that involves inducible
              nitric oxide synthase (iNOS), which is highly upregulated in the
              skin of TEN patients. We show that activated T cells secrete high
              amounts of tumor necrosis factor-$\alpha$ (TNF-$\alpha$) and
              IFN-$\gamma$, and that both cytokines lead to increased
              expression and activity of keratinocyte iNOS. A similar
              observation has been made with drug-specific T lymphocytes from a
              TEN patient exposed to the culprit drug. The resulting increase
              in nitric oxide significantly upregulates keratinocyte FasL
              expression, resulting in Fas- and caspase-8-mediated keratinocyte
              cell death. Taken together, our data suggest that T-lymphocyte
              activation by drugs in TEN patients may indirectly lead to
              FasL-mediated keratinocyte apoptosis, via a molecular bridge
              involving TNF-$\alpha$, IFN-$\gamma$, and iNOS.",
  journal  = "J. Invest. Dermatol.",
  volume   =  133,
  number   =  2,
  pages    = "489--498",
  month    =  feb,
  year     =  2013,
  language = "en"
}

@ARTICLE{Dekker2008-ui,
  title    = "Survival analysis: time-dependent effects and time-varying risk
              factors",
  author   = "Dekker, Friedo W and de Mutsert, Ren{\'e}e and van Dijk, Paul C
              and Zoccali, Carmine and Jager, Kitty J",
  abstract = "In traditional Kaplan-Meier or Cox regression analysis, usually a
              risk factor measured at baseline is related to mortality
              thereafter. During follow-up, however, things may change: either
              the effect of a fixed baseline risk factor may vary over time,
              resulting in a weakening or strengthening of associations over
              time, or the risk factor itself may vary over time. In this
              paper, short-term versus long-term effects (so-called
              time-dependent effects) of a fixed baseline risk factor are
              addressed. An example is presented showing that underweight is a
              strong risk factor for mortality in dialysis patients, especially
              in the short run. In contrast, overweight is a risk factor for
              mortality, which is stronger in the long run than in the short
              run. In addition, the analysis of how time-varying risk factors
              (so-called time-dependent risk factors) are related to mortality
              is demonstrated by paying attention to the pitfall of adjusting
              for sequelae. The proper analysis of effects over time should be
              driven by a clear research question. Both kinds of research
              questions, that is those of time-dependent effects as well those
              of time-dependent risk factors, can be analyzed with
              time-dependent Cox regression analysis. It will be shown that
              using time-dependent risk factors usually implies focusing on
              short-term effects only.",
  journal  = "Kidney Int.",
  volume   =  74,
  number   =  8,
  pages    = "994--997",
  month    =  oct,
  year     =  2008,
  language = "en"
}

@ARTICLE{Orth2011-nh,
  title    = "A comprehensive genome-scale reconstruction of Escherichia coli
              metabolism--2011",
  author   = "Orth, Jeffrey D and Conrad, Tom M and Na, Jessica and Lerman,
              Joshua A and Nam, Hojung and Feist, Adam M and Palsson, Bernhard
              {\O}",
  abstract = "The initial genome-scale reconstruction of the metabolic network
              of Escherichia coli K-12 MG1655 was assembled in 2000. It has
              been updated and periodically released since then based on new
              and curated genomic and biochemical knowledge. An update has now
              been built, named iJO1366, which accounts for 1366 genes, 2251
              metabolic reactions, and 1136 unique metabolites. iJO1366 was (1)
              updated in part using a new experimental screen of 1075 gene
              knockout strains, illuminating cases where alternative pathways
              and isozymes are yet to be discovered, (2) compared with its
              predecessor and to experimental data sets to confirm that it
              continues to make accurate phenotypic predictions of growth on
              different substrates and for gene knockout strains, and (3)
              mapped to the genomes of all available sequenced E. coli strains,
              including pathogens, leading to the identification of hundreds of
              unannotated genes in these organisms. Like its predecessors, the
              iJO1366 reconstruction is expected to be widely deployed for
              studying the systems biology of E. coli and for metabolic
              engineering applications.",
  journal  = "Mol. Syst. Biol.",
  volume   =  7,
  pages    = "535",
  month    =  oct,
  year     =  2011,
  language = "en"
}

@ARTICLE{Stingele2012-gv,
  title    = "Global analysis of genome, transcriptome and proteome reveals the
              response to aneuploidy in human cells",
  author   = "Stingele, Silvia and Stoehr, Gabriele and Peplowska, Karolina and
              Cox, J{\"u}rgen and Mann, Matthias and Storchova, Zuzana",
  abstract = "Extra chromosome copies markedly alter the physiology of
              eukaryotic cells, but the underlying reasons are not well
              understood. We created human trisomic and tetrasomic cell lines
              and determined the quantitative changes in their transcriptome
              and proteome in comparison with their diploid counterparts. We
              found that whereas transcription levels reflect the chromosome
              copy number changes, the abundance of some proteins, such as
              subunits of protein complexes and protein kinases, is reduced
              toward diploid levels. Furthermore, using the quantitative data
              we investigated the changes of cellular pathways in response to
              aneuploidy. This analysis revealed specific and uniform
              alterations in pathway regulation in cells with extra
              chromosomes. For example, the DNA and RNA metabolism pathways
              were downregulated, whereas several pathways such as energy
              metabolism, membrane metabolism and lysosomal pathways were
              upregulated. In particular, we found that the p62-dependent
              selective autophagy is activated in the human trisomic and
              tetrasomic cells. Our data present the first broad proteomic
              analysis of human cells with abnormal karyotypes and suggest a
              uniform cellular response to the presence of an extra chromosome.",
  journal  = "Mol. Syst. Biol.",
  volume   =  8,
  pages    = "608",
  year     =  2012,
  language = "en"
}

@ARTICLE{Mempel2004-eg,
  title    = "T-cell priming by dendritic cells in lymph nodes occurs in three
              distinct phases",
  author   = "Mempel, Thorsten R and Henrickson, Sarah E and Von Andrian,
              Ulrich H",
  abstract = "Primary T-cell responses in lymph nodes (LNs) require
              contact-dependent information exchange between T cells and
              dendritic cells (DCs). Because lymphocytes continually enter and
              leave normal LNs, the resident lymphocyte pool is composed of
              non-synchronized cells with different dwell times that display
              heterogeneous behaviour in mouse LNs in vitro. Here we employ
              two-photon microscopy in vivo to study antigen-presenting DCs and
              naive T cells whose dwell time in LNs was synchronized. During
              the first 8 h after entering from the blood, T cells underwent
              multiple short encounters with DCs, progressively decreased their
              motility, and upregulated activation markers. During the
              subsequent 12 h T cells formed long-lasting stable conjugates
              with DCs and began to secrete interleukin-2 and interferon-gamma.
              On the second day, coinciding with the onset of proliferation, T
              cells resumed their rapid migration and short DC contacts. Thus,
              T-cell priming by DCs occurs in three successive stages:
              transient serial encounters during the first activation phase are
              followed by a second phase of stable contacts culminating in
              cytokine production, which makes a transition into a third phase
              of high motility and rapid proliferation.",
  journal  = "Nature",
  volume   =  427,
  number   =  6970,
  pages    = "154--159",
  month    =  jan,
  year     =  2004,
  language = "en"
}

@ARTICLE{Bartkova2005-hv,
  title    = "{DNA} damage response as a candidate anti-cancer barrier in early
              human tumorigenesis",
  author   = "Bartkova, Jirina and Horejs{\'\i}, Zuzana and Koed, Karen and
              Kr{\"a}mer, Alwin and Tort, Frederic and Zieger, Karsten and
              Guldberg, Per and Sehested, Maxwell and Nesland, Jahn M and
              Lukas, Claudia and {\O}rntoft, Torben and Lukas, Jiri and Bartek,
              Jiri",
  abstract = "During the evolution of cancer, the incipient tumour experiences
              'oncogenic stress', which evokes a counter-response to eliminate
              such hazardous cells. However, the nature of this stress remains
              elusive, as does the inducible anti-cancer barrier that elicits
              growth arrest or cell death. Here we show that in clinical
              specimens from different stages of human tumours of the urinary
              bladder, breast, lung and colon, the early precursor lesions (but
              not normal tissues) commonly express markers of an activated DNA
              damage response. These include phosphorylated kinases ATM and
              Chk2, and phosphorylated histone H2AX and p53. Similar checkpoint
              responses were induced in cultured cells upon expression of
              different oncogenes that deregulate DNA replication. Together
              with genetic analyses, including a genome-wide assessment of
              allelic imbalances, our data indicate that early in tumorigenesis
              (before genomic instability and malignant conversion), human
              cells activate an ATR/ATM-regulated DNA damage response network
              that delays or prevents cancer. Mutations compromising this
              checkpoint, including defects in the ATM-Chk2-p53 pathway, might
              allow cell proliferation, survival, increased genomic instability
              and tumour progression.",
  journal  = "Nature",
  volume   =  434,
  number   =  7035,
  pages    = "864--870",
  month    =  apr,
  year     =  2005,
  language = "en"
}

@ARTICLE{Gorgoulis2005-cs,
  title    = "Activation of the {DNA} damage checkpoint and genomic instability
              in human precancerous lesions",
  author   = "Gorgoulis, Vassilis G and Vassiliou, Leandros-Vassilios F and
              Karakaidos, Panagiotis and Zacharatos, Panayotis and Kotsinas,
              Athanassios and Liloglou, Triantafillos and Venere, Monica and
              Ditullio, Jr, Richard A and Kastrinakis, Nikolaos G and Levy,
              Brynn and Kletsas, Dimitris and Yoneta, Akihiro and Herlyn,
              Meenhard and Kittas, Christos and Halazonetis, Thanos D",
  abstract = "DNA damage checkpoint genes, such as p53, are frequently mutated
              in human cancer, but the selective pressure for their
              inactivation remains elusive. We analysed a panel of human lung
              hyperplasias, all of which retained wild-type p53 genes and had
              no signs of gross chromosomal instability, and found signs of a
              DNA damage response, including histone H2AX and Chk2
              phosphorylation, p53 accumulation, focal staining of p53 binding
              protein 1 (53BP1) and apoptosis. Progression to carcinoma was
              associated with p53 or 53BP1 inactivation and decreased
              apoptosis. A DNA damage response was also observed in dysplastic
              nevi and in human skin xenografts, in which hyperplasia was
              induced by overexpression of growth factors. Both lung and
              experimentally-induced skin hyperplasias showed allelic imbalance
              at loci that are prone to DNA double-strand break formation when
              DNA replication is compromised (common fragile sites). We propose
              that, from its earliest stages, cancer development is associated
              with DNA replication stress, which leads to DNA double-strand
              breaks, genomic instability and selective pressure for p53
              mutations.",
  journal  = "Nature",
  volume   =  434,
  number   =  7035,
  pages    = "907--913",
  month    =  apr,
  year     =  2005,
  language = "en"
}

@ARTICLE{Storchova2006-ul,
  title    = "Genome-wide genetic analysis of polyploidy in yeast",
  author   = "Storchov{\'a}, Zuzana and Breneman, Amanda and Cande, Jessica and
              Dunn, Joshua and Burbank, Kendra and O'Toole, Eileen and Pellman,
              David",
  abstract = "Polyploidy, increased sets of chromosomes, occurs during
              development, cellular stress, disease and evolution. Despite its
              prevalence, little is known about the physiological alterations
              that accompany polyploidy. We previously described
              'ploidy-specific lethality', where a gene deletion that is not
              lethal in haploid or diploid budding yeast causes lethality in
              triploids or tetraploids. Here we report a genome-wide screen to
              identify ploidy-specific lethal functions. Only 39 out of 3,740
              mutations screened exhibited ploidy-specific lethality. Almost
              all of these mutations affect genomic stability by impairing
              homologous recombination, sister chromatid cohesion, or mitotic
              spindle function. We uncovered defects in wild-type tetraploids
              predicted by the screen, and identified mechanisms by which
              tetraploidization affects genomic stability. We show that
              tetraploids have a high incidence of syntelic/monopolar
              kinetochore attachments to the spindle pole. We suggest that this
              defect can be explained by mismatches in the ability to scale the
              size of the spindle pole body, spindle and kinetochores. Thus,
              geometric constraints may have profound effects on genome
              stability; the phenomenon described here may be relevant in a
              variety of biological contexts, including disease states such as
              cancer.",
  journal  = "Nature",
  volume   =  443,
  number   =  7111,
  pages    = "541--547",
  month    =  oct,
  year     =  2006,
  keywords = "energetics of aneuploidy",
  language = "en"
}

@ARTICLE{Mizushima2008-fk,
  title    = "Autophagy fights disease through cellular self-digestion",
  author   = "Mizushima, Noboru and Levine, Beth and Cuervo, Ana Maria and
              Klionsky, Daniel J",
  abstract = "Autophagy, or cellular self-digestion, is a cellular pathway
              involved in protein and organelle degradation, with an
              astonishing number of connections to human disease and
              physiology. For example, autophagic dysfunction is associated
              with cancer, neurodegeneration, microbial infection and ageing.
              Paradoxically, although autophagy is primarily a protective
              process for the cell, it can also play a role in cell death.
              Understanding autophagy may ultimately allow scientists and
              clinicians to harness this process for the purpose of improving
              human health.",
  journal  = "Nature",
  volume   =  451,
  number   =  7182,
  pages    = "1069--1075",
  month    =  feb,
  year     =  2008,
  language = "en"
}

@ARTICLE{Ganem2009-ff,
  title    = "A mechanism linking extra centrosomes to chromosomal instability",
  author   = "Ganem, Neil J and Godinho, Susana A and Pellman, David",
  abstract = "Chromosomal instability (CIN) is a hallmark of many tumours and
              correlates with the presence of extra centrosomes. However, a
              direct mechanistic link between extra centrosomes and CIN has not
              been established. It has been proposed that extra centrosomes
              generate CIN by promoting multipolar anaphase, a highly abnormal
              division that produces three or more aneuploid daughter cells.
              Here we use long-term live-cell imaging to demonstrate that cells
              with multiple centrosomes rarely undergo multipolar cell
              divisions, and the progeny of these divisions are typically
              inviable. Thus, multipolar divisions cannot explain observed
              rates of CIN. In contrast, we observe that CIN cells with extra
              centrosomes routinely undergo bipolar cell divisions, but display
              a significantly increased frequency of lagging chromosomes during
              anaphase. To define the mechanism underlying this mitotic defect,
              we generated cells that differ only in their centrosome number.
              We demonstrate that extra centrosomes alone are sufficient to
              promote chromosome missegregation during bipolar cell division.
              These segregation errors are a consequence of cells passing
              through a transient 'multipolar spindle intermediate' in which
              merotelic kinetochore-microtubule attachment errors accumulate
              before centrosome clustering and anaphase. These findings provide
              a direct mechanistic link between extra centrosomes and CIN, two
              common characteristics of solid tumours. We propose that this
              mechanism may be a common underlying cause of CIN in human
              cancer.",
  journal  = "Nature",
  volume   =  460,
  number   =  7252,
  pages    = "278--282",
  month    =  jul,
  year     =  2009,
  language = "en"
}

@ARTICLE{Lane2010-sd,
  title    = "The energetics of genome complexity",
  author   = "Lane, Nick and Martin, William",
  abstract = "All complex life is composed of eukaryotic (nucleated) cells. The
              eukaryotic cell arose from prokaryotes just once in four billion
              years, and otherwise prokaryotes show no tendency to evolve
              greater complexity. Why not? Prokaryotic genome size is
              constrained by bioenergetics. The endosymbiosis that gave rise to
              mitochondria restructured the distribution of DNA in relation to
              bioenergetic membranes, permitting a remarkable 200,000-fold
              expansion in the number of genes expressed. This vast leap in
              genomic capacity was strictly dependent on mitochondrial power,
              and prerequisite to eukaryote complexity: the key innovation en
              route to multicellular life.",
  journal  = "Nature",
  volume   =  467,
  number   =  7318,
  pages    = "929--934",
  month    =  oct,
  year     =  2010,
  language = "en"
}

@ARTICLE{Pavelka2010-oh,
  title    = "Aneuploidy confers quantitative proteome changes and phenotypic
              variation in budding yeast",
  author   = "Pavelka, Norman and Rancati, Giulia and Zhu, Jin and Bradford,
              William D and Saraf, Anita and Florens, Laurence and Sanderson,
              Brian W and Hattem, Gaye L and Li, Rong",
  abstract = "Aneuploidy, referring here to genome contents characterized by
              abnormal numbers of chromosomes, has been associated with
              developmental defects, cancer and adaptive evolution in
              experimental organisms. However, it remains unresolved how
              aneuploidy impacts gene expression and whether aneuploidy could
              directly bring about phenotypic variation and improved fitness
              over that of euploid counterparts. Here we show, using
              quantitative mass spectrometry-based proteomics and phenotypic
              profiling, that levels of protein expression in aneuploid yeast
              strains largely scale with chromosome copy numbers, following the
              same trend as that observed for the transcriptome, and that
              aneuploidy confers diverse phenotypes. We designed a novel scheme
              to generate, through random meiotic segregation, 38 stable and
              fully isogenic aneuploid yeast strains with distinct karyotypes
              and genome contents between 1N and 3N without involving any
              genetic selection. Through quantitative growth assays under
              various conditions or in the presence of a panel of
              chemotherapeutic or antifungal drugs, we found that some
              aneuploid strains grew significantly better than euploid control
              strains under conditions suboptimal for the latter. These results
              provide strong evidence that aneuploidy directly affects gene
              expression at both the transcriptome and proteome levels and can
              generate significant phenotypic variation that could bring about
              fitness gains under diverse conditions. Our findings suggest that
              the fitness ranking between euploid and aneuploid cells is
              dependent on context and karyotype, providing the basis for the
              notion that aneuploidy can directly underlie phenotypic evolution
              and cellular adaptation.",
  journal  = "Nature",
  volume   =  468,
  number   =  7321,
  pages    = "321--325",
  month    =  nov,
  year     =  2010,
  language = "en"
}

@ARTICLE{Hartl2011-zj,
  title    = "Molecular chaperones in protein folding and proteostasis",
  author   = "Hartl, F Ulrich and Bracher, Andreas and Hayer-Hartl, Manajit",
  abstract = "Most proteins must fold into defined three-dimensional structures
              to gain functional activity. But in the cellular environment,
              newly synthesized proteins are at great risk of aberrant folding
              and aggregation, potentially forming toxic species. To avoid
              these dangers, cells invest in a complex network of molecular
              chaperones, which use ingenious mechanisms to prevent aggregation
              and promote efficient folding. Because protein molecules are
              highly dynamic, constant chaperone surveillance is required to
              ensure protein homeostasis (proteostasis). Recent advances
              suggest that an age-related decline in proteostasis capacity
              allows the manifestation of various protein-aggregation diseases,
              including Alzheimer's disease and Parkinson's disease.
              Interventions in these and numerous other pathological states may
              spring from a detailed understanding of the pathways underlying
              proteome maintenance.",
  journal  = "Nature",
  volume   =  475,
  number   =  7356,
  pages    = "324--332",
  month    =  jul,
  year     =  2011,
  language = "en"
}

@ARTICLE{Mellman2011-xg,
  title    = "Cancer immunotherapy comes of age",
  author   = "Mellman, Ira and Coukos, George and Dranoff, Glenn",
  abstract = "Activating the immune system for therapeutic benefit in cancer
              has long been a goal in immunology and oncology. After decades of
              disappointment, the tide has finally changed due to the success
              of recent proof-of-concept clinical trials. Most notable has been
              the ability of the anti-CTLA4 antibody, ipilimumab, to achieve a
              significant increase in survival for patients with metastatic
              melanoma, for which conventional therapies have failed. In the
              context of advances in the understanding of how tolerance,
              immunity and immunosuppression regulate antitumour immune
              responses together with the advent of targeted therapies, these
              successes suggest that active immunotherapy represents a path to
              obtain a durable and long-lasting response in cancer patients.",
  journal  = "Nature",
  volume   =  480,
  number   =  7378,
  pages    = "480--489",
  month    =  dec,
  year     =  2011,
  language = "en"
}

@ARTICLE{Lu2012-du,
  title    = "{IDH} mutation impairs histone demethylation and results in a
              block to cell differentiation",
  author   = "Lu, Chao and Ward, Patrick S and Kapoor, Gurpreet S and Rohle,
              Dan and Turcan, Sevin and Abdel-Wahab, Omar and Edwards,
              Christopher R and Khanin, Raya and Figueroa, Maria E and Melnick,
              Ari and Wellen, Kathryn E and O'Rourke, Donald M and Berger,
              Shelley L and Chan, Timothy A and Levine, Ross L and Mellinghoff,
              Ingo K and Thompson, Craig B",
  abstract = "Recurrent mutations in isocitrate dehydrogenase 1 (IDH1) and IDH2
              have been identified in gliomas, acute myeloid leukaemias (AML)
              and chondrosarcomas, and share a novel enzymatic property of
              producing 2-hydroxyglutarate (2HG) from $\alpha$-ketoglutarate.
              Here we report that 2HG-producing IDH mutants can prevent the
              histone demethylation that is required for lineage-specific
              progenitor cells to differentiate into terminally differentiated
              cells. In tumour samples from glioma patients, IDH mutations were
              associated with a distinct gene expression profile enriched for
              genes expressed in neural progenitor cells, and this was
              associated with increased histone methylation. To test whether
              the ability of IDH mutants to promote histone methylation
              contributes to a block in cell differentiation in non-transformed
              cells, we tested the effect of neomorphic IDH mutants on
              adipocyte differentiation in vitro. Introduction of either mutant
              IDH or cell-permeable 2HG was associated with repression of the
              inducible expression of lineage-specific differentiation genes
              and a block to differentiation. This correlated with a
              significant increase in repressive histone methylation marks
              without observable changes in promoter DNA methylation. Gliomas
              were found to have elevated levels of similar histone repressive
              marks. Stable transfection of a 2HG-producing mutant IDH into
              immortalized astrocytes resulted in progressive accumulation of
              histone methylation. Of the marks examined, increased H3K9
              methylation reproducibly preceded a rise in DNA methylation as
              cells were passaged in culture. Furthermore, we found that the
              2HG-inhibitable H3K9 demethylase KDM4C was induced during
              adipocyte differentiation, and that RNA-interference suppression
              of KDM4C was sufficient to block differentiation. Together these
              data demonstrate that 2HG can inhibit histone demethylation and
              that inhibition of histone demethylation can be sufficient to
              block the differentiation of non-transformed cells.",
  journal  = "Nature",
  volume   =  483,
  number   =  7390,
  pages    = "474--478",
  month    =  feb,
  year     =  2012,
  language = "en"
}

@ARTICLE{Turcan2012-rz,
  title    = "{IDH1} mutation is sufficient to establish the glioma
              hypermethylator phenotype",
  author   = "Turcan, Sevin and Rohle, Daniel and Goenka, Anuj and Walsh, Logan
              A and Fang, Fang and Yilmaz, Emrullah and Campos, Carl and
              Fabius, Armida W M and Lu, Chao and Ward, Patrick S and Thompson,
              Craig B and Kaufman, Andrew and Guryanova, Olga and Levine, Ross
              and Heguy, Adriana and Viale, Agnes and Morris, Luc G T and Huse,
              Jason T and Mellinghoff, Ingo K and Chan, Timothy A",
  abstract = "Both genome-wide genetic and epigenetic alterations are
              fundamentally important for the development of cancers, but the
              interdependence of these aberrations is poorly understood.
              Glioblastomas and other cancers with the CpG island methylator
              phenotype (CIMP) constitute a subset of tumours with extensive
              epigenomic aberrations and a distinct biology. Glioma CIMP
              (G-CIMP) is a powerful determinant of tumour pathogenicity, but
              the molecular basis of G-CIMP remains unresolved. Here we show
              that mutation of a single gene, isocitrate dehydrogenase 1
              (IDH1), establishes G-CIMP by remodelling the methylome. This
              remodelling results in reorganization of the methylome and
              transcriptome. Examination of the epigenome of a large set of
              intermediate-grade gliomas demonstrates a distinct G-CIMP
              phenotype that is highly dependent on the presence of IDH
              mutation. Introduction of mutant IDH1 into primary human
              astrocytes alters specific histone marks, induces extensive DNA
              hypermethylation, and reshapes the methylome in a fashion that
              mirrors the changes observed in G-CIMP-positive lower-grade
              gliomas. Furthermore, the epigenomic alterations resulting from
              mutant IDH1 activate key gene expression programs, characterize
              G-CIMP-positive proneural glioblastomas but not other
              glioblastomas, and are predictive of improved survival. Our
              findings demonstrate that IDH mutation is the molecular basis of
              CIMP in gliomas, provide a framework for understanding
              oncogenesis in these gliomas, and highlight the interplay between
              genomic and epigenomic changes in human cancers.",
  journal  = "Nature",
  volume   =  483,
  number   =  7390,
  pages    = "479--483",
  month    =  feb,
  year     =  2012,
  language = "en"
}

@ARTICLE{Landsberg2012-aj,
  title    = "Melanomas resist T-cell therapy through inflammation-induced
              reversible dedifferentiation",
  author   = "Landsberg, Jennifer and Kohlmeyer, Judith and Renn, Marcel and
              Bald, Tobias and Rogava, Meri and Cron, Mira and Fatho, Martina
              and Lennerz, Volker and W{\"o}lfel, Thomas and H{\"o}lzel,
              Michael and T{\"u}ting, Thomas",
  abstract = "Adoptive cell transfer therapies (ACTs) with cytotoxic T cells
              that target melanocytic antigens can achieve remissions in
              patients with metastatic melanomas, but tumours frequently
              relapse. Hypotheses explaining the acquired resistance to ACTs
              include the selection of antigen-deficient tumour cell variants
              and the induction of T-cell tolerance. However, the lack of
              appropriate experimental melanoma models has so far impeded clear
              insights into the underlying mechanisms. Here we establish an
              effective ACT protocol in a genetically engineered mouse melanoma
              model that recapitulates tumour regression, remission and relapse
              as seen in patients. We report the unexpected observation that
              melanomas acquire ACT resistance through an inflammation-induced
              reversible loss of melanocytic antigens. In serial
              transplantation experiments, melanoma cells switch between a
              differentiated and a dedifferentiated phenotype in response to
              T-cell-driven inflammatory stimuli. We identified the
              proinflammatory cytokine tumour necrosis factor (TNF)-$\alpha$ as
              a crucial factor that directly caused reversible
              dedifferentiation of mouse and human melanoma cells. Tumour cells
              exposed to TNF-$\alpha$ were poorly recognized by T cells
              specific for melanocytic antigens, whereas recognition by T cells
              specific for non-melanocytic antigens was unaffected or even
              increased. Our results demonstrate that the phenotypic plasticity
              of melanoma cells in an inflammatory microenvironment contributes
              to tumour relapse after initially successful T-cell
              immunotherapy. On the basis of our work, we propose that future
              ACT protocols should simultaneously target melanocytic and
              non-melanocytic antigens to ensure broad recognition of both
              differentiated and dedifferentiated melanoma cells, and include
              strategies to sustain T-cell effector functions by blocking
              immune-inhibitory mechanisms in the tumour microenvironment.",
  journal  = "Nature",
  volume   =  490,
  number   =  7420,
  pages    = "412--416",
  month    =  oct,
  year     =  2012,
  language = "en"
}

@ARTICLE{Maddocks2013-ne,
  title    = "Serine starvation induces stress and p53-dependent metabolic
              remodelling in cancer cells",
  author   = "Maddocks, Oliver D K and Berkers, Celia R and Mason, Susan M and
              Zheng, Liang and Blyth, Karen and Gottlieb, Eyal and Vousden,
              Karen H",
  abstract = "Cancer cells acquire distinct metabolic adaptations to survive
              stress associated with tumour growth and to satisfy the anabolic
              demands of proliferation. The tumour suppressor protein p53 (also
              known as TP53) influences a range of cellular metabolic
              processes, including glycolysis, oxidative phosphorylation,
              glutaminolysis and anti-oxidant response. In contrast to its role
              in promoting apoptosis during DNA-damaging stress, p53 can
              promote cell survival during metabolic stress, a function that
              may contribute not only to tumour suppression but also to
              non-cancer-associated functions of p53. Here we show that human
              cancer cells rapidly use exogenous serine and that serine
              deprivation triggered activation of the serine synthesis pathway
              and rapidly suppressed aerobic glycolysis, resulting in an
              increased flux to the tricarboxylic acid cycle. Transient p53-p21
              (also known as CDKN1A) activation and cell-cycle arrest promoted
              cell survival by efficiently channelling depleted serine stores
              to glutathione synthesis, thus preserving cellular anti-oxidant
              capacity. Cells lacking p53 failed to complete the response to
              serine depletion, resulting in oxidative stress, reduced
              viability and severely impaired proliferation. The role of p53 in
              supporting cancer cell proliferation under serine starvation was
              translated to an in vivo model, indicating that serine depletion
              has a potential role in the treatment of p53-deficient tumours.",
  journal  = "Nature",
  volume   =  493,
  number   =  7433,
  pages    = "542--546",
  month    =  jan,
  year     =  2013,
  language = "en"
}

@ARTICLE{Burrell2013-ng,
  title    = "The causes and consequences of genetic heterogeneity in cancer
              evolution",
  author   = "Burrell, Rebecca A and McGranahan, Nicholas and Bartek, Jiri and
              Swanton, Charles",
  abstract = "Recent studies have revealed extensive genetic diversity both
              between and within tumours. This heterogeneity affects key cancer
              pathways, driving phenotypic variation, and poses a significant
              challenge to personalized cancer medicine. A major cause of
              genetic heterogeneity in cancer is genomic instability. This
              instability leads to an increased mutation rate and can shape the
              evolution of the cancer genome through a plethora of mechanisms.
              By understanding these mechanisms we can gain insight into the
              common pathways of tumour evolution that could support the
              development of future therapeutic strategies.",
  journal  = "Nature",
  volume   =  501,
  number   =  7467,
  pages    = "338--345",
  month    =  sep,
  year     =  2013,
  language = "en"
}

@ARTICLE{Klein2013-ys,
  title    = "Selection and adaptation during metastatic cancer progression",
  author   = "Klein, Christoph A",
  abstract = "Cancer is often regarded as a process of asexual evolution driven
              by genomic and genetic instability. Mutation, selection and
              adaptation are by convention thought to occur primarily within,
              and to a lesser degree outside, the primary tumour. However,
              disseminated cancer cells that remain after 'curative' surgery
              exhibit extreme genomic heterogeneity before the manifestation of
              metastasis. This heterogeneity is later reduced by selected
              clonal expansion, suggesting that the disseminated cells had yet
              to acquire key traits of fully malignant cells. Abrogation of the
              cells' progression outside the primary tumour implies new
              challenges and opportunities for diagnosis and adjuvant
              therapies.",
  journal  = "Nature",
  volume   =  501,
  number   =  7467,
  pages    = "365--372",
  month    =  sep,
  year     =  2013,
  language = "en"
}

@ARTICLE{Birsoy2014-ka,
  title    = "Metabolic determinants of cancer cell sensitivity to glucose
              limitation and biguanides",
  author   = "Birsoy, K{\i}van{\c c} and Possemato, Richard and Lorbeer,
              Franziska K and Bayraktar, Erol C and Thiru, Prathapan and Yucel,
              Burcu and Wang, Tim and Chen, Walter W and Clish, Clary B and
              Sabatini, David M",
  abstract = "As the concentrations of highly consumed nutrients, particularly
              glucose, are generally lower in tumours than in normal tissues,
              cancer cells must adapt their metabolism to the tumour
              microenvironment. A better understanding of these adaptations
              might reveal cancer cell liabilities that can be exploited for
              therapeutic benefit. Here we developed a continuous-flow culture
              apparatus (Nutrostat) for maintaining proliferating cells in
              low-nutrient media for long periods of time, and used it to
              undertake competitive proliferation assays on a pooled collection
              of barcoded cancer cell lines cultured in low-glucose conditions.
              Sensitivity to low glucose varies amongst cell lines, and an RNA
              interference (RNAi) screen pinpointed mitochondrial oxidative
              phosphorylation (OXPHOS) as the major pathway required for
              optimal proliferation in low glucose. We found that cell lines
              most sensitive to low glucose are defective in the OXPHOS
              upregulation that is normally caused by glucose limitation as a
              result of either mitochondrial DNA (mtDNA) mutations in complex I
              genes or impaired glucose utilization. These defects predict
              sensitivity to biguanides, antidiabetic drugs that inhibit
              OXPHOS, when cancer cells are grown in low glucose or as tumour
              xenografts. Notably, the biguanide sensitivity of cancer cells
              with mtDNA mutations was reversed by ectopic expression of yeast
              NDI1, a ubiquinone oxidoreductase that allows bypass of complex I
              function. Thus, we conclude that mtDNA mutations and impaired
              glucose utilization are potential biomarkers for identifying
              tumours with increased sensitivity to OXPHOS inhibitors.",
  journal  = "Nature",
  volume   =  508,
  number   =  7494,
  pages    = "108--112",
  month    =  apr,
  year     =  2014,
  language = "en"
}

@ARTICLE{Powles2014-yn,
  title    = "{MPDL3280A} ({anti-PD-L1}) treatment leads to clinical activity
              in metastatic bladder cancer",
  author   = "Powles, Thomas and Eder, Joseph Paul and Fine, Gregg D and
              Braiteh, Fadi S and Loriot, Yohann and Cruz, Cristina and
              Bellmunt, Joaquim and Burris, Howard A and Petrylak, Daniel P and
              Teng, Siew-Leng and Shen, Xiaodong and Boyd, Zachary and Hegde,
              Priti S and Chen, Daniel S and Vogelzang, Nicholas J",
  abstract = "There have been no major advances for the treatment of metastatic
              urothelial bladder cancer (UBC) in the last 30 years.
              Chemotherapy is still the standard of care. Patient outcomes,
              especially for those in whom chemotherapy is not effective or is
              poorly tolerated, remain poor. One hallmark of UBC is the
              presence of high rates of somatic mutations. These alterations
              may enhance the ability of the host immune system to recognize
              tumour cells as foreign owing to an increased number of antigens.
              However, these cancers may also elude immune surveillance and
              eradication through the expression of programmed death-ligand 1
              (PD-L1; also called CD274 or B7-H1) in the tumour
              microenvironment. Therefore, we examined the anti-PD-L1 antibody
              MPDL3280A, a systemic cancer immunotherapy, for the treatment of
              metastatic UBC. MPDL3280A is a high-affinity engineered human
              anti-PD-L1 monoclonal immunoglobulin-G1 antibody that inhibits
              the interaction of PD-L1 with PD-1 (PDCD1) and B7.1 (CD80).
              Because PD-L1 is expressed on activated T cells, MPDL3280A was
              engineered with a modification in the Fc domain that eliminates
              antibody-dependent cellular cytotoxicity at clinically relevant
              doses to prevent the depletion of T cells expressing PD-L1. Here
              we show that MPDL3280A has noteworthy activity in metastatic UBC.
              Responses were often rapid, with many occurring at the time of
              the first response assessment (6 weeks) and nearly all were
              ongoing at the data cutoff. This phase I expansion study, with an
              adaptive design that allowed for biomarker-positive enriched
              cohorts, demonstrated that tumours expressing PD-L1-positive
              tumour-infiltrating immune cells had particularly high response
              rates. Moreover, owing to the favourable toxicity profile,
              including a lack of renal toxicity, patients with UBC, who are
              often older and have a higher incidence of renal impairment, may
              be better able to tolerate MPDL3280A versus chemotherapy. These
              results suggest that MPDL3280A may have an important role in
              treating UBC-the drug received breakthrough designation status by
              the US Food and Drug Administration (FDA) in June 2014.",
  journal  = "Nature",
  volume   =  515,
  number   =  7528,
  pages    = "558--562",
  month    =  nov,
  year     =  2014,
  language = "en"
}

@ARTICLE{Selmecki2015-uw,
  title    = "Polyploidy can drive rapid adaptation in yeast",
  author   = "Selmecki, Anna M and Maruvka, Yosef E and Richmond, Phillip A and
              Guillet, Marie and Shoresh, Noam and Sorenson, Amber L and De,
              Subhajyoti and Kishony, Roy and Michor, Franziska and Dowell,
              Robin and Pellman, David",
  abstract = "Polyploidy is observed across the tree of life, yet its influence
              on evolution remains incompletely understood. Polyploidy, usually
              whole-genome duplication, is proposed to alter the rate of
              evolutionary adaptation. This could occur through complex effects
              on the frequency or fitness of beneficial mutations. For example,
              in diverse cell types and organisms, immediately after a
              whole-genome duplication, newly formed polyploids missegregate
              chromosomes and undergo genetic instability. The instability
              following whole-genome duplications is thought to provide
              adaptive mutations in microorganisms and can promote
              tumorigenesis in mammalian cells. Polyploidy may also affect
              adaptation independently of beneficial mutations through
              ploidy-specific changes in cell physiology. Here we perform in
              vitro evolution experiments to test directly whether polyploidy
              can accelerate evolutionary adaptation. Compared with haploids
              and diploids, tetraploids undergo significantly faster
              adaptation. Mathematical modelling suggests that rapid adaptation
              of tetraploids is driven by higher rates of beneficial mutations
              with stronger fitness effects, which is supported by whole-genome
              sequencing and phenotypic analyses of evolved clones. Chromosome
              aneuploidy, concerted chromosome loss, and point mutations all
              provide large fitness gains. We identify several mutations whose
              beneficial effects are manifest specifically in the tetraploid
              strains. Together, these results provide direct quantitative
              evidence that in some environments polyploidy can accelerate
              evolutionary adaptation.",
  journal  = "Nature",
  volume   =  519,
  number   =  7543,
  pages    = "349--352",
  month    =  mar,
  year     =  2015,
  language = "en"
}

@ARTICLE{Waclaw2015-fx,
  title    = "A spatial model predicts that dispersal and cell turnover limit
              intratumour heterogeneity",
  author   = "Waclaw, Bartlomiej and Bozic, Ivana and Pittman, Meredith E and
              Hruban, Ralph H and Vogelstein, Bert and Nowak, Martin A",
  abstract = "Most cancers in humans are large, measuring centimetres in
              diameter, and composed of many billions of cells. An equivalent
              mass of normal cells would be highly heterogeneous as a result of
              the mutations that occur during each cell division. What is
              remarkable about cancers is that virtually every neoplastic cell
              within a large tumour often contains the same core set of genetic
              alterations, with heterogeneity confined to mutations that emerge
              late during tumour growth. How such alterations expand within the
              spatially constrained three-dimensional architecture of a tumour,
              and come to dominate a large, pre-existing lesion, has been
              unclear. Here we describe a model for tumour evolution that shows
              how short-range dispersal and cell turnover can account for rapid
              cell mixing inside the tumour. We show that even a small
              selective advantage of a single cell within a large tumour allows
              the descendants of that cell to replace the precursor mass in a
              clinically relevant time frame. We also demonstrate that the same
              mechanisms can be responsible for the rapid onset of resistance
              to chemotherapy. Our model not only provides insights into
              spatial and temporal aspects of tumour growth, but also suggests
              that targeting short-range cellular migratory activity could have
              marked effects on tumour growth rates.",
  journal  = "Nature",
  volume   =  525,
  number   =  7568,
  pages    = "261--264",
  month    =  sep,
  year     =  2015,
  language = "en"
}

@ARTICLE{Rabinovich2015-uo,
  title    = "Diversion of aspartate in {ASS1-deficient} tumours fosters de
              novo pyrimidine synthesis",
  author   = "Rabinovich, Shiran and Adler, Lital and Yizhak, Keren and Sarver,
              Alona and Silberman, Alon and Agron, Shani and Stettner, Noa and
              Sun, Qin and Brandis, Alexander and Helbling, Daniel and Korman,
              Stanley and Itzkovitz, Shalev and Dimmock, David and Ulitsky,
              Igor and Nagamani, Sandesh Cs and Ruppin, Eytan and Erez, Ayelet",
  abstract = "Cancer cells hijack and remodel existing metabolic pathways for
              their benefit. Argininosuccinate synthase (ASS1) is a urea cycle
              enzyme that is essential in the conversion of nitrogen from
              ammonia and aspartate to urea. A decrease in nitrogen flux
              through ASS1 in the liver causes the urea cycle disorder
              citrullinaemia. In contrast to the well-studied consequences of
              loss of ASS1 activity on ureagenesis, the purpose of its somatic
              silencing in multiple cancers is largely unknown. Here we show
              that decreased activity of ASS1 in cancers supports proliferation
              by facilitating pyrimidine synthesis via CAD (carbamoyl-phosphate
              synthase 2, aspartate transcarbamylase, and dihydroorotase
              complex) activation. Our studies were initiated by delineating
              the consequences of loss of ASS1 activity in humans with two
              types of citrullinaemia. We find that in citrullinaemia type I
              (CTLN I), which is caused by deficiency of ASS1, there is
              increased pyrimidine synthesis and proliferation compared with
              citrullinaemia type II (CTLN II), in which there is decreased
              substrate availability for ASS1 caused by deficiency of the
              aspartate transporter citrin. Building on these results, we
              demonstrate that ASS1 deficiency in cancer increases cytosolic
              aspartate levels, which increases CAD activation by upregulating
              its substrate availability and by increasing its phosphorylation
              by S6K1 through the mammalian target of rapamycin (mTOR) pathway.
              Decreasing CAD activity by blocking citrin, the mTOR signalling,
              or pyrimidine synthesis decreases proliferation and thus may
              serve as a therapeutic strategy in multiple cancers where ASS1 is
              downregulated. Our results demonstrate that ASS1 downregulation
              is a novel mechanism supporting cancerous proliferation, and they
              provide a metabolic link between the urea cycle enzymes and
              pyrimidine synthesis.",
  journal  = "Nature",
  volume   =  527,
  number   =  7578,
  pages    = "379--383",
  month    =  nov,
  year     =  2015,
  language = "en"
}

@ARTICLE{Bakhoum2018-hb,
  title    = "Chromosomal instability drives metastasis through a cytosolic
              {DNA} response",
  author   = "Bakhoum, Samuel F and Ngo, Bryan and Laughney, Ashley M and
              Cavallo, Julie-Ann and Murphy, Charles J and Ly, Peter and Shah,
              Pragya and Sriram, Roshan K and Watkins, Thomas B K and Taunk,
              Neil K and Duran, Mercedes and Pauli, Chantal and Shaw, Christine
              and Chadalavada, Kalyani and Rajasekhar, Vinagolu K and Genovese,
              Giulio and Venkatesan, Subramanian and Birkbak, Nicolai J and
              McGranahan, Nicholas and Lundquist, Mark and LaPlant, Quincey and
              Healey, John H and Elemento, Olivier and Chung, Christine H and
              Lee, Nancy Y and Imielenski, Marcin and Nanjangud, Gouri and
              Pe'er, Dana and Cleveland, Don W and Powell, Simon N and
              Lammerding, Jan and Swanton, Charles and Cantley, Lewis C",
  abstract = "Chromosomal instability is a hallmark of cancer that results from
              ongoing errors in chromosome segregation during mitosis. Although
              chromosomal instability is a major driver of tumour evolution,
              its role in metastasis has not been established. Here we show
              that chromosomal instability promotes metastasis by sustaining a
              tumour cell-autonomous response to cytosolic DNA. Errors in
              chromosome segregation create a preponderance of micronuclei
              whose rupture spills genomic DNA into the cytosol. This leads to
              the activation of the cGAS-STING (cyclic GMP-AMP
              synthase-stimulator of interferon genes) cytosolic DNA-sensing
              pathway and downstream noncanonical NF-$\kappa$B signalling.
              Genetic suppression of chromosomal instability markedly delays
              metastasis even in highly aneuploid tumour models, whereas
              continuous chromosome segregation errors promote cellular
              invasion and metastasis in a STING-dependent manner. By
              subverting lethal epithelial responses to cytosolic DNA,
              chromosomally unstable tumour cells co-opt chronic activation of
              innate immune pathways to spread to distant organs.",
  journal  = "Nature",
  volume   =  553,
  number   =  7689,
  pages    = "467--472",
  month    =  jan,
  year     =  2018,
  language = "en"
}

@ARTICLE{Bakhoum2009-gv,
  title    = "Genome stability is ensured by temporal control of
              kinetochore-microtubule dynamics",
  author   = "Bakhoum, Samuel F and Thompson, Sarah L and Manning, Amity L and
              Compton, Duane A",
  abstract = "Most solid tumours are aneuploid and many frequently
              mis-segregate chromosomes. This chromosomal instability is
              commonly caused by persistent mal-oriented attachment of
              chromosomes to spindle microtubules. Chromosome segregation
              requires stable microtubule attachment at kinetochores, yet those
              attachments must be sufficiently dynamic to permit correction of
              mal-orientations. How this balance is achieved is unknown, and
              the permissible boundaries of attachment stability versus
              dynamics essential for genome stability remain poorly understood.
              Here we show that two microtubule-depolymerizing kinesins, Kif2b
              and MCAK, stimulate kinetochore-microtubule dynamics during
              distinct phases of mitosis to correct mal-orientations. Few-fold
              reductions in kinetochore-microtubule turnover, particularly in
              early mitosis, induce severe chromosome segregation defects. In
              addition, we show that stimulation of microtubule dynamics at
              kinetochores restores stability to chromosomally unstable tumour
              cell lines, establishing a causal relationship between
              deregulation of kinetochore-microtubule dynamics and chromosomal
              instability. Thus, temporal control of microtubule attachment to
              chromosomes during mitosis is central to genome stability in
              human cells.",
  journal  = "Nat. Cell Biol.",
  volume   =  11,
  number   =  1,
  pages    = "27--35",
  month    =  jan,
  year     =  2009,
  language = "en"
}

@ARTICLE{Kim2011-ht,
  title    = "{AMPK} and {mTOR} regulate autophagy through direct
              phosphorylation of Ulk1",
  author   = "Kim, Joungmok and Kundu, Mondira and Viollet, Benoit and Guan,
              Kun-Liang",
  abstract = "Autophagy is a process by which components of the cell are
              degraded to maintain essential activity and viability in response
              to nutrient limitation. Extensive genetic studies have shown that
              the yeast ATG1 kinase has an essential role in autophagy
              induction. Furthermore, autophagy is promoted by AMP activated
              protein kinase (AMPK), which is a key energy sensor and regulates
              cellular metabolism to maintain energy homeostasis. Conversely,
              autophagy is inhibited by the mammalian target of rapamycin
              (mTOR), a central cell-growth regulator that integrates growth
              factor and nutrient signals. Here we demonstrate a molecular
              mechanism for regulation of the mammalian autophagy-initiating
              kinase Ulk1, a homologue of yeast ATG1. Under glucose starvation,
              AMPK promotes autophagy by directly activating Ulk1 through
              phosphorylation of Ser 317 and Ser 777. Under nutrient
              sufficiency, high mTOR activity prevents Ulk1 activation by
              phosphorylating Ulk1 Ser 757 and disrupting the interaction
              between Ulk1 and AMPK. This coordinated phosphorylation is
              important for Ulk1 in autophagy induction. Our study has revealed
              a signalling mechanism for Ulk1 regulation and autophagy
              induction in response to nutrient signalling.",
  journal  = "Nat. Cell Biol.",
  volume   =  13,
  number   =  2,
  pages    = "132--141",
  month    =  feb,
  year     =  2011,
  language = "en"
}

@ARTICLE{Zeman2014-jm,
  title    = "Causes and consequences of replication stress",
  author   = "Zeman, Michelle K and Cimprich, Karlene A",
  abstract = "Replication stress is a complex phenomenon that has serious
              implications for genome stability, cell survival and human
              disease. Generation of aberrant replication fork structures
              containing single-stranded DNA activates the replication stress
              response, primarily mediated by the kinase ATR (ATM- and
              Rad3-related). Along with its downstream effectors, ATR
              stabilizes and helps to restart stalled replication forks,
              avoiding the generation of DNA damage and genome instability.
              Understanding this response may be key to diagnosing and treating
              human diseases caused by defective responses to replication
              stress.",
  journal  = "Nat. Cell Biol.",
  volume   =  16,
  number   =  1,
  pages    = "2--9",
  month    =  jan,
  year     =  2014,
  language = "en"
}

@ARTICLE{Ertych2014-vm,
  title    = "Increased microtubule assembly rates influence chromosomal
              instability in colorectal cancer cells",
  author   = "Ertych, Norman and Stolz, Ailine and Stenzinger, Albrecht and
              Weichert, Wilko and Kaulfu{\ss}, Silke and Burfeind, Peter and
              Aigner, Achim and Wordeman, Linda and Bastians, Holger",
  abstract = "Chromosomal instability (CIN) is defined as the perpetual
              missegregation of whole chromosomes during mitosis and represents
              a hallmark of human cancer. However, the mechanisms influencing
              CIN and its consequences on tumour growth are largely unknown. We
              identified an increase in microtubule plus-end assembly rates as
              a mechanism influencing CIN in colorectal cancer cells. This
              phenotype is induced by overexpression of the oncogene AURKA or
              by loss of the tumour suppressor gene CHK2, a genetic
              constitution found in 73\% of human colorectal cancers. Increased
              microtubule assembly rates are associated with transient
              abnormalities in mitotic spindle geometry promoting the
              generation of lagging chromosomes and influencing CIN.
              Reconstitution of proper microtubule assembly rates by chemical
              or genetic means suppresses CIN and thereby, unexpectedly,
              accelerates tumour growth in vitro and in vivo. Thus, we identify
              a fundamental mechanism influencing CIN in cancer cells and
              reveal its adverse consequence on tumour growth.",
  journal  = "Nat. Cell Biol.",
  volume   =  16,
  number   =  8,
  pages    = "779--791",
  month    =  aug,
  year     =  2014,
  language = "en"
}

@ARTICLE{Chugh2017-ru,
  title    = "Actin cortex architecture regulates cell surface tension",
  author   = "Chugh, Priyamvada and Clark, Andrew G and Smith, Matthew B and
              Cassani, Davide A D and Dierkes, Kai and Ragab, Anan and Roux,
              Philippe P and Charras, Guillaume and Salbreux, Guillaume and
              Paluch, Ewa K",
  abstract = "Animal cell shape is largely determined by the cortex, a thin
              actin network underlying the plasma membrane in which
              myosin-driven stresses generate contractile tension. Tension
              gradients result in local contractions and drive cell
              deformations. Previous cortical tension regulation studies have
              focused on myosin motors. Here, we show that cortical actin
              network architecture is equally important. First, we observe that
              actin cortex thickness and tension are inversely correlated
              during cell-cycle progression. We then show that the actin
              filament length regulators CFL1, CAPZB and DIAPH1 regulate
              mitotic cortex thickness and find that both increasing and
              decreasing thickness decreases tension in mitosis. This suggests
              that the mitotic cortex is poised close to a tension maximum.
              Finally, using a computational model, we identify a physical
              mechanism by which maximum tension is achieved at intermediate
              actin filament lengths. Our results indicate that actin network
              architecture, alongside myosin activity, is key to cell surface
              tension regulation.",
  journal  = "Nat. Cell Biol.",
  volume   =  19,
  number   =  6,
  pages    = "689--697",
  month    =  jun,
  year     =  2017,
  language = "en"
}

@ARTICLE{Passerini2016-pz,
  title    = "The presence of extra chromosomes leads to genomic instability",
  author   = "Passerini, Verena and Ozeri-Galai, Efrat and de Pagter, Mirjam S
              and Donnelly, Neysan and Schmalbrock, Sarah and Kloosterman,
              Wigard P and Kerem, Batsheva and Storchov{\'a}, Zuzana",
  abstract = "Aneuploidy is a hallmark of cancer and underlies genetic
              disorders characterized by severe developmental defects, yet the
              molecular mechanisms explaining its effects on cellular
              physiology remain elusive. Here we show, using a series of human
              cells with defined aneuploid karyotypes, that gain of a single
              chromosome increases genomic instability. Next-generation
              sequencing and SNP-array analysis reveal accumulation of
              chromosomal rearrangements in aneuploids, with break point
              junction patterns suggestive of replication defects. Trisomic and
              tetrasomic cells also show increased DNA damage and sensitivity
              to replication stress. Strikingly, we find that
              aneuploidy-induced genomic instability can be explained by the
              reduced expression of the replicative helicase MCM2-7.
              Accordingly, restoring near-wild-type levels of chromatin-bound
              MCM helicase partly rescues the genomic instability phenotypes.
              Thus, gain of chromosomes triggers replication stress, thereby
              promoting genomic instability and possibly contributing to
              tumorigenesis.",
  journal  = "Nat. Commun.",
  volume   =  7,
  pages    = "10754",
  month    =  feb,
  year     =  2016,
  language = "en"
}

@ARTICLE{Dolega2017-jq,
  title    = "Cell-like pressure sensors reveal increase of mechanical stress
              towards the core of multicellular spheroids under compression",
  author   = "Dolega, M E and Delarue, M and Ingremeau, F and Prost, J and
              Delon, A and Cappello, G",
  abstract = "The surrounding microenvironment limits tumour expansion,
              imposing a compressive stress on the tumour, but little is known
              how pressure propagates inside the tumour. Here we present
              non-destructive cell-like microsensors to locally quantify
              mechanical stress distribution in three-dimensional tissue. Our
              sensors are polyacrylamide microbeads of well-defined elasticity,
              size and surface coating to enable internalization within the
              cellular environment. By isotropically compressing multicellular
              spheroids (MCS), which are spherical aggregates of cells
              mimicking a tumour, we show that the pressure is transmitted in a
              non-trivial manner inside the MCS, with a pressure rise towards
              the core. This observed pressure profile is explained by the
              anisotropic arrangement of cells and our results suggest that
              such anisotropy alone is sufficient to explain the pressure rise
              inside MCS composed of a single cell type. Furthermore, such
              pressure distribution suggests a direct link between increased
              mechanical stress and previously observed lack of proliferation
              within the spheroids core.",
  journal  = "Nat. Commun.",
  volume   =  8,
  pages    = "14056",
  month    =  jan,
  year     =  2017,
  language = "en"
}

@ARTICLE{Rice2017-ju,
  title    = "Dosage sensitivity is a major determinant of human copy number
              variant pathogenicity",
  author   = "Rice, Alan M and McLysaght, Aoife",
  abstract = "Human copy number variants (CNVs) account for genome variation an
              order of magnitude larger than single-nucleotide polymorphisms.
              Although much of this variation has no phenotypic consequences,
              some variants have been associated with disease, in particular
              neurodevelopmental disorders. Pathogenic CNVs are typically very
              large and contain multiple genes, and understanding the cause of
              the pathogenicity remains a major challenge. Here we show that
              pathogenic CNVs are significantly enriched for genes involved in
              development and genes that have greater evolutionary copy number
              conservation across mammals, indicative of functional
              constraints. Conversely, genes found in benign CNV regions have
              more variable copy number. These evolutionary constraints are
              characteristic of genes in pathogenic CNVs and can only be
              explained by dosage sensitivity of those genes. These results
              implicate dosage sensitivity of individual genes as a common
              cause of CNV pathogenicity. These evolutionary metrics suggest a
              path to identifying disease genes in pathogenic CNVs.",
  journal  = "Nat. Commun.",
  volume   =  8,
  pages    = "14366",
  month    =  feb,
  year     =  2017,
  language = "en"
}

@ARTICLE{Yao2017-cf,
  title    = "Antigen-specific {CD8+} {T} cell feedback activates {NLRP3}
              inflammasome in antigen-presenting cells through perforin",
  author   = "Yao, Yikun and Chen, Siyuan and Cao, Mengtao and Fan, Xing and
              Yang, Tao and Huang, Yin and Song, Xinyang and Li, Yongqin and
              Ye, Lilin and Shen, Nan and Shi, Yufang and Li, Xiaoxia and Wang,
              Feng and Qian, Youcun",
  abstract = "The connection between innate and adaptive immunity is best
              exemplified by antigen presentation. Although antigen-presenting
              cells (APCs) are required for antigen receptor-mediated T-cell
              activation, how T-cells feedback to APCs to sustain an
              antigen-specific immune response is not completely clear. Here we
              show that CD8+ T-cell (also called cytotoxic T lymphocytes, CTL)
              feedback activates the NLRP3 inflammasome in APCs in an
              antigen-dependent manner to promote IL-1$\beta$ maturation.
              Perforin from antigen-specific CTLs is required for NLRP3
              inflammasome activation in APCs. Furthermore, such activation of
              NLRP3 inflammasome contributes to the induction of
              antigen-specific antitumour immunity and pathogenesis of
              graft-versus-host diseases. Our study reveals a positive feedback
              loop between antigen-specific CTLs and APC to amplify adaptive
              immunity.",
  journal  = "Nat. Commun.",
  volume   =  8,
  pages    = "15402",
  month    =  may,
  year     =  2017,
  language = "en"
}

@ARTICLE{Sucker2017-fh,
  title    = "Acquired {IFN$\gamma$} resistance impairs anti-tumor immunity and
              gives rise to T-cell-resistant melanoma lesions",
  author   = "Sucker, Antje and Zhao, Fang and Pieper, Natalia and Heeke,
              Christina and Maltaner, Raffaela and Stadtler, Nadine and Real,
              Birgit and Bielefeld, Nicola and Howe, Sebastian and Weide,
              Benjamin and Gutzmer, Ralf and Utikal, Jochen and Loquai, Carmen
              and Gogas, Helen and Klein-Hitpass, Ludger and Zeschnigk, Michael
              and Westendorf, Astrid M and Trilling, Mirko and Horn, Susanne
              and Schilling, Bastian and Schadendorf, Dirk and Griewank, Klaus
              G and Paschen, Annette",
  abstract = "Melanoma treatment has been revolutionized by antibody-based
              immunotherapies. IFN$\gamma$ secretion by CD8+ T cells is
              critical for therapy efficacy having anti-proliferative and
              pro-apoptotic effects on tumour cells. Our study demonstrates a
              genetic evolution of IFN$\gamma$ resistance in different melanoma
              patient models. Chromosomal alterations and subsequent
              inactivating mutations in genes of the IFN$\gamma$ signalling
              cascade, most often JAK1 or JAK2, protect melanoma cells from
              anti-tumour IFN$\gamma$ activity. JAK1/2 mutants further evolve
              into T-cell-resistant HLA class I-negative lesions with genes
              involved in antigen presentation silenced and no longer inducible
              by IFN$\gamma$. Allelic JAK1/2 losses predisposing to IFN$\gamma$
              resistance development are frequent in melanoma. Subclones
              harbouring inactivating mutations emerge under various
              immunotherapies but are also detectable in pre-treatment
              biopsies. Our data demonstrate that JAK1/2 deficiency protects
              melanoma from anti-tumour IFN$\gamma$ activity and results in
              T-cell-resistant HLA class I-negative lesions. Screening for
              mechanisms of IFN$\gamma$ resistance should be considered in
              therapeutic decision-making.",
  journal  = "Nat. Commun.",
  volume   =  8,
  pages    = "15440",
  month    =  may,
  year     =  2017,
  language = "en"
}

@ARTICLE{Mikucki2015-xt,
  title    = "Non-redundant requirement for {CXCR3} signalling during
              tumoricidal T-cell trafficking across tumour vascular checkpoints",
  author   = "Mikucki, M E and Fisher, D T and Matsuzaki, J and Skitzki, J J
              and Gaulin, N B and Muhitch, J B and Ku, A W and Frelinger, J G
              and Odunsi, K and Gajewski, T F and Luster, A D and Evans, S S",
  abstract = "T-cell trafficking at vascular sites has emerged as a key step in
              antitumour immunity. Chemokines are credited with guiding the
              multistep recruitment of CD8(+) T cells across tumour vessels.
              However, the multiplicity of chemokines within tumours has
              obscured the contributions of individual chemokine
              receptor/chemokine pairs to this process. Moreover, recent
              studies have challenged whether T cells require chemokine
              receptor signalling at effector sites. Here we investigate the
              hierarchy of chemokine receptor requirements during T-cell
              trafficking to murine and human melanoma. These studies reveal a
              non-redundant role for G$\alpha$i-coupled CXCR3 in stabilizing
              intravascular adhesion and extravasation of adoptively
              transferred CD8(+) effectors that is indispensable for
              therapeutic efficacy. In contrast, functional CCR2 and CCR5 on
              CD8(+) effectors fail to support trafficking despite the presence
              of intratumoral cognate chemokines. Taken together, these studies
              identify CXCR3-mediated trafficking at the tumour vascular
              interface as a critical checkpoint to effective T-cell-based
              cancer immunotherapy.",
  journal  = "Nat. Commun.",
  volume   =  6,
  pages    = "7458",
  month    =  jun,
  year     =  2015,
  language = "en"
}

@ARTICLE{Gogendeau2015-xo,
  title    = "Aneuploidy causes premature differentiation of neural and
              intestinal stem cells",
  author   = "Gogendeau, Delphine and Siudeja, Katarzyna and Gambarotto, Davide
              and Pennetier, Carole and Bardin, Allison J and Basto, Renata",
  abstract = "Aneuploidy is associated with a variety of diseases such as
              cancer and microcephaly. Although many studies have addressed the
              consequences of a non-euploid genome in cells, little is known
              about their overall consequences in tissue and organism
              development. Here we use two different mutant conditions to
              address the consequences of aneuploidy during tissue development
              and homeostasis in Drosophila. We show that aneuploidy causes
              brain size reduction due to a decrease in the number of
              proliferative neural stem cells (NSCs), but not through
              apoptosis. Instead, aneuploid NSCs present an extended G1 phase,
              which leads to cell cycle exit and premature differentiation.
              Moreover, we show that this response to aneuploidy is also
              present in adult intestinal stem cells but not in the wing disc.
              Our work highlights a neural and intestine stem cell-specific
              response to aneuploidy, which prevents their proliferation and
              expansion.",
  journal  = "Nat. Commun.",
  volume   =  6,
  pages    = "8894",
  month    =  nov,
  year     =  2015,
  language = "en"
}

@ARTICLE{Zack2013-pe,
  title    = "Pan-cancer patterns of somatic copy number alteration",
  author   = "Zack, Travis I and Schumacher, Stephen E and Carter, Scott L and
              Cherniack, Andre D and Saksena, Gordon and Tabak, Barbara and
              Lawrence, Michael S and Zhsng, Cheng-Zhong and Wala, Jeremiah and
              Mermel, Craig H and Sougnez, Carrie and Gabriel, Stacey B and
              Hernandez, Bryan and Shen, Hui and Laird, Peter W and Getz, Gad
              and Meyerson, Matthew and Beroukhim, Rameen",
  abstract = "Determining how somatic copy number alterations (SCNAs) promote
              cancer is an important goal. We characterized SCNA patterns in
              4,934 cancers from The Cancer Genome Atlas Pan-Cancer data set.
              Whole-genome doubling, observed in 37\% of cancers, was
              associated with higher rates of every other type of SCNA, TP53
              mutations, CCNE1 amplifications and alterations of the PPP2R
              complex. SCNAs that were internal to chromosomes tended to be
              shorter than telomere-bounded SCNAs, suggesting different
              mechanisms underlying their generation. Significantly recurrent
              focal SCNAs were observed in 140 regions, including 102 without
              known oncogene or tumor suppressor gene targets and 50 with
              significantly mutated genes. Amplified regions without known
              oncogenes were enriched for genes involved in epigenetic
              regulation. When levels of genomic disruption were accounted for,
              7\% of region pairs were anticorrelated, and these regions tended
              to encompass genes whose proteins physically interact, suggesting
              related functions. These results provide insights into mechanisms
              of generation and functional consequences of cancer-related
              SCNAs.",
  journal  = "Nat. Genet.",
  volume   =  45,
  number   =  10,
  pages    = "1134--1140",
  month    =  oct,
  year     =  2013,
  language = "en"
}

@ARTICLE{Cancer_Genome_Atlas_Research_Network2013-ps,
  title    = "The Cancer Genome Atlas {Pan-Cancer} analysis project",
  author   = "{Cancer Genome Atlas Research Network} and Weinstein, John N and
              Collisson, Eric A and Mills, Gordon B and Shaw, Kenna R Mills and
              Ozenberger, Brad A and Ellrott, Kyle and Shmulevich, Ilya and
              Sander, Chris and Stuart, Joshua M",
  abstract = "The Cancer Genome Atlas (TCGA) Research Network has profiled and
              analyzed large numbers of human tumors to discover molecular
              aberrations at the DNA, RNA, protein and epigenetic levels. The
              resulting rich data provide a major opportunity to develop an
              integrated picture of commonalities, differences and emergent
              themes across tumor lineages. The Pan-Cancer initiative compares
              the first 12 tumor types profiled by TCGA. Analysis of the
              molecular aberrations and their functional roles across tumor
              types will teach us how to extend therapies effective in one
              cancer type to others with a similar genomic profile.",
  journal  = "Nat. Genet.",
  volume   =  45,
  number   =  10,
  pages    = "1113--1120",
  month    =  oct,
  year     =  2013,
  language = "en"
}

@ARTICLE{Fehrmann2015-zh,
  title    = "Gene expression analysis identifies global gene dosage
              sensitivity in cancer",
  author   = "Fehrmann, Rudolf S N and Karjalainen, Juha M and Krajewska,
              Ma{\l}gorzata and Westra, Harm-Jan and Maloney, David and
              Simeonov, Anton and Pers, Tune H and Hirschhorn, Joel N and
              Jansen, Ritsert C and Schultes, Erik A and van Haagen, Herman H H
              B M and de Vries, Elisabeth G E and te Meerman, Gerard J and
              Wijmenga, Cisca and van Vugt, Marcel A T M and Franke, Lude",
  abstract = "Many cancer-associated somatic copy number alterations (SCNAs)
              are known. Currently, one of the challenges is to identify the
              molecular downstream effects of these variants. Although several
              SCNAs are known to change gene expression levels, it is not clear
              whether each individual SCNA affects gene expression. We
              reanalyzed 77,840 expression profiles and observed a limited set
              of 'transcriptional components' that describe well-known biology,
              explain the vast majority of variation in gene expression and
              enable us to predict the biological function of genes. On
              correcting expression profiles for these components, we observed
              that the residual expression levels (in 'functional genomic mRNA'
              profiling) correlated strongly with copy number. DNA copy number
              correlated positively with expression levels for 99\% of all
              abundantly expressed human genes, indicating global gene dosage
              sensitivity. By applying this method to 16,172 patient-derived
              tumor samples, we replicated many loci with aberrant copy numbers
              and identified recurrently disrupted genes in genomically
              unstable cancers.",
  journal  = "Nat. Genet.",
  volume   =  47,
  number   =  2,
  pages    = "115--125",
  month    =  feb,
  year     =  2015,
  language = "en"
}

@ARTICLE{Sottoriva2015-hm,
  title    = "A Big Bang model of human colorectal tumor growth",
  author   = "Sottoriva, Andrea and Kang, Haeyoun and Ma, Zhicheng and Graham,
              Trevor A and Salomon, Matthew P and Zhao, Junsong and Marjoram,
              Paul and Siegmund, Kimberly and Press, Michael F and Shibata,
              Darryl and Curtis, Christina",
  abstract = "What happens in early, still undetectable human malignancies is
              unknown because direct observations are impractical. Here we
              present and validate a 'Big Bang' model, whereby tumors grow
              predominantly as a single expansion producing numerous intermixed
              subclones that are not subject to stringent selection and where
              both public (clonal) and most detectable private (subclonal)
              alterations arise early during growth. Genomic profiling of 349
              individual glands from 15 colorectal tumors showed an absence of
              selective sweeps, uniformly high intratumoral heterogeneity (ITH)
              and subclone mixing in distant regions, as postulated by our
              model. We also verified the prediction that most detectable ITH
              originates from early private alterations and not from later
              clonal expansions, thus exposing the profile of the primordial
              tumor. Moreover, some tumors appear 'born to be bad', with
              subclone mixing indicative of early malignant potential. This new
              model provides a quantitative framework to interpret tumor growth
              dynamics and the origins of ITH, with important clinical
              implications.",
  journal  = "Nat. Genet.",
  volume   =  47,
  number   =  3,
  pages    = "209--216",
  month    =  mar,
  year     =  2015,
  language = "en"
}

@ARTICLE{Williams2016-hq,
  title    = "Identification of neutral tumor evolution across cancer types",
  author   = "Williams, Marc J and Werner, Benjamin and Barnes, Chris P and
              Graham, Trevor A and Sottoriva, Andrea",
  abstract = "Despite extraordinary efforts to profile cancer genomes,
              interpreting the vast amount of genomic data in the light of
              cancer evolution remains challenging. Here we demonstrate that
              neutral tumor evolution results in a power-law distribution of
              the mutant allele frequencies reported by next-generation
              sequencing of tumor bulk samples. We find that the neutral power
              law fits with high precision 323 of 904 cancers from 14 types and
              from different cohorts. In malignancies identified as evolving
              neutrally, all clonal selection seemingly occurred before the
              onset of cancer growth and not in later-arising subclones,
              resulting in numerous passenger mutations that are responsible
              for intratumoral heterogeneity. Reanalyzing cancer sequencing
              data within the neutral framework allowed the measurement, in
              each patient, of both the in vivo mutation rate and the order and
              timing of mutations. This result provides a new way to interpret
              existing cancer genomic data and to discriminate between
              functional and non-functional intratumoral heterogeneity.",
  journal  = "Nat. Genet.",
  volume   =  48,
  number   =  3,
  pages    = "238--244",
  month    =  mar,
  year     =  2016,
  language = "en"
}

@ARTICLE{Ben-David2017-ff,
  title    = "Patient-derived xenografts undergo mouse-specific tumor evolution",
  author   = "Ben-David, Uri and Ha, Gavin and Tseng, Yuen-Yi and Greenwald,
              Noah F and Oh, Coyin and Shih, Juliann and McFarland, James M and
              Wong, Bang and Boehm, Jesse S and Beroukhim, Rameen and Golub,
              Todd R",
  abstract = "Patient-derived xenografts (PDXs) have become a prominent cancer
              model system, as they are presumed to faithfully represent the
              genomic features of primary tumors. Here we monitored the
              dynamics of copy number alterations (CNAs) in 1,110 PDX samples
              across 24 cancer types. We observed rapid accumulation of CNAs
              during PDX passaging, often due to selection of preexisting minor
              clones. CNA acquisition in PDXs was correlated with the
              tissue-specific levels of aneuploidy and genetic heterogeneity
              observed in primary tumors. However, the particular CNAs acquired
              during PDX passaging differed from those acquired during tumor
              evolution in patients. Several CNAs recurrently observed in
              primary tumors gradually disappeared in PDXs, indicating that
              events undergoing positive selection in humans can become
              dispensable during propagation in mice. Notably, the genomic
              stability of PDXs was associated with their response to
              chemotherapy and targeted drugs. These findings have major
              implications for PDX-based modeling of human cancer.",
  journal  = "Nat. Genet.",
  volume   =  49,
  number   =  11,
  pages    = "1567--1575",
  month    =  nov,
  year     =  2017,
  language = "en"
}

@ARTICLE{Wherry2011-ig,
  title    = "{T} cell exhaustion",
  author   = "Wherry, E John",
  abstract = "T cell exhaustion is a state of T cell dysfunction that arises
              during many chronic infections and cancer. It is defined by poor
              effector function, sustained expression of inhibitory receptors
              and a transcriptional state distinct from that of functional
              effector or memory T cells. Exhaustion prevents optimal control
              of infection and tumors. Recently, a clearer picture of the
              functional and phenotypic profile of exhausted T cells has
              emerged and T cell exhaustion has been defined in many
              experimental and clinical settings. Although the pathways
              involved remain to be fully defined, advances in the molecular
              delineation of T cell exhaustion are clarifying the underlying
              causes of this state of differentiation and also suggest
              promising therapeutic opportunities.",
  journal  = "Nat. Immunol.",
  volume   =  12,
  number   =  6,
  pages    = "492--499",
  month    =  jun,
  year     =  2011,
  language = "en"
}

@ARTICLE{Purbhoo2004-tr,
  title    = "{T} cell killing does not require the formation of a stable
              mature immunological synapse",
  author   = "Purbhoo, Marco A and Irvine, Darrell J and Huppa, Johannes B and
              Davis, Mark M",
  abstract = "A notable feature of T lymphocyte recognition on other cell
              surfaces is the formation of a stable mature immunological
              synapse. Here we use a single-molecule labeling method to
              directly measure the number of ligands a cytotoxic T cell engages
              and track the consequences of that interaction by
              three-dimensional video microscopy. Like helper T cells,
              cytotoxic T cells were able to detect even a single foreign
              antigen but required about ten complexes of peptide-major
              histocompatibility complex (pMHC) to achieve full calcium
              increase and to form a mature synapse. Thus, cytotoxic T cells
              and helper T cells are more uniform in their antigen
              sensitivities than previously thought. Furthermore, only three
              pMHC complexes were required for killing, showing that stable
              synapse formation and complete signaling are not required for
              cytotoxicity.",
  journal  = "Nat. Immunol.",
  volume   =  5,
  number   =  5,
  pages    = "524--530",
  month    =  may,
  year     =  2004,
  language = "en"
}

@ARTICLE{Dunn2002-ie,
  title    = "Cancer immunoediting: from immunosurveillance to tumor escape",
  author   = "Dunn, Gavin P and Bruce, Allen T and Ikeda, Hiroaki and Old,
              Lloyd J and Schreiber, Robert D",
  abstract = "The concept that the immune system can recognize and destroy
              nascent transformed cells was originally embodied in the cancer
              immunosurveillance hypothesis of Burnet and Thomas. This
              hypothesis was abandoned shortly afterwards because of the
              absence of strong experimental evidence supporting the concept.
              New data, however, clearly show the existence of cancer
              immunosurveillance and also indicate that it may function as a
              component of a more general process of cancer immunoediting. This
              process is responsible for both eliminating tumors and sculpting
              the immunogenic phenotypes of tumors that eventually form in
              immunocompetent hosts. In this review, we will summarize the
              historical and experimental basis of cancer immunoediting and
              discuss its dual roles in promoting host protection against
              cancer and facilitating tumor escape from immune destruction.",
  journal  = "Nat. Immunol.",
  volume   =  3,
  number   =  11,
  pages    = "991--998",
  month    =  nov,
  year     =  2002,
  language = "en"
}

@ARTICLE{Wherry2003-ub,
  title    = "Lineage relationship and protective immunity of memory {CD8} {T}
              cell subsets",
  author   = "Wherry, E John and Teichgr{\"a}ber, Volker and Becker, Todd C and
              Masopust, David and Kaech, Susan M and Antia, Rustom and von
              Andrian, Ulrich H and Ahmed, Rafi",
  abstract = "Memory CD8 T cells can be divided into two subsets, central
              (T(CM)) and effector (T(EM)), but their lineage relationships and
              their ability to persist and confer protective immunity are not
              well understood. Our results show that T(CM) have a greater
              capacity than T(EM) to persist in vivo and are more efficient in
              mediating protective immunity because of their increased
              proliferative potential. We also demonstrate that, following
              antigen clearance, T(EM) convert to T(CM) and that the duration
              of this differentiation is programmed within the first week after
              immunization. We propose that T(CM) and T(EM) do not necessarily
              represent distinct subsets, but are part of a continuum in a
              linear naive --> effector --> T(EM) --> T(CM) differentiation
              pathway.",
  journal  = "Nat. Immunol.",
  volume   =  4,
  number   =  3,
  pages    = "225--234",
  month    =  mar,
  year     =  2003,
  language = "en"
}

@ARTICLE{Andor2016-dq,
  title    = "Pan-cancer analysis of the extent and consequences of intratumor
              heterogeneity",
  author   = "Andor, Noemi and Graham, Trevor A and Jansen, Marnix and Xia, Li
              C and Aktipis, C Athena and Petritsch, Claudia and Ji, Hanlee P
              and Maley, Carlo C",
  abstract = "Intratumor heterogeneity (ITH) drives neoplastic progression and
              therapeutic resistance. We used the bioinformatics tools
              'expanding ploidy and allele frequency on nested subpopulations'
              (EXPANDS) and PyClone to detect clones that are present at a
              $\geq$10\% frequency in 1,165 exome sequences from tumors in The
              Cancer Genome Atlas. 86\% of tumors across 12 cancer types had at
              least two clones. ITH in the morphology of nuclei was associated
              with genetic ITH (Spearman's correlation coefficient, $\rho$ =
              0.24-0.41; P 2 clones coexisted in the same tumor sample (HR =
              1.49, 95\% CI: 1.20-1.87). In two independent data sets,
              copy-number alterations affecting either 75\% of a tumor's genome
              predicted reduced risk (HR = 0.15, 95\% CI: 0.08-0.29). Mortality
              risk also declined when >4 clones coexisted in the sample,
              suggesting a trade-off between the costs and benefits of genomic
              instability. ITH and genomic instability thus have the potential
              to be useful measures that can universally be applied to all
              cancers.",
  journal  = "Nat. Med.",
  volume   =  22,
  number   =  1,
  pages    = "105--113",
  month    =  jan,
  year     =  2016,
  language = "en"
}

% The entry below contains non-ASCII chars that could not be converted
% to a LaTeX equivalent.
@ARTICLE{Palmer2011-uy,
  title    = "In vivo optical molecular imaging and analysis in mice using
              dorsal window chamber models applied to hypoxia, vasculature and
              fluorescent reporters",
  author   = "Palmer, Gregory M and Fontanella, Andrew N and Shan, Siqing and
              Hanna, Gabi and Zhang, Guoqing and Fraser, Cassandra L and
              Dewhirst, Mark W",
  abstract = "Optical techniques for functional imaging in mice have a number
              of key advantages over other common imaging modalities such as
              magnetic resonance imaging, positron emission tomography or
              computed tomography, including high resolution, low cost and an
              extensive library of available contrast agents and reporter
              genes. A major challenge to such work is the limited penetration
              depth imposed by tissue turbidity. We describe a window chamber
              technique by which these limitations can be avoided. This
              facilitates the study of a wide range of processes, with
              potential endpoints including longitudinal gene expression,
              vascular remodeling and angiogenesis, and tumor growth and
              invasion. We further describe several quantitative imaging and
              analysis techniques for characterizing in vivo fluorescence
              properties and functional endpoints, including vascular
              morphology and oxygenation. The procedure takes 2 h to complete,
              plus up to several weeks for tumor growth and treatment
              procedures.",
  journal  = "Nat. Protoc.",
  volume   =  6,
  number   =  9,
  pages    = "1355--1366",
  month    =  aug,
  year     =  2011,
  language = "en"
}

@ARTICLE{Restifo2016-tu,
  title    = "Acquired resistance to immunotherapy and future challenges",
  author   = "Restifo, Nicholas P and Smyth, Mark J and Snyder, Alexandra",
  abstract = "Advances in immunotherapy have resulted in remarkable clinical
              responses in some patients. However, one of the biggest
              challenges in cancer therapeutics is the development of resistant
              disease and disease progression on or after therapy. Given that
              many patients have now received various types of immunotherapy,
              we asked three scientists to give their views on the current
              evidence for whether acquired resistance to immunotherapy exists
              in patients and the future challenges posed by immunotherapy.",
  journal  = "Nat. Rev. Cancer",
  volume   =  16,
  number   =  2,
  pages    = "121--126",
  month    =  feb,
  year     =  2016,
  language = "en"
}

@ARTICLE{Hay2016-mj,
  title    = "Reprogramming glucose metabolism in cancer: can it be exploited
              for cancer therapy?",
  author   = "Hay, Nissim",
  abstract = "In recent years there has been a growing interest among cancer
              biologists in cancer metabolism. This Review summarizes past and
              recent advances in our understanding of the reprogramming of
              glucose metabolism in cancer cells, which is mediated by
              oncogenic drivers and by the undifferentiated character of cancer
              cells. The reprogrammed glucose metabolism in cancer cells is
              required to fulfil anabolic demands. This Review discusses the
              possibility of exploiting the reprogrammed glucose metabolism for
              therapeutic approaches that selectively target cancer cells.",
  journal  = "Nat. Rev. Cancer",
  volume   =  16,
  number   =  10,
  pages    = "635--649",
  month    =  oct,
  year     =  2016,
  language = "en"
}

@ARTICLE{Byrne2010-ez,
  title    = "Dissecting cancer through mathematics: from the cell to the
              animal model",
  author   = "Byrne, Helen M",
  abstract = "This Timeline article charts progress in mathematical modelling
              of cancer over the past 50 years, highlighting the different
              theoretical approaches that have been used to dissect the disease
              and the insights that have arisen. Although most of this research
              was conducted with little involvement from experimentalists or
              clinicians, there are signs that the tide is turning and that
              increasing numbers of those involved in cancer research and
              mathematical modellers are recognizing that by working together
              they might more rapidly advance our understanding of cancer and
              improve its treatment.",
  journal  = "Nat. Rev. Cancer",
  volume   =  10,
  number   =  3,
  pages    = "221--230",
  month    =  mar,
  year     =  2010,
  language = "en"
}

@ARTICLE{Gaillard2015-if,
  title    = "Replication stress and cancer",
  author   = "Gaillard, H{\'e}l{\`e}ne and Garc{\'\i}a-Muse, Tatiana and
              Aguilera, Andr{\'e}s",
  abstract = "Genome instability is a hallmark of cancer, and DNA replication
              is the most vulnerable cellular process that can lead to it. Any
              condition leading to high levels of DNA damage will result in
              replication stress, which is a source of genome instability and a
              feature of pre-cancerous and cancerous cells. Therefore,
              understanding the molecular basis of replication stress is
              crucial to the understanding of tumorigenesis. Although a
              negative aspect of replication stress is its prominent role in
              tumorigenesis, a positive aspect is that it provides a potential
              target for cancer therapy. In this Review, we discuss the link
              between persistent replication stress and tumorigenesis, with the
              goal of shedding light on the mechanisms underlying the
              initiation of an oncogenic process, which should open up new
              possibilities for cancer diagnostics and treatment.",
  journal  = "Nat. Rev. Cancer",
  volume   =  15,
  number   =  5,
  pages    = "276--289",
  month    =  may,
  year     =  2015,
  language = "en"
}

@ARTICLE{Melero2015-sc,
  title    = "Evolving synergistic combinations of targeted immunotherapies to
              combat cancer",
  author   = "Melero, Ignacio and Berman, David M and Aznar, M Angela and
              Korman, Alan J and P{\'e}rez Gracia, Jos{\'e} Luis and Haanen,
              John",
  abstract = "Immunotherapy has now been clinically validated as an effective
              treatment for many cancers. There is tremendous potential for
              synergistic combinations of immunotherapy agents and for
              combining immunotherapy agents with conventional cancer
              treatments. Clinical trials combining blockade of cytotoxic T
              lymphocyte-associated antigen 4 (CTLA4) and programmed cell death
              protein 1 (PD1) may serve as a paradigm to guide future
              approaches to immuno-oncology combination therapy. In this
              Review, we discuss progress in the synergistic design of
              immune-targeting combination therapies and highlight the
              challenges involved in tailoring such strategies to provide
              maximal benefit to patients.",
  journal  = "Nat. Rev. Cancer",
  volume   =  15,
  number   =  8,
  pages    = "457--472",
  month    =  aug,
  year     =  2015,
  language = "en"
}

@ARTICLE{Weichselbaum2017-mw,
  title    = "Radiotherapy and immunotherapy: a beneficial liaison?",
  author   = "Weichselbaum, Ralph R and Liang, Hua and Deng, Liufu and Fu,
              Yang-Xin",
  abstract = "Investigations into the interaction between radiotherapy and the
              host immune system have uncovered new mechanisms that can
              potentially be exploited to improve the efficacy of radiotherapy.
              Radiation promotes the release of danger signals and chemokines
              that recruit inflammatory cells into the tumour microenvironment,
              including antigen-presenting cells that activate cytotoxic T-cell
              function. By contrast, radiation can attract immunosuppressive
              cells into the tumour microenvironment. In rare circumstances,
              the antitumour effect of radiotherapy has been observed outside
              of the radiation field, known as the abscopal effect. This
              phenomenon is proposed to have an immune origin and indicates
              that local radiotherapy elicits systemic effects. Herein, we
              highlight data that provide new mechanistic explanations for the
              success or failure of radiotherapy, and postulate how the
              combination of immune-modulation and radiation could tip the
              balance of the host immune response to promote cure. We use the
              concept of radiation- induced tumour equilibrium (RITE) as a
              starting point to discuss the mechanistic influence of
              immune-checkpoint therapies on radiotherapy efficacy.",
  journal  = "Nat. Rev. Clin. Oncol.",
  volume   =  14,
  number   =  6,
  pages    = "365--379",
  month    =  jun,
  year     =  2017,
  language = "en"
}

@ARTICLE{Sansregret2018-ki,
  title    = "Determinants and clinical implications of chromosomal instability
              in cancer",
  author   = "Sansregret, Laurent and Vanhaesebroeck, Bart and Swanton, Charles",
  abstract = "Aberrant chromosomal architecture, ranging from small insertions
              or deletions to large chromosomal alterations, is one of the most
              common characteristics of cancer genomes. Chromosomal instability
              (CIN) underpins much of the intratumoural heterogeneity observed
              in cancers and drives phenotypic adaptation during tumour
              evolution. Thus, an urgent need exists to increase our efforts to
              target CIN as if it were a molecular entity. Indeed, CIN
              accelerates the development of anticancer drug resistance, often
              leading to treatment failure and disease recurrence, which limit
              the effectiveness of most current therapies. Identifying novel
              strategies to modulate CIN and to exploit the fitness cost
              associated with aneuploidy in cancer is, therefore, of paramount
              importance for the successful treatment of cancer. Modern
              sequencing and analytical methods greatly facilitate the
              identification and cataloguing of somatic copy-number alterations
              and offer new possibilities to better exploit the dynamic process
              of CIN. In this Review, we describe the principles governing CIN
              propagation in cancer and how CIN might influence sensitivity to
              immune-checkpoint inhibition, and survey the vulnerabilities
              associated with CIN that offer potential therapeutic
              opportunities.",
  journal  = "Nat. Rev. Clin. Oncol.",
  volume   =  15,
  number   =  3,
  pages    = "139--150",
  month    =  mar,
  year     =  2018,
  language = "en"
}

@ARTICLE{Yip2018-kz,
  title    = "The market for chimeric antigen receptor {T} cell therapies",
  author   = "Yip, Amy and Webster, Rachel M",
  journal  = "Nat. Rev. Drug Discov.",
  volume   =  17,
  number   =  3,
  pages    = "161--162",
  month    =  mar,
  year     =  2018,
  language = "en"
}

@ARTICLE{Tang2018-he,
  title    = "Trends in the global immuno-oncology landscape",
  author   = "Tang, Jun and Pearce, Laura and O'Donnell-Tormey, Jill and
              Hubbard-Lucey, Vanessa M",
  journal  = "Nat. Rev. Drug Discov.",
  volume   =  17,
  number   =  11,
  pages    = "783--784",
  month    =  nov,
  year     =  2018,
  language = "en"
}

@ARTICLE{Tang2018-gv,
  title    = "The global landscape of cancer cell therapy",
  author   = "Tang, Jun and Hubbard-Lucey, Vanessa M and Pearce, Laura and
              O'Donnell-Tormey, Jill and Shalabi, Aiman",
  journal  = "Nat. Rev. Drug Discov.",
  volume   =  17,
  number   =  7,
  pages    = "465--466",
  month    =  jul,
  year     =  2018,
  language = "en"
}

@ARTICLE{Kaufman2015-lz,
  title    = "Oncolytic viruses: a new class of immunotherapy drugs",
  author   = "Kaufman, Howard L and Kohlhapp, Frederick J and Zloza, Andrew",
  abstract = "Oncolytic viruses represent a new class of therapeutic agents
              that promote anti-tumour responses through a dual mechanism of
              action that is dependent on selective tumour cell killing and the
              induction of systemic anti-tumour immunity. The molecular and
              cellular mechanisms of action are not fully elucidated but are
              likely to depend on viral replication within transformed cells,
              induction of primary cell death, interaction with tumour cell
              antiviral elements and initiation of innate and adaptive
              anti-tumour immunity. A variety of native and genetically
              modified viruses have been developed as oncolytic agents, and the
              approval of the first oncolytic virus by the US Food and Drug
              Administration (FDA) is anticipated in the near future. This
              Review provides a comprehensive overview of the basic biology
              supporting oncolytic viruses as cancer therapeutic agents,
              describes oncolytic viruses in advanced clinical trials and
              discusses the unique challenges in the development of oncolytic
              viruses as a new class of drugs for the treatment of cancer.",
  journal  = "Nat. Rev. Drug Discov.",
  volume   =  14,
  number   =  9,
  pages    = "642--662",
  month    =  sep,
  year     =  2015,
  language = "en"
}

@ARTICLE{Van_de_Peer2017-mi,
  title    = "The evolutionary significance of polyploidy",
  author   = "Van de Peer, Yves and Mizrachi, Eshchar and Marchal, Kathleen",
  abstract = "Polyploidy, or the duplication of entire genomes, has been
              observed in prokaryotic and eukaryotic organisms, and in somatic
              and germ cells. The consequences of polyploidization are complex
              and variable, and they differ greatly between systems (clonal or
              non-clonal) and species, but the process has often been
              considered to be an evolutionary 'dead end'. Here, we review the
              accumulating evidence that correlates polyploidization with
              environmental change or stress, and that has led to an increased
              recognition of its short-term adaptive potential. In addition, we
              discuss how, once polyploidy has been established, the unique
              retention profile of duplicated genes following whole-genome
              duplication might explain key longer-term evolutionary
              transitions and a general increase in biological complexity.",
  journal  = "Nat. Rev. Genet.",
  volume   =  18,
  number   =  7,
  pages    = "411--424",
  month    =  jul,
  year     =  2017,
  language = "en"
}

@ARTICLE{Gordon2012-gs,
  title    = "Causes and consequences of aneuploidy in cancer",
  author   = "Gordon, David J and Resio, Benjamin and Pellman, David",
  abstract = "Genetic instability, which includes both numerical and structural
              chromosomal abnormalities, is a hallmark of cancer. Whereas the
              structural chromosome rearrangements have received substantial
              attention, the role of whole-chromosome aneuploidy in cancer is
              much less well-understood. Here we review recent progress in
              understanding the roles of whole-chromosome aneuploidy in cancer,
              including the mechanistic causes of aneuploidy, the cellular
              responses to chromosome gains or losses and how cells might adapt
              to tolerate these usually detrimental alterations. We also
              explore the role of aneuploidy in cellular transformation and
              discuss the possibility of developing aneuploidy-specific
              therapies.",
  journal  = "Nat. Rev. Genet.",
  volume   =  13,
  number   =  3,
  pages    = "189--203",
  month    =  jan,
  year     =  2012,
  language = "en"
}

@ARTICLE{De_Visser2014-kp,
  title    = "Empirical fitness landscapes and the predictability of evolution",
  author   = "de Visser, J Arjan G M and Krug, Joachim",
  abstract = "The genotype-fitness map (that is, the fitness landscape) is a
              key determinant of evolution, yet it has mostly been used as a
              superficial metaphor because we know little about its structure.
              This is now changing, as real fitness landscapes are being
              analysed by constructing genotypes with all possible combinations
              of small sets of mutations observed in phylogenies or in
              evolution experiments. In turn, these first glimpses of empirical
              fitness landscapes inspire theoretical analyses of the
              predictability of evolution. Here, we review these recent
              empirical and theoretical developments, identify methodological
              issues and organizing principles, and discuss possibilities to
              develop more realistic fitness landscape models.",
  journal  = "Nat. Rev. Genet.",
  volume   =  15,
  number   =  7,
  pages    = "480--490",
  month    =  jul,
  year     =  2014,
  language = "en"
}

@ARTICLE{Sharpe2018-ga,
  title    = "The diverse functions of the {PD1} inhibitory pathway",
  author   = "Sharpe, Arlene H and Pauken, Kristen E",
  abstract = "T cell activation is a highly regulated process involving
              peptide-MHC engagement of the T cell receptor and positive
              costimulatory signals. Upon activation, coinhibitory
              'checkpoints', including programmed cell death protein 1 (PD1),
              become induced to regulate T cells. PD1 has an essential role in
              balancing protective immunity and immunopathology, homeostasis
              and tolerance. However, during responses to chronic pathogens and
              tumours, PD1 expression can limit protective immunity. Recently
              developed PD1 pathway inhibitors have revolutionized cancer
              treatment for some patients, but the majority of patients do not
              show complete responses, and adverse events have been noted. This
              Review discusses the diverse roles of the PD1 pathway in
              regulating immune responses and how this knowledge can improve
              cancer immunotherapy as well as restore and/or maintain tolerance
              during autoimmunity and transplantation.",
  journal  = "Nat. Rev. Immunol.",
  volume   =  18,
  number   =  3,
  pages    = "153--167",
  month    =  mar,
  year     =  2018,
  language = "en"
}

@ARTICLE{Finn2003-yp,
  title    = "Cancer vaccines: between the idea and the reality",
  author   = "Finn, Olivera J",
  abstract = "Whether vaccines are designed to prepare the immune system for
              the encounter with a pathogen or with cancer, certain common
              challenges need to be faced, such as what antigen and what
              adjuvant to use, what type of immune response to generate and how
              to make it long lasting. Cancer, additionally, presents several
              unique hurdles. Cancer vaccines must overcome immune suppression
              exerted by the tumour, by previous therapy or by the effects of
              advanced age of the patient. If used for cancer prevention,
              vaccines must elicit effective long-term memory without the
              potential of causing autoimmunity. This article addresses the
              common and the unique challenges to cancer vaccines and the
              progress that has been made in meeting them. Considering how
              refractory cancer has been to standard therapy, efforts to
              achieve immune control of this disease are well justified.",
  journal  = "Nat. Rev. Immunol.",
  volume   =  3,
  number   =  8,
  pages    = "630--641",
  month    =  aug,
  year     =  2003,
  language = "en"
}

@ARTICLE{Voskoboinik2015-wo,
  title    = "Perforin and granzymes: function, dysfunction and human pathology",
  author   = "Voskoboinik, Ilia and Whisstock, James C and Trapani, Joseph A",
  abstract = "A defining property of cytotoxic lymphocytes is their expression
              and regulated secretion of potent toxins, including the
              pore-forming protein perforin and serine protease granzymes.
              Until recently, mechanisms of pore formation and granzyme
              transfer into the target cell were poorly understood, but
              advances in structural and cellular biology have now begun to
              unravel how synergy between perforin and granzymes brings about
              target cell death. These and other advances are demonstrating the
              surprisingly broad pathophysiological roles of the
              perforin--granzyme pathway, and this has important implications
              for understanding immune homeostasis and for developing
              immunotherapies for cancer and other diseases. In particular, we
              are beginning to define and understand a range of human diseases
              that are associated with a failure to deliver active perforin to
              target cells. In this Review, we discuss the current
              understanding of the structural, cellular and clinical aspects of
              perforin and granzyme biology.",
  journal  = "Nat. Rev. Immunol.",
  volume   =  15,
  number   =  6,
  pages    = "388--400",
  month    =  jun,
  year     =  2015,
  language = "en"
}

@ARTICLE{Wherry2015-jm,
  title    = "Molecular and cellular insights into {T} cell exhaustion",
  author   = "Wherry, E John and Kurachi, Makoto",
  abstract = "In chronic infections and cancer, T cells are exposed to
              persistent antigen and/or inflammatory signals. This scenario is
              often associated with the deterioration of T cell function: a
              state called 'exhaustion'. Exhausted T cells lose robust effector
              functions, express multiple inhibitory receptors and are defined
              by an altered transcriptional programme. T cell exhaustion is
              often associated with inefficient control of persisting
              infections and tumours, but revitalization of exhausted T cells
              can reinvigorate immunity. Here, we review recent advances that
              provide a clearer molecular understanding of T cell exhaustion
              and reveal new therapeutic targets for persisting infections and
              cancer.",
  journal  = "Nat. Rev. Immunol.",
  volume   =  15,
  number   =  8,
  pages    = "486--499",
  month    =  aug,
  year     =  2015,
  language = "en"
}

@ARTICLE{Herzig2018-cw,
  title    = "{AMPK}: guardian of metabolism and mitochondrial homeostasis",
  author   = "Herzig, S{\'e}bastien and Shaw, Reuben J",
  abstract = "Cells constantly adapt their metabolism to meet their energy
              needs and respond to nutrient availability. Eukaryotes have
              evolved a very sophisticated system to sense low cellular ATP
              levels via the serine/threonine kinase AMP-activated protein
              kinase (AMPK) complex. Under conditions of low energy, AMPK
              phosphorylates specific enzymes and growth control nodes to
              increase ATP generation and decrease ATP consumption. In the past
              decade, the discovery of numerous new AMPK substrates has led to
              a more complete understanding of the minimal number of steps
              required to reprogramme cellular metabolism from anabolism to
              catabolism. This energy switch controls cell growth and several
              other cellular processes, including lipid and glucose metabolism
              and autophagy. Recent studies have revealed that one ancestral
              function of AMPK is to promote mitochondrial health, and multiple
              newly discovered targets of AMPK are involved in various aspects
              of mitochondrial homeostasis, including mitophagy. This Review
              discusses how AMPK functions as a central mediator of the
              cellular response to energetic stress and mitochondrial insults
              and coordinates multiple features of autophagy and mitochondrial
              biology.",
  journal  = "Nat. Rev. Mol. Cell Biol.",
  volume   =  19,
  number   =  2,
  pages    = "121--135",
  month    =  feb,
  year     =  2018,
  language = "en"
}

@ARTICLE{Hetz2012-wc,
  title    = "The unfolded protein response: controlling cell fate decisions
              under {ER} stress and beyond",
  author   = "Hetz, Claudio",
  abstract = "Protein-folding stress at the endoplasmic reticulum (ER) is a
              salient feature of specialized secretory cells and is also
              involved in the pathogenesis of many human diseases. ER stress is
              buffered by the activation of the unfolded protein response
              (UPR), a homeostatic signalling network that orchestrates the
              recovery of ER function, and failure to adapt to ER stress
              results in apoptosis. Progress in the field has provided insight
              into the regulatory mechanisms and signalling crosstalk of the
              three branches of the UPR, which are initiated by the stress
              sensors protein kinase RNA-like ER kinase (PERK),
              inositol-requiring protein 1$\alpha$ (IRE1$\alpha$) and
              activating transcription factor 6 (ATF6). In addition, novel
              physiological outcomes of the UPR that are not directly related
              to protein-folding stress, such as innate immunity, metabolism
              and cell differentiation, have been revealed.",
  journal  = "Nat. Rev. Mol. Cell Biol.",
  volume   =  13,
  number   =  2,
  pages    = "89--102",
  month    =  jan,
  year     =  2012,
  language = "en"
}

@ARTICLE{Edgar2014-gc,
  title    = "Endocycles: a recurrent evolutionary innovation for post-mitotic
              cell growth",
  author   = "Edgar, Bruce A and Zielke, Norman and Gutierrez, Crisanto",
  abstract = "In endoreplication cell cycles, known as endocycles, cells
              successively replicate their genomes without segregating
              chromosomes during mitosis and thereby become polyploid. Such
              cycles, for which there are many variants, are widespread in
              protozoa, plants and animals. Endocycling cells can achieve
              ploidies of >200,000 C (chromatin-value); this increase in
              genomic DNA content allows a higher genomic output, which can
              facilitate the construction of very large cells or enhance
              macromolecular secretion. These cells execute normal S phases,
              using a G1-S regulatory apparatus similar to the one used by
              mitotic cells, but their capability to segregate chromosomes has
              been suppressed, typically by downregulation of mitotic
              cyclin-dependent kinase activity. Endocycles probably evolved
              many times, and the various endocycle mechanisms found in nature
              highlight the versatility of the cell cycle control machinery.",
  journal  = "Nat. Rev. Mol. Cell Biol.",
  volume   =  15,
  number   =  3,
  pages    = "197--210",
  month    =  mar,
  year     =  2014,
  language = "en"
}

@ARTICLE{Santaguida2015-bx,
  title    = "Short- and long-term effects of chromosome mis-segregation and
              aneuploidy",
  author   = "Santaguida, Stefano and Amon, Angelika",
  abstract = "Dividing cells that experience chromosome mis-segregation
              generate aneuploid daughter cells, which contain an incorrect
              number of chromosomes. Although aneuploidy interferes with the
              proliferation of untransformed cells, it is also, paradoxically,
              a hallmark of cancer, a disease defined by increased
              proliferative potential. These contradictory effects are also
              observed in mouse models of chromosome instability (CIN). CIN can
              inhibit and promote tumorigenesis. Recent work has provided
              insights into the cellular consequences of CIN and aneuploidy.
              Chromosome mis-segregation per se can alter the genome in many
              more ways than just causing the gain or loss of chromosomes. The
              short- and long-term effects of aneuploidy are caused by
              gene-specific effects and a stereotypic aneuploidy stress
              response. Importantly, these recent findings provide insights
              into the role of aneuploidy in tumorigenesis.",
  journal  = "Nat. Rev. Mol. Cell Biol.",
  volume   =  16,
  number   =  8,
  pages    = "473--485",
  month    =  aug,
  year     =  2015,
  language = "en"
}

@ARTICLE{Bidle2004-ao,
  title    = "Cell death in planktonic, photosynthetic microorganisms",
  author   = "Bidle, Kay D and Falkowski, Paul G",
  journal  = "Nat. Rev. Microbiol.",
  volume   =  2,
  number   =  8,
  pages    = "643--655",
  month    =  aug,
  year     =  2004,
  language = "en"
}

@ARTICLE{Zhang2014-de,
  title    = "Generation of cancer stem-like cells through the formation of
              polyploid giant cancer cells",
  author   = "Zhang, S and Mercado-Uribe, I and Xing, Z and Sun, B and Kuang, J
              and Liu, J",
  abstract = "Polyploid giant cancer cells (PGCCs) have been observed by
              pathologists for over a century. PGCCs contribute to solid tumor
              heterogeneity, but their functions are largely undefined. Little
              attention has been given to these cells, largely because PGCCs
              have been generally thought to originate from repeated failure of
              mitosis/cytokinesis and have no capacity for long-term survival
              or proliferation. Here we report our successful purification and
              culture of PGCCs from human ovarian cancer cell lines and primary
              ovarian cancer. These cells are highly resistant to oxygen
              deprivation and could form through endoreduplication or cell
              fusion, generating regular-sized cancer cells quickly through
              budding or bursting similar to simple organisms like fungi. They
              express normal and cancer stem cell markers, they divide
              asymmetrically and they cycle slowly. They can differentiate into
              adipose, cartilage and bone. A single PGCC formed cancer
              spheroids in vitro and generated tumors in immunodeficient mice.
              These PGCC-derived tumors gained a mesenchymal phenotype with
              increased expression of cancer stem cell markers CD44 and CD133
              and become more resistant to treatment with cisplatin. Taken
              together, our results reveal that PGCCs represent a resistant
              form of human cancer using an ancient, evolutionarily conserved
              mechanism in response to hypoxia stress; they can contribute to
              the generation of cancer stem-like cells, and also play a
              fundamental role in regulating tumor heterogeneity, tumor growth
              and chemoresistance in human cancer.",
  journal  = "Oncogene",
  volume   =  33,
  number   =  1,
  pages    = "116--128",
  month    =  jan,
  year     =  2014,
  language = "en"
}

@ARTICLE{Shaukat2015-ly,
  title    = "Chromosomal instability causes sensitivity to metabolic stress",
  author   = "Shaukat, Z and Liu, D and Choo, A and Hussain, R and O'Keefe, L
              and Richards, R and Saint, R and Gregory, S L",
  abstract = "Chromosomal INstability (CIN), a hallmark of cancer, refers to
              cells with an increased rate of gain or loss of whole chromosomes
              or chromosome parts. CIN is linked to the progression of tumors
              with poor clinical outcomes such as drug resistance. CIN can give
              tumors the diversity to resist therapy, but it comes at the cost
              of significant stress to tumor cells. To tolerate this, cancer
              cells must modify their energy use to provide adaptation against
              genetic changes as well as to promote their survival and growth.
              In this study, we have demonstrated that CIN induction causes
              sensitivity to metabolic stress. We show that mild metabolic
              disruption that does not affect normal cells, can lead to high
              levels of oxidative stress and subsequent cell death in CIN cells
              because they are already managing elevated stress levels. Altered
              metabolism is a differential characteristic of cancer cells, so
              our identification of key regulators that can exploit these
              changes to cause cell death may provide cancer-specific potential
              drug targets, especially for advanced cancers that exhibit CIN.",
  journal  = "Oncogene",
  volume   =  34,
  number   =  31,
  pages    = "4044--4055",
  month    =  jul,
  year     =  2015,
  language = "en"
}

@ARTICLE{Lieu2020-dk,
  title    = "Amino acids in cancer",
  author   = "Lieu, Elizabeth L and Nguyen, Tu and Rhyne, Shawn and Kim, Jiyeon",
  abstract = "Over 90 years ago, Otto Warburg's seminal discovery of aerobic
              glycolysis established metabolic reprogramming as one of the
              first distinguishing characteristics of cancer1. The field of
              cancer metabolism subsequently revealed additional metabolic
              alterations in cancer by focusing on central carbon metabolism,
              including the citric acid cycle and pentose phosphate pathway.
              Recent reports have, however, uncovered substantial non-carbon
              metabolism contributions to cancer cell viability and growth.
              Amino acids, nutrients vital to the survival of all cell types,
              experience reprogrammed metabolism in cancer. This review
              outlines the diverse roles of amino acids within the tumor and in
              the tumor microenvironment. Beyond their role in biosynthesis,
              they serve as energy sources and help maintain redox balance. In
              addition, amino acid derivatives contribute to epigenetic
              regulation and immune responses linked to tumorigenesis and
              metastasis. Furthermore, in discussing the transporters and
              transaminases that mediate amino acid uptake and synthesis, we
              identify potential metabolic liabilities as targets for
              therapeutic intervention.",
  journal  = "Exp. Mol. Med.",
  volume   =  52,
  number   =  1,
  pages    = "15--30",
  month    =  jan,
  year     =  2020,
  language = "en"
}

@ARTICLE{Vettore2020-sz,
  title    = "New aspects of amino acid metabolism in cancer",
  author   = "Vettore, Lisa and Westbrook, Rebecca L and Tennant, Daniel A",
  abstract = "An abundant supply of amino acids is important for cancers to
              sustain their proliferative drive. Alongside their direct role as
              substrates for protein synthesis, they can have roles in energy
              generation, driving the synthesis of nucleosides and maintenance
              of cellular redox homoeostasis. As cancer cells exist within a
              complex and often nutrient-poor microenvironment, they sometimes
              exist as part of a metabolic community, forming relationships
              that can be both symbiotic and parasitic. Indeed, this is
              particularly evident in cancers that are auxotrophic for
              particular amino acids. This review discusses the stromal/cancer
              cell relationship, by using examples to illustrate a number of
              different ways in which cancer cells can rely on and contribute
              to their microenvironment - both as a stable network and in
              response to therapy. In addition, it examines situations when
              amino acid synthesis is driven through metabolic coupling to
              other reactions, and synthesis is in excess of the cancer cell's
              proliferative demand. Finally, it highlights the understudied
              area of non-proteinogenic amino acids in cancer metabolism and
              their potential role.",
  journal  = "Br. J. Cancer",
  volume   =  122,
  number   =  2,
  pages    = "150--156",
  month    =  jan,
  year     =  2020,
  language = "en"
}

@ARTICLE{Martin2023-jo,
  title    = "Mitochondrial {RNA} methyltransferase {TRMT61B} is a new,
              potential biomarker and therapeutic target for highly aneuploid
              cancers",
  author   = "Mart{\'\i}n, Alberto and Epifano, Carolina and Vilaplana-Marti,
              Borja and Hern{\'a}ndez, Iv{\'a}n and Mac{\'\i}as, Roc{\'\i}o I R
              and Mart{\'\i}nez-Ram{\'\i}rez, {\'A}ngel and Cerezo, Ana and
              Cabezas-Sainz, Pablo and Garranzo-Asensio, Maria and
              Amarilla-Quintana, Sandra and G{\'o}mez-Dom{\'\i}nguez,
              D{\'e}borah and Caleiras, Eduardo and Camps, Jordi and
              G{\'o}mez-L{\'o}pez, Gonzalo and G{\'o}mez de Cedr{\'o}n, Marta
              and Ram{\'\i}rez de Molina, Ana and Barderas, Rodrigo and
              S{\'a}nchez, Laura and Velasco-Miguel, Susana and P{\'e}rez de
              Castro, Ignacio",
  abstract = "Despite being frequently observed in cancer cells, chromosomal
              instability (CIN) and its immediate consequence, aneuploidy,
              trigger adverse effects on cellular homeostasis that need to be
              overcome by anti-stress mechanisms. As such, these safeguard
              responses represent a tumor-specific Achilles heel, since CIN and
              aneuploidy are rarely observed in normal cells. Recent data have
              revealed that epitranscriptomic marks catalyzed by RNA-modifying
              enzymes change under various stress insults. However, whether
              aneuploidy is associated with such RNA modifying pathways remains
              to be determined. Through an in silico search for aneuploidy
              biomarkers in cancer cells, we found TRMT61B, a mitochondrial RNA
              methyltransferase enzyme, to be associated with high levels of
              aneuploidy. Accordingly, TRMT61B protein levels are increased in
              tumor cell lines with an imbalanced karyotype as well as in
              different tumor types when compared to control tissues.
              Interestingly, while TRMT61B depletion induces senescence in
              melanoma cell lines with low levels of aneuploidy, it leads to
              apoptosis in cells with high levels. The therapeutic potential of
              these results was further validated by targeting TRMT61B in
              transwell and xenografts assays. We show that TRM61B depletion
              reduces the expression of several mitochondrial encoded proteins
              and limits mitochondrial function. Taken together, these results
              identify a new biomarker of aneuploidy in cancer cells that could
              potentially be used to selectively target highly aneuploid
              tumors.",
  journal  = "Cell Death Differ.",
  volume   =  30,
  number   =  1,
  pages    = "37--53",
  month    =  jan,
  year     =  2023,
  language = "en"
}

@ARTICLE{Faletti2018-tx,
  title    = "{TNF$\alpha$} sensitizes hepatocytes to {FasL-induced} apoptosis
              by {NF$\kappa$B-mediated} Fas upregulation",
  author   = "Faletti, Laura and Peintner, Lukas and Neumann, Simon and
              Sandler, Sandra and Grabinger, Thomas and Mac Nelly, Sabine and
              Merfort, Irmgard and Huang, Chun-Hao and Tschaharganeh, Darjus
              and Kang, Tae-Won and Heinzmann, Florian and D'Artista, Luana and
              Maurer, Ulrich and Brunner, Thomas and Lowe, Scott and Zender,
              Lars and Borner, Christoph",
  abstract = "Although it is well established that TNF$\alpha$ contributes to
              hepatitis, liver failure and associated hepatocarcinogenesis via
              the regulation of inflammation, its pro-apoptotic role in the
              liver has remained enigmatic. On its own, TNF$\alpha$ is unable
              to trigger apoptosis. However, when combined with the
              transcriptional inhibitor GaLN, it can cause hepatocyte apoptosis
              and liver failure in mice. Moreover, along with others, we have
              shown that TNF$\alpha$ is capable of sensitizing cells to FasL-
              or drug-induced cell death via c-Jun N-terminal kinase (JNK)
              activation and phosphorylation/activation of the BH3-only protein
              Bim. In this context, TNF$\alpha$ could exacerbate hepatocyte
              cell death during simultaneous inflammatory and T-cell-mediated
              immune responses in the liver. Here we show that TNF$\alpha$
              sensitizes primary hepatocytes, established hepatocyte cell lines
              and mouse embryo fibroblasts to FasL-induced apoptosis by the
              transcriptional induction and higher surface expression of Fas
              via the NF$\kappa$B pathway. Genetic deletion, diminished
              expression or dominant-negative inhibition of the NF$\kappa$B
              subunit p65 resulted in lower Fas expression and inhibited
              TNF$\alpha$-induced Fas upregulation and sensitization to
              FasL-induced cell death. By hydrodynamic injection of p65 shRNA
              into the tail vein of mice, we confirm that Fas upregulation by
              TNF$\alpha$ is also NF$\kappa$B-mediated in the liver. In
              conclusion, TNF$\alpha$ sensitization of FasL-induced apoptosis
              in the liver proceeds via two parallel signaling pathways,
              activation of JNK and Bim phosphorylation and
              NF$\kappa$B-mediated Fas upregulation.",
  journal  = "Cell Death Dis.",
  volume   =  9,
  number   =  9,
  pages    = "909",
  month    =  sep,
  year     =  2018,
  language = "en"
}

@ARTICLE{Ock2017-uy,
  title    = "Genomic landscape associated with potential response to
              {anti-CTLA-4} treatment in cancers",
  author   = "Ock, Chan-Young and Hwang, Jun-Eul and Keam, Bhumsuk and Kim,
              Sang-Bae and Shim, Jae-Jun and Jang, Hee-Jin and Park, Sarang and
              Sohn, Bo Hwa and Cha, Minse and Ajani, Jaffer A and Kopetz, Scott
              and Lee, Keun-Wook and Kim, Tae Min and Heo, Dae Seog and Lee,
              Ju-Seog",
  abstract = "Immunotherapy has emerged as a promising anti-cancer treatment,
              however, little is known about the genetic characteristics that
              dictate response to immunotherapy. We develop a transcriptional
              predictor of immunotherapy response and assess its prediction in
              genomic data from ~10,000 human tissues across 30 different
              cancer types to estimate the potential response to immunotherapy.
              The integrative analysis reveals two distinct tumor types: the
              mutator type is positively associated with potential response to
              immunotherapy, whereas the chromosome-instable type is negatively
              associated with it. We identify somatic mutations and copy number
              alterations significantly associated with potential response to
              immunotherapy, in particular treatment with anti-CTLA-4 antibody.
              Our findings suggest that tumors may evolve through two different
              paths that would lead to marked differences in immunotherapy
              response as well as different strategies for evading immune
              surveillance. Our analysis provides resources to facilitate the
              discovery of predictive biomarkers for immunotherapy that could
              be tested in clinical trials.",
  journal  = "Nat. Commun.",
  volume   =  8,
  number   =  1,
  pages    = "1050",
  month    =  oct,
  year     =  2017,
  language = "en"
}

@ARTICLE{Liu2017-tt,
  title    = "Systematic proteome and proteostasis profiling in human Trisomy
              21 fibroblast cells",
  author   = "Liu, Yansheng and Borel, Christelle and Li, Li and M{\"u}ller,
              Torsten and Williams, Evan G and Germain, Pierre-Luc and Buljan,
              Marija and Sajic, Tatjana and Boersema, Paul J and Shao, Wenguang
              and Faini, Marco and Testa, Giuseppe and Beyer, Andreas and
              Antonarakis, Stylianos E and Aebersold, Ruedi",
  abstract = "Down syndrome (DS) is mostly caused by a trisomy of the entire
              Chromosome 21 (Trisomy 21, T21). Here, we use SWATH mass
              spectrometry to quantify protein abundance and protein turnover
              in fibroblasts from a monozygotic twin pair discordant for T21,
              and to profile protein expression in 11 unrelated DS individuals
              and matched controls. The integration of the steady-state and
              turnover proteomic data indicates that protein-specific
              degradation of members of stoichiometric complexes is a major
              determinant of T21 gene dosage outcome, both within and between
              individuals. This effect is not apparent from genomic and
              transcriptomic data. The data also reveal that T21 results in
              extensive proteome remodeling, affecting proteins encoded by all
              chromosomes. Finally, we find broad, organelle-specific
              post-transcriptional effects such as significant downregulation
              of the mitochondrial proteome contributing to T21 hallmarks.
              Overall, we provide a valuable proteomic resource to understand
              the origin of DS phenotypic manifestations.",
  journal  = "Nat. Commun.",
  volume   =  8,
  number   =  1,
  pages    = "1212",
  month    =  oct,
  year     =  2017,
  language = "en"
}

@ARTICLE{Lauss2017-lw,
  title    = "Mutational and putative neoantigen load predict clinical benefit
              of adoptive {T} cell therapy in melanoma",
  author   = "Lauss, Martin and Donia, Marco and Harbst, Katja and Andersen,
              Rikke and Mitra, Shamik and Rosengren, Frida and Salim, Maryem
              and Vallon-Christersson, Johan and T{\"o}rngren, Therese and
              Kvist, Anders and Ringn{\'e}r, Markus and Svane, Inge Marie and
              J{\"o}nsson, G{\"o}ran",
  abstract = "Adoptive T-cell therapy (ACT) is a highly intensive immunotherapy
              regime that has yielded remarkable response rates and many
              durable responses in clinical trials in melanoma; however,
              50-60\% of the patients have no clinical benefit. Here, we
              searched for predictive biomarkers to ACT in melanoma. Whole
              exome- and transcriptome sequencing and neoantigen prediction
              were applied to pre-treatment samples from 27 patients recruited
              to a clinical phase I/II trial of ACT in stage IV melanoma. All
              patients had previously progressed on other immunotherapies. We
              report that clinical benefit is associated with significantly
              higher predicted neoantigen load. High mutation and predicted
              neoantigen load are significantly associated with improved
              progression-free and overall survival. Further, clinical benefit
              is associated with the expression of immune activation signatures
              including a high MHC-I antigen processing and presentation score.
              These results improve our understanding of mechanisms behind
              clinical benefit of ACT in melanoma.",
  journal  = "Nat. Commun.",
  volume   =  8,
  number   =  1,
  pages    = "1738",
  month    =  nov,
  year     =  2017,
  language = "en"
}

@ARTICLE{Bacevic2017-uh,
  title    = "Spatial competition constrains resistance to targeted cancer
              therapy",
  author   = "Bacevic, Katarina and Noble, Robert and Soffar, Ahmed and Wael
              Ammar, Orchid and Boszonyik, Benjamin and Prieto, Susana and
              Vincent, Charles and Hochberg, Michael E and Krasinska, Liliana
              and Fisher, Daniel",
  abstract = "Adaptive therapy (AT) aims to control tumour burden by
              maintaining therapy-sensitive cells to exploit their competition
              with resistant cells. This relies on the assumption that
              resistant cells have impaired cellular fitness. Here, using a
              model of resistance to a pharmacological cyclin-dependent kinase
              inhibitor (CDKi), we show that this assumption is valid when
              competition between cells is spatially structured. We generate
              CDKi-resistant cancer cells and find that they have reduced
              proliferative fitness and stably rewired cell cycle control
              pathways. Low-dose CDKi outperforms high-dose CDKi in controlling
              tumour burden and resistance in tumour spheroids, but not in
              monolayer culture. Mathematical modelling indicates that tumour
              spatial structure amplifies the fitness penalty of resistant
              cells, and identifies their relative fitness as a critical
              determinant of the clinical benefit of AT. Our results justify
              further investigation of AT with kinase inhibitors.",
  journal  = "Nat. Commun.",
  volume   =  8,
  number   =  1,
  pages    = "1995",
  month    =  dec,
  year     =  2017,
  language = "en"
}

@ARTICLE{Zhang2017-vx,
  title    = "Integrating evolutionary dynamics into treatment of metastatic
              castrate-resistant prostate cancer",
  author   = "Zhang, Jingsong and Cunningham, Jessica J and Brown, Joel S and
              Gatenby, Robert A",
  abstract = "Abiraterone treats metastatic castrate-resistant prostate cancer
              by inhibiting CYP17A, an enzyme for testosterone auto-production.
              With standard dosing, evolution of resistance with treatment
              failure (radiographic progression) occurs at a median of ~16.5
              months. We hypothesize time to progression (TTP) could be
              increased by integrating evolutionary dynamics into therapy. We
              developed an evolutionary game theory model using Lotka-Volterra
              equations with three competing cancer ``species'': androgen
              dependent, androgen producing, and androgen independent.
              Simulations with standard abiraterone dosing demonstrate strong
              selection for androgen-independent cells and rapid treatment
              failure. Adaptive therapy, using patient-specific tumor dynamics
              to inform on/off treatment cycles, suppresses proliferation of
              androgen-independent cells and lowers cumulative drug dose. In a
              pilot clinical trial, 10 of 11 patients maintained stable
              oscillations of tumor burdens; median TTP is at least 27 months
              with reduced cumulative drug use of 47\% of standard dosing. The
              outcomes show significant improvement over published studies and
              a contemporaneous population.",
  journal  = "Nat. Commun.",
  volume   =  8,
  number   =  1,
  pages    = "1816",
  month    =  nov,
  year     =  2017,
  language = "en"
}

@ARTICLE{Pavel2018-pu,
  title    = "Contact inhibition controls cell survival and proliferation via
              {YAP/TAZ-autophagy} axis",
  author   = "Pavel, Mariana and Renna, Maurizio and Park, So Jung and Menzies,
              Fiona M and Ricketts, Thomas and F{\"u}llgrabe, Jens and
              Ashkenazi, Avraham and Frake, Rebecca A and Lombarte, Alejandro
              Carnicer and Bento, Carla F and Franze, Kristian and Rubinsztein,
              David C",
  abstract = "Contact inhibition enables noncancerous cells to cease
              proliferation and growth when they contact each other. This
              characteristic is lost when cells undergo malignant
              transformation, leading to uncontrolled proliferation and solid
              tumor formation. Here we report that autophagy is compromised in
              contact-inhibited cells in 2D or 3D-soft extracellular matrix
              cultures. In such cells, YAP/TAZ fail to co-transcriptionally
              regulate the expression of myosin-II genes, resulting in the loss
              of F-actin stress fibers, which impairs autophagosome formation.
              The decreased proliferation resulting from contact inhibition is
              partly autophagy-dependent, as is their increased sensitivity to
              hypoxia and glucose starvation. These findings define how
              mechanically repressed YAP/TAZ activity impacts autophagy to
              contribute to core phenotypes resulting from high cell confluence
              that are lost in various cancers.",
  journal  = "Nat. Commun.",
  volume   =  9,
  number   =  1,
  pages    = "2961",
  month    =  jul,
  year     =  2018,
  language = "en"
}

@ARTICLE{Huda2018-ne,
  title    = "L{\'e}vy-like movement patterns of metastatic cancer cells
              revealed in microfabricated systems and implicated in vivo",
  author   = "Huda, Sabil and Weigelin, Bettina and Wolf, Katarina and
              Tretiakov, Konstantin V and Polev, Konstantin and Wilk, Gary and
              Iwasa, Masatomo and Emami, Fateme S and Narojczyk, Jakub W and
              Banaszak, Michal and Soh, Siowling and Pilans, Didzis and Vahid,
              Amir and Makurath, Monika and Friedl, Peter and Borisy, Gary G
              and Kandere-Grzybowska, Kristiana and Grzybowski, Bartosz A",
  abstract = "Metastatic cancer cells differ from their non-metastatic
              counterparts not only in terms of molecular composition and
              genetics, but also by the very strategy they employ for
              locomotion. Here, we analyzed large-scale statistics for cells
              migrating on linear microtracks to show that metastatic cancer
              cells follow a qualitatively different movement strategy than
              their non-invasive counterparts. The trajectories of metastatic
              cells display clusters of small steps that are interspersed with
              long ``flights''. Such movements are characterized by
              heavy-tailed, truncated power law distributions of persistence
              times and are consistent with the L{\'e}vy walks that are also
              often employed by animal predators searching for scarce prey or
              food sources. In contrast, non-metastatic cancerous cells perform
              simple diffusive movements. These findings are supported by
              preliminary experiments with cancer cells migrating away from
              primary tumors in vivo. The use of chemical inhibitors targeting
              actin-binding proteins allows for ``reprogramming'' the L{\'e}vy
              walks into either diffusive or ballistic movements.",
  journal  = "Nat. Commun.",
  volume   =  9,
  number   =  1,
  pages    = "4539",
  month    =  oct,
  year     =  2018,
  language = "en"
}

@ARTICLE{Hausser2019-be,
  title    = "Central dogma rates and the trade-off between precision and
              economy in gene expression",
  author   = "Hausser, Jean and Mayo, Avi and Keren, Leeat and Alon, Uri",
  abstract = "Steady-state protein abundance is set by four rates:
              transcription, translation, mRNA decay and protein decay. A given
              protein abundance can be obtained from infinitely many
              combinations of these rates. This raises the question of whether
              the natural rates for each gene result from historical accidents,
              or are there rules that give certain combinations a selective
              advantage? We address this question using high-throughput
              measurements in rapidly growing cells from diverse organisms to
              find that about half of the rate combinations do not exist: genes
              that combine high transcription with low translation are strongly
              depleted. This depletion is due to a trade-off between precision
              and economy: high transcription decreases stochastic fluctuations
              but increases transcription costs. Our theory quantitatively
              explains which rate combinations are missing, and predicts the
              curvature of the fitness function for each gene. It may guide the
              design of gene circuits with desired expression levels and noise.",
  journal  = "Nat. Commun.",
  volume   =  10,
  number   =  1,
  pages    = "68",
  month    =  jan,
  year     =  2019,
  language = "en"
}

@ARTICLE{Serin_Harmanci2020-ti,
  title    = "{CaSpER} identifies and visualizes {CNV} events by integrative
              analysis of single-cell or bulk {RNA-sequencing} data",
  author   = "Serin Harmanci, Akdes and Harmanci, Arif O and Zhou, Xiaobo",
  abstract = "RNA sequencing experiments generate large amounts of information
              about expression levels of genes. Although they are mainly used
              for quantifying expression levels, they contain much more
              biologically important information such as copy number variants
              (CNVs). Here, we present CaSpER, a signal processing approach for
              identification, visualization, and integrative analysis of focal
              and large-scale CNV events in multiscale resolution using either
              bulk or single-cell RNA sequencing data. CaSpER integrates the
              multiscale smoothing of expression signal and allelic shift
              signals for CNV calling. The allelic shift signal measures the
              loss-of-heterozygosity (LOH) which is valuable for CNV
              identification. CaSpER employs an efficient methodology for the
              generation of a genome-wide B-allele frequency (BAF) signal
              profile from the reads and utilizes it for correction of CNVs
              calls. CaSpER increases the utility of RNA-sequencing datasets
              and complements other tools for complete characterization and
              visualization of the genomic and transcriptomic landscape of
              single cell and bulk RNA sequencing data.",
  journal  = "Nat. Commun.",
  volume   =  11,
  number   =  1,
  pages    = "89",
  month    =  jan,
  year     =  2020,
  language = "en"
}

@ARTICLE{Shukla2020-qi,
  title    = "Chromosome arm aneuploidies shape tumour evolution and drug
              response",
  author   = "Shukla, Ankit and Nguyen, Thu H M and Moka, Sarat B and Ellis,
              Jonathan J and Grady, John P and Oey, Harald and Cristino,
              Alexandre S and Khanna, Kum Kum and Kroese, Dirk P and Krause,
              Lutz and Dray, Eloise and Fink, J Lynn and Duijf, Pascal H G",
  abstract = "Chromosome arm aneuploidies (CAAs) are pervasive in cancers.
              However, how they affect cancer development, prognosis and
              treatment remains largely unknown. Here, we analyse CAA profiles
              of 23,427 tumours, identifying aspects of tumour evolution
              including probable orders in which CAAs occur and CAAs predicting
              tissue-specific metastasis. Both haematological and solid cancers
              initially gain chromosome arms, while only solid cancers
              subsequently preferentially lose multiple arms. 72 CAAs and 88
              synergistically co-occurring CAA pairs multivariately predict
              good or poor survival for 58\% of 6977 patients, with negligible
              impact of whole-genome doubling. Additionally, machine learning
              identifies 31 CAAs that robustly alter response to 56
              chemotherapeutic drugs across cell lines representing 17 cancer
              types. We also uncover 1024 potential synthetic lethal
              pharmacogenomic interactions. Notably, in predicting drug
              response, CAAs substantially outperform mutations and focal
              deletions/amplifications combined. Thus, CAAs predict cancer
              prognosis, shape tumour evolution, metastasis and drug response,
              and may advance precision oncology.",
  journal  = "Nat. Commun.",
  volume   =  11,
  number   =  1,
  pages    = "449",
  month    =  jan,
  year     =  2020,
  language = "en"
}

@ARTICLE{Reich2020-te,
  title    = "A multi-omics analysis reveals the unfolded protein response
              regulon and stress-induced resistance to folate-based
              antimetabolites",
  author   = "Reich, Stefan and Nguyen, Chi D L and Has, Canan and Steltgens,
              Sascha and Soni, Himanshu and Coman, Cristina and Freyberg,
              Moritz and Bichler, Anna and Seifert, Nicole and Conrad, Dominik
              and Knobbe-Thomsen, Christiane B and Tews, Bj{\"o}rn and Toedt,
              Grischa and Ahrends, Robert and Medenbach, Jan",
  abstract = "Stress response pathways are critical for cellular homeostasis,
              promoting survival through adaptive changes in gene expression
              and metabolism. They play key roles in numerous diseases and are
              implicated in cancer progression and chemoresistance. However,
              the underlying mechanisms are only poorly understood. We have
              employed a multi-omics approach to monitor changes to gene
              expression after induction of a stress response pathway, the
              unfolded protein response (UPR), probing in parallel the
              transcriptome, the proteome, and changes to translation.
              Stringent filtering reveals the induction of 267 genes, many of
              which have not previously been implicated in stress response
              pathways. We experimentally demonstrate that UPR-mediated
              translational control induces the expression of enzymes involved
              in a pathway that diverts intermediate metabolites from
              glycolysis to fuel mitochondrial one-carbon metabolism.
              Concomitantly, the cells become resistant to the folate-based
              antimetabolites Methotrexate and Pemetrexed, establishing a
              direct link between UPR-driven changes to gene expression and
              resistance to pharmacological treatment.",
  journal  = "Nat. Commun.",
  volume   =  11,
  number   =  1,
  pages    = "2936",
  month    =  jun,
  year     =  2020,
  language = "en"
}

@ARTICLE{Brulois2020-rk,
  title    = "A molecular map of murine lymph node blood vascular endothelium
              at single cell resolution",
  author   = "Brulois, Kevin and Rajaraman, Anusha and Szade, Agata and
              Nordling, Sofia and Bogoslowski, Ania and Dermadi, Denis and
              Rahman, Milladur and Kiefel, Helena and O'Hara, Edward and
              Koning, Jasper J and Kawashima, Hiroto and Zhou, Bin and
              Vestweber, Dietmar and Red-Horse, Kristy and Mebius, Reina E and
              Adams, Ralf H and Kubes, Paul and Pan, Junliang and Butcher,
              Eugene C",
  abstract = "Blood vascular endothelial cells (BECs) control the immune
              response by regulating blood flow and immune cell recruitment in
              lymphoid tissues. However, the diversity of BEC and their origins
              during immune angiogenesis remain unclear. Here we profile
              transcriptomes of BEC from peripheral lymph nodes and map
              phenotypes to the vasculature. We identify multiple subsets,
              including a medullary venous population whose gene signature
              predicts a selective role in myeloid cell (vs lymphocyte)
              recruitment to the medulla, confirmed by videomicroscopy. We
              define five capillary subsets, including a capillary resident
              precursor (CRP) that displays stem cell and migratory gene
              signatures, and contributes to homeostatic BEC turnover and to
              neogenesis of high endothelium after immunization. Cell
              alignments show retention of developmental programs along
              trajectories from CRP to mature venous and arterial populations.
              Our single cell atlas provides a molecular roadmap of the lymph
              node blood vasculature and defines subset specialization for
              leukocyte recruitment and vascular homeostasis.",
  journal  = "Nat. Commun.",
  volume   =  11,
  number   =  1,
  pages    = "3798",
  month    =  jul,
  year     =  2020,
  language = "en"
}

@ARTICLE{Yang2021-ht,
  title    = "Multi-domain translation between single-cell imaging and
              sequencing data using autoencoders",
  author   = "Yang, Karren Dai and Belyaeva, Anastasiya and Venkatachalapathy,
              Saradha and Damodaran, Karthik and Katcoff, Abigail and
              Radhakrishnan, Adityanarayanan and Shivashankar, G V and Uhler,
              Caroline",
  abstract = "The development of single-cell methods for capturing different
              data modalities including imaging and sequencing has
              revolutionized our ability to identify heterogeneous cell states.
              Different data modalities provide different perspectives on a
              population of cells, and their integration is critical for
              studying cellular heterogeneity and its function. While various
              methods have been proposed to integrate different sequencing data
              modalities, coupling imaging and sequencing has been an open
              challenge. We here present an approach for integrating vastly
              different modalities by learning a probabilistic coupling between
              the different data modalities using autoencoders to map to a
              shared latent space. We validate this approach by integrating
              single-cell RNA-seq and chromatin images to identify distinct
              subpopulations of human naive CD4+ T-cells that are poised for
              activation. Collectively, our approach provides a framework to
              integrate and translate between data modalities that cannot yet
              be measured within the same cell for diverse applications in
              biomedical discovery.",
  journal  = "Nat. Commun.",
  volume   =  12,
  number   =  1,
  pages    = "31",
  month    =  jan,
  year     =  2021,
  language = "en"
}

@ARTICLE{Marquis2021-dd,
  title    = "Chromosomally unstable tumor cells specifically require {KIF18A}
              for proliferation",
  author   = "Marquis, Carolyn and Fonseca, Cindy L and Queen, Katelyn A and
              Wood, Lisa and Vandal, Sarah E and Malaby, Heidi L H and Clayton,
              Joseph E and Stumpff, Jason",
  abstract = "Chromosomal instability (CIN) is a hallmark of tumor cells caused
              by changes in the dynamics and control of microtubules that
              compromise the mitotic spindle. Thus, CIN cells may respond
              differently than diploid cells to treatments that target mitotic
              spindle regulation. Here, we test this idea by inhibiting a
              subset of kinesin motor proteins involved in mitotic spindle
              control. KIF18A is required for proliferation of CIN cells
              derived from triple negative breast cancer or colorectal cancer
              tumors but is not required in near-diploid cells. Following
              KIF18A inhibition, CIN tumor cells exhibit mitotic delays,
              multipolar spindles, and increased cell death. Sensitivity to
              KIF18A knockdown is strongly correlated with centrosome
              fragmentation, which requires dynamic microtubules but does not
              depend on bipolar spindle formation or mitotic arrest. Our
              results indicate the altered spindle microtubule dynamics
              characteristic of CIN tumor cells can be exploited to reduce the
              proliferative capacity of CIN cells.",
  journal  = "Nat. Commun.",
  volume   =  12,
  number   =  1,
  pages    = "1213",
  month    =  feb,
  year     =  2021,
  language = "en"
}

@ARTICLE{Garcia-Bermudez2018-ck,
  title    = "Aspartate is a limiting metabolite for cancer cell proliferation
              under hypoxia and in tumours",
  author   = "Garcia-Bermudez, Javier and Baudrier, Lou and La, Konnor and Zhu,
              Xiphias Ge and Fidelin, Justine and Sviderskiy, Vladislav O and
              Papagiannakopoulos, Thales and Molina, Henrik and Snuderl, Matija
              and Lewis, Caroline A and Possemato, Richard L and Birsoy,
              K{\i}van{\c c}",
  abstract = "As oxygen is essential for many metabolic pathways, tumour
              hypoxia may impair cancer cell proliferation1-4. However, the
              limiting metabolites for proliferation under hypoxia and in
              tumours are unknown. Here, we assessed proliferation of a
              collection of cancer cells following inhibition of the
              mitochondrial electron transport chain (ETC), a major metabolic
              pathway requiring molecular oxygen5. Sensitivity to ETC
              inhibition varied across cell lines, and subsequent metabolomic
              analysis uncovered aspartate availability as a major determinant
              of sensitivity. Cell lines least sensitive to ETC inhibition
              maintain aspartate levels by importing it through an
              aspartate/glutamate transporter, SLC1A3. Genetic or pharmacologic
              modulation of SLC1A3 activity markedly altered cancer cell
              sensitivity to ETC inhibitors. Interestingly, aspartate levels
              also decrease under low oxygen, and increasing aspartate import
              by SLC1A3 provides a competitive advantage to cancer cells at low
              oxygen levels and in tumour xenografts. Finally, aspartate levels
              in primary human tumours negatively correlate with the expression
              of hypoxia markers, suggesting that tumour hypoxia is sufficient
              to inhibit ETC and, consequently, aspartate synthesis in vivo.
              Therefore, aspartate may be a limiting metabolite for tumour
              growth, and aspartate availability could be targeted for cancer
              therapy.",
  journal  = "Nat. Cell Biol.",
  volume   =  20,
  number   =  7,
  pages    = "775--781",
  month    =  jul,
  year     =  2018,
  language = "en"
}

@ARTICLE{Sullivan2018-ao,
  title    = "Aspartate is an endogenous metabolic limitation for tumour growth",
  author   = "Sullivan, Lucas B and Luengo, Alba and Danai, Laura V and Bush,
              Lauren N and Diehl, Frances F and Hosios, Aaron M and Lau,
              Allison N and Elmiligy, Sarah and Malstrom, Scott and Lewis,
              Caroline A and Vander Heiden, Matthew G",
  abstract = "Defining the metabolic limitations of tumour growth will help to
              develop cancer therapies1. Cancer cells proliferate slower in
              tumours than in standard culture conditions, indicating that a
              metabolic limitation may restrict cell proliferation in vivo.
              Aspartate synthesis can limit cancer cell proliferation when
              respiration is impaired2-4; however, whether acquiring aspartate
              is endogenously limiting for tumour growth is unknown. We confirm
              that aspartate has poor cell permeability, which prevents
              environmental acquisition, whereas the related amino acid
              asparagine is available to cells in tumours, but cancer cells
              lack asparaginase activity to convert asparagine to aspartate.
              Heterologous expression of guinea pig asparaginase 1 (gpASNase1),
              an enzyme that produces aspartate from asparagine5, confers the
              ability to use asparagine to supply intracellular aspartate to
              cancer cells in vivo. Tumours expressing gpASNase1 grow at a
              faster rate, indicating that aspartate acquisition is an
              endogenous metabolic limitation for the growth of some tumours.
              Tumours expressing gpASNase1 are also refractory to the growth
              suppressive effects of metformin, suggesting that metformin
              inhibits tumour growth by depleting aspartate. These findings
              suggest that therapeutic aspartate suppression could be effective
              to treat cancer.",
  journal  = "Nat. Cell Biol.",
  volume   =  20,
  number   =  7,
  pages    = "782--788",
  month    =  jul,
  year     =  2018,
  language = "en"
}

@ARTICLE{Fu2018-hx,
  title    = "Grasping for aspartate in tumour metabolism",
  author   = "Fu, Accalia and Danial, Nika N",
  journal  = "Nat. Cell Biol.",
  volume   =  20,
  number   =  7,
  pages    = "738--739",
  month    =  jul,
  year     =  2018,
  language = "en"
}

@ARTICLE{Chunduri2019-mk,
  title    = "The diverse consequences of aneuploidy",
  author   = "Chunduri, Narendra Kumar and Storchov{\'a}, Zuzana",
  abstract = "Aneuploidy, or imbalanced chromosome number, has profound effects
              on eukaryotic cells. In humans, aneuploidy is associated with
              various pathologies, including cancer, which suggests that it
              mediates a proliferative advantage under these conditions. Here,
              we discuss physiological changes triggered by aneuploidy, such as
              altered cell growth, transcriptional changes, proteotoxic stress,
              genomic instability and response to interferons, and how cancer
              cells adapt to the changing aneuploid genome.",
  journal  = "Nat. Cell Biol.",
  volume   =  21,
  number   =  1,
  pages    = "54--62",
  month    =  jan,
  year     =  2019,
  language = "en"
}

@ARTICLE{Diehl2022-uv,
  title    = "Nucleotide imbalance decouples cell growth from cell
              proliferation",
  author   = "Diehl, Frances F and Miettinen, Teemu P and Elbashir, Ryan and
              Nabel, Christopher S and Darnell, Alicia M and Do, Brian T and
              Manalis, Scott R and Lewis, Caroline A and Vander Heiden, Matthew
              G",
  abstract = "Nucleotide metabolism supports RNA synthesis and DNA replication
              to enable cell growth and division. Nucleotide depletion can
              inhibit cell growth and proliferation, but how cells sense and
              respond to changes in the relative levels of individual
              nucleotides is unclear. Moreover, the nucleotide requirement for
              biomass production changes over the course of the cell cycle, and
              how cells coordinate differential nucleotide demands with cell
              cycle progression is not well understood. Here we find that
              excess levels of individual nucleotides can inhibit proliferation
              by disrupting the relative levels of nucleotide bases needed for
              DNA replication and impeding DNA replication. The resulting
              purine and pyrimidine imbalances are not sensed by canonical
              growth regulatory pathways like mTORC1, Akt and AMPK signalling
              cascades, causing excessive cell growth despite inhibited
              proliferation. Instead, cells rely on replication stress
              signalling to survive during, and recover from, nucleotide
              imbalance during S phase. We find that ATR-dependent replication
              stress signalling is activated during unperturbed S phases and
              promotes nucleotide availability to support DNA replication.
              Together, these data reveal that imbalanced nucleotide levels are
              not detected until S phase, rendering cells reliant on
              replication stress signalling to cope with this metabolic problem
              and disrupting the coordination of cell growth and division.",
  journal  = "Nat. Cell Biol.",
  volume   =  24,
  number   =  8,
  pages    = "1252--1264",
  month    =  aug,
  year     =  2022,
  language = "en"
}

@ARTICLE{Bruckner2019-te,
  title    = "Stochastic nonlinear dynamics of confined cell migration in
              two-state systems",
  author   = "Br{\"u}ckner, David B and Fink, Alexandra and Schreiber,
              Christoph and R{\"o}ttgermann, Peter J F and R{\"a}dler, Joachim
              O and Broedersz, Chase P",
  abstract = "Migrating cells in physiological processes, including
              development, homeostasis and cancer, encounter structured
              environments and are forced to overcome physical obstacles. Yet,
              the dynamics of confined cell migration remains poorly
              understood, and thus there is a need to study the complex
              motility of cells in controlled confining microenvironments.
              Here, we develop two-state micropatterns, consisting of two
              adhesive sites connected by a thin constriction, in which
              migrating cells perform repeated stochastic transitions. This
              minimal system enables us to obtain a large ensemble of
              single-cell trajectories. From these trajectories, we infer an
              equation of cell motion, which decomposes the dynamics into
              deterministic and stochastic contributions in position--velocity
              phase space. Our results reveal that cells in two-state
              micropatterns exhibit intricate nonlinear migratory dynamics,
              with qualitatively similar features for a cancerous (MDA-MB-231)
              and a non-cancerous (MCF10A) cell line. In both cases, the cells
              drive themselves deterministically into the thin constriction; a
              process that is sped up by noise. Interestingly, however, these
              two cell lines have distinct deterministic dynamics: MDA-MB-231
              cells exhibit a limit cycle, while MCF10A cells show excitable
              bistable dynamics. Our approach yields a conceptual framework
              that may be extended to understand cell migration in more complex
              confining environments.",
  journal  = "Nat. Phys.",
  month    =  mar,
  year     =  2019
}

@ARTICLE{Lens2019-yg,
  title    = "Cytokinesis defects and cancer",
  author   = "Lens, Susanne M A and Medema, Ren{\'e} H",
  abstract = "Whole-genome and centrosome duplication as a consequence of
              cytokinesis failure can drive tumorigenesis in experimental model
              systems. However, whether cytokinesis failure is in fact an
              important cause of human cancers has remained unclear. In this
              Review, we summarize evidence that whole-genome-doubling events
              are frequently observed in human cancers and discuss the
              contribution that cytokinesis defects can make to tumorigenesis.
              We provide an overview of the potential causes of cytokinesis
              failure and discuss how tetraploid cells that are generated
              through cytokinesis defects are used in cancer as a transitory
              state on the route to aneuploidy. Finally, we discuss how
              cytokinesis defects can facilitate genetic diversification within
              the tumour to promote cancer development and could constitute the
              path of least resistance in tumour evolution.",
  journal  = "Nat. Rev. Cancer",
  volume   =  19,
  number   =  1,
  pages    = "32--45",
  month    =  jan,
  year     =  2019,
  language = "en"
}

@ARTICLE{Shih2024-zg,
  title    = "Discovering new drivers of cancer aneuploidy",
  author   = "Shih, Juliann",
  journal  = "Nat. Rev. Cancer",
  volume   =  24,
  number   =  4,
  pages    = "229",
  month    =  apr,
  year     =  2024,
  language = "en"
}

@ARTICLE{Ben-David2020-xy,
  title    = "Context is everything: aneuploidy in cancer",
  author   = "Ben-David, Uri and Amon, Angelika",
  abstract = "Cancer is driven by multiple types of genetic alterations, which
              range in size from point mutations to whole-chromosome gains and
              losses, known as aneuploidy. Chromosome instability, the process
              that gives rise to aneuploidy, can promote tumorigenesis by
              increasing genetic heterogeneity and promoting tumour evolution.
              However, much less is known about how aneuploidy itself
              contributes to tumour formation and progression. Unlike some
              pan-cancer oncogenes and tumour suppressor genes that drive
              transformation in virtually all cell types and cellular contexts,
              aneuploidy is not a universal promoter of tumorigenesis. Instead,
              recent studies suggest that aneuploidy is a context-dependent,
              cancer-type-specific oncogenic event that may have clinical
              relevance as a prognostic marker and as a potential therapeutic
              target.",
  journal  = "Nat. Rev. Genet.",
  volume   =  21,
  number   =  1,
  pages    = "44--62",
  month    =  jan,
  year     =  2020,
  language = "en"
}

@ARTICLE{Blank2019-so,
  title    = "Defining 'T cell exhaustion'",
  author   = "Blank, Christian U and Haining, W Nicholas and Held, Werner and
              Hogan, Patrick G and Kallies, Axel and Lugli, Enrico and Lynn,
              Rachel C and Philip, Mary and Rao, Anjana and Restifo, Nicholas P
              and Schietinger, Andrea and Schumacher, Ton N and Schwartzberg,
              Pamela L and Sharpe, Arlene H and Speiser, Daniel E and Wherry, E
              John and Youngblood, Benjamin A and Zehn, Dietmar",
  abstract = "'T cell exhaustion' is a broad term that has been used to
              describe the response of T cells to chronic antigen stimulation,
              first in the setting of chronic viral infection but more recently
              in response to tumours. Understanding the features of and
              pathways to exhaustion has crucial implications for the success
              of checkpoint blockade and adoptive T cell transfer therapies. In
              this Viewpoint article, 18 experts in the field tell us what
              exhaustion means to them, ranging from complete lack of effector
              function to altered functionality to prevent immunopathology,
              with potential differences between cancer and chronic infection.
              Their responses highlight the dichotomy between terminally
              differentiated exhausted T cells that are TCF1- and the
              self-renewing TCF1+ population from which they derive. These
              TCF1+ cells are considered by some to have stem cell-like
              properties akin to memory T cell populations, but the
              developmental relationships are unclear at present. Recent
              studies have also highlighted an important role for the
              transcriptional regulator TOX in driving the epigenetic
              enforcement of exhaustion, but key questions remain about the
              potential to reverse the epigenetic programme of exhaustion and
              how this might affect the persistence of T cell populations.",
  journal  = "Nat. Rev. Immunol.",
  volume   =  19,
  number   =  11,
  pages    = "665--674",
  month    =  nov,
  year     =  2019,
  language = "en"
}

@ARTICLE{Li2022-ll,
  title    = "Effects of aneuploidy on cell behaviour and function",
  author   = "Li, Rong and Zhu, Jin",
  abstract = "Aneuploidy, a genomic alternation characterized by deviations in
              the copy number of chromosomes, affects organisms from early
              development through to aging. Although it is a main cause of
              human pregnancy loss and a hallmark of cancer, how aneuploidy
              affects cellular function has been elusive. The last two decades
              have seen rapid advances in the understanding of the causes and
              consequences of aneuploidy at the molecular and cellular levels.
              These studies have uncovered effects of aneuploidy that can be
              beneficial or detrimental to cells and organisms in an
              environmental context-dependent and karyotype-dependent manner.
              Aneuploidy also imposes general stress on cells that stems from
              an imbalanced genome and, consequently, also an imbalanced
              proteome. These insights provide the fundamental framework for
              understanding the impact of aneuploidy in genome evolution, human
              pathogenesis and drug resistance.",
  journal  = "Nat. Rev. Mol. Cell Biol.",
  volume   =  23,
  number   =  4,
  pages    = "250--265",
  month    =  apr,
  year     =  2022,
  language = "en"
}

@ARTICLE{Hamieh2019-fu,
  title    = "{CAR} {T} cell trogocytosis and cooperative killing regulate
              tumour antigen escape",
  author   = "Hamieh, Mohamad and Dobrin, Anton and Cabriolu, Annalisa and van
              der Stegen, Sjoukje J C and Giavridis, Theodoros and
              Mansilla-Soto, Jorge and Eyquem, Justin and Zhao, Zeguo and
              Whitlock, Benjamin M and Miele, Matthew M and Li, Zhuoning and
              Cunanan, Kristen M and Huse, Morgan and Hendrickson, Ronald C and
              Wang, Xiuyan and Rivi{\`e}re, Isabelle and Sadelain, Michel",
  abstract = "Chimeric antigen receptors (CARs) are synthetic antigen receptors
              that reprogram T cell specificity, function and persistence1.
              Patient-derived CAR T cells have demonstrated remarkable efficacy
              against a range of B-cell malignancies1-3, and the results of
              early clinical trials suggest activity in multiple myeloma4.
              Despite high complete response rates, relapses occur in a large
              fraction of patients; some of these are antigen-negative and
              others are antigen-low1,2,4-9. Unlike the mechanisms that result
              in complete and permanent antigen loss6,8,9, those that lead to
              escape of antigen-low tumours remain unclear. Here, using mouse
              models of leukaemia, we show that CARs provoke reversible antigen
              loss through trogocytosis, an active process in which the target
              antigen is transferred to T cells, thereby decreasing target
              density on tumour cells and abating T cell activity by promoting
              fratricide T cell killing and T cell exhaustion. These mechanisms
              affect both CD28- and 4-1BB-based CARs, albeit differentially,
              depending on antigen density. These dynamic features can be
              offset by cooperative killing and combinatorial targeting to
              augment tumour responses to immunotherapy.",
  journal  = "Nature",
  volume   =  568,
  number   =  7750,
  pages    = "112--116",
  month    =  apr,
  year     =  2019,
  language = "en"
}

@ARTICLE{Tsai2019-wa,
  title    = "Hypo-osmotic-like stress underlies general cellular defects of
              aneuploidy",
  author   = "Tsai, Hung-Ji and Nelliat, Anjali R and Choudhury, Mohammad Ikbal
              and Kucharavy, Andrei and Bradford, William D and Cook, Malcolm E
              and Kim, Jisoo and Mair, Devin B and Sun, Sean X and Schatz,
              Michael C and Li, Rong",
  abstract = "Aneuploidy, which refers to unbalanced chromosome numbers,
              represents a class of genetic variation that is associated with
              cancer, birth defects and eukaryotic micro-organisms1-4. Whereas
              it is known that each aneuploid chromosome stoichiometry can give
              rise to a distinct pattern of gene expression and phenotypic
              profile4,5, it remains a fundamental question as to whether there
              are common cellular defects that are associated with aneuploidy.
              Here we show the existence in budding yeast of a common
              aneuploidy gene-expression signature that is suggestive of
              hypo-osmotic stress, using a strategy that enables the
              observation of common transcriptome changes of aneuploidy by
              averaging out karyotype-specific dosage effects in aneuploid
              yeast-cell populations with random and diverse chromosome
              stoichiometry. Consistently, aneuploid yeast exhibited increased
              plasma-membrane stress that led to impaired endocytosis, and this
              defect was also observed in aneuploid human cells. Thermodynamic
              modelling showed that hypo-osmotic-like stress is a general
              outcome of the proteome imbalance that is caused by aneuploidy,
              and also predicted a relationship between ploidy and cell size
              that was observed in yeast and aneuploid cancer cells. A
              genome-wide screen uncovered a general dependency of aneuploid
              cells on a pathway of ubiquitin-mediated endocytic recycling of
              nutrient transporters. Loss of this pathway, coupled with the
              endocytic defect inherent to aneuploidy, leads to a marked
              alteration of intracellular nutrient homeostasis.",
  journal  = "Nature",
  volume   =  570,
  number   =  7759,
  pages    = "117--121",
  month    =  jun,
  year     =  2019,
  language = "en"
}

@ARTICLE{Cohen-Sharir2021-th,
  title    = "Aneuploidy renders cancer cells vulnerable to mitotic checkpoint
              inhibition",
  author   = "Cohen-Sharir, Yael and McFarland, James M and Abdusamad, Mai and
              Marquis, Carolyn and Bernhard, Sara V and Kazachkova, Mariya and
              Tang, Helen and Ippolito, Marica R and Laue, Kathrin and Zerbib,
              Johanna and Malaby, Heidi L H and Jones, Andrew and Stautmeister,
              Lisa-Marie and Bockaj, Irena and Wardenaar, Ren{\'e} and Lyons,
              Nicholas and Nagaraja, Ankur and Bass, Adam J and Spierings,
              Diana C J and Foijer, Floris and Beroukhim, Rameen and
              Santaguida, Stefano and Golub, Todd R and Stumpff, Jason and
              Storchov{\'a}, Zuzana and Ben-David, Uri",
  abstract = "Selective targeting of aneuploid cells is an attractive strategy
              for cancer treatment1. However, it is unclear whether aneuploidy
              generates any clinically relevant vulnerabilities in cancer
              cells. Here we mapped the aneuploidy landscapes of about 1,000
              human cancer cell lines, and analysed genetic and chemical
              perturbation screens2-9 to identify cellular vulnerabilities
              associated with aneuploidy. We found that aneuploid cancer cells
              show increased sensitivity to genetic perturbation of core
              components of the spindle assembly checkpoint (SAC), which
              ensures the proper segregation of chromosomes during mitosis10.
              Unexpectedly, we also found that aneuploid cancer cells were less
              sensitive than diploid cells to short-term exposure to multiple
              SAC inhibitors. Indeed, aneuploid cancer cells became
              increasingly sensitive to inhibition of SAC over time. Aneuploid
              cells exhibited aberrant spindle geometry and dynamics, and kept
              dividing when the SAC was inhibited, resulting in the
              accumulation of mitotic defects, and in unstable and less-fit
              karyotypes. Therefore, although aneuploid cancer cells could
              overcome inhibition of SAC more readily than diploid cells, their
              long-term proliferation was jeopardized. We identified a specific
              mitotic kinesin, KIF18A, whose activity was perturbed in
              aneuploid cancer cells. Aneuploid cancer cells were particularly
              vulnerable to depletion of KIF18A, and KIF18A overexpression
              restored their response to SAC inhibition. Our results identify a
              therapeutically relevant, synthetic lethal interaction between
              aneuploidy and the SAC.",
  journal  = "Nature",
  volume   =  590,
  number   =  7846,
  pages    = "486--491",
  month    =  feb,
  year     =  2021,
  language = "en"
}

@ARTICLE{Quinton2021-ld,
  title    = "Whole-genome doubling confers unique genetic vulnerabilities on
              tumour cells",
  author   = "Quinton, Ryan J and DiDomizio, Amanda and Vittoria, Marc A and
              Kot{\'y}nkov{\'a}, Krist{\'y}na and Ticas, Carlos J and Patel,
              Sheena and Koga, Yusuke and Vakhshoorzadeh, Jasmine and Hermance,
              Nicole and Kuroda, Taruho S and Parulekar, Neha and Taylor,
              Alison M and Manning, Amity L and Campbell, Joshua D and Ganem,
              Neil J",
  abstract = "Whole-genome doubling (WGD) is common in human cancers, occurring
              early in tumorigenesis and generating genetically unstable
              tetraploid cells that fuel tumour development1,2. Cells that
              undergo WGD (WGD+ cells) must adapt to accommodate their abnormal
              tetraploid state; however, the nature of these adaptations, and
              whether they confer vulnerabilities that can be exploited
              therapeutically, is unclear. Here, using sequencing data from
              roughly 10,000 primary human cancer samples and essentiality data
              from approximately 600 cancer cell lines, we show that WGD gives
              rise to common genetic traits that are accompanied by unique
              vulnerabilities. We reveal that WGD+ cells are more dependent
              than WGD- cells on signalling from the spindle-assembly
              checkpoint, DNA-replication factors and proteasome function. We
              also identify KIF18A, which encodes a mitotic kinesin protein, as
              being specifically required for the viability of WGD+ cells.
              Although KIF18A is largely dispensable for accurate chromosome
              segregation during mitosis in WGD- cells, its loss induces
              notable mitotic errors in WGD+ cells, ultimately impairing cell
              viability. Collectively, our results suggest new strategies for
              specifically targeting WGD+ cancer cells while sparing the
              normal, non-transformed WGD- cells that comprise human tissue.",
  journal  = "Nature",
  volume   =  590,
  number   =  7846,
  pages    = "492--497",
  month    =  feb,
  year     =  2021,
  language = "en"
}

@ARTICLE{ICGCTCGA_Pan-Cancer_Analysis_of_Whole_Genomes_Consortium2020-hw,
  title    = "Pan-cancer analysis of whole genomes",
  author   = "{ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Consortium}",
  abstract = "Cancer is driven by genetic change, and the advent of massively
              parallel sequencing has enabled systematic documentation of this
              variation at the whole-genome scale1-3. Here we report the
              integrative analysis of 2,658 whole-cancer genomes and their
              matching normal tissues across 38 tumour types from the
              Pan-Cancer Analysis of Whole Genomes (PCAWG) Consortium of the
              International Cancer Genome Consortium (ICGC) and The Cancer
              Genome Atlas (TCGA). We describe the generation of the PCAWG
              resource, facilitated by international data sharing using compute
              clouds. On average, cancer genomes contained 4-5 driver mutations
              when combining coding and non-coding genomic elements; however,
              in around 5\% of cases no drivers were identified, suggesting
              that cancer driver discovery is not yet complete. Chromothripsis,
              in which many clustered structural variants arise in a single
              catastrophic event, is frequently an early event in tumour
              evolution; in acral melanoma, for example, these events precede
              most somatic point mutations and affect several cancer-associated
              genes simultaneously. Cancers with abnormal telomere maintenance
              often originate from tissues with low replicative activity and
              show several mechanisms of preventing telomere attrition to
              critical levels. Common and rare germline variants affect
              patterns of somatic mutation, including point mutations,
              structural variants and somatic retrotransposition. A collection
              of papers from the PCAWG Consortium describes non-coding
              mutations that drive cancer beyond those in the TERT promoter4;
              identifies new signatures of mutational processes that cause base
              substitutions, small insertions and deletions and structural
              variation5,6; analyses timings and patterns of tumour evolution7;
              describes the diverse transcriptional consequences of somatic
              mutation on splicing, expression levels, fusion genes and
              promoter activity8,9; and evaluates a range of more-specialized
              features of cancer genomes8,10-18.",
  journal  = "Nature",
  volume   =  578,
  number   =  7793,
  pages    = "82--93",
  month    =  feb,
  year     =  2020,
  language = "en"
}

@ARTICLE{Kanarek2020-md,
  title    = "Dietary modifications for enhanced cancer therapy",
  author   = "Kanarek, Naama and Petrova, Boryana and Sabatini, David M",
  abstract = "Tumours depend on nutrients supplied by the host for their growth
              and survival. Modifications to the host's diet can change
              nutrient availability in the tumour microenvironment, which might
              represent a promising strategy for inhibiting tumour growth.
              Dietary modifications can limit tumour-specific nutritional
              requirements, alter certain nutrients that target the metabolic
              vulnerabilities of the tumour, or enhance the cytotoxicity of
              anti-cancer drugs. Recent reports have suggested that
              modification of several nutrients in the diet can alter the
              efficacy of cancer therapies, and some of the newest developments
              in this quickly expanding field are reviewed here. The results
              discussed indicate that the dietary habits and nutritional state
              of a patient must be taken into account during cancer research
              and therapy.",
  journal  = "Nature",
  volume   =  579,
  number   =  7800,
  pages    = "507--517",
  month    =  mar,
  year     =  2020,
  language = "en"
}

@ARTICLE{Watkins2020-ge,
  title    = "Pervasive chromosomal instability and karyotype order in tumour
              evolution",
  author   = "Watkins, Thomas B K and Lim, Emilia L and Petkovic, Marina and
              Elizalde, Sergi and Birkbak, Nicolai J and Wilson, Gareth A and
              Moore, David A and Gr{\"o}nroos, Eva and Rowan, Andrew and
              Dewhurst, Sally M and Demeulemeester, Jonas and Dentro, Stefan C
              and Horswell, Stuart and Au, Lewis and Haase, Kerstin and
              Escudero, Mickael and Rosenthal, Rachel and Bakir, Maise Al and
              Xu, Hang and Litchfield, Kevin and Lu, Wei Ting and Mourikis,
              Thanos P and Dietzen, Michelle and Spain, Lavinia and Cresswell,
              George D and Biswas, Dhruva and Lamy, Philippe and Nordentoft,
              Iver and Harbst, Katja and Castro-Giner, Francesc and Yates, Lucy
              R and Caramia, Franco and Jaulin, Fanny and Vicier, C{\'e}cile
              and Tomlinson, Ian P M and Brastianos, Priscilla K and Cho,
              Raymond J and Bastian, Boris C and Dyrskj{\o}t, Lars and
              J{\"o}nsson, G{\"o}ran B and Savas, Peter and Loi, Sherene and
              Campbell, Peter J and Andre, Fabrice and Luscombe, Nicholas M and
              Steeghs, Neeltje and Tjan-Heijnen, Vivianne C G and Szallasi,
              Zoltan and Turajlic, Samra and Jamal-Hanjani, Mariam and Van Loo,
              Peter and Bakhoum, Samuel F and Schwarz, Roland F and McGranahan,
              Nicholas and Swanton, Charles",
  abstract = "Chromosomal instability in cancer consists of dynamic changes to
              the number and structure of chromosomes1,2. The resulting
              diversity in somatic copy number alterations (SCNAs) may provide
              the variation necessary for tumour evolution1,3,4. Here we use
              multi-sample phasing and SCNA analysis of 1,421 samples from 394
              tumours across 22 tumour types to show that continuous
              chromosomal instability results in pervasive SCNA heterogeneity.
              Parallel evolutionary events, which cause disruption in the same
              genes (such as BCL9, MCL1, ARNT (also known as HIF1B), TERT and
              MYC) within separate subclones, were present in 37\% of tumours.
              Most recurrent losses probably occurred before whole-genome
              doubling, that was found as a clonal event in 49\% of tumours.
              However, loss of heterozygosity at the human leukocyte antigen
              (HLA) locus and loss of chromosome 8p to a single haploid copy
              recurred at substantial subclonal frequencies, even in tumours
              with whole-genome doubling, indicating ongoing karyotype
              remodelling. Focal amplifications that affected chromosomes 1q21
              (which encompasses BCL9, MCL1 and ARNT), 5p15.33 (TERT), 11q13.3
              (CCND1), 19q12 (CCNE1) and 8q24.1 (MYC) were frequently subclonal
              yet appeared to be clonal within single samples. Analysis of an
              independent series of 1,024 metastatic samples revealed that 13
              focal SCNAs were enriched in metastatic samples, including gains
              in chromosome 8q24.1 (encompassing MYC) in clear cell renal cell
              carcinoma and chromosome 11q13.3 (encompassing CCND1) in HER2+
              breast cancer. Chromosomal instability may enable the continuous
              selection of SCNAs, which are established as ordered events that
              often occur in parallel, throughout tumour evolution.",
  journal  = "Nature",
  volume   =  587,
  number   =  7832,
  pages    = "126--132",
  month    =  nov,
  year     =  2020,
  language = "en"
}

@ARTICLE{Salehi2021-kw,
  title    = "Clonal fitness inferred from time-series modelling of single-cell
              cancer genomes",
  author   = "Salehi, Sohrab and Kabeer, Farhia and Ceglia, Nicholas and
              Andronescu, Mirela and Williams, Marc J and Campbell, Kieran R
              and Masud, Tehmina and Wang, Beixi and Biele, Justina and
              Brimhall, Jazmine and Gee, David and Lee, Hakwoo and Ting, Jerome
              and Zhang, Allen W and Tran, Hoa and O'Flanagan, Ciara and Dorri,
              Fatemeh and Rusk, Nicole and de Algara, Teresa Ruiz and Lee, So
              Ra and Cheng, Brian Yu Chieh and Eirew, Peter and Kono, Takako
              and Pham, Jenifer and Grewal, Diljot and Lai, Daniel and Moore,
              Richard and Mungall, Andrew J and Marra, Marco A and {IMAXT
              Consortium} and McPherson, Andrew and Bouchard-C{\^o}t{\'e},
              Alexandre and Aparicio, Samuel and Shah, Sohrab P",
  abstract = "Progress in defining genomic fitness landscapes in cancer,
              especially those defined by copy number alterations (CNAs), has
              been impeded by lack of time-series single-cell sampling of
              polyclonal populations and temporal statistical models1-7. Here
              we generated 42,000 genomes from multi-year time-series
              single-cell whole-genome sequencing of breast epithelium and
              primary triple-negative breast cancer (TNBC) patient-derived
              xenografts (PDXs), revealing the nature of CNA-defined clonal
              fitness dynamics induced by TP53 mutation and cisplatin
              chemotherapy. Using a new Wright-Fisher population genetics
              model8,9 to infer clonal fitness, we found that TP53 mutation
              alters the fitness landscape, reproducibly distributing fitness
              over a larger number of clones associated with distinct CNAs.
              Furthermore, in TNBC PDX models with mutated TP53, inferred
              fitness coefficients from CNA-based genotypes accurately forecast
              experimentally enforced clonal competition dynamics. Drug
              treatment in three long-term serially passaged TNBC PDXs resulted
              in cisplatin-resistant clones emerging from low-fitness
              phylogenetic lineages in the untreated setting. Conversely,
              high-fitness clones from treatment-naive controls were
              eradicated, signalling an inversion of the fitness landscape.
              Finally, upon release of drug, selection pressure dynamics were
              reversed, indicating a fitness cost of treatment resistance.
              Together, our findings define clonal fitness linked to both CNA
              and therapeutic resistance in polyclonal tumours.",
  journal  = "Nature",
  volume   =  595,
  number   =  7868,
  pages    = "585--590",
  month    =  jul,
  year     =  2021,
  language = "en"
}

@ARTICLE{Lien2021-fj,
  title    = "Low glycaemic diets alter lipid metabolism to influence tumour
              growth",
  author   = "Lien, Evan C and Westermark, Anna M and Zhang, Yin and Yuan, Chen
              and Li, Zhaoqi and Lau, Allison N and Sapp, Kiera M and Wolpin,
              Brian M and Vander Heiden, Matthew G",
  abstract = "Dietary interventions can change metabolite levels in the tumour
              microenvironment, which might then affect cancer cell metabolism
              to alter tumour growth1-5. Although caloric restriction (CR) and
              a ketogenic diet (KD) are often thought to limit tumour
              progression by lowering blood glucose and insulin levels6-8, we
              found that only CR inhibits the growth of select tumour
              allografts in mice, suggesting that other mechanisms contribute
              to tumour growth inhibition. A change in nutrient availability
              observed with CR, but not with KD, is lower lipid levels in the
              plasma and tumours. Upregulation of stearoyl-CoA desaturase
              (SCD), which synthesises monounsaturated fatty acids, is required
              for cancer cells to proliferate in a lipid-depleted environment,
              and CR also impairs tumour SCD activity to cause an imbalance
              between unsaturated and saturated fatty acids to slow tumour
              growth. Enforcing cancer cell SCD expression or raising
              circulating lipid levels through a higher-fat CR diet confers
              resistance to the effects of CR. By contrast, although KD also
              impairs tumour SCD activity, KD-driven increases in lipid
              availability maintain the unsaturated to saturated fatty acid
              ratios in tumours, and changing the KD fat composition to
              increase tumour saturated fatty acid levels cooperates with
              decreased tumour SCD activity to slow tumour growth. These data
              suggest that diet-induced mismatches between tumour fatty acid
              desaturation activity and the availability of specific fatty acid
              species determine whether low glycaemic diets impair tumour
              growth.",
  journal  = "Nature",
  volume   =  599,
  number   =  7884,
  pages    = "302--307",
  month    =  nov,
  year     =  2021,
  language = "en"
}

@ARTICLE{Zhao2022-ws,
  title    = "Spatial genomics enables multi-modal study of clonal
              heterogeneity in tissues",
  author   = "Zhao, Tongtong and Chiang, Zachary D and Morriss, Julia W and
              LaFave, Lindsay M and Murray, Evan M and Del Priore, Isabella and
              Meli, Kevin and Lareau, Caleb A and Nadaf, Naeem M and Li, Jilong
              and Earl, Andrew S and Macosko, Evan Z and Jacks, Tyler and
              Buenrostro, Jason D and Chen, Fei",
  abstract = "The state and behaviour of a cell can be influenced by both
              genetic and environmental factors. In particular, tumour
              progression is determined by underlying genetic aberrations1-4 as
              well as the makeup of the tumour microenvironment5,6. Quantifying
              the contributions of these factors requires new technologies that
              can accurately measure the spatial location of genomic sequence
              together with phenotypic readouts. Here we developed
              slide-DNA-seq, a method for capturing spatially resolved DNA
              sequences from intact tissue sections. We demonstrate that this
              method accurately preserves local tumour architecture and enables
              the de novo discovery of distinct tumour clones and their copy
              number alterations. We then apply slide-DNA-seq to a mouse model
              of metastasis and a primary human cancer, revealing that clonal
              populations are confined to distinct spatial regions. Moreover,
              through integration with spatial transcriptomics, we uncover
              distinct sets of genes that are associated with clone-specific
              genetic aberrations, the local tumour microenvironment, or both.
              Together, this multi-modal spatial genomics approach provides a
              versatile platform for quantifying how cell-intrinsic and
              cell-extrinsic factors contribute to gene expression, protein
              abundance and other cellular phenotypes.",
  journal  = "Nature",
  volume   =  601,
  number   =  7891,
  pages    = "85--91",
  month    =  jan,
  year     =  2022,
  language = "en"
}

@ARTICLE{Gemble2022-le,
  title    = "Genetic instability from a single {S} phase after whole-genome
              duplication",
  author   = "Gemble, Simon and Wardenaar, Ren{\'e} and Keuper, Kristina and
              Srivastava, Nishit and Nano, Maddalena and Mac{\'e}, Anne-Sophie
              and Tijhuis, Andr{\'e}a E and Bernhard, Sara Vanessa and
              Spierings, Diana C J and Simon, Anthony and Goundiam, Oumou and
              Hochegger, Helfrid and Piel, Matthieu and Foijer, Floris and
              Storchov{\'a}, Zuzana and Basto, Renata",
  abstract = "Diploid and stable karyotypes are associated with health and
              fitness in animals. By contrast, whole-genome
              duplications-doublings of the entire complement of
              chromosomes-are linked to genetic instability and frequently
              found in human cancers1-3. It has been established that
              whole-genome duplications fuel chromosome instability through
              abnormal mitosis4-8; however, the immediate consequences of
              tetraploidy in the first interphase are not known. This is a key
              question because single whole-genome duplication events such as
              cytokinesis failure can promote tumorigenesis9. Here we find that
              human cells undergo high rates of DNA damage during DNA
              replication in the first S phase following induction of
              tetraploidy. Using DNA combing and single-cell sequencing, we
              show that DNA replication dynamics is perturbed, generating
              under- and over-replicated regions. Mechanistically, we find that
              these defects result from a shortage of proteins during the G1/S
              transition, which impairs the fidelity of DNA replication. This
              work shows that within a single interphase, unscheduled
              tetraploid cells can acquire highly abnormal karyotypes. These
              findings provide an explanation for the genetic instability
              landscape that favours tumorigenesis after tetraploidization.",
  journal  = "Nature",
  volume   =  604,
  number   =  7904,
  pages    = "146--151",
  month    =  apr,
  year     =  2022,
  language = "en"
}

@ARTICLE{Steele2022-uk,
  title    = "Signatures of copy number alterations in human cancer",
  author   = "Steele, Christopher D and Abbasi, Ammal and Islam, S M Ashiqul
              and Bowes, Amy L and Khandekar, Azhar and Haase, Kerstin and
              Hames-Fathi, Shadi and Ajayi, Dolapo and Verfaillie, Annelien and
              Dhami, Pawan and McLatchie, Alex and Lechner, Matt and Light,
              Nicholas and Shlien, Adam and Malkin, David and Feber, Andrew and
              Proszek, Paula and Lesluyes, Tom and Mertens, Fredrik and
              Flanagan, Adrienne M and Tarabichi, Maxime and Van Loo, Peter and
              Alexandrov, Ludmil B and Pillay, Nischalan",
  abstract = "Gains and losses of DNA are prevalent in cancer and emerge as a
              consequence of inter-related processes of replication stress,
              mitotic errors, spindle multipolarity and breakage-fusion-bridge
              cycles, among others, which may lead to chromosomal instability
              and aneuploidy1,2. These copy number alterations contribute to
              cancer initiation, progression and therapeutic resistance3-5.
              Here we present a conceptual framework to examine the patterns of
              copy number alterations in human cancer that is widely applicable
              to diverse data types, including whole-genome sequencing,
              whole-exome sequencing, reduced representation bisulfite
              sequencing, single-cell DNA sequencing and SNP6 microarray data.
              Deploying this framework to 9,873 cancers representing 33 human
              cancer types from The Cancer Genome Atlas6 revealed a set of 21
              copy number signatures that explain the copy number patterns of
              97\% of samples. Seventeen copy number signatures were attributed
              to biological phenomena of whole-genome doubling, aneuploidy,
              loss of heterozygosity, homologous recombination deficiency,
              chromothripsis and haploidization. The aetiologies of four copy
              number signatures remain unexplained. Some cancer types harbour
              amplicon signatures associated with extrachromosomal DNA,
              disease-specific survival and proto-oncogene gains such as MDM2.
              In contrast to base-scale mutational signatures, no copy number
              signature was associated with many known exogenous cancer risk
              factors. Our results synthesize the global landscape of copy
              number alterations in human cancer by revealing a diversity of
              mutational processes that give rise to these alterations.",
  journal  = "Nature",
  volume   =  606,
  number   =  7916,
  pages    = "984--991",
  month    =  jun,
  year     =  2022,
  language = "en"
}

@ARTICLE{Drews2022-sk,
  title    = "A pan-cancer compendium of chromosomal instability",
  author   = "Drews, Ruben M and Hernando, Barbara and Tarabichi, Maxime and
              Haase, Kerstin and Lesluyes, Tom and Smith, Philip S and Morrill
              Gavarr{\'o}, Lena and Couturier, Dominique-Laurent and Liu, Lydia
              and Schneider, Michael and Brenton, James D and Van Loo, Peter
              and Macintyre, Geoff and Markowetz, Florian",
  abstract = "Chromosomal instability (CIN) results in the accumulation of
              large-scale losses, gains and rearrangements of DNA1. The broad
              genomic complexity caused by CIN is a hallmark of cancer2;
              however, there is no systematic framework to measure different
              types of CIN and their effect on clinical phenotypes pan-cancer.
              Here we evaluate the extent, diversity and origin of CIN across
              7,880 tumours representing 33 cancer types. We present a
              compendium of 17 copy number signatures that characterize
              specific types of CIN, with putative aetiologies supported by
              multiple independent data sources. The signatures predict drug
              response and identify new drug targets. Our framework refines the
              understanding of impaired homologous recombination, which is one
              of the most therapeutically targetable types of CIN. Our results
              illuminate a fundamental structure underlying genomic complexity
              in human cancers and provide a resource to guide future CIN
              research.",
  journal  = "Nature",
  volume   =  606,
  number   =  7916,
  pages    = "976--983",
  month    =  jun,
  year     =  2022,
  language = "en"
}

@ARTICLE{Erickson2022-rj,
  title    = "Spatially resolved clonal copy number alterations in benign and
              malignant tissue",
  author   = "Erickson, Andrew and He, Mengxiao and Berglund, Emelie and
              Marklund, Maja and Mirzazadeh, Reza and Schultz, Niklas and
              Kvastad, Linda and Andersson, Alma and Bergenstr{\aa}hle, Ludvig
              and Bergenstr{\aa}hle, Joseph and Larsson, Ludvig and Alonso
              Galicia, Leire and Shamikh, Alia and Basmaci, Elisa and D{\'\i}az
              De St{\aa}hl, Teresita and Rajakumar, Timothy and Doultsinos,
              Dimitrios and Thrane, Kim and Ji, Andrew L and Khavari, Paul A
              and Tarish, Firaz and Tanoglidi, Anna and Maaskola, Jonas and
              Colling, Richard and Mirtti, Tuomas and Hamdy, Freddie C and
              Woodcock, Dan J and Helleday, Thomas and Mills, Ian G and Lamb,
              Alastair D and Lundeberg, Joakim",
  abstract = "Defining the transition from benign to malignant tissue is
              fundamental to improving early diagnosis of cancer1. Here we use
              a systematic approach to study spatial genome integrity in situ
              and describe previously unidentified clonal relationships. We
              used spatially resolved transcriptomics2 to infer spatial copy
              number variations in >120,000 regions across multiple organs, in
              benign and malignant tissues. We demonstrate that genome-wide
              copy number variation reveals distinct clonal patterns within
              tumours and in nearby benign tissue using an organ-wide approach
              focused on the prostate. Our results suggest a model for how
              genomic instability arises in histologically benign tissue that
              may represent early events in cancer evolution. We highlight the
              power of capturing the molecular and spatial continuums in a
              tissue context and challenge the rationale for treatment
              paradigms, including focal therapy.",
  journal  = "Nature",
  volume   =  608,
  number   =  7922,
  pages    = "360--367",
  month    =  aug,
  year     =  2022,
  language = "en"
}

@ARTICLE{Baslan2022-ah,
  title    = "Ordered and deterministic cancer genome evolution after p53 loss",
  author   = "Baslan, Timour and Morris, 4th, John P and Zhao, Zhen and Reyes,
              Jose and Ho, Yu-Jui and Tsanov, Kaloyan M and Bermeo, Jonathan
              and Tian, Sha and Zhang, Sean and Askan, Gokce and Yavas, Aslihan
              and Lecomte, Nicolas and Erakky, Amanda and Varghese, Anna M and
              Zhang, Amy and Kendall, Jude and Ghiban, Elena and Chorbadjiev,
              Lubomir and Wu, Jie and Dimitrova, Nevenka and Chadalavada,
              Kalyani and Nanjangud, Gouri J and Bandlamudi, Chaitanya and
              Gong, Yixiao and Donoghue, Mark T A and Socci, Nicholas D and
              Krasnitz, Alex and Notta, Faiyaz and Leach, Steve D and
              Iacobuzio-Donahue, Christine A and Lowe, Scott W",
  abstract = "Although p53 inactivation promotes genomic instability1 and
              presents a route to malignancy for more than half of all human
              cancers2,3, the patterns through which heterogenous TP53
              (encoding human p53) mutant genomes emerge and influence
              tumorigenesis remain poorly understood. Here, in a mouse model of
              pancreatic ductal adenocarcinoma that reports sporadic p53 loss
              of heterozygosity before cancer onset, we find that malignant
              properties enabled by p53 inactivation are acquired through a
              predictable pattern of genome evolution. Single-cell sequencing
              and in situ genotyping of cells from the point of p53
              inactivation through progression to frank cancer reveal that this
              deterministic behaviour involves four sequential phases-Trp53
              (encoding mouse p53) loss of heterozygosity, accumulation of
              deletions, genome doubling, and the emergence of gains and
              amplifications-each associated with specific histological stages
              across the premalignant and malignant spectrum. Despite rampant
              heterogeneity, the deletion events that follow p53 inactivation
              target functionally relevant pathways that can shape genomic
              evolution and remain fixed as homogenous events in diverse
              malignant populations. Thus, loss of p53-the 'guardian of the
              genome'-is not merely a gateway to genetic chaos but, rather, can
              enable deterministic patterns of genome evolution that may point
              to new strategies for the treatment of TP53-mutant tumours.",
  journal  = "Nature",
  month    =  aug,
  year     =  2022,
  language = "en"
}

@ARTICLE{Karlsson2023-nu,
  title    = "Deterministic evolution and stringent selection during
              preneoplasia",
  author   = "Karlsson, Kasper and Przybilla, Moritz J and Kotler, Eran and
              Khan, Aziz and Xu, Hang and Karagyozova, Kremena and Sockell,
              Alexandra and Wong, Wing H and Liu, Katherine and Mah, Amanda and
              Lo, Yuan-Hung and Lu, Bingxin and Houlahan, Kathleen E and Ma,
              Zhicheng and Suarez, Carlos J and Barnes, Chris P and Kuo, Calvin
              J and Curtis, Christina",
  abstract = "The earliest events during human tumour initiation, although
              poorly characterized, may hold clues to malignancy detection and
              prevention1. Here we model occult preneoplasia by biallelic
              inactivation of TP53, a common early event in gastric cancer, in
              human gastric organoids. Causal relationships between this
              initiating genetic lesion and resulting phenotypes were
              established using experimental evolution in multiple clonally
              derived cultures over 2 years. TP53 loss elicited progressive
              aneuploidy, including copy number alterations and structural
              variants prevalent in gastric cancers, with evident preferred
              orders. Longitudinal single-cell sequencing of TP53-deficient
              gastric organoids similarly indicates progression towards
              malignant transcriptional programmes. Moreover, high-throughput
              lineage tracing with expressed cellular barcodes demonstrates
              reproducible dynamics whereby initially rare subclones with
              shared transcriptional programmes repeatedly attain clonal
              dominance. This powerful platform for experimental evolution
              exposes stringent selection, clonal interference and a marked
              degree of phenotypic convergence in premalignant epithelial
              organoids. These data imply predictability in the earliest stages
              of tumorigenesis and show evolutionary constraints and barriers
              to malignant transformation, with implications for earlier
              detection and interception of aggressive, genome-instable
              tumours.",
  journal  = "Nature",
  volume   =  618,
  number   =  7964,
  pages    = "383--393",
  month    =  jun,
  year     =  2023,
  language = "en"
}

@ARTICLE{Shih2023-xy,
  title    = "Cancer aneuploidies are shaped primarily by effects on tumour
              fitness",
  author   = "Shih, Juliann and Sarmashghi, Shahab and Zhakula-Kostadinova,
              Nadja and Zhang, Shu and Georgis, Yohanna and Hoyt, Stephanie H
              and Cuoco, Michael S and Gao, Galen F and Spurr, Liam F and
              Berger, Ashton C and Ha, Gavin and Rendo, Veronica and Shen, Hui
              and Meyerson, Matthew and Cherniack, Andrew D and Taylor, Alison
              M and Beroukhim, Rameen",
  abstract = "Aneuploidies-whole-chromosome or whole-arm imbalances-are the
              most prevalent alteration in cancer genomes1,2. However, it is
              still debated whether their prevalence is due to selection or
              ease of generation as passenger events1,2. Here we developed a
              method, BISCUT, that identifies loci subject to fitness
              advantages or disadvantages by interrogating length distributions
              of telomere- or centromere-bounded copy-number events. These loci
              were significantly enriched for known cancer driver genes,
              including genes not detected through analysis of focal
              copy-number events, and were often lineage specific. BISCUT
              identified the helicase-encoding gene WRN as a haploinsufficient
              tumour-suppressor gene on chromosome 8p, which is supported by
              several lines of evidence. We also formally quantified the role
              of selection and mechanical biases in driving aneuploidy, finding
              that rates of arm-level copy-number alterations are most highly
              correlated with their effects on cellular fitness1,2. These
              results provide insight into the driving forces behind aneuploidy
              and its contribution to tumorigenesis.",
  journal  = "Nature",
  month    =  jun,
  year     =  2023,
  language = "en"
}

@ARTICLE{Gao2021-my,
  title    = "Delineating copy number and clonal substructure in human tumors
              from single-cell transcriptomes",
  author   = "Gao, Ruli and Bai, Shanshan and Henderson, Ying C and Lin, Yiyun
              and Schalck, Aislyn and Yan, Yun and Kumar, Tapsi and Hu, Min and
              Sei, Emi and Davis, Alexander and Wang, Fang and Shaitelman,
              Simona F and Wang, Jennifer Rui and Chen, Ken and Moulder, Stacy
              and Lai, Stephen Y and Navin, Nicholas E",
  abstract = "Single-cell transcriptomic analysis is widely used to study human
              tumors. However, it remains challenging to distinguish normal
              cell types in the tumor microenvironment from malignant cells and
              to resolve clonal substructure within the tumor. To address these
              challenges, we developed an integrative Bayesian segmentation
              approach called copy number karyotyping of aneuploid tumors
              (CopyKAT) to estimate genomic copy number profiles at an average
              genomic resolution of 5 Mb from read depth in high-throughput
              single-cell RNA sequencing (scRNA-seq) data. We applied CopyKAT
              to analyze 46,501 single cells from 21 tumors, including
              triple-negative breast cancer, pancreatic ductal adenocarcinoma,
              anaplastic thyroid cancer, invasive ductal carcinoma and
              glioblastoma, to accurately (98\%) distinguish cancer cells from
              normal cell types. In three breast tumors, CopyKAT resolved
              clonal subpopulations that differed in the expression of cancer
              genes, such as KRAS, and signatures, including
              epithelial-to-mesenchymal transition, DNA repair, apoptosis and
              hypoxia. These data show that CopyKAT can aid in the analysis of
              scRNA-seq data in a variety of solid human tumors.",
  journal  = "Nat. Biotechnol.",
  volume   =  39,
  number   =  5,
  pages    = "599--608",
  month    =  may,
  year     =  2021,
  language = "en"
}

@ARTICLE{Zaccaria2021-xy,
  title    = "Characterizing allele- and haplotype-specific copy numbers in
              single cells with {CHISEL}",
  author   = "Zaccaria, Simone and Raphael, Benjamin J",
  abstract = "Single-cell barcoding technologies enable genome sequencing of
              thousands of individual cells in parallel, but with extremely low
              sequencing coverage (<0.05$\times$) per cell. While the total
              copy number of large multi-megabase segments can be derived from
              such data, important allele-specific mutations-such as
              copy-neutral loss of heterozygosity (LOH) in cancer-are missed.
              We introduce copy-number haplotype inference in single cells
              using evolutionary links (CHISEL), a method to infer allele- and
              haplotype-specific copy numbers in single cells and
              subpopulations of cells by aggregating sparse signal across
              hundreds or thousands of individual cells. We applied CHISEL to
              ten single-cell sequencing datasets of ~2,000 cells from two
              patients with breast cancer. We identified extensive
              allele-specific copy-number aberrations (CNAs) in these samples,
              including copy-neutral LOHs, whole-genome duplications (WGDs) and
              mirrored-subclonal CNAs. These allele-specific CNAs affect
              genomic regions containing well-known breast-cancer genes. We
              also refined the reconstruction of tumor evolution, timing
              allele-specific CNAs before and after WGDs, identifying
              low-frequency subpopulations distinguished by unique CNAs and
              uncovering evidence of convergent evolution.",
  journal  = "Nat. Biotechnol.",
  volume   =  39,
  number   =  2,
  pages    = "207--214",
  month    =  feb,
  year     =  2021,
  language = "en"
}

@ARTICLE{Bielski2018-ku,
  title    = "Genome doubling shapes the evolution and prognosis of advanced
              cancers",
  author   = "Bielski, Craig M and Zehir, Ahmet and Penson, Alexander V and
              Donoghue, Mark T A and Chatila, Walid and Armenia, Joshua and
              Chang, Matthew T and Schram, Alison M and Jonsson, Philip and
              Bandlamudi, Chaitanya and Razavi, Pedram and Iyer, Gopa and
              Robson, Mark E and Stadler, Zsofia K and Schultz, Nikolaus and
              Baselga, Jose and Solit, David B and Hyman, David M and Berger,
              Michael F and Taylor, Barry S",
  abstract = "Ploidy abnormalities are a hallmark of cancer, but their impact
              on the evolution and outcomes of cancers is unknown. Here, we
              identified whole-genome doubling (WGD) in the tumors of nearly
              30\% of 9,692 prospectively sequenced advanced cancer patients.
              WGD varied by tumor lineage and molecular subtype, and arose
              early in carcinogenesis after an antecedent transforming driver
              mutation. While associated with TP53 mutations, 46\% of all WGD
              arose in TP53-wild-type tumors and in such cases was associated
              with an E2F-mediated G1 arrest defect, although neither
              aberration was obligate in WGD tumors. The variability of WGD
              across cancer types can be explained in part by cancer cell
              proliferation rates. WGD predicted for increased morbidity across
              cancer types, including KRAS-mutant colorectal cancers and
              estrogen receptor-positive breast cancers, independently of
              established clinical prognostic factors. We conclude that WGD is
              highly common in cancer and is a macro-evolutionary event
              associated with poor prognosis across cancer types.",
  journal  = "Nat. Genet.",
  volume   =  50,
  number   =  8,
  pages    = "1189--1195",
  month    =  aug,
  year     =  2018,
  language = "en"
}

@ARTICLE{Bhandari2019-ot,
  title    = "Molecular landmarks of tumor hypoxia across cancer types",
  author   = "Bhandari, Vinayak and Hoey, Christianne and Liu, Lydia Y and
              Lalonde, Emilie and Ray, Jessica and Livingstone, Julie and
              Lesurf, Robert and Shiah, Yu-Jia and Vujcic, Tina and Huang,
              Xiaoyong and Espiritu, Shadrielle M G and Heisler, Lawrence E and
              Yousif, Fouad and Huang, Vincent and Yamaguchi, Takafumi N and
              Yao, Cindy Q and Sabelnykova, Veronica Y and Fraser, Michael and
              Chua, Melvin L K and van der Kwast, Theodorus and Liu, Stanley K
              and Boutros, Paul C and Bristow, Robert G",
  abstract = "Many primary-tumor subregions have low levels of molecular
              oxygen, termed hypoxia. Hypoxic tumors are at elevated risk for
              local failure and distant metastasis, but the molecular hallmarks
              of tumor hypoxia remain poorly defined. To fill this gap, we
              quantified hypoxia in 8,006 tumors across 19 tumor types. In ten
              tumor types, hypoxia was associated with elevated genomic
              instability. In all 19 tumor types, hypoxic tumors exhibited
              characteristic driver-mutation signatures. We observed widespread
              hypoxia-associated dysregulation of microRNAs (miRNAs) across
              cancers and functionally validated miR-133a-3p as a
              hypoxia-modulated miRNA. In localized prostate cancer, hypoxia
              was associated with elevated rates of chromothripsis, allelic
              loss of PTEN and shorter telomeres. These associations are
              particularly enriched in polyclonal tumors, representing a
              constellation of features resembling tumor nimbosus, an
              aggressive cellular phenotype. Overall, this work establishes
              that tumor hypoxia may drive aggressive molecular features across
              cancers and shape the clinical trajectory of individual tumors.",
  journal  = "Nat. Genet.",
  volume   =  51,
  number   =  2,
  pages    = "308--318",
  month    =  feb,
  year     =  2019,
  language = "en"
}

@ARTICLE{Bolhaqueiro2019-zm,
  title    = "Ongoing chromosomal instability and karyotype evolution in human
              colorectal cancer organoids",
  author   = "Bolhaqueiro, Ana C F and Ponsioen, Bas and Bakker, Bjorn and
              Klaasen, Sjoerd J and Kucukkose, Emre and van Jaarsveld, Richard
              H and Vivi{\'e}, Judith and Verlaan-Klink, Ingrid and Hami, Nizar
              and Spierings, Diana C J and Sasaki, Nobuo and Dutta, Devanjali
              and Boj, Sylvia F and Vries, Robert G J and Lansdorp, Peter M and
              van de Wetering, Marc and van Oudenaarden, Alexander and Clevers,
              Hans and Kranenburg, Onno and Foijer, Floris and Snippert, Hugo J
              G and Kops, Geert J P L",
  abstract = "Chromosome segregation errors cause aneuploidy and genomic
              heterogeneity, which are hallmarks of cancer in humans. A
              persistent high frequency of these errors (chromosomal
              instability (CIN)) is predicted to profoundly impact tumor
              evolution and therapy response. It is unknown, however, how
              prevalent CIN is in human tumors. Using three-dimensional
              live-cell imaging of patient-derived tumor organoids (tumor
              PDOs), we show that CIN is widespread in colorectal carcinomas
              regardless of background genetic alterations, including
              microsatellite instability. Cell-fate tracking showed that,
              although mitotic errors are frequently followed by cell death,
              some tumor PDOs are largely insensitive to mitotic errors.
              Single-cell karyotype sequencing confirmed heterogeneity of copy
              number alterations in tumor PDOs and showed that monoclonal lines
              evolved novel karyotypes over time in vitro. We conclude that
              ongoing CIN is common in colorectal cancer organoids, and propose
              that CIN levels and the tolerance for mitotic errors shape
              aneuploidy landscapes and karyotype heterogeneity.",
  journal  = "Nat. Genet.",
  volume   =  51,
  number   =  5,
  pages    = "824--834",
  month    =  may,
  year     =  2019,
  language = "en"
}

@ARTICLE{Lopez2020-wi,
  title    = "Interplay between whole-genome doubling and the accumulation of
              deleterious alterations in cancer evolution",
  author   = "L{\'o}pez, Saioa and Lim, Emilia L and Horswell, Stuart and
              Haase, Kerstin and Huebner, Ariana and Dietzen, Michelle and
              Mourikis, Thanos P and Watkins, Thomas B K and Rowan, Andrew and
              Dewhurst, Sally M and Birkbak, Nicolai J and Wilson, Gareth A and
              Van Loo, Peter and Jamal-Hanjani, Mariam and {TRACERx Consortium}
              and Swanton, Charles and McGranahan, Nicholas",
  abstract = "Whole-genome doubling (WGD) is a prevalent event in cancer,
              involving a doubling of the entire chromosome complement.
              However, despite its prevalence and prognostic relevance, the
              evolutionary selection pressures for WGD in cancer have not been
              investigated. Here, we combine evolutionary simulations with an
              analysis of cancer sequencing data to explore WGD during cancer
              evolution. Simulations suggest that WGD can be selected to
              mitigate the irreversible, ratchet-like, accumulation of
              deleterious somatic alterations, provided that they occur at a
              sufficiently high rate. Consistent with this, we observe an
              enrichment for WGD in tumor types with extensive loss of
              heterozygosity, including lung squamous cell carcinoma and
              triple-negative breast cancers, and we find evidence for negative
              selection against homozygous loss of essential genes before, but
              not after, WGD. Finally, we demonstrate that loss of
              heterozygosity and temporal dissection of mutations can be
              exploited to identify novel tumor suppressor genes and to obtain
              a deeper characterization of known cancer genes.",
  journal  = "Nat. Genet.",
  volume   =  52,
  number   =  3,
  pages    = "283--293",
  month    =  mar,
  year     =  2020,
  language = "en"
}

@ARTICLE{Watson2024-zo,
  title    = "Chromosome evolution screens recapitulate tissue-specific tumor
              aneuploidy patterns",
  author   = "Watson, Emma V and Lee, Jake June-Koo and Gulhan, Doga C and
              Melloni, Giorgio E M and Venev, Sergey V and Magesh, Rayna Y and
              Frederick, Abdulrazak and Chiba, Kunitoshi and Wooten, Eric C and
              Naxerova, Kamila and Dekker, Job and Park, Peter J and Elledge,
              Stephen J",
  abstract = "Whole chromosome and arm-level copy number alterations occur at
              high frequencies in tumors, but their selective advantages, if
              any, are poorly understood. Here, utilizing unbiased whole
              chromosome genetic screens combined with in vitro evolution to
              generate arm- and subarm-level events, we iteratively selected
              the fittest karyotypes from aneuploidized human renal and mammary
              epithelial cells. Proliferation-based karyotype selection in
              these epithelial lines modeled tissue-specific tumor aneuploidy
              patterns in patient cohorts in the absence of driver mutations.
              Hi-C-based translocation mapping revealed that arm-level events
              usually emerged in multiples of two via centromeric
              translocations and occurred more frequently in tetraploids than
              diploids, contributing to the increased diversity in evolving
              tetraploid populations. Isogenic clonal lineages enabled
              elucidation of pro-tumorigenic mechanisms associated with common
              copy number alterations, revealing Notch signaling potentiation
              as a driver of 1q gain in breast cancer. We propose that
              intrinsic, tissue-specific proliferative effects underlie tumor
              copy number patterns in cancer.",
  journal  = "Nat. Genet.",
  month    =  feb,
  year     =  2024,
  language = "en"
}

@ARTICLE{Richard2018-zc,
  title    = "{T} cell cytolytic capacity is independent of initial stimulation
              strength",
  author   = "Richard, Arianne C and Lun, Aaron T L and Lau, Winnie W Y and
              G{\"o}ttgens, Berthold and Marioni, John C and Griffiths, Gillian
              M",
  abstract = "How cells respond to myriad stimuli with finite signaling
              machinery is central to immunology. In naive T cells, the
              inherent effect of ligand strength on activation pathways and
              endpoints has remained controversial, confounded by environmental
              fluctuations and intercellular variability within populations.
              Here we studied how ligand potency affected the activation of
              CD8+ T cells in vitro, through the use of genome-wide RNA,
              multi-dimensional protein and functional measurements in single
              cells. Our data revealed that strong ligands drove more efficient
              and uniform activation than did weak ligands, but all activated
              cells were fully cytolytic. Notably, activation followed the same
              transcriptional pathways regardless of ligand potency. Thus,
              stimulation strength did not intrinsically dictate the T
              cell-activation route or phenotype; instead, it controlled how
              rapidly and simultaneously the cells initiated activation,
              allowing limited machinery to elicit wide-ranging responses.",
  journal  = "Nat. Immunol.",
  volume   =  19,
  number   =  8,
  pages    = "849--858",
  month    =  aug,
  year     =  2018,
  language = "en"
}

@ARTICLE{Richard2018-xt,
  title    = "{T} cell cytolytic capacity is independent of initial stimulation
              strength",
  author   = "Richard, Arianne C and Lun, Aaron T L and Lau, Winnie W Y and
              G{\"o}ttgens, Berthold and Marioni, John C and Griffiths, Gillian
              M",
  abstract = "How cells respond to myriad stimuli with finite signaling
              machinery is central to immunology. In naive T cells, the
              inherent effect of ligand strength on activation pathways and
              endpoints has remained controversial, confounded by environmental
              fluctuations and intercellular variability within populations.
              Here we studied how ligand potency affected the activation of
              CD8+ T cells in vitro, through the use of genome-wide RNA,
              multi-dimensional protein and functional measurements in single
              cells. Our data revealed that strong ligands drove more efficient
              and uniform activation than did weak ligands, but all activated
              cells were fully cytolytic. Notably, activation followed the same
              transcriptional pathways regardless of ligand potency. Thus,
              stimulation strength did not intrinsically dictate the T
              cell-activation route or phenotype; instead, it controlled how
              rapidly and simultaneously the cells initiated activation,
              allowing limited machinery to elicit wide-ranging responses.",
  journal  = "Nat. Immunol.",
  volume   =  19,
  number   =  8,
  pages    = "849--858",
  month    =  aug,
  year     =  2018,
  language = "en"
}

@ARTICLE{Lai2020-mr,
  title    = "Adoptive cellular therapy with {T} cells expressing the dendritic
              cell growth factor {Flt3L} drives epitope spreading and antitumor
              immunity",
  author   = "Lai, Junyun and Mardiana, Sherly and House, Imran G and Sek,
              Kevin and Henderson, Melissa A and Giuffrida, Lauren and Chen,
              Amanda X Y and Todd, Kirsten L and Petley, Emma V and Chan, Jack
              D and Carrington, Emma M and Lew, Andrew M and Solomon, Benjamin
              J and Trapani, Joseph A and Kedzierska, Katherine and Evrard,
              Maximilien and Vervoort, Stephin J and Waithman, Jason and Darcy,
              Phillip K and Beavis, Paul A",
  abstract = "Adoptive cell therapies using genetically engineered T cell
              receptor or chimeric antigen receptor T cells are emerging forms
              of immunotherapy that redirect T cells to specifically target
              cancer. However, tumor antigen heterogeneity remains a key
              challenge limiting their efficacy against solid cancers. Here, we
              engineered T cells to secrete the dendritic cell (DC) growth
              factor Fms-like tyrosine kinase 3 ligand (Flt3L). Flt3L-secreting
              T cells expanded intratumoral conventional type 1 DCs and
              substantially increased host DC and T cell activation when
              combined with immune agonists poly (I:C) and anti-4-1BB.
              Importantly, combination therapy led to enhanced inhibition of
              tumor growth and the induction of epitope spreading towards
              antigens beyond those recognized by adoptively transferred T
              cells in solid tumor models of T cell receptor and chimeric
              antigen receptor T cell therapy. Our data suggest that augmenting
              endogenous DCs is a promising strategy to overcome the clinical
              problem of antigen-negative tumor escape following adoptive cell
              therapy.",
  journal  = "Nat. Immunol.",
  month    =  may,
  year     =  2020,
  language = "en"
}

@ARTICLE{Jiang2018-ya,
  title    = "Signatures of {T} cell dysfunction and exclusion predict cancer
              immunotherapy response",
  author   = "Jiang, Peng and Gu, Shengqing and Pan, Deng and Fu, Jingxin and
              Sahu, Avinash and Hu, Xihao and Li, Ziyi and Traugh, Nicole and
              Bu, Xia and Li, Bo and Liu, Jun and Freeman, Gordon J and Brown,
              Myles A and Wucherpfennig, Kai W and Liu, X Shirley",
  abstract = "Cancer treatment by immune checkpoint blockade (ICB) can bring
              long-lasting clinical benefits, but only a fraction of patients
              respond to treatment. To predict ICB response, we developed TIDE,
              a computational method to model two primary mechanisms of tumor
              immune evasion: the induction of T cell dysfunction in tumors
              with high infiltration of cytotoxic T lymphocytes (CTL) and the
              prevention of T cell infiltration in tumors with low CTL level.
              We identified signatures of T cell dysfunction from large tumor
              cohorts by testing how the expression of each gene in tumors
              interacts with the CTL infiltration level to influence patient
              survival. We also modeled factors that exclude T cell
              infiltration into tumors using expression signatures from
              immunosuppressive cells. Using this framework and pre-treatment
              RNA-Seq or NanoString tumor expression profiles, TIDE predicted
              the outcome of melanoma patients treated with first-line anti-PD1
              or anti-CTLA4 more accurately than other biomarkers such as PD-L1
              level and mutation load. TIDE also revealed new candidate ICB
              resistance regulators, such as SERPINB9, demonstrating utility
              for immunotherapy research.",
  journal  = "Nat. Med.",
  volume   =  24,
  number   =  10,
  pages    = "1550--1558",
  month    =  oct,
  year     =  2018,
  language = "en"
}

@ARTICLE{Braun2020-dq,
  title    = "Interplay of somatic alterations and immune infiltration
              modulates response to {PD-1} blockade in advanced clear cell
              renal cell carcinoma",
  author   = "Braun, David A and Hou, Yue and Bakouny, Ziad and Ficial, Miriam
              and Sant' Angelo, Miriam and Forman, Juliet and Ross-Macdonald,
              Petra and Berger, Ashton C and Jegede, Opeyemi A and Elagina,
              Liudmilla and Steinharter, John and Sun, Maxine and Wind-Rotolo,
              Megan and Pignon, Jean-Christophe and Cherniack, Andrew D and
              Lichtenstein, Lee and Neuberg, Donna and Catalano, Paul and
              Freeman, Gordon J and Sharpe, Arlene H and McDermott, David F and
              Van Allen, Eliezer M and Signoretti, Sabina and Wu, Catherine J
              and Shukla, Sachet A and Choueiri, Toni K",
  abstract = "PD-1 blockade has transformed the management of advanced clear
              cell renal cell carcinoma (ccRCC), but the drivers and resistors
              of the PD-1 response remain incompletely elucidated. Here, we
              analyzed 592 tumors from patients with advanced ccRCC enrolled in
              prospective clinical trials of treatment with PD-1 blockade by
              whole-exome and RNA sequencing, integrated with
              immunofluorescence analysis, to uncover the immunogenomic
              determinants of the therapeutic response. Although conventional
              genomic markers (such as tumor mutation burden and neoantigen
              load) and the degree of CD8+ T cell infiltration were not
              associated with clinical response, we discovered numerous
              chromosomal alterations associated with response or resistance to
              PD-1 blockade. These advanced ccRCC tumors were highly CD8+ T
              cell infiltrated, with only 27\% having a non-infiltrated
              phenotype. Our analysis revealed that infiltrated tumors are
              depleted of favorable PBRM1 mutations and enriched for
              unfavorable chromosomal losses of 9p21.3, as compared with
              non-infiltrated tumors, demonstrating how the potential interplay
              of immunophenotypes with somatic alterations impacts therapeutic
              efficacy.",
  journal  = "Nat. Med.",
  volume   =  26,
  number   =  6,
  pages    = "909--918",
  month    =  jun,
  year     =  2020,
  language = "en"
}

@ARTICLE{Weigert2018-nq,
  title    = "Content-aware image restoration: pushing the limits of
              fluorescence microscopy",
  author   = "Weigert, Martin and Schmidt, Uwe and Boothe, Tobias and
              M{\"u}ller, Andreas and Dibrov, Alexandr and Jain, Akanksha and
              Wilhelm, Benjamin and Schmidt, Deborah and Broaddus, Coleman and
              Culley, Si{\^a}n and Rocha-Martins, Mauricio and Segovia-Miranda,
              Fabi{\'a}n and Norden, Caren and Henriques, Ricardo and Zerial,
              Marino and Solimena, Michele and Rink, Jochen and Tomancak, Pavel
              and Royer, Loic and Jug, Florian and Myers, Eugene W",
  abstract = "Fluorescence microscopy is a key driver of discoveries in the
              life sciences, with observable phenomena being limited by the
              optics of the microscope, the chemistry of the fluorophores, and
              the maximum photon exposure tolerated by the sample. These limits
              necessitate trade-offs between imaging speed, spatial resolution,
              light exposure, and imaging depth. In this work we show how
              content-aware image restoration based on deep learning extends
              the range of biological phenomena observable by microscopy. We
              demonstrate on eight concrete examples how microscopy images can
              be restored even if 60-fold fewer photons are used during
              acquisition, how near isotropic resolution can be achieved with
              up to tenfold under-sampling along the axial direction, and how
              tubular and granular structures smaller than the diffraction
              limit can be resolved at 20-times-higher frame rates compared to
              state-of-the-art methods. All developed image restoration methods
              are freely available as open source software in Python, FIJI, and
              KNIME.",
  journal  = "Nat. Methods",
  volume   =  15,
  number   =  12,
  pages    = "1090--1097",
  month    =  dec,
  year     =  2018,
  language = "en"
}

@ARTICLE{Berg2019-my,
  title    = "ilastik: interactive machine learning for (bio)image analysis",
  author   = "Berg, Stuart and Kutra, Dominik and Kroeger, Thorben and
              Straehle, Christoph N and Kausler, Bernhard X and Haubold,
              Carsten and Schiegg, Martin and Ales, Janez and Beier, Thorsten
              and Rudy, Markus and Eren, Kemal and Cervantes, Jaime I and Xu,
              Buote and Beuttenmueller, Fynn and Wolny, Adrian and Zhang, Chong
              and Koethe, Ullrich and Hamprecht, Fred A and Kreshuk, Anna",
  abstract = "We present ilastik, an easy-to-use interactive tool that brings
              machine-learning-based (bio)image analysis to end users without
              substantial computational expertise. It contains pre-defined
              workflows for image segmentation, object classification, counting
              and tracking. Users adapt the workflows to the problem at hand by
              interactively providing sparse training annotations for a
              nonlinear classifier. ilastik can process data in up to five
              dimensions (3D, time and number of channels). Its computational
              back end runs operations on-demand wherever possible, allowing
              for interactive prediction on data larger than RAM. Once the
              classifiers are trained, ilastik workflows can be applied to new
              data from the command line without further user interaction. We
              describe all ilastik workflows in detail, including three case
              studies and a discussion on the expected performance.",
  journal  = "Nat. Methods",
  volume   =  16,
  number   =  12,
  pages    = "1226--1232",
  month    =  dec,
  year     =  2019,
  language = "en"
}

@ARTICLE{Hu2018-gx,
  title    = "Combined {SEP} and {anti-PD-L1} antibody produces a synergistic
              antitumor effect in {B16-F10} melanoma-bearing mice",
  author   = "Hu, Zhengping and Ye, Liang and Xing, Yingying and Hu, Jinhang
              and Xi, Tao",
  abstract = "The increased PD-L1 induces poorer prognosis in melanoma. The
              treatment with PD-1/PD-L1 antibodies have a low response rate.
              The combination immunotherapies are the encouraging drug
              development strategy to receive maximal therapeutic benefit. In
              this study, we investigated the enhanced antitumor and
              immunomodulatory activity of combined SEP and $\alpha$PD-L1 in
              B16-F10 melanoma-bearing mice. The results shown that combined
              SEP and $\alpha$PD-L1 presented significant synergistic antitumor
              effects, increased the frequency of CD8+ and CD4+ T cells in
              spleen and tumor, cytotoxic activity of CTL in spleen, and IL-2
              and IFN-$\gamma$ levels in splenocytes and tumor. The combination
              treatment also produced synergistic increase in P-ERK1/2 level in
              spleen. Immunohistochemistry shown that SEP induced the PD-L1
              expression in melanoma tissue possibly by promoting IFN-$\gamma$
              excretion, which led to the synergistic anti-tumor effects of
              aPD-L1 and SEP. Furthermore, in the purified T lymphocyte from
              the naive mice, the combination of SEP and $\alpha$PD-L1 had more
              potent than SEP or $\alpha$PD-L1 in promoting T lymphocyte
              proliferation and cytokines secretion including IL-2 and
              IFN-$\gamma$, at least partially by activating MEK/ERK pathway.
              Our study provides the scientific basis for a clinical trial that
              would involve combination of anti-PD-L1 mAb and SEP for sustained
              melanoma control.",
  journal  = "Sci. Rep.",
  volume   =  8,
  number   =  1,
  pages    = "217",
  month    =  jan,
  year     =  2018,
  language = "en"
}

@ARTICLE{Hosoi2018-mp,
  title    = "Increased diversity with reduced ``diversity evenness'' of tumor
              infiltrating T-cells for the successful cancer immunotherapy",
  author   = "Hosoi, Akihiro and Takeda, Kazuyoshi and Nagaoka, Koji and Iino,
              Tamaki and Matsushita, Hirokazu and Ueha, Satoshi and Aoki, Shin
              and Matsushima, Kouji and Kubo, Masato and Morikawa, Teppei and
              Kitaura, Kazutaka and Suzuki, Ryuji and Kakimi, Kazuhiro",
  abstract = "To facilitate the optimization of cancer immunotherapy lacking
              immune-related adverse events, we performed TCR repertoire
              analysis of tumor-infiltrating CD8+ T-cells in B16
              melanoma-bearing mice receiving anti-PD-1, anti-CTLA-4,
              anti-4-1BB, anti-CD4 or a combination of anti-PD-1 and 4-1BB
              antibodies. Although CD8+ T-cells in the tumor were activated and
              expanded to a greater or lesser extent by these therapies, tumor
              growth suppression was achieved only by anti-PD-1,
              anti-PD-1/4-1BB combined, or by anti-CD4 treatment, but not by
              anti-CTLA-4 or anti-4-1BB monotherapy. Increased CD8+ T cell
              effector function and TCR diversity with enrichment of certain
              TCR clonotypes in the tumor was associated with anti-tumor
              effects. In contrast, polyclonal activation of T-cells in the
              periphery was associated with tissue damage. Thus, optimal
              combination therapy increases TCR diversity with extended
              activation of selective CD8+ T-cells specifically in the tumor
              but not in the periphery. Incorporation of the concept of
              evenness for the TCR diversity is proposed.",
  journal  = "Sci. Rep.",
  volume   =  8,
  number   =  1,
  pages    = "1058",
  month    =  jan,
  year     =  2018,
  language = "en"
}

@ARTICLE{Milberg2019-pn,
  title    = "A {QSP} Model for Predicting Clinical Responses to Monotherapy,
              Combination and Sequential Therapy Following {CTLA-4}, {PD-1},
              and {PD-L1} Checkpoint Blockade",
  author   = "Milberg, Oleg and Gong, Chang and Jafarnejad, Mohammad and
              Bartelink, Imke H and Wang, Bing and Vicini, Paolo and Narwal,
              Rajesh and Roskos, Lorin and Popel, Aleksander S",
  abstract = "Over the past decade, several immunotherapies have been approved
              for the treatment of melanoma. The most prominent of these are
              the immune checkpoint inhibitors, which are antibodies that block
              the inhibitory effects on the immune system by checkpoint
              receptors, such as CTLA-4, PD-1 and PD-L1. Preclinically,
              blocking these receptors has led to increased activation and
              proliferation of effector cells following stimulation and antigen
              recognition, and subsequently, more effective elimination of
              cancer cells. Translation from preclinical to clinical outcomes
              in solid tumors has shown the existence of a wide diversity of
              individual patient responses, linked to several patient-specific
              parameters. We developed a quantitative systems pharmacology
              (QSP) model that looks at the mentioned checkpoint blockade
              therapies administered as mono-, combo- and sequential therapies,
              to show how different combinations of specific patient parameters
              defined within physiological ranges distinguish different types
              of virtual patient responders to these therapies for melanoma.
              Further validation by fitting and subsequent simulations of
              virtual clinical trials mimicking actual patient trials
              demonstrated that the model can capture a wide variety of tumor
              dynamics that are observed in the clinic and can predict median
              clinical responses. Our aim here is to present a QSP model for
              combination immunotherapy specific to melanoma.",
  journal  = "Sci. Rep.",
  volume   =  9,
  number   =  1,
  pages    = "11286",
  month    =  aug,
  year     =  2019,
  language = "en"
}

@ARTICLE{Khazen2019-nx,
  title    = "Sequential adjustment of cytotoxic {T} lymphocyte densities
              improves efficacy in controlling tumor growth",
  author   = "Khazen, Roxana and M{\"u}ller, Sabina and Lafouresse, Fanny and
              Valitutti, Salvatore and Cussat-Blanc, Sylvain",
  abstract = "Understanding the human cytotoxic T lymphocyte (CTL) biology is
              crucial to develop novel strategies aiming at maximizing their
              lytic capacity against cancer cells. Here we introduce an
              agent-based model, calibrated on population-scale experimental
              data that allows quantifying human CTL per capita killing. Our
              model highlights higher individual CTL killing capacity at lower
              CTL densities and fits experimental data of human melanoma cell
              killing. The model allows extending the analysis over prolonged
              time frames, difficult to investigate experimentally, and reveals
              that initial high CTL densities hamper efficacy to control
              melanoma growth. Computational analysis forecasts that sequential
              addition of fresh CTL cohorts improves tumor growth control. In
              vivo experimental data, obtained in a mouse melanoma model,
              confirm this prediction. Taken together, our results unveil the
              impact that sequential adjustment of cellular densities has on
              enhancing CTL efficacy over long-term confrontation with tumor
              cells. In perspective, they can be instrumental to refine
              CTL-based therapeutic strategies aiming at controlling tumor
              growth.",
  journal  = "Sci. Rep.",
  volume   =  9,
  number   =  1,
  pages    = "12308",
  month    =  aug,
  year     =  2019,
  language = "en"
}

@ARTICLE{Hwang2020-gr,
  title    = "Immune gene signatures for predicting durable clinical benefit of
              {anti-PD-1} immunotherapy in patients with non-small cell lung
              cancer",
  author   = "Hwang, Sohyun and Kwon, Ah-Young and Jeong, Ju-Yeon and Kim,
              Sewha and Kang, Haeyoun and Park, Joonsuk and Kim, Joo-Hang and
              Han, Ok Jin and Lim, Sun Min and An, Hee Jung",
  abstract = "Immune checkpoint blockade is promising for treating
              non-small-cell lung cancer (NSCLC). We used multipanel markers to
              predict the response to immune checkpoint inhibitors (ICIs) by
              characterizing gene expression signatures or individual genes in
              patients who showed durable clinical benefit to ICIs. Twenty-one
              patients with NSCLC treated with single-agent anti-programmed
              cell death protein (PD)-1 antibody were analyzed and their
              clinicopathological characteristics and response to ICIs were
              characterized. Nine (43\%) showed a durable clinical benefit
              (DCB), while the remaining 12 (57\%) patients showed non-durable
              benefit (NDB). The M1 and peripheral T cell signatures showed the
              best performance for discriminating DCB from NDB (sensitivity,
              specificity, accuracy = 0.89, 1.0, 0.95, respectively).
              Progression-free survival (PFS) was significantly longer in
              patients with high M1 signature or high peripheral T cell
              signature scores. CD137 and PSMB9 mRNA expression was higher in
              the DCB group than in the NDB group. Patients with high PSMB9
              expression showed longer PFS. M1 signature, peripheral T cell
              signature and high mRNA expression level of CD137 and PSMB9
              showed better predictive performance than known biomarkers, such
              as PD-L1 immunohistochemistry, tumor mutation burden, or
              tumor-infiltrating lymphocytes.",
  journal  = "Sci. Rep.",
  volume   =  10,
  number   =  1,
  pages    = "643",
  month    =  jan,
  year     =  2020,
  language = "en"
}

@ARTICLE{Sun2020-xh,
  title    = "Clinical efficacy and safety of {anti-PD-1/PD-L1} inhibitors for
              the treatment of advanced or metastatic cancer: a systematic
              review and meta-analysis",
  author   = "Sun, Leitao and Zhang, Leyin and Yu, Jieru and Zhang, Yinan and
              Pang, Xi and Ma, Chenghao and Shen, Minhe and Ruan, Shanming and
              Wasan, Harpreet S and Qiu, Shengliang",
  abstract = "Anti-PD-1/PD-L1 inhibitors provide a survival advantage over
              conventional therapies for treatment of advanced or metastatic
              cancer. However, the factors determining which patients benefit
              the most from anti-PD-1/PD-L1 inhibitors are unknown, making
              treatment-related decisions difficult. We performed a systematic
              review and meta-analysis of acquired data to assess the efficacy
              and toxicity of anti-PD-1/PD-L1 inhibitors in advanced and
              metastatic cancer. A thorough search strategy was applied to
              identify randomised controlled trials (RCTs) in Pubmed, Embase,
              Cochrane, and major conferences. Studies meeting predefined
              selection criteria were selected, and two independent
              investigators performed data extraction; overall survival (OS),
              progression-free survival (PFS), and overall response rate were
              compared between anti-PD-1/PD-L1 inhibitors and control
              therapies. We calculated the pooled response rate and 95\% CIs of
              all-grade and high-grade ($\geq$3) adverse effects and evaluated
              the within-study heterogeneity using subgroup, sensitivity, and
              meta-regression analyses. In final, we included eligible 35 RCTs
              (21047 patients). The main estimated hazard ratios (HRs) for OS
              and PFS were 0.76 (0.71-0.82) and 0.81 (0.73-0.89) in a
              random-effects model. The anti-PD-1/PD-L1 inhibitor group had a
              significantly high risk for all-grade immune-related adverse
              events. Anti-PD-1/PD-L1 inhibitors were identified as a
              preferable treatment option for advanced or metastatic cancer
              patients who are male, aged < 65 years, current or former
              smokers, had no CNS or liver metastasis, had not EGFR mutation,
              and had high PD-L1 expression.",
  journal  = "Sci. Rep.",
  volume   =  10,
  number   =  1,
  pages    = "2083",
  month    =  feb,
  year     =  2020,
  language = "en"
}

@ARTICLE{DeBerardinis2020-sm,
  title    = "We need to talk about the Warburg effect",
  author   = "DeBerardinis, Ralph J and Chandel, Navdeep S",
  journal  = "Nat Metab",
  volume   =  2,
  number   =  2,
  pages    = "127--129",
  month    =  feb,
  year     =  2020,
  language = "en"
}

% The entry below contains non-ASCII chars that could not be converted
% to a LaTeX equivalent.
@ARTICLE{Hoekstra2020-tc,
  title    = "Long-distance modulation of bystander tumor cells by {CD8+}
              T-cell-secreted {IFN-$\gamma$}",
  author   = "Hoekstra, Mirjam E and Bornes, Laura and Dijkgraaf, Feline E and
              Philips, Daisy and Pardieck, Iris N and Toebes, Mireille and
              Thommen, Daniela S and van Rheenen, Jacco and Schumacher, Ton N M",
  abstract = "T-cell-secreted interferon (IFN)-$\gamma$ can exert pleiotropic
              effects on tumor cells that include induction of immune
              checkpoints and antigen presentation machinery components, and
              inhibition of cell growth. Despite its role as a key effector
              molecule, little is known about the spatiotemporal spreading of
              IFN-$\gamma$ secreted by activated CD8+ T cells within the tumor
              environment. Using multiday intravital imaging, we demonstrate
              that T cell recognition of a minor fraction of tumor cells leads
              to sensing of IFN-$\gamma$ by a large part of the tumor mass.
              Furthermore, imaging of tumors in which antigen-positive and
              antigen-negative tumor cells are separated in space reveals
              spreading of the IFN-$\gamma$ response, reaching distances of
              >800 m. Notably, long-range sensing of IFN-$\gamma$ can modify
              tumor behavior, as shown by both induction of PD-L1 expression
              and inhibition of tumor growth. Collectively, these data reveal
              how, through IFN-$\gamma$, CD8+ T cells modulate the behavior of
              remote tumor cells, including antigen-loss variants.",
  journal  = "Nature Cancer",
  volume   =  1,
  number   =  3,
  pages    = "291--301",
  month    =  mar,
  year     =  2020
}

@ARTICLE{Thibaut2020-vx,
  title    = "Bystander {IFN-$\gamma$} activity promotes widespread and
              sustained cytokine signaling altering the tumor microenvironment",
  author   = "Thibaut, Ronan and Bost, Pierre and Milo, Idan and Cazaux, Marine
              and Lema{\^\i}tre, Fabrice and Garcia, Zacarias and Amit, Ido and
              Breart, B{\'e}atrice and Cornuot, Cl{\'e}mence and Schwikowski,
              Benno and Bousso, Philippe",
  abstract = "The cytokine interferon (IFN)-$\gamma$ produced by tumor-reactive
              T cells is a key effector molecule with pleiotropic effects
              during anti-tumor immune responses. Although IFN-$\gamma$
              production is targeted at the immunologic synapse, its
              spatiotemporal activity within the tumor remains elusive. In the
              present study, we report that, although IFN-$\gamma$ secretion
              requires local antigen recognition, IFN-$\gamma$ diffuses
              extensively to alter the tumor microenvironment in distant areas.
              Using intravital imaging and a reporter for STAT1 translocation,
              we provide evidence that T cells mediate sustained IFN-$\gamma$
              signaling in remote tumor cells. Furthermore, tumor phenotypic
              alterations required several hours of exposure to IFN-$\gamma$, a
              feature that disfavored local IFN-$\gamma$ activity over
              diffusion and bystander activity. Finally, single-cell
              RNA-sequencing data from melanoma patients also suggested
              bystander IFN-$\gamma$ activity in human tumors. Thus,
              tumor-reactive T cells act collectively to create large cytokine
              fields that profoundly modify the tumor microenvironment.",
  journal  = "Nature Cancer",
  volume   =  1,
  number   =  3,
  pages    = "302--314",
  month    =  mar,
  year     =  2020
}

@ARTICLE{Leshchiner2023-yz,
  title    = "Inferring early genetic progression in cancers with unobtainable
              premalignant disease",
  author   = "Leshchiner, Ignaty and Mroz, Edmund A and Cha, Justin and
              Rosebrock, Daniel and Spiro, Oliver and Bonilla-Velez, Juliana
              and Faquin, William C and Lefranc-Torres, Armida and Lin, Derrick
              T and Michaud, William A and Getz, Gad and Rocco, James W",
  abstract = "Analysis of premalignant tissue has identified the typical order
              of somatic events leading to invasive tumors in several cancer
              types. For other cancers, premalignant tissue is unobtainable,
              leaving genetic progression unknown. Here, we demonstrate how to
              infer progression from exome sequencing of primary tumors. Our
              computational method, PhylogicNDT, recapitulated the previous
              experimentally determined genetic progression of human
              papillomavirus-negative (HPV-) head and neck squamous cell
              carcinoma (HNSCC). We then evaluated HPV+ HNSCC, which lacks
              premalignant tissue, and uncovered its previously unknown
              progression, identifying early drivers. We converted relative
              timing estimates of driver mutations and HPV integration to years
              before diagnosis based on a clock-like mutational signature. We
              associated the timing of transitions to aneuploidy with increased
              intratumor genetic heterogeneity and shorter overall survival.
              Our approach can establish previously unknown early genetic
              progression of cancers with unobtainable premalignant tissue,
              supporting development of experimental models and methods for
              early detection, interception and prognostication.",
  journal  = "Nat Cancer",
  volume   =  4,
  number   =  4,
  pages    = "550--563",
  month    =  apr,
  year     =  2023,
  language = "en"
}

@ARTICLE{Baker2024-lf,
  title    = "Aneuploidy and complex genomic rearrangements in cancer evolution",
  author   = "Baker, Toby M and Waise, Sara and Tarabichi, Maxime and Van Loo,
              Peter",
  abstract = "Mutational processes that alter large genomic regions occur
              frequently in developing tumors. They range from simple copy
              number gains and losses to the shattering and reassembly of
              entire chromosomes. These catastrophic events, such as
              chromothripsis, chromoplexy and the formation of extrachromosomal
              DNA, affect the expression of many genes and therefore have a
              substantial effect on the fitness of the cells in which they
              arise. In this review, we cover large genomic alterations, the
              mechanisms that cause them and their effect on tumor development
              and evolution.",
  journal  = "Nat Cancer",
  volume   =  5,
  number   =  2,
  pages    = "228--239",
  month    =  feb,
  year     =  2024,
  language = "en"
}

@ARTICLE{Strobl2022-yn,
  title    = "Spatial structure impacts adaptive therapy by shaping
              intra-tumoral competition",
  author   = "Strobl, Maximilian A R and Gallaher, Jill and West, Jeffrey and
              Robertson-Tessi, Mark and Maini, Philip K and Anderson, Alexander
              R A",
  abstract = "BACKGROUND: Adaptive therapy aims to tackle cancer drug
              resistance by leveraging resource competition between
              drug-sensitive and resistant cells. Here, we present a
              theoretical study of intra-tumoral competition during adaptive
              therapy, to investigate under which circumstances it will be
              superior to aggressive treatment. METHODS: We develop and analyse
              a simple, 2-D, on-lattice, agent-based tumour model in which
              cells are classified as fully drug-sensitive or resistant.
              Subsequently, we compare this model to its corresponding
              non-spatial ordinary differential equation model, and fit it to
              longitudinal prostate-specific antigen data from 65 prostate
              cancer patients undergoing intermittent androgen deprivation
              therapy following biochemical recurrence. RESULTS: Leveraging the
              individual-based nature of our model, we explicitly demonstrate
              competitive suppression of resistance during adaptive therapy,
              and examine how different factors, such as the initial resistance
              fraction or resistance costs, alter competition. This not only
              corroborates our theoretical understanding of adaptive therapy,
              but also reveals that competition of resistant cells with each
              other may play a more important role in adaptive therapy in solid
              tumours than was previously thought. To conclude, we present two
              case studies, which demonstrate the implications of our work for:
              (i) mathematical modelling of adaptive therapy, and (ii) the
              intra-tumoral dynamics in prostate cancer patients during
              intermittent androgen deprivation treatment, a precursor of
              adaptive therapy. CONCLUSION: Our work shows that the tumour's
              spatial architecture is an important factor in adaptive therapy
              and provides insights into how adaptive therapy leverages both
              inter- and intra-specific competition to control resistance.",
  journal  = "Commun. Med.",
  volume   =  2,
  pages    = "46",
  month    =  apr,
  year     =  2022,
  keywords = "Cancer therapeutic resistance; Dynamical systems; Prostate
              cancer; Tumour heterogeneity",
  language = "en"
}

@ARTICLE{Yang2010-bl,
  title    = "A randomised phase {II} study of pegylated arginine deiminase
              ({ADI-PEG} 20) in Asian advanced hepatocellular carcinoma
              patients",
  author   = "Yang, T-S and Lu, S-N and Chao, Y and Sheen, I-S and Lin, C-C and
              Wang, T-E and Chen, S-C and Wang, J-H and Liao, L-Y and Thomson,
              J A and Wang-Peng, J and Chen, P-J and Chen, L-T",
  abstract = "BACKGROUND: Human hepatocellular carcinoma (HCC) cells are
              largely deficient of argininosuccinate synthetase and thus
              auxotrophic for arginine. This study aims to investigate the
              efficacy and pharmacodynamics of pegylated arginine deiminase
              (ADI-PEG 20), a systemic arginine deprivation agent, in Asian HCC
              patients. METHODS: Patients with advanced HCC who were not
              candidates for local therapy were eligible and randomly assigned
              to receive weekly intramuscular injections of ADI-PEG 20 at doses
              of 160 or 320 IU m(-2). The primary end point was disease-control
              rate (DCR). RESULTS: Of the 71 accruals, 43.6\% had failed
              previous systemic treatment. There were no objective responders.
              The DCR and the median overall survival (OS) of the
              intent-to-treat population were 31.0\% (95\% confidence interval
              (CI): 20.5-43.1) and 7.3 (95\% CI: 4.7-9.9) months respectively.
              Both efficacy parameters were comparable between the two study
              arms. The median OS of patients with undetectable circulating
              arginine for more than or equal to and <4 weeks was 10.0 (95\%
              CI: 2.1-17.9) and 5.8 (95\% CI: 1.4-10.1) months respectively
              (P=0.251, log-rank test). The major treatment-related adverse
              events were grades 1-2 local and/or allergic reactions.
              CONCLUSIONS: ADI-PEG 20 is safe and efficacious in stabilising
              the progression of heavily pretreated advanced HCC in an Asian
              population, and deserves further exploration.",
  journal  = "Br. J. Cancer",
  volume   =  103,
  number   =  7,
  pages    = "954--960",
  month    =  sep,
  year     =  2010,
  language = "en"
}

@ARTICLE{Abedin2007-oq,
  title    = "Autophagy delays apoptotic death in breast cancer cells following
              {DNA} damage",
  author   = "Abedin, M J and Wang, D and McDonnell, M A and Lehmann, U and
              Kelekar, A",
  abstract = "Early signaling in camptothecin-treated MCF-7 cells followed an
              intrinsic pathway, but death was delayed and late events
              exhibited few hallmarks of apoptosis. BH3-only proteins, such as
              Noxa, Puma and BimEL, were activated and localized to
              mitochondrial sites within 24 h following drug exposure. However,
              caspase activity was low and death was unaffected by caspase
              inhibition. Transmission electron micrographs showed the presence
              of large vacuoles in drug-treated cells. An autophagic survival
              response has been attributed to MCF-7 cells following nutrient
              starvation or exposure to tamoxifen. Here, we show that autophagy
              also plays an important role in the delayed DNA damage response.
              Confocal microscopy revealed colocalization of mitochondria with
              large autophagic vacuoles and inhibitors of autophagy increased
              mitochondrial depolarization and caspase-9 activity, and
              accelerated cell death. Furthermore, downregulation of autophagy
              proteins, Beclin 1 and Atg7, unmasked a caspase-dependent,
              apoptotic response to DNA damage. We propose that a
              post-mitochondrial caspase cascade is delayed as a result of
              early disposal of damaged mitochondria within autophagosomes. Our
              data also suggest that the use of autophagy as a means of
              delaying apoptosis or prolonging survival may be characteristic
              of noninvasive breast tumor cells. These studies underscore a
              potential role for autophagy inhibitors in combination with
              conventional chemotherapeutic drugs in early breast cancer
              therapy.",
  journal  = "Cell Death Differ.",
  volume   =  14,
  number   =  3,
  pages    = "500--510",
  month    =  mar,
  year     =  2007,
  language = "en"
}

@ARTICLE{Castedo2006-si,
  title    = "Apoptosis regulation in tetraploid cancer cells",
  author   = "Castedo, Maria and Coquelle, Arnaud and Vivet, Sonia and Vitale,
              Ilio and Kauffmann, Audrey and Dessen, Philippe and Pequignot,
              Marie O and Casares, Noelia and Valent, Alexandre and Mouhamad,
              Shahul and Schmitt, Elise and Modjtahedi, Nazanine and
              Vainchenker, William and Zitvogel, Laurence and Lazar, Vladimir
              and Garrido, Carmen and Kroemer, Guido",
  abstract = "Tetraploidy can result in cancer-associated aneuploidy. As shown
              here, freshly generated tetraploid cells arising due to mitotic
              slippage or failed cytokinesis are prone to undergo Bax-dependent
              mitochondrial membrane permeabilization and subsequent apoptosis.
              Knockout of Bax or overexpression of Bcl-2 facilitated the
              survival of tetraploid cells at least as efficiently as the p53
              or p21 knockout. When tetraploid cells were derived from diploid
              p53 and Bax-proficient precursors, such cells exhibited an
              enhanced transcription of p53 target genes. Tetraploid cells
              exhibited an enhanced rate of spontaneous apoptosis that could be
              suppressed by inhibition of p53 or by knockdown of proapoptotic
              p53 target genes such as BBC3/Puma, GADD45A and ferredoxin
              reductase. Unexpectedly, tetraploid cells were more resistant to
              DNA damaging agents (cisplatin, oxaliplatin and camptothecin)
              than their diploid counterparts, and this difference disappeared
              upon inhibition of p53 or knockdown of p53-inducible
              ribonucleotide reductase. Tetraploid cells were also more
              resistant against UVC and gamma-irradiation. These data indicate
              the existence of p53-dependent alterations in apoptosis
              regulation in tetraploid cells.",
  journal  = "EMBO J.",
  volume   =  25,
  number   =  11,
  pages    = "2584--2595",
  month    =  jun,
  year     =  2006,
  language = "en"
}

@ARTICLE{Regoes2007-mf,
  title    = "Mathematical models of cytotoxic T-lymphocyte killing",
  author   = "Regoes, Roland R and Yates, Andrew and Antia, Rustom",
  abstract = "By killing infected host cells, cytotoxic T lymphocytes (CTL)
              mediate an important defense mechanism against viruses and other
              intracellular pathogens. Quantitative aspects of this killing
              process have been studied for several decades in vitro. More
              recently, methods have been developed to measure the timescales
              of CTL killing in vivo. Here, we review the estimates of kinetic
              rates involved in CTL killing which were obtained in these
              studies, and elaborate on the differences between them.",
  journal  = "Immunol. Cell Biol.",
  volume   =  85,
  number   =  4,
  pages    = "274--279",
  month    =  jun,
  year     =  2007,
  language = "en"
}

@ARTICLE{Harasawa2002-td,
  title    = "Chemotherapy targeting methylthioadenosine phosphorylase ({MTAP})
              deficiency in adult {T} cell leukemia ({ATL})",
  author   = "Harasawa, H and Yamada, Y and Kudoh, M and Sugahara, K and Soda,
              H and Hirakata, Y and Sasaki, H and Ikeda, S and Matsuo, T and
              Tomonaga, M and Nobori, T and Kamihira, S",
  abstract = "Methylthioadenosine phosphorylase (MTAP) is an important enzyme
              used for the salvage of adenine and methionine. Cells lacking
              this enzyme are expected to be sensitive to purine synthesis
              inhibitors and/or methionine starvation. We reported previously
              that the MTAP gene is deleted in adult T cell leukemia (ATL)
              cells. In the present study, we expanded our series and used a
              real-time quantitative PCR assay for accurate diagnosis of the
              deletion and nine of 65 primary ATL samples (13.8\%) were MTAP
              negative. In spite of this low incidence, ATL cells showed
              significantly higher sensitivity to L-alanosine, an inhibitor of
              de novo adenosine monophosphate (AMP) synthesis, than normal
              lymphocytes, suggesting that the MTAP gene is inactivated not
              only by deletion but also by other mechanisms. Indeed, a
              real-time quantitative RT-PCR assay disclosed that primary ATL
              cells had significantly lower MTAP mRNA expression than normal
              lymphocytes. Since MTAP-negative ATL cell lines also showed much
              higher sensitivity to L-alanosine than MTAP-positive ATL cell
              lines, we used these cell lines to investigate whether it is
              possible to develop selective therapy targeting MTAP deficiency.
              A substrate of MTAP, methylthioadenosine (MTA) or its substitutes
              rescued concanavalin A (Con A)-activated normal lymphocyte
              proliferation from L-alanosine toxicity. All the compounds except
              5'-deoxyadenosine, however, also caused the undesirable rescue of
              MTAP-negative ATL cell lines. 5'-Deoxyadenosine had the desired
              ability to rescue hematopoietic progenitor cells without rescuing
              ATL cell lines. These results support the rationale for a
              chemotherapy regimen of L-alanosine combined with
              5'-deoxyadenosine rescue in MTAP-deficient ATL.",
  journal  = "Leukemia",
  volume   =  16,
  number   =  9,
  pages    = "1799--1807",
  month    =  sep,
  year     =  2002,
  language = "en"
}

@ARTICLE{Harvat1997-pn,
  title    = "The role of p27Kip1 in gamma interferon-mediated growth arrest of
              mammary epithelial cells and related defects in mammary carcinoma
              cells",
  author   = "Harvat, B L and Seth, P and Jetten, A M",
  abstract = "Interferon gamma (IFNgamma) induces growth arrest in normal human
              mammary epithelial cells by establishing a block during mid-G1
              corresponding to the time when the retinoblastoma protein (Rb)
              would normally be inactivated by hyperphosphorylation. IFNgamma
              inhibits the kinase activities of cdk2, cdk4 and cdk6 within 24 h
              of treatment. Protein levels of the cdks and G1 cyclins do not
              change within this time period, although cdk4 levels are
              significantly reduced by 48 h. IFNgamma treatment induces p27Kip1
              protein levels, presumably by a post-transcriptional mechanism as
              no change was observed in the mRNA levels. In addition,
              IFNgamma-induced inhibition of cdk2 and cyclin E-associated
              kinase activities is accompanied by a 4.5-fold or greater
              increase of p27Kip1 in cdk2 complexes. p27 may also have a role
              in the inhibition of cdk4/6 kinase activities, as p27 protein
              associated with these complexes was increase by 55-70\% after
              IFNgamma. In mammary carcinoma cell lines which are resistant to
              growth inhibition by IFNgamma, p27 levels are not induced by
              IFNgamma nor is cdk2 kinase activity inhibited, despite high
              baseline levels of p27 in cdk2 complexes. However, exogenous
              expression of p27 in these cells induces growth arrest. In
              addition, purified p27 protein added to cdk2 complexes
              immunoprecipitated from carcinoma cells is able to inhibit the
              kinase activity in a dose dependent manner. Our results suggest
              that p27Kip1 has a role in mediating IFNgamma-induced terminal
              growth arrest. Resistance of mammary carcinomas to growth
              inhibition by IFNgamma does not appear to involve resistance of
              cdk2 complexes to the action of p27, but rather an inability to
              appropriately regulate the balance of cdk2, cyclin E and p27
              levels.",
  journal  = "Oncogene",
  volume   =  14,
  number   =  17,
  pages    = "2111--2122",
  month    =  may,
  year     =  1997,
  language = "en"
}

@ARTICLE{Wang2003-ja,
  title    = "{TRAIL} and apoptosis induction by {TNF-family} death receptors",
  author   = "Wang, Shulin and El-Deiry, Wafik S",
  abstract = "Tumor necrosis factor-related apoptosis-inducing ligand or Apo 2
              ligand (TRAIL/Apo2L) is a member of the tumor necrosis factor
              (TNF) family of ligands capable of initiating apoptosis through
              engagement of its death receptors. TRAIL selectively induces
              apoptosis of a variety of tumor cells and transformed cells, but
              not most normal cells, and therefore has garnered intense
              interest as a promising agent for cancer therapy. TRAIL is
              expressed on different cells of the immune system and plays a
              role in both T-cell- and natural killer cell-mediated tumor
              surveillance and suppression of suppressing tumor metastasis.
              Some mismatch-repair-deficient tumors evade TRAIL-induced
              apoptosis and acquire TRAIL resistance through different
              mechanisms. Death receptors, members of the TNF receptor family,
              signal apoptosis independently of the p53 tumor-suppressor gene.
              TRAIL treatment in combination with chemo- or radiotherapy
              enhances TRAIL sensitivity or reverses TRAIL resistance by
              regulating the downstream effectors. Efforts to identify agents
              that activate death receptors or block specific effectors may
              improve therapeutic design. In this review, we summarize recent
              insights into the apoptosis-signaling pathways stimulated by
              TRAIL, present our current understanding of the physiological
              role of this ligand and the potential of its application for
              cancer therapy and prevention.",
  journal  = "Oncogene",
  volume   =  22,
  number   =  53,
  pages    = "8628--8633",
  month    =  nov,
  year     =  2003,
  language = "en"
}

@ARTICLE{Nevanlinna2006-ts,
  title    = "The {CHEK2} gene and inherited breast cancer susceptibility",
  author   = "Nevanlinna, H and Bartek, J",
  abstract = "Checkpoint kinase 2 (CHEK2, Chk2) emerges as an important signal
              transducer of cellular responses to DNA damage and a candidate
              tumor suppressor whose defects contribute to molecular
              pathogenesis of diverse types of human malignancies, both
              sporadic and hereditary. Here, we briefly outline the molecular
              properties, regulation and physiological role of CHEK2, and
              review in more detail its defects that predispose to tumors, with
              particular emphasis on familial breast cancer. The frequency,
              penetrance and epidemiological as well as clinical significance
              of the two most studied breast cancer-predisposing variants of
              the CHEK2 gene, 1100delC and I157T, are highlighted in more
              depth, and additional CHEK2 mutations and their cancer relevance
              are discussed as well. These recent findings are considered also
              from a broader perspective of CHEK2 as the integral component of
              the ataxia telangiectasia-mutated-CHEK2-p53 pathway within the
              genome integrity maintenance system and a barrier against tumor
              progression. Finally, the potential value of information about
              the CHEK2 status in family counseling and optimizition of
              individualized cancer treatment is discussed.",
  journal  = "Oncogene",
  volume   =  25,
  number   =  43,
  pages    = "5912--5919",
  month    =  sep,
  year     =  2006,
  language = "en"
}

@ARTICLE{Hecht2015-ns,
  title    = "Tumor invasion optimization by mesenchymal-amoeboid heterogeneity",
  author   = "Hecht, Inbal and Bar-El, Yasmin and Balmer, Frederic and Natan,
              Sari and Tsarfaty, Ilan and Schweitzer, Frank and Ben-Jacob,
              Eshel",
  abstract = "Metastasizing tumor cells migrate through the surrounding tissue
              and extracellular matrix toward the blood vessels, in order to
              colonize distant organs. They typically move in a dense
              environment, filled with other cells. In this work we study
              cooperative effects between neighboring cells of different types,
              migrating in a maze-like environment with directional cue. Using
              a computerized model, we measure the percentage of cells that
              arrive to the defined target, for different mesenchymal/amoeboid
              ratios. Wall degradation of mesenchymal cells, as well as
              motility of both types of cells, are coupled to metabolic
              energy-like resource level. We find that indirect cooperation
              emerges in mid-level energy, as mesenchymal cells create paths
              that are used by amoeboids. Therefore, we expect to see a small
              population of mesenchymals kept in a mostly-amoeboid population.
              We also study different forms of direct interaction between the
              cells, and show that energy-dependent interaction strength is
              optimal for the migration of both mesenchymals and amoeboids. The
              obtained characteristics of cellular cluster size are in
              agreement with experimental results. We therefore predict that
              hybrid states, e.g. epithelial-mesenchymal, should be utilized as
              a stress-response mechanism.",
  journal  = "Sci. Rep.",
  volume   =  5,
  pages    = "10622",
  month    =  may,
  year     =  2015,
  language = "en"
}

@ARTICLE{Van_Oosten2016-xz,
  title    = "Uncoupling shear and uniaxial elastic moduli of semiflexible
              biopolymer networks: compression-softening and stretch-stiffening",
  author   = "van Oosten, Anne S G and Vahabi, Mahsa and Licup, Albert J and
              Sharma, Abhinav and Galie, Peter A and MacKintosh, Fred C and
              Janmey, Paul A",
  abstract = "Gels formed by semiflexible filaments such as most biopolymers
              exhibit non-linear behavior in their response to shear
              deformation, e.g., with a pronounced strain stiffening and
              negative normal stress. These negative normal stresses suggest
              that networks would collapse axially when subject to shear
              stress. This coupling of axial and shear deformations can have
              particularly important consequences for extracellular matrices
              and collagenous tissues. Although measurements of uniaxial moduli
              have been made on biopolymer gels, these have not directly been
              related to the shear response. Here, we report measurements and
              simulations of axial and shear stresses exerted by a range of
              hydrogels subjected to simultaneous uniaxial and shear strains.
              These studies show that, in contrast to volume-conserving
              linearly elastic hydrogels, the Young's moduli of networks formed
              by the biopolymers are not proportional to their shear moduli and
              both shear and uniaxial moduli are strongly affected by even
              modest degrees of uniaxial strain.",
  journal  = "Sci. Rep.",
  volume   =  6,
  pages    = "19270",
  month    =  jan,
  year     =  2016,
  language = "en"
}

@ARTICLE{Rutledge2016-mj,
  title    = "Selective advantage of trisomic human cells cultured in
              non-standard conditions",
  author   = "Rutledge, Samuel D and Douglas, Temple A and Nicholson, Joshua M
              and Vila-Casades{\'u}s, Maria and Kantzler, Courtney L and
              Wangsa, Darawalee and Barroso-Vilares, Monika and Kale, Shiv D
              and Logarinho, Elsa and Cimini, Daniela",
  abstract = "An abnormal chromosome number, a condition known as aneuploidy,
              is a ubiquitous feature of cancer cells. A number of studies have
              shown that aneuploidy impairs cellular fitness. However, there is
              also evidence that aneuploidy can arise in response to specific
              challenges and can confer a selective advantage under certain
              environmental stresses. Cancer cells are likely exposed to a
              number of challenging conditions arising within the tumor
              microenvironment. To investigate whether aneuploidy may confer a
              selective advantage to cancer cells, we employed a controlled
              experimental system. We used the diploid, colorectal cancer cell
              line DLD1 and two DLD1-derived cell lines carrying
              single-chromosome aneuploidies to assess a number of cancer cell
              properties. Such properties, which included rates of
              proliferation and apoptosis, anchorage-independent growth, and
              invasiveness, were assessed both under standard culture
              conditions and under conditions of stress (i.e., serum
              starvation, drug treatment, hypoxia). Similar experiments were
              performed in diploid vs. aneuploid non-transformed human primary
              cells. Overall, our data show that aneuploidy can confer
              selective advantage to human cells cultured under non-standard
              conditions. These findings indicate that aneuploidy can increase
              the adaptability of cells, even those, such as cancer cells, that
              are already characterized by increased proliferative capacity and
              aggressive tumorigenic phenotypes.",
  journal  = "Sci. Rep.",
  volume   =  6,
  pages    = "22828",
  month    =  mar,
  year     =  2016,
  language = "en"
}

@ARTICLE{Vergara2016-tw,
  title    = "Artificial Autopolyploidization Modifies the Tricarboxylic Acid
              Cycle and {GABA} Shunt in Arabidopsis thaliana Col-0",
  author   = "Vergara, Fredd and Kikuchi, Jun and Breuer, Christian",
  abstract = "Autopolyploidy is a process whereby the chromosome set is
              multiplied and it is a common phenomenon in angiosperms.
              Autopolyploidy is thought to be an important evolutionary force
              that has led to the formation of new plant species. Despite its
              relevance, the consequences of autopolyploidy in plant metabolism
              are poorly understood. This study compares the metabolic profiles
              of natural diploids and artificial autotetraploids of Arabidopsis
              thaliana Col-0. Different physiological parameters are compared
              between diploids and autotetraploids using nuclear magnetic
              resonance (NMR), elemental analysis (carbon:nitrogen balance) and
              quantitative real-time PCR (qRT-PCR). The main difference between
              diploid and autotetraploid A. thaliana Col-0 is observed in the
              concentration of metabolites related to the tricarboxylic acid
              cycle (TCA) and $\gamma$-amino butyric acid (GABA) shunt, as
              shown by multivariate statistical analysis of NMR spectra.
              qRT-PCR shows that genes related to the TCA and GABA shunt are
              also differentially expressed between diploids and
              autotetraploids following similar trends as their corresponding
              metabolites. Solid evidence is presented to demonstrate that
              autopolyploidy influences core plant metabolic processes.",
  journal  = "Sci. Rep.",
  volume   =  6,
  pages    = "26515",
  month    =  may,
  year     =  2016,
  language = "en"
}

@ARTICLE{Nguyen2016-jc,
  title    = "Na{\"\i}ve {CD8(+}) {T} cell derived tumor-specific cytotoxic
              effectors as a potential remedy for overcoming {TGF-$\beta$}
              immunosuppression in the tumor microenvironment",
  author   = "Nguyen, Hong Hanh and Kim, Therasa and Song, Sang Yun and Park,
              Somang and Cho, Hyang Hee and Jung, Sung-Hoon and Ahn, Jae-Sook
              and Kim, Hyeoung-Joon and Lee, Je-Jung and Kim, Hee-Ok and Cho,
              Jae-Ho and Yang, Deok-Hwan",
  abstract = "Despite of the potential implications for cancer immunotherapy,
              conventional approaches using in vitro expanded CD8(+) T cells
              have suboptimal outcomes, mostly due to loss of functionality
              from cellular exhaustion. We therefore investigated the
              phenotypic and functional differences among in vitro activated
              CD8(+) T cells of three different sources, namely na{\"\i}ve
              (NTeff), memory (MTeff) and tumor-infiltrating lymphocytes
              (TILeff) from human and mice, to better understand mechanisms
              behind potent effector functions and potential for overcoming
              current limitations. In line with the greater proliferation
              activity and longer telomere lengths of NTeff populations, cells
              of na{\"\i}ve origin exhibited significantly less amounts of T
              cell exhaustion markers than those of MTeff and TILeff, and
              moreover, acquired distinct expression patterns of
              memory-promoting transcription factors, T-bet and Eomes, induced
              in a rapid and sustainable manner. NTeff cells appeared to have
              lower expression of Foxp1 and were refractory to apoptosis upon
              TGF-$\beta$ conditioning, implying better survival potential and
              resistance to tumor-induced immune suppression. Of CD8(+) T cell
              pools activated to tumor-specific CTLs, na{\"\i}ve cell generated
              effectors possessed the most potent cytotoxic activity,
              validating implications for use in rational design of adoptive
              immunotherapy.",
  journal  = "Sci. Rep.",
  volume   =  6,
  pages    = "28208",
  month    =  jun,
  year     =  2016,
  language = "en"
}

@ARTICLE{Enderling2015-dm,
  title    = "Cancer stem cells: small subpopulation or evolving fraction?",
  author   = "Enderling, Heiko",
  abstract = "Central to the debate about cancer stem cells in solid tumors is
              the proportion of cells that can initiate, propagate, and
              re-initiate tumors. An initially assumed minor subpopulation is
              confronted with recent data suggesting as many as 30\% of primary
              tumor cells have stem cell characteristics. This review discusses
              quantitative modeling studies that augment our understanding of
              stem and non-stem cancer cell interactions during tumor
              progression and the resulting fraction of cancer stem cells. A
              discussion of how these findings can be carefully evaluated in
              novel, integrated interdisciplinary studies is offered.",
  journal  = "Integr. Biol.",
  volume   =  7,
  number   =  1,
  pages    = "14--23",
  month    =  jan,
  year     =  2015,
  language = "en"
}

@ARTICLE{Emmert2016-vv,
  title    = "Challenges in tissue engineering - towards cell control inside
              artificial scaffolds",
  author   = "Emmert, M and Witzel, P and Heinrich, D",
  abstract = "Control of living cells is vital for the survival of organisms.
              Each cell inside an organism is exposed to diverse external
              mechano-chemical cues, all coordinated in a spatio-temporal
              pattern triggering individual cell functions. This complex
              interplay between external chemical cues and mechanical 3D
              environments is translated into intracellular signaling loops.
              Here, we describe how external mechano-chemical cues control cell
              functions, especially cell migration, and influence intracellular
              information transport. In particular, this work focuses on the
              quantitative analysis of (1) intracellular vesicle transport to
              understand intracellular state changes in response to external
              cues, (2) cellular sensing of external chemotactic cues, and (3)
              the cells' ability to migrate in 3D structured environments,
              artificially fabricated to mimic the 3D environment of tissue in
              the human body.",
  journal  = "Soft Matter",
  volume   =  12,
  number   =  19,
  pages    = "4287--4294",
  month    =  may,
  year     =  2016,
  language = "en"
}

@ARTICLE{Polakis1966-tv,
  title    = "Changes in dry weight, protein, deoxyribonucleic acid,
              ribonucleic acid and reserve and structural carbohydrate during
              the aerobic growth cycle of yeast",
  author   = "Polakis, E S and Bartley, W",
  abstract = "1. Changes in dry weight, DNA, RNA, protein and reserve and
              structural carbohydrate were measured during the aerobic growth
              of yeast on 0.9\% glucose in an aerobic synthetic medium. 2.
              After glucose had been consumed and during the growth of yeast on
              ethanol and acetate, the rate of formation of DNA remained about
              the same but the rate of increase of dry weight was greatly
              diminished. 3. During the second stage of growth the ratios dry
              weight/DNA, protein/DNA, RNA/DNA and carbohydrate/DNA decreased
              to about 30\% of the corresponding values during the first stage
              of growth. 4. A higher fraction of the dry weight of the yeast
              cells could be accounted for by the reserve carbohydrate content
              of the cells during the second stage of growth. 5. By the end of
              the first stage of growth an increase in the reserve carbohydrate
              content of the cells was observed. Part of this reserve
              carbohydrate was consumed by the cells in the beginning of the
              second stage of growth. The possibility of adaptation of cells at
              the expense of their reserves is discussed.",
  journal  = "Biochem. J",
  volume   =  98,
  number   =  3,
  pages    = "883--887",
  month    =  mar,
  year     =  1966,
  language = "en"
}

@ARTICLE{Buttgereit1995-zj,
  title    = "A hierarchy of {ATP-consuming} processes in mammalian cells",
  author   = "Buttgereit, F and Brand, M D",
  abstract = "The rates of different ATP-consuming reactions were measured in
              concanavalin A-stimulated thymocytes, a model system in which
              more than 80\% of the ATP consumption can be accounted for. There
              was a clear hierarchy of the responses of different
              energy-consuming reactions to changes in energy supply: pathways
              of macromolecule biosynthesis (protein synthesis and RNA/DNA
              synthesis) were most sensitive to energy supply, followed by
              sodium cycling and then calcium cycling across the plasma
              membrane. Mitochondrial proton leak was the least sensitive to
              energy supply. Control analysis was used to quantify the relative
              control over ATP production exerted by the individual groups of
              ATP-consuming reactions. Control was widely shared; no block of
              reactions had more than one-third of the control. A fuller
              control analysis showed that there appeared to be a hierarchy of
              control over the flux through ATP: protein synthesis > RNA/DNA
              synthesis and substrate oxidation > Na+ cycling and Ca2+ cycling
              > other ATP consumers and mitochondrial proton leak. Control
              analysis also indicated that there was significant control over
              the rates of individual ATP consumers by energy supply. Each ATP
              consumer had strong control over its own rate but very little
              control over the rates of the other ATP consumers.",
  journal  = "Biochem. J",
  volume   = "312 ( Pt 1)",
  pages    = "163--167",
  month    =  nov,
  year     =  1995,
  language = "en"
}

@ARTICLE{Wieser2001-ch,
  title     = "Hierarchies of {ATP-consuming} processes: direct compared with
               indirect measurements, and comparative aspects",
  author    = "Wieser, Wolfgang and Krumschnabel, Gerhard",
  journal   = "Biochem. J",
  publisher = "Portland Press",
  volume    =  355,
  number    =  2,
  pages     = "389--395",
  month     =  apr,
  year      =  2001
}

@ARTICLE{Pappalardo2012-hj,
  title     = "Mathematical and Computational Models in Tumor Immunology",
  author    = "Pappalardo, F and Palladini, A and Pennisi, M and Castiglione, F
               and Motta, S",
  abstract  = "The immune system is able to protect the host from tumor onset,
               and immune deficiencies are accompanied by an increased risk of
               cancer. Immunology is one of the fields in biology where the
               role of computational and mathematical modeling and analysis
               were recognized the earliest, beginning from 60s of the last
               century. We introduce the two most common methods in simulating
               the competition among the immune system, cancers and tumor
               immunology strategies: differential equations and rule-based
               models. Several specific implementations are presented,
               describing in details how they work and how they advance or
               contribute the field of tumor immunology.",
  journal   = "Math. Model. Nat. Phenom.",
  publisher = "EDP Sciences",
  volume    =  7,
  number    =  3,
  pages     = "186--203",
  year      =  2012,
  keywords  = "cancers; tumor immunology; agent based models; mathematical
               modeling; vaccines",
  language  = "en"
}

@ARTICLE{Santillan2008-rm,
  title     = "On the Use of the Hill Functions in Mathematical Models of Gene
               Regulatory Networks",
  author    = "Santill{\'a}n, M",
  abstract  = "Hill functions follow from the equilibrium state of the reaction
               in which n ligands simultaneously bind a single receptor. This
               result if often employed to interpret the Hill coefficient as
               the number of ligand binding sites in all kinds of reaction
               schemes. Here, we study the equilibrium states of the reactions
               in which n ligand bind a receptor sequentially, both
               non-cooperatively and in a cooperative fashion. The main
               outcomes of such analysis are that: n is not a good estimate,
               but only an upper bound, for the Hill coefficient; while the
               Hill coefficient depends quite strongly on the cooperativity
               level among ligands. We finally use these results to discuss the
               feasibility and constrains of using Hill functions to model the
               regulatory functions in mathematical models of gene regulatory
               networks.",
  journal   = "Math. Model. Nat. Phenom.",
  publisher = "EDP Sciences",
  volume    =  3,
  number    =  2,
  pages     = "85--97",
  year      =  2008,
  keywords  = "systems biology; molecular biology; cooperativity; Hill
               coefficient",
  language  = "en"
}

@ARTICLE{Zhang2003-ju,
  title    = "Intratumoral {T} cells, recurrence, and survival in epithelial
              ovarian cancer",
  author   = "Zhang, Lin and Conejo-Garcia, Jose R and Katsaros, Dionyssios and
              Gimotty, Phyllis A and Massobrio, Marco and Regnani, Giorgia and
              Makrigiannakis, Antonis and Gray, Heidi and Schlienger, Katia and
              Liebman, Michael N and Rubin, Stephen C and Coukos, George",
  abstract = "BACKGROUND: Although tumor-infiltrating T cells have been
              documented in ovarian carcinoma, a clear association with
              clinical outcome has not been established. METHODS: We performed
              immunohistochemical analysis of 186 frozen specimens from
              advanced-stage ovarian carcinomas to assess the distribution of
              tumor-infiltrating T cells and conducted outcome analyses.
              Molecular analyses were performed in some tumors by real-time
              polymerase chain reaction. RESULTS: CD3+ tumor-infiltrating T
              cells were detected within tumor-cell islets (intratumoral T
              cells) in 102 of the 186 tumors (54.8 percent); they were
              undetectable in 72 tumors (38.7 percent); the remaining 12 tumors
              (6.5 percent) could not be evaluated. There were significant
              differences in the distributions of progression-free survival and
              overall survival according to the presence or absence of
              intratumoral T cells (P<0.001 for both comparisons). The
              five-year overall survival rate was 38.0 percent among patients
              whose tumors contained T cells and 4.5 percent among patients
              whose tumors contained no T cells in islets. Significant
              differences in the distributions of progression-free survival and
              overall survival according to the presence or absence of
              intratumoral T cells (P<0.001 for both comparisons) were also
              seen among 74 patients with a complete clinical response after
              debulking and platinum-based chemotherapy: the five-year overall
              survival rate was 73.9 percent among patients whose tumors
              contained T cells and 11.9 percent among patients whose tumors
              contained no T cells in islets. The presence of intratumoral T
              cells independently correlated with delayed recurrence or delayed
              death in multivariate analysis and was associated with increased
              expression of interferon-gamma, interleukin-2, and
              lymphocyte-attracting chemokines within the tumor. The absence of
              intratumoral T cells was associated with increased levels of
              vascular endothelial growth factor. CONCLUSIONS: The presence of
              intratumoral T cells correlates with improved clinical outcome in
              advanced ovarian carcinoma.",
  journal  = "N. Engl. J. Med.",
  volume   =  348,
  number   =  3,
  pages    = "203--213",
  month    =  jan,
  year     =  2003,
  language = "en"
}

@ARTICLE{Hodi2010-zp,
  title    = "Improved survival with ipilimumab in patients with metastatic
              melanoma",
  author   = "Hodi, F Stephen and O'Day, Steven J and McDermott, David F and
              Weber, Robert W and Sosman, Jeffrey A and Haanen, John B and
              Gonzalez, Rene and Robert, Caroline and Schadendorf, Dirk and
              Hassel, Jessica C and Akerley, Wallace and van den Eertwegh,
              Alfons J M and Lutzky, Jose and Lorigan, Paul and Vaubel, Julia M
              and Linette, Gerald P and Hogg, David and Ottensmeier, Christian
              H and Lebb{\'e}, Celeste and Peschel, Christian and Quirt, Ian
              and Clark, Joseph I and Wolchok, Jedd D and Weber, Jeffrey S and
              Tian, Jason and Yellin, Michael J and Nichol, Geoffrey M and
              Hoos, Axel and Urba, Walter J",
  abstract = "BACKGROUND: An improvement in overall survival among patients
              with metastatic melanoma has been an elusive goal. In this phase
              3 study, ipilimumab--which blocks cytotoxic
              T-lymphocyte-associated antigen 4 to potentiate an antitumor
              T-cell response--administered with or without a glycoprotein 100
              (gp100) peptide vaccine was compared with gp100 alone in patients
              with previously treated metastatic melanoma. METHODS: A total of
              676 HLA-A*0201-positive patients with unresectable stage III or
              IV melanoma, whose disease had progressed while they were
              receiving therapy for metastatic disease, were randomly assigned,
              in a 3:1:1 ratio, to receive ipilimumab plus gp100 (403
              patients), ipilimumab alone (137), or gp100 alone (136).
              Ipilimumab, at a dose of 3 mg per kilogram of body weight, was
              administered with or without gp100 every 3 weeks for up to four
              treatments (induction). Eligible patients could receive
              reinduction therapy. The primary end point was overall survival.
              RESULTS: The median overall survival was 10.0 months among
              patients receiving ipilimumab plus gp100, as compared with 6.4
              months among patients receiving gp100 alone (hazard ratio for
              death, 0.68; P<0.001). The median overall survival with
              ipilimumab alone was 10.1 months (hazard ratio for death in the
              comparison with gp100 alone, 0.66; P=0.003). No difference in
              overall survival was detected between the ipilimumab groups
              (hazard ratio with ipilimumab plus gp100, 1.04; P=0.76). Grade 3
              or 4 immune-related adverse events occurred in 10 to 15\% of
              patients treated with ipilimumab and in 3\% treated with gp100
              alone. There were 14 deaths related to the study drugs (2.1\%),
              and 7 were associated with immune-related adverse events.
              CONCLUSIONS: Ipilimumab, with or without a gp100 peptide vaccine,
              as compared with gp100 alone, improved overall survival in
              patients with previously treated metastatic melanoma. Adverse
              events can be severe, long-lasting, or both, but most are
              reversible with appropriate treatment. (Funded by Medarex and
              Bristol-Myers Squibb; ClinicalTrials.gov number, NCT00094653.)",
  journal  = "N. Engl. J. Med.",
  volume   =  363,
  number   =  8,
  pages    = "711--723",
  month    =  aug,
  year     =  2010,
  language = "en"
}

@ARTICLE{Robert2011-jx,
  title    = "Ipilimumab plus dacarbazine for previously untreated metastatic
              melanoma",
  author   = "Robert, Caroline and Thomas, Luc and Bondarenko, Igor and O'Day,
              Steven and Weber, Jeffrey and Garbe, Claus and Lebbe, Celeste and
              Baurain, Jean-Fran{\c c}ois and Testori, Alessandro and Grob,
              Jean-Jacques and Davidson, Neville and Richards, Jon and Maio,
              Michele and Hauschild, Axel and Miller, Jr, Wilson H and Gascon,
              Pere and Lotem, Michal and Harmankaya, Kaan and Ibrahim, Ramy and
              Francis, Stephen and Chen, Tai-Tsang and Humphrey, Rachel and
              Hoos, Axel and Wolchok, Jedd D",
  abstract = "BACKGROUND: Ipilimumab monotherapy (at a dose of 3 mg per
              kilogram of body weight), as compared with glycoprotein 100,
              improved overall survival in a phase 3 study involving patients
              with previously treated metastatic melanoma. We conducted a phase
              3 study of ipilimumab (10 mg per kilogram) plus dacarbazine in
              patients with previously untreated metastatic melanoma. METHODS:
              We randomly assigned 502 patients with previously untreated
              metastatic melanoma, in a 1:1 ratio, to ipilimumab (10 mg per
              kilogram) plus dacarbazine (850 mg per square meter of
              body-surface area) or dacarbazine (850 mg per square meter) plus
              placebo, given at weeks 1, 4, 7, and 10, followed by dacarbazine
              alone every 3 weeks through week 22. Patients with stable disease
              or an objective response and no dose-limiting toxic effects
              received ipilimumab or placebo every 12 weeks thereafter as
              maintenance therapy. The primary end point was overall survival.
              RESULTS: Overall survival was significantly longer in the group
              receiving ipilimumab plus dacarbazine than in the group receiving
              dacarbazine plus placebo (11.2 months vs. 9.1 months, with higher
              survival rates in the ipilimumab-dacarbazine group at 1 year
              (47.3\% vs. 36.3\%), 2 years (28.5\% vs. 17.9\%), and 3 years
              (20.8\% vs. 12.2\%) (hazard ratio for death, 0.72; P<0.001).
              Grade 3 or 4 adverse events occurred in 56.3\% of patients
              treated with ipilimumab plus dacarbazine, as compared with 27.5\%
              treated with dacarbazine and placebo (P<0.001). No drug-related
              deaths or gastrointestinal perforations occurred in the
              ipilimumab-dacarbazine group. CONCLUSIONS: Ipilimumab (at a dose
              of 10 mg per kilogram) in combination with dacarbazine, as
              compared with dacarbazine plus placebo, improved overall survival
              in patients with previously untreated metastatic melanoma. The
              types of adverse events were consistent with those seen in prior
              studies of ipilimumab; however, the rates of elevated
              liver-function values were higher and the rates of
              gastrointestinal events were lower than expected on the basis of
              prior studies. (Funded by Bristol-Myers Squibb;
              ClinicalTrials.gov number, NCT00324155.).",
  journal  = "N. Engl. J. Med.",
  volume   =  364,
  number   =  26,
  pages    = "2517--2526",
  month    =  jun,
  year     =  2011,
  language = "en"
}

@ARTICLE{Larkin2015-jd,
  title    = "Combined Nivolumab and Ipilimumab or Monotherapy in Untreated
              Melanoma",
  author   = "Larkin, James and Chiarion-Sileni, Vanna and Gonzalez, Rene and
              Grob, Jean Jacques and Cowey, C Lance and Lao, Christopher D and
              Schadendorf, Dirk and Dummer, Reinhard and Smylie, Michael and
              Rutkowski, Piotr and Ferrucci, Pier F and Hill, Andrew and
              Wagstaff, John and Carlino, Matteo S and Haanen, John B and Maio,
              Michele and Marquez-Rodas, Ivan and McArthur, Grant A and
              Ascierto, Paolo A and Long, Georgina V and Callahan, Margaret K
              and Postow, Michael A and Grossmann, Kenneth and Sznol, Mario and
              Dreno, Brigitte and Bastholt, Lars and Yang, Arvin and Rollin,
              Linda M and Horak, Christine and Hodi, F Stephen and Wolchok,
              Jedd D",
  abstract = "BACKGROUND: Nivolumab (a programmed death 1 [PD-1] checkpoint
              inhibitor) and ipilimumab (a cytotoxic T-lymphocyte-associated
              antigen 4 [CTLA-4] checkpoint inhibitor) have been shown to have
              complementary activity in metastatic melanoma. In this
              randomized, double-blind, phase 3 study, nivolumab alone or
              nivolumab plus ipilimumab was compared with ipilimumab alone in
              patients with metastatic melanoma. METHODS: We assigned, in a
              1:1:1 ratio, 945 previously untreated patients with unresectable
              stage III or IV melanoma to nivolumab alone, nivolumab plus
              ipilimumab, or ipilimumab alone. Progression-free survival and
              overall survival were coprimary end points. Results regarding
              progression-free survival are presented here. RESULTS: The median
              progression-free survival was 11.5 months (95\% confidence
              interval [CI], 8.9 to 16.7) with nivolumab plus ipilimumab, as
              compared with 2.9 months (95\% CI, 2.8 to 3.4) with ipilimumab
              (hazard ratio for death or disease progression, 0.42; 99.5\% CI,
              0.31 to 0.57; P<0.001), and 6.9 months (95\% CI, 4.3 to 9.5) with
              nivolumab (hazard ratio for the comparison with ipilimumab, 0.57;
              99.5\% CI, 0.43 to 0.76; P<0.001). In patients with tumors
              positive for the PD-1 ligand (PD-L1), the median progression-free
              survival was 14.0 months in the nivolumab-plus-ipilimumab group
              and in the nivolumab group, but in patients with PD-L1-negative
              tumors, progression-free survival was longer with the combination
              therapy than with nivolumab alone (11.2 months [95\% CI, 8.0 to
              not reached] vs. 5.3 months [95\% CI, 2.8 to 7.1]).
              Treatment-related adverse events of grade 3 or 4 occurred in
              16.3\% of the patients in the nivolumab group, 55.0\% of those in
              the nivolumab-plus-ipilimumab group, and 27.3\% of those in the
              ipilimumab group. CONCLUSIONS: Among previously untreated
              patients with metastatic melanoma, nivolumab alone or combined
              with ipilimumab resulted in significantly longer progression-free
              survival than ipilimumab alone. In patients with PD-L1-negative
              tumors, the combination of PD-1 and CTLA-4 blockade was more
              effective than either agent alone. (Funded by Bristol-Myers
              Squibb; CheckMate 067 ClinicalTrials.gov number, NCT01844505.).",
  journal  = "N. Engl. J. Med.",
  volume   =  373,
  number   =  1,
  pages    = "23--34",
  month    =  jul,
  year     =  2015,
  language = "en"
}

@ARTICLE{Wolchok2017-an,
  title    = "Overall Survival with Combined Nivolumab and Ipilimumab in
              Advanced Melanoma",
  author   = "Wolchok, Jedd D and Chiarion-Sileni, Vanna and Gonzalez, Rene and
              Rutkowski, Piotr and Grob, Jean-Jacques and Cowey, C Lance and
              Lao, Christopher D and Wagstaff, John and Schadendorf, Dirk and
              Ferrucci, Pier F and Smylie, Michael and Dummer, Reinhard and
              Hill, Andrew and Hogg, David and Haanen, John and Carlino, Matteo
              S and Bechter, Oliver and Maio, Michele and Marquez-Rodas, Ivan
              and Guidoboni, Massimo and McArthur, Grant and Lebb{\'e}, Celeste
              and Ascierto, Paolo A and Long, Georgina V and Cebon, Jonathan
              and Sosman, Jeffrey and Postow, Michael A and Callahan, Margaret
              K and Walker, Dana and Rollin, Linda and Bhore, Rafia and Hodi, F
              Stephen and Larkin, James",
  abstract = "BACKGROUND: Nivolumab combined with ipilimumab resulted in longer
              progression-free survival and a higher objective response rate
              than ipilimumab alone in a phase 3 trial involving patients with
              advanced melanoma. We now report 3-year overall survival outcomes
              in this trial. METHODS: We randomly assigned, in a 1:1:1 ratio,
              patients with previously untreated advanced melanoma to receive
              nivolumab at a dose of 1 mg per kilogram of body weight plus
              ipilimumab at a dose of 3 mg per kilogram every 3 weeks for four
              doses, followed by nivolumab at a dose of 3 mg per kilogram every
              2 weeks; nivolumab at a dose of 3 mg per kilogram every 2 weeks
              plus placebo; or ipilimumab at a dose of 3 mg per kilogram every
              3 weeks for four doses plus placebo, until progression, the
              occurrence of unacceptable toxic effects, or withdrawal of
              consent. Randomization was stratified according to programmed
              death ligand 1 (PD-L1) status, BRAF mutation status, and
              metastasis stage. The two primary end points were
              progression-free survival and overall survival in the
              nivolumab-plus-ipilimumab group and in the nivolumab group versus
              the ipilimumab group. RESULTS: At a minimum follow-up of 36
              months, the median overall survival had not been reached in the
              nivolumab-plus-ipilimumab group and was 37.6 months in the
              nivolumab group, as compared with 19.9 months in the ipilimumab
              group (hazard ratio for death with nivolumab plus ipilimumab vs.
              ipilimumab, 0.55 [P<0.001]; hazard ratio for death with nivolumab
              vs. ipilimumab, 0.65 [P<0.001]). The overall survival rate at 3
              years was 58\% in the nivolumab-plus-ipilimumab group and 52\% in
              the nivolumab group, as compared with 34\% in the ipilimumab
              group. The safety profile was unchanged from the initial report.
              Treatment-related adverse events of grade 3 or 4 occurred in 59\%
              of the patients in the nivolumab-plus-ipilimumab group, in 21\%
              of those in the nivolumab group, and in 28\% of those in the
              ipilimumab group. CONCLUSIONS: Among patients with advanced
              melanoma, significantly longer overall survival occurred with
              combination therapy with nivolumab plus ipilimumab or with
              nivolumab alone than with ipilimumab alone. (Funded by
              Bristol-Myers Squibb and others; CheckMate 067 ClinicalTrials.gov
              number, NCT01844505 .).",
  journal  = "N. Engl. J. Med.",
  volume   =  377,
  number   =  14,
  pages    = "1345--1356",
  month    =  oct,
  year     =  2017,
  language = "en"
}

@ARTICLE{Schuster2019-ui,
  title    = "Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large
              {B-Cell} Lymphoma",
  author   = "Schuster, Stephen J and Bishop, Michael R and Tam, Constantine S
              and Waller, Edmund K and Borchmann, Peter and McGuirk, Joseph P
              and J{\"a}ger, Ulrich and Jaglowski, Samantha and Andreadis,
              Charalambos and Westin, Jason R and Fleury, Isabelle and
              Bachanova, Veronika and Foley, S Ronan and Ho, P Joy and Mielke,
              Stephan and Magenau, John M and Holte, Harald and Pantano,
              Serafino and Pacaud, Lida B and Awasthi, Rakesh and Chu, Jufen
              and Anak, {\"O}zlem and Salles, Gilles and Maziarz, Richard T and
              {JULIET Investigators}",
  abstract = "BACKGROUND: Patients with diffuse large B-cell lymphoma that is
              refractory to primary and second-line therapies or that has
              relapsed after stem-cell transplantation have a poor prognosis.
              The chimeric antigen receptor (CAR) T-cell therapy
              tisagenlecleucel targets and eliminates CD19-expressing B cells
              and showed efficacy against B-cell lymphomas in a single-center,
              phase 2a study. METHODS: We conducted an international, phase 2,
              pivotal study of centrally manufactured tisagenlecleucel
              involving adult patients with relapsed or refractory diffuse
              large B-cell lymphoma who were ineligible for or had disease
              progression after autologous hematopoietic stem-cell
              transplantation. The primary end point was the best overall
              response rate (i.e., the percentage of patients who had a
              complete or partial response), as judged by an independent review
              committee. RESULTS: A total of 93 patients received an infusion
              and were included in the evaluation of efficacy. The median time
              from infusion to data cutoff was 14 months (range, 0.1 to 26).
              The best overall response rate was 52\% (95\% confidence
              interval, 41 to 62); 40\% of the patients had complete responses,
              and 12\% had partial responses. Response rates were consistent
              across prognostic subgroups. At 12 months after the initial
              response, the rate of relapse-free survival was estimated to be
              65\% (79\% among patients with a complete response). The most
              common grade 3 or 4 adverse events of special interest included
              cytokine release syndrome (22\%), neurologic events (12\%),
              cytopenias lasting more than 28 days (32\%), infections (20\%),
              and febrile neutropenia (14\%). Three patients died from disease
              progression within 30 days after infusion. No deaths were
              attributed to tisagenlecleucel, cytokine release syndrome, or
              cerebral edema. No differences between response groups in tumor
              expression of CD19 or immune checkpoint-related proteins were
              found. CONCLUSIONS: In this international study of CAR T-cell
              therapy in relapsed or refractory diffuse large B-cell lymphoma
              in adults, high rates of durable responses were produced with the
              use of tisagenlecleucel. (Funded by Novartis; JULIET
              ClinicalTrials.gov number, NCT02445248 .).",
  journal  = "N. Engl. J. Med.",
  volume   =  380,
  number   =  1,
  pages    = "45--56",
  month    =  jan,
  year     =  2019,
  language = "en"
}

@ARTICLE{Larkin2019-fe,
  title    = "{Five-Year} Survival with Combined Nivolumab and Ipilimumab in
              Advanced Melanoma",
  author   = "Larkin, James and Chiarion-Sileni, Vanna and Gonzalez, Rene and
              Grob, Jean-Jacques and Rutkowski, Piotr and Lao, Christopher D
              and Cowey, C Lance and Schadendorf, Dirk and Wagstaff, John and
              Dummer, Reinhard and Ferrucci, Pier F and Smylie, Michael and
              Hogg, David and Hill, Andrew and M{\'a}rquez-Rodas, Ivan and
              Haanen, John and Guidoboni, Massimo and Maio, Michele and
              Sch{\"o}ffski, Patrick and Carlino, Matteo S and Lebb{\'e},
              C{\'e}leste and McArthur, Grant and Ascierto, Paolo A and
              Daniels, Gregory A and Long, Georgina V and Bastholt, Lars and
              Rizzo, Jasmine I and Balogh, Agnes and Moshyk, Andriy and Hodi, F
              Stephen and Wolchok, Jedd D",
  abstract = "BACKGROUND: Nivolumab plus ipilimumab or nivolumab alone resulted
              in longer progression-free and overall survival than ipilimumab
              alone in a trial involving patients with advanced melanoma. We
              now report 5-year outcomes in the trial. METHODS: We randomly
              assigned patients with previously untreated advanced melanoma to
              receive one of the following regimens: nivolumab (at a dose of 1
              mg per kilogram of body weight) plus ipilimumab (3 mg per
              kilogram) every 3 weeks for four doses, followed by nivolumab (3
              mg per kilogram every 2 weeks); nivolumab (3 mg per kilogram
              every 2 weeks) plus ipilimumab-matched placebo; or ipilimumab (3
              mg per kilogram every 3 weeks for four doses) plus
              nivolumab-matched placebo. The two primary end points were
              progression-free survival and overall survival in the
              nivolumab-plus-ipilimumab group and in the nivolumab group, as
              compared with the ipilimumab group. RESULTS: At a minimum
              follow-up of 60 months, the median overall survival was more than
              60.0 months (median not reached) in the nivolumab-plus-ipilimumab
              group and 36.9 months in the nivolumab group, as compared with
              19.9 months in the ipilimumab group (hazard ratio for death with
              nivolumab plus ipilimumab vs. ipilimumab, 0.52; hazard ratio for
              death with nivolumab vs. ipilimumab, 0.63). Overall survival at 5
              years was 52\% in the nivolumab-plus-ipilimumab group and 44\% in
              the nivolumab group, as compared with 26\% in the ipilimumab
              group. No sustained deterioration of health-related quality of
              life was observed during or after treatment with nivolumab plus
              ipilimumab or with nivolumab alone. No new late toxic effects
              were noted. CONCLUSIONS: Among patients with advanced melanoma,
              sustained long-term overall survival at 5 years was observed in a
              greater percentage of patients who received nivolumab plus
              ipilimumab or nivolumab alone than in those who received
              ipilimumab alone, with no apparent loss of quality of life in the
              patients who received regimens containing nivolumab. (Funded by
              Bristol-Myers Squibb and others; CheckMate 067 ClinicalTrials.gov
              number, NCT01844505.).",
  journal  = "N. Engl. J. Med.",
  volume   =  381,
  number   =  16,
  pages    = "1535--1546",
  month    =  oct,
  year     =  2019,
  language = "en"
}

% The entry below contains non-ASCII chars that could not be converted
% to a LaTeX equivalent.
@ARTICLE{Nicolai1995-hm,
  title     = "Particle velocity fluctuations and hydrodynamic selfdiffusion
               of sedimenting nonBrownian spheres",
  author    = "Nicolai, H and Herzhaft, B and Hinch, E J and Oger, L and
               Guazzelli, E",
  abstract  = "The motion of non?Brownian spheres settling in the midst of a
               suspension of like spheres has been experimentally studied under
               creeping flow conditions. A few glass spheres, marked with a
               thin coating of silver, were tracked in a suspension of unmarked
               glass spheres, made optically transparent by matching the index
               of refraction of the suspending fluid to that of the glass
               spheres. Particles were tracked with a real time digital imaging
               processing system. Particle trajectories were examined in the
               bulk region of the suspension for particle volume fractions
               ranging from 0\% to 40\% in 5\% steps. Statistical analyses of
               local particle velocities yield the mean settling velocity, the
               RMS of the fluctuations of the vertical and horizontal particle
               velocity and the particle velocity autocorrelation functions.
               The long time fluctuating particle motion is demonstrated to be
               diffusive in nature. Vertical and horizontal correlation times
               and self?diffusivities are found as a function of particle
               volume fraction, and a strongly anisotropic diffusion noted.",
  journal   = "Phys. Fluids",
  publisher = "American Institute of Physics",
  volume    =  7,
  number    =  1,
  pages     = "12--23",
  month     =  jan,
  year      =  1995
}

@ARTICLE{Regoes2007-mf,
  title    = "Estimation of the rate of killing by cytotoxic {T} lymphocytes in
              vivo",
  author   = "Regoes, Roland R and Barber, Daniel L and Ahmed, Rafi and Antia,
              Rustom",
  abstract = "Cytotoxic T lymphocytes (CTL) help control virus infections by
              killing virus-infected (target) cells. How fast do CTL find and
              kill target cells in vivo? Experiments allow us to follow
              populations of labeled target cells after their transfer into
              immune mice where they are killed by CTL. Here, we develop models
              of the migration and killing processes involved in these
              experiments and use them to quantitatively analyze the in vivo
              killing data. These models allow us to estimate the rate constant
              for killing of target cells by CTL.",
  journal  = "Proc. Natl. Acad. Sci. U. S. A.",
  volume   =  104,
  number   =  5,
  pages    = "1599--1603",
  month    =  jan,
  year     =  2007,
  language = "en"
}

@ARTICLE{Wiedemann2006-by,
  title    = "Cytotoxic {T} lymphocytes kill multiple targets simultaneously
              via spatiotemporal uncoupling of lytic and stimulatory synapses",
  author   = "Wiedemann, Aurelie and Depoil, David and Faroudi, Mustapha and
              Valitutti, Salvatore",
  abstract = "A longstanding paradox in the activation of cytotoxic T
              lymphocytes (CTL) arises from the observation that CTL recognize
              and rapidly destroy target cells with exquisite sensitivity
              despite the fact that cytokine production requires sustained
              signaling at the immunological synapse. Here we solve this
              paradox by showing that CTL establish sustained synapses with
              targets offering strong antigenic stimuli and that these synapses
              persist after target cell death. Simultaneously, CTL polarize
              lytic granules toward different cells without discrimination
              regarding antigenic potential. Our results show that
              spatiotemporal uncoupling of immunological synapse and lytic
              granule secretion allows multiple killing and sustained signaling
              by individual CTL. This unique mechanism of responding to
              multiple contacts provides remarkable efficiency to CTL function.",
  journal  = "Proc. Natl. Acad. Sci. U. S. A.",
  volume   =  103,
  number   =  29,
  pages    = "10985--10990",
  month    =  jul,
  year     =  2006,
  language = "en"
}

@ARTICLE{Wiedemann2006-wv,
  title    = "Cytotoxic {T} lymphocytes kill multiple targets simultaneously
              via spatiotemporal uncoupling of lytic and stimulatory synapses",
  author   = "Wiedemann, Aurelie and Depoil, David and Faroudi, Mustapha and
              Valitutti, Salvatore",
  abstract = "A longstanding paradox in the activation of cytotoxic T
              lymphocytes (CTL) arises from the observation that CTL recognize
              and rapidly destroy target cells with exquisite sensitivity
              despite the fact that cytokine production requires sustained
              signaling at the immunological synapse. Here we solve this
              paradox by showing that CTL establish sustained synapses with
              targets offering strong antigenic stimuli and that these synapses
              persist after target cell death. Simultaneously, CTL polarize
              lytic granules toward different cells without discrimination
              regarding antigenic potential. Our results show that
              spatiotemporal uncoupling of immunological synapse and lytic
              granule secretion allows multiple killing and sustained signaling
              by individual CTL. This unique mechanism of responding to
              multiple contacts provides remarkable efficiency to CTL function.",
  journal  = "Proc. Natl. Acad. Sci. U. S. A.",
  volume   =  103,
  number   =  29,
  pages    = "10985--10990",
  month    =  jul,
  year     =  2006,
  keywords = "Direct Killing (Perf/Gzym/FAS)",
  language = "en"
}

@ARTICLE{Akashi2002-il,
  title    = "Metabolic efficiency and amino acid composition in the proteomes
              of \textit{Escherichia coli} and \textit{Bacillus subtilis}",
  author   = "Akashi, Hiroshi and Gojobori, Takashi",
  abstract = "Biosynthesis of an Escherichia coli cell, with organic compounds
              as sources of energy and carbon, requires approximately 20 to 60
              billion high-energy phosphate bonds [Stouthamer, A. H. (1973)
              Antonie van Leeuwenhoek 39, 545-565]. A substantial fraction of
              this energy budget is devoted to biosynthesis of amino acids, the
              building blocks of proteins. The fueling reactions of central
              metabolism provide precursor metabolites for synthesis of the 20
              amino acids incorporated into proteins. Thus, synthesis of an
              amino acid entails a dual cost: energy is lost by diverting
              chemical intermediates from fueling reactions and additional
              energy is required to convert precursor metabolites to amino
              acids. Among amino acids, costs of synthesis vary from 12 to 74
              high-energy phosphate bonds per molecule. The energetic advantage
              to encoding a less costly amino acid in a highly expressed gene
              can be greater than 0.025\% of the total energy budget. Here, we
              provide evidence that amino acid composition in the proteomes of
              E. coli and Bacillus subtilis reflects the action of natural
              selection to enhance metabolic efficiency. We employ synonymous
              codon usage bias as a measure of translation rates and show
              increases in the abundance of less energetically costly amino
              acids in highly expressed proteins.",
  journal  = "Proc. Natl. Acad. Sci. U. S. A.",
  volume   =  99,
  number   =  6,
  pages    = "3695--3700",
  month    =  mar,
  year     =  2002,
  language = "en"
}

@ARTICLE{DeBerardinis2007-fm,
  title    = "Beyond aerobic glycolysis: transformed cells can engage in
              glutamine metabolism that exceeds the requirement for protein and
              nucleotide synthesis",
  author   = "DeBerardinis, Ralph J and Mancuso, Anthony and Daikhin, Evgueni
              and Nissim, Ilana and Yudkoff, Marc and Wehrli, Suzanne and
              Thompson, Craig B",
  abstract = "Tumor cell proliferation requires rapid synthesis of
              macromolecules including lipids, proteins, and nucleotides. Many
              tumor cells exhibit rapid glucose consumption, with most of the
              glucose-derived carbon being secreted as lactate despite abundant
              oxygen availability (the Warburg effect). Here, we used 13C NMR
              spectroscopy to examine the metabolism of glioblastoma cells
              exhibiting aerobic glycolysis. In these cells, the tricarboxylic
              acid (TCA) cycle was active but was characterized by an efflux of
              substrates for use in biosynthetic pathways, particularly fatty
              acid synthesis. The success of this synthetic activity depends on
              activation of pathways to generate reductive power (NADPH) and to
              restore oxaloacetate for continued TCA cycle function
              (anaplerosis). Surprisingly, both these needs were met by a high
              rate of glutamine metabolism. First, conversion of glutamine to
              lactate (glutaminolysis) was rapid enough to produce sufficient
              NADPH to support fatty acid synthesis. Second, despite
              substantial mitochondrial pyruvate metabolism, pyruvate
              carboxylation was suppressed, and anaplerotic oxaloacetate was
              derived from glutamine. Glutamine catabolism was accompanied by
              secretion of alanine and ammonia, such that most of the amino
              groups from glutamine were lost from the cell rather than
              incorporated into other molecules. These data demonstrate that
              transformed cells exhibit a high rate of glutamine consumption
              that cannot be explained by the nitrogen demand imposed by
              nucleotide synthesis or maintenance of nonessential amino acid
              pools. Rather, glutamine metabolism provides a carbon source that
              facilitates the cell's ability to use glucose-derived carbon and
              TCA cycle intermediates as biosynthetic precursors.",
  journal  = "Proc. Natl. Acad. Sci. U. S. A.",
  volume   =  104,
  number   =  49,
  pages    = "19345--19350",
  month    =  dec,
  year     =  2007,
  language = "en"
}

@ARTICLE{Busse2010-aq,
  title    = "Competing feedback loops shape {IL-2} signaling between helper
              and regulatory {T} lymphocytes in cellular microenvironments",
  author   = "Busse, Dorothea and de la Rosa, Maurus and Hobiger, Kirstin and
              Thurley, Kevin and Flossdorf, Michael and Scheffold, Alexander
              and H{\"o}fer, Thomas",
  abstract = "Cytokines are pleiotropic and readily diffusible messenger
              molecules, raising the question of how their action can be
              confined to specific target cells. The T cell cytokine
              interleukin-2 (IL-2) is essential for the homeostasis of
              regulatory T (Treg) cells that suppress (auto)immunity and
              stimulates immune responses mediated by conventional T cells. We
              combined mathematical modeling and experiments to dissect the
              dynamics of the IL-2 signaling network that links the
              prototypical IL-2 producers, conventional T helper (Th) cells,
              and Treg cells. We show how the IL-2-induced upregulation of
              high-affinity IL-2 receptors (IL-2R) establishes a positive
              feedback loop of IL-2 signaling. This feedback mediates a digital
              switch for the proliferation of Th cells and functions as an
              analog amplifier for the IL-2 uptake capacity of Treg cells.
              Unlike other positive feedbacks in cell signaling that augment
              signal propagation, the IL-2/IL-2R loop enhances the capture of
              the signal molecule and its degradation. Thus Treg and Th cells
              can compete for IL-2 and restrict its range of action through
              efficient cellular uptake. Depending on activation status and
              spatial localization of the cells, IL-2 may be consumed
              exclusively by Treg or Th cells, or be shared between them. In
              particular, a Treg cell can deprive a stimulated Th cell of its
              IL-2, but only when the cells are located in close proximity,
              within a few tens of micrometers. The present findings explain
              how IL-2 can play two distinct roles in immune regulation and
              point to a hitherto largely unexplored spatiotemporal complexity
              of cytokine signaling.",
  journal  = "Proc. Natl. Acad. Sci. U. S. A.",
  volume   =  107,
  number   =  7,
  pages    = "3058--3063",
  month    =  feb,
  year     =  2010,
  language = "en"
}

@ARTICLE{Lu2009-rz,
  title    = "Efficient acquisition of dual metastasis organotropism to bone
              and lung through stable spontaneous fusion between {MDA-MB-231}
              variants",
  author   = "Lu, Xin and Kang, Yibin",
  abstract = "Cell fusion is involved in many critical developmental processes,
              including zygote formation and organogenesis of placenta, bone,
              and skeletal muscle. In adult tissues, cell fusion has been shown
              to play an active role in tissue regeneration and repair, and its
              frequency of occurrence is significantly increased during chronic
              inflammation. Fusion between tumor cells and normal cells, or
              among tumor cells themselves, has also been speculated to
              contribute to tumor initiation, as well as phenotypic evolution
              during cancer progression and metastasis. Here, we show that dual
              metastasis organotropisms can be acquired in the same cell
              through in vitro or in vivo spontaneous fusion between bone- and
              lung-tropic sublines of the MDA-MB-231 human breast cancer cell
              line. The synkaryonic hybrids assimilate organ-specific
              metastasis gene signatures from both parental cells and are
              genetically and phenotypically stable. Our study suggests cell
              fusion as an efficient means of phenotypic evolution during tumor
              progression and additionally demonstrates the compatibility of
              different metastasis organotropisms.",
  journal  = "Proc. Natl. Acad. Sci. U. S. A.",
  volume   =  106,
  number   =  23,
  pages    = "9385--9390",
  month    =  jun,
  year     =  2009,
  language = "en"
}

@ARTICLE{Curran2010-rp,
  title    = "{PD-1} and {CTLA-4} combination blockade expands infiltrating {T}
              cells and reduces regulatory {T} and myeloid cells within {B16}
              melanoma tumors",
  author   = "Curran, Michael A and Montalvo, Welby and Yagita, Hideo and
              Allison, James P",
  abstract = "Vaccination with irradiated B16 melanoma cells expressing either
              GM-CSF (Gvax) or Flt3-ligand (Fvax) combined with antibody
              blockade of the negative T-cell costimulatory receptor cytotoxic
              T-lymphocyte antigen-4 (CTLA-4) promotes rejection of
              preimplanted tumors. Despite CTLA-4 blockade, T-cell
              proliferation and cytokine production can be inhibited by the
              interaction of programmed death-1 (PD-1) with its ligands PD-L1
              and PD-L2 or by the interaction of PD-L1 with B7-1. Here, we show
              that the combination of CTLA-4 and PD-1 blockade is more than
              twice as effective as either alone in promoting the rejection of
              B16 melanomas in conjunction with Fvax. Adding alphaPD-L1 to this
              regimen results in rejection of 65\% of preimplanted tumors vs.
              10\% with CTLA-4 blockade alone. Combination PD-1 and CTLA-4
              blockade increases effector T-cell (Teff) infiltration, resulting
              in highly advantageous Teff-to-regulatory T-cell ratios with the
              tumor. The fraction of tumor-infiltrating Teffs expressing CTLA-4
              and PD-1 increases, reflecting the proliferation and accumulation
              of cells that would otherwise be anergized. Combination blockade
              also synergistically increases Teff-to-myeloid-derived suppressor
              cell ratios within B16 melanomas. IFN-gamma production increases
              in both the tumor and vaccine draining lymph nodes, as does the
              frequency of IFN-gamma/TNF-alpha double-producing CD8(+) T cells
              within the tumor. These results suggest that combination blockade
              of the PD-1/PD-L1- and CTLA-4-negative costimulatory pathways
              allows tumor-specific T cells that would otherwise be inactivated
              to continue to expand and carry out effector functions, thereby
              shifting the tumor microenvironment from suppressive to
              inflammatory.",
  journal  = "Proc. Natl. Acad. Sci. U. S. A.",
  volume   =  107,
  number   =  9,
  pages    = "4275--4280",
  month    =  mar,
  year     =  2010,
  language = "en"
}

@ARTICLE{Li2010-zl,
  title    = "The {ATM-p53} pathway suppresses aneuploidy-induced tumorigenesis",
  author   = "Li, Min and Fang, Xiao and Baker, Darren J and Guo, Linjie and
              Gao, Xue and Wei, Zhubo and Han, Shuhua and van Deursen, Jan M
              and Zhang, Pumin",
  abstract = "The spindle assembly checkpoint (SAC) is essential for proper
              sister chromatid segregation. Defects in this checkpoint can lead
              to chromosome missegregation and aneuploidy. An increasing body
              of evidence suggests that aneuploidy can play a causal role in
              tumorigenesis. However, mutant mice that are prone to aneuploidy
              have only mild tumor phenotypes, suggesting that there are
              limiting factors in the aneuploidy-induced tumorigenesis. Here we
              provide evidence that p53 is such a limiting factor. We show that
              aneuploidy activates p53 and that loss of p53 drastically
              accelerates tumor development in two independent aneuploidy
              models. The p53 activation depends on the ataxia-telangiectasia
              mutated (ATM) gene product and increased levels of reactive
              oxygen species. Thus, the ATM-p53 pathway safeguards not only DNA
              damage but also aneuploidy.",
  journal  = "Proc. Natl. Acad. Sci. U. S. A.",
  volume   =  107,
  number   =  32,
  pages    = "14188--14193",
  month    =  aug,
  year     =  2010,
  language = "en"
}

@ARTICLE{Sanderson2012-ob,
  title    = "Cytotoxic immunological synapses do not restrict the action of
              interferon-$\gamma$ to antigenic target cells",
  author   = "Sanderson, Nicholas Stephen Rennie and Puntel, Mariana and
              Kroeger, Kurt M and Bondale, Niyati S and Swerdlow, Mark and
              Iranmanesh, Niloufar and Yagita, Hideo and Ibrahim, Ahmed and
              Castro, Maria G and Lowenstein, Pedro R",
  abstract = "Following antigen recognition on target cells, effector T cells
              establish immunological synapses and secrete cytokines. It is
              thought that T cells secrete cytokines in one of two modes:
              either synaptically (i.e., toward antigenic target cells) or
              multidirectionally, affecting a wider population of cells. This
              paradigm predicts that synaptically secreted cytokines such as
              IFN-$\gamma$ will preferentially signal to antigenic target cells
              contacted by the T cell through an immunological synapse. Despite
              its physiological significance, this prediction has never been
              tested. We developed a live-cell imaging system to compare the
              responses of target cells and nonantigenic bystanders to
              IFN-$\gamma$ secreted by CD8+, antigen-specific, cytotoxic T
              cells. Both target cells and surrounding nontarget cells respond
              robustly. This pattern of response was detected even at minimal
              antigenic T-cell stimulation using low doses of antigenic
              peptide, or altered peptide ligands. Although cytotoxic
              immunological synapses restrict killing to antigenic target
              cells, the effects of IFN-$\gamma$ are more widespread.",
  journal  = "Proc. Natl. Acad. Sci. U. S. A.",
  volume   =  109,
  number   =  20,
  pages    = "7835--7840",
  month    =  may,
  year     =  2012,
  language = "en"
}

@ARTICLE{Han2012-pd,
  title    = "Polyfunctional responses by human {T} cells result from
              sequential release of cytokines",
  author   = "Han, Qing and Bagheri, Neda and Bradshaw, Elizabeth M and Hafler,
              David A and Lauffenburger, Douglas A and Love, J Christopher",
  abstract = "The release of cytokines by T cells defines a significant part of
              their functional activity in vivo, and their ability to produce
              multiple cytokines has been associated with beneficial immune
              responses. To date, time-integrated end-point measurements have
              obscured whether these polyfunctional states arise from the
              simultaneous or successive release of cytokines. Here, we used
              serial, time-dependent, single-cell analysis of primary human T
              cells to resolve the temporal dynamics of cytokine secretion from
              individual cells after activation ex vivo. We show that
              multifunctional, Th1-skewed cytokine responses (IFN-$\gamma$,
              IL-2, TNF$\alpha$) are initiated asynchronously, but the ensuing
              dynamic trajectories of these responses evolve programmatically
              in a sequential manner. That is, cells predominantly release one
              of these cytokines at a time rather than maintain active
              secretion of multiple cytokines simultaneously. Furthermore,
              these dynamic trajectories are strongly associated with the
              various states of cell differentiation suggesting that transient
              programmatic activities of many individual T cells contribute to
              sustained, population-level responses. The trajectories of
              responses by single cells may also provide unique, time-dependent
              signatures for immune monitoring that are less compromised by the
              timing and duration of integrated measures.",
  journal  = "Proc. Natl. Acad. Sci. U. S. A.",
  volume   =  109,
  number   =  5,
  pages    = "1607--1612",
  month    =  jan,
  year     =  2012,
  language = "en"
}

@ARTICLE{Ariotti2012-cj,
  title    = "Tissue-resident memory {CD8+} {T} cells continuously patrol skin
              epithelia to quickly recognize local antigen",
  author   = "Ariotti, Silvia and Beltman, Joost B and Chodaczek, Grzegorz and
              Hoekstra, Mirjam E and van Beek, Anna E and Gomez-Eerland, Raquel
              and Ritsma, Laila and van Rheenen, Jacco and Mar{\'e}e,
              Athanasius F M and Zal, Tomasz and de Boer, Rob J and Haanen,
              John B A G and Schumacher, Ton N",
  abstract = "Recent work has demonstrated that following the clearance of
              infection a stable population of memory T cells remains present
              in peripheral organs and contributes to the control of secondary
              infections. However, little is known about how tissue-resident
              memory T cells behave in situ and how they encounter newly
              infected target cells. Here we demonstrate that antigen-specific
              CD8(+) T cells that remain in skin following herpes simplex virus
              infection show a steady-state crawling behavior in between
              keratinocytes. Spatially explicit simulations of the migration of
              these tissue-resident memory T cells indicate that the migratory
              dendritic behavior of these cells allows the detection of
              antigen-expressing target cells in physiologically relevant time
              frames of minutes to hours. Furthermore, we provide direct
              evidence for the identification of rare antigen-expressing
              epithelial cells by skin-patrolling memory T cells in vivo. These
              data demonstrate the existence of skin patrol by memory T cells
              and reveal the value of this patrol in the rapid detection of
              renewed infections at a previously infected site.",
  journal  = "Proc. Natl. Acad. Sci. U. S. A.",
  volume   =  109,
  number   =  48,
  pages    = "19739--19744",
  month    =  nov,
  year     =  2012,
  language = "en"
}

@ARTICLE{Sheltzer2012-al,
  title    = "Transcriptional consequences of aneuploidy",
  author   = "Sheltzer, Jason M and Torres, Eduardo M and Dunham, Maitreya J
              and Amon, Angelika",
  abstract = "Aneuploidy, or an aberrant karyotype, results in developmental
              disabilities and has been implicated in tumorigenesis. However,
              the causes of aneuploidy-induced phenotypes and the consequences
              of aneuploidy on cell physiology remain poorly understood. We
              have performed a metaanalysis on gene expression data from
              aneuploid cells in diverse organisms, including yeast, plants,
              mice, and humans. We found highly related gene expression
              patterns that are conserved between species: genes that were
              involved in the response to stress were consistently upregulated,
              and genes associated with the cell cycle and cell proliferation
              were downregulated in aneuploid cells. Within species, different
              aneuploidies induced similar changes in gene expression,
              independent of the specific chromosomal aberrations. Taken
              together, our results demonstrate that aneuploidies of different
              chromosomes and in different organisms impact similar cellular
              pathways and cause a stereotypical antiproliferative response
              that must be overcome before transformation.",
  journal  = "Proc. Natl. Acad. Sci. U. S. A.",
  volume   =  109,
  number   =  31,
  pages    = "12644--12649",
  month    =  jul,
  year     =  2012,
  language = "en"
}

@ARTICLE{Yona2012-de,
  title    = "Chromosomal duplication is a transient evolutionary solution to
              stress",
  author   = "Yona, Avihu H and Manor, Yair S and Herbst, Rebecca H and Romano,
              Gal H and Mitchell, Amir and Kupiec, Martin and Pilpel, Yitzhak
              and Dahan, Orna",
  abstract = "Aneuploidy, an abnormal number of chromosomes, is a widespread
              phenomenon found in unicellulars such as yeast, as well as in
              plants and in mammalians, especially in cancer. Aneuploidy is a
              genome-scale aberration that imposes a severe burden on the cell,
              yet under stressful conditions specific aneuploidies confer a
              selective advantage. This dual nature of aneuploidy raises the
              question of whether it can serve as a stable and sustainable
              evolutionary adaptation. To clarify this, we conducted a set of
              laboratory evolution experiments in yeast and followed the
              long-term dynamics of aneuploidy under diverse conditions. Here
              we show that chromosomal duplications are first acquired as a
              crude solution to stress, yet only as transient solutions that
              are eliminated and replaced by more efficient solutions obtained
              at the individual gene level. These transient dynamics of
              aneuploidy were repeatedly observed in our laboratory evolution
              experiments; chromosomal duplications gained under stress were
              eliminated not only when the stress was relieved, but even if it
              persisted. Furthermore, when stress was applied gradually rather
              than abruptly, alternative solutions appear to have emerged, but
              not aneuploidy. Our findings indicate that chromosomal
              duplication is a first evolutionary line of defense, that retains
              survivability under strong and abrupt selective pressures, yet it
              merely serves as a ``quick fix,'' whereas more refined and
              sustainable solutions take over. Thus, in the perspective of
              genome evolution trajectory, aneuploidy is a useful yet
              short-lived intermediate that facilitates further adaptation.",
  journal  = "Proc. Natl. Acad. Sci. U. S. A.",
  volume   =  109,
  number   =  51,
  pages    = "21010--21015",
  month    =  dec,
  year     =  2012,
  language = "en"
}

@ARTICLE{Mollova2013-md,
  title    = "Cardiomyocyte proliferation contributes to heart growth in young
              humans",
  author   = "Mollova, Mariya and Bersell, Kevin and Walsh, Stuart and Savla,
              Jainy and Das, Lala Tanmoy and Park, Shin-Young and Silberstein,
              Leslie E and Dos Remedios, Cristobal G and Graham, Dionne and
              Colan, Steven and K{\"u}hn, Bernhard",
  abstract = "The human heart is believed to grow by enlargement but not
              proliferation of cardiomyocytes (heart muscle cells) during
              postnatal development. However, recent studies have shown that
              cardiomyocyte proliferation is a mechanism of cardiac growth and
              regeneration in animals. Combined with evidence for cardiomyocyte
              turnover in adult humans, this suggests that cardiomyocyte
              proliferation may play an unrecognized role during the period of
              developmental heart growth between birth and adolescence. We
              tested this hypothesis by examining the cellular growth
              mechanisms of the left ventricle on a set of healthy hearts from
              humans aged 0-59 y (n = 36). The percentages of cardiomyocytes in
              mitosis and cytokinesis were highest in infants, decreasing to
              low levels by 20 y. Although cardiomyocyte mitosis was detectable
              throughout life, cardiomyocyte cytokinesis was not evident after
              20 y. Between the first year and 20 y of life, the number of
              cardiomyocytes in the left ventricle increased 3.4-fold, which
              was consistent with our predictions based on measured
              cardiomyocyte cell cycle activity. Our findings show that
              cardiomyocyte proliferation contributes to developmental heart
              growth in young humans. This suggests that children and
              adolescents may be able to regenerate myocardium, that abnormal
              cardiomyocyte proliferation may be involved in myocardial
              diseases that affect this population, and that these diseases
              might be treatable through stimulation of cardiomyocyte
              proliferation.",
  journal  = "Proc. Natl. Acad. Sci. U. S. A.",
  volume   =  110,
  number   =  4,
  pages    = "1446--1451",
  month    =  jan,
  year     =  2013,
  language = "en"
}

@ARTICLE{Bashour2014-xb,
  title    = "{CD28} and {CD3} have complementary roles in T-cell traction
              forces",
  author   = "Bashour, Keenan T and Gondarenko, Alexander and Chen, Haoqian and
              Shen, Keyue and Liu, Xin and Huse, Morgan and Hone, James C and
              Kam, Lance C",
  abstract = "Mechanical forces have key roles in regulating activation of T
              cells and coordination of the adaptive immune response. A recent
              example is the ability of T cells to sense the rigidity of an
              underlying substrate through the T-cell receptor (TCR) coreceptor
              CD3 and CD28, a costimulation signal essential for cell
              activation. In this report, we show that these two receptor
              systems provide complementary functions in regulating the
              cellular forces needed to test the mechanical properties of the
              extracellular environment. Traction force microscopy was carried
              out on primary human cells interacting with micrometer-scale
              elastomer pillar arrays presenting activation antibodies to CD3
              and/or CD28. T cells generated traction forces of 100 pN on
              arrays with both antibodies. By providing one antibody or the
              other in solution instead of on the pillars, we show that force
              generation is associated with CD3 and the TCR complex. Engagement
              of CD28 increases traction forces associated with CD3 through the
              signaling pathway involving PI3K, rather than providing
              additional coupling between the cell and surface. Force
              generation is concentrated to the cell periphery and associated
              with molecular complexes containing phosphorylated Pyk2,
              suggesting that T cells use processes that share features with
              integrin signaling in force generation. Finally, the ability of T
              cells to apply forces through the TCR itself, rather than the CD3
              coreceptor, was tested. Mouse cells expressing the 5C.C7 TCR
              exerted traction forces on pillars presenting peptide-loaded MHCs
              that were similar to those with $\alpha$-CD3, suggesting that
              forces are applied to antigen-presenting cells during activation.",
  journal  = "Proc. Natl. Acad. Sci. U. S. A.",
  volume   =  111,
  number   =  6,
  pages    = "2241--2246",
  month    =  feb,
  year     =  2014,
  language = "en"
}

@ARTICLE{Otwinowski2014-ga,
  title    = "Inferring fitness landscapes by regression produces biased
              estimates of epistasis",
  author   = "Otwinowski, Jakub and Plotkin, Joshua B",
  abstract = "The genotype-fitness map plays a fundamental role in shaping the
              dynamics of evolution. However, it is difficult to directly
              measure a fitness landscape in practice, because the number of
              possible genotypes is astronomical. One approach is to sample as
              many genotypes as possible, measure their fitnesses, and fit a
              statistical model of the landscape that includes additive and
              pairwise interactive effects between loci. Here, we elucidate the
              pitfalls of using such regressions by studying artificial but
              mathematically convenient fitness landscapes. We identify two
              sources of bias inherent in these regression procedures, each of
              which tends to underestimate high fitnesses and overestimate low
              fitnesses. We characterize these biases for random sampling of
              genotypes as well as samples drawn from a population under
              selection in the Wright-Fisher model of evolutionary dynamics. We
              show that common measures of epistasis, such as the number of
              monotonically increasing paths between ancestral and derived
              genotypes, the prevalence of sign epistasis, and the number of
              local fitness maxima, are distorted in the inferred landscape. As
              a result, the inferred landscape will provide systematically
              biased predictions for the dynamics of adaptation. We identify
              the same biases in a computational RNA-folding landscape as well
              as regulatory sequence binding data treated with the same fitting
              procedure. Finally, we present a method to ameliorate these
              biases in some cases.",
  journal  = "Proc. Natl. Acad. Sci. U. S. A.",
  volume   =  111,
  number   =  22,
  pages    = "E2301--9",
  month    =  jun,
  year     =  2014,
  keywords = "experimental evolution; molecular evolution; penalized regression",
  language = "en"
}

@ARTICLE{Foijer2014-jf,
  title    = "Chromosome instability induced by Mps1 and p53 mutation generates
              aggressive lymphomas exhibiting aneuploidy-induced stress",
  author   = "Foijer, Floris and Xie, Stephanie Z and Simon, Judith E and
              Bakker, Petra L and Conte, Nathalie and Davis, Stephanie H and
              Kregel, Eva and Jonkers, Jos and Bradley, Allan and Sorger, Peter
              K",
  abstract = "Aneuploidy is a hallmark of human solid cancers that arises from
              errors in mitosis and results in gain and loss of oncogenes and
              tumor suppressors. Aneuploidy poses a growth disadvantage for
              cells grown in vitro, suggesting that cancer cells adapt to this
              burden. To understand better the consequences of aneuploidy in a
              rapidly proliferating adult tissue, we engineered a mouse in
              which chromosome instability was selectively induced in T cells.
              A flanked by Lox mutation was introduced into the monopolar
              spindle 1 (Mps1) spindle-assembly checkpoint gene so that
              Cre-mediated recombination would create a truncated protein
              (Mps1(DK)) that retained the kinase domain but lacked the
              kinetochore-binding domain and thereby weakened the checkpoint.
              In a sensitized p53(+/-) background we observed that Mps1(DK/DK)
              mice suffered from rapid-onset acute lymphoblastic lymphoma. The
              tumors were highly aneuploid and exhibited a metabolic burden
              similar to that previously characterized in aneuploid yeast and
              cultured cells. The tumors nonetheless grew rapidly and were
              lethal within 3-4 mo after birth.",
  journal  = "Proc. Natl. Acad. Sci. U. S. A.",
  volume   =  111,
  number   =  37,
  pages    = "13427--13432",
  month    =  sep,
  year     =  2014,
  keywords = "CIN; T-cell acute lymphoblastic lymphoma; chromosomal
              instability; mouse models; tumor metabolism",
  language = "en"
}

@ARTICLE{Hao2014-fj,
  title    = "Mathematical model of sarcoidosis",
  author   = "Hao, Wenrui and Crouser, Elliott D and Friedman, Avner",
  abstract = "Sarcoidosis is a disease involving abnormal collection of
              inflammatory cells forming nodules, called granulomas. Such
              granulomas occur in the lung and the mediastinal lymph nodes, in
              the heart, and in other vital and nonvital organs. The origin of
              the disease is unknown, and there are only limited clinical data
              on lung tissue of patients. No current model of sarcoidosis
              exists. In this paper we develop a mathematical model on the
              dynamics of the disease in the lung and use patients' lung tissue
              data to validate the model. The model is used to explore
              potential treatments.",
  journal  = "Proc. Natl. Acad. Sci. U. S. A.",
  volume   =  111,
  number   =  45,
  pages    = "16065--16070",
  month    =  nov,
  year     =  2014,
  keywords = "granuloma; math modeling; sarcoidosis",
  language = "en"
}

@ARTICLE{Weigelin2015-gm,
  title    = "Focusing and sustaining the antitumor {CTL} effector killer
              response by agonist {anti-CD137} mAb",
  author   = "Weigelin, Bettina and Bola{\~n}os, Elixabet and Teijeira, Alvaro
              and Martinez-Forero, Ivan and Labiano, Sara and Azpilikueta,
              Arantza and Morales-Kastresana, Aizea and Quetglas, Jos{\'e} I
              and Wagena, Esther and S{\'a}nchez-Paulete, Alfonso
              Rodr{\'\i}guez and Chen, Lieping and Friedl, Peter and Melero,
              Ignacio",
  abstract = "Cancer immunotherapy is undergoing significant progress due to
              recent clinical successes by refined adoptive T-cell transfer and
              immunostimulatory monoclonal Ab (mAbs). B16F10-derived
              OVA-expressing mouse melanomas resist curative immunotherapy with
              either adoptive transfer of activated anti-OVA OT1 CTLs or
              agonist anti-CD137 (4-1BB) mAb. However, when acting in
              synergistic combination, these treatments consistently achieve
              tumor eradication. Tumor-infiltrating lymphocytes that accomplish
              tumor rejection exhibit enhanced effector functions in both
              transferred OT-1 and endogenous cytotoxic T lymphocytes (CTLs).
              This is consistent with higher levels of expression of
              eomesodermin in transferred and endogenous CTLs and with
              intravital live-cell two-photon microscopy evidence for more
              efficacious CTL-mediated tumor cell killing. Anti-CD137 mAb
              treatment resulted in prolonged intratumor persistence of the OT1
              CTL-effector cells and improved function with focused and
              confined interaction kinetics of OT-1 CTL with target cells and
              increased apoptosis induction lasting up to six days postadoptive
              transfer. The synergy of adoptive T-cell therapy and agonist
              anti-CD137 mAb thus results from in vivo enhancement and
              sustainment of effector functions.",
  journal  = "Proc. Natl. Acad. Sci. U. S. A.",
  volume   =  112,
  number   =  24,
  pages    = "7551--7556",
  month    =  jun,
  year     =  2015,
  keywords = "CD137; Cytotoxic T lymphocyte; adoptive T-cell therapy;
              costimulation; immunotherapy;B16F10\_specific",
  language = "en"
}

@ARTICLE{Demaria2015-cq,
  title    = "{STING} activation of tumor endothelial cells initiates
              spontaneous and therapeutic antitumor immunity",
  author   = "Demaria, Olivier and De Gassart, Aude and Coso, Sanja and
              Gestermann, Nicolas and Di Domizio, Jeremy and Flatz, Lukas and
              Gaide, Olivier and Michielin, Olivier and Hwu, Patrick and
              Petrova, Tatiana V and Martinon, Fabio and Modlin, Robert L and
              Speiser, Daniel E and Gilliet, Michel",
  abstract = "Spontaneous CD8 T-cell responses occur in growing tumors but are
              usually poorly effective. Understanding the molecular and
              cellular mechanisms that drive these responses is of major
              interest as they could be exploited to generate a more
              efficacious antitumor immunity. As such, stimulator of IFN genes
              (STING), an adaptor molecule involved in cytosolic DNA sensing,
              is required for the induction of antitumor CD8 T responses in
              mouse models of cancer. Here, we find that enforced activation of
              STING by intratumoral injection of cyclic dinucleotide GMP-AMP
              (cGAMP), potently enhanced antitumor CD8 T responses leading to
              growth control of injected and contralateral tumors in mouse
              models of melanoma and colon cancer. The ability of cGAMP to
              trigger antitumor immunity was further enhanced by the blockade
              of both PD1 and CTLA4. The STING-dependent antitumor immunity,
              either induced spontaneously in growing tumors or induced by
              intratumoral cGAMP injection was dependent on type I IFNs
              produced in the tumor microenvironment. In response to cGAMP
              injection, both in the mouse melanoma model and an ex vivo model
              of cultured human melanoma explants, the principal source of type
              I IFN was not dendritic cells, but instead endothelial cells.
              Similarly, endothelial cells but not dendritic cells were found
              to be the principal source of spontaneously induced type I IFNs
              in growing tumors. These data identify an unexpected role of the
              tumor vasculature in the initiation of CD8 T-cell antitumor
              immunity and demonstrate that tumor endothelial cells can be
              targeted for immunotherapy of melanoma.",
  journal  = "Proc. Natl. Acad. Sci. U. S. A.",
  volume   =  112,
  number   =  50,
  pages    = "15408--15413",
  month    =  dec,
  year     =  2015,
  keywords = "CD8 T cells; STING; antitumor immunity; tumor endothelial cells;
              type I IFNs",
  language = "en"
}

@ARTICLE{Lynch2015-so,
  title    = "The bioenergetic costs of a gene",
  author   = "Lynch, Michael and Marinov, Georgi K",
  abstract = "An enduring mystery of evolutionary genomics concerns the
              mechanisms responsible for lineage-specific expansions of genome
              size in eukaryotes, especially in multicellular species. One idea
              is that all excess DNA is mutationally hazardous, but weakly
              enough so that genome-size expansion passively emerges in species
              experiencing relatively low efficiency of selection owing to
              small effective population sizes. Another idea is that
              substantial gene additions were impossible without the energetic
              boost provided by the colonizing mitochondrion in the eukaryotic
              lineage. Contrary to this latter view, analysis of cellular
              energetics and genomics data from a wide variety of species
              indicates that, relative to the lifetime ATP requirements of a
              cell, the costs of a gene at the DNA, RNA, and protein levels
              decline with cell volume in both bacteria and eukaryotes.
              Moreover, these costs are usually sufficiently large to be
              perceived by natural selection in bacterial populations, but not
              in eukaryotes experiencing high levels of random genetic drift.
              Thus, for scaling reasons that are not yet understood, by virtue
              of their large size alone, eukaryotic cells are subject to a
              broader set of opportunities for the colonization of novel genes
              manifesting weakly advantageous or even transiently
              disadvantageous phenotypic effects. These results indicate that
              the origin of the mitochondrion was not a prerequisite for
              genome-size expansion.",
  journal  = "Proc. Natl. Acad. Sci. U. S. A.",
  volume   =  112,
  number   =  51,
  pages    = "15690--15695",
  month    =  dec,
  year     =  2015,
  keywords = "cellular bioenergetics; evolutionary genomics; gene cost;
              transcription; translation",
  language = "en"
}

@ARTICLE{Ritter2017-hk,
  title    = "Cortical actin recovery at the immunological synapse leads to
              termination of lytic granule secretion in cytotoxic {T}
              lymphocytes",
  author   = "Ritter, Alex T and Kapnick, Senta M and Murugesan, Sricharan and
              Schwartzberg, Pamela L and Griffiths, Gillian M and
              Lippincott-Schwartz, Jennifer",
  abstract = "CD8+ cytotoxic T lymphocytes (CTLs) eliminate virally infected
              cells through directed secretion of specialized lytic granules.
              Because a single CTL can kill multiple targets, degranulation
              must be tightly regulated. However, how CTLs regulate the
              termination of granule secretion remains unclear. Previous work
              demonstrated that centralized actin reduction at the immune
              synapse precedes degranulation. Using a combination of live
              confocal, total internal reflection fluorescence, and
              superresolution microscopy, we now show that, after granule
              fusion, actin recovers at the synapse and no further secretion is
              observed. Depolymerization of actin led to resumed granule
              secretion, suggesting that recovered actin acts as a barrier
              preventing sustained degranulation. Furthermore, RAB27a-deficient
              CTLs, which do not secrete cytotoxic granules, failed to recover
              actin at the synapse, suggesting that RAB27a-mediated granule
              secretion is required for actin recovery. Finally, we show that
              both actin clearance and recovery correlated with synaptic
              phosphatidylinositol 4,5-bisphosphate (PIP2) and that alterations
              in PIP2 at the immunological synapse regulate cortical actin in
              CTLs, providing a potential mechanism through which CTLs control
              cortical actin density. Our work provides insight into
              actin-related mechanisms regulating CTL secretion that may
              facilitate serial killing during immune responses.",
  journal  = "Proc. Natl. Acad. Sci. U. S. A.",
  volume   =  114,
  number   =  32,
  pages    = "E6585--E6594",
  month    =  aug,
  year     =  2017,
  keywords = "PIP2; RAB27a; actin; cytotoxic T lymphocytes; lytic granule
              secretion",
  language = "en"
}

@ARTICLE{Puschel2020-wa,
  title    = "Starvation and antimetabolic therapy promote cytokine release and
              recruitment of immune cells",
  author   = "P{\"u}schel, Franziska and Favaro, Francesca and Redondo-Pedraza,
              Jaime and Lucendo, Estefan{\'\i}a and Iurlaro, Raffaella and
              Marchetti, Sandrine and Majem, Blanca and Eldering, Eric and
              Nadal, Ernest and Ricci, Jean-Ehrland and Chevet, Eric and
              Mu{\~n}oz-Pinedo, Cristina",
  abstract = "Cellular starvation is typically a consequence of tissue injury
              that disrupts the local blood supply but can also occur where
              cell populations outgrow the local vasculature, as observed in
              solid tumors. Cells react to nutrient deprivation by adapting
              their metabolism, or, if starvation is prolonged, it can result
              in cell death. Cell starvation also triggers adaptive responses,
              like angiogenesis, that promote tissue reorganization and repair,
              but other adaptive responses and their mediators are still poorly
              characterized. To explore this issue, we analyzed secretomes from
              glucose-deprived cells, which revealed up-regulation of multiple
              cytokines and chemokines, including IL-6 and IL-8, in response to
              starvation stress. Starvation-induced cytokines were cell
              type-dependent, and they were also released from primary
              epithelial cells. Most cytokines were up-regulated in a manner
              dependent on NF-$\kappa$B and the transcription factor of the
              integrated stress response ATF4, which bound directly to the IL-8
              promoter. Furthermore, glutamine deprivation, as well as the
              antimetabolic drugs 2-deoxyglucose and metformin, also promoted
              the release of IL-6 and IL-8. Finally, some of the factors
              released from starved cells induced chemotaxis of B cells,
              macrophages, and neutrophils, suggesting that nutrient
              deprivation in the tumor environment can serve as an initiator of
              tumor inflammation.",
  journal  = "Proc. Natl. Acad. Sci. U. S. A.",
  volume   =  117,
  number   =  18,
  pages    = "9932--9941",
  month    =  may,
  year     =  2020,
  keywords = "cancer immunity; cancer metabolism; cytokines; glucose",
  language = "en"
}

@ARTICLE{Nicolet2020-hn,
  title    = "{CD29} identifies {IFN-$\gamma$-producing} human {CD8+} {T} cells
              with an increased cytotoxic potential",
  author   = "Nicolet, Beno{\^\i}t P and Guislain, Aur{\'e}lie and van Alphen,
              Floris P J and Gomez-Eerland, Raquel and Schumacher, Ton N M and
              van den Biggelaar, Maartje and Wolkers, Monika C",
  abstract = "Cytotoxic CD8+ T cells can effectively kill target cells by
              producing cytokines, chemokines, and granzymes. Expression of
              these effector molecules is however highly divergent, and tools
              that identify and preselect CD8+ T cells with a cytotoxic
              expression profile are lacking. Human CD8+ T cells can be divided
              into IFN-$\gamma$- and IL-2-producing cells. Unbiased
              transcriptomics and proteomics analysis on cytokine-producing
              fixed CD8+ T cells revealed that IL-2+ cells produce helper
              cytokines, and that IFN-$\gamma$+ cells produce cytotoxic
              molecules. IFN-$\gamma$+ T cells expressed the surface marker
              CD29 already prior to stimulation. CD29 also marked T cells with
              cytotoxic gene expression from different tissues in single-cell
              RNA-sequencing data. Notably, CD29+ T cells maintained the
              cytotoxic phenotype during cell culture, suggesting a stable
              phenotype. Preselecting CD29-expressing MART1 TCR-engineered T
              cells potentiated the killing of target cells. We therefore
              propose that CD29 expression can help evaluate and select for
              potent therapeutic T cell products.",
  journal  = "Proc. Natl. Acad. Sci. U. S. A.",
  month    =  mar,
  year     =  2020,
  keywords = "CD29; IFN-$\gamma$; IL-2; T cells; cytotoxicity",
  language = "en"
}

@ARTICLE{Replogle2020-gn,
  title    = "Aneuploidy increases resistance to chemotherapeutics by
              antagonizing cell division",
  author   = "Replogle, John Michael and Zhou, Wen and Amaro, Adrianna E and
              McFarland, James M and Villalobos-Ortiz, Mariana and Ryan, Jeremy
              and Letai, Anthony and Yilmaz, Omer and Sheltzer, Jason and
              Lippard, Stephen J and Ben-David, Uri and Amon, Angelika",
  abstract = "Aneuploidy, defined as whole chromosome gains and losses, is
              associated with poor patient prognosis in many cancer types.
              However, the condition causes cellular stress and cell cycle
              delays, foremost in G1 and S phase. Here, we investigate how
              aneuploidy causes both slow proliferation and poor disease
              outcome. We test the hypothesis that aneuploidy brings about
              resistance to chemotherapies because of a general feature of the
              aneuploid condition-G1 delays. We show that single chromosome
              gains lead to increased resistance to the frontline
              chemotherapeutics cisplatin and paclitaxel. Furthermore, G1 cell
              cycle delays are sufficient to increase chemotherapeutic
              resistance in euploid cells. Mechanistically, G1 delays increase
              drug resistance to cisplatin and paclitaxel by reducing their
              ability to damage DNA and microtubules, respectively. Finally, we
              show that our findings are clinically relevant. Aneuploidy
              correlates with slowed proliferation and drug resistance in the
              Cancer Cell Line Encyclopedia (CCLE) dataset. We conclude that a
              general and seemingly detrimental effect of aneuploidy, slowed
              proliferation, provides a selective benefit to cancer cells
              during chemotherapy treatment.",
  journal  = "Proc. Natl. Acad. Sci. U. S. A.",
  volume   =  117,
  number   =  48,
  pages    = "30566--30576",
  month    =  dec,
  year     =  2020,
  keywords = "aneuploidy; cell cycle; chemotherapy resistance; cisplatin;
              paclitaxel",
  language = "en"
}

@ARTICLE{Yang2021-kf,
  title    = "Physical bioenergetics: Energy fluxes, budgets, and constraints
              in cells",
  author   = "Yang, Xingbo and Heinemann, Matthias and Howard, Jonathon and
              Huber, Greg and Iyer-Biswas, Srividya and Le Treut, Guillaume and
              Lynch, Michael and Montooth, Kristi L and Needleman, Daniel J and
              Pigolotti, Simone and Rodenfels, Jonathan and Ronceray, Pierre
              and Shankar, Sadasivan and Tavassoly, Iman and Thutupalli, Shashi
              and Titov, Denis V and Wang, Jin and Foster, Peter J",
  abstract = "Cells are the basic units of all living matter which harness the
              flow of energy to drive the processes of life. While the
              biochemical networks involved in energy transduction are
              well-characterized, the energetic costs and constraints for
              specific cellular processes remain largely unknown. In
              particular, what are the energy budgets of cells? What are the
              constraints and limits energy flows impose on cellular processes?
              Do cells operate near these limits, and if so how do energetic
              constraints impact cellular functions? Physics has provided many
              tools to study nonequilibrium systems and to define physical
              limits, but applying these tools to cell biology remains a
              challenge. Physical bioenergetics, which resides at the interface
              of nonequilibrium physics, energy metabolism, and cell biology,
              seeks to understand how much energy cells are using, how they
              partition this energy between different cellular processes, and
              the associated energetic constraints. Here we review recent
              advances and discuss open questions and challenges in physical
              bioenergetics.",
  journal  = "Proc. Natl. Acad. Sci. U. S. A.",
  volume   =  118,
  number   =  26,
  month    =  jun,
  year     =  2021,
  keywords = "energetic constraints; energetic costs; energy fluxes; physical
              bioenergetics",
  language = "en"
}

@ARTICLE{Barnd1989-sz,
  title    = "Specific, major histocompatibility complex-unrestricted
              recognition of tumor-associated mucins by human cytotoxic {T}
              cells",
  author   = "Barnd, D L and Lan, M S and Metzgar, R S and Finn, O J",
  abstract = "We have previously reported the establishment of cytotoxic T-cell
              lines from pancreatic cancer patients, by continuously
              stimulating tumor-draining lymph node cells with allogeneic
              pancreatic tumor cell lines. After the preliminary
              characterization of their phenotype and tumor specificity,
              detailed studies performed with one of the cell lines, W.D., show
              that it recognizes a specific antigen, a large and heavily
              glycosylated mucin molecule, expressed on pancreatic and breast
              tumors and tumor cell lines. Although this recognition appears
              major histocompatibility complex (MHC)-unrestricted, the antigen
              receptor used by the cytotoxic T cell is the alpha/beta
              heterodimer, typically found on MHC-restricted T cells. The
              target antigen is atypical, however, in its ability to directly
              bind and activate the T cells in the absence of self MHC,
              presumably by abundant and regularly repeated antigenic epitopes.
              These findings are important because they demonstrate a specific
              T-cell response against a human tumor-associated antigen. In
              addition to pancreatic and breast tumors, various mucin molecules
              are known to be produced by other tumors of epithelial cell
              origin and could be expected to stimulate similar T-cell-mediated
              immune responses.",
  journal  = "Proc. Natl. Acad. Sci. U. S. A.",
  volume   =  86,
  number   =  18,
  pages    = "7159--7163",
  month    =  sep,
  year     =  1989,
  language = "en"
}

@ARTICLE{Shim1997-mc,
  title    = "c-Myc transactivation of {LDH-A}: implications for tumor
              metabolism and growth",
  author   = "Shim, H and Dolde, C and Lewis, B C and Wu, C S and Dang, G and
              Jungmann, R A and Dalla-Favera, R and Dang, C V",
  abstract = "Cancer cells are able to overproduce lactic acid aerobically,
              whereas normal cells undergo anaerobic glycolysis only when
              deprived of oxygen. Tumor aerobic glycolysis was recognized about
              seven decades ago; however, its molecular basis has remained
              elusive. The lactate dehydrogenase-A gene (LDH-A), whose product
              participates in normal anaerobic glycolysis and is frequently
              increased in human cancers, was identified as a c-Myc-responsive
              gene. Stably transfected Rat1a fibroblasts that overexpress LDH-A
              alone or those transformed by c-Myc overproduce lactic acid.
              LDH-A overexpression is required for c-Myc-mediated
              transformation because lowering its level through antisense LDH-A
              expression reduces soft agar clonogenicity of c-Myc-transformed
              Rat1a fibroblasts, c-Myc-transformed human lymphoblastoid cells,
              and Burkitt lymphoma cells. Although antisense expression of
              LDH-A did not affect the growth of c-Myc-transformed fibroblasts
              adherent to culture dishes under normoxic conditions, the growth
              of these adherent cells in hypoxia was reduced. These
              observations suggest that an increased LDH-A level is required
              for the growth of a transformed spheroid cell mass, which has a
              hypoxic internal microenvironment. Our studies have linked c-Myc
              to the induction of LDH-A, whose expression increases lactate
              production and is necessary for c-Myc-mediated transformation.",
  journal  = "Proc. Natl. Acad. Sci. U. S. A.",
  volume   =  94,
  number   =  13,
  pages    = "6658--6663",
  month    =  jun,
  year     =  1997,
  language = "en"
}

@ARTICLE{Kaplan1998-np,
  title    = "Demonstration of an interferon gamma-dependent tumor surveillance
              system in immunocompetent mice",
  author   = "Kaplan, D H and Shankaran, V and Dighe, A S and Stockert, E and
              Aguet, M and Old, L J and Schreiber, R D",
  abstract = "This study demonstrates that endogenously produced interferon
              gamma (IFN-gamma) forms the basis of a tumor surveillance system
              that controls development of both chemically induced and
              spontaneously arising tumors in mice. Compared with wild-type
              mice, mice lacking sensitivity to either IFN-gamma (i.e.,
              IFN-gamma receptor-deficient mice) or all IFN family members
              (i.e., Stat1-deficient mice) developed tumors more rapidly and
              with greater frequency when challenged with different doses of
              the chemical carcinogen methylcholanthrene. In addition,
              IFN-gamma-insensitive mice developed tumors more rapidly than
              wild-type mice when bred onto a background deficient in the p53
              tumor-suppressor gene. IFN-gamma-insensitive p53(-/-) mice also
              developed a broader spectrum of tumors compared with mice lacking
              p53 alone. Using tumor cells derived from
              methylcholanthrene-treated IFN-gamma-insensitive mice, we found
              IFN-gamma's actions to be mediated at least partly through its
              direct effects on the tumor cell leading to enhanced tumor cell
              immunogenicity. The importance and generality of this system is
              evidenced by the finding that certain types of human tumors
              become selectively unresponsive to IFN-gamma. Thus, IFN-gamma
              forms the basis of an extrinsic tumor-suppressor mechanism in
              immunocompetent hosts.",
  journal  = "Proc. Natl. Acad. Sci. U. S. A.",
  volume   =  95,
  number   =  13,
  pages    = "7556--7561",
  month    =  jun,
  year     =  1998,
  language = "en"
}

@ARTICLE{Mookerjee2017-wh,
  title    = "Quantifying intracellular rates of glycolytic and oxidative {ATP}
              production and consumption using extracellular flux measurements",
  author   = "Mookerjee, Shona A and Gerencser, Akos A and Nicholls, David G
              and Brand, Martin D",
  abstract = "Partitioning of ATP generation between glycolysis and oxidative
              phosphorylation is central to cellular bioenergetics but
              cumbersome to measure. We describe here how rates of ATP
              generation by each pathway can be calculated from simultaneous
              measurements of extracellular acidification and oxygen
              consumption. We update theoretical maximum ATP yields by
              mitochondria and cells catabolizing different substrates.
              Mitochondrial P/O ratios (mol of ATP generated per mol of [O]
              consumed) are 2.73 for oxidation of pyruvate plus malate and 1.64
              for oxidation of succinate. Complete oxidation of glucose by
              cells yields up to 33.45 ATP/glucose with a maximum P/O of 2.79.
              We introduce novel indices to quantify bioenergetic phenotypes.
              The glycolytic index reports the proportion of ATP production
              from glycolysis and identifies cells as primarily glycolytic
              (glycolytic index > 50\%) or primarily oxidative. The Warburg
              effect is a chronic increase in glycolytic index, quantified by
              the Warburg index. Additional indices quantify the acute
              flexibility of ATP supply. The Crabtree index and Pasteur index
              quantify the responses of oxidative and glycolytic ATP production
              to alterations in glycolysis and oxidative reactions,
              respectively; the supply flexibility index quantifies overall
              flexibility of ATP supply; and the bioenergetic capacity
              quantifies the maximum rate of total ATP production. We
              illustrate the determination of these indices using C2C12
              myoblasts. Measurement of ATP use revealed no significant
              preference for glycolytic or oxidative ATP by specific ATP
              consumers. Overall, we demonstrate how extracellular fluxes
              quantitatively reflect intracellular ATP turnover and cellular
              bioenergetics. We provide a simple spreadsheet to calculate
              glycolytic and oxidative ATP production rates from raw
              extracellular acidification and respiration data.",
  journal  = "J. Biol. Chem.",
  volume   =  292,
  number   =  17,
  pages    = "7189--7207",
  month    =  apr,
  year     =  2017,
  keywords = "ATP; ECAR; OCR; bioenergetics; energy metabolism; glycolysis;
              metabolic index; mitochondria; oxidative phosphorylation",
  language = "en"
}

@ARTICLE{Babini2002-sp,
  title    = "Alternative splicing and interaction with di- and polyvalent
              cations control the dynamic range of acid-sensing ion channel 1
              ({ASIC1})",
  author   = "Babini, Elena and Paukert, Martin and Geisler, Hyun-Soon and
              Grunder, Stefan",
  abstract = "Homomeric acid-sensing ion channel 1 (ASIC1) can be activated by
              extracellular H(+) in the physiological pH range and may,
              therefore, contribute to neurotransmission and peripheral pain
              perception. ASIC1a and ASIC1b are alternative splice products of
              the ASIC1 gene. Here we show that both splice variants show
              steady-state inactivation when exposed to slightly decreased pH,
              limiting their operational range. Compared with ASIC1a,
              steady-state inactivation and pH activation of ASIC1b are shifted
              to more acidic values by 0.25 and 0.7 pH units, respectively,
              extending the dynamic range of ASIC1. Shifts of inactivation and
              activation are intimately linked; only two amino acids in the
              ectodomain, which are exchanged by alternative splicing, control
              both properties. Moreover, we show that extracellular, divalent
              cations like Ca(2+) and Mg(2+) as well as the polyvalent cation
              spermine shift the steady-state inactivation of ASIC1a and ASIC1b
              to more acidic values. This leads to a potentiation of the
              channel response and is due to a stabilization of the resting
              state. Our results indicate that ASIC1b is an effective sensor of
              transient H(+) signals during slight acidosis and that, in
              addition to alternative splicing, interaction with di- and
              polyvalent cations extends the dynamic range of ASIC H(+)
              sensors.",
  journal  = "J. Biol. Chem.",
  volume   =  277,
  number   =  44,
  pages    = "41597--41603",
  month    =  nov,
  year     =  2002,
  language = "en"
}

@ARTICLE{Adrain2005-ng,
  title    = "Molecular ordering of the caspase activation cascade initiated by
              the cytotoxic {T} lymphocyte/natural killer ({CTL/NK}) protease
              granzyme {B}",
  author   = "Adrain, Colin and Murphy, Brona M and Martin, Seamus J",
  abstract = "Granzyme B is a major cytotoxic T lymphocyte/natural killer
              (CTL/NK) granule protease that can activate members of the
              caspase family of cysteine proteases through processing of
              caspase zymogens. However, the molecular order and relative
              importance of caspase activation events that occur in target
              cells during granzyme B-initiated apoptosis has not been
              established. Here, we have examined the hierarchy of granzyme
              B-initiated caspase activation events using a cell-free system
              where all caspases are present at physiological levels. We show
              that granzyme B initiates a two-tiered caspase activation cascade
              involving seven caspases, where caspase-3 is required for the
              second tier of caspase activation events. Using a two-dimensional
              gel-based proteomics approach we have also examined the scale of
              granzyme B-initiated alterations to the proteome in the presence
              or absence of effector caspase-3 or -7. These studies indicate
              that granzyme B targets a highly restricted range of substrates
              and orchestrates cellular demolition largely through activation
              of caspase-3.",
  journal  = "J. Biol. Chem.",
  volume   =  280,
  number   =  6,
  pages    = "4663--4673",
  month    =  feb,
  year     =  2005,
  language = "en"
}

@ARTICLE{Ogilvie2009-pl,
  title    = "Tristetraprolin mediates interferon-gamma {mRNA} decay",
  author   = "Ogilvie, Rachel L and Sternjohn, Julius R and Rattenbacher, Bernd
              and Vlasova, Irina A and Williams, Darlisha A and Hau, Heidi H
              and Blackshear, Perry J and Bohjanen, Paul R",
  abstract = "Tristetraprolin (TTP) regulates expression at the level of mRNA
              decay of several cytokines, including the T cell-specific
              cytokine, interleukin-2. We performed experiments to determine
              whether another T cell-specific cytokine, interferon-gamma
              (IFN-gamma), is also regulated by TTP and found that T cell
              receptor-activated T cells from TTP knock-out mice overproduced
              IFN-gamma mRNA and protein compared with activated T cells from
              wild-type mice. The half-life of IFN-gamma mRNA was 23 min in
              anti-CD3-stimulated T cells from wild-type mice, whereas it was
              51 min in anti-CD3-stimulated T cells from TTP knock-out mice,
              suggesting that the overexpression of IFN-gamma mRNA in TTP
              knock-out mice was due to stabilization of IFN-gamma mRNA.
              Insertion of a 70-nucleotide AU-rich sequence from the murine
              IFN-gamma 3'-untranslated region, which contained a high affinity
              binding site for TTP, into the 3'-untranslated region of a
              beta-globin reporter transcript conferred TTP-dependent
              destabilization on the beta-globin transcript. Together these
              results suggest that TTP binds to a functional AU-rich element in
              the 3'-untranslated region of IFN-gamma mRNA and mediates rapid
              degradation of the IFN-gamma transcript. Thus, TTP plays an
              important role in turning off IFN-gamma expression at the
              appropriate time during an immune response.",
  journal  = "J. Biol. Chem.",
  volume   =  284,
  number   =  17,
  pages    = "11216--11223",
  month    =  apr,
  year     =  2009,
  language = "en"
}

@ARTICLE{Mathis2017-sw,
  title    = "Mechanisms of In Vivo Ribosome Maintenance Change in Response to
              Nutrient Signals",
  author   = "Mathis, Andrew D and Naylor, Bradley C and Carson, Richard H and
              Evans, Eric and Harwell, Justin and Knecht, Jared and Hexem, Eric
              and Peelor, 3rd, Fredrick F and Miller, Benjamin F and Hamilton,
              Karyn L and Transtrum, Mark K and Bikman, Benjamin T and Price,
              John C",
  abstract = "Control of protein homeostasis is fundamental to the health and
              longevity of all organisms. Because the rate of protein synthesis
              by ribosomes is a central control point in this process,
              regulation, and maintenance of ribosome function could have
              amplified importance in the overall regulatory circuit. Indeed,
              ribosomal defects are commonly associated with loss of protein
              homeostasis, aging, and disease (1-4), whereas improved protein
              homeostasis, implying optimal ribosomal function, is associated
              with disease resistance and increased lifespan (5-7). To maintain
              a high-quality ribosome population within the cell, dysfunctional
              ribosomes are targeted for autophagic degradation. It is not
              known if complete degradation is the only mechanism for
              eukaryotic ribosome maintenance or if they might also be repaired
              by replacement of defective components. We used stable-isotope
              feeding and protein mass spectrometry to measure the kinetics of
              turnover of ribosomal RNA (rRNA) and 71 ribosomal proteins
              (r-proteins) in mice. The results indicate that exchange of
              individual proteins and whole ribosome degradation both
              contribute to ribosome maintenance in vivo In general, peripheral
              r-proteins and those with more direct roles in peptide-bond
              formation are replaced multiple times during the lifespan of the
              assembled structure, presumably by exchange with a free
              cytoplasmic pool, whereas the majority of r-proteins are stably
              incorporated for the lifetime of the ribosome. Dietary signals
              impact the rates of both new ribosome assembly and component
              exchange. Signal-specific modulation of ribosomal repair and
              degradation could provide a mechanistic link in the frequently
              observed associations among diminished rates of protein
              synthesis, increased autophagy, and greater longevity (5, 6, 8,
              9).",
  journal  = "Mol. Cell. Proteomics",
  volume   =  16,
  number   =  2,
  pages    = "243--254",
  month    =  feb,
  year     =  2017,
  language = "en"
}

@ARTICLE{Sullivan2019-ny,
  title    = "Determinants of nutrient limitation in cancer",
  author   = "Sullivan, Mark R and Vander Heiden, Matthew G",
  abstract = "Proliferation requires that cells accumulate sufficient biomass
              to grow and divide. Cancer cells within tumors must acquire a
              variety of nutrients, and tumor growth slows or stops if
              necessary metabolites are not obtained in sufficient quantities.
              Importantly, the metabolic demands of cancer cells can be
              different from those of untransformed cells, and nutrient
              accessibility in tumors is different than in many normal tissues.
              Thus, cancer cell survival and proliferation may be limited by
              different metabolic factors than those that are necessary to
              maintain noncancerous cells. Understanding the variables that
              dictate which nutrients are critical to sustain tumor growth may
              identify vulnerabilities that could be used to treat cancer. This
              review examines the various cell-autonomous, local, and systemic
              factors that determine which nutrients are limiting for tumor
              growth.",
  journal  = "Crit. Rev. Biochem. Mol. Biol.",
  volume   =  54,
  number   =  3,
  pages    = "193--207",
  month    =  jun,
  year     =  2019,
  keywords = "Cancer; collateral lethality; metabolism; nutrient limitation;
              tumor microenvironment",
  language = "en"
}

@ARTICLE{Kuznetsova2015-fe,
  title    = "Chromosomal instability, tolerance of mitotic errors and
              multidrug resistance are promoted by tetraploidization in human
              cells",
  author   = "Kuznetsova, Anastasia Y and Seget, Katarzyna and Moeller,
              Giuliana K and de Pagter, Mirjam S and de Roos, Jeroen A D M and
              D{\"u}rrbaum, Milena and Kuffer, Christian and M{\"u}ller, Stefan
              and Zaman, Guido J R and Kloosterman, Wigard P and Storchov{\'a},
              Zuzana",
  abstract = "Up to 80\% of human cancers, in particular solid tumors, contain
              cells with abnormal chromosomal numbers, or aneuploidy, which is
              often linked with marked chromosomal instability. Whereas in some
              tumors the aneuploidy occurs by missegregation of one or a few
              chromosomes, aneuploidy can also arise during proliferation of
              inherently unstable tetraploid cells generated by whole genome
              doubling from diploid cells. Recent findings from cancer genome
              sequencing projects suggest that nearly 40\% of tumors underwent
              whole genome doubling at some point of tumorigenesis, yet its
              contribution to cancer phenotypes and benefits for malignant
              growth remain unclear. Here, we investigated the consequences of
              a whole genome doubling in both cancerous and non-transformed p53
              positive human cells. SNP array analysis and multicolor
              karyotyping revealed that induced whole-genome doubling led to
              variable aneuploidy. We found that chromosomal instability (CIN)
              is a frequent, but not a default outcome of whole genome
              doubling. The CIN phenotypes were accompanied by increased
              tolerance to mitotic errors that was mediated by suppression of
              the p53 signaling. Additionally, the expression of pro-apoptotic
              factors, such as iASPP and cIAP2, was downregulated. Furthermore,
              we found that whole genome doubling promotes resistance to a
              broad spectrum of chemotherapeutic drugs and stimulates
              anchorage-independent growth even in non-transformed p53-positive
              human cells. Taken together, whole genome doubling provides
              multifaceted benefits for malignant growth. Our findings provide
              new insight why genome-doubling promotes tumorigenesis and
              correlates with poor survival in cancer.",
  journal  = "Cell Cycle",
  volume   =  14,
  number   =  17,
  pages    = "2810--2820",
  year     =  2015,
  keywords = "CIN; aneuploidy; cancer; drug resistance; p53; tetraploidy; whole
              genome doubling",
  language = "en"
}

@ARTICLE{Ruijtenberg2016-zr,
  title    = "Coordinating cell proliferation and differentiation: Antagonism
              between cell cycle regulators and cell type-specific gene
              expression",
  author   = "Ruijtenberg, Suzan and van den Heuvel, Sander",
  abstract = "Cell proliferation and differentiation show a remarkable inverse
              relationship. Precursor cells continue division before acquiring
              a fully differentiated state, while terminal differentiation
              usually coincides with proliferation arrest and permanent exit
              from the division cycle. Mechanistic insight in the temporal
              coordination between cell cycle exit and differentiation has come
              from studies of cells in culture and genetic animal models. As
              initially described for skeletal muscle differentiation, temporal
              coordination involves mutual antagonism between cyclin-dependent
              kinases that promote cell cycle entry and transcription factors
              that induce tissue-specific gene expression. Recent insights
              highlight the contribution of chromatin-regulating complexes that
              act in conjunction with the transcription factors and determine
              their activity. In particular SWI/SNF chromatin remodelers
              contribute to dual regulation of cell cycle and tissue-specific
              gene expression during terminal differentiation. We review the
              concerted regulation of the cell cycle and cell type-specific
              transcription, and discuss common mutations in human cancer that
              emphasize the clinical importance of proliferation versus
              differentiation control.",
  journal  = "Cell Cycle",
  volume   =  15,
  number   =  2,
  pages    = "196--212",
  year     =  2016,
  keywords = "SWI/SNF; cell cycle; chromatin remodeling; differentiation;
              proliferation",
  language = "en"
}

@ARTICLE{Cheng2021-dr,
  title    = "Energy restriction causes metaphase delay and chromosome
              mis-segregation in cancer cells",
  author   = "Cheng, Aoxing and Jiang, Ya and Wang, Ting and Yu, Fazhi and
              Ishrat, Iqra and Zhang, Dongming and Ji, Xiaoyang and Chen,
              Minhua and Xiao, Weihua and Li, Qing and Zhang, Kaiguang and Niu,
              Gang and Shi, Jue and Pan, Yueyin and Yang, Zhenye and Guo, Jing",
  abstract = "ATP metabolism during mitosis needs to be coordinated with
              numerous energy-demanding activities, especially in cancer cells
              whose metabolic pathways are reprogramed to sustain rapid
              proliferation in a nutrient-deficient environment. Although
              strategies targeting the energy metabolic pathways have shown
              therapeutic efficacy in preclinical cancer models, how normal
              cells and cancer cells differentially respond to energy shortage
              is unclear. In this study, using time-lapse microscopy, we found
              that cancer cells displayed unique mitotic phenotypes in a
              dose-dependent manner upon decreasing ATP (i.e. energy) supply.
              When reduction in ATP concentration was moderate, chromosome
              movements in mitosis were barely affected, while the
              metaphase-anaphase transition was significantly prolonged due to
              reduced tension between the sister-kinetochores, which delayed
              the satisfaction of the spindle assembly checkpoint. Further
              reduction in ATP concentration led to a decreased level of
              Aurora-B at the centromere, resulting in increased chromosome
              mis-segregation after metaphase delay. In contrast to cancer
              cells, ATP restriction in non-transformed cells induced cell
              cycle arrest in interphase, rather than causing mitotic defects.
              In addition, data mining of cancer patient database showed a
              correlation between signatures of energy production and
              chromosomal instability possibly resulted from mitotic defects.
              Together, these results reveal that energy restriction induces
              differential responses in normal and cancer cells, with
              chromosome mis-segregation only observed in cancer cells. This
              points to targeting energy metabolism as a potentially
              cancer-selective therapeutic strategy.",
  journal  = "Cell Cycle",
  volume   =  20,
  number   =  12,
  pages    = "1195--1208",
  month    =  jun,
  year     =  2021,
  keywords = "ATP; cancer cells; chromosome mis-segregation; energy
              restriction; metaphase-anaphase transition",
  language = "en"
}

@ARTICLE{Hirano2015-yg,
  title    = "The nitric oxide radical scavenger {carboxy-PTIO} reduces the
              immunosuppressive activity of myeloid-derived suppressor cells
              and potentiates the antitumor activity of adoptive cytotoxic {T}
              lymphocyte immunotherapy",
  author   = "Hirano, Kosuke and Hosoi, Akihiro and Matsushita, Hirokazu and
              Iino, Tamaki and Ueha, Satoshi and Matsushima, Kouji and Seto,
              Yasuyuki and Kakimi, Kazuhiro",
  abstract = "Adoptive immunotherapy with cytotoxic T lymphocytes (CTLs) can
              result in robust and durable antitumor responses.
              Tumor-infiltrating CTLs produce IFN$\gamma$ and mediate antitumor
              activity, but they simultaneously induce counter-regulatory
              immunosuppressive mechanisms in the tumor by recruiting monocytic
              myeloid-derived suppressor cells (MDSCs) that limit their
              proliferation and effector function. Using a murine model of
              adoptive immunotherapy for B16 melanoma, we developed a strategy
              to augment CTL activity by downregulating immunosuppression by
              MDSCs. Intravenous injection of transgenic pmel-1 CTLs into
              tumor-bearing mice, resulted in their infiltration into the
              tumor, but this was accompanied by the accumulation of large
              numbers of monocytic MDSCs (M-MDSCs). These cells hampered CTL
              function and reduced their numbers in the tumor. We determined
              that one mechanism responsible for this immunosuppression was the
              production of nitric oxide (NO) by MDSCs in the tumor. Therefore,
              mice were given the NO scavenger carboxy-PTIO (C-PTIO) on the day
              after CTL transfer. This led to the restoration of impaired
              proliferative capacity and function of the CTLs, resulting in
              sustained suppression of tumor growth. Thus, we conclude that CTL
              therapy can be improved by counter-acting immunosuppression.
              Targeting NO, one mediator of the immunosuppressive activity of
              M-MDSCs, may be an appropriate strategy to restore impaired CTL
              function and improve the efficacy of immunotherapy.",
  journal  = "Oncoimmunology",
  volume   =  4,
  number   =  8,
  pages    = "e1019195",
  month    =  aug,
  year     =  2015,
  keywords = "CTL; adoptive transfer; carboxy-PTIO; myeloid-derived suppressor
              cells (MDSCs); nitric oxide (NO);B16F10\_specific",
  language = "en"
}

@ARTICLE{Kather2018-og,
  title    = "Large-scale database mining reveals hidden trends and future
              directions for cancer immunotherapy",
  author   = "Kather, Jakob Nikolas and Berghoff, Anna Sophie and Ferber, Dyke
              and Suarez-Carmona, Meggy and Reyes-Aldasoro, Constantino Carlos
              and Valous, Nektarios A and Rojas-Moraleda, Rodrigo and
              J{\"a}ger, Dirk and Halama, Niels",
  abstract = "Cancer immunotherapy has fundamentally changed the landscape of
              oncology in recent years and significant resources are invested
              into immunotherapy research. It is in the interests of
              researchers and clinicians to identify promising and less
              promising trends in this field in order to rationally allocate
              resources. This requires a quantitative large-scale analysis of
              cancer immunotherapy related databases. We developed a novel tool
              for text mining, statistical analysis and data visualization of
              scientific literature data. We used this tool to analyze 72002
              cancer immunotherapy publications and 1469 clinical trials from
              public databases. All source codes are available under an open
              access license. The contribution of specific topics within the
              cancer immunotherapy field has markedly shifted over the years.
              We show that the focus is moving from cell-based therapy and
              vaccination towards checkpoint inhibitors, with these trends
              reaching statistical significance. Rapidly growing subfields
              include the combination of chemotherapy with checkpoint blockade.
              Translational studies have shifted from hematological and skin
              neoplasms to gastrointestinal and lung cancer and from tumor
              antigens and angiogenesis to tumor stroma and apoptosis. This
              work highlights the importance of unbiased large-scale database
              mining to assess trends in cancer research and cancer
              immunotherapy in particular. Researchers, clinicians and funding
              agencies should be aware of quantitative trends in the
              immunotherapy field, allocate resources to the most promising
              areas and find new approaches for currently immature topics.",
  journal  = "Oncoimmunology",
  volume   =  7,
  number   =  7,
  pages    = "e1444412",
  month    =  mar,
  year     =  2018,
  keywords = "Cancer immunotherapy; checkpoint inhibition; database mining;
              gastrointestinal cancer; lung cancer; translational research",
  language = "en"
}

@ARTICLE{Kather2018-kd,
  title    = "Large-scale database mining reveals hidden trends and future
              directions for cancer immunotherapy",
  author   = "Kather, Jakob Nikolas and Berghoff, Anna Sophie and Ferber, Dyke
              and Suarez-Carmona, Meggy and Reyes-Aldasoro, Constantino Carlos
              and Valous, Nektarios A and Rojas-Moraleda, Rodrigo and
              J{\"a}ger, Dirk and Halama, Niels",
  abstract = "Cancer immunotherapy has fundamentally changed the landscape of
              oncology in recent years and significant resources are invested
              into immunotherapy research. It is in the interests of
              researchers and clinicians to identify promising and less
              promising trends in this field in order to rationally allocate
              resources. This requires a quantitative large-scale analysis of
              cancer immunotherapy related databases. We developed a novel tool
              for text mining, statistical analysis and data visualization of
              scientific literature data. We used this tool to analyze 72002
              cancer immunotherapy publications and 1469 clinical trials from
              public databases. All source codes are available under an open
              access license. The contribution of specific topics within the
              cancer immunotherapy field has markedly shifted over the years.
              We show that the focus is moving from cell-based therapy and
              vaccination towards checkpoint inhibitors, with these trends
              reaching statistical significance. Rapidly growing subfields
              include the combination of chemotherapy with checkpoint blockade.
              Translational studies have shifted from hematological and skin
              neoplasms to gastrointestinal and lung cancer and from tumor
              antigens and angiogenesis to tumor stroma and apoptosis. This
              work highlights the importance of unbiased large-scale database
              mining to assess trends in cancer research and cancer
              immunotherapy in particular. Researchers, clinicians and funding
              agencies should be aware of quantitative trends in the
              immunotherapy field, allocate resources to the most promising
              areas and find new approaches for currently immature topics.",
  journal  = "Oncoimmunology",
  volume   =  7,
  number   =  7,
  pages    = "e1444412",
  month    =  mar,
  year     =  2018,
  keywords = "Cancer immunotherapy; checkpoint inhibition; database mining;
              gastrointestinal cancer; lung cancer; translational research",
  language = "en"
}

@ARTICLE{Carmona2020-yu,
  title    = "Deciphering the transcriptomic landscape of tumor-infiltrating
              {CD8} lymphocytes in {B16} melanoma tumors with single-cell
              {RNA-Seq}",
  author   = "Carmona, Santiago J and Siddiqui, Imran and Bilous, Mariia and
              Held, Werner and Gfeller, David",
  abstract = "Recent studies have proposed that tumor-specific
              tumor-infiltrating CD8+ T lymphocytes (CD8 TIL) can be classified
              into two main groups: ``exhausted'' TILs, characterized by high
              expression of the inhibitory receptors PD-1 and TIM-3 and lack of
              transcription factor 1 (Tcf1); and ``memory-like'' TILs, with
              self-renewal capacity and co-expressing Tcf1 and PD-1. However, a
              comprehensive definition of the heterogeneity existing within CD8
              TILs has yet to be clearly established. To investigate this
              heterogeneity at the transcriptomic level, we performed paired
              single-cell RNA and TCR sequencing of CD8 T cells infiltrating
              B16 murine melanoma tumors, including cells of known tumor
              specificity. Unsupervised clustering and gene-signature analysis
              revealed four distinct CD8 TIL states - exhausted, memory-like,
              na{\"\i}ve and effector memory-like (EM-like) - and predicted
              novel markers, including Ly6C for the EM-like cells, that were
              validated by flow cytometry. Tumor-specific PMEL T cells were
              predominantly found within the exhausted and memory-like states
              but also within the EM-like state. Further, T cell receptor
              sequencing revealed a large clonal expansion of exhausted,
              memory-like and EM-like cells with partial clonal relatedness
              between them. Finally, meta-analyses of public bulk and
              single-cell RNA-seq data suggested that anti-PD-1 treatment
              induces the expansion of EM-like cells. Our reference map of the
              transcriptomic landscape of murine CD8 TILs will help
              interpreting future bulk and single-cell transcriptomic studies
              and may guide the analysis of CD8IL subpopulations in response to
              therapeutic interventions.",
  journal  = "Oncoimmunology",
  volume   =  9,
  number   =  1,
  pages    = "1737369",
  month    =  mar,
  year     =  2020,
  keywords = "B16-F10 melanoma; CD8 TIL classifier; Single-cell RNA-Seq;
              effector memory T cells; tumor-infiltrating CD8 T cells",
  language = "en"
}

@ARTICLE{Nikolopoulou2018-bh,
  title     = "Tumour-immune dynamics with an immune checkpoint inhibitor",
  author    = "Nikolopoulou, Elpiniki and Johnson, Lauren R and Harris, Duane
               and Nagy, John D and Stites, Edward C and Kuang, Yang",
  abstract  = "AbstractThe use of immune checkpoint inhibitors is becoming more
               commonplace in clinical trials across the nation. Two important
               factors in the tumour-immune response are the checkpoint protein
               programmed death-1 (PD-1) and its ligand PD-L1. We propose a
               mathematical tumour-immune model using a system of ordinary
               differential equations to study dynamics with and without the
               use of anti-PD-1. A sensitivity analysis is conducted, and
               series of simulations are performed to investigate the effects
               of intermittent and continuous treatments on the tumour-immune
               dynamics. We consider the system without the anti-PD-1 drug to
               conduct a mathematical analysis to determine the stability of
               the tumour-free and tumorous equilibria. Through simulations, we
               found that a normally functioning immune system may control
               tumour. We observe treatment with anti-PD-1 alone may not be
               sufficient to eradicate tumour cells. Therefore, it may be
               beneficial to combine single agent treatments with additional
               therapies to obtain a better antitumour response.",
  journal   = "Letters in Biomathematics",
  publisher = "Taylor \& Francis",
  volume    =  5,
  number    = "sup1",
  pages     = "S137--S159",
  month     =  jun,
  year      =  2018
}

@ARTICLE{Leitao2017-ya,
  title    = "The duration of mitosis and daughter cell size are modulated by
              nutrients in budding yeast",
  author   = "Leitao, Ricardo M and Kellogg, Douglas R",
  abstract = "The size of nearly all cells is modulated by nutrients. Thus,
              cells growing in poor nutrients can be nearly half the size of
              cells in rich nutrients. In budding yeast, cell size is thought
              to be controlled almost entirely by a mechanism that delays cell
              cycle entry until sufficient growth has occurred in G1 phase.
              Here, we show that most growth of a new daughter cell occurs in
              mitosis. When the rate of growth is slowed by poor nutrients, the
              duration of mitosis is increased, which suggests that cells
              compensate for slow growth in mitosis by increasing the duration
              of growth. The amount of growth required to complete mitosis is
              reduced in poor nutrients, leading to a large reduction in cell
              size. Together, these observations suggest that mechanisms that
              control the extent of growth in mitosis play a major role in cell
              size control in budding yeast.",
  journal  = "J. Cell Biol.",
  volume   =  216,
  number   =  11,
  pages    = "3463--3470",
  month    =  nov,
  year     =  2017,
  language = "en"
}

@ARTICLE{Peters1991-av,
  title    = "Cytotoxic {T} lymphocyte granules are secretory lysosomes,
              containing both perforin and granzymes",
  author   = "Peters, P J and Borst, J and Oorschot, V and Fukuda, M and
              Kr{\"a}henb{\"u}hl, O and Tschopp, J and Slot, J W and Geuze, H J",
  abstract = "Cytotoxic T lymphocytes (CTL) contain granules that are
              exocytosed during specific interaction with target cells (TC). In
              this process, the granule contents, including the lethal protein
              perforin, as well as granzymes, a family of serine esterases, are
              delivered to the TC. Information regarding the routing of these
              proteins towards the granule and their exact localization within
              the granule is of primary importance to resolve the mechanism of
              granule-mediated TC killing. In this study, the subcellular
              localization of perforin, granzymes, and known endosomal and
              lysosomal marker proteins was determined in human and murine CTL,
              by immunogold labeling of ultrathin cryosections followed by
              electron microscopy. Perforin and granzymes can be detected in
              rough endoplasmic reticulum, Golgi complex, trans-Golgi
              reticulum, and in all cytotoxic granules. Within the granules,
              they have a similar distribution and are localized not only in
              the so-called dense core but also over the region containing
              small internal vesicles. This finding implies that perforin and
              granzymes can be released in membrane-enveloped and/or
              -associated form into the intercellular cleft formed upon CTL-TC
              interaction. On the basis of the present evidence, additional
              release of these molecules in soluble form cannot be excluded.
              The lysosomal membrane glycoproteins lamp-1, lamp-2, and CD63,
              are abundantly present on the granule-delimiting outer membrane,
              which becomes incorporated into the CTL plasma membrane during
              lethal hit delivery. In contrast, the cation-dependent mannose
              6-phosphate receptor, known to be present in endosomes and absent
              from lysosomes, is found only in a minority of the granules.
              Together with our previous findings that the granules are acidic
              and connected to the endocytic pathway, these observations define
              CTL granules as secretory lysosomes.",
  journal  = "J. Exp. Med.",
  volume   =  173,
  number   =  5,
  pages    = "1099--1109",
  month    =  may,
  year     =  1991,
  keywords = "Direct Killing (Perf/Gzym/FAS)",
  language = "en"
}

@ARTICLE{Van_den_Broek1996-oh,
  title    = "Decreased tumor surveillance in perforin-deficient mice",
  author   = "van den Broek, M E and K{\"a}gi, D and Ossendorp, F and Toes, R
              and Vamvakas, S and Lutz, W K and Melief, C J and Zinkernagel, R
              M and Hengartner, H",
  abstract = "Immune surveillance against tumors usually depends on T cell
              recognition of tumor antigens presented by major
              histocompatibility complex (MHC) molecules, whereas MHC class I-
              tumors may be controlled by natural killer (NK) cells.
              Perforin-dependent cytotoxicity is a major effector function of
              CD8+ MHC class I-restricted T cells and of NK cells. Here, we
              used perforin-deficient C57BL/6 (PKO) mice to study involvement
              of perforin and Fas ligand in tumor surveillance in vivo. We
              induced tumors in PKO and normal C57BL/6 mice by (a) injection of
              different syngeneic tumor cell lines of different tissue origin
              in naive and primed mice; (b) administration of the chemical
              carcinogens methylcholanthrene (MCA) or
              12-O-tetradecanoylphorbol-13-acetate (TPA) plus
              7,12-dimethylbenzanthracene (DMBA), or (c) by injection of
              acutely oncogenic Moloney sarcoma virus. The first set of models
              analyzes the defense against a tumor load given at once, whereas
              the last two sets give information on immune defense against
              tumors at the very moment of their generation. Most of the tumor
              cell lines tested were eliminated 10-100-fold better by C57BL/6
              mice in an unprimed situation; after priming, the differences
              were more pronounced. Lymphoma cells transfected with Fas were
              controlled 10-fold better by PKO and C57BL/6 mice when compared
              to untransfected control cells, indicating some role for FasL in
              tumor control. MCA-induced tumors arose more rapidly and with a
              higher incidence in PKO mice compared to C57BL/6 or CD8-deficient
              mice. DMBA+TPA-induced skin papillomas arose with similar high
              incidence and comparable kinetics in both mouse strains. C57BL/6
              and PKO mice have a similar incidence of Moloney murine sarcoma
              and leukemia virus-induced sarcomas, but tumors are larger and
              regression is retarded in PKO mice. Thus, perforin-dependent
              cytotoxicity is not only a crucial mechanism of both cytotoxic T
              lymphocyte- and NK-dependent resistance to injected tumor cell
              lines, but also operates during viral and chemical carcinogenesis
              in vivo. Experiments addressing the role of Fas-dependent
              cytotoxicity by studying resistance to tumor cell lines that were
              stably transfected with Fas neither provided evidence for a major
              role of Fas nor excluded a minor contribution of Fas in tumor
              surveillance.",
  journal  = "J. Exp. Med.",
  volume   =  184,
  number   =  5,
  pages    = "1781--1790",
  month    =  nov,
  year     =  1996,
  language = "en"
}

@ARTICLE{Leist1997-de,
  title    = "Intracellular adenosine triphosphate ({ATP}) concentration: a
              switch in the decision between apoptosis and necrosis",
  author   = "Leist, M and Single, B and Castoldi, A F and K{\"u}hnle, S and
              Nicotera, P",
  abstract = "Apoptosis and necrosis are considered conceptually and
              morphologically distinct forms of cell death. Here, we report
              that demise of human T cells caused by two classic apoptotic
              triggers (staurosporin and CD95 stimulation) changed from
              apoptosis to necrosis, when cells were preemptied of adenosine
              triphosphate (ATP). Nuclear condensation and DNA fragmentation
              did not occur in cells predepleted of ATP and treated with either
              of the two inducers, although the kinetics of cell death were
              unchanged. Selective and graded repletion of the
              extramitochondrial ATP/pool with glucose prevented necrosis and
              restored the ability of the cells to undergo apoptosis. Pulsed
              ATP/depletion/repletion experiments also showed that ATP
              generation either by glycolysis or by mitochondria was required
              for the active execution of the final phase of apoptosis, which
              involves nuclear condensation and DNA degradation.",
  journal  = "J. Exp. Med.",
  volume   =  185,
  number   =  8,
  pages    = "1481--1486",
  month    =  apr,
  year     =  1997,
  language = "en"
}

@ARTICLE{Shuford1997-jr,
  title    = "{4-1BB} costimulatory signals preferentially induce {CD8+} {T}
              cell proliferation and lead to the amplification in vivo of
              cytotoxic {T} cell responses",
  author   = "Shuford, W W and Klussman, K and Tritchler, D D and Loo, D T and
              Chalupny, J and Siadak, A W and Brown, T J and Emswiler, J and
              Raecho, H and Larsen, C P and Pearson, T C and Ledbetter, J A and
              Aruffo, A and Mittler, R S",
  abstract = "The 4-1BB receptor is an inducible type I membrane protein and
              member of the tumor necrosis factor receptor (TNFR) superfamily
              that is rapidly expressed on the surface of CD4+ and CD8+ T cells
              after antigen- or mitogen-induced activation. Cross-linking of
              4-1BB and the T cell receptor (TCR) on activated T cells has been
              shown to deliver a costimulatory signal to T cells. Here, we
              expand upon previously published studies by demonstrating that
              CD8+ T cells when compared with CD4+ T cells are preferentially
              responsive to both early activation events and proliferative
              signals provided via the TCR and 4-1BB. In comparison,
              CD28-mediated costimulatory signals appear to function in a
              reciprocal manner to those induced through 4-1BB costimulation.
              In vivo examination of the effects of anti-4-1BB monoclonal
              antibodies (mAbs) on antigen-induced T cell activation have shown
              that the administration of epitope-specific anti-4-1BB mAbs
              amplified the generation of H-2d-specific cytotoxic T cells in a
              murine model of acute graft versus host disease (GVHD) and
              enhanced the rapidity of cardiac allograft or skin transplant
              rejection in mice. Cytokine analysis of in vitro activated CD4+
              and CD8+ T cells revealed that anti-4-1BB costimulation markedly
              enhanced interferon-gamma production by CD8+ T cells and that
              anti-4-1BB mediated proliferation of CD8+ T cells appears to be
              IL-2 independent. The results of these studies suggest that
              regulatory signals delivered by the 4-1BB receptor play an
              important role in the regulation of cytotoxic T cells in cellular
              immune responses to antigen.",
  journal  = "J. Exp. Med.",
  volume   =  186,
  number   =  1,
  pages    = "47--55",
  month    =  jul,
  year     =  1997,
  language = "en"
}

@ARTICLE{Smyth2000-op,
  title    = "Perforin-mediated cytotoxicity is critical for surveillance of
              spontaneous lymphoma",
  author   = "Smyth, M J and Thia, K Y and Street, S E and MacGregor, D and
              Godfrey, D I and Trapani, J A",
  abstract = "Immune surveillance by cytotoxic lymphocytes against cancer has
              been postulated for decades, but direct evidence for the role of
              cytotoxic lymphocytes in protecting against spontaneous
              malignancy has been lacking. As the rejection of many
              experimental cancers by cytotoxic T lymphocytes and natural
              killer cells is dependent on the pore-forming protein perforin
              (pfp), we examined pfp-deficient mice for increased cancer
              susceptibility. Here we show that pfp-deficient mice have a high
              incidence of malignancy in distinct lymphoid cell lineages (T, B,
              NKT), indicating a specific requirement for pfp in protection
              against lymphomagenesis. The susceptibility to lymphoma was
              accentuated by simultaneous lack of expression of the p53 gene,
              mutations in which also commonly predispose to human
              malignancies, including lymphoma. In contrast, the incidence and
              age of onset of sarcoma was unaffected in p53-deficient mice.
              Pfp-deficient mice were at least 1,000-fold more susceptible to
              these lymphomas when transplanted, compared with immunocompetent
              mice in which tumor rejection was controlled by CD8(+) T
              lymphocytes. This study is the first that implicates direct
              cytotoxicity by lymphocytes in regulating lymphomagenesis.",
  journal  = "J. Exp. Med.",
  volume   =  192,
  number   =  5,
  pages    = "755--760",
  month    =  sep,
  year     =  2000,
  language = "en"
}

@ARTICLE{Beltman2007-rb,
  title    = "Lymph node topology dictates {T} cell migration behavior",
  author   = "Beltman, Joost B and Mar{\'e}e, Athanasius F M and Lynch,
              Jennifer N and Miller, Mark J and de Boer, Rob J",
  abstract = "Adaptive immunity is initiated by T cell recognition of foreign
              peptides presented on dendritic cells (DCs) by major
              histocompatibility molecules. These interactions take place in
              secondary lymphoid tissues, such as lymph nodes (LNs) and spleen,
              and hence the anatomical structure of these tissues plays a
              crucial role in the development of immune responses. Two-photon
              microscopy (2PM) imaging in LNs suggests that T cells walk in a
              consistent direction for several minutes, pause briefly with a
              regular period, and then take off in a new, random direction.
              Here, we construct a spatially explicit model of T cell and DC
              migration in LNs and show that all dynamical properties of T
              cells could be a consequence of the densely packed LN
              environment. By means of 2PM experiments, we confirm that the
              large velocity fluctuations of T cells are indeed environmentally
              determined rather than resulting from an intrinsic motility
              program. Our simulations further predict that T cells
              self-organize into microscopically small, highly dynamic streams.
              We present experimental evidence for the presence of such
              turbulent streams in LNs. Finally, the model allows us to
              estimate the scanning rates of DCs (2,000 different T cells per
              hour) and T cells (100 different DCs per hour).",
  journal  = "J. Exp. Med.",
  volume   =  204,
  number   =  4,
  pages    = "771--780",
  month    =  apr,
  year     =  2007,
  language = "en"
}

@ARTICLE{Boissonnas2007-cf,
  title    = "In vivo imaging of cytotoxic {T} cell infiltration and
              elimination of a solid tumor",
  author   = "Boissonnas, Alexandre and Fetler, Luc and Zeelenberg, Ingrid S
              and Hugues, St{\'e}phanie and Amigorena, Sebastian",
  abstract = "Although the immune system evolved to fight infections, it may
              also attack and destroy solid tumors. In most cases, tumor
              rejection is initiated by CD8(+) cytotoxic T lymphocytes (CTLs),
              which infiltrate solid tumors, recognize tumor antigens, and kill
              tumor cells. We use a combination of two-photon intravital
              microscopy and immunofluorescence on ordered sequential sections
              to analyze the infiltration and destruction of solid tumors by
              CTLs. We show that in the periphery of a thymoma growing
              subcutaneously, activated CTLs migrate with high instantaneous
              velocities. The CTLs arrest in close contact to tumor cells
              expressing their cognate antigen. In regions where most tumor
              cells are dead, CTLs resume migration, sometimes following
              collagen fibers or blood vessels. CTLs migrating along blood
              vessels preferentially adopt an elongated morphology. CTLs also
              infiltrate tumors in depth, but only when the tumor cells express
              the cognate CTL antigen. In tumors that do not express the
              cognate antigen, CTL infiltration is restricted to peripheral
              regions, and lymphocytes neither stop moving nor kill tumor
              cells. Antigen expression by tumor cells therefore determines
              both CTL motility within the tumor and profound tumor
              infiltration.",
  journal  = "J. Exp. Med.",
  volume   =  204,
  number   =  2,
  pages    = "345--356",
  month    =  feb,
  year     =  2007,
  language = "en"
}

@ARTICLE{Gerlach2010-js,
  title    = "One naive {T} cell, multiple fates in {CD8+} {T} cell
              differentiation",
  author   = "Gerlach, Carmen and van Heijst, Jeroen W J and Swart, Erwin and
              Sie, Daoud and Armstrong, Nicola and Kerkhoven, Ron M and Zehn,
              Dietmar and Bevan, Michael J and Schepers, Koen and Schumacher,
              Ton N M",
  abstract = "The mechanism by which the immune system produces effector and
              memory T cells is largely unclear. To allow a large-scale
              assessment of the development of single naive T cells into
              different subsets, we have developed a technology that introduces
              unique genetic tags (barcodes) into naive T cells. By comparing
              the barcodes present in antigen-specific effector and memory T
              cell populations in systemic and local infection models, at
              different anatomical sites, and for TCR-pMHC interactions of
              different avidities, we demonstrate that under all conditions
              tested, individual naive T cells yield both effector and memory
              CD8+ T cell progeny. This indicates that effector and memory fate
              decisions are not determined by the nature of the priming
              antigen-presenting cell or the time of T cell priming. Instead,
              for both low and high avidity T cells, individual naive T cells
              have multiple fates and can differentiate into effector and
              memory T cell subsets.",
  journal  = "J. Exp. Med.",
  volume   =  207,
  number   =  6,
  pages    = "1235--1246",
  month    =  jun,
  year     =  2010,
  language = "en"
}

@ARTICLE{Fourcade2010-da,
  title    = "Upregulation of Tim-3 and {PD-1} expression is associated with
              tumor antigen-specific {CD8+} {T} cell dysfunction in melanoma
              patients",
  author   = "Fourcade, Julien and Sun, Zhaojun and Benallaoua, Mourad and
              Guillaume, Philippe and Luescher, Immanuel F and Sander, Cindy
              and Kirkwood, John M and Kuchroo, Vijay and Zarour, Hassane M",
  abstract = "The paradoxical coexistence of spontaneous tumor antigen-specific
              immune responses with progressive disease in cancer patients
              furthers the need to dissect the molecular pathways involved in
              tumor-induced T cell dysfunction. In patients with advanced
              melanoma, we have previously shown that the cancer-germline
              antigen NY-ESO-1 stimulates spontaneous NY-ESO-1-specific CD8(+)
              T cells that up-regulate PD-1 expression. We also observed that
              PD-1 regulates NY-ESO-1-specific CD8(+) T cell expansion upon
              chronic antigen stimulation. In the present study, we show that a
              fraction of PD-1(+) NY-ESO-1-specific CD8(+) T cells in patients
              with advanced melanoma up-regulates Tim-3 expression and that
              Tim-3(+)PD-1(+) NY-ESO-1-specific CD8(+) T cells are more
              dysfunctional than Tim-3(-)PD-1(+) and Tim-3(-)PD-1(-)
              NY-ESO-1-specific CD8(+) T cells, producing less IFN-$\gamma$,
              TNF, and IL-2. Tim-3-Tim-3L blockade enhanced cytokine production
              by NY-ESO-1-specific CD8(+) T cells upon short ex vivo
              stimulation with cognate peptide, thus enhancing their functional
              capacity. In addition, Tim-3-Tim-3L blockade enhanced cytokine
              production and proliferation of NY-ESO-1-specific CD8(+) T cells
              upon prolonged antigen stimulation and acted in synergy with
              PD-1-PD-L1 blockade. Collectively, our findings support the use
              of Tim-3-Tim-3L blockade together with PD-1-PD-L1 blockade to
              reverse tumor-induced T cell exhaustion/dysfunction in patients
              with advanced melanoma.",
  journal  = "J. Exp. Med.",
  volume   =  207,
  number   =  10,
  pages    = "2175--2186",
  month    =  sep,
  year     =  2010,
  language = "en"
}

@ARTICLE{Juneja2017-bj,
  title     = "{PD-L1} on tumor cells is sufficient for immune evasion in
               immunogenic tumors and inhibits {CD8} {T} cell cytotoxicity",
  author    = "Juneja, Vikram R and McGuire, Kathleen A and Manguso, Robert T
               and LaFleur, Martin W and Collins, Natalie and Haining, W
               Nicholas and Freeman, Gordon J and Sharpe, Arlene H",
  abstract  = "It is unclear whether PD-L1 on tumor cells is sufficient for
               tumor immune evasion or simply correlates with an inflamed tumor
               microenvironment. We used three mouse tumor models sensitive to
               PD-1 blockade to evaluate the significance of PD-L1 on tumor
               versus nontumor cells. PD-L1 on nontumor cells is critical for
               inhibiting antitumor immunity in B16 melanoma and a genetically
               engineered melanoma. In contrast, PD-L1 on MC38 colorectal
               adenocarcinoma cells is sufficient to suppress antitumor
               immunity, as deletion of PD-L1 on highly immunogenic MC38 tumor
               cells allows effective antitumor immunity. MC38-derived PD-L1
               potently inhibited CD8+ T cell cytotoxicity. Wild-type MC38
               cells outcompeted PD-L1-deleted MC38 cells in vivo,
               demonstrating tumor PD-L1 confers a selective advantage. Thus,
               both tumor- and host-derived PD-L1 can play critical roles in
               immunosuppression. Differences in tumor immunogenicity appear to
               underlie their relative importance. Our findings establish
               reduced cytotoxicity as a key mechanism by which tumor PD-L1
               suppresses antitumor immunity and demonstrate that tumor PD-L1
               is not just a marker of suppressed antitumor immunity.",
  journal   = "J. Exp. Med.",
  publisher = "jem.rupress.org",
  volume    =  214,
  number    =  4,
  pages     = "895--904",
  month     =  apr,
  year      =  2017,
  keywords  = "B16F10\_specific",
  language  = "en"
}

@ARTICLE{Prager2019-tm,
  title    = "{NK} cells switch from granzyme {B} to death receptor-mediated
              cytotoxicity during serial killing",
  author   = "Prager, Isabel and Liesche, Clarissa and van Ooijen, Hanna and
              Urlaub, Doris and Verron, Quentin and Sandstr{\"o}m, Niklas and
              Fasbender, Frank and Claus, Maren and Eils, Roland and Beaudouin,
              Jo{\"e}l and {\"O}nfelt, Bj{\"o}rn and Watzl, Carsten",
  abstract = "NK cells eliminate virus-infected and tumor cells by releasing
              cytotoxic granules containing granzyme B (GrzB) or by engaging
              death receptors that initiate caspase cascades. The orchestrated
              interplay between both cell death pathways remains poorly
              defined. Here we simultaneously measure the activities of GrzB
              and caspase-8 in tumor cells upon contact with human NK cells. We
              observed that NK cells switch from inducing a fast GrzB-mediated
              cell death in their first killing events to a slow death
              receptor-mediated killing during subsequent tumor cell
              encounters. Target cell contact reduced intracellular GrzB and
              perforin and increased surface-CD95L in NK cells over time,
              showing how the switch in cytotoxicity pathways is controlled.
              Without perforin, NK cells were unable to perform GrzB-mediated
              serial killing and only killed once via death receptors. In
              contrast, the absence of CD95 on tumor targets did not impair
              GrzB-mediated serial killing. This demonstrates that GrzB and
              death receptor-mediated cytotoxicity are differentially regulated
              during NK cell serial killing.",
  journal  = "J. Exp. Med.",
  month    =  jul,
  year     =  2019,
  language = "en"
}

@ARTICLE{Cazaux2019-pv,
  title     = "Single-cell imaging of {CAR} {T} cell activity in vivo reveals
               extensive functional and anatomical heterogeneity",
  author    = "Cazaux, Marine and Grandjean, Capucine L and Lema{\^\i}tre,
               Fabrice and Garcia, Zacarias and Beck, Richard J and Milo, Idan
               and Postat, J{\'e}r{\'e}my and Beltman, Joost B and Cheadle,
               Eleanor J and Bousso, Philippe",
  abstract  = "CAR T cells represent a potentially curative strategy for B cell
               malignancies. However, the outcome and dynamics of CAR T cell
               interactions in distinct anatomical sites are poorly understood.
               Using intravital imaging, we tracked interactions established by
               anti-CD19 CAR T cells in B cell lymphoma--bearing mice.
               Circulating targets trapped CAR T cells in the lungs, reducing
               their access to lymphoid organs. In the bone marrow, tumor
               apoptosis was largely due to CAR T cells that engaged, killed,
               and detached from their targets within 25 min. Notably, not all
               CAR T cell contacts elicited calcium signaling or killing while
               interacting with tumors, uncovering extensive functional
               heterogeneity. Mathematical modeling revealed that direct
               killing was sufficient for tumor regression. Finally,
               antigen-loss variants emerged in the bone marrow, but not in
               lymph nodes, where CAR T cell cytotoxic activity was reduced.
               Our results identify a previously unappreciated level of
               diversity in the outcomes of CAR T cell interactions in vivo,
               with important clinical implications.",
  journal   = "J. Exp. Med.",
  publisher = "Rockefeller University Press",
  pages     = "jem.20182375",
  month     =  apr,
  year      =  2019,
  language  = "en"
}

@ARTICLE{Cazaux2019-ut,
  title    = "Single-cell imaging of {CAR} {T} cell activity in vivo reveals
              extensive functional and anatomical heterogeneity",
  author   = "Cazaux, Marine and Grandjean, Capucine L and Lema{\^\i}tre,
              Fabrice and Garcia, Zacarias and Beck, Richard J and Milo, Idan
              and Postat, J{\'e}r{\'e}my and Beltman, Joost B and Cheadle,
              Eleanor J and Bousso, Philippe",
  abstract = "CAR T cells represent a potentially curative strategy for B cell
              malignancies. However, the outcome and dynamics of CAR T cell
              interactions in distinct anatomical sites are poorly understood.
              Using intravital imaging, we tracked interactions established by
              anti-CD19 CAR T cells in B cell lymphoma-bearing mice.
              Circulating targets trapped CAR T cells in the lungs, reducing
              their access to lymphoid organs. In the bone marrow, tumor
              apoptosis was largely due to CAR T cells that engaged, killed,
              and detached from their targets within 25 min. Notably, not all
              CAR T cell contacts elicited calcium signaling or killing while
              interacting with tumors, uncovering extensive functional
              heterogeneity. Mathematical modeling revealed that direct killing
              was sufficient for tumor regression. Finally, antigen-loss
              variants emerged in the bone marrow, but not in lymph nodes,
              where CAR T cell cytotoxic activity was reduced. Our results
              identify a previously unappreciated level of diversity in the
              outcomes of CAR T cell interactions in vivo, with important
              clinical implications.",
  journal  = "J. Exp. Med.",
  volume   =  216,
  number   =  5,
  pages    = "1038--1049",
  month    =  may,
  year     =  2019,
  language = "en"
}

@ARTICLE{Gorelashvili2014-hy,
  title     = "Amoeboid migration mode adaption in quasi-3D spatial density
               gradients of varying lattice geometry",
  author    = "Gorelashvili, Mari and Emmert, Martin and Hodeck, Kai F and
               Heinrich, Doris",
  journal   = "New J. Phys.",
  publisher = "IOP Publishing",
  volume    =  16,
  number    =  7,
  pages     = "075012",
  month     =  jul,
  year      =  2014,
  language  = "en"
}

@ARTICLE{Zaidi2019-un,
  title    = "The {Interferon-Gamma} Paradox in Cancer",
  author   = "Zaidi, M Raza",
  abstract = "Interferon-gamma (IFNG) has long been implicated as a central
              orchestrator of antitumor immune responses in the elimination
              stage of the immunoediting paradigm. However, mounting evidence
              suggests that IFNG may also have important and significant
              protumor roles to play in the equilibrium and escape phases
              through its regulatory effects on immunoevasive functions that
              promote tumorigenesis. These seemingly contradictory effects of
              IFNG undoubtedly play profound roles in not only the activation
              of inflammatory response to cancer but also in the determination
              of its outcome. In the face of the recent explosion of anticancer
              immunotherapeutic strategies in the clinic, it is critical that a
              complete understanding is achieved of the underpinnings of the
              mechanisms that determine the two faces of IFNG signaling in
              cancer. Here, the current state of this dichotomy is reviewed.",
  journal  = "J. Interferon Cytokine Res.",
  volume   =  39,
  number   =  1,
  pages    = "30--38",
  month    =  jan,
  year     =  2019,
  keywords = "cancer; cytokine signaling; immunoediting; immunoevasion;
              immunosurveillance; interferon-gamma",
  language = "en"
}

@ARTICLE{Andreassen2001-sw,
  title    = "Tetraploid state induces p53-dependent arrest of nontransformed
              mammalian cells in {G1}",
  author   = "Andreassen, P R and Lohez, O D and Lacroix, F B and Margolis, R L",
  abstract = "A ``spindle assembly'' checkpoint has been described that arrests
              cells in G1 following inappropriate exit from mitosis in the
              presence of microtubule inhibitors. We have here addressed the
              question of whether the resulting tetraploid state itself, rather
              than failure of spindle function or induction of spindle damage,
              acts as a checkpoint to arrest cells in G1. Dihydrocytochalasin B
              induces cleavage failure in cells where spindle function and
              chromatid segregation are both normal. Notably, we show here that
              nontransformed REF-52 cells arrest indefinitely in tetraploid G1
              following cleavage failure. The spindle assembly checkpoint and
              the tetraploidization checkpoint that we describe here are likely
              to be equivalent. Both involve arrest in G1 with inactive cdk2
              kinase, hypophosphorylated retinoblastoma protein, and elevated
              levels of p21(WAF1) and cyclin E. Furthermore, both require p53.
              We show that failure to arrest in G1 following tetraploidization
              rapidly results in aneuploidy. Similar tetraploid G1 arrest
              results have been obtained with mouse NIH3T3 and human IMR-90
              cells. Thus, we propose that a general checkpoint control acts in
              G1 to recognize tetraploid cells and induce their arrest and
              thereby prevents the propagation of errors of late mitosis and
              the generation of aneuploidy. As such, the tetraploidy checkpoint
              may be a critical activity of p53 in its role of ensuring genomic
              integrity.",
  journal  = "Mol. Biol. Cell",
  volume   =  12,
  number   =  5,
  pages    = "1315--1328",
  month    =  may,
  year     =  2001,
  language = "en"
}

@ARTICLE{Thorburn2013-ke,
  title    = "Aneuploid yeast strains exhibit defects in cell growth and
              passage through {START}",
  author   = "Thorburn, Rebecca R and Gonzalez, Christian and Brar, Gloria A
              and Christen, Stefan and Carlile, Thomas M and Ingolia, Nicholas
              T and Sauer, Uwe and Weissman, Jonathan S and Amon, Angelika",
  abstract = "Aneuploidy, a chromosome content that is not a multiple of the
              haploid karyotype, is associated with reduced fitness in all
              organisms analyzed to date. In budding yeast aneuploidy causes
              cell proliferation defects, with many different aneuploid strains
              exhibiting a delay in G1, a cell cycle stage governed by
              extracellular cues, growth rate, and cell cycle events. Here we
              characterize this G1 delay. We show that 10 of 14 aneuploid yeast
              strains exhibit a growth defect during G1. Furthermore, 10 of 14
              aneuploid strains display a cell cycle entry delay that
              correlates with the size of the additional chromosome. This cell
              cycle entry delay is due to a delayed accumulation of G1 cyclins
              that can be suppressed by supplying cells with high levels of a
              G1 cyclin. Our results indicate that aneuploidy frequently
              interferes with the ability of cells to grow and, as with many
              other cellular stresses, entry into the cell cycle.",
  journal  = "Mol. Biol. Cell",
  volume   =  24,
  number   =  9,
  pages    = "1274--1289",
  month    =  may,
  year     =  2013,
  language = "en"
}

@ARTICLE{Flamholz2014-vw,
  title    = "The quantified cell",
  author   = "Flamholz, Avi and Phillips, Rob and Milo, Ron",
  abstract = "The microscopic world of a cell can be as alien to our
              human-centered intuition as the confinement of quarks within
              protons or the event horizon of a black hole. We are prone to
              thinking by analogy-Golgi cisternae stack like pancakes, red
              blood cells look like donuts-but very little in our human
              experience is truly comparable to the immensely crowded,
              membrane-subdivided interior of a eukaryotic cell or the
              intricately layered structures of a mammalian tissue. So in our
              daily efforts to understand how cells work, we are faced with a
              challenge: how do we develop intuition that works at the
              microscopic scale?",
  journal  = "Mol. Biol. Cell",
  volume   =  25,
  number   =  22,
  pages    = "3497--3500",
  month    =  nov,
  year     =  2014,
  language = "en"
}

@ARTICLE{Garon2014-yk,
  title     = "{LBA43ANTITUMOR} {ACTIVITY} {OF} {PEMBROLIZUMAB} ({PEMBRO};
               {MK-3475}) {AND} {CORRELATION} {WITH} {PROGRAMMED} {DEATH}
               {LIGAND} 1 ({PD-L1}) {EXPRESSION} {IN} A {POOLED} {ANALYSIS}
               {OF} {PATIENTS} ({PTS}) {WITH} {ADVANCED} {NON--SMALL} {CELL}
               {LUNG} {CARCINOMA} ({NSCLC})",
  author    = "Garon, E B and Gandhi, L and Rizvi, N and Hui, R and
               Balmanoukian, A S and Patnaik, A and Eder, J P and Blumenshein,
               G R and Aggarwal, C and Soria, J-C and Ahn, M A and Gubens, M A
               and Ramalingam, S S and Johnson, E and Arkenau, H and
               Lubiniecki, G M and Zhang, J and Rutledge, R Z and Emancipator,
               K and Leighl, N",
  abstract  = "Aim: The anti-PD-1 antibody pembro has shown durable antitumor
               activity and acceptable toxicity in treatment-naive and
               previously treated advanced NSCLC. Correlation between tumor
               PD-L1 expression and improved pembro antitumor activity has been
               observed.Methods: 282 pts with treatment-naive or previously
               treated advanced NSCLC enrolled in randomized and nonrandomized
               cohorts of the phase 1 KEYNOTE-001 study were analyzed. To
               inform enrollment, tumor PD-L1 expression was determined
               prospectively by a prototype IHC assay (PA) in all pts. Samples
               were independently reanalyzed using a clinical trial IHC assay
               (CTA). Pembro was given at 2 mg/kg every 3 weeks (Q3W), 10 mg/kg
               Q3W, or 10 mg/kg Q2W until progression, death, or unacceptable
               toxicity. Overall response rate (ORR) was assessed per RECIST
               v1.1 by central review and per immune-related response criteria
               (irRC) by investigator review.Results: Mature data are available
               for 262 pts (5.4-mo median follow-up). Grade 3--5 drug-related
               AEs occurred in 24 (9\%) pts, most commonly pneumonitis (n = 5
               [n = 3 grade 3, n = 2 grade 4]). ORR (RECIST/irRC) in pts with
               measurable disease at baseline was 21\%/23\% overall (26\%/47\%
               treatment naive, 20\%/18\% previously treated) and was similar
               in pts with squamous (18\%/25\%) and nonsquamous (23\%/23\%)
               histology. ORR was 33\%/67\% at 2 mg/kg Q3W (n = 6), 21\%/22\%
               at 10 mg/kg Q3W (n = 141), and 21\%/22\% at 10 mg/kg Q2W (n =
               115). As assessed by the PA, ORR was 23\%/25\% in pts with
               $\geq$1\% PD-L1 staining and 9\%/13\% in pts with no PD-L1
               staining. Preliminary median PFS will be presented, as will data
               for an additional 20 previously treated pts who received pembro
               2 mg/kg Q3W. To date, data for PD-L1 staining using the CTA are
               available for nearly one-half of pts. In these pts, ORR
               (RECIST/irRC) was 39\%/47\% in pts with strong PD-L1 expression
               ($\geq$50\% staining) and 16\%/9\% in pts with weak/negative
               PD-L1 expression.Conclusions: Pembro is tolerable and provides
               antitumor activity in treatment-naive or previously treated
               advanced NSCLC, regardless of dose/schedule. Pts with strong
               PD-L1 tumor expression may derive particular benefit from
               pembro.Disclosure: E.B. Garon: Corporate-sponsored research:
               Merck, Pfizer, Genentech, AstraZeneca, Novartis, Puma; L.
               Gandhi: Serves on advisory boards for Genentech/Roche and has
               received consulting fees from Merck; N. Rizvi: Has served on
               advisory boards for Bristol-Myers Squibb, Merck, Roche, and
               AstraZeneca; R. Hui: Has served on advisory boards for Merck; A.
               Patnaik: Has received research grants from Merck; J-C. Soria:
               Has served as consultant to Merck; M.A. Gubens: Has served as
               advisory board member, without compensation, for Celgene and
               Roche/Genentech, and has received research grants from Merck,
               Celgene, and MedImmune; S.S. Ramalingam: Has served on advisory
               boards for Genentech and AstraZeneca; G.M. Lubiniecki, J. Zhang
               and K. Emancipator: Is an employee of Merck \& Co., Inc.; R.Z.
               Rutledge: Is an employee of and holds stock in Merck \& Co.,
               Inc. All other authors have declared no conflicts of interest.",
  journal   = "Ann. Oncol.",
  publisher = "Oxford University Press",
  volume    =  25,
  number    = "suppl\_4",
  month     =  sep,
  year      =  2014,
  keywords  = "brachial plexus neuritis; therapy naive; computed tomographic
               angiography; consultation; fees and charges; histology"
}

@ARTICLE{Dang2016-ax,
  title    = "{IDH} mutations in cancer and progress toward development of
              targeted therapeutics",
  author   = "Dang, L and Yen, K and Attar, E C",
  abstract = "Isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) are key
              metabolic enzymes, converting isocitrate to
              $\alpha$-ketoglutarate ($\alpha$KG).IDH1 and IDH2 mutations have
              been identified in multiple tumor types, including gliomas and
              myeloid malignancies such as acute myeloid leukemia (AML) and
              myelodysplastic syndromes (MDS). Here we provide an overview of
              the function of normal and mutated IDH, discuss the role of IDH
              mutations in tumorigenesis and progression and review the key
              clinical considerations when treating IDH-mutated tumors based on
              emerging clinical data from mutant IDH1/2 inhibitor trials. IDH1
              and IDH2 mutations confer neomorphic activity in the mutant
              protein, resulting in the conversion of $\alpha$KG to the
              oncometabolite, D-2-hydroxyglutarate (2-HG). The subsequent
              accumulation of 2-HG results in epigenetic dysregulation via
              inhibition of $\alpha$KG-dependent histone and DNA demethylases,
              and a block in cellular differentiation. There is growing
              preclinical and clinical evidence suggesting that IDHmutations
              are involved in neoplasia. Furthermore, preclinical studies
              assessing small molecule inhibitors of mutant IDH1/2 enzymes have
              provided proof of concept that this approach decreases
              intracellular 2-HG levels, reverses epigenetic dysregulation and
              induces cellular differentiation. Phase I studies of mutant IDH
              inhibitors are currently ongoing in patients with IDH-mutant
              hematologic and solid tumors, with early data in hematologic
              tumors suggesting a manageable safety profile as well as clinical
              benefit, with a mechanism of action based on differentiation of
              malignant cells. Inhibition of mutant IDH shows promise as a
              treatment approach in hematologic malignancies, with further
              development ongoing in solid tumors and glioma. The mutant IDH
              inhibitors may have clinical utility both as single agents and in
              combination strategies that target additional oncogenic pathways.",
  journal  = "Ann. Oncol.",
  volume   =  27,
  number   =  4,
  pages    = "599--608",
  month    =  apr,
  year     =  2016,
  keywords = "IDH1; IDH2; glioma; hematologic malignancy; isocitrate
              dehydrogenase; small molecule inhibitor",
  language = "en"
}

@ARTICLE{Tang2018-qk,
  title    = "Comprehensive analysis of the clinical immuno-oncology landscape",
  author   = "Tang, J and Shalabi, A and Hubbard-Lucey, V M",
  abstract = "Advances from immuno-oncology (IO) are changing the standard of
              care of many types of cancer, and the paradigm of cancer
              treatments and drug development is being rewritten on a regular
              basis. Moreover, an unprecedented number of new investigational
              agents and companies are entering the field of IO. As such, it
              has become challenging for oncology physicians conducting
              clinical trials, industry veterans developing IO drugs, and even
              regulators reviewing novel IO agents to keep track of the rapidly
              evolving landscape. To help the key stake holders in the field
              understand the latest IO landscape, we sought to present an
              unbiased, neutral, scientifically curated, and timely updated
              analysis of all the current IO agents in clinical development and
              the clinical trials testing these agents. We based our analyses
              on information collected from numerous trusted and publicly
              available sources. We have developed two databases. One database
              tracks 2004 IO agents (940 in clinical stage and 1064 in
              preclinical stage) against 303 targets, from 864 companies; the
              other tracks 3042 active clinical trials of these agents with a
              target enrollment of 577 076 patients. This report provides key
              analyses of these data. Furthermore, we will discuss a number of
              important and actionable trends in the current IO landscape: a
              large number of companies developing agents against the same IO
              targets; a rapid increase in the number of anti-PD-1/L1
              combination studies, many of which are testing the same
              combinations and following inefficient patterns; and a
              significant increase in the number of small,
              investigator-initiated studies. For each of the findings, we
              speculate the causes and discuss a few initiatives that aim to
              address some of these challenges. Finally, by making these
              landscape analyses available, we aspire to inform the cancer
              community as they seek to strive for efficiencies and innovation
              while avoiding duplication.",
  journal  = "Ann. Oncol.",
  volume   =  29,
  number   =  1,
  pages    = "84--91",
  month    =  jan,
  year     =  2018,
  keywords = "cancer immunotherapy; clinical trials; immuno-oncology; landscape
              analysis; tumor immunology",
  language = "en"
}

@ARTICLE{Lesk2008-mp,
  title    = "{3D-Garden}: a system for modelling protein-protein complexes
              based on conformational refinement of ensembles generated with
              the marching cubes algorithm",
  author   = "Lesk, Victor I and Sternberg, Michael J E",
  abstract = "MOTIVATION: Reliable structural modelling of protein-protein
              complexes has widespread application, from drug design to
              advancing our knowledge of protein interactions and function.
              This work addresses three important issues in protein-protein
              docking: implementing backbone flexibility, incorporating prior
              indications from experiment and bioinformatics, and providing
              public access via a server. 3D-Garden (Global And Restrained
              Docking Exploration Nexus), our benchmarked and server-ready
              flexible docking system, allows sophisticated programming of
              surface patches by the user via a facet representation of the
              interactors' molecular surfaces (generated with the marching
              cubes algorithm). Flexibility is implemented as a weighted
              exhaustive conformer search for each clashing pair of molecular
              branches in a set of 5000 models filtered from around
              approximately 340,000 initially. RESULTS: In a non-global
              assessment, carried out strictly according to the protocols for
              number of models considered and model quality of the Critical
              Assessment of Protein Interactions (CAPRI) experiment, over the
              widely-used Benchmark 2.0 of 84 complexes, 3D-Garden identifies a
              set of ten models containing an acceptable or better model in
              29/45 test cases, including one with large conformational change.
              In 19/45 cases an acceptable or better model is ranked first or
              second out of 340,000 candidates. AVAILABILITY:
              http://www.sbg.bio.ic.ac.uk/3dgarden (server).",
  journal  = "Bioinformatics",
  volume   =  24,
  number   =  9,
  pages    = "1137--1144",
  month    =  may,
  year     =  2008,
  language = "en"
}

@ARTICLE{Starrus2014-ou,
  title    = "Morpheus: a user-friendly modeling environment for multiscale and
              multicellular systems biology",
  author   = "Starru{\ss}, J{\"o}rn and de Back, Walter and Brusch, Lutz and
              Deutsch, Andreas",
  abstract = "Morpheus is a modeling environment for the simulation and
              integration of cell-based models with ordinary differential
              equations and reaction-diffusion systems. It allows rapid
              development of multiscale models in biological terms and
              mathematical expressions rather than programming code. Its
              graphical user interface supports the entire workflow from model
              construction and simulation to visualization, archiving and batch
              processing.",
  journal  = "Bioinformatics",
  volume   =  30,
  number   =  9,
  pages    = "1331--1332",
  month    =  may,
  year     =  2014,
  language = "en"
}

@ARTICLE{Kreutz2018-zl,
  title    = "An easy and efficient approach for testing identifiability",
  author   = "Kreutz, Clemens",
  abstract = "Motivation: The feasibility of uniquely estimating parameters of
              dynamical systems from observations is a widely discussed aspect
              of mathematical modelling. Several approaches have been published
              for analyzing this so-called identifiability of model parameters.
              However, they are typically computationally demanding, difficult
              to perform and/or not applicable in many application settings.
              Results: Here, an approach is presented which enables quickly
              testing of parameter identifiability. Numerical optimization with
              a penalty in radial direction enforcing displacement of the
              parameters is used to check whether estimated parameters are
              unique, or whether the parameters can be altered without loss of
              agreement with the data indicating non-identifiability. This
              Identifiability-Test by Radial Penalization (ITRP) can be
              employed for every model where optimization-based parameter
              estimation like least-squares or maximum likelihood is feasible
              and is therefore applicable for all typical systems biology
              models. The approach is illustrated and tested using 11 ordinary
              differential equation (ODE) models. Availability and
              implementation: The presented approach can be implemented without
              great efforts in any modelling framework. It is available within
              the free Matlab-based modelling toolbox Data2Dynamics. Source
              code is available at https://github.com/Data2Dynamics. Contact:
              ckreutz@fdm.uni-freiburg.de. Supplementary information:
              Supplementary data are available at Bioinformatics online.",
  journal  = "Bioinformatics",
  volume   =  34,
  number   =  11,
  pages    = "1913--1921",
  month    =  jun,
  year     =  2018,
  language = "en"
}

@ARTICLE{Hong2019-wz,
  title    = "{SIAN}: software for structural identifiability analysis of {ODE}
              models",
  author   = "Hong, Hoon and Ovchinnikov, Alexey and Pogudin, Gleb and Yap,
              Chee",
  abstract = "SUMMARY: Biological processes are often modeled by ordinary
              differential equations with unknown parameters. The unknown
              parameters are usually estimated from experimental data. In some
              cases, due to the structure of the model, this estimation problem
              does not have a unique solution even in the case of continuous
              noise-free data. It is therefore desirable to check the
              uniqueness a priori before carrying out actual experiments. We
              present a new software SIAN (Structural Identifiability ANalyser)
              that does this. Our software can tackle problems that could not
              be tackled by previously developed packages. AVAILABILITY AND
              IMPLEMENTATION: SIAN is open-source software written in Maple and
              is available at https://github.com/pogudingleb/SIAN.
              SUPPLEMENTARY INFORMATION: Supplementary data are available at
              Bioinformatics online.",
  journal  = "Bioinformatics",
  volume   =  35,
  number   =  16,
  pages    = "2873--2874",
  month    =  aug,
  year     =  2019,
  language = "en"
}

@ARTICLE{Kimura1962-au,
  title    = "On the probability of fixation of mutant genes in a population",
  author   = "Kimura, M",
  journal  = "Genetics",
  volume   =  47,
  number   =  6,
  pages    = "713--719",
  month    =  jun,
  year     =  1962,
  keywords = "CHROMOSOMES",
  language = "en"
}

@ARTICLE{Matzavinos2004-uf,
  title    = "Mathematical modelling of the spatio-temporal response of
              cytotoxic T-lymphocytes to a solid tumour",
  author   = "Matzavinos, Anastasios and Chaplain, Mark A J and Kuznetsov,
              Vladimir A",
  abstract = "In this paper a mathematical model describing the growth of a
              solid tumour in the presence of an immune system response is
              presented. In particular, attention is focused upon the attack of
              tumour cells by so-called tumour-infiltrating cytotoxic
              lymphocytes (TICLs), in a small, multicellular tumour, without
              necrosis and at some stage prior to (tumour-induced)
              angiogenesis. At this stage the immune cells and the tumour cells
              are considered to be in a state of dynamic equilibrium--cancer
              dormancy--a phenomenon which has been observed in primary
              tumours, micrometastases and residual disease after ablation of
              the primary tumour. Nonetheless, the precise biochemical and
              cellular mechanisms by which TICLs control cancer dormancy are
              still poorly understood from a biological and immunological point
              of view. Therefore we focus on the analysis of the
              spatio-temporal dynamics of tumour cells, immune cells and
              chemokines in an immunogenic tumour. The lymphocytes are assumed
              to migrate into the growing solid tumour and interact with the
              tumour cells in such a way that lymphocyte-tumour cell complexes
              are formed. These complexes result in either the death of the
              tumour cells (the normal situation) or the inactivation
              (sometimes even the death) of the lymphocytes. The migration of
              the TICLs is determined by a combination of random motility and
              chemotaxis in response to the presence of chemokines. The
              resulting system of four nonlinear partial differential equations
              (TICLs, tumour cells, complexes and chemokines) is analysed and
              numerical simulations are presented. We consider two different
              tumour geometries--multi-layered cell growth and multi-cellular
              spheroid growth. The numerical simulations demonstrate the
              existence of cell distributions that are quasi-stationary in time
              and heterogeneous in space. A linear stability analysis of the
              underlying (spatially homogeneous) ordinary differential equation
              (ODE) kinetics coupled with a numerical investigation of the ODE
              system reveals the existence of a stable limit cycle. This is
              verified further when a subsequent bifurcation analysis is
              undertaken using a numerical continuation package. These results
              then explain the complex heterogeneous spatio-temporal dynamics
              observed in the partial differential equation (PDE) system. Our
              approach may lead to a deeper understanding of the phenomenon of
              cancer dormancy and may be helpful in the future development of
              more effective anti-cancer vaccines.",
  journal  = "Math. Med. Biol.",
  volume   =  21,
  number   =  1,
  pages    = "1--34",
  month    =  mar,
  year     =  2004,
  language = "en"
}

% The entry below contains non-ASCII chars that could not be converted
% to a LaTeX equivalent.
@ARTICLE{Kelso2002-fl,
  title     = "The genes for perforin, granzymes {A--C} and {IFN$\gamma$} are
               differentially expressed in single {CD8+} {T} cells during
               primary activation",
  author    = "Kelso, Anne and Costelloe, Elaine O and Johnson, Barbara J and
               Groves, Penny and Buttigieg, Kathy and Fitzpatrick, David R",
  abstract  = "Here we show that the genes for perforin, the three major T cell
               granzymes (A--C) and IFN$\gamma$ are differentially expressed
               during primary activation of naive CD8+ T cells, kinetically and
               at the singlecell level. When CD44lowCD62LhighCD8+ lymph node T
               cells were activated with IL2 and immobilized antibodies to
               CD3, CD8 and CD11a, expression of perforin, granzyme B and
               IFN$\gamma$ mRNAs was induced by day 2, and increased in
               parallel with perforindependent cytolytic activity. Granzyme C
               and A transcripts were not detected until 1 and 3 days later
               respectively. Singlecell PCR showed that expression frequencies
               rose in parallel with total levels of each mRNA, but that
               individual cells expressed diverse combinations of perforin,
               granzyme A--C and IFN$\gamma$ mRNAs. These expression patterns
               indicated that the delayed expression of granzymes A and C was
               not due to late activation of distinct cell subpopulations.
               Statistical analysis of the data suggested that each gene was
               differentially regulated at the singlecell level. Individual
               naive CD8+ T cells gave rise over 7 days to clones that
               expressed all five products at the clonal level, but also
               expressed diverse combinations at the singlecell level. We
               conclude that, during primary activation, CD8+ T cells
               progressively acquired the ability to express most or all of
               these genes, and that the variable expression patterns observed
               among single cells within clones and populations reflected
               transient rather than heritable differences in expression
               profile.",
  journal   = "Int. Immunol.",
  publisher = "Narnia",
  volume    =  14,
  number    =  6,
  pages     = "605--613",
  month     =  jun,
  year      =  2002,
  keywords  = "perforin; rna, messenger"
}

@ARTICLE{Andrews1974-mu,
  title    = "Failure of immunosurveillance against chemically induced in situ
              tumors in mice",
  author   = "Andrews, E J",
  journal  = "J. Natl. Cancer Inst.",
  volume   =  52,
  number   =  3,
  pages    = "729--732",
  month    =  mar,
  year     =  1974,
  language = "en"
}

@ARTICLE{Formenti2013-qg,
  title     = "Combining radiotherapy and cancer immunotherapy: a paradigm
               shift",
  author    = "Formenti, Silvia C and Demaria, Sandra",
  abstract  = "The therapeutic application of ionizing radiation has been
               largely based on its cytocidal power combined with the ability
               to selectively target tumors. Radiotherapy effects on survival
               of cancer patients are generally interpreted as the consequence
               of improved local control of the tumor, directly decreasing
               systemic spread. Experimental data from multiple cancer models
               have provided sufficient evidence to propose a paradigm shift,
               whereby some of the effects of ionizing radiation are recognized
               as contributing to systemic antitumor immunity. Recent examples
               of objective responses achieved by adding radiotherapy to
               immunotherapy in metastatic cancer patients support this view.
               Therefore, the traditional palliative role of radiotherapy in
               metastatic disease is evolving into that of a powerful adjuvant
               for immunotherapy. This combination strategy adds to the current
               anticancer arsenal and offers opportunities to harness the
               immune system to extend survival, even among metastatic and
               heavily pretreated cancer patients. We briefly summarize key
               evidence supporting the role of radiotherapy as an immune
               adjuvant. A critical appraisal of the current status of
               knowledge must include potential immunosuppressive effects of
               radiation that can hamper its capacity to convert the irradiated
               tumor into an in situ, individualized vaccine. Moreover, we
               discuss some of the current challenges to translate this
               knowledge to the clinic as more trials testing radiation with
               different immunotherapies are proposed.",
  journal   = "J. Natl. Cancer Inst.",
  publisher = "academic.oup.com",
  volume    =  105,
  number    =  4,
  pages     = "256--265",
  month     =  feb,
  year      =  2013,
  language  = "en"
}

@ARTICLE{Wagner2005-se,
  title    = "Energy constraints on the evolution of gene expression",
  author   = "Wagner, Andreas",
  abstract = "I here estimate the energy cost of changes in gene expression for
              several thousand genes in the yeast Saccharomyces cerevisiae. A
              doubling of gene expression, as it occurs in a gene duplication
              event, is significantly selected against for all genes for which
              expression data is available. It carries a median selective
              disadvantage of s > 10(-5), several times greater than the
              selection coefficient s = 1.47 x 10(-7) below which genetic drift
              dominates a mutant's fate. When considered separately, increases
              in messenger RNA expression or protein expression by more than a
              factor 2 also have significant energy costs for most genes. This
              means that the evolution of transcription and translation rates
              is not an evolutionarily neutral process. They are under active
              selection opposing them. My estimates are based on genome-scale
              information of gene expression in the yeast S. cerevisiae as well
              as information on the energy cost of biosynthesizing amino acids
              and nucleotides.",
  journal  = "Mol. Biol. Evol.",
  volume   =  22,
  number   =  6,
  pages    = "1365--1374",
  month    =  jun,
  year     =  2005,
  language = "en"
}

@ARTICLE{Du_Plessis2016-hd,
  title    = "How Good Are Statistical Models at Approximating Complex Fitness
              Landscapes?",
  author   = "du Plessis, Louis and Leventhal, Gabriel E and Bonhoeffer,
              Sebastian",
  abstract = "Fitness landscapes determine the course of adaptation by
              constraining and shaping evolutionary trajectories. Knowledge of
              the structure of a fitness landscape can thus predict
              evolutionary outcomes. Empirical fitness landscapes, however,
              have so far only offered limited insight into real-world
              questions, as the high dimensionality of sequence spaces makes it
              impossible to exhaustively measure the fitness of all variants of
              biologically meaningful sequences. We must therefore revert to
              statistical descriptions of fitness landscapes that are based on
              a sparse sample of fitness measurements. It remains unclear,
              however, how much data are required for such statistical
              descriptions to be useful. Here, we assess the ability of
              regression models accounting for single and pairwise mutations to
              correctly approximate a complex quasi-empirical fitness
              landscape. We compare approximations based on various sampling
              regimes of an RNA landscape and find that the sampling regime
              strongly influences the quality of the regression. On the one
              hand it is generally impossible to generate sufficient samples to
              achieve a good approximation of the complete fitness landscape,
              and on the other hand systematic sampling schemes can only
              provide a good description of the immediate neighborhood of a
              sequence of interest. Nevertheless, we obtain a remarkably good
              and unbiased fit to the local landscape when using sequences from
              a population that has evolved under strong selection. Thus,
              current statistical methods can provide a good approximation to
              the landscape of naturally evolving populations.",
  journal  = "Mol. Biol. Evol.",
  volume   =  33,
  number   =  9,
  pages    = "2454--2468",
  month    =  sep,
  year     =  2016,
  keywords = "RNA secondary structure; epistasis; fitness landscapes; penalized
              regression.",
  language = "en"
}

@ARTICLE{Cannataro2018-ck,
  title    = "Neutral Theory and the Somatic Evolution of Cancer",
  author   = "Cannataro, Vincent L and Townsend, Jeffrey P",
  abstract = "Kimura's neutral theory argued that positive selection was not
              responsible for an appreciable fraction of molecular
              substitutions. Correspondingly, quantitative analysis reveals
              that the vast majority of substitutions in cancer genomes are not
              detectably under selection. Insights from the somatic evolution
              of cancer reveal that beneficial substitutions in cancer
              constitute a small but important fraction of the molecular
              variants. The molecular evolution of cancer community will
              benefit by incorporating the neutral theory of molecular
              evolution into their understanding and analysis of cancer
              evolution-and accepting the use of tractable, predictive models,
              even when there is some evidence that they are not perfect.",
  journal  = "Mol. Biol. Evol.",
  volume   =  35,
  number   =  6,
  pages    = "1308--1315",
  month    =  jun,
  year     =  2018,
  language = "en"
}

@ARTICLE{Hounkpe2021-vf,
  title    = "{HRT} Atlas v1.0 database: redefining human and mouse
              housekeeping genes and candidate reference transcripts by mining
              massive {RNA-seq} datasets",
  author   = "Hounkpe, Bidossessi Wilfried and Chenou, Francine and de Lima,
              Franciele and De Paula, Erich Vinicius",
  abstract = "Housekeeping (HK) genes are constitutively expressed genes that
              are required for the maintenance of basic cellular functions.
              Despite their importance in the calibration of gene expression,
              as well as the understanding of many genomic and evolutionary
              features, important discrepancies have been observed in studies
              that previously identified these genes. Here, we present
              Housekeeping and Reference Transcript Atlas (HRT Atlas v1.0,
              www.housekeeping.unicamp.br) a web-based database which addresses
              some of the previously observed limitations in the identification
              of these genes, and offers a more accurate database of human and
              mouse HK genes and transcripts. The database was generated by
              mining massive human and mouse RNA-seq data sets, including 11
              281 and 507 high-quality RNA-seq samples from 52 human
              non-disease tissues/cells and 14 healthy tissues/cells of C57BL/6
              wild type mouse, respectively. User can visualize the expression
              and download lists of 2158 human HK transcripts from 2176 HK
              genes and 3024 mouse HK transcripts from 3277 mouse HK genes. HRT
              Atlas also offers the most stable and suitable tissue selective
              candidate reference transcripts for normalization of qPCR
              experiments. Specific primers and predicted modifiers of gene
              expression for some of these HK transcripts are also proposed.
              HRT Atlas has also been integrated with a regulatory elements
              resource from Epiregio server.",
  journal  = "Nucleic Acids Res.",
  volume   =  49,
  number   = "D1",
  pages    = "D947--D955",
  month    =  jan,
  year     =  2021,
  language = "en"
}

@ARTICLE{Lane2015-jy,
  title    = "Regulation of mammalian nucleotide metabolism and biosynthesis",
  author   = "Lane, Andrew N and Fan, Teresa W-M",
  abstract = "Nucleotides are required for a wide variety of biological
              processes and are constantly synthesized de novo in all cells.
              When cells proliferate, increased nucleotide synthesis is
              necessary for DNA replication and for RNA production to support
              protein synthesis at different stages of the cell cycle, during
              which these events are regulated at multiple levels. Therefore
              the synthesis of the precursor nucleotides is also strongly
              regulated at multiple levels. Nucleotide synthesis is an energy
              intensive process that uses multiple metabolic pathways across
              different cell compartments and several sources of carbon and
              nitrogen. The processes are regulated at the transcription level
              by a set of master transcription factors but also at the enzyme
              level by allosteric regulation and feedback inhibition. Here we
              review the cellular demands of nucleotide biosynthesis, their
              metabolic pathways and mechanisms of regulation during the cell
              cycle. The use of stable isotope tracers for delineating the
              biosynthetic routes of the multiple intersecting pathways and how
              these are quantitatively controlled under different conditions is
              also highlighted. Moreover, the importance of nucleotide
              synthesis for cell viability is discussed and how this may lead
              to potential new approaches to drug development in diseases such
              as cancer.",
  journal  = "Nucleic Acids Res.",
  volume   =  43,
  number   =  4,
  pages    = "2466--2485",
  month    =  feb,
  year     =  2015,
  language = "en"
}

@ARTICLE{Andor2020-ga,
  title    = "Joint single cell {DNA-seq} and {RNA-seq} of gastric cancer cell
              lines reveals rules of in vitro evolution",
  author   = "Andor, Noemi and Lau, Billy T and Catalanotti, Claudia and Sathe,
              Anuja and Kubit, Matthew and Chen, Jiamin and Blaj, Cristina and
              Cherry, Athena and Bangs, Charles D and Grimes, Susan M and
              Suarez, Carlos J and Ji, Hanlee P",
  abstract = "Cancer cell lines are not homogeneous nor are they static in
              their genetic state and biological properties. Genetic,
              transcriptional and phenotypic diversity within cell lines
              contributes to the lack of experimental reproducibility
              frequently observed in tissue-culture-based studies. While cancer
              cell line heterogeneity has been generally recognized, there are
              no studies which quantify the number of clones that coexist
              within cell lines and their distinguishing characteristics. We
              used a single-cell DNA sequencing approach to characterize the
              cellular diversity within nine gastric cancer cell lines and
              integrated this information with single-cell RNA sequencing.
              Overall, we sequenced the genomes of 8824 cells, identifying
              between 2 and 12 clones per cell line. Using the transcriptomes
              of more than 28 000 single cells from the same cell lines, we
              independently corroborated 88\% of the clonal structure
              determined from single cell DNA analysis. For one of these cell
              lines, we identified cell surface markers that distinguished two
              subpopulations and used flow cytometry to sort these two clones.
              We identified substantial proportions of replicating cells in
              each cell line, assigned these cells to subclones detected among
              the G0/G1 population and used the proportion of replicating cells
              per subclone as a surrogate of each subclone's growth rate.",
  journal  = "NAR Genom Bioinform",
  volume   =  2,
  number   =  2,
  pages    = "lqaa016",
  month    =  jun,
  year     =  2020,
  language = "en"
}

@ARTICLE{Chang2000-vk,
  title    = "Phosphatidylserine-dependent phagocytosis of apoptotic glioma
              cells by normal human microglia, astrocytes, and glioma cells",
  author   = "Chang, G H and Barbaro, N M and Pieper, R O",
  abstract = "Apoptotic cells display signals that trigger phagocytic removal
              by macrophages or neighboring cells. To better understand the
              signals triggering phagocytosis of apoptotic glioma cells, and to
              identify the cells that might be involved in the phagocytic
              process, U-251 MG glioma cells were made apoptotic by etoposide
              (25 microg/ml) treatment and were incubated with normal human
              astrocytes (NHA), glioma cells, or microglia. Extent of
              phagocytosis was assessed by an in vitro phagocytosis assay.
              After 3 h of incubation with apoptotic cells, phagocytes tested
              were washed to remove nonengulfed cells, then fixed, stained, and
              counted to determine phagocytosis index (PI). NHA, glioma cells,
              and microglia all phagocytosed apoptotic, but not nonapoptotic,
              glioma cells. Microglia, however, had a PI approximately 4-fold
              higher than did either NHA or glioma cells. Binding of
              phosphatidylserine (PS) on apoptotic glioma cell membranes by
              annexin-V inhibited phagocytosis by 90\% in both microglia and
              NHA. The activity of an enzyme (scramblase) that moves PS from
              the inner cell membrane to the outer cell membrane was also
              increased in apoptotic glioma cells. These results suggest that a
              variety of cells present in and near gliomas in vivo can remove
              glioma cells in a PS-dependent scramblase-mediated fashion.
              Manipulation of scramblase and/or PS exposure in glioma cells may
              therefore be a means of triggering phagocytic removal of glioma
              cells.",
  journal  = "Neuro. Oncol.",
  volume   =  2,
  number   =  3,
  pages    = "174--183",
  month    =  jul,
  year     =  2000,
  language = "en"
}

@ARTICLE{Burnet1964-nh,
  title    = "{IMMUNOLOGICAL} {FACTORS} {IN} {THE} {PROCESS} {OF}
              {CARCINOGENESIS}",
  author   = "Burnet, M",
  journal  = "Br. Med. Bull.",
  volume   =  20,
  pages    = "154--158",
  month    =  may,
  year     =  1964,
  keywords = "BENZANTHRACENES; CARCINOGENS; EXPERIMENTAL LAB STUDY;
              METHYLCHOLANTHRENE; NEOPLASM IMMUNOLOGY; NEOPLASMS, EXPERIMENTAL;
              ONCOGENIC VIRUSES; REVIEW; TRANSPLANTATION IMMUNOLOGY",
  language = "en"
}

@ARTICLE{Barth1956-mj,
  title    = "Strong and weak histocompatibility gene differences in mice and
              their role in the rejection of homografts of tumors and skin",
  author   = "Barth, R and Counce, S and Smith, P and Snell, G D",
  journal  = "Ann. Surg.",
  volume   =  144,
  number   =  2,
  pages    = "198--204",
  month    =  aug,
  year     =  1956,
  keywords = "GENETICS; NEOPLASMS/experimental; SKIN
              TRANSPLANTATION/experimental",
  language = "en"
}

@ARTICLE{Rong2006-bu,
  title    = "'Pseudopalisading' necrosis in glioblastoma: a familiar
              morphologic feature that links vascular pathology, hypoxia, and
              angiogenesis",
  author   = "Rong, Yuan and Durden, Donald L and Van Meir, Erwin G and Brat,
              Daniel J",
  abstract = "Glioblastoma (GBM) is a highly malignant, rapidly progressive
              astrocytoma that is distinguished pathologically from lower grade
              tumors by necrosis and microvascular hyperplasia. Necrotic foci
              are typically surrounded by ``pseudopalisading'' cells-a
              configuration that is relatively unique to malignant gliomas and
              has long been recognized as an ominous prognostic feature.
              Precise mechanisms that relate morphology to biologic behavior
              have not been described. Recent investigations have demonstrated
              that pseudopalisades are severely hypoxic, overexpress
              hypoxia-inducible factor (HIF-1), and secrete proangiogenic
              factors such as VEGF and IL-8. Thus, the microvascular
              hyperplasia in GBM that provides a new vasculature and promotes
              peripheral tumor expansion is tightly linked with the emergence
              of pseudopalisades. Both pathologic observations and experimental
              evidence have indicated that the development of hypoxia and
              necrosis within astrocytomas could arise secondary to
              vaso-occlusion and intravascular thrombosis. This emerging model
              suggests that pseudopalisades represent a wave of tumor cells
              actively migrating away from central hypoxia that arises after a
              vascular insult. Experimental glioma models have shown that
              endothelial apoptosis, perhaps resulting from angiopoetin-2,
              initiates vascular pathology, whereas observations in human
              tumors have clearly demonstrated that intravascular thrombosis
              develops with high frequency in the transition to GBM. Tissue
              factor, the main cellular initiator of thrombosis, is
              dramatically upregulated in response to PTEN loss and hypoxia in
              human GBM and could promote a prothrombotic environment that
              precipitates these events. A prothrombotic environment also
              activates the family of protease activated receptors (PARs) on
              tumor cells, which are G-protein-coupled and enhance invasive and
              proangiogenic properties. Vaso-occlusive and prothrombotic
              mechanisms in GBM could readily explain the presence of
              pseudopalisading necrosis in tissue sections, the rapid
              peripheral expansion on neuroimaging, and the dramatic shift to
              an accelerated rate of clinical progression resulting from
              hypoxia-induced angiogenesis.",
  journal  = "J. Neuropathol. Exp. Neurol.",
  volume   =  65,
  number   =  6,
  pages    = "529--539",
  month    =  jun,
  year     =  2006,
  language = "en"
}

@ARTICLE{Sauce2007-kq,
  title    = "{PD-1} expression on human {CD8} {T} cells depends on both state
              of differentiation and activation status",
  author   = "Sauce, Delphine and Almeida, Jorge R and Larsen, Martin and Haro,
              Laurine and Autran, Brigitte and Freeman, Gordon J and Appay,
              Victor",
  abstract = "OBJECTIVE AND DESIGN: PD-1 expression on HIV-specific CD8 T cells
              was recently reported to reflect functional exhaustion, resulting
              in uncontrolled HIV-1 replication. Assessing PD-1 expression on T
              cells may be highly relevant in T-cell immunology and vaccine
              monitoring. However, this requires us to gain further insights
              into the significance of PD-1 expression on CD8 T cells in
              humans. METHODS: We performed a detailed analysis of PD-1
              expression pattern on various CD8 T cell subsets from healthy or
              HIV infected donors. RESULTS: PD-1 expression has two facets in
              vivo. On the one hand, it is linked to T-cell differentiation:
              PD-1 is up-regulated on early/intermediate differentiated
              subsets, which include HIV and Epstein-Barr virus-specific CD8
              T-cell populations, but is down-regulated during late stages of
              differentiation. On the other hand, it is linked to T-cell
              activation: on PD-1 positive cells, PD-1 over-expression occurs
              along with the up-regulation of activation markers such as CD38
              or HLA-DR. CONCLUSIONS: PD-1 expression on CD8 T cells, including
              those specific for HIV, can be related both to their
              differentiation stage and their activation status. It is
              important to consider these findings when assessing the
              expression of PD-1 on T cells.",
  journal  = "AIDS",
  volume   =  21,
  number   =  15,
  pages    = "2005--2013",
  month    =  oct,
  year     =  2007,
  language = "en"
}

@ARTICLE{Konstorum2017-bk,
  title    = "Addressing current challenges in cancer immunotherapy with
              mathematical and computational modelling",
  author   = "Konstorum, Anna and Vella, Anthony T and Adler, Adam J and
              Laubenbacher, Reinhard C",
  abstract = "The goal of cancer immunotherapy is to boost a patient's immune
              response to a tumour. Yet, the design of an effective
              immunotherapy is complicated by various factors, including a
              potentially immunosuppressive tumour microenvironment,
              immune-modulating effects of conventional treatments and
              therapy-related toxicities. These complexities can be
              incorporated into mathematical and computational models of cancer
              immunotherapy that can then be used to aid in rational therapy
              design. In this review, we survey modelling approaches under the
              umbrella of the major challenges facing immunotherapy
              development, which encompass tumour classification, optimal
              treatment scheduling and combination therapy design. Although
              overlapping, each challenge has presented unique opportunities
              for modellers to make contributions using analytical and
              numerical analysis of model outcomes, as well as optimization
              algorithms. We discuss several examples of models that have grown
              in complexity as more biological information has become
              available, showcasing how model development is a dynamic process
              interlinked with the rapid advances in tumour-immune biology. We
              conclude the review with recommendations for modellers both with
              respect to methodology and biological direction that might help
              keep modellers at the forefront of cancer immunotherapy
              development.",
  journal  = "J. R. Soc. Interface",
  volume   =  14,
  number   =  131,
  month    =  jun,
  year     =  2017,
  keywords = "cancer immunotherapy; mathematical modelling; optimal control",
  language = "en"
}

@ARTICLE{Gong2017-nb,
  title    = "A computational multiscale agent-based model for simulating
              spatio-temporal tumour immune response to {PD1} and {PDL1}
              inhibition",
  author   = "Gong, Chang and Milberg, Oleg and Wang, Bing and Vicini, Paolo
              and Narwal, Rajesh and Roskos, Lorin and Popel, Aleksander S",
  abstract = "When the immune system responds to tumour development, patterns
              of immune infiltrates emerge, highlighted by the expression of
              immune checkpoint-related molecules such as PDL1 on the surface
              of cancer cells. Such spatial heterogeneity carries information
              on intrinsic characteristics of the tumour lesion for individual
              patients, and thus is a potential source for biomarkers for
              anti-tumour therapeutics. We developed a systems biology
              multiscale agent-based model to capture the interactions between
              immune cells and cancer cells, and analysed the emergent global
              behaviour during tumour development and immunotherapy. Using this
              model, we are able to reproduce temporal dynamics of cytotoxic T
              cells and cancer cells during tumour progression, as well as
              three-dimensional spatial distributions of these cells. By
              varying the characteristics of the neoantigen profile of
              individual patients, such as mutational burden and antigen
              strength, a spectrum of pretreatment spatial patterns of PDL1
              expression is generated in our simulations, resembling
              immuno-architectures obtained via immunohistochemistry from
              patient biopsies. By correlating these spatial characteristics
              with in silico treatment results using immune checkpoint
              inhibitors, the model provides a framework for use to predict
              treatment/biomarker combinations in different cancer types based
              on cancer-specific experimental data.",
  journal  = "J. R. Soc. Interface",
  volume   =  14,
  number   =  134,
  month    =  sep,
  year     =  2017,
  keywords = "biomarker; immune checkpoint; immuno-oncology; immunotherapy;
              systems biology",
  language = "en"
}

@ARTICLE{Nichol2019-xh,
  title    = "Model genotype-phenotype mappings and the algorithmic structure
              of evolution",
  author   = "Nichol, Daniel and Robertson-Tessi, Mark and Anderson, Alexander
              R A and Jeavons, Peter",
  abstract = "Cancers are complex dynamic systems that undergo evolution and
              selection. Personalized medicine approaches in the clinic
              increasingly rely on predictions of tumour response to one or
              more therapies; these predictions are complicated by the
              inevitable evolution of the tumour. Despite enormous amounts of
              data on the mutational status of cancers and numerous therapies
              developed in recent decades to target these mutations, many of
              these treatments fail after a time due to the development of
              resistance in the tumour. The emergence of these resistant
              phenotypes is not easily predicted from genomic data, since the
              relationship between genotypes and phenotypes, termed the
              genotype-phenotype (GP) mapping, is neither injective nor
              functional. We present a review of models of this mapping within
              a generalized evolutionary framework that takes into account the
              relation between genotype, phenotype, environment and fitness.
              Different modelling approaches are described and compared, and
              many evolutionary results are shown to be conserved across
              studies despite using different underlying model systems. In
              addition, several areas for future work that remain understudied
              are identified, including plasticity and bet-hedging. The
              GP-mapping provides a pathway for understanding the potential
              routes of evolution taken by cancers, which will be necessary
              knowledge for improving personalized therapies.",
  journal  = "J. R. Soc. Interface",
  volume   =  16,
  number   =  160,
  pages    = "20190332",
  month    =  nov,
  year     =  2019,
  keywords = "genotype--phenotype mapping; mathematical model; mathematical
              oncology; personalized medicine",
  language = "en"
}

@ARTICLE{Zhou2020-ez,
  title    = "Exploiting aneuploidy-imposed stresses and coping mechanisms to
              battle cancer",
  author   = "Zhou, Lin and Jilderda, Laura J and Foijer, Floris",
  abstract = "Aneuploidy, an irregular number of chromosomes in cells, is a
              hallmark feature of cancer. Aneuploidy results from chromosomal
              instability (CIN) and occurs in almost 90\% of all tumours. While
              many cancers display an ongoing CIN phenotype, cells can also be
              aneuploid without displaying CIN. CIN drives tumour evolution as
              ongoing chromosomal missegregation will yield a progeny of cells
              with variable aneuploid karyotypes. The resulting aneuploidy is
              initially toxic to cells because it leads to proteotoxic and
              metabolic stress, cell cycle arrest, cell death, immune cell
              activation and further genomic instability. In order to overcome
              these aneuploidy-imposed stresses and adopt a malignant fate,
              aneuploid cancer cells must develop aneuploidy-tolerating
              mechanisms to cope with CIN. Aneuploidy-coping mechanisms can
              thus be considered as promising therapeutic targets. However,
              before such therapies can make it into the clinic, we first need
              to better understand the molecular mechanisms that are activated
              upon aneuploidization and the coping mechanisms that are selected
              for in aneuploid cancer cells. In this review, we discuss the key
              biological responses to aneuploidization, some of the recently
              uncovered aneuploidy-coping mechanisms and some strategies to
              exploit these in cancer therapy.",
  journal  = "Open Biol.",
  volume   =  10,
  number   =  9,
  pages    = "200148",
  month    =  sep,
  year     =  2020,
  keywords = "aneuploidy; aneuploidy tolerance; cancer; chromosomal
              instability; intervention",
  language = "en"
}

@ARTICLE{Wang2019-uk,
  title    = "In silico simulation of a clinical trial with {anti-CTLA-4} and
              {anti-PD-L1} immunotherapies in metastatic breast cancer using a
              systems pharmacology model",
  author   = "Wang, Hanwen and Milberg, Oleg and Bartelink, Imke H and Vicini,
              Paolo and Wang, Bing and Narwal, Rajesh and Roskos, Lorin and
              Santa-Maria, Cesar A and Popel, Aleksander S",
  abstract = "The low response rate of immune checkpoint blockade in breast
              cancer has highlighted the need for predictive biomarkers to
              identify responders. While a number of clinical trials are
              ongoing, testing all possible combinations is not feasible. In
              this study, a quantitative systems pharmacology model is built to
              integrate immune-cancer cell interactions in patients with breast
              cancer, including central, peripheral, tumour-draining lymph node
              (TDLN) and tumour compartments. The model can describe the immune
              suppression and evasion in both TDLN and the tumour
              microenvironment due to checkpoint expression, and mimic the
              tumour response to checkpoint blockade therapy. We investigate
              the relationship between the tumour response to checkpoint
              blockade therapy and composite tumour burden, PD-L1 expression
              and antigen intensity, including their individual and combined
              effects on the immune system, using model-based simulations. The
              proposed model demonstrates the potential to make predictions of
              tumour response of individual patients given sufficient clinical
              measurements, and provides a platform that can be further adapted
              to other types of immunotherapy and their combination with
              molecular-targeted therapies. The patient predictions demonstrate
              how this systems pharmacology model can be used to individualize
              immunotherapy treatments. When appropriately validated, these
              approaches may contribute to optimization of breast cancer
              treatment.",
  journal  = "R Soc Open Sci",
  volume   =  6,
  number   =  5,
  pages    = "190366",
  month    =  may,
  year     =  2019,
  keywords = "computational biology; computational model; immune checkpoint
              inhibitor; immuno-oncology; systems biology",
  language = "en"
}

@ARTICLE{Medawar1958-hh,
  title     = "The Croonian Lecture: The homograft reaction",
  author    = "Medawar, Peter Brian",
  journal   = "Proceedings of the Royal Society of London. Series B -
               Biological Sciences",
  publisher = "Royal Society",
  volume    =  149,
  number    =  935,
  pages     = "145--166",
  month     =  dec,
  year      =  1958
}

@ARTICLE{Baeder2016-gh,
  title    = "Antimicrobial combinations: Bliss independence and Loewe
              additivity derived from mechanistic multi-hit models",
  author   = "Baeder, Desiree Y and Yu, Guozhi and Hoz{\'e}, Nathana{\"e}l and
              Rolff, Jens and Regoes, Roland R",
  abstract = "Antimicrobial peptides (AMPs) and antibiotics reduce the net
              growth rate of bacterial populations they target. It is relevant
              to understand if effects of multiple antimicrobials are
              synergistic or antagonistic, in particular for AMP responses,
              because naturally occurring responses involve multiple AMPs.
              There are several competing proposals describing how multiple
              types of antimicrobials add up when applied in combination, such
              as Loewe additivity or Bliss independence. These additivity terms
              are defined ad hoc from abstract principles explaining the
              supposed interaction between the antimicrobials. Here, we link
              these ad hoc combination terms to a mathematical model that
              represents the dynamics of antimicrobial molecules hitting
              targets on bacterial cells. In this multi-hit model, bacteria are
              killed when a certain number of targets are hit by
              antimicrobials. Using this bottom-up approach reveals that Bliss
              independence should be the model of choice if no interaction
              between antimicrobial molecules is expected. Loewe additivity, on
              the other hand, describes scenarios in which antimicrobials
              affect the same components of the cell, i.e. are not acting
              independently. While our approach idealizes the dynamics of
              antimicrobials, it provides a conceptual underpinning of the
              additivity terms. The choice of the additivity term is essential
              to determine synergy or antagonism of antimicrobials.This article
              is part of the themed issue 'Evolutionary ecology of arthropod
              antimicrobial peptides'.",
  journal  = "Philos. Trans. R. Soc. Lond. B Biol. Sci.",
  volume   =  371,
  number   =  1695,
  month    =  may,
  year     =  2016,
  keywords = "antagonism; antibiotics; antimicrobial peptide responses;
              mathematical modelling; pharmacodynamic function; synergy",
  language = "en"
}

@UNPUBLISHED{Van_Liedekerke2018-ev,
  title    = "Quantitative agent-based modeling reveals mechanical stress
              response of growing tumor spheroids is predictable over various
              growth conditions and cell lines",
  author   = "Van Liedekerke, Paul and Neitsch, Johannes and Johann, Tim and
              Alessandri, Kevin and Nassoy, Pierre and Drasdo, Dirk",
  abstract = "Model simulations indicate that the response of growing cell
              populations on mechanical stress follows the same functional
              relationship and is predictable over different cell lines and
              growth conditions despite the response curves look largely
              different. We develop a hybrid model strategy in which cells are
              represented by coarse-grained individual units calibrated with a
              high resolution cell model and parameterized measurable
              biophysical and cell-biological parameters. Cell cycle
              progression in our model is controlled by volumetric strain, the
              latter being derived from a bio-mechanical relation between
              applied pressure and cell compressibility. After parameter
              calibration from experiments with mouse colon carcinoma cells
              growing against the resistance of an elastic alginate capsule,
              the model adequately predicts the growth curve in i) soft and
              rigid capsules, ii) in different experimental conditions where
              the mechanical stress is generated by osmosis via a high
              molecular weight dextran solution, and iii) for other cell types
              with varying doubling times. Our model simulation results suggest
              that the growth response of cell population upon externally
              applied mechanical stress is the same, as it can be
              quantitatively predicted using the same growth progression
              function.",
  journal  = "bioRxiv",
  pages    = "122614",
  month    =  jun,
  year     =  2018,
  language = "en"
}

@UNPUBLISHED{Beck2020-uz,
  title    = "{CD137-stimulated} cytotoxic {T} lymphocytes exert superior
              tumour control due to an enhanced antimitotic effect on tumour
              cells",
  author   = "Beck, Richard J and Weigelin, Bettina and Beltman, Joost B",
  abstract = "Several immunotherapeutic strategies for the treatment of cancer
              are under development. Two prominent strategies are adoptive cell
              transfer (ACT) of cytotoxic T lymphocytes (CTLs) and modulation
              of CTL function with immune checkpoint inhibitors or with
              costimulatory antibodies. Despite some success with these
              approaches, there remains a lack of detailed and quantitative
              descriptions of the events following CTL transfer and the impact
              of immunomodulation. Here, we have applied ordinary differential
              equation models to two photon imaging data derived from a B16F10
              murine melanoma. Models were parameterised with data from two
              different treatment conditions: either ACT-only, or ACT with
              intratumoural costimulation using a CD137 targeted antibody.
              Model dynamics and best fitting parameters were compared, in
              order to assess the mode of action of the CTLs and examine how
              the CD137 antibody influenced their activities. We found that the
              cytolytic activity of the transferred CTLs was minimal without
              CD137 costimulation, and that the CD137 targeted antibody did not
              enhance the per-capita killing ability of the transferred CTLs.
              Instead, the results of our modelling study suggest that an
              antiproliferative effect of CTLs exerted upon the tumour likely
              accounted for the majority of the reduction in tumour growth
              after CTL transfer. We found that CD137 most likely improved
              tumour control via enhancement of this antiproliferative effect,
              as well as prolonging the period in which CTLs were inside the
              tumour, leading to a sustained duration of their antitumour
              effects following CD137 stimulation. Significance CTLs play an
              important role in controlling tumours, and improved understanding
              of how they accomplish this will benefit immunotherapeutic cancer
              treatment strategies. Stimulation of CTLs by targeting their
              CD137 receptor is a strategy currently under investigation for
              enhancing responses against tumours, yet so far only limited
              quantitative knowledge regarding the effects of such stimulation
              upon CTLs has been obtained. Here, we develop mathematical models
              to describe dynamic in vivo two-photon imaging of tumour
              infiltrating CTLs, to characterise differences in their function
              either in the presence or absence of a CD137 agonist antibody. We
              showed that an increased antiproliferative effect and a more
              sustained presence of CTLs within the tumour were the most
              significant effects associated with anti-CD137 treatment. \#\#\#
              Competing Interest Statement The authors have declared no
              competing interest.",
  journal  = "bioRxiv",
  pages    = "2020.12.15.411538",
  month    =  dec,
  year     =  2020,
  language = "en"
}

@UNPUBLISHED{Karlsson2022-rq,
  title    = "Experimental evolution in {TP53} deficient human gastric
              organoids recapitulates tumorigenesis",
  author   = "Karlsson, Kasper and Przybilla, Moritz and Xu, Hang and Kotler,
              Eran and Karagyozova, Kremena and Sockell, Alexandra and Liu,
              Katherine and Mah, Amanda and Lo, Yuan-Hung and Lu, Bingxin and
              Houlahan, Kathleen E and Khan, Aziz and Ma, Zhicheng and Suarez,
              Carlos J and Barnes, Chris P and Kuo, Calvin J and Curtis,
              Christina",
  abstract = "The earliest events during human tumor initiation are poorly
              characterized but may hold clues as to how to detect and prevent
              malignancy. Here we model occult pre-neoplasia by engineering
              TP53 deficiency, a common and early event in gastric cancer, into
              human gastric organoids. By performing experimental evolution in
              multiple clonally derived cultures over two years we define
              causal relationships between this common initiating genetic
              lesion and resulting phenotypes. TP53 loss elicited progressive
              aneuploidy, including copy number alterations and complex
              structural variants that are common in gastric cancers and which
              follow preferred temporal orders. Longitudinal single cell
              sequencing of TP53 deficient gastric organoids similarly
              indicates progression towards malignant transcriptional programs.
              Moreover, lineage tracing with expressed cellular barcodes
              demonstrates reproducible dynamics whereby initially rare
              subclones with shared transcriptional programs repeatedly attain
              clonal dominance. This powerful platform for experimental
              evolution exposes stringent selection, clonal interference and a
              striking degree of phenotypic convergence in pre-malignant
              epithelial organoids, implying that the earliest stages of
              tumorigenesis may be predictable while illuminating evolutionary
              constraints and barriers to malignant transformation.
              ![Figure][1] \#\#\# Competing Interest Statement CK is a founder
              and stockholder for Surrozen Inc, Mozart Therapeutics and
              NextVivo Inc. C.C. is an advisor and stockholder in Grail, Ravel,
              DeepCell and an advisor to Genentech, Bristol Myers Squibb, 3T
              Biosciences and NanoString. All other authors declare no
              competing interests. [1]: pending:yes",
  journal  = "bioRxiv",
  pages    = "2022.04.09.487529",
  month    =  apr,
  year     =  2022,
  language = "en"
}

@UNPUBLISHED{Chang2022-vm,
  title    = "Fraction of copy-number alterations significantly predicts
              survival following immunotherapy in a few cancers",
  author   = "Chang, Tiangen and Cao, Yingying and Shulman, Eldad D and
              Sch{\"a}ffer, Alejandro A and Ruppin, Eytan",
  abstract = "Various studies have shown that high tumor mutation burden (TMB)
              may predict response to immune checkpoint therapy, at least in
              some cancer types [1][1],[2][2]. However, identifying patients
              with low TMB that are still likely to respond to cancer
              immunotherapy is an important open challenge. Recently, Spurr et
              al. [3][3] reported that the tumor aneuploidy score (AS), defined
              as the fraction of chromosome arms with arm-level copy number
              alterations in a sample, is predictive of survival following
              immunotherapy in low-TMB patients across multiple cancers. By
              re-analyzing the same data set by performing survival analysis in
              individual cancer types separately, we find that AS only
              significantly predicts survival in one single cancer indication.
              We further find that another metric conceptually related to the
              AS, the fraction of genome encompassed by copy number alterations
              (FGA) , if called with a conventional copy number calling cutoff,
              has stronger predictive power than the AS proposed in [3][3], and
              that this observation holds even if the FGA and AS thresholds for
              presence/absence of copy number events are set comparably.
              However, with the current available data, even FGA can predict
              survival following immunotherapy in only a few cancer
              indications. \#\#\# Competing Interest Statement E.R. is a
              co-founder of MedAware, Metabomed and Pangea Biomed (divested),
              and an unpaid member of Pangea Biomed scientific advisory board.
              The other authors have no competing interests. [1]: \#ref-1 [2]:
              \#ref-2 [3]: \#ref-3",
  journal  = "bioRxiv",
  pages    = "2022.12.28.522101",
  month    =  dec,
  year     =  2022,
  language = "en"
}

@ARTICLE{Girish2023-xu,
  title    = "Oncogene-like addiction to aneuploidy in human cancers",
  author   = "Girish, Vishruth and Lakhani, Asad A and Scaduto, Christine M and
              Thompson, Sarah L and Brown, Leanne M and Hagenson, Ryan A and
              Sausville, Erin L and Mendelson, Brianna E and Lukow, Devon A and
              Yuan, Monet Lou and Kandikuppa, Pranav K and Stevens, Eric C and
              Lee, Sophia N and Salovska, Barbora and Li, Wenxue and Smith,
              Joan C and Taylor, Alison M and Martienssen, Robert A and Liu,
              Yansheng and Sun, Ruping and Sheltzer, Jason M",
  abstract = "Most cancers exhibit aneuploidy, but its functional significance
              in tumor development is controversial. Here, we describe ReDACT
              (Restoring Disomy in Aneuploid cells using CRISPR Targeting), a
              set of chromosome engineering tools that allow us to eliminate
              specific aneuploidies from cancer genomes. Using ReDACT, we
              created a panel of isogenic cells that have or lack common
              aneuploidies, and we demonstrate that trisomy of chromosome 1q is
              required for malignant growth in cancers harboring this
              alteration. Mechanistically, gaining chromosome 1q increases the
              expression of MDM4 and suppresses TP53 signaling, and we show
              that TP53 mutations are mutually-exclusive with 1q aneuploidy in
              human cancers. Thus, specific aneuploidies play essential roles
              in tumorigenesis, raising the possibility that targeting these
              ``aneuploidy addictions'' could represent a novel approach for
              cancer treatment.",
  journal  = "bioRxiv",
  month    =  jan,
  year     =  2023,
  language = "en"
}

@UNPUBLISHED{Rastogi2019-yk,
  title    = "Evaluation of {CD8} {T} cell killing models with computer
              simulations of 2-photon imaging experiments",
  author   = "Rastogi, Ananya and Robert, Philippe and Halle, Stephan and
              Meyer-Hermann, Michael",
  abstract = "In vivo imaging of cytotoxic T lymphocyte (CTL) killing activity
              revealed that infected cells have a higher observed probability
              of dying after multiple contacts with CTLs, suggesting memory
              effect in CTLs or infected cells. We developed a
              three-dimensional agent-based model of CTL killing activity to
              discriminate different hypotheses about how infected cells get
              killed based on quantitative 2-photon in vivo observations. We
              compared a constant CTL killing probability with mechanisms of
              signal integration in CTL or infected cells. The most likely
              scenario implied increased susceptibility of infected cells with
              increasing number of CTL contacts where the total number of
              contacts was a critical factor as opposed to signal integration
              over many contacts. However, when allowing in silico T cells to
              interact with apoptotic target cells (zombie contacts), a contact
              history independent killing mechanism was also in agreement with
              the experimental datasets. We showed that contacts that take
              place between CTLs and dying infected cells impact the observed
              killing dynamics because even in absence of modulation of cell
              properties, we saw an increase of the observed probability of
              killing infected cells with more interactions. The duration taken
              by an infected cell to die and the per capita killing rate (PCKR)
              of CTLs, parameters hard to measure directly, were determined
              from the model and turned out predictive to distinguish the
              different CTL killing models in future experiments. The
              comparison of observed datasets to simulation results, revealed
              limitations in interpreting 2-photon data, and provided
              prediction for additional measurements to distinguish CTL killing
              models. Highlights Significance Statement Despite having a clear
              understanding of cytotoxic T lymphocyte (CTL) mediated
              cytotoxicity mechanisms, the quantitative dynamics remain
              unexplored at a cellular level. We developed an agent-based model
              to compare different hypotheses for mechanisms of CTL mediated
              cytotoxicity that could lead to an increase in observed
              probability of killing infected cells at higher interactions with
              CTLs as seen in vivo . We showed that this behaviour can be
              explained by modulation of properties by infected cells or CTLs
              with increasing number of contacts. For the modulation, we
              compared two modes of signal integration and showed that time is
              not a relevant parameter in signal integration. We also studied
              the impact of contacts between CTLs and apoptotic infected cells
              on observed killing properties.",
  journal  = "bioRxiv",
  pages    = "830505",
  month    =  nov,
  year     =  2019,
  language = "en"
}

@ARTICLE{Mizushima2007-sn,
  title    = "Autophagy: process and function",
  author   = "Mizushima, Noboru",
  abstract = "Autophagy is an intracellular degradation system that delivers
              cytoplasmic constituents to the lysosome. Despite its simplicity,
              recent progress has demonstrated that autophagy plays a wide
              variety of physiological and pathophysiological roles, which are
              sometimes complex. Autophagy consists of several sequential
              steps--sequestration, transport to lysosomes, degradation, and
              utilization of degradation products--and each step may exert
              different function. In this review, the process of autophagy is
              summarized, and the role of autophagy is discussed in a
              process-based manner.",
  journal  = "Genes Dev.",
  volume   =  21,
  number   =  22,
  pages    = "2861--2873",
  month    =  nov,
  year     =  2007,
  language = "en"
}

@ARTICLE{Oromendia2012-dl,
  title    = "Aneuploidy causes proteotoxic stress in yeast",
  author   = "Oromendia, Ana B and Dodgson, Stacie E and Amon, Angelika",
  abstract = "Gains or losses of entire chromosomes lead to aneuploidy, a
              condition tolerated poorly in all eukaryotes analyzed to date.
              How aneuploidy affects organismal and cellular physiology is
              poorly understood. We found that aneuploid budding yeast cells
              are under proteotoxic stress. Aneuploid strains are prone to
              aggregation of endogenous proteins as well as of ectopically
              expressed hard-to-fold proteins such as those containing
              polyglutamine (polyQ) stretches. Protein aggregate formation in
              aneuploid yeast strains is likely due to limiting protein
              quality-control systems, since the proteasome and at least one
              chaperone family, Hsp90, are compromised in many aneuploid
              strains. The link between aneuploidy and the formation and
              persistence of protein aggregates could have important
              implications for diseases such as cancer and neurodegeneration.",
  journal  = "Genes Dev.",
  volume   =  26,
  number   =  24,
  pages    = "2696--2708",
  month    =  dec,
  year     =  2012,
  language = "en"
}

@ARTICLE{Santaguida2015-fv,
  title    = "Aneuploidy-induced cellular stresses limit autophagic degradation",
  author   = "Santaguida, Stefano and Vasile, Eliza and White, Eileen and Amon,
              Angelika",
  abstract = "An unbalanced karyotype, a condition known as aneuploidy, has a
              profound impact on cellular physiology and is a hallmark of
              cancer. Aneuploid cells experience a number of stresses that are
              caused by aneuploidy-induced proteomic changes. How the
              aneuploidy-associated stresses affect cells and whether cells
              respond to them are only beginning to be understood. Here we show
              that autophagosomal cargo such as protein aggregates accumulate
              within lysosomes in aneuploid cells. This causes a lysosomal
              stress response. Aneuploid cells activate the transcription
              factor TFEB, a master regulator of autophagic and lysosomal gene
              expression, thereby increasing the expression of genes needed for
              autophagy-mediated protein degradation. Accumulation of
              autophagic cargo within the lysosome and activation of
              TFEB-responsive genes are also observed in cells in which
              proteasome function is inhibited, suggesting that proteotoxic
              stress causes TFEB activation. Our results reveal a TFEB-mediated
              lysosomal stress response as a universal feature of the aneuploid
              state.",
  journal  = "Genes Dev.",
  volume   =  29,
  number   =  19,
  pages    = "2010--2021",
  month    =  oct,
  year     =  2015,
  keywords = "TFEB; aneuploidy; autophagy; cancer; proteotoxicity",
  language = "en"
}

@ARTICLE{Dodgson2016-es,
  title    = "The pleiotropic deubiquitinase Ubp3 confers aneuploidy tolerance",
  author   = "Dodgson, Stacie E and Santaguida, Stefano and Kim, Sharon and
              Sheltzer, Jason and Amon, Angelika",
  abstract = "Aneuploidy-or an unbalanced karyotype in which whole chromosomes
              are gained or lost-causes reduced fitness at both the cellular
              and organismal levels but is also a hallmark of human cancers.
              Aneuploidy causes a variety of cellular stresses, including
              genomic instability, proteotoxic and oxidative stresses, and
              impaired protein trafficking. The deubiquitinase Ubp3, which was
              identified by a genome-wide screen for gene deletions that impair
              the fitness of aneuploid yeast, is a key regulator of aneuploid
              cell homeostasis. We show that deletion of UBP3 exacerbates both
              karyotype-specific phenotypes and global stresses of aneuploid
              cells, including oxidative and proteotoxic stress. Indeed, Ubp3
              is essential for proper proteasome function in euploid cells, and
              deletion of this deubiquitinase leads to further
              proteasome-mediated proteotoxicity in aneuploid yeast. Notably,
              the importance of UBP3 in aneuploid cells is conserved. Depletion
              of the human homolog of UBP3, USP10, is detrimental to the
              fitness of human cells upon chromosome missegregation, and this
              fitness defect is accompanied by autophagy inhibition. We thus
              used a genome-wide screen in yeast to identify a guardian of
              aneuploid cell fitness conserved across species. We propose that
              interfering with Ubp3/USP10 function could be a productive avenue
              in the development of novel cancer therapeutics.",
  journal  = "Genes Dev.",
  volume   =  30,
  number   =  20,
  pages    = "2259--2271",
  month    =  oct,
  year     =  2016,
  keywords = "Ubp3; aneuploidy; deubiquitinase; proteasome",
  language = "en"
}

@ARTICLE{Brennan2019-mi,
  title    = "Protein aggregation mediates stoichiometry of protein complexes
              in aneuploid cells",
  author   = "Brennan, Christopher M and Vaites, Laura Pontano and Wells,
              Jonathan N and Santaguida, Stefano and Paulo, Joao A and
              Storchova, Zuzana and Harper, J Wade and Marsh, Joseph A and
              Amon, Angelika",
  abstract = "Aneuploidy, a condition characterized by chromosome gains and
              losses, causes reduced fitness and numerous cellular stresses,
              including increased protein aggregation. Here, we identify
              protein complex stoichiometry imbalances as a major cause of
              protein aggregation in aneuploid cells. Subunits of protein
              complexes encoded on excess chromosomes aggregate in aneuploid
              cells, which is suppressed when expression of other subunits is
              coordinately altered. We further show that excess subunits are
              either degraded or aggregate and that protein aggregation is
              nearly as effective as protein degradation at lowering levels of
              excess proteins. Our study explains why proteotoxic stress is a
              universal feature of the aneuploid state and reveals protein
              aggregation as a form of dosage compensation to cope with
              disproportionate expression of protein complex subunits.",
  journal  = "Genes Dev.",
  volume   =  33,
  number   = "15-16",
  pages    = "1031--1047",
  month    =  aug,
  year     =  2019,
  keywords = "aneuploidy; protein aggregation; protein homeostasis",
  language = "en"
}

@ARTICLE{Trakala2021-yb,
  title    = "Clonal selection of stable aneuploidies in progenitor cells
              drives high-prevalence tumorigenesis",
  author   = "Trakala, Marianna and Aggarwal, Muskaan and Sniffen, Courtney and
              Zasadil, Lauren and Carroll, Allison and Ma, Duanduan and Su,
              Xiaofeng A and Wangsa, Darawalee and Meyer, Ashleigh and Sieben,
              Cynthia J and Zhong, Jian and Hsu, Pei-Hsin and Paradis, Glenn
              and Ried, Thomas and Holland, Andrew and Van Deursen, Jan and
              Amon, Angelika",
  abstract = "Chromosome gains and losses are a frequent feature of human
              cancers. However, how these aberrations can outweigh the
              detrimental effects of aneuploidy remains unclear. An initial
              comparison of existing chromosomal instability (CIN) mouse models
              suggests that aneuploidy accumulates to low levels in these
              animals. We therefore developed a novel mouse model that enables
              unprecedented levels of chromosome missegregation in the adult
              animal. At the earliest stages of T-cell development, cells with
              random chromosome gains and/or losses are selected against, but
              CIN eventually results in the expansion of progenitors with
              clonal chromosomal imbalances. Clonal selection leads to the
              development of T-cell lymphomas with stereotypic karyotypes in
              which chromosome 15, containing the Myc oncogene, is gained with
              high prevalence. Expressing human MYC from chromosome 6 (MYCChr6)
              is sufficient to change the karyotype of these lymphomas to
              include universal chromosome 6 gains. Interestingly, while
              chromosome 15 is still gained in MYCChr6 tumors after genetic
              ablation of the endogenous Myc locus, this chromosome is not
              efficiently gained after deletion of one copy of Rad21,
              suggesting a synergistic effect of both MYC and RAD21 in driving
              chromosome 15 gains. Our results show that the initial
              detrimental effects of random missegregation are outbalanced by
              clonal selection, which is dictated by the chromosomal location
              and nature of certain genes and is sufficient to drive cancer
              with high prevalence.",
  journal  = "Genes Dev.",
  volume   =  35,
  number   = "15-16",
  pages    = "1079--1092",
  month    =  aug,
  year     =  2021,
  keywords = "MYC; RAD21; aneuploidy; cancer; chromosomal instability; oncogene",
  language = "en"
}

@ARTICLE{Yang2003-ty,
  title    = "Decay rates of human {mRNAs}: correlation with functional
              characteristics and sequence attributes",
  author   = "Yang, Edward and van Nimwegen, Erik and Zavolan, Mihaela and
              Rajewsky, Nikolaus and Schroeder, Mark and Magnasco, Marcelo and
              Darnell, Jr, James E",
  abstract = "Although mRNA decay rates are a key determinant of the
              steady-state concentration for any given mRNA species, relatively
              little is known, on a population level, about what factors
              influence turnover rates and how these rates are integrated into
              cellular decisions. We decided to measure mRNA decay rates in two
              human cell lines with high-density oligonucleotide arrays that
              enable the measurement of decay rates simultaneously for
              thousands of mRNA species. Using existing annotation and the Gene
              Ontology hierarchy of biological processes, we assign mRNAs to
              functional classes at various levels of resolution and compare
              the decay rate statistics between these classes. The results show
              statistically significant organizational principles in the
              variation of decay rates among functional classes. In particular,
              transcription factor mRNAs have increased average decay rates
              compared with other transcripts and are enriched in
              ``fast-decaying'' mRNAs with half-lives <2 h. In contrast, we
              find that mRNAs for biosynthetic proteins have decreased average
              decay rates and are deficient in fast-decaying mRNAs. Our
              analysis of data from a previously published study of
              Saccharomyces cerevisiae mRNA decay shows the same functional
              organization of decay rates, implying that it is a general
              organizational scheme for eukaryotes. Additionally, we
              investigated the dependence of decay rates on sequence
              composition, that is, the presence or absence of short mRNA
              motifs in various regions of the mRNA transcript. Our analysis
              recovers the positive correlation of mRNA decay with known
              AU-rich mRNA motifs, but we also uncover further short mRNA
              motifs that show statistically significant correlation with
              decay. However, we also note that none of these motifs are strong
              predictors of mRNA decay rate, indicating that the regulation of
              mRNA decay is more complex and may involve the cooperative
              binding of several RNA-binding proteins at different sites.",
  journal  = "Genome Res.",
  volume   =  13,
  number   =  8,
  pages    = "1863--1872",
  month    =  aug,
  year     =  2003,
  language = "en"
}

@ARTICLE{Duncan2012-gz,
  title    = "A heterozygous {IDH1R132H/WT} mutation induces genome-wide
              alterations in {DNA} methylation",
  author   = "Duncan, Christopher G and Barwick, Benjamin G and Jin, Genglin
              and Rago, Carlo and Kapoor-Vazirani, Priya and Powell, Doris R
              and Chi, Jen-Tsan and Bigner, Darell D and Vertino, Paula M and
              Yan, Hai",
  abstract = "Monoallelic point mutations of the NADP(+)-dependent isocitrate
              dehydrogenases IDH1 and IDH2 occur frequently in gliomas, acute
              myeloid leukemias, and chondromas, and display robust association
              with specific DNA hypermethylation signatures. Here we show that
              heterozygous expression of the IDH1(R132H) allele is sufficient
              to induce the genome-wide alterations in DNA methylation
              characteristic of these tumors. Using a gene-targeting approach,
              we knocked-in a single copy of the most frequently observed IDH1
              mutation, R132H, into a human cancer cell line and profiled
              changes in DNA methylation at over 27,000 CpG dinucleotides
              relative to wild-type parental cells. We find that IDH1(R132H/WT)
              mutation induces widespread alterations in DNA methylation,
              including hypermethylation of 2010 and hypomethylation of 842 CpG
              loci. We demonstrate that many of these alterations are
              consistent with those observed in IDH1-mutant and G-CIMP+ primary
              gliomas and can segregate IDH wild-type and mutated tumors as
              well as those exhibiting the G-CIMP phenotype in unsupervised
              analysis of two primary glioma cohorts. Further, we show that the
              direction of IDH1(R132H/WT)-mediated DNA methylation change is
              largely dependent upon preexisting DNA methylation levels,
              resulting in depletion of moderately methylated loci.
              Additionally, whereas the levels of multiple histone H3 and H4
              methylation modifications were globally increased, consistent
              with broad inhibition of histone demethylation, hypermethylation
              at H3K9 in particular accompanied locus-specific DNA
              hypermethylation at several genes down-regulated in
              IDH1(R132H/WT) knock-in cells. These data provide insight on
              epigenetic alterations induced by IDH1 mutations and support a
              causal role for IDH1(R132H/WT) mutants in driving epigenetic
              instability in human cancer cells.",
  journal  = "Genome Res.",
  volume   =  22,
  number   =  12,
  pages    = "2339--2355",
  month    =  dec,
  year     =  2012,
  language = "en"
}

@ARTICLE{Buccitelli2017-in,
  title    = "Pan-cancer analysis distinguishes transcriptional changes of
              aneuploidy from proliferation",
  author   = "Buccitelli, Christopher and Salgueiro, Lorena and Rowald,
              Konstantina and Sotillo, Rocio and Mardin, Balca R and Korbel,
              Jan O",
  abstract = "Patterns of gene expression in tumors can arise as a consequence
              of or result in genomic instability, characterized by the
              accumulation of somatic copy number alterations (SCNAs) and point
              mutations (PMs). Expression signatures have been widely used as
              markers for genomic instability, and both SCNAs and PMs could be
              thought to associate with distinct signatures given their
              different formation mechanisms. Here we test this notion by
              systematically investigating SCNA, PM, and transcriptome data
              from 2660 cancer patients representing 11 tumor types. Notably,
              our data indicate that similar expression signatures can be
              derived from correlating gene expression with either SCNA or PM
              load. Gene sets related to cell growth and proliferation
              generally associated positively, and immunoregulatory gene sets
              negatively, with variant burden. In-depth analyses revealed
              several genes whose de-regulation correlates with SCNA but not
              with PM burden, yielding downstream effectors of TP53 and MYC
              signaling unique to high-SCNA tumors. We compared our findings to
              expression changes observed in two different cancer mouse models
              with persistent mitotic chromosomal instability, observing a
              decrease in proliferative expression signatures. Our results
              suggest that overexpression of cell-cycle-related genes are a
              characteristic of proliferation, and likely tumor evolution,
              rather than ongoing genomic instability.",
  journal  = "Genome Res.",
  volume   =  27,
  number   =  4,
  pages    = "501--511",
  month    =  apr,
  year     =  2017,
  language = "en"
}

@ARTICLE{Hsiao2020-kp,
  title    = "Characterizing and inferring quantitative cell cycle phase in
              single-cell {RNA-seq} data analysis",
  author   = "Hsiao, Chiaowen Joyce and Tung, Poyuan and Blischak, John D and
              Burnett, Jonathan E and Barr, Kenneth A and Dey, Kushal K and
              Stephens, Matthew and Gilad, Yoav",
  abstract = "Cellular heterogeneity in gene expression is driven by cellular
              processes, such as cell cycle and cell-type identity, and
              cellular environment such as spatial location. The cell cycle, in
              particular, is thought to be a key driver of cell-to-cell
              heterogeneity in gene expression, even in otherwise homogeneous
              cell populations. Recent advances in single-cell RNA-sequencing
              (scRNA-seq) facilitate detailed characterization of gene
              expression heterogeneity and can thus shed new light on the
              processes driving heterogeneity. Here, we combined fluorescence
              imaging with scRNA-seq to measure cell cycle phase and gene
              expression levels in human induced pluripotent stem cells
              (iPSCs). By using these data, we developed a novel approach to
              characterize cell cycle progression. Although standard methods
              assign cells to discrete cell cycle stages, our method goes
              beyond this and quantifies cell cycle progression on a continuum.
              We found that, on average, scRNA-seq data from only five genes
              predicted a cell's position on the cell cycle continuum to within
              14\% of the entire cycle and that using more genes did not
              improve this accuracy. Our data and predictor of cell cycle phase
              can directly help future studies to account for cell
              cycle-related heterogeneity in iPSCs. Our results and methods
              also provide a foundation for future work to characterize the
              effects of the cell cycle on expression heterogeneity in other
              cell types.",
  journal  = "Genome Res.",
  volume   =  30,
  number   =  4,
  pages    = "611--621",
  month    =  apr,
  year     =  2020,
  language = "en"
}

@ARTICLE{Graner1992-uf,
  title    = "Simulation of biological cell sorting using a two-dimensional
              extended Potts model",
  author   = "Graner, F and Glazier, J A",
  journal  = "Phys. Rev. Lett.",
  volume   =  69,
  number   =  13,
  pages    = "2013--2016",
  month    =  sep,
  year     =  1992,
  language = "en"
}

@ARTICLE{Graner1992-fp,
  title    = "Simulation of biological cell sorting using a two-dimensional
              extended Potts model",
  author   = "Graner, F and Glazier, J A",
  journal  = "Phys. Rev. Lett.",
  volume   =  69,
  number   =  13,
  pages    = "2013--2016",
  month    =  sep,
  year     =  1992,
  language = "en"
}

@ARTICLE{Hayashi2019-aq,
  title    = "Hypoxia/pseudohypoxia-mediated activation of hypoxia-inducible
              factor-1$\alpha$ in cancer",
  author   = "Hayashi, Yoshihiro and Yokota, Asumi and Harada, Hironori and
              Huang, Gang",
  abstract = "Since the first identification of hypoxic cells in sections of
              carcinomas in the 1950s, hypoxia has been known as a central
              hallmark of cancer cells and their microenvironment. Indeed,
              hypoxia benefits cancer cells in their growth, survival, and
              metastasis. The historical discovery of hypoxia-inducible
              factor-1$\alpha$ (HIF1A) in the early 1990s had a great influence
              on the field as many phenomena in hypoxia could be explained by
              HIF1A. However, not all regions or types of tumors are
              necessarily hypoxic. Thus, it is difficult to explain whole
              cancer pathobiology by hypoxia, especially in the early stage of
              cancer. Upregulation of glucose metabolism in cancer cells has
              been well known. Oxygen-independent glycolysis is activated in
              cancer cells even in the normoxia condition, which is known as
              the Warburg effect. Accumulating evidence and recent advances in
              cancer metabolism research suggest that hypoxia-independent
              mechanisms for HIF signaling activation is a hallmark for cancer.
              There are various mechanisms that generate pseudohypoxic
              conditions, even in normoxia. Given the importance of HIF1A for
              cancer pathobiology, the pseudohypoxia concept could shed light
              on the longstanding mystery of the Warburg effect and accelerate
              better understanding of the diverse phenomena seen in a variety
              of cancers.",
  journal  = "Cancer Sci.",
  volume   =  110,
  number   =  5,
  pages    = "1510--1517",
  month    =  may,
  year     =  2019,
  keywords = "HIF1A; Warburg effect; hypoxia; oncometabolite; pseudohypoxia",
  language = "en"
}

@ARTICLE{Kreutz2013-bw,
  title    = "Profile likelihood in systems biology",
  author   = "Kreutz, Clemens and Raue, Andreas and Kaschek, Daniel and Timmer,
              Jens",
  abstract = "Inferring knowledge about biological processes by a mathematical
              description is a major characteristic of Systems Biology. To
              understand and predict system's behavior the available
              experimental information is translated into a mathematical model.
              Since the availability of experimental data is often limited and
              measurements contain noise, it is essential to appropriately
              translate experimental uncertainty to model parameters as well as
              to model predictions. This is especially important in Systems
              Biology because typically large and complex models are applied
              and therefore the limited experimental knowledge might yield
              weakly specified model components. Likelihood profiles have been
              recently suggested and applied in the Systems Biology for
              assessing parameter and prediction uncertainty. In this article,
              the profile likelihood concept is reviewed and the potential of
              the approach is demonstrated for a model of the erythropoietin
              (EPO) receptor.",
  journal  = "FEBS J.",
  volume   =  280,
  number   =  11,
  pages    = "2564--2571",
  month    =  jun,
  year     =  2013,
  language = "en"
}

@ARTICLE{Lavania2012-nw,
  title    = "Autopolyploidy differentially influences body size in plants, but
              facilitates enhanced accumulation of secondary metabolites,
              causing increased cytosine methylation",
  author   = "Lavania, Umesh C and Srivastava, Sarita and Lavania, Seshu and
              Basu, Surochita and Misra, Nandeesh Kumar and Mukai, Yasuhiko",
  abstract = "Whole genome duplication leads to autopolyploidy and brings about
              an increase in cell size, concentration of secondary metabolites
              and enhanced cytosine methylation. The increased cell size offers
              a positive advantage to polyploids for cell-surface-related
              activities, but there is a differential response to change in
              body size across species and taxonomic groups. Although
              polyploidy has been very extensively studied, having genetic,
              ecological and evolutionary implications, there is no report that
              underscores the significance of native secondary metabolites
              vis-{\`a}-vis body size with ploidy change. To address this
              problem we targeted unique diploid-autotetraploid paired sets of
              eight diverse clones of six species of Cymbopogon- a species
              complex of aromatic grasses that accumulate qualitatively
              different monoterpene essential oils (secondary metabolite) in
              their vegetative biomass. Based on the qualitative composition of
              essential oils and the plant body size relationship between the
              diploid versus autotetraploid paired sets, we show that
              polyploidy brings about enhanced accumulation of secondary
              metabolites in all cases, but exerts differential effects on body
              size in various species. It is observed that the accumulation of
              alcohol-type metabolites (e.g. geraniol) does not inhibit
              increase in body size with ploidy change from 2$\times$ to
              4$\times$ (r = 0.854, P < 0.01), but aldehyde-type metabolites
              (e.g. citral) appear to drastically impede body development (r =
              -0.895). Such a differential response may be correlated to the
              metabolic steps involved in the synthesis of essential oil
              components. When changed to tetraploidy, the progenitor diploids
              requiring longer metabolic steps in production of their secondary
              metabolites are stressed, and those having shorter metabolite
              routes better utilize their resources for growth and vigour. In
              situ immunodetection of 5-methylcytosine sites reveals enhanced
              DNA methylation in autopolyploids. It is underpinned that the
              qualitative composition of secondary metabolites found in the
              vegetative biomass of the progenitor diploid has a decisive
              bearing on the body size of the derived autotetraploids and
              brings about an enhancement in genome-wide cytosine methylation.",
  journal  = "Plant J.",
  volume   =  71,
  number   =  4,
  pages    = "539--549",
  month    =  aug,
  year     =  2012,
  language = "en"
}

@ARTICLE{Anselin2010-rm,
  title     = "Local indicators of spatial {association-LISA}",
  author    = "Anselin, Luc",
  abstract  = "The capabilities for visualization, rapid data retrieval, and
               manipulation in geographic information systems (GIS) have
               created the need for new techniques of exploratory data analysis
               that focus on the ?spatial? aspects of the data. The
               identification of local patterns of spatial association is an
               important concern in this respect. In this paper, I outline a
               new general class of local indicators of spatial association
               (LISA) and show how they allow for the decomposition of global
               indicators, such as Moran's I, into the contribution of each
               observation. The LISA statistics serve two purposes. On one
               hand, they may be interpreted as indicators of local pockets of
               nonstationarity, or hot spots, similar to the Gi and G*i
               statistics of Getis and Ord (1992). On the other hand, they may
               be used to assess the influence of individual locations on the
               magnitude of the global statistic and to identify ?outliers,? as
               in Anselin's Moran scatterplot (1993a). An initial evaluation of
               the properties of a LISA statistic is carried out for the local
               Moran, which is applied in a study of the spatial pattern of
               conflict for African countries and in a number of Monte Carlo
               simulations.",
  journal   = "Geogr. Anal.",
  publisher = "Wiley",
  volume    =  27,
  number    =  2,
  pages     = "93--115",
  month     =  sep,
  year      =  2010,
  language  = "en"
}

@ARTICLE{Caramalho2009-zf,
  title    = "Visualizing {CTL/melanoma} cell interactions: multiple hits must
              be delivered for tumour cell annihilation",
  author   = "Caramalho, Iris and Faroudi, Mustapha and Padovan, Elisabetta and
              M{\"u}ller, Sabina and Valitutti, Salvatore",
  abstract = "It is well established that cytotoxic T lymphocytes (CTL) can
              kill target cells offering a very small number of specific
              peptide/MHC complexes (pMHC). It is also known that lethal hit
              delivery is a very rapid response that occurs within a few
              minutes after cell-cell contact. Whether cytotoxicity is
              efficient and rapid in the context of CTL interaction with target
              cells derived from solid tumours is still elusive. We addressed
              this question by visualizing the dynamics of human CTL
              interaction with melanoma cells and their efficiency in eliciting
              cytotoxicity. Our results show that in spite of CTL activation to
              lethal hit delivery, killing of melanoma cells is not efficient.
              Time-lapse microscopy experiments demonstrate that individual CTL
              rapidly polarize their lytic machinery towards target cells, yet
              the apoptotic process in melanoma cells is defective or 'delayed'
              as compared to conventional targets. These results indicate that
              although CTL activation to lethal hit delivery can be viewed as a
              'digital' phenomenon rapidly triggered by a few ligands, melanoma
              cell annihilation is an 'analogue' response requiring multiple
              hits and prolonged contact time.",
  journal  = "J. Cell. Mol. Med.",
  volume   =  13,
  number   = "9B",
  pages    = "3834--3846",
  month    =  sep,
  year     =  2009,
  language = "en"
}

@ARTICLE{Croft2009-pd,
  title    = "The significance of {OX40} and {OX40L} to T-cell biology and
              immune disease",
  author   = "Croft, Michael and So, Takanori and Duan, Wei and Soroosh, Pejman",
  abstract = "SUMMARY: OX40 (CD134) and its binding partner, OX40L (CD252), are
              members of the tumor necrosis factor receptor/tumor necrosis
              factor superfamily and are expressed on activated CD4(+) and
              CD8(+) T cells as well as on a number of other lymphoid and
              non-lymphoid cells. Costimulatory signals from OX40 to a
              conventional T cell promote division and survival, augmenting the
              clonal expansion of effector and memory populations as they are
              being generated to antigen. OX40 additionally suppresses the
              differentiation and activity of T-regulatory cells, further
              amplifying this process. OX40 and OX40L also regulate cytokine
              production from T cells, antigen-presenting cells, natural killer
              cells, and natural killer T cells, and modulate cytokine receptor
              signaling. In line with these important modulatory functions,
              OX40-OX40L interactions have been found to play a central role in
              the development of multiple inflammatory and autoimmune diseases,
              making them attractive candidates for intervention in the clinic.
              Conversely, stimulating OX40 has shown it to be a candidate for
              therapeutic immunization strategies for cancer and infectious
              disease. This review provides a broad overview of the biology of
              OX40 including the intracellular signals from OX40 that impact
              many aspects of immune function and have promoted OX40 as one of
              the most prominent costimulatory molecules known to control T
              cells.",
  journal  = "Immunol. Rev.",
  volume   =  229,
  number   =  1,
  pages    = "173--191",
  month    =  may,
  year     =  2009,
  language = "en"
}

% The entry below contains non-ASCII chars that could not be converted
% to a LaTeX equivalent.
@ARTICLE{Prehn1971-ho,
  title     = "An immunostimulation theory of tumor development",
  author    = "Prehn, R T and Lapp{\'e}, M A",
  abstract  = "The theory of immunosurveillance of neoplasia is so well
               established that its further discussion and demonstration risk
               becoming rather boring. Anyone with the temerity to question its
               overriding importance is likely to be the subject of discrete
               but possibly weE ",
  journal   = "Transplant. Rev.",
  publisher = "Wiley Online Library",
  volume    =  7,
  pages     = "26--54",
  year      =  1971,
  language  = "en"
}

% The entry below contains non-ASCII chars that could not be converted
% to a LaTeX equivalent.
@ARTICLE{Rygaard1974-sj,
  title     = "The mouse mutant nude does not develop spontaneous tumours. An
               argument against immunological surveillance",
  author    = "Rygaard, J and Povlsen, C O",
  abstract  = "The mouse mutant nude is immunologically deficient due to
               congenital absence of the thymus. It will accept allografts and
               heterografts from closely and remotely related donors. Its
               humoral immune response to a number of other antigens is also
               imperfect. De novo ",
  journal   = "Acta Pathol. Microbiol. Scand. B Microbiol. Immunol.",
  publisher = "Wiley Online Library",
  volume    =  82,
  number    =  1,
  pages     = "99--106",
  month     =  feb,
  year      =  1974,
  language  = "en"
}

@ARTICLE{Guo2008-vi,
  title    = "How is {mRNA} expression predictive for protein expression? A
              correlation study on human circulating monocytes",
  author   = "Guo, Yanfang and Xiao, Peng and Lei, Shufeng and Deng, Feiyan and
              Xiao, Gary Guishan and Liu, Yaozhong and Chen, Xiangding and Li,
              Liming and Wu, Shan and Chen, Yuan and Jiang, Hui and Tan, Lijun
              and Xie, Jingyun and Zhu, Xuezhen and Liang, Songping and Deng,
              Hongwen",
  abstract = "A key assumption in studying mRNA expression is that it is
              informative in the prediction of protein expression. However,
              only limited studies have explored the mRNA-protein expression
              correlation in yeast or human tissues and the results have been
              relatively inconsistent. We carried out correlation analyses on
              mRNA-protein expressions in freshly isolated human circulating
              monocytes from 30 unrelated women. The expressed proteins for 71
              genes were quantified and identified by 2-D electrophoresis
              coupled with mass spectrometry. The corresponding mRNA
              expressions were quantified by Affymetrix gene chips. Significant
              correlation (r=0.235, P<0.0001) was observed for the whole
              dataset including all studied genes and all samples. The
              correlations varied in different biological categories of gene
              ontology. For example, the highest correlation was achieved for
              genes of the extracellular region in terms of cellular component
              (r=0.643, P<0.0001) and the lowest correlation was obtained for
              genes of regulation (r=0.099, P=0.213) in terms of biological
              process. In the genome, half of the samples showed significant
              positive correlation for the 71 genes and significant correlation
              was found between the average mRNA and the average protein
              expression levels in all samples (r=0.296, P<0.01). However, at
              the study group level, only five studied genes had significant
              positive correlation across all the samples. Our results showed
              an overall positive correlation between mRNA and protein
              expression levels. However, the moderate and varied correlations
              suggest that mRNA expression might be sometimes useful, but
              certainly far from perfect, in predicting protein expression
              levels.",
  journal  = "Acta Biochim. Biophys. Sin.",
  volume   =  40,
  number   =  5,
  pages    = "426--436",
  month    =  may,
  year     =  2008,
  language = "en"
}

@ARTICLE{Soille1990-dk,
  title     = "Determining watersheds in digital pictures via flooding
               simulations",
  author    = "Soille, Pierre and Vincent, Luc M",
  abstract  = "The watershed transformation is a very powerful image analysis
               tool provided by mathematical morphology. However, most existing
               watershed algorithms are either too time consuming or
               insufficiently accurate. The purpose of this paper is to
               introduce a new and flexible implementation of this
               transformation. It is based on a progressive flooding of the
               picture and it works for n-dimensional images. Pixels are first
               sorted in the increasing order of their gray values. Then, the
               successive gray levels are processed in order to simulate the
               flooding propagation. A distributive sorting technique combined
               with breadth-first scannings of each gray level allow an
               extremely fast computation. Furthermore, the present algorithm
               is very general since it deals with any kind of digital grid and
               its extension to general graphs is straightforward. Its interest
               with respect to image segmentation is illustrated by the
               extraction of geometrical shapes from a noisy image, the
               separation of 3-dimensional overlapping particles and by the
               segmentation of a digital elevation model using watersheds on
               images and graphs.",
  publisher = "International Society for Optics and Photonics",
  volume    =  1360,
  pages     = "240--250",
  month     =  sep,
  year      =  1990
}

@ARTICLE{Galon2006-cd,
  title    = "Type, density, and location of immune cells within human
              colorectal tumors predict clinical outcome",
  author   = "Galon, J{\'e}r{\^o}me and Costes, Anne and Sanchez-Cabo, Fatima
              and Kirilovsky, Amos and Mlecnik, Bernhard and Lagorce-Pag{\`e}s,
              Christine and Tosolini, Marie and Camus, Matthieu and Berger,
              Anne and Wind, Philippe and Zinzindohou{\'e}, Franck and
              Bruneval, Patrick and Cugnenc, Paul-Henri and Trajanoski, Zlatko
              and Fridman, Wolf-Herman and Pag{\`e}s, Franck",
  abstract = "The role of the adaptive immune response in controlling the
              growth and recurrence of human tumors has been controversial. We
              characterized the tumor-infiltrating immune cells in large
              cohorts of human colorectal cancers by gene expression profiling
              and in situ immunohistochemical staining. Collectively, the
              immunological data (the type, density, and location of immune
              cells within the tumor samples) were found to be a better
              predictor of patient survival than the histopathological methods
              currently used to stage colorectal cancer. The results were
              validated in two additional patient populations. These data
              support the hypothesis that the adaptive immune response
              influences the behavior of human tumors. In situ analysis of
              tumor-infiltrating immune cells may therefore be a valuable
              prognostic tool in the treatment of colorectal cancer and
              possibly other malignancies.",
  journal  = "Science",
  volume   =  313,
  number   =  5795,
  pages    = "1960--1964",
  month    =  sep,
  year     =  2006,
  language = "en"
}

@ARTICLE{Torres2007-ln,
  title    = "Effects of aneuploidy on cellular physiology and cell division in
              haploid yeast",
  author   = "Torres, Eduardo M and Sokolsky, Tanya and Tucker, Cheryl M and
              Chan, Leon Y and Boselli, Monica and Dunham, Maitreya J and Amon,
              Angelika",
  abstract = "Aneuploidy is a condition frequently found in tumor cells, but
              its effect on cellular physiology is not known. We have
              characterized one aspect of aneuploidy: the gain of extra
              chromosomes. We created a collection of haploid yeast strains
              that each bear an extra copy of one or more of almost all of the
              yeast chromosomes. Their characterization revealed that aneuploid
              strains share a number of phenotypes, including defects in cell
              cycle progression, increased glucose uptake, and increased
              sensitivity to conditions interfering with protein synthesis and
              protein folding. These phenotypes were observed only in strains
              carrying additional yeast genes, which indicates that they
              reflect the consequences of additional protein production as well
              as the resulting imbalances in cellular protein composition. We
              conclude that aneuploidy causes not only a proliferative
              disadvantage but also a set of phenotypes that is independent of
              the identity of the individual extra chromosomes.",
  journal  = "Science",
  volume   =  317,
  number   =  5840,
  pages    = "916--924",
  month    =  aug,
  year     =  2007,
  keywords = "energetics of aneuploidy",
  language = "en"
}

@ARTICLE{Reiner2007-id,
  title    = "Division of labor with a workforce of one: challenges in
              specifying effector and memory {T} cell fate",
  author   = "Reiner, Steven L and Sallusto, Federica and Lanzavecchia, Antonio",
  abstract = "In the course of the immune response against microbes, na{\"\i}ve
              T cells proliferate and generate varied classes of effector
              cells, as well as memory cells with distinct properties and
              functions. Owing to recent technological advances, some of the
              most imposing questions regarding effector and memory T cell
              differentiation are now becoming experimentally soluble: How many
              classes of antigen-specific T cells exist, and how malleable are
              they in their fate and in their functional state? How might a
              spectrum of cell fates be imparted to the clonal descendants of a
              single lymphocyte? Where, when, and how does pathogen-associated
              information refine the instruction, selection, and direction of
              newly activated T cells as they perform their tasks in different
              locations and times? Some surprising new glimpses ahead on these
              subjects and other yet-unanswered questions are discussed.",
  journal  = "Science",
  volume   =  317,
  number   =  5838,
  pages    = "622--625",
  month    =  aug,
  year     =  2007,
  language = "en"
}

@ARTICLE{Feinerman2008-py,
  title    = "Variability and robustness in {T} cell activation from regulated
              heterogeneity in protein levels",
  author   = "Feinerman, Ofer and Veiga, Jo{\"e}l and Dorfman, Jeffrey R and
              Germain, Ronald N and Altan-Bonnet, Gr{\'e}goire",
  abstract = "In T cells, the stochasticity of protein expression could
              contribute to the useful diversification of biological functions
              within a clonal population or interfere with accurate antigen
              discrimination. Combining computer modeling and single-cell
              measurements, we examined how endogenous variation in the
              expression levels of signaling proteins might affect antigen
              responsiveness during T cell activation. We found that the CD8
              co-receptor fine-tunes activation thresholds, whereas the soluble
              hematopoietic phosphatase 1 (SHP-1) digitally regulates cell
              responsiveness. Stochastic variation in the expression of these
              proteins generates substantial diversity of activation within a
              clonal population of T cells, but co-regulation of CD8 and SHP-1
              levels ultimately limits this very diversity. These findings
              reveal how eukaryotic cells can draw on regulated variation in
              gene expression to achieve phenotypic variability in a controlled
              manner.",
  journal  = "Science",
  volume   =  321,
  number   =  5892,
  pages    = "1081--1084",
  month    =  aug,
  year     =  2008,
  language = "en"
}

@ARTICLE{Williams2008-dw,
  title    = "Aneuploidy affects proliferation and spontaneous immortalization
              in mammalian cells",
  author   = "Williams, Bret R and Prabhu, Vineet R and Hunter, Karen E and
              Glazier, Christina M and Whittaker, Charles A and Housman, David
              E and Amon, Angelika",
  abstract = "Aneuploidy, an incorrect number of chromosomes, is the leading
              cause of miscarriages and mental retardation in humans and is a
              hallmark of cancer. We examined the effects of aneuploidy on
              primary mouse cells by generating a series of cell lines that
              carry an extra copy of one of four mouse chromosomes. In all four
              trisomic lines, proliferation was impaired and metabolic
              properties were altered. Immortalization, the acquisition of the
              ability to proliferate indefinitely, was also affected by the
              presence of an additional copy of certain chromosomes. Our data
              indicate that aneuploidy decreases not only organismal but also
              cellular fitness and elicits traits that are shared between
              different aneuploid cells.",
  journal  = "Science",
  volume   =  322,
  number   =  5902,
  pages    = "703--709",
  month    =  oct,
  year     =  2008,
  language = "en"
}

@ARTICLE{Eden2011-aq,
  title    = "Proteome half-life dynamics in living human cells",
  author   = "Eden, Eran and Geva-Zatorsky, Naama and Issaeva, Irina and Cohen,
              Ariel and Dekel, Erez and Danon, Tamar and Cohen, Lydia and Mayo,
              Avi and Alon, Uri",
  abstract = "Cells remove proteins by two processes: degradation and dilution
              due to cell growth. The balance between these basic processes is
              poorly understood. We addressed this by developing an accurate
              and noninvasive method for measuring protein half-lives, called
              ``bleach-chase,'' that is applicable to fluorescently tagged
              proteins. Assaying 100 proteins in living human cancer cells
              showed half-lives that ranged between 45 minutes and 22.5 hours.
              A variety of stresses that stop cell division showed the same
              general effect: Long-lived proteins became longer-lived, whereas
              short-lived proteins remained largely unaffected. This effect is
              due to the relative strengths of degradation and dilution and
              suggests a mechanism for differential killing of rapidly growing
              cells by growth-arresting drugs. This approach opens a way to
              understand proteome half-life dynamics in living cells.",
  journal  = "Science",
  volume   =  331,
  number   =  6018,
  pages    = "764--768",
  month    =  feb,
  year     =  2011,
  language = "en"
}

@ARTICLE{Stutman1974-uo,
  title    = "Tumor development after 3-methylcholanthrene in immunologically
              deficient athymic-nude mice",
  author   = "Stutman, O",
  abstract = "Athymic-nude (nu/nu) mice and normal (nu/+) mice showed no
              differences in either latent period or incidence of local
              sarcomas or lung adenomas within 120 days after administration of
              3-methylcholanthrene at birth. However, nu/nu mice were incapable
              of rejecting allogeneic skin grafts for the duration of the
              experiment. These results argue against an active role of
              thymus-dependent immunity as a surveillance mechanism preventing
              tumor development.",
  journal  = "Science",
  volume   =  183,
  number   =  4124,
  pages    = "534--536",
  month    =  feb,
  year     =  1974,
  language = "en"
}

@ARTICLE{Van_der_Bruggen1991-yw,
  title    = "A gene encoding an antigen recognized by cytolytic {T}
              lymphocytes on a human melanoma",
  author   = "van der Bruggen, P and Traversari, C and Chomez, P and Lurquin, C
              and De Plaen, E and Van den Eynde, B and Knuth, A and Boon, T",
  abstract = "Many human melanoma tumors express antigens that are recognized
              in vitro by cytolytic T lymphocytes (CTLs) derived from the
              tumor-bearing patient. A gene was identified that directed the
              expression of antigen MZ2-E on a human melanoma cell line. This
              gene shows no similarity to known sequences and belongs to a
              family of at least three genes. It is expressed by the original
              melanoma cells, other melanoma cell lines, and by some tumor
              cells of other histological types. No expression was observed in
              a panel of normal tissues. Antigen MZ2-E appears to be presented
              by HLA-A1; anti-MZ2-E CTLs of the original patient recognized two
              melanoma cell lines of other HLA-A1 patients that expressed the
              gene. Thus, precisely targeted immunotherapy directed against
              antigen MZ2-E could be provided to individuals identified by HLA
              typing and analysis of the RNA of a small tumor sample.",
  journal  = "Science",
  volume   =  254,
  number   =  5038,
  pages    = "1643--1647",
  month    =  dec,
  year     =  1991,
  language = "en"
}

@ARTICLE{Chin1996-jd,
  title    = "Cell growth arrest and induction of cyclin-dependent kinase
              inhibitor p21 {WAF1/CIP1} mediated by {STAT1}",
  author   = "Chin, Y E and Kitagawa, M and Su, W C and You, Z H and Iwamoto, Y
              and Fu, X Y",
  abstract = "Signal transducers and activators of transcription (STAT)
              proteins can be conditionally activated in response to epidermal
              growth factor (EGF) and interferon (IFN)-gamma. STAT activation
              was correlated with cell growth inhibition in response to EGF and
              IFN-gamma. Activated STAT proteins specifically recognized the
              conserved STAT-responsive elements in the promoter of the gene
              encoding the cyclin-dependent kinase (CDK) inhibitor p21
              WAF1/CIP1 and regulated the induction of p21 messenger RNA.
              IFN-gamma did not inhibit the growth of U3A cells, which are
              deficient in STAT1, but did inhibit the growth of U3A cells into
              which STAT1 alpha was reintroduced. Thus, STAT1 protein is
              essential for cell growth suppression in response to IFN-gamma.
              The STAT signaling pathway appears to negatively regulate the
              cell cycle by inducing CDK inhibitors in response to cytokines.",
  journal  = "Science",
  volume   =  272,
  number   =  5262,
  pages    = "719--722",
  month    =  may,
  year     =  1996,
  language = "en"
}

@ARTICLE{Chin1996-wb,
  title    = "Cell growth arrest and induction of cyclin-dependent kinase
              inhibitor p21 {WAF1/CIP1} mediated by {STAT1}",
  author   = "Chin, Y E and Kitagawa, M and Su, W C and You, Z H and Iwamoto, Y
              and Fu, X Y",
  abstract = "Signal transducers and activators of transcription (STAT)
              proteins can be conditionally activated in response to epidermal
              growth factor (EGF) and interferon (IFN)-gamma. STAT activation
              was correlated with cell growth inhibition in response to EGF and
              IFN-gamma. Activated STAT proteins specifically recognized the
              conserved STAT-responsive elements in the promoter of the gene
              encoding the cyclin-dependent kinase (CDK) inhibitor p21
              WAF1/CIP1 and regulated the induction of p21 messenger RNA.
              IFN-gamma did not inhibit the growth of U3A cells, which are
              deficient in STAT1, but did inhibit the growth of U3A cells into
              which STAT1 alpha was reintroduced. Thus, STAT1 protein is
              essential for cell growth suppression in response to IFN-gamma.
              The STAT signaling pathway appears to negatively regulate the
              cell cycle by inducing CDK inhibitors in response to cytokines.",
  journal  = "Science",
  volume   =  272,
  number   =  5262,
  pages    = "719--722",
  month    =  may,
  year     =  1996,
  language = "en"
}

@ARTICLE{Gasser1981-uu,
  title    = "Novel single-pass exchange of circulating uridine in rat liver",
  author   = "Gasser, T and Moyer, J D and Handschumacher, R E",
  abstract = "Evidence is presented that the liver effects an essentially
              complete degradation of plasma uridine in a single pass and
              replaces it largely from hepatic pools of acid-soluble uridine
              nucleotides. The concentration of uridine in the hepatic vein of
              the rat was essentially the same as that in the arterial
              circulation and portal vein. However, the isolated perfused rat
              liver degraded more than 90 percent of infused [5-3H]uridine in a
              single passage. Similar results were found in vivo when tracer
              amounts of [3H]uridine and [14C]uridine were infused into the
              portal vein of an intact rat. Furthermore, less than 2 percent of
              the infused uridine entered the acid-soluble nucleotide pools of
              the liver after 30 minutes of infusion. Intraperitoneal injection
              of [3H]orotate allowed selective labeling of liver (and kidney)
              pyrimidines. After 3 hours, the specific activity of uridine in
              the hepatic vein was more than three times that in the arterial
              circulation. This unusual exchange, which is not saturated even
              at uridine concentrations as high as 50 microM, contributes to
              the rapid turnover of plasma uridine and explains its inefficient
              utilization in peripheral tissues.",
  journal  = "Science",
  volume   =  213,
  number   =  4509,
  pages    = "777--778",
  month    =  aug,
  year     =  1981,
  language = "en"
}

@ARTICLE{Joyce2015-kg,
  title    = "{T} cell exclusion, immune privilege, and the tumor
              microenvironment",
  author   = "Joyce, Johanna A and Fearon, Douglas T",
  abstract = "Effective immunotherapy promotes the killing of cancer cells by
              cytotoxic T cells. This requires not only that cancer-specific T
              cells be generated, but also that these T cells physically
              contact cancer cells. The coexistence in some patients of cancer
              cells and T cells that recognize them indicates that tumors may
              exhibit the phenomenon of immune privilege, in which immunogenic
              tissue is protected from immune attack. Here, we review the
              evidence that stromal cells of the tumor microenvironment mediate
              this restriction by excluding T cells from the vicinity of cancer
              cells. Overcoming this T cell checkpoint may thus enable optimal
              immunotherapy.",
  journal  = "Science",
  volume   =  348,
  number   =  6230,
  pages    = "74--80",
  month    =  apr,
  year     =  2015,
  language = "en"
}

@ARTICLE{Van_Allen2015-ww,
  title    = "Genomic correlates of response to {CTLA-4} blockade in metastatic
              melanoma",
  author   = "Van Allen, Eliezer M and Miao, Diana and Schilling, Bastian and
              Shukla, Sachet A and Blank, Christian and Zimmer, Lisa and
              Sucker, Antje and Hillen, Uwe and Foppen, Marnix H Geukes and
              Goldinger, Simone M and Utikal, Jochen and Hassel, Jessica C and
              Weide, Benjamin and Kaehler, Katharina C and Loquai, Carmen and
              Mohr, Peter and Gutzmer, Ralf and Dummer, Reinhard and Gabriel,
              Stacey and Wu, Catherine J and Schadendorf, Dirk and Garraway,
              Levi A",
  abstract = "Monoclonal antibodies directed against cytotoxic T
              lymphocyte-associated antigen-4 (CTLA-4), such as ipilimumab,
              yield considerable clinical benefit for patients with metastatic
              melanoma by inhibiting immune checkpoint activity, but clinical
              predictors of response to these therapies remain incompletely
              characterized. To investigate the roles of tumor-specific
              neoantigens and alterations in the tumor microenvironment in the
              response to ipilimumab, we analyzed whole exomes from
              pretreatment melanoma tumor biopsies and matching germline tissue
              samples from 110 patients. For 40 of these patients, we also
              obtained and analyzed transcriptome data from the pretreatment
              tumor samples. Overall mutational load, neoantigen load, and
              expression of cytolytic markers in the immune microenvironment
              were significantly associated with clinical benefit. However, no
              recurrent neoantigen peptide sequences predicted responder
              patient populations. Thus, detailed integrated molecular
              characterization of large patient cohorts may be needed to
              identify robust determinants of response and resistance to immune
              checkpoint inhibitors.",
  journal  = "Science",
  volume   =  350,
  number   =  6257,
  pages    = "207--211",
  month    =  oct,
  year     =  2015,
  language = "en"
}

@ARTICLE{Balint2020-my,
  title    = "Supramolecular attack particles are autonomous killing entities
              released from cytotoxic {T} cells",
  author   = "B{\'a}lint, {\v S} and M{\"u}ller, S and Fischer, R and Kessler,
              B M and Harkiolaki, M and Valitutti, S and Dustin, M L",
  abstract = "Cytotoxic T lymphocytes (CTLs) kill infected and cancerous cells.
              We detected transfer of cytotoxic multiprotein complexes, called
              supramolecular attack particles (SMAPs), from CTLs to target
              cells. SMAPs were rapidly released from CTLs and were
              autonomously cytotoxic. Mass spectrometry, immunochemical
              analysis, and CRISPR editing identified a carboxyl-terminal
              fragment of thrombospondin-1 as an unexpected SMAP component that
              contributed to target killing. Direct stochastic optical
              reconstruction microscopy resolved a cytotoxic core surrounded by
              a thrombospondin-1 shell of ~120 nanometer diameter. Cryo-soft
              x-ray tomography analysis revealed that SMAPs had a carbon-dense
              shell and were stored in multicore granules. We propose that
              SMAPs are autonomous extracellular killing entities that deliver
              cytotoxic cargo targeted by the specificity of shell components.",
  journal  = "Science",
  volume   =  368,
  number   =  6493,
  pages    = "897--901",
  month    =  may,
  year     =  2020,
  keywords = "B16F10\_specific",
  language = "en"
}

@ARTICLE{Stadtmauer2020-pt,
  title    = "{CRISPR-engineered} {T} cells in patients with refractory cancer",
  author   = "Stadtmauer, Edward A and Fraietta, Joseph A and Davis, Megan M
              and Cohen, Adam D and Weber, Kristy L and Lancaster, Eric and
              Mangan, Patricia A and Kulikovskaya, Irina and Gupta, Minnal and
              Chen, Fang and Tian, Lifeng and Gonzalez, Vanessa E and Xu, Jun
              and Jung, In-Young and Melenhorst, J Joseph and Plesa, Gabriela
              and Shea, Joanne and Matlawski, Tina and Cervini, Amanda and
              Gaymon, Avery L and Desjardins, Stephanie and Lamontagne, Anne
              and Salas-Mckee, January and Fesnak, Andrew and Siegel, Donald L
              and Levine, Bruce L and Jadlowsky, Julie K and Young, Regina M
              and Chew, Anne and Hwang, Wei-Ting and Hexner, Elizabeth O and
              Carreno, Beatriz M and Nobles, Christopher L and Bushman,
              Frederic D and Parker, Kevin R and Qi, Yanyan and Satpathy,
              Ansuman T and Chang, Howard Y and Zhao, Yangbing and Lacey, Simon
              F and June, Carl H",
  abstract = "CRISPR-Cas9 gene editing provides a powerful tool to enhance the
              natural ability of human T cells to fight cancer. We report a
              first-in-human phase 1 clinical trial to test the safety and
              feasibility of multiplex CRISPR-Cas9 editing to engineer T cells
              in three patients with refractory cancer. Two genes encoding the
              endogenous T cell receptor (TCR) chains, TCR$\alpha$ (TRAC) and
              TCR$\beta$ (TRBC), were deleted in T cells to reduce TCR
              mispairing and to enhance the expression of a synthetic,
              cancer-specific TCR transgene (NY-ESO-1). Removal of a third gene
              encoding programmed cell death protein 1 (PD-1; PDCD1), was
              performed to improve antitumor immunity. Adoptive transfer of
              engineered T cells into patients resulted in durable engraftment
              with edits at all three genomic loci. Although chromosomal
              translocations were detected, the frequency decreased over time.
              Modified T cells persisted for up to 9 months, suggesting that
              immunogenicity is minimal under these conditions and
              demonstrating the feasibility of CRISPR gene editing for cancer
              immunotherapy.",
  journal  = "Science",
  volume   =  367,
  number   =  6481,
  month    =  feb,
  year     =  2020,
  language = "en"
}

@ARTICLE{Stolp2020-rr,
  title    = "Salivary gland macrophages and tissue-resident {CD8+} {T} cells
              cooperate for homeostatic organ surveillance",
  author   = "Stolp, Bettina and Thelen, Flavian and Ficht, Xenia and
              Altenburger, Lukas M and Ruef, Nora and Inavalli, V V G Krishna
              and Germann, Philipp and Page, Nicolas and Moalli, Federica and
              Raimondi, Andrea and Keyser, Kirsten A and Seyed Jafari, S
              Morteza and Barone, Francesca and Dettmer, Matthias S and
              Merkler, Doron and Iannacone, Matteo and Sharpe, James and
              Schlapbach, Christoph and Fackler, Oliver T and N{\"a}gerl, U
              Valentin and Stein, Jens V",
  abstract = "It is well established that tissue macrophages and
              tissue-resident memory CD8+ T cells (TRM) play important roles
              for pathogen sensing and rapid protection of barrier tissues. In
              contrast, the mechanisms by which these two cell types cooperate
              for homeostatic organ surveillance after clearance of infections
              is poorly understood. Here, we used intravital imaging to show
              that TRM dynamically followed tissue macrophage topology in
              noninflamed murine submandibular salivary glands (SMGs).
              Depletion of tissue macrophages interfered with SMG TRM motility
              and caused a reduction of interepithelial T cell crossing. In the
              absence of macrophages, SMG TRM failed to cluster in response to
              local inflammatory chemokines. A detailed analysis of the SMG
              microarchitecture uncovered discontinuous attachment of tissue
              macrophages to neighboring epithelial cells, with occasional
              macrophage protrusions bridging adjacent acini and ducts. When
              dissecting the molecular mechanisms that drive homeostatic SMG
              TRM motility, we found that these cells exhibit a wide range of
              migration modes: In addition to chemokine- and adhesion
              receptor-driven motility, resting SMG TRM displayed a remarkable
              capacity for autonomous motility in the absence of
              chemoattractants and adhesive ligands. Autonomous SMG TRM
              motility was mediated by friction and insertion of protrusions
              into gaps offered by the surrounding microenvironment. In sum,
              SMG TRM display a unique continuum of migration modes, which are
              supported in vivo by tissue macrophages to allow homeostatic
              patrolling of the complex SMG architecture.",
  journal  = "Sci Immunol",
  volume   =  5,
  number   =  46,
  month    =  apr,
  year     =  2020,
  language = "en"
}

@ARTICLE{Enriquez-Navas2016-rm,
  title    = "Exploiting evolutionary principles to prolong tumor control in
              preclinical models of breast cancer",
  author   = "Enriquez-Navas, Pedro M and Kam, Yoonseok and Das, Tuhin and
              Hassan, Sabrina and Silva, Ariosto and Foroutan, Parastou and
              Ruiz, Epifanio and Martinez, Gary and Minton, Susan and Gillies,
              Robert J and Gatenby, Robert A",
  abstract = "Conventional cancer treatment strategies assume that maximum
              patient benefit is achieved through maximum killing of tumor
              cells. However, by eliminating the therapy-sensitive population,
              this strategy accelerates emergence of resistant clones that
              proliferate unopposed by competitors-an evolutionary phenomenon
              termed ``competitive release.'' We present an evolution-guided
              treatment strategy designed to maintain a stable population of
              chemosensitive cells that limit proliferation of resistant clones
              by exploiting the fitness cost of the resistant phenotype. We
              treated MDA-MB-231/luc triple-negative and MCF7 estrogen
              receptor-positive (ER(+)) breast cancers growing orthotopically
              in a mouse mammary fat pad with paclitaxel, using algorithms
              linked to tumor response monitored by magnetic resonance imaging.
              We found that initial control required more intensive therapy
              with regular application of drug to deflect the exponential tumor
              growth curve onto a plateau. Dose-skipping algorithms during this
              phase were less successful than variable dosing algorithms.
              However, once initial tumor control was achieved, it was
              maintained with progressively smaller drug doses. In 60 to 80\%
              of animals, continued decline in tumor size permitted intervals
              as long as several weeks in which no treatment was necessary.
              Magnetic resonance images and histological analysis of tumors
              controlled by adaptive therapy demonstrated increased vascular
              density and less necrosis, suggesting that vascular normalization
              resulting from enforced stabilization of tumor volume may
              contribute to ongoing tumor control with lower drug doses. Our
              study demonstrates that an evolution-based therapeutic strategy
              using an available chemotherapeutic drug and conventional
              clinical imaging can prolong the progression-free survival in
              different preclinical models of breast cancer.",
  journal  = "Sci. Transl. Med.",
  volume   =  8,
  number   =  327,
  pages    = "327ra24",
  month    =  feb,
  year     =  2016,
  language = "en"
}

@ARTICLE{Scribano2021-tt,
  title    = "Chromosomal instability sensitizes patient breast tumors to
              multipolar divisions induced by paclitaxel",
  author   = "Scribano, Christina M and Wan, Jun and Esbona, Karla and Tucker,
              John B and Lasek, Amber and Zhou, Amber S and Zasadil, Lauren M
              and Molini, Ryan and Fitzgerald, Jonathan and Lager, Angela M and
              Laffin, Jennifer J and Correia-Staudt, Kayla and Wisinski, Kari B
              and Tevaarwerk, Amye J and O'Regan, Ruth and McGregor, Stephanie
              M and Fowler, Amy M and Chappell, Richard J and Bugni, Tim S and
              Burkard, Mark E and Weaver, Beth A",
  abstract = "Paclitaxel (Taxol) is a cornerstone of cancer treatment. However,
              its mechanism of cytotoxicity is incompletely understood and not
              all patients benefit from treatment. We show that patients with
              breast cancer did not accumulate sufficient intratumoral
              paclitaxel to induce mitotic arrest in tumor cells. Instead,
              clinically relevant concentrations induced multipolar mitotic
              spindle formation. However, the extent of early multipolarity did
              not predict patient response. Whereas multipolar divisions
              frequently led to cell death, multipolar spindles focused into
              bipolar spindles before division at variable frequency, and
              maintaining multipolarity throughout mitosis was critical to
              induce the high rates of chromosomal instability necessary for
              paclitaxel to elicit cell death. Increasing multipolar divisions
              in paclitaxel resulted in improved cytotoxicity. Conversely,
              decreasing paclitaxel-induced multipolar divisions reduced
              paclitaxel efficacy. Moreover, we found that preexisting
              chromosomal instability sensitized breast cancer cells to
              paclitaxel. Both genetic and pharmacological methods of inducing
              chromosomal instability were sufficient to increase paclitaxel
              efficacy. In patients, the amount of pretreatment chromosomal
              instability directly correlated with taxane response in
              metastatic breast cancer such that patients with a higher rate of
              preexisting chromosomal instability showed improved response to
              taxanes. Together, these results support the use of baseline
              rates of chromosomal instability as a predictive biomarker for
              paclitaxel response. Furthermore, they suggest that agents that
              increase chromosomal instability or maintain multipolar spindles
              throughout mitosis will improve the clinical utility of
              paclitaxel.",
  journal  = "Sci. Transl. Med.",
  volume   =  13,
  number   =  610,
  pages    = "eabd4811",
  month    =  sep,
  year     =  2021,
  language = "en"
}

@ARTICLE{Fink2005-ks,
  title    = "Apoptosis, pyroptosis, and necrosis: mechanistic description of
              dead and dying eukaryotic cells",
  author   = "Fink, Susan L and Cookson, Brad T",
  journal  = "Infect. Immun.",
  volume   =  73,
  number   =  4,
  pages    = "1907--1916",
  month    =  apr,
  year     =  2005,
  language = "en"
}

@ARTICLE{Ganusov2008-ab,
  title    = "Estimating in vivo death rates of targets due to {CD8}
              T-cell-mediated killing",
  author   = "Ganusov, Vitaly V and De Boer, Rob J",
  abstract = "Despite recent advances in immunology, several key parameters
              determining virus dynamics in infected hosts remain largely
              unknown. For example, the rate at which specific effector and
              memory CD8 T cells clear virus-infected cells in vivo is hardly
              known for any viral infection. We propose a framework to quantify
              T-cell-mediated killing of infected or peptide-pulsed target
              cells using the widely used in vivo cytotoxicity assay. We have
              reanalyzed recently published data on killing of peptide-pulsed
              splenocytes by cytotoxic T lymphocytes and memory CD8 T cells
              specific to NP396 and GP276 epitopes of lymphocytic
              choriomeningitis virus (LCMV) in the mouse spleen. Because there
              are so many effector CD8 T cells in spleens of mice at the peak
              of the immune response, NP396- and GP276-pulsed targets are
              estimated to have very short half-lives of 2 and 14 min,
              respectively. After the effector numbers have diminished, i.e.,
              in LCMV-immune mice, the half-lives become 48 min and 2.8 h for
              NP396- and GP276-expressing targets, respectively. Analysis of
              several alternative models demonstrates that the estimates of
              half-life times of peptide-pulsed targets are not affected when
              changes are made in the model assumptions. Our report provides a
              unifying framework to compare killing efficacies of CD8 T-cell
              responses specific to different viral and bacterial infections in
              vivo, which may be used to compare efficacies of various
              cytotoxic-T-lymphocyte-based vaccines.",
  journal  = "J. Virol.",
  volume   =  82,
  number   =  23,
  pages    = "11749--11757",
  month    =  dec,
  year     =  2008,
  language = "en"
}

@ARTICLE{Wick2005-zj,
  title    = "How many human immunodeficiency virus type 1-infected target
              cells can a cytotoxic T-lymphocyte kill?",
  author   = "Wick, W David and Yang, Otto O and Corey, Lawrence and Self,
              Steven G",
  abstract = "The antiviral role of CD8+ cytotoxic T lymphocytes (CTLs) in
              human immunodeficiency virus type 1 (HIV-1) infection is poorly
              understood. Specifically, the degree to which CTLs reduce viral
              replication by killing HIV-1-infected cells in vivo is not known.
              Here we employ mathematical models of the infection process and
              CTL action to estimate the rate that CTLs can kill HIV-1-infected
              cells from in vitro and in vivo data. Our estimates, which are
              surprisingly consistent considering the disparities between the
              two experimental systems, demonstrate that on average CTLs can
              kill from 0.7 to 3 infected target cells per day, with the
              variability in this figure due to epitope specificity or other
              factors. These results are compatible with the observed decline
              in viremia after primary infection being primarily a consequence
              of CTL activity and have interesting implications for vaccine
              design.",
  journal  = "J. Virol.",
  volume   =  79,
  number   =  21,
  pages    = "13579--13586",
  month    =  nov,
  year     =  2005,
  language = "en"
}

@ARTICLE{Russell1995-hr,
  title    = "Energetics of bacterial growth: balance of anabolic and catabolic
              reactions",
  author   = "Russell, J B and Cook, G M",
  abstract = "Biomass formation represents one of the most basic aspects of
              bacterial metabolism. While there is an abundance of information
              concerning individual reactions that result in cell duplication,
              there has been surprisingly little information on the
              bioenergetics of growth. For many years, it was assumed that
              biomass production (anabolism) was proportional to the amount of
              ATP which could be derived from energy-yielding pathways
              (catabolism), but later work showed that the ATP yield (YATP) was
              not necessarily a constant. Continuous-culture experiments
              indicated that bacteria utilized ATP for metabolic reactions that
              were not directly related to growth (maintenance functions).
              Mathematical derivations showed that maintenance energy appeared
              to be a growth rate-independent function of the cell mass and
              time. Later work, however, showed that maintenance energy alone
              could not account for all the variations in yield. Because only
              some of the discrepancy could be explained by the secretion of
              metabolites (overflow metabolism) or the diversion of catabolism
              to metabolic pathways which produced less ATP, it appeared that
              energy-excess cultures had mechanisms of spilling energy.
              Bacteria have the potential to spill excess ATP in futile enzyme
              cycles, but there has been little proof that such cycles are
              significant. Recent work indicated that bacteria can also use
              futile cycles of potassium, ammonia, and protons through the cell
              membrane to dissipate ATP either directly or indirectly. The
              utility of energy spilling in bacteria has been a curiosity. The
              deprivation of energy from potential competitors is at best a
              teleological explanation that cannot be easily supported by
              standard theories of natural selection. The priming of
              intracellular intermediates for future growth or protection of
              cells from potentially toxic end products (e.g., methylglyoxal)
              seems a more plausible explanation.",
  journal  = "Microbiol. Rev.",
  volume   =  59,
  number   =  1,
  pages    = "48--62",
  month    =  mar,
  year     =  1995,
  language = "en"
}

@ARTICLE{Burnet1957-dl,
  title    = "Cancer: a biological approach. {III}. Viruses associated with
              neoplastic conditions. {IV}. Practical applications",
  author   = "Burnet, M",
  journal  = "Br. Med. J.",
  volume   =  1,
  number   =  5023,
  pages    = "841--847",
  month    =  apr,
  year     =  1957,
  keywords = "NEOPLASMS/etiology and pathogenesis; VIRUSES",
  language = "en"
}

@ARTICLE{Doll1970-kr,
  title    = "Immunosurveillance and cancer: epidemiological evidence",
  author   = "Doll, R and Kinlen, L",
  journal  = "Br. Med. J.",
  volume   =  4,
  number   =  5732,
  pages    = "420--422",
  month    =  nov,
  year     =  1970,
  language = "en"
}

@ARTICLE{Etxeberria2020-kr,
  title    = "New emerging targets in cancer immunotherapy: {CD137/4-1BB}
              costimulatory axis",
  author   = "Etxeberria, I{\~n}aki and Glez-Vaz, Javier and Teijeira,
              {\'A}lvaro and Melero, Ignacio",
  abstract = "CD137 (4-1BB) is a surface glycoprotein that belongs to the
              tumour necrosis factor receptor family (TNFRSF9). Its expression
              is induced on activation on a number of leucocyte types.
              Interestingly, for cancer immunotherapy, CD137 becomes expressed
              on primed T and natural killer (NK) cells, which on ligation
              provides powerful costimulatory signals. Perturbation of CD137 by
              CD137L or agonist monoclonal antibodies on activated CD8 T cells
              protects such antigen-specific cytotoxic T lymphocytes from
              apoptosis, enhances effector functionalities and favours
              persistence and memory differentiation. As a consequence, agonist
              antibodies exert potent antitumour effects in mouse models and
              the CD137 signalling domain is critical in chimeric antigen
              receptors (CAR) of CAR T cells approved to be used in the clinic.
              New formats of CD137 agonist moieties are being clinically
              developed, seeking potent costimulation targeted to the tumour
              microenvironment to avoid liver inflammation side effects, that
              have thus far limited and delayed clinical development.",
  journal  = "ESMO Open",
  volume   =  4,
  number   = "Suppl 3",
  month    =  jul,
  year     =  2020,
  keywords = "4-1BB; CD137; cancer immunotherapy; mAb",
  language = "en"
}

@ARTICLE{Walther2008-pk,
  title    = "Association between chromosomal instability and prognosis in
              colorectal cancer: a meta-analysis",
  author   = "Walther, A and Houlston, R and Tomlinson, I",
  abstract = "BACKGROUND: Several studies have suggested that microsatellite
              instability (MSI) resulting from defective DNA mismatch repair
              confers a better prognosis in colorectal cancer (CRC). Recently,
              however, data have suggested this is secondary to the effects of
              ploidy/chromosomal instability (CIN). To estimate the prognostic
              significance of CIN for survival, data from published studies
              have been reviewed and pooled. METHODS: Studies stratifying
              survival in CRC by CIN status were identified by searching PubMed
              and hand-searching bibliographies of identified studies. Two
              reviewers confirmed study eligibility and extracted data
              independently, and data were pooled using a fixed-effects model.
              The principal outcome measure was the HR for death. RESULTS: 63
              eligible studies reported outcome in 10 126 patients, 60.0\% of
              whom had CIN+ (aneuploid/polyploid) tumours. The overall HR
              associated with CIN was 1.45 (95\% CI 1.35 to 1.55, p<0.001). In
              patients with stage II-III CRCs, the HR was 1.45 (95\% CI 1.27 to
              1.65, p<0.001). The effect was similar for progression-free
              survival (HR = 1.71, 95\% CI 1.51 to 1.94, p<0.001). There was no
              evidence of significant interstudy heterogeneity. CONCLUSION: CIN
              is associated with a worse prognosis in CRC, and should be
              evaluated as a prognostic marker, together with MSI status, in
              all clinical trials, particularly those involving adjuvant
              therapies.",
  journal  = "Gut",
  volume   =  57,
  number   =  7,
  pages    = "941--950",
  month    =  jul,
  year     =  2008,
  language = "en"
}

@ARTICLE{Wortman2020-cv,
  title     = "Occupancy and Fractal Dimension Analyses of the Spatial
               Distribution of Cytotoxic ({CD8+}) {T} Cells Infiltrating the
               Tumor Microenvironment in Triple Negative Breast Cancer",
  author    = "Wortman, Juliana C and He, Ting-Fang and Rosario, Anthony and
               Wang, Roger and Schmolze, Daniel and Yuan, Yuan and Yost, Susan
               E and Li, Xuefei and Levine, Herbert and Atwal, Gurinder and
               Lee, Peter and Yu, Clare C",
  abstract  = "Favorable outcomes have been associated with high densities of
               tumor infiltrating lymphocytes (TILs) such as cytotoxic (CD8+) T
               cells. However, the clinical significance of the spatial
               distribution of TILs is less well understood. We have developed
               novel statistical techniques to characterize the spatial
               distribution of TILs at various length scales. These include a
               box counting method that we call ?occupancy? and novel
               applications of fractal dimensions. We apply these techniques to
               the spatial distribution of CD8+ T cells in the tumor
               microenvironment of tissue resected from 35 triple negative
               breast cancer patients. We find that there is a distinct
               difference in the spatial distribution of CD8+ T cells between
               good clinical outcome (no recurrence within at least 5 years of
               diagnosis) and poor clinical outcome (recurrence within 3 years
               of diagnosis). The statistical significance of the difference
               between good and poor outcome in the occupancy, fractal
               dimension (FD), and FD difference of CD8+ T cells is comparable
               to that of the CD8+ T cell density. Even when we randomly
               exclude some of the cells so that the images have the same cell
               density, we still find that the fractal dimension at short
               length scales is correlated with cancer recurrence, implying
               that the actual spatial distribution of CD8+ cells, and not just
               the CD8+ cell density, is associated with clinical outcome. The
               occupancy and FD difference indicate that the CD8+ T cells are
               more spatially dispersed in good outcome and more aggregated in
               poor outcome. We discuss possible interpretations.",
  journal   = "Biophys. Rev. Lett.",
  publisher = "World Scientific Publishing Co.",
  volume    =  15,
  number    =  02,
  pages     = "83--98",
  month     =  jun,
  year      =  2020
}

@ARTICLE{Lunt2011-lm,
  title    = "Aerobic glycolysis: meeting the metabolic requirements of cell
              proliferation",
  author   = "Lunt, Sophia Y and Vander Heiden, Matthew G",
  abstract = "Warburg's observation that cancer cells exhibit a high rate of
              glycolysis even in the presence of oxygen (aerobic glycolysis)
              sparked debate over the role of glycolysis in normal and cancer
              cells. Although it has been established that defects in
              mitochondrial respiration are not the cause of cancer or aerobic
              glycolysis, the advantages of enhanced glycolysis in cancer
              remain controversial. Many cells ranging from microbes to
              lymphocytes use aerobic glycolysis during rapid proliferation,
              which suggests it may play a fundamental role in supporting cell
              growth. Here, we review how glycolysis contributes to the
              metabolic processes of dividing cells. We provide a detailed
              accounting of the biosynthetic requirements to construct a new
              cell and illustrate the importance of glycolysis in providing
              carbons to generate biomass. We argue that the major function of
              aerobic glycolysis is to maintain high levels of glycolytic
              intermediates to support anabolic reactions in cells, thus
              providing an explanation for why increased glucose metabolism is
              selected for in proliferating cells throughout nature.",
  journal  = "Annu. Rev. Cell Dev. Biol.",
  volume   =  27,
  pages    = "441--464",
  year     =  2011,
  language = "en"
}

@ARTICLE{Siegel2012-pw,
  title    = "New insights into the troubles of aneuploidy",
  author   = "Siegel, Jake J and Amon, Angelika",
  abstract = "Deviation from a balanced genome by either gain or loss of entire
              chromosomes is generally tolerated poorly in all eukaryotic
              systems studied to date. Errors in mitotic or meiotic cell
              division lead to aneuploidy, which places a burden of additional
              or insufficient gene products from the missegregated chromosomes
              on the daughter cells. The burden of aneuploidy often manifests
              itself as impaired fitness of individual cells and whole
              organisms, in which abnormal development is also characteristic.
              However, most human cancers, noted for their rapid growth, also
              display various levels of aneuploidy. Here we discuss the
              detrimental, potentially beneficial, and sometimes puzzling
              effects of aneuploidy on cellular and organismal fitness and
              tissue function as well as its role in diseases such as cancer
              and neurodegeneration.",
  journal  = "Annu. Rev. Cell Dev. Biol.",
  volume   =  28,
  pages    = "189--214",
  month    =  jul,
  year     =  2012,
  language = "en"
}

@ARTICLE{Buchholz2016-md,
  title    = "{T} Cell Fate at the {Single-Cell} Level",
  author   = "Buchholz, Veit R and Schumacher, Ton N M and Busch, Dirk H",
  abstract = "T cell responses display two key characteristics. First, a small
              population of epitope-specific naive T cells expands by several
              orders of magnitude. Second, the T cells within this
              proliferating population take on diverse functional and
              phenotypic properties that determine their ability to exert
              effector functions and contribute to T cell memory. Recent
              technological advances in lineage tracing allow us for the first
              time to study these processes in vivo at single-cell resolution.
              Here, we summarize resulting data demonstrating that although
              epitope-specific T cell responses are reproducibly similar at the
              population level, expansion potential and diversification
              patterns of the offspring derived from individual T cells are
              highly variable during both primary and recall immune responses.
              In spite of this stochastic response variation, individual memory
              T cells can serve as adult stem cells that provide robust
              regeneration of an epitope-specific tissue through population
              averaging. We discuss the relevance of these findings for T cell
              memory formation and clinical immunotherapy.",
  journal  = "Annu. Rev. Immunol.",
  volume   =  34,
  pages    = "65--92",
  month    =  may,
  year     =  2016,
  keywords = "T cell differentiation; T cell memory; immunotherapy; robustness;
              stemness; stochasticity",
  language = "en"
}

@ARTICLE{Chowdhury2008-rl,
  title    = "Death by a thousand cuts: granzyme pathways of programmed cell
              death",
  author   = "Chowdhury, Dipanjan and Lieberman, Judy",
  abstract = "The granzymes are cell death-inducing enzymes, stored in the
              cytotoxic granules of cytotoxic T lymphocytes and natural killer
              cells, that are released during granule exocytosis when a
              specific virus-infected or transformed target cell is marked for
              elimination. Recent work suggests that this homologous family of
              serine esterases can activate at least three distinct pathways of
              cell death. This redundancy likely evolved to provide protection
              against pathogens and tumors with diverse strategies for evading
              cell death. This review discusses what is known about
              granzyme-mediated pathways of cell death as well as recent
              studies that implicate granzymes in immune regulation and
              extracellular proteolytic functions in inflammation.",
  journal  = "Annu. Rev. Immunol.",
  volume   =  26,
  pages    = "389--420",
  year     =  2008,
  keywords = "Direct Killing (Perf/Gzym/FAS)",
  language = "en"
}

@ARTICLE{Matzinger1994-uy,
  title    = "Tolerance, danger, and the extended family",
  author   = "Matzinger, P",
  abstract = "For many years immunologists have been well served by the
              viewpoint that the immune system's primary goal is to
              discriminate between self and non-self. I believe that it is time
              to change viewpoints and, in this essay, I discuss the
              possibility that the immune system does not care about self and
              non-self, that its primary driving force is the need to detect
              and protect against danger, and that it does not do the job
              alone, but receives positive and negative communications from an
              extended network of other bodily tissues.",
  journal  = "Annu. Rev. Immunol.",
  volume   =  12,
  pages    = "991--1045",
  year     =  1994,
  language = "en"
}

@ARTICLE{Liang2006-bs,
  title    = "{PGC-1alpha}: a key regulator of energy metabolism",
  author   = "Liang, Huiyun and Ward, Walter F",
  abstract = "Peroxisome proliferator-activated receptor-gamma coactivator
              (PGC)-1alpha is a member of a family of transcription
              coactivators that plays a central role in the regulation of
              cellular energy metabolism. It is strongly induced by cold
              exposure, linking this environmental stimulus to adaptive
              thermogenesis. PGC-1alpha stimulates mitochondrial biogenesis and
              promotes the remodeling of muscle tissue to a fiber-type
              composition that is metabolically more oxidative and less
              glycolytic in nature, and it participates in the regulation of
              both carbohydrate and lipid metabolism. It is highly likely that
              PGC-1alpha is intimately involved in disorders such as obesity,
              diabetes, and cardiomyopathy. In particular, its regulatory
              function in lipid metabolism makes it an inviting target for
              pharmacological intervention in the treatment of obesity and Type
              2 diabetes.",
  journal  = "Adv. Physiol. Educ.",
  volume   =  30,
  number   =  4,
  pages    = "145--151",
  month    =  dec,
  year     =  2006,
  language = "en"
}

@ARTICLE{Liang2006-fx,
  title    = "{PGC-1alpha}: a key regulator of energy metabolism",
  author   = "Liang, Huiyun and Ward, Walter F",
  abstract = "Peroxisome proliferator-activated receptor-gamma coactivator
              (PGC)-1alpha is a member of a family of transcription
              coactivators that plays a central role in the regulation of
              cellular energy metabolism. It is strongly induced by cold
              exposure, linking this environmental stimulus to adaptive
              thermogenesis. PGC-1alpha stimulates mitochondrial biogenesis and
              promotes the remodeling of muscle tissue to a fiber-type
              composition that is metabolically more oxidative and less
              glycolytic in nature, and it participates in the regulation of
              both carbohydrate and lipid metabolism. It is highly likely that
              PGC-1alpha is intimately involved in disorders such as obesity,
              diabetes, and cardiomyopathy. In particular, its regulatory
              function in lipid metabolism makes it an inviting target for
              pharmacological intervention in the treatment of obesity and Type
              2 diabetes.",
  journal  = "Adv. Physiol. Educ.",
  volume   =  30,
  number   =  4,
  pages    = "145--151",
  month    =  dec,
  year     =  2006,
  language = "en"
}

@ARTICLE{Pirkmajer2011-jk,
  title    = "Serum starvation: caveat emptor",
  author   = "Pirkmajer, Sergej and Chibalin, Alexander V",
  abstract = "Serum starvation is one of the most frequently performed
              procedures in molecular biology and there are literally thousands
              of research papers reporting its use. In fact, this method has
              become so ingrained in certain areas of research that reports
              often simply state that cells were serum starved without
              providing any factual details as to how the procedure was carried
              out. Even so, we quite obviously lack unequivocal terminology,
              standard protocols, and perhaps most surprisingly, a common
              conceptual basis when performing serum starvation. Such
              inconsistencies not only hinder interstudy comparability but can
              lead to opposing and inconsistent experimental results. Although
              it is frequently assumed that serum starvation reduces basal
              activity of cells, available experimental data do not entirely
              support this notion. To address this important issue, we studied
              primary human myotubes, rat L6 myotubes and human embryonic
              kidney (HEK)293 cells under different serum starvation conditions
              and followed time-dependent changes in important signaling
              pathways such as the extracellular signal-regulated kinase 1/2,
              the AMP-activated protein kinase, and the mammalian target of
              rapamycin. Serum starvation induced a swift and dynamic response,
              which displayed obvious qualitative and quantitative differences
              across different cell types and experimental conditions despite
              certain unifying features. There was no uniform reduction in
              basal signaling activity. Serum starvation clearly represents a
              major event that triggers a plethora of divergent responses and
              has therefore great potential to interfere with the experimental
              results and affect subsequent conclusions.",
  journal  = "Am. J. Physiol. Cell Physiol.",
  volume   =  301,
  number   =  2,
  pages    = "C272--9",
  month    =  aug,
  year     =  2011,
  language = "en"
}

@ARTICLE{Soonpaa1996-py,
  title    = "Cardiomyocyte {DNA} synthesis and binucleation during murine
              development",
  author   = "Soonpaa, M H and Kim, K K and Pajak, L and Franklin, M and Field,
              L J",
  abstract = "Cardiomyocyte DNA synthesis and binucleation indexes were
              determined during murine development. Cardiomyocyte DNA synthesis
              occurred in two temporally distinct phases. The first phase
              occurred during fetal life and was associated exclusively with
              cardiomyocyte proliferation. The second phase occurred during
              early neonatal life and was associated with binucleation.
              Collectively, these results suggest that cardiomyocyte
              reduplication ceases during late fetal life. Northern and Western
              blot analyses identified several candidate genes that were
              differentially expressed during the reduplicative and
              binucleation phases of cardiomyocyte growth.",
  journal  = "Am. J. Physiol.",
  volume   =  271,
  number   = "5 Pt 2",
  pages    = "H2183--9",
  month    =  nov,
  year     =  1996,
  language = "en"
}

@ARTICLE{Rolfe1997-qe,
  title    = "Cellular energy utilization and molecular origin of standard
              metabolic rate in mammals",
  author   = "Rolfe, D F and Brown, G C",
  abstract = "The molecular origin of standard metabolic rate and thermogenesis
              in mammals is examined. It is pointed out that there are
              important differences and distinctions between the cellular
              reactions that 1) couple to oxygen consumption, 2) uncouple
              metabolism, 3) hydrolyze ATP, 4) control metabolic rate, 5)
              regulate metabolic rate, 6) produce heat, and 7) dissipate free
              energy. The quantitative contribution of different cellular
              reactions to these processes is assessed in mammals. We estimate
              that approximately 90\% of mammalian oxygen consumption in the
              standard state is mitochondrial, of which approximately 20\% is
              uncoupled by the mitochondrial proton leak and 80\% is coupled to
              ATP synthesis. The consequences of the significant contribution
              of proton leak to standard metabolic rate for tissue P-to-O
              ratio, heat production, and free energy dissipation by oxidative
              phosphorylation and the estimated contribution of ATP-consuming
              processes to tissue oxygen consumption rate are discussed. Of the
              80\% of oxygen consumption coupled to ATP synthesis,
              approximately 25-30\% is used by protein synthesis, 19-28\% by
              the Na(+)-K(+)-ATPase, 4-8\% by the Ca2(+)-ATPase, 2-8\% by the
              actinomyosin ATPase, 7-10\% by gluconeogenesis, and 3\% by
              ureagenesis, with mRNA synthesis and substrate cycling also
              making significant contributions. The main cellular reactions
              that uncouple standard energy metabolism are the Na+, K+, H+, and
              Ca2+ channels and leaks of cell membranes and protein breakdown.
              Cellular metabolic rate is controlled by a number of processes
              including metabolic demand and substrate supply. The differences
              in standard metabolic rate between animals of different body mass
              and phylogeny appear to be due to proportionate changes in the
              whole of energy metabolism. Heat is produced by some reactions
              and taken up by others but is mainly produced by the reactions of
              mitochondrial respiration, oxidative phosphorylation, and proton
              leak on the inner mitochondrial membrane. Free energy is
              dissipated by all cellular reactions, but the major contributions
              are by the ATP-utilizing reactions and the uncoupling reactions.
              The functions and evolutionary significance of standard metabolic
              rate are discussed.",
  journal  = "Physiol. Rev.",
  volume   =  77,
  number   =  3,
  pages    = "731--758",
  month    =  jul,
  year     =  1997,
  language = "en"
}

@ARTICLE{Pennisi2012-tk,
  title    = "A mathematical model of immune-system-melanoma competition",
  author   = "Pennisi, Marzio",
  abstract = "We present a mathematical model developed to reproduce the immune
              response entitled with the combined administration of activated
              OT1 cytotoxic T lymphocytes (CTLs) and Anti-CD137 monoclonal
              antibodies. The treatment is directed against melanoma in B16 OVA
              mouse models exposed to a specific immunotherapy strategy. We
              model two compartments: the injection point compartment where the
              treatment is administered and the skin compartment where melanoma
              tumor cells proliferate. To model the migration of OT1 CTLs and
              antibodies from the injection to the skin compartment, we use
              delay differential equations (DDEs). The outcomes of the
              mathematical model are in good agreement with the in vivo
              results. Moreover, sensitivity analysis of the mathematical model
              underlines the key role of OT1 CTLs and suggests that a possible
              reduction of the number of injected antibodies should not affect
              substantially the treatment efficacy.",
  journal  = "Comput. Math. Methods Med.",
  volume   =  2012,
  pages    = "850754",
  month    =  jun,
  year     =  2012,
  keywords = "B16F10\_specific",
  language = "en"
}

@ARTICLE{Chen2018-ms,
  title    = "Activation of {CD137} Signaling Enhances Vascular Calcification
              through c-Jun {N-Terminal} {Kinase-Dependent} Disruption of
              Autophagic Flux",
  author   = "Chen, Rui and Xu, Yao and Zhong, Wei and Li, Bo and Yang, Ping
              and Wang, Zhong Qun and Shao, Chen and Wang, Cui Ping and Yan,
              Jin Chuan",
  abstract = "Background: Vascular calcification is widespread and clinically
              significant, contributing to substantial morbidity and mortality.
              Calcifying vascular cells are partly derived from local vascular
              smooth muscle cells (VSMCs), which can undergo chondrogenic or
              osteogenic differentiation under inflammatory environment.
              Recently, we have found activation of CD137 signaling accelerated
              vascular calcification. However, the underlying mechanism remains
              unknown. This study aims to identify key mediators involved in
              CD137 signaling-induced vascular calcification in vivo and in
              vitro. Methods: Autophagy flux was measured through mRFP-GFP-LC3
              adenovirus and transmission electron microscopy. Von Kossa assay
              and alkaline phosphatase (ALP) activity were used to observe
              calcification in vivo and in vitro, respectively.
              Autophagosome-containing vesicles were collected and identified
              by flow cytometry and Western blot. Autophagy or
              calcification-associated targets were measured by Western blot,
              quantitative real-time PCR, and immunohistochemistry. Results:
              Treatment with the agonist-CD137 displayed c-Jun N-terminal
              kinase- (JNK-) dependent increase in the expression of various
              markers of autophagy and the number of autophagosomes relative to
              the control group. Autophagy flux experiments suggested that
              agonist-CD137 blocked the fusion of autophagosomes with lysosomes
              in cultured VSMCs. Calcium deposition, ALP activity, and the
              expression of calcification-associated proteins also increased in
              agonist-CD137 group compared with anti-CD137 group, which could
              be recovered by autophagy stimulator rapamycin.
              Autophagosome-containing vesicles collected from agonist-CD137
              VSMCs supernatant promoted VSMC calcification. Conclusion: The
              present study identified a new pathway in which CD137 promotes
              VSMC calcification through the activation of JNK signaling,
              subsequently leading to the disruption of autophagic flux, which
              is responsible for CD137-induced acceleration of vascular
              calcification.",
  journal  = "Mediators Inflamm.",
  volume   =  2018,
  pages    = "8407137",
  month    =  sep,
  year     =  2018,
  language = "en"
}

@ARTICLE{De_Pillis2005-dn,
  title    = "A validated mathematical model of cell-mediated immune response
              to tumor growth",
  author   = "de Pillis, Lisette G and Radunskaya, Ami E and Wiseman, Charles L",
  abstract = "Mathematical models of tumor-immune interactions provide an
              analytic framework in which to address specific questions about
              tumor-immune dynamics. We present a new mathematical model that
              describes tumor-immune interactions, focusing on the role of
              natural killer (NK) and CD8+ T cells in tumor surveillance, with
              the goal of understanding the dynamics of immune-mediated tumor
              rejection. The model describes tumor-immune cell interactions
              using a system of differential equations. The functions
              describing tumor-immune growth, response, and interaction rates,
              as well as associated variables, are developed using a
              least-squares method combined with a numerical differential
              equations solver. Parameter estimates and model validations use
              data from published mouse and human studies. Specifically, CD8+
              T-tumor and NK-tumor lysis data from chromium release assays as
              well as in vivo tumor growth data are used. A variable
              sensitivity analysis is done on the model. The new functional
              forms developed show that there is a clear distinction between
              the dynamics of NK and CD8+ T cells. Simulations of tumor growth
              using different levels of immune stimulating ligands, effector
              cells, and tumor challenge are able to reproduce data from the
              published studies. A sensitivity analysis reveals that the
              variable to which the model is most sensitive is patient
              specific, and can be measured with a chromium release assay. The
              variable sensitivity analysis suggests that the model can predict
              which patients may positively respond to treatment. Computer
              simulations highlight the importance of CD8+ T-cell activation in
              cancer therapy.",
  journal  = "Cancer Res.",
  volume   =  65,
  number   =  17,
  pages    = "7950--7958",
  month    =  sep,
  year     =  2005,
  language = "en"
}

@ARTICLE{Hwang2006-mz,
  title    = "The in vivo expansion rate of properly stimulated transferred
              {CD8+} {T} cells exceeds that of an aggressively growing mouse
              tumor",
  author   = "Hwang, Leroy N and Yu, Zhiya and Palmer, Douglas C and Restifo,
              Nicholas P",
  abstract = "It has been hypothesized that rapidly dividing tumor cells can
              outpace adoptively transferred antitumor lymphocytes when tumors
              are large. However, this hypothesis is at odds with clinical
              observations indicating that bulky tumors can be destroyed by
              small numbers of adoptively transferred antitumor T cells. We
              sought to measure the relative growth rates of T cells and tumor
              cells in a model using transgenic CD8(+) T cells specific for the
              gp100(25-33) H-2D(b) epitope (called pmel-1) to treat large,
              well-established s.c. B16 melanoma. We tested the effect of the
              immunization using an altered peptide ligand vaccine alone or in
              combination with interleukin-2 (IL-2) by analyzing the kinetics
              of T-cell expansion using direct enumeration. We found that
              pmel-1 T cells proliferated explosively during a 5-day period
              following transfer. Calculations from net changes in population
              suggest that, at the peak of cell division, pmel-1 T cells divide
              at a rate of 5.3 hours per cell division, which was much faster
              than B16 tumor cells during optimal growth (24.9 hours per cell
              division). These results clearly indicate that the notion of a
              kinetic ``race'' between the tumor and the lymphocyte is no
              contest when adoptively transferred cells are stimulated with
              immunization and IL-2. When appropriately stimulated,
              tumor-reactive T-cell expansion can far exceed the growth of even
              an aggressively growing mouse tumor.",
  journal  = "Cancer Res.",
  volume   =  66,
  number   =  2,
  pages    = "1132--1138",
  month    =  jan,
  year     =  2006,
  language = "en"
}

@ARTICLE{Ko2007-ac,
  title    = "Mouse dendritic-endothelial cell hybrids and {4-1BB}
              costimulation elicit antitumor effects mediated by broad
              antiangiogenic immunity",
  author   = "Ko, Eric and Luo, Wei and Peng, Liaomin and Wang, Xinhui and
              Ferrone, Soldano",
  abstract = "Antiangiogenic immunotherapy, which targets molecules critical to
              tumor angiogenesis, is expected to counteract the negative effect
              of tumor cell genetic instability on the outcome of immunotherapy
              targeting tumor antigens. Previously, targeting of individual
              angiogenic molecules has been shown to inhibit tumor angiogenesis
              and limit tumor growth. Nevertheless, this approach may be
              bypassed by redundant angiogenic pathways. To overcome this
              limitation, we have developed an immunization strategy targeting
              multiple molecules critical to angiogenesis. To this end, hybrids
              of dendritic cells (DC) and syngeneic endothelial cells (EC) were
              used as immunogens, because (a) whole EC express multiple
              molecules involved in angiogenesis and (b) DC tumor cell hybrids
              are effective in generating self-antigen-specific immune
              responses. The immunization strategy included the administration
              of an agonist 4-1BB-specific monoclonal antibody (mAb), because
              it augments self-antigen-specific immune responses elicited by DC
              hybrids. Immunization of mice with DC-EC hybrids and
              4-1BB-specific mAb inhibited the growth of B16.F10 melanoma and
              MC38 colon adenocarcinoma tumors. This effect is mediated by
              EC-specific CD4+ and CD8+ T-cell responses, which markedly
              inhibited tumor angiogenesis. No therapy-related side effects,
              except minor and transient hematologic changes, were observed.
              Our findings represent a useful background for the design of
              antiangiogenic immunotherapeutic strategies to control tumor
              growth in a clinical setting.",
  journal  = "Cancer Res.",
  volume   =  67,
  number   =  16,
  pages    = "7875--7884",
  month    =  aug,
  year     =  2007,
  keywords = "B16F10\_specific",
  language = "en"
}

@ARTICLE{Gatenby2009-qp,
  title    = "Adaptive therapy",
  author   = "Gatenby, Robert A and Silva, Ariosto S and Gillies, Robert J and
              Frieden, B Roy",
  abstract = "A number of successful systemic therapies are available for
              treatment of disseminated cancers. However, tumor response is
              often transient, and therapy frequently fails due to emergence of
              resistant populations. The latter reflects the temporal and
              spatial heterogeneity of the tumor microenvironment as well as
              the evolutionary capacity of cancer phenotypes to adapt to
              therapeutic perturbations. Although cancers are highly dynamic
              systems, cancer therapy is typically administered according to a
              fixed, linear protocol. Here we examine an adaptive therapeutic
              approach that evolves in response to the temporal and spatial
              variability of tumor microenvironment and cellular phenotype as
              well as therapy-induced perturbations. Initial mathematical
              models find that when resistant phenotypes arise in the untreated
              tumor, they are typically present in small numbers because they
              are less fit than the sensitive population. This reflects the
              ``cost'' of phenotypic resistance such as additional substrate
              and energy used to up-regulate xenobiotic metabolism, and
              therefore not available for proliferation, or the growth
              inhibitory nature of environments (i.e., ischemia or hypoxia)
              that confer resistance on phenotypically sensitive cells. Thus,
              in the Darwinian environment of a cancer, the fitter
              chemosensitive cells will ordinarily proliferate at the expense
              of the less fit chemoresistant cells. The models show that, if
              resistant populations are present before administration of
              therapy, treatments designed to kill maximum numbers of cancer
              cells remove this inhibitory effect and actually promote more
              rapid growth of the resistant populations. We present an
              alternative approach in which treatment is continuously modulated
              to achieve a fixed tumor population. The goal of adaptive therapy
              is to enforce a stable tumor burden by permitting a significant
              population of chemosensitive cells to survive so that they, in
              turn, suppress proliferation of the less fit but chemoresistant
              subpopulations. Computer simulations show that this strategy can
              result in prolonged survival that is substantially greater than
              that of high dose density or metronomic therapies. The
              feasibility of adaptive therapy is supported by in vivo
              experiments. [Cancer Res 2009;69(11):4894-903] Major FindingsWe
              present mathematical analysis of the evolutionary dynamics of
              tumor populations with and without therapy. Analytic solutions
              and numerical simulations show that, with pretreatment,
              therapy-resistant cancer subpopulations are present due to
              phenotypic or microenvironmental factors; maximum dose density
              chemotherapy hastens rapid expansion of resistant populations.
              The models predict that host survival can be maximized if
              ``treatment-for-cure strategy'' is replaced by
              ``treatment-for-stability.'' Specifically, the models predict
              that an optimal treatment strategy will modulate therapy to
              maintain a stable population of chemosensitive cells that can, in
              turn, suppress the growth of resistant populations under normal
              tumor conditions (i.e., when therapy-induced toxicity is absent).
              In vivo experiments using OVCAR xenografts treated with
              carboplatin show that adaptive therapy is feasible and, in this
              system, can produce long-term survival.",
  journal  = "Cancer Res.",
  volume   =  69,
  number   =  11,
  pages    = "4894--4903",
  month    =  jun,
  year     =  2009,
  language = "en"
}

@ARTICLE{Palazon2011-wz,
  title    = "Agonist {anti-CD137} mAb act on tumor endothelial cells to
              enhance recruitment of activated {T} lymphocytes",
  author   = "Palaz{\'o}n, As{\'\i}s and Teijeira, Alvaro and
              Mart{\'\i}nez-Forero, Iv{\'a}n and Herv{\'a}s-Stubbs, Sandra and
              Roncal, Carmen and Pe{\~n}uelas, Iv{\'a}n and Dubrot, Juan and
              Morales-Kastresana, Aizea and P{\'e}rez-Gracia, Jos{\'e} Luis and
              Ochoa, M Carmen and Ochoa-Callejero, Laura and Mart{\'\i}nez,
              Alfredo and Luque, Alfonso and Dinchuk, Joseph and Rouzaut, Ana
              and Jure-Kunkel, Maria and Melero, Ignacio",
  abstract = "Agonist monoclonal antibodies (mAb) to the immune costimulatory
              molecule CD137, also known as 4-1BB, are presently in clinical
              trials for cancer treatment on the basis of their costimulatory
              effects on primed T cells and perhaps other cells of the immune
              system. Here we provide evidence that CD137 is selectively
              expressed on the surface of tumor endothelial cells. Hypoxia
              upregulated CD137 on murine endothelial cells. Treatment of
              tumor-bearing immunocompromised Rag(-/-) mice with agonist CD137
              mAb did not elicit any measurable antiangiogenic effects. In
              contrast, agonist mAb stimulated tumor endothelial cells,
              increasing cell surface expression of the adhesion molecules
              intercellular adhesion molecule (ICAM)-1, vascular cell adhesion
              molecule (VCAM)-1, and E-selectin. When adoptively transferred
              into mice, activated T lymphocytes derived from CD137-deficient
              animals entered more avidly into tumor tissue after treatment
              with agonist mAb. This effect could be neutralized with
              anti-ICAM-1 and anti-VCAM-1 blocking antibodies. Thus,
              stimulation of CD137 not only enhanced T-cell activation but also
              augmented their trafficking into malignant tissue, through direct
              actions on the blood vessels that irrigate the tumor. Our
              findings identify an additional mechanism of action that can
              explain the immunotherapeutic effects of agonist CD137
              antibodies.",
  journal  = "Cancer Res.",
  volume   =  71,
  number   =  3,
  pages    = "801--811",
  month    =  feb,
  year     =  2011,
  language = "en"
}

@ARTICLE{Lee2011-ix,
  title    = "Chromosomal instability confers intrinsic multidrug resistance",
  author   = "Lee, Alvin J X and Endesfelder, David and Rowan, Andrew J and
              Walther, Axel and Birkbak, Nicolai J and Futreal, P Andrew and
              Downward, Julian and Szallasi, Zoltan and Tomlinson, Ian P M and
              Howell, Michael and Kschischo, Maik and Swanton, Charles",
  abstract = "Aneuploidy is associated with poor prognosis in solid tumors.
              Spontaneous chromosome missegregation events in aneuploid cells
              promote chromosomal instability (CIN) that may contribute to the
              acquisition of multidrug resistance in vitro and heighten risk
              for tumor relapse in animal models. Identification of distinct
              therapeutic agents that target tumor karyotypic complexity has
              important clinical implications. To identify distinct therapeutic
              approaches to specifically limit the growth of CIN tumors, we
              focused on a panel of colorectal cancer (CRC) cell lines,
              previously classified as either chromosomally unstable (CIN(+))
              or diploid/near-diploid (CIN(-)), and treated them individually
              with a library of kinase inhibitors targeting components of
              signal transduction, cell cycle, and transmembrane receptor
              signaling pathways. CIN(+) cell lines displayed significant
              intrinsic multidrug resistance compared with CIN(-) cancer cell
              lines, and this seemed to be independent of somatic mutation
              status and proliferation rate. Confirming the association of CIN
              rather than ploidy status with multidrug resistance, tetraploid
              isogenic cells that had arisen from diploid cell lines displayed
              lower drug sensitivity than their diploid parental cells only
              with increasing chromosomal heterogeneity and isogenic cell line
              models of CIN(+) displayed multidrug resistance relative to their
              CIN(-) parental cancer cell line derivatives. In a meta-analysis
              of CRC outcome following cytotoxic treatment, CIN(+) predicted
              worse progression-free or disease-free survival relative to
              patients with CIN(-) disease. Our results suggest that
              stratifying tumor responses according to CIN status should be
              considered within the context of clinical trials to minimize the
              confounding effects of tumor CIN status on drug sensitivity.",
  journal  = "Cancer Res.",
  volume   =  71,
  number   =  5,
  pages    = "1858--1870",
  month    =  mar,
  year     =  2011,
  language = "en"
}

@ARTICLE{Ngiow2011-yn,
  title    = "{Anti-TIM3} antibody promotes {T} cell {IFN-$\gamma$-mediated}
              antitumor immunity and suppresses established tumors",
  author   = "Ngiow, Shin Foong and von Scheidt, Bianca and Akiba, Hisaya and
              Yagita, Hideo and Teng, Michele W L and Smyth, Mark J",
  abstract = "Strategies to activate and rescue exhausted tumor-specific T
              cells, including the use of monoclonal antibodies (mAb) that
              block the negative costimulatory receptors CTLA-4 and PD-1 are
              proving very effective, but TIM3 has been relatively neglected as
              a target. Here we report an extensive characterization of the
              therapeutic activity and mechanism of action of an anti-mouse
              TIM3 mAb against experimental and carcinogen-induced tumors. For
              the first time we specifically define the mechanism of antitumor
              action of anti-TIM3 requiring IFN-$\gamma$ producing CD8(+) T
              cells and CD4(+) T cells, and a higher ratio of tumor
              infiltrating CD8(+):CD4(+) T cells correlating with therapeutic
              success. Interestingly, in some models, anti-TIM3 appeared to be
              effective sometime before the appearance and accumulation of
              significant TIM3(+)PD-1(+) T cell populations in tumor bearing
              mice. Anti-TIM3 displayed modest prophylactic and therapeutic
              activity against a small fraction of carcinogen-induced sarcomas,
              but comparative and combination studies of anti-TIM3 with
              anti-CTLA-4 and anti-PD-1 against experimental and
              carcinogen-induced tumors suggested that these agents might be
              well-tolerated and very effective in combination.",
  journal  = "Cancer Res.",
  volume   =  71,
  number   =  10,
  pages    = "3540--3551",
  month    =  may,
  year     =  2011,
  language = "en"
}

@ARTICLE{Song2011-ms,
  title    = "In vivo persistence, tumor localization, and antitumor activity
              of {CAR-engineered} {T} cells is enhanced by costimulatory
              signaling through {CD137} ({4-1BB})",
  author   = "Song, De-Gang and Ye, Qunrui and Carpenito, Carmine and Poussin,
              Mathilde and Wang, Li-Ping and Ji, Chunyan and Figini, Mariangela
              and June, Carl H and Coukos, George and Powell, Jr, Daniel J",
  abstract = "Human T cells engineered to express a chimeric antigen receptor
              (CAR) specific for folate receptor-$\alpha$ (FR$\alpha$) have
              shown robust antitumor activity against epithelial cancers in
              vitro but not in the clinic because of their inability to persist
              and home to tumor in vivo. In this study, CARs were constructed
              containing a FR$\alpha$-specific scFv (MOv19) coupled to the
              T-cell receptor CD3$\zeta$ chain signaling module alone
              (MOv19-$\zeta$) or in combination with the CD137 (4-1BB)
              costimulatory motif in tandem (MOv19-BB$\zeta$). Primary human T
              cells transduced to express conventional MOv19-$\zeta$ or
              costimulated MOv19-BB$\zeta$ CARs secreted various
              proinflammatory cytokines, and exerted cytotoxic function when
              cocultured with FR$\alpha$(+) tumor cells in vitro. However, only
              transfer of human T cells expressing the costimulated
              MOv19-BB$\zeta$ CAR mediated tumor regression in immunodeficient
              mice bearing large, established FR$\alpha$(+) human cancer.
              MOv19-BB$\zeta$ CAR T-cell infusion mediated tumor regression in
              models of metastatic intraperitoneal, subcutaneous, and
              lung-involved human ovarian cancer. Importantly, tumor response
              was associated with the selective survival and tumor localization
              of human T cells in vivo and was only observed in mice receiving
              costimulated MOv19-BB$\zeta$ CAR T cells. T-cell persistence and
              antitumor activity were primarily antigen-driven; however,
              antigen-independent CD137 signaling by CAR improved T-cell
              persistence but not antitumor activity in vivo. Our results show
              that anti-FR$\alpha$ CAR outfitted with CD137 costimulatory
              signaling in tandem overcome issues of T-cell persistence and
              tumor localization that limit the conventional FR$\alpha$ T-cell
              targeting strategy to provide potent antitumor activity in vivo.",
  journal  = "Cancer Res.",
  volume   =  71,
  number   =  13,
  pages    = "4617--4627",
  month    =  jul,
  year     =  2011,
  language = "en"
}

@ARTICLE{Martinet2011-hs,
  title    = "Human solid tumors contain high endothelial venules: association
              with {T-} and B-lymphocyte infiltration and favorable prognosis
              in breast cancer",
  author   = "Martinet, Ludovic and Garrido, Ignacio and Filleron, Thomas and
              Le Guellec, Sophie and Bellard, Elisabeth and Fournie,
              Jean-Jacques and Rochaix, Philippe and Girard, Jean-Philippe",
  abstract = "The mechanisms governing infiltration of lymphocytes into tumors
              remain poorly characterized, in spite of the critical impact of
              these cells on patient prognosis and therapeutic responses. High
              endothelial venules (HEV) are blood vessels found in lymphoid
              tissues, specialized in lymphocyte recruitment, but their
              implications in human cancer are unknown. In this article, we
              report the presence of MECA 79(+) blood vessels displaying all
              the phenotypic characteristics of HEVs in most of the 319 human
              primary solid tumors, including melanomas, breast, ovarian,
              colon, and lung carcinomas, analyzed. Tumor HEVs were
              specifically located within lymphocyte-rich areas, and their
              density within the tumor stroma was a strong predictor of
              infiltration by CD3(+) and CD8(+) T cells as well as B cells.
              Large-scale flow cytometric and quantitative reverse
              transcriptase-PCR analyses in freshly operated breast tumors
              revealed that high densities of tumor HEVs correlated with
              increased naive, central memory and activated effector memory
              T-cell infiltration and upregulation of genes related to T-helper
              1 adaptive immunity and T-cell cytotoxicity. Finally, in a
              retrospective cohort of 146 invasive breast cancer patients, we
              found that high densities of tumor HEVs independently conferred a
              lower risk of relapse and significantly correlated with longer
              metastasis-free, disease-free, and overall survival rates.
              Together, our findings suggest that tumor HEVs function as major
              gateways for lymphocyte infiltration into human tumors, and may
              represent attractive targets for cancer diagnosis and therapy.",
  journal  = "Cancer Res.",
  volume   =  71,
  number   =  17,
  pages    = "5678--5687",
  month    =  sep,
  year     =  2011,
  language = "en"
}

@ARTICLE{Silva2012-ci,
  title    = "Evolutionary approaches to prolong progression-free survival in
              breast cancer",
  author   = "Silva, Ariosto S and Kam, Yoonseok and Khin, Zayar P and Minton,
              Susan E and Gillies, Robert J and Gatenby, Robert A",
  abstract = "Many cancers adapt to chemotherapeutic agents by upregulating
              membrane efflux pumps that export drugs from the cytoplasm, but
              this response comes at an energetic cost. In breast cancer
              patients, expression of these pumps is low in tumors before
              therapy but increases after treatment. While the evolution of
              therapeutic resistance is virtually inevitable, proliferation of
              resistant clones is not, suggesting strategies of adaptive
              therapy. Chemoresistant cells must consume excess resources to
              maintain resistance mechanisms, so adaptive therapy strategies
              explicitly aim to maintain a stable population of
              therapy-sensitive cells to suppress growth of resistant
              phenotypes through intratumoral competition. We used
              computational models parameterized by in vitro experiments to
              illustrate the efficacy of such approaches. Here, we show that
              low doses of verapamil and 2-deoxyglucose, to accentuate the cost
              of resistance and to decrease energy production, respectively,
              could suppress the proliferation of drug-resistant clones in
              vivo. Compared with standard high-dose-density treatment, the
              novel treatment we developed achieved a 2-fold to 10-fold
              increase in time to progression in tumor models. Our findings
              challenge the existing flawed paradigm of maximum dose treatment,
              a strategy that inevitably produces drug resistance that can be
              avoided by the adaptive therapy strategies we describe.",
  journal  = "Cancer Res.",
  volume   =  72,
  number   =  24,
  pages    = "6362--6370",
  month    =  dec,
  year     =  2012,
  language = "en"
}

@ARTICLE{Kather2017-jg,
  title     = "In Silico Modeling of Immunotherapy and {Stroma-Targeting}
               Therapies in Human Colorectal Cancer",
  author    = "Kather, Jakob Nikolas and Poleszczuk, Jan and Suarez-Carmona,
               Meggy and Krisam, Johannes and Charoentong, Pornpimol and
               Valous, Nektarios A and Weis, Cleo-Aron and Tavernar, Luca and
               Leiss, Florian and Herpel, Esther and Klupp, Fee and Ulrich,
               Alexis and Schneider, Martin and Marx, Alexander and J{\"a}ger,
               Dirk and Halama, Niels",
  abstract  = "Despite the fact that the local immunological microenvironment
               shapes the prognosis of colorectal cancer, immunotherapy has
               shown no benefit for the vast majority of colorectal cancer
               patients. A better understanding of the complex immunological
               interplay within the microenvironment is required. In this
               study, we utilized wet lab migration experiments and
               quantitative histological data of human colorectal cancer tissue
               samples (n = 20) including tumor cells, lymphocytes, stroma, and
               necrosis to generate a multiagent spatial model. The resulting
               data accurately reflected a wide range of situations of
               successful and failed immune surveillance. Validation of
               simulated tissue outcomes on an independent set of human
               colorectal cancer specimens (n = 37) revealed the model
               recapitulated the spatial layout typically found in human
               tumors. Stroma slowed down tumor growth in a lymphocyte-deprived
               environment but promoted immune escape in a lymphocyte-enriched
               environment. A subgroup of tumors with less stroma and high
               numbers of immune cells showed high rates of tumor control.
               These findings were validated using data from colorectal cancer
               patients (n = 261). Low-density stroma and high lymphocyte
               levels showed increased overall survival (hazard ratio 0.322, P
               = 0.0219) as compared with high stroma and high lymphocyte
               levels. To guide immunotherapy in colorectal cancer, simulation
               of immunotherapy in preestablished tumors showed that a complex
               landscape with optimal stroma permeabilization and immune cell
               activation is able to markedly increase therapy response in
               silico These results can help guide the rational design of
               complex therapeutic interventions, which target the colorectal
               cancer microenvironment. Cancer Res; 77(22); 6442-52.
               \copyright{}2017 AACR.",
  journal   = "Cancer Res.",
  publisher = "AACR",
  volume    =  77,
  number    =  22,
  pages     = "6442--6452",
  month     =  nov,
  year      =  2017,
  language  = "en"
}

@ARTICLE{Dharmadhikari2018-os,
  title    = "{Anti-CD137} Cancer Immunotherapy Suppresses Tumor
              {Growth-Letter}",
  author   = "Dharmadhikari, Bhushan and Zeng, Qun and Wu, Meihui and Schwarz,
              Herbert",
  journal  = "Cancer Res.",
  volume   =  78,
  number   =  6,
  pages    = "1571",
  month    =  mar,
  year     =  2018,
  language = "en"
}

@ARTICLE{Kwon2018-hv,
  title    = "{Anti-CD137} Cancer Immunotherapy Suppresses Tumor
              {Growth-Response}",
  author   = "Kwon, Byungsuk",
  journal  = "Cancer Res.",
  volume   =  78,
  number   =  6,
  pages    = "1572--1573",
  month    =  mar,
  year     =  2018,
  language = "en"
}

@ARTICLE{Beck2019-nr,
  title    = "Contact-dependent killing by cytotoxic {T} lymphocytes is
              insufficient for {EL4} tumor regression in vivo",
  author   = "Beck, Richard J and Slagter, Maarten and Beltman, Joost B",
  abstract = "Immunotherapies are an emerging strategy for treatment of solid
              tumors. Improved understanding of the mechanisms employed by
              cytotoxic T lymphocytes (CTLs) to control tumors will aid in the
              development of immunotherapies. CTLs can directly kill tumor
              cells in a contact-dependent manner or may exert indirect effects
              on tumor cells via secretion of cytokines. Here we aim to
              quantify the importance of these mechanisms in murine thymoma
              EL4/EG7 cells. We developed an agent-based model (ABM) and an
              ordinary differential equation (ODE) model of tumor regression
              after adoptive transfer of a population of CTLs. Models were
              parameterized based on in vivo measurements of CTL infiltration
              and killing rates applied to EL4/EG7 tumors and OTI T cells. We
              quantified whether infiltrating CTLs are capable of controlling
              tumors through only direct, contact-dependent killing. Both
              models agreed that the low measured killing rate of CTLs in vivo
              was insufficient to cause tumor regression. In our ABM we also
              simulated CTL production of the cytokine interferon gamma
              (IFN$\gamma$) in order to explore how an antiproliferative effect
              of IFN$\gamma$ might aid CTLs in tumor control. In this model
              IFN$\gamma$ substantially reduced tumor growth compared to direct
              killing alone. Collectively these data demonstrate that
              contact-dependent killing is insufficient for EL4 regression in
              vivo and highlight the potential importance of cytokine-induced
              antiproliferative effects in T cell-mediated tumor control.",
  journal  = "Cancer Res.",
  month    =  apr,
  year     =  2019,
  language = "en"
}

@ARTICLE{Beck2019-no,
  title    = "{Contact-Dependent} Killing by Cytotoxic {T} Lymphocytes Is
              Insufficient for {EL4} Tumor Regression In Vivo",
  author   = "Beck, Richard J and Slagter, Maarten and Beltman, Joost B",
  abstract = "Immunotherapies are an emerging strategy for treatment of solid
              tumors. Improved understanding of the mechanisms employed by
              cytotoxic T lymphocytes (CTL) to control tumors will aid in the
              development of immunotherapies. CTLs can directly kill tumor
              cells in a contact-dependent manner or may exert indirect effects
              on tumor cells via secretion of cytokines. Here, we aim to
              quantify the importance of these mechanisms in murine thymoma
              EL4/EG7 cells. We developed an agent-based model (ABM) and an
              ordinary differential equation model of tumor regression after
              adoptive transfer of a population of CTLs. Models were
              parameterized based on in vivo measurements of CTL infiltration
              and killing rates applied to EL4/EG7 tumors and OTI T cells. We
              quantified whether infiltrating CTLs are capable of controlling
              tumors through only direct, contact-dependent killing. Both
              models agreed that the low measured killing rate of CTLs in vivo
              was insufficient to cause tumor regression. In our ABM, we also
              simulated CTL production of the cytokine IFN$\gamma$ in order to
              explore how an antiproliferative effect of IFN$\gamma$ might aid
              CTLs in tumor control. In this model, IFN$\gamma$ substantially
              reduced tumor growth compared with direct killing alone.
              Collectively, these data demonstrate that contact-dependent
              killing is insufficient for EL4 regression in vivo and highlight
              the potential importance of cytokine-induced antiproliferative
              effects in T-cell-mediated tumor control. SIGNIFICANCE:
              Computational modeling highlights the importance of
              cytokine-induced antiproliferative effects in T-cell-mediated
              control of tumor progression.",
  journal  = "Cancer Res.",
  volume   =  79,
  number   =  13,
  pages    = "3406--3416",
  month    =  jul,
  year     =  2019,
  language = "en"
}

@ARTICLE{West2020-yh,
  title    = "Towards Multidrug Adaptive Therapy",
  author   = "West, Jeffrey and You, Li and Zhang, Jingsong and Gatenby, Robert
              A and Brown, Joel S and Newton, Paul K and Anderson, Alexander R
              A",
  abstract = "A new ecologically inspired paradigm in cancer treatment known as
              ``adaptive therapy'' capitalizes on competitive interactions
              between drug-sensitive and drug-resistant subclones. The goal of
              adaptive therapy is to maintain a controllable stable tumor
              burden by allowing a significant population of
              treatment-sensitive cells to survive. These, in turn, suppress
              proliferation of the less-fit resistant populations. However,
              there remain several open challenges in designing adaptive
              therapies, particularly in extending these therapeutic concepts
              to multiple treatments. We present a cancer treatment case study
              (metastatic castrate-resistant prostate cancer) as a point of
              departure to illustrate three novel concepts to aid the design of
              multidrug adaptive therapies. First, frequency-dependent
              ``cycles'' of tumor evolution can trap tumor evolution in a
              periodic, controllable loop. Second, the availability and
              selection of treatments may limit the evolutionary ``absorbing
              region'' reachable by the tumor. Third, the velocity of evolution
              significantly influences the optimal timing of drug sequences.
              These three conceptual advances provide a path forward for
              multidrug adaptive therapy. SIGNIFICANCE: Driving tumor evolution
              into periodic, repeatable treatment cycles provides a path
              forward for multidrug adaptive therapy.",
  journal  = "Cancer Res.",
  volume   =  80,
  number   =  7,
  pages    = "1578--1589",
  month    =  apr,
  year     =  2020,
  language = "en"
}

@ARTICLE{Strobl2021-un,
  title    = "Turnover Modulates the Need for a Cost of Resistance in Adaptive
              Therapy",
  author   = "Strobl, Maximilian A R and West, Jeffrey and Viossat, Yannick and
              Damaghi, Mehdi and Robertson-Tessi, Mark and Brown, Joel S and
              Gatenby, Robert A and Maini, Philip K and Anderson, Alexander R A",
  abstract = "Adaptive therapy seeks to exploit intratumoral competition to
              avoid, or at least delay, the emergence of therapy resistance in
              cancer. Motivated by promising results in prostate cancer, there
              is growing interest in extending this approach to other
              neoplasms. As such, it is urgent to understand the
              characteristics of a cancer that determine whether or not it will
              respond well to adaptive therapy. A plausible candidate for such
              a selection criterion is the fitness cost of resistance. In this
              article, we study a general, but simple, mathematical model to
              investigate whether the presence of a cost is necessary for
              adaptive therapy to extend the time to progression beyond that of
              a standard-of-care continuous therapy. Tumor cells were divided
              into sensitive and resistant populations and we model their
              competition using a system of two ordinary differential equations
              based on the Lotka-Volterra model. For tumors close to their
              environmental carrying capacity, a cost was not required.
              However, for tumors growing far from carrying capacity, a cost
              may be required to see meaningful gains. Notably, it is important
              to consider cell turnover in the tumor, and we discuss its role
              in modulating the impact of a resistance cost. To conclude, we
              present evidence for the predicted cost-turnover interplay in
              data from 67 patients with prostate cancer undergoing
              intermittent androgen deprivation therapy. Our work helps to
              clarify under which circumstances adaptive therapy may be
              beneficial and suggests that turnover may play an unexpectedly
              important role in the decision-making process. SIGNIFICANCE:
              Tumor cell turnover modulates the speed of selection against drug
              resistance by amplifying the effects of competition and
              resistance costs; as such, turnover is an important factor in
              resistance management via adaptive therapy.See related commentary
              by Strobl et al., p. 811.",
  journal  = "Cancer Res.",
  volume   =  81,
  number   =  4,
  pages    = "1135--1147",
  month    =  feb,
  year     =  2021,
  language = "en"
}

@ARTICLE{Schonhoft2020-uc,
  title    = "{Morphology-Predicted} {Large-Scale} Transition Number in
              Circulating Tumor Cells Identifies a Chromosomal Instability
              Biomarker Associated with Poor Outcome in {Castration-Resistant}
              Prostate Cancer",
  author   = "Schonhoft, Joseph D and Zhao, Jimmy L and Jendrisak, Adam and
              Carbone, Emily A and Barnett, Ethan S and Hullings, Melanie A and
              Gill, Audrey and Sutton, Ramsay and Lee, Jerry and Dago, Angel E
              and Landers, Mark and Bakhoum, Samuel F and Wang, Yipeng and
              Gonen, Mithat and Dittamore, Ryan and Scher, Howard I",
  abstract = "Chromosomal instability (CIN) increases a tumor cell's ability to
              acquire chromosomal alterations, a mechanism by which tumor cells
              evolve, adapt, and resist therapeutics. We sought to develop a
              biomarker of CIN in circulating tumor cells (CTC) that are more
              likely to reflect the genetic diversity of patient's disease than
              a single-site biopsy and be assessed rapidly so as to inform
              treatment management decisions in real time. Large-scale
              transitions (LST) are genomic alterations defined as chromosomal
              breakages that generate chromosomal gains or losses of greater
              than or equal to10 Mb. Here we studied the relationship between
              the number of LST in an individual CTC determined by direct
              sequencing and morphologic features of the cells. This
              relationship was then used to develop a computer vision algorithm
              that utilizes CTC image features to predict the presence of a
              high (9 or more) versus low (8 or fewer) LST number in a single
              cell. As LSTs are a primary functional component of homologous
              recombination deficient cellular phenotypes, the image-based
              algorithm was studied prospectively on 10,240 CTCs in 367 blood
              samples obtained from 294 patients with progressing metastatic
              castration-resistant prostate cancer taken prior to starting a
              standard-of-care approved therapy. The resultant computer
              vision-based biomarker of CIN in CTCs in a pretreatment sample
              strongly associated with poor overall survival times in patients
              treated with androgen receptor signaling inhibitors and taxanes.
              SIGNIFICANCE: A rapidly assessable biomarker of chromosomal
              instability in CTC is associated with poor outcomes when detected
              in men with progressing mCRPC.",
  journal  = "Cancer Res.",
  volume   =  80,
  number   =  22,
  pages    = "4892--4903",
  month    =  nov,
  year     =  2020,
  language = "en"
}

@ARTICLE{Kimmel2020-ls,
  title    = "Integrating Mathematical Modeling with {High-Throughput} Imaging
              Explains How Polyploid Populations Behave in {Nutrient-Sparse}
              Environments",
  author   = "Kimmel, Gregory J and Dane, Mark and Heiser, Laura M and Altrock,
              Philipp M and Andor, Noemi",
  abstract = "Breast cancer progresses in a multistep process from primary
              tumor growth and stroma invasion to metastasis. Nutrient-limiting
              environments promote chemotaxis with aggressive morphologies
              characteristic of invasion. It is unknown how coexisting cells
              differ in their response to nutrient limitations and how this
              impacts invasion of the metapopulation as a whole. In this study,
              we integrate mathematical modeling with microenvironmental
              perturbation data to investigate invasion in nutrient-limiting
              environments inhabited by one or two cancer cell subpopulations.
              Subpopulations were defined by their energy efficiency and
              chemotactic ability. Invasion distance traveled by a homogeneous
              population was estimated. For heterogeneous populations, results
              suggest that an imbalance between nutrient efficacy and
              chemotactic superiority accelerates invasion. Such imbalance will
              spatially segregate the two populations and only one type will
              dominate at the invasion front. Only if these two phenotypes are
              balanced, the two subpopulations compete for the same space,
              which decelerates invasion. We investigate ploidy as a candidate
              biomarker of this phenotypic heterogeneity and discuss its
              potential to inform the dose of mTOR inhibitors (mTOR-I) that can
              inhibit chemotaxis just enough to facilitate such competition.
              SIGNIFICANCE: This study identifies the double-edged sword of
              high ploidy as a prerequisite to personalize combination
              therapies with cytotoxic drugs and inhibitors of signal
              transduction pathways such as mTOR-Is. GRAPHICAL ABSTRACT:
              http://cancerres.aacrjournals.org/content/canres/80/22/5109/F1.large.jpg.",
  journal  = "Cancer Res.",
  volume   =  80,
  number   =  22,
  pages    = "5109--5120",
  month    =  nov,
  year     =  2020,
  language = "en"
}

@ARTICLE{Prasad2022-bc,
  title    = "{Whole-Genome} Duplication Shapes the Aneuploidy Landscape of
              Human Cancers",
  author   = "Prasad, Kavya and Bloomfield, Mathew and Levi, Hagai and Keuper,
              Kristina and Bernhard, Sara V and Baudoin, Nicolaas C and Leor,
              Gil and Eliezer, Yonatan and Giam, Maybelline and Wong, Cheng Kit
              and Rancati, Giulia and Storchov{\'a}, Zuzana and Cimini, Daniela
              and Ben-David, Uri",
  abstract = "UNLABELLED: Aneuploidy is a hallmark of cancer with
              tissue-specific prevalence patterns that suggest it plays a
              driving role in cancer initiation and progression. However, the
              contribution of aneuploidy to tumorigenesis depends on both
              cellular and genomic contexts. Whole-genome duplication (WGD) is
              a common macroevolutionary event that occurs in more than 30\% of
              human tumors early in tumorigenesis. Although tumors that have
              undergone WGD are reported to be more permissive to aneuploidy,
              it remains unknown whether WGD also affects aneuploidy prevalence
              patterns. Here we analyzed clinical tumor samples from 5,586 WGD-
              tumors and 3,435 WGD+ tumors across 22 tumor types and found
              distinct patterns of aneuploidy in WGD- and WGD+ tumors. WGD+
              tumors were characterized by more promiscuous aneuploidy
              patterns, in line with increased aneuploidy tolerance. Moreover,
              the genetic interactions between chromosome arms differed between
              WGD- and WGD+ tumors, giving rise to distinct cooccurrence and
              mutual exclusivity aneuploidy patterns. The proportion of
              whole-chromosome aneuploidy compared with arm-level aneuploidy
              was significantly higher in WGD+ tumors, indicating distinct
              dominant mechanisms for aneuploidy formation. Human cancer cell
              lines successfully reproduced these WGD/aneuploidy interactions,
              confirming the relevance of studying this phenomenon in culture.
              Finally, induction of WGD and assessment of aneuploidy in
              isogenic WGD-/WGD+ human colon cancer cell lines under standard
              or selective conditions validated key findings from the clinical
              tumor analysis, supporting a causal link between WGD and altered
              aneuploidy landscapes. We conclude that WGD shapes the aneuploidy
              landscape of human tumors and propose that this interaction
              contributes to tumor evolution. SIGNIFICANCE: These findings
              suggest that the interactions between whole-genome duplication
              and aneuploidy are important for tumor evolution, highlighting
              the need to consider genome status in the analysis and modeling
              of cancer aneuploidy.",
  journal  = "Cancer Res.",
  volume   =  82,
  number   =  9,
  pages    = "1736--1752",
  month    =  may,
  year     =  2022,
  language = "en"
}

@ARTICLE{Andor2022-ty,
  title    = "Tipping Cancer Cells Over the Edge: The {Context-Dependent} Cost
              of High Ploidy",
  author   = "Andor, Noemi and Altrock, Philipp M and Jain, Navami and Gomes,
              Ana P",
  abstract = "Tetraploidy is an aneuploidy-permissive condition that can fuel
              tumorgenesis. The tip-over hypothesis of cytotoxic therapy
              sensitivity proposes that therapy is effective if it pushes a
              cell's aneuploidy above a viable tipping point. But elevated
              aneuploidy alone may not account for this tipping point. Tissue
              microenvironments that lack sufficient resources to support
              tetraploid cells can explain the fitness cost of aneuploidy. Raw
              materials needed to generate deoxynucleotides, the building
              blocks of DNA, are candidate rate-limiting factors for the
              evolution of high-ploidy cancer cells. Understanding the resource
              cost of high ploidy is key to uncover its therapeutic
              vulnerabilities across tissue sites with versatile energy
              supplies.",
  journal  = "Cancer Res.",
  volume   =  82,
  number   =  5,
  pages    = "741--748",
  month    =  mar,
  year     =  2022,
  language = "en"
}

@ARTICLE{Kronenwett2004-wp,
  title    = "Improved grading of breast adenocarcinomas based on genomic
              instability",
  author   = "Kronenwett, Ulrike and Huwendiek, S{\"o}ren and Ostring, Carin
              and Portwood, Neil and Roblick, Uwe J and Pawitan, Yudi and
              Alaiya, Ayodele and Sennerstam, Roland and Zetterberg, Anders and
              Auer, Gert",
  abstract = "Numerous investigations have shown that in primary breast
              adenocarcinomas DNA aneuploidy in contrast to DNA diploidy
              indicates high malignancy potential. On the basis of the study of
              104 breast carcinomas, we describe a subtype of aneuploidy, which
              demonstrates a low degree of malignancy. In image cytometric DNA
              histograms, this subtype possessed a low percentage (8.8\%),
              compared with those with a low SSI. A pilot study demonstrated
              centrosomal aberrations in an average of 9.6\% of the measured
              cells in four aneuploid carcinomas with high SSI values and in an
              average of 2.5\% of the cells in three aneuploid and three
              diploid tumors with low SSI. Our data indicate that the SSI, most
              likely reflecting the degree of genomic instability, allows
              additional classifying of the known aneuploid, diploid, and
              tetraploid categories of primary breast adenocarcinomas into low
              and high malignant subtypes.",
  journal  = "Cancer Res.",
  volume   =  64,
  number   =  3,
  pages    = "904--909",
  month    =  feb,
  year     =  2004,
  language = "en"
}

@ARTICLE{Besser2010-km,
  title    = "Clinical responses in a phase {II} study using adoptive transfer
              of short-term cultured tumor infiltration lymphocytes in
              metastatic melanoma patients",
  author   = "Besser, Michal J and Shapira-Frommer, Ronnie and Treves, Avraham
              J and Zippel, Dov and Itzhaki, Orit and Hershkovitz, Liat and
              Levy, Daphna and Kubi, Adva and Hovav, Einat and Chermoshniuk,
              Natalia and Shalmon, Bruria and Hardan, Izhar and Catane, Raphael
              and Markel, Gal and Apter, Sara and Ben-Nun, Alon and Kuchuk,
              Iryna and Shimoni, Avichai and Nagler, Arnon and Schachter, Jacob",
  abstract = "PURPOSE: Adoptive cell therapy with autologous tumor-infiltrating
              lymphocytes (TIL) has shown promising results in metastatic
              melanoma patients. Although objective response rates of over 50\%
              have been reported, disadvantages of this approach are the
              labor-intensive TIL production and a very high drop-out rate of
              enrolled patients, limiting its widespread applicability.
              Previous studies showed a clear correlation between short TIL
              culture periods and clinical response. Therefore, we used a new
              TIL production technique using unselected, minimally cultured,
              bulk TIL (Young-TIL). The use of Young-TIL is not restricted to
              human leukocyte antigen (HLA)-A2 patients. The purpose of this
              study is to explore the efficacy and toxicity of adoptively
              transferred Young-TIL following lympho-depleting chemotherapy in
              metastatic melanoma patients, refractory to interleukin-2 and
              chemotherapy. EXPERIMENTAL DESIGN: Young-TIL cultures for 90\% of
              the patients were successfully generated, enabling the treatment
              of most enrolled patients. We report here the results of 20
              evaluated patients. RESULTS: Fifty percent of the patients
              achieved an objective clinical response according to the Response
              Evaluation Criteria in Solid Tumors, including two ongoing
              complete remissions (20+, 4+ months) and eight partial responses
              (progression-free survival: 18+, 13+, 10+, 9, 6+, 4, 3+, and 3
              months). All responders are currently alive. Four additional
              patients showed disease stabilization. Side effects were
              transient and manageable. CONCLUSION: We showed that
              lympho-depleting chemotherapy followed by transfer of short-term
              cultured TIL can mediate tumor regression in 50\% of metastatic
              melanoma with manageable toxicity. The convincing clinical
              results combined with the simplification of the process may thus
              have a major effect on cell therapy of cancer.",
  journal  = "Clin. Cancer Res.",
  volume   =  16,
  number   =  9,
  pages    = "2646--2655",
  month    =  may,
  year     =  2010,
  language = "en"
}

@ARTICLE{Rosenberg2011-rb,
  title    = "Durable complete responses in heavily pretreated patients with
              metastatic melanoma using T-cell transfer immunotherapy",
  author   = "Rosenberg, Steven A and Yang, James C and Sherry, Richard M and
              Kammula, Udai S and Hughes, Marybeth S and Phan, Giao Q and
              Citrin, Deborah E and Restifo, Nicholas P and Robbins, Paul F and
              Wunderlich, John R and Morton, Kathleen E and Laurencot, Carolyn
              M and Steinberg, Seth M and White, Donald E and Dudley, Mark E",
  abstract = "PURPOSE: Most treatments for patients with metastatic melanoma
              have a low rate of complete regression and thus overall survival
              in these patients is poor. We investigated the ability of
              adoptive cell transfer utilizing autologous tumor-infiltrating
              lymphocytes (TIL) to mediate durable complete regressions in
              heavily pretreated patients with metastatic melanoma.
              EXPERIMENTAL DESIGN: Ninety-three patients with measurable
              metastatic melanoma were treated with the adoptive transfer of
              autologous TILs administered in conjunction with interleukin-2
              following a lymphodepleting preparative regimen on three
              sequential clinical trials. Ninety-five percent of these patients
              had progressive disease following a prior systemic treatment.
              Median potential follow-up was 62 months. RESULTS: Objective
              response rates by Response Evaluation Criteria in Solid Tumors
              (RECIST) in the 3 trials using lymphodepleting preparative
              regimens (chemotherapy alone or with 2 or 12 Gy irradiation) were
              49\%, 52\%, and 72\%, respectively. Twenty of the 93 patients
              (22\%) achieved a complete tumor regression, and 19 have ongoing
              complete regressions beyond 3 years. The actuarial 3- and 5-year
              survival rates for the entire group were 36\% and 29\%,
              respectively, but for the 20 complete responders were 100\% and
              93\%. The likelihood of achieving a complete response was similar
              regardless of prior therapy. Factors associated with objective
              response included longer telomeres of the infused cells, the
              number of CD8(+)CD27(+) cells infused, and the persistence of the
              infused cells in the circulation at 1 month (all P(2) < 0.001).
              CONCLUSIONS: Cell transfer therapy with autologous TILs can
              mediate durable complete responses in patients with metastatic
              melanoma and has similar efficacy irrespective of prior
              treatment. Clin Cancer Res; 17(13); 4550-7. \copyright{}2011
              AACR.",
  journal  = "Clin. Cancer Res.",
  volume   =  17,
  number   =  13,
  pages    = "4550--4557",
  month    =  jul,
  year     =  2011,
  language = "en"
}

@ARTICLE{Yonezawa2015-ri,
  title    = "Boosting Cancer Immunotherapy with {Anti-CD137} Antibody Therapy",
  author   = "Yonezawa, Atsushi and Dutt, Suparna and Chester, Cariad and Kim,
              Jeewon and Kohrt, Holbrook E",
  abstract = "In the past 5 years, immunomodulatory antibodies have
              revolutionized cancer immunotherapy. CD137, a member of the tumor
              necrosis factor receptor superfamily, represents a promising
              target for enhancing antitumor immune responses. CD137 helps
              regulate the activation of many immune cells, including CD4(+) T
              cells, CD8(+) T cells, dendritic cells, and natural killer cells.
              Recent studies indicate that the antitumor efficacy of
              therapeutic tumor-targeting antibodies can be augmented by the
              addition of agonistic antibodies targeting CD137. As ligation of
              CD137 provides a costimulatory signal in multiple immune cell
              subsets, combination therapy of CD137 antibody with therapeutic
              antibodies and/or vaccination has the potential to improve cancer
              treatment. Recently, clinical trials of combination therapies
              with agonistic anti-CD137 mAbs have been launched. In this
              review, we discuss the recent advances and clinical promise of
              agonistic anti-CD137 monoclonal antibody therapy.",
  journal  = "Clin. Cancer Res.",
  volume   =  21,
  number   =  14,
  pages    = "3113--3120",
  month    =  jul,
  year     =  2015,
  language = "en"
}

@ARTICLE{Jardim2018-lw,
  title    = "Analysis of Drug Development Paradigms for Immune Checkpoint
              Inhibitors",
  author   = "Jardim, Denis L and de Melo Gagliato, D{\'e}bora and Giles,
              Francis J and Kurzrock, Razelle",
  abstract = "Immune checkpoint inhibitors have unique toxicities and response
              kinetics compared with cytotoxic and gene-targeted anticancer
              agents. We investigated the impact of innovative/accelerated
              immunotherapy drug development/approval models on the accuracy of
              safety and efficacy assessments by searching the FDA website.
              Initial phase I trials for each agent were reviewed and safety
              and efficacy data compared with that found in later trials
              leading to regulatory approvals of the same agents. As of June
              2017, the FDA approved six checkpoint inhibitors for a variety of
              cancer types. All checkpoint inhibitors received a priority
              review status and access to at least two additional FDA special
              access programs, more often breakthrough therapy designation and
              accelerated approval. Median clinical development time
              (investigational new drug application to approval) was 60.77
              months [avelumab had the shortest timeline (52.33 months)].
              Response rates during early phase I trials (median = 16\%) are
              higher than for phase I trials of other agents (with the
              exception of gene-targeted agents tested with a biomarker). Doses
              approved were usually not identical to doses recommended on phase
              I trials. Approximately 50\% of types of immune-related and 43\%
              of types of clinically relevant toxicities from later trials were
              identified in early-phase trials. Even so, treatment-related
              mortality remains exceedingly low in later studies (0.33\% of
              patients). In conclusion, efficacy and safety of immune
              checkpoint inhibitors appear to be reasonably predicted from the
              dose-finding portion of phase I trials, indicating that the
              fast-track development of these agents is safe and justified.
              Clin Cancer Res; 24(8); 1785-94. \copyright{}2017 AACR.",
  journal  = "Clin. Cancer Res.",
  volume   =  24,
  number   =  8,
  pages    = "1785--1794",
  month    =  apr,
  year     =  2018,
  language = "en"
}

@ARTICLE{Ribba2018-ci,
  title    = "Prediction of the Optimal Dosing Regimen Using a Mathematical
              Model of Tumor Uptake for {Immunocytokine-Based} Cancer
              Immunotherapy",
  author   = "Ribba, Benjamin and Boetsch, Christophe and Nayak, Tapan and
              Grimm, Hans Peter and Charo, Jehad and Evers, Stefan and Klein,
              Christian and Tessier, Jean and Charoin, Jean Eric and Phipps,
              Alex and Pisa, Pavel and Teichgr{\"a}ber, Volker",
  abstract = "Purpose: Optimal dosing is critical for immunocytokine-based
              cancer immunotherapy to maximize efficacy and minimize toxicity.
              Cergutuzumab amunaleukin (CEA-IL2v) is a novel CEA-targeted
              immunocytokine. We set out to develop a mathematical model to
              predict intratumoral CEA-IL2v concentrations following various
              systemic dosing intensities.Experimental Design: Sequential
              measurements of CEA-IL2v plasma concentrations in 74 patients
              with solid tumors were applied in a series of differential
              equations to devise a model that also incorporates the peripheral
              concentrations of IL2 receptor-positive cell populations (i.e.,
              CD8+, CD4+, NK, and B cells), which affect tumor bioavailability
              of CEA-IL2v. Imaging data from a subset of 14 patients were
              subsequently utilized to additionally predict antibody uptake in
              tumor tissues.Results: We created a
              pharmacokinetic/pharmacodynamic mathematical model that
              incorporates the expansion of IL2R-positive target cells at
              multiple dose levels and different schedules of CEA-IL2v.
              Model-based prediction of drug levels correlated with the
              concentration of IL2R-positive cells in the peripheral blood of
              patients. The pharmacokinetic model was further refined and
              extended by adding a model of antibody uptake, which is based on
              drug dose and the biological properties of the tumor. In silico
              predictions of our model correlated with imaging data and
              demonstrated that a dose-dense schedule comprising escalating
              doses and shortened intervals of drug administration can improve
              intratumoral drug uptake and overcome consumption of CEA-IL2v by
              the expanding population of IL2R-positive cells.Conclusions: The
              model presented here allows simulation of individualized
              treatment plans for optimal dosing and scheduling of
              immunocytokines for anticancer immunotherapy. Clin Cancer Res;
              24(14); 3325-33. \copyright{}2018 AACRSee related commentary by
              Ruiz-Cerd{\'a} et al., p. 3236.",
  journal  = "Clin. Cancer Res.",
  volume   =  24,
  number   =  14,
  pages    = "3325--3333",
  month    =  jul,
  year     =  2018,
  language = "en"
}

@ARTICLE{Kang2004-te,
  title    = "Identification of genes with differential expression in acquired
              drug-resistant gastric cancer cells using high-density
              oligonucleotide microarrays",
  author   = "Kang, Hio Chung and Kim, Il-Jin and Park, Jae-Hyun and Shin, Yong
              and Ku, Ja-Lok and Jung, Mi Sun and Yoo, Byong Chul and Kim, Hark
              Kyun and Park, Jae-Gahb",
  abstract = "PURPOSE: A major obstacle in chemotherapy is treatment failure
              due to anticancer drug resistance. The emergence of acquired
              resistance results from host factors and genetic or epigenetic
              changes in the cancer cells. The purpose of this study was to
              identify differentially expressed genes associated with
              acquisition of resistance in human gastric cancer cells.
              EXPERIMENTAL DESIGN: We performed global gene expression analysis
              in the acquired drug-resistant gastric cancer cell lines to the
              commonly used drugs 5-fluorouracil, doxorubicin, and cisplatin
              using Affymetrix HG-U133A microarray. The gene expression
              patterns of 10 chemoresistant gastric cancer cell lines were
              compared with those of four parent cell lines using fold-change
              and Wilcoxon's test for data analysis. RESULTS: We identified
              over 250 genes differentially expressed in 5-fluorouracil-,
              cisplatin-, or doxorubicin-resistant gastric cancer cell lines.
              Our expression analysis also identified eight multidrug
              resistance candidate genes that were associated with resistance
              to two or more of the tested chemotherapeutic agents. Among
              these, midkine (MDK), a heparin-binding growth factor, was
              overexpressed in all drug-resistant cell lines, strongly
              suggesting that MDK might contribute to multidrug resistance in
              gastric cancer cells. CONCLUSIONS: Our investigation provides
              comprehensive gene information associated with acquired
              resistance to anticancer drugs in gastric cancer cells and a
              basis for additional functional studies.",
  journal  = "Clin. Cancer Res.",
  volume   =  10,
  number   = "1 Pt 1",
  pages    = "272--284",
  month    =  jan,
  year     =  2004,
  language = "en"
}

@ARTICLE{Long2013-dd,
  title    = "Arginine deiminase resistance in melanoma cells is associated
              with metabolic reprogramming, glucose dependence, and glutamine
              addiction",
  author   = "Long, Yan and Tsai, Wen-Bin and Wangpaichitr, Medhi and
              Tsukamoto, Takashi and Savaraj, Niramol and Feun, Lynn G and Kuo,
              Macus Tien",
  abstract = "Many malignant human tumors, including melanomas, are auxotrophic
              for arginine due to reduced expression of argininosuccinate
              synthetase-1 (ASS1), the rate-limiting enzyme for arginine
              biosynthesis. Pegylated arginine deiminase (ADI-PEG20), which
              degrades extracellular arginine, resulting in arginine
              deprivation, has shown favorable results in clinical trials for
              treating arginine-auxotrophic tumors. Drug resistance is the
              major obstacle for effective ADI-PEG20 usage. To elucidate
              mechanisms of resistance, we established several
              ADI-PEG20-resistant (ADI(R)) variants from A2058 and SK-Mel-2
              melanoma cells. Compared with the parental lines, these ADI(R)
              variants showed the following characteristics: (i) all ADI(R)
              cell lines showed elevated ASS1 expression, resulting from the
              constitutive binding of the transcription factor c-Myc on the
              ASS1 promoter, suggesting that elevated ASS1 is the major
              mechanism of resistance; (ii) the ADI(R) cell lines exhibited
              enhanced AKT signaling and were preferentially sensitive to
              PI3K/AKT inhibitors, but reduced mTOR signaling, and were
              preferentially resistant to mTOR inhibitor; (iii) these variants
              showed enhanced expression of glucose transporter-1 and lactate
              dehydrogenase-A, reduced expression of pyruvate dehydrogenase,
              and elevated sensitivity to the glycolytic inhibitors
              2-deoxy-glucose and 3-bromopyruvate, consistent with the enhanced
              glycolytic pathway (the Warburg effect); (iv) the resistant cells
              showed higher glutamine dehydrogenase and glutaminase expression
              and were preferentially vulnerable to glutamine inhibitors. We
              showed that c-Myc, not elevated ASS1 expression, is involved in
              upregulation of many of these enzymes because knockdown of c-Myc
              reduced their expression, whereas overexpressed ASS1 by
              transfection reduced their expression. This study identified
              multiple targets for overcoming ADI-PEG resistance in cancer
              chemotherapy using recombinant arginine-degrading enzymes.",
  journal  = "Mol. Cancer Ther.",
  volume   =  12,
  number   =  11,
  pages    = "2581--2590",
  month    =  nov,
  year     =  2013,
  language = "en"
}

@ARTICLE{Gross2014-uj,
  title    = "Antitumor activity of the glutaminase inhibitor {CB-839} in
              triple-negative breast cancer",
  author   = "Gross, Matt I and Demo, Susan D and Dennison, Jennifer B and
              Chen, Lijing and Chernov-Rogan, Tania and Goyal, Bindu and Janes,
              Julie R and Laidig, Guy J and Lewis, Evan R and Li, Jim and
              Mackinnon, Andrew L and Parlati, Francesco and Rodriguez, Mirna L
              M and Shwonek, Peter J and Sjogren, Eric B and Stanton, Timothy F
              and Wang, Taotao and Yang, Jinfu and Zhao, Frances and Bennett,
              Mark K",
  abstract = "Glutamine serves as an important source of energy and building
              blocks for many tumor cells. The first step in glutamine
              utilization is its conversion to glutamate by the mitochondrial
              enzyme glutaminase. CB-839 is a potent, selective, and orally
              bioavailable inhibitor of both splice variants of glutaminase
              (KGA and GAC). CB-839 had antiproliferative activity in a
              triple-negative breast cancer (TNBC) cell line, HCC-1806, that
              was associated with a marked decrease in glutamine consumption,
              glutamate production, oxygen consumption, and the steady-state
              levels of glutathione and several tricarboxylic acid cycle
              intermediates. In contrast, no antiproliferative activity was
              observed in an estrogen receptor-positive cell line, T47D, and
              only modest effects on glutamine consumption and downstream
              metabolites were observed. Across a panel of breast cancer cell
              lines, GAC protein expression and glutaminase activity were
              elevated in the majority of TNBC cell lines relative to receptor
              positive cells. Furthermore, the TNBC subtype displayed the
              greatest sensitivity to CB-839 treatment and this sensitivity was
              correlated with (i) dependence on extracellular glutamine for
              growth, (ii) intracellular glutamate and glutamine levels, and
              (iii) GAC (but not KGA) expression, a potential biomarker for
              sensitivity. CB-839 displayed significant antitumor activity in
              two xenograft models: as a single agent in a patient-derived TNBC
              model and in a basal like HER2(+) cell line model, JIMT-1, both
              as a single agent and in combination with paclitaxel. Together,
              these data provide a strong rationale for the clinical
              investigation of CB-839 as a targeted therapeutic in patients
              with TNBC and other glutamine-dependent tumors.",
  journal  = "Mol. Cancer Ther.",
  volume   =  13,
  number   =  4,
  pages    = "890--901",
  month    =  apr,
  year     =  2014,
  language = "en"
}

@ARTICLE{Goodman2017-le,
  title    = "Tumor Mutational Burden as an Independent Predictor of Response
              to Immunotherapy in Diverse Cancers",
  author   = "Goodman, Aaron M and Kato, Shumei and Bazhenova, Lyudmila and
              Patel, Sandip P and Frampton, Garrett M and Miller, Vincent and
              Stephens, Philip J and Daniels, Gregory A and Kurzrock, Razelle",
  abstract = "Immunotherapy induces durable responses in a subset of patients
              with cancer. High tumor mutational burden (TMB) may be a response
              biomarker for PD-1/PD-L1 blockade in tumors such as melanoma and
              non-small cell lung cancer (NSCLC). Our aim was to examine the
              relationship between TMB and outcome in diverse cancers treated
              with various immunotherapies. We reviewed data on 1,638 patients
              who had undergone comprehensive genomic profiling and had TMB
              assessment. Immunotherapy-treated patients (N = 151) were
              analyzed for response rate (RR), progression-free survival (PFS),
              and overall survival (OS). Higher TMB was independently
              associated with better outcome parameters (multivariable
              analysis). The RR for patients with high ($\geq$20 mutations/mb)
              versus low to intermediate TMB was 22/38 (58\%) versus 23/113
              (20\%; P = 0.0001); median PFS, 12.8 months vs. 3.3 months (P
              $\leq$ 0.0001); median OS, not reached versus 16.3 months (P =
              0.0036). Results were similar when anti-PD-1/PD-L1 monotherapy
              was analyzed (N = 102 patients), with a linear correlation
              between higher TMB and favorable outcome parameters; the median
              TMB for responders versus nonresponders treated with
              anti-PD-1/PD-L1 monotherapy was 18.0 versus 5.0 mutations/mb (P <
              0.0001). Interestingly, anti-CTLA4/anti-PD-1/PD-L1 combinations
              versus anti-PD-1/PD-L1 monotherapy was selected as a factor
              independent of TMB for predicting better RR (77\% vs. 21\%; P =
              0.004) and PFS (P = 0.024). Higher TMB predicts favorable outcome
              to PD-1/PD-L1 blockade across diverse tumors. Benefit from dual
              checkpoint blockade did not show a similarly strong dependence on
              TMB. Mol Cancer Ther; 16(11); 2598-608. \copyright{}2017 AACR.",
  journal  = "Mol. Cancer Ther.",
  volume   =  16,
  number   =  11,
  pages    = "2598--2608",
  month    =  nov,
  year     =  2017,
  language = "en"
}

@ARTICLE{Lucas2024-os,
  title     = "Abstract {PR010}: Linking proliferation rate to the evolution of
               single-cell primary and metastatic tumor clones",
  author    = "Lucas, Olivia and Ward, Sophia and Zaidi, Rija and Bunkum,
               Abigail and Frankell, Alexander M and Moore, David A and Hill,
               Mark S and Liu, Wing Kin and Marinelli, Daniele and Lim, Emilia
               L and Hessey, Sonya and Naceur-Lombardelli, Cristina and Rowan,
               Andrew and Mann, Sukhveer and Zhai, Haoran and Dietzen, Michelle
               and Ding, Boyue and Royle, Gary and McGranahan, Nicholas and
               Jamal-Hanjani, Mariam and Kanu, Nnennaya and Swanton, Charles
               and Zaccaria, Simone",
  abstract  = "Abstract. Proliferation is a key phenotypic feature of cancer,
               with higher rates associated with poorer clinical outcomes. Thus
               far, proliferation rates have been measured using pathological
               or experimental techniques on bulk tumor samples. However,
               tumors are heterogeneous compositions of distinct clones.
               Measuring the proliferation of individual clones has been
               unfeasible to date since proliferation and clonal diversity
               cannot easily be measured for the same set of cells, but it is
               potentially important as it may allow the identification of
               clones that develop more aggressive phenotypes (e.g., metastatic
               potential or treatment resistance). We have developed SPRINTER,
               a novel algorithm that uses single-cell whole-genome DNA
               sequencing (scDNA-seq) data to enable the accurate
               identification of actively replicating cells in both the S and
               G2 phases of the cell cycle and their assignment to distinct
               tumor clones, thus providing a proxy to estimate clone-specific
               proliferation rates. To evaluate SPRINTER's accuracy, we
               generated a ground truth dataset of 8,844 diploid and tetraploid
               cancer cells by coupling scDNA-seq with 5-Ethynyl-2-deoxyuridine
               (EdU) labeling, and demonstrated that SPRINTER can accurately
               distinguish clone proliferation rates in contrast to previous
               approaches. We further generated a longitudinal,
               primary-metastasis matched dataset of 23,001 cancer cells
               obtained from 5 samples from the primary tumor and 5 samples
               from distinct metastases from a patient with non-small cell lung
               cancer, allowing us to integrate analyses of proliferation and
               cancer evolution through the metastatic disease course. We
               revealed widespread heterogeneity in clone proliferation rates
               both between and within samples, supported by multiple
               orthogonal analyses including Ki-67 pathology, nuclei microscopy
               imaging, and patient clinical imaging, with high proliferation
               seen in fast-growing metastatic lesions. We demonstrated an
               association between clones with high proliferation and increased
               metastatic potential, as well as increased shedding of
               circulating tumor DNA. We further illustrated SPRINTER's broad
               applicability on previous datasets of 42,009 breast cancer cells
               and 19,905 ovarian cancer cells, revealing an association
               between high proliferation and increased rates of different
               genetic variants. In conclusion, SPRINTER infers the
               proliferation rates of distinct tumor clones from scDNA-seq
               data, allowing the identification of clones with potentially
               aggressive phenotypes, such as metastatic potential.Citation
               Format: Olivia Lucas, Sophia Ward, Rija Zaidi, Abigail Bunkum,
               Alexander M. Frankell, David A. Moore, Mark S. Hill, Wing Kin
               Liu, Daniele Marinelli, Emilia L. Lim, Sonya Hessey, Cristina
               Naceur-Lombardelli, Andrew Rowan, Sukhveer Mann, Haoran Zhai,
               Michelle Dietzen, Boyue Ding, Gary Royle, Nicholas McGranahan,
               Mariam Jamal-Hanjani, Nnennaya Kanu, Charles Swanton, Simone
               Zaccaria. Linking proliferation rate to the evolution of
               single-cell primary and metastatic tumor clones [abstract]. In:
               Proceedings of the AACR Special Conference in Cancer Research:
               Translating Cancer Evolution and Data Science: The Next
               Frontier; 2023 Dec 3-6; Boston, Massachusetts. Philadelphia
               (PA): AACR; Cancer Res 2024;84(3 Suppl\_2):Abstract nr PR010.",
  journal   = "Cancer Res.",
  publisher = "American Association for Cancer Research",
  volume    =  84,
  number    = "3\_Supplement\_2",
  pages     = "PR010--PR010",
  month     =  feb,
  year      =  2024,
  language  = "en"
}

@ARTICLE{Dewhurst2014-qw,
  title    = "Tolerance of whole-genome doubling propagates chromosomal
              instability and accelerates cancer genome evolution",
  author   = "Dewhurst, Sally M and McGranahan, Nicholas and Burrell, Rebecca A
              and Rowan, Andrew J and Gr{\"o}nroos, Eva and Endesfelder, David
              and Joshi, Tejal and Mouradov, Dmitri and Gibbs, Peter and Ward,
              Robyn L and Hawkins, Nicholas J and Szallasi, Zoltan and Sieber,
              Oliver M and Swanton, Charles",
  abstract = "UNLABELLED: The contribution of whole-genome doubling to
              chromosomal instability (CIN) and tumor evolution is unclear. We
              use long-term culture of isogenic tetraploid cells from a stable
              diploid colon cancer progenitor to investigate how a
              genome-doubling event affects genome stability over time. Rare
              cells that survive genome doubling demonstrate increased
              tolerance to chromosome aberrations. Tetraploid cells do not
              exhibit increased frequencies of structural or numerical CIN per
              chromosome. However, the tolerant phenotype in tetraploid cells,
              coupled with a doubling of chromosome aberrations per cell,
              allows chromosome abnormalities to evolve specifically in
              tetraploids, recapitulating chromosomal changes in genomically
              complex colorectal tumors. Finally, a genome-doubling event is
              independently predictive of poor relapse-free survival in
              early-stage disease in two independent cohorts in multivariate
              analyses [discovery data: hazard ratio (HR), 4.70, 95\%
              confidence interval (CI), 1.04-21.37; validation data: HR, 1.59,
              95\% CI, 1.05-2.42]. These data highlight an important role for
              the tolerance of genome doubling in driving cancer genome
              evolution. SIGNIFICANCE: Our work sheds light on the importance
              of whole-genome--doubling events in colorectal cancer evolution.
              We show that tetraploid cells undergo rapid genomic changes and
              recapitulate the genetic alterations seen in chromosomally
              unstable tumors. Furthermore, we demonstrate that a
              genome-doubling event is prognostic of poor relapse-free survival
              in this disease type.",
  journal  = "Cancer Discov.",
  volume   =  4,
  number   =  2,
  pages    = "175--185",
  month    =  feb,
  year     =  2014,
  language = "en"
}

@ARTICLE{Hanahan2022-ry,
  title    = "Hallmarks of Cancer: New Dimensions",
  author   = "Hanahan, Douglas",
  abstract = "The hallmarks of cancer conceptualization is a heuristic tool for
              distilling the vast complexity of cancer phenotypes and genotypes
              into a provisional set of underlying principles. As knowledge of
              cancer mechanisms has progressed, other facets of the disease
              have emerged as potential refinements. Herein, the prospect is
              raised that phenotypic plasticity and disrupted differentiation
              is a discrete hallmark capability, and that nonmutational
              epigenetic reprogramming and polymorphic microbiomes both
              constitute distinctive enabling characteristics that facilitate
              the acquisition of hallmark capabilities. Additionally, senescent
              cells, of varying origins, may be added to the roster of
              functionally important cell types in the tumor microenvironment.
              SIGNIFICANCE: Cancer is daunting in the breadth and scope of its
              diversity, spanning genetics, cell and tissue biology, pathology,
              and response to therapy. Ever more powerful experimental and
              computational tools and technologies are providing an avalanche
              of ``big data'' about the myriad manifestations of the diseases
              that cancer encompasses. The integrative concept embodied in the
              hallmarks of cancer is helping to distill this complexity into an
              increasingly logical science, and the provisional new dimensions
              presented in this perspective may add value to that endeavor, to
              more fully understand mechanisms of cancer development and
              malignant progression, and apply that knowledge to cancer
              medicine.",
  journal  = "Cancer Discov.",
  volume   =  12,
  number   =  1,
  pages    = "31--46",
  month    =  jan,
  year     =  2022,
  language = "en"
}

@ARTICLE{Matsushita2015-qc,
  title    = "Cytotoxic {T} lymphocytes block tumor growth both by lytic
              activity and {IFN$\gamma$-dependent} cell-cycle arrest",
  author   = "Matsushita, Hirokazu and Hosoi, Akihiro and Ueha, Satoshi and
              Abe, Jun and Fujieda, Nao and Tomura, Michio and Maekawa, Ryuji
              and Matsushima, Kouji and Ohara, Osamu and Kakimi, Kazuhiro",
  abstract = "To understand global effector mechanisms of CTL therapy, we
              performed microarray gene expression analysis in a murine model
              using pmel-1 T-cell receptor (TCR) transgenic T cells as
              effectors and B16 melanoma cells as targets. In addition to
              upregulation of genes related to antigen presentation and the MHC
              class I pathway, and cytotoxic effector molecules,
              cell-cycle-promoting genes were downregulated in the tumor on
              days 3 and 5 after CTL transfer. To investigate the impact of CTL
              therapy on the cell cycle of tumor cells in situ, we generated
              B16 cells expressing a fluorescent ubiquitination-based
              cell-cycle indicator (B16-fucci) and performed CTL therapy in
              mice bearing B16-fucci tumors. Three days after CTL transfer, we
              observed diffuse infiltration of CTLs into the tumor with a large
              number of tumor cells arrested at the G1 phase of the cell cycle,
              and the presence of spotty apoptotic or necrotic areas. Thus,
              tumor growth suppression was largely dependent on G1 cell-cycle
              arrest rather than killing by CTLs. Neutralizing antibody to
              IFN$\gamma$ prevented both tumor growth inhibition and G1 arrest.
              The mechanism of G1 arrest involved the downregulation of S-phase
              kinase-associated protein 2 (Skp2) and the accumulation of its
              target cyclin-dependent kinase inhibitor p27 in the B16-fucci
              tumor cells. Because tumor-infiltrating CTLs are far fewer in
              number than the tumor cells, we propose that CTLs predominantly
              regulate tumor growth via IFN$\gamma$-mediated profound
              cytostatic effects rather than via cytotoxicity. This dominance
              of G1 arrest over other mechanisms may be widespread but not
              universal because IFN$\gamma$ sensitivity varied among tumors.",
  journal  = "Cancer Immunol Res",
  volume   =  3,
  number   =  1,
  pages    = "26--36",
  month    =  jan,
  year     =  2015,
  keywords = "B16F10\_specific",
  language = "en"
}

@ARTICLE{Chen2015-zw,
  title    = "Combination of {4-1BB} agonist and {PD-1} antagonist promotes
              antitumor effector/memory {CD8} {T} cells in a poorly immunogenic
              tumor model",
  author   = "Chen, Shihao and Lee, Li-Fen and Fisher, Timothy S and Jessen,
              Bart and Elliott, Mark and Evering, Winston and Logronio, Kathryn
              and Tu, Guang Huan and Tsaparikos, Konstantinos and Li, Xiaoai
              and Wang, Hui and Ying, Chi and Xiong, Mengli and VanArsdale,
              Todd and Lin, John C",
  abstract = "Immunotherapies targeting the programmed death 1 (PD-1)
              coinhibitory receptor have shown great promise for a subset of
              patients with cancer. However, robust and safe combination
              therapies are still needed to bring the benefit of cancer
              immunotherapy to broader patient populations. To search for an
              optimal strategy of combinatorial immunotherapy, we have compared
              the antitumor activity of the anti-4-1BB/anti-PD-1 combination
              with that of the anti-PD-1/anti-LAG-3 combination in the poorly
              immunogenic B16F10 melanoma model. Pronounced tumor inhibition
              occurred only in animals receiving anti-PD-1 and anti-4-1BB
              concomitantly, while combining anti-PD-1 with anti-LAG-3 led to a
              modest degree of tumor suppression. The activity of the
              anti-4-1BB/anti-PD-1 combination was dependent on IFN$\gamma$ and
              CD8(+) T cells. Both 4-1BB and PD-1 proteins were elevated on the
              surface of CD8(+) T cells by anti-4-1BB/anti-PD-1 cotreatment. In
              the tumor microenvironment, an effective antitumor immune
              response was induced as indicated by the increased CD8(+)/Treg
              ratio and the enrichment of genes such as Cd3e, Cd8a, Ifng, and
              Eomes. In the spleen, the combination treatment shaped the immune
              system to an effector/memory phenotype and increased the overall
              activity of tumor-specific CD8(+) CTLs, reflecting a long-lasting
              systemic antitumor response. Furthermore, combination treatment
              in C57BL/6 mice showed no additional safety signals, and only
              minimally increased severity of the known toxicity relative to
              4-1BB agonist alone. Therefore, in the absence of any cancer
              vaccine, anti-4-1BB/anti-PD-1 combination therapy is sufficient
              to elicit a robust antitumor effector/memory T-cell response in
              an aggressive tumor model and is therefore a candidate for
              combination trials in patients.",
  journal  = "Cancer Immunol Res",
  volume   =  3,
  number   =  2,
  pages    = "149--160",
  month    =  feb,
  year     =  2015,
  keywords = "B16F10\_specific",
  language = "en"
}

@ARTICLE{Horton2018-tr,
  title    = "Intratumoral {CD8+} T-cell Apoptosis Is a Major Component of
              T-cell Dysfunction and Impedes Antitumor Immunity",
  author   = "Horton, Brendan L and Williams, Jason B and Cabanov, Alexandra
              and Spranger, Stefani and Gajewski, Thomas F",
  abstract = "Subsets of human tumors are infiltrated with tumor
              antigen-specific CD8+ T cells [tumor-infiltrating lymphocytes
              (TILs)] despite tumor progression. These TILs are thought to be
              inactivated by the immunosuppressive tumor microenvironment,
              through the engagement of inhibitory receptors such as CTLA-4 and
              PD-1. However, antigen-specific CD8+ TILs are not functionally
              inert but are undergoing activation in situ Here, we show that
              antigen-specific CD8+ TILs are actively proliferating, yet also
              undergo high rates of apoptosis, leading to a vicious cycle of
              activation and death that limits immune efficacy. Preventing CD8+
              TIL apoptosis by Bcl-xL overexpression enabled accumulation and
              improved tumor control. Effective combination immunotherapy with
              an agonist 4-1BB mAb plus either CTLA-4 or PD-L1 neutralization
              led to a marked accumulation of specific CD8+ TILs through
              decreased apoptosis rather than increased T-cell entry or
              proliferation. Our data suggest that antigen-driven apoptosis of
              CD8+ TILs is a barrier to effective spontaneous antitumor
              immunity and should be considered as a critical factor in the
              development of cancer immunotherapies. Cancer Immunol Res; 6(1);
              14-24. \copyright{}2017 AACR.",
  journal  = "Cancer Immunol Res",
  volume   =  6,
  number   =  1,
  pages    = "14--24",
  month    =  jan,
  year     =  2018,
  language = "en"
}

@ARTICLE{Nirmal2018-zf,
  title    = "Immune Cell Gene Signatures for Profiling the Microenvironment of
              Solid Tumors",
  author   = "Nirmal, Ajit J and Regan, Tim and Shih, Barbara B and Hume, David
              A and Sims, Andrew H and Freeman, Tom C",
  abstract = "The immune composition of the tumor microenvironment regulates
              processes including angiogenesis, metastasis, and the response to
              drugs or immunotherapy. To facilitate the characterization of the
              immune component of tumors from transcriptomics data, a number of
              immune cell transcriptome signatures have been reported that are
              made up of lists of marker genes indicative of the presence a
              given immune cell population. The majority of these gene
              signatures have been defined through analysis of isolated blood
              cells. However, blood cells do not reflect the differentiation or
              activation state of similar cells within tissues, including
              tumors, and consequently markers derived from blood cells do not
              necessarily transfer well to tissues. To address this issue, we
              generated a set of immune gene signatures derived directly from
              tissue transcriptomics data using a network-based deconvolution
              approach. We define markers for seven immune cell types,
              collectively named ImSig, and demonstrate how these markers can
              be used for the quantitative estimation of the immune cell
              content of tumor and nontumor tissue samples. The utility of
              ImSig is demonstrated through the stratification of melanoma
              patients into subgroups of prognostic significance and the
              identification of immune cells with the use of single-cell
              RNA-sequencing data derived from tumors. Use of ImSig is
              facilitated by an R package (imsig). Cancer Immunol Res; 6(11);
              1388-400. \copyright{}2018 AACR.",
  journal  = "Cancer Immunol Res",
  volume   =  6,
  number   =  11,
  pages    = "1388--1400",
  month    =  nov,
  year     =  2018,
  language = "en"
}

@ARTICLE{Chong2017-ob,
  title    = "Tortuous Microvessels Contribute to Wound Healing via Sprouting
              Angiogenesis",
  author   = "Chong, Diana C and Yu, Zhixian and Brighton, Hailey E and Bear,
              James E and Bautch, Victoria L",
  abstract = "OBJECTIVE: Wound healing is accompanied by neoangiogenesis, and
              new vessels are thought to originate primarily from the
              microcirculation; however, how these vessels form and resolve
              during wound healing is poorly understood. Here, we investigated
              properties of the smallest capillaries during wound healing to
              determine their spatial organization and the kinetics of
              formation and resolution. APPROACH AND RESULTS: We used
              intravital imaging and high-resolution microscopy to identify a
              new type of vessel in wounds, called tortuous microvessels.
              Longitudinal studies showed that tortuous microvessels increased
              in frequency after injury, normalized as the wound healed, and
              were closely associated with the wound site. Tortuous
              microvessels had aberrant cell shapes, increased permeability,
              and distinct interactions with circulating microspheres,
              suggesting altered flow dynamics. Moreover, tortuous microvessels
              disproportionately contributed to wound angiogenesis by sprouting
              exuberantly and significantly more frequently than nearby normal
              capillaries. CONCLUSIONS: A new type of transient wound vessel,
              tortuous microvessels, sprout dynamically and disproportionately
              contribute to wound-healing neoangiogenesis, likely as a result
              of altered properties downstream of flow disturbances. These new
              findings suggest entry points for therapeutic intervention.",
  journal  = "Arterioscler. Thromb. Vasc. Biol.",
  volume   =  37,
  number   =  10,
  pages    = "1903--1912",
  month    =  oct,
  year     =  2017,
  keywords = "angiogenesis; cell shape; intravital imaging; microcirculation;
              tortuous microvessels; wound healing",
  language = "en"
}

@ARTICLE{Levine2005-lm,
  title    = "Autophagy in cell death: an innocent convict?",
  author   = "Levine, Beth and Yuan, Junying",
  abstract = "The visualization of autophagosomes in dying cells has led to the
              belief that autophagy is a nonapoptotic form of programmed cell
              death. This concept has now been evaluated using cells and
              organisms deficient in autophagy genes. Most evidence indicates
              that, at least in cells with intact apoptotic machinery,
              autophagy is primarily a pro-survival rather than a pro-death
              mechanism. This review summarizes the evidence linking autophagy
              to cell survival and cell death, the complex interplay between
              autophagy and apoptosis pathways, and the role of
              autophagy-dependent survival and death pathways in clinical
              diseases.",
  journal  = "J. Clin. Invest.",
  volume   =  115,
  number   =  10,
  pages    = "2679--2688",
  month    =  oct,
  year     =  2005,
  language = "en"
}

@ARTICLE{Zhang2007-ti,
  title    = "Immune suppression or enhancement by {CD137} {T} cell
              costimulation during acute viral infection is time dependent",
  author   = "Zhang, Benyue and Maris, Charles H and Foell, Juergen and
              Whitmire, Jason and Niu, Liguo and Song, Jing and Kwon, Byoung S
              and Vella, Anthony T and Ahmed, Rafi and Jacob, Joshy and
              Mittler, Robert S",
  abstract = "CD137 is expressed on activated T cells and ligands to this
              costimulatory molecule have clinical potential for amplifying CD8
              T cell immunity to tumors and viruses, while suppressing CD4
              autoimmune T cell responses. To understand the basis for this
              dichotomy in T cell function, CD4 and CD8 antiviral immunity was
              measured in lymphocytic choriomeningitis virus (LCMV) Armstrong-
              or A/PR8/34 influenza-infected mice injected with anti-CD137
              mAbs. We found that the timing of administration of anti-CD137
              mAbs profoundly altered the nature of the antiviral immune
              response during acute infection. Antiviral immunity progressed
              normally for the first 72 hours when the mAb was administered
              early in infection before undergoing complete collapse by day 8
              postinfection. Anti-CD137-injected LCMV-infected mice became
              tolerant to, and persistently infected with, LCMV Armstrong.
              Elevated levels of IL-10 early in the response was key to the
              loss of CD4(+) T cells, whereas CD8(+) T cell deletion was
              dependent on a prolonged TNF-alpha response, IL-10, and
              upregulation of Fas. Blocking IL-10 function rescued CD4
              antiviral immunity but not CD8(+) T cell deletion. Anti-CD137
              treatment given beyond 72 hours after infection significantly
              enhanced antiviral immunity. Mice treated with anti-CD137 mAb 1
              day before infection with A/PR8/34 virus experienced 80\%
              mortality compared with 40\% mortality of controls. When
              treatment was delayed until day 1 postinfection, 100\% of the
              infected mice survived. These data show that anti-CD137 mAbs can
              induce T cell activation-induced cell death or enhance antiviral
              immunity depending on the timing of treatment, which may be
              important for vaccine development.",
  journal  = "J. Clin. Invest.",
  volume   =  117,
  number   =  10,
  pages    = "3029--3041",
  month    =  oct,
  year     =  2007,
  language = "en"
}

@ARTICLE{Breart2008-je,
  title    = "Two-photon imaging of intratumoral {CD8+} {T} cell cytotoxic
              activity during adoptive {T} cell therapy in mice",
  author   = "Breart, B{\'e}atrice and Lema{\^\i}tre, Fabrice and Celli,
              Susanna and Bousso, Philippe",
  abstract = "CTLs have the potential to attack tumors, and adoptive transfer
              of CTLs can lead to tumor regression in mouse models and human
              clinical settings. However, the dynamics of tumor cell
              elimination during efficient T cell therapy is unknown, and it is
              unclear whether CTLs act directly by destroying tumor cells or
              indirectly by initiating the recruitment of innate immune cells
              that mediate tumor damage. To address these questions, we report
              real-time imaging of tumor cell apoptosis in vivo using
              intravital 2-photon microscopy and a F{\"o}rster resonance energy
              transfer-based (FRET-based) reporter of caspase 3 activity. In a
              mouse model of solid tumor, we found that tumor regression after
              transfer of in vitro-activated CTLs occurred primarily through
              the direct action of CTLs on each individual tumor cell, with a
              minimal bystander effect. Surprisingly, the killing of 1 target
              cell by an individual CTL took an extended period of time, 6
              hours on average, which suggested that the slow rate of killing
              intrinsically limits the efficiency of antitumor T cell
              responses. The ability to visualize when, where, and how tumor
              cells are killed in vivo offers new perspectives for
              understanding how immune effectors survey cancer cells and how
              local tumor microenvironments may subvert immune responses.",
  journal  = "J. Clin. Invest.",
  volume   =  118,
  number   =  4,
  pages    = "1390--1397",
  month    =  apr,
  year     =  2008,
  language = "en"
}

% The entry below contains non-ASCII chars that could not be converted
% to a LaTeX equivalent.
@ARTICLE{Varadarajan2011-ti,
  title    = "A high-throughput single-cell analysis of human {CD8} {T} cell
              functions reveals discordance for cytokine secretion and
              cytolysis",
  author   = "Varadarajan, Navin and Julg, Boris and Yamanaka, Yvonne J and
              Chen, Huabiao and Ogunniyi, Adebola O and McAndrew, Elizabeth and
              Porter, Lindsay C and Piechocka-Trocha, Alicja and Hill, Brenna J
              and Douek, Daniel C and Pereyra, Florencia and Walker, Bruce D
              and Love, J Christopher",
  abstract = "CD8+ T cells are a key component of the adaptive immune response
              to viral infection. An inadequate CD8+ T cell response is thought
              to be partly responsible for the persistent chronic infection
              that arises following infection with HIV. It is therefore
              critical to identify ways to define what constitutes an adequate
              or inadequate response. IFN-$\gamma$ production has been used as
              a measure of T cell function, but the relationship between
              cytokine production and the ability of a cell to lyse
              virus-infected cells is not clear. Moreover, the ability to
              assess multiple CD8+ T cell functions with single-cell resolution
              using freshly isolated blood samples, and subsequently to recover
              these cells for further functional analyses, has not been
              achieved. As described here, to address this need, we have
              developed a high-throughput, automated assay in 125-pl microwells
              to simultaneously evaluate the ability of thousands of individual
              CD8+ T cells from HIV-infected patients to mediate lysis and to
              produce cytokines. This concurrent, direct analysis enabled us to
              investigate the correlation between immediate cytotoxic activity
              and short-term cytokine secretion. The majority of in vivo
              primed, circulating HIV-specific CD8+ T cells were discordant for
              cytolysis and cytokine secretion, notably IFN-$\gamma$, when
              encountering cognate antigen presented on defined numbers of
              cells. Our approach should facilitate determination of signatures
              of functional variance among individual effector CD8+ T cells,
              including those from mucosal samples and those induced by
              vaccines.",
  journal  = "J. Clin. Invest.",
  volume   =  121,
  number   =  11,
  pages    = "4322--4331",
  month    =  nov,
  year     =  2011,
  language = "en"
}

% The entry below contains non-ASCII chars that could not be converted
% to a LaTeX equivalent.
@ARTICLE{Varadarajan2011-bm,
  title    = "A high-throughput single-cell analysis of human {CD8} {T} cell
              functions reveals discordance for cytokine secretion and
              cytolysis",
  author   = "Varadarajan, Navin and Julg, Boris and Yamanaka, Yvonne J and
              Chen, Huabiao and Ogunniyi, Adebola O and McAndrew, Elizabeth and
              Porter, Lindsay C and Piechocka-Trocha, Alicja and Hill, Brenna J
              and Douek, Daniel C and Pereyra, Florencia and Walker, Bruce D
              and Love, J Christopher",
  abstract = "CD8+ T cells are a key component of the adaptive immune response
              to viral infection. An inadequate CD8+ T cell response is thought
              to be partly responsible for the persistent chronic infection
              that arises following infection with HIV. It is therefore
              critical to identify ways to define what constitutes an adequate
              or inadequate response. IFN-$\gamma$ production has been used as
              a measure of T cell function, but the relationship between
              cytokine production and the ability of a cell to lyse
              virus-infected cells is not clear. Moreover, the ability to
              assess multiple CD8+ T cell functions with single-cell resolution
              using freshly isolated blood samples, and subsequently to recover
              these cells for further functional analyses, has not been
              achieved. As described here, to address this need, we have
              developed a high-throughput, automated assay in 125-pl microwells
              to simultaneously evaluate the ability of thousands of individual
              CD8+ T cells from HIV-infected patients to mediate lysis and to
              produce cytokines. This concurrent, direct analysis enabled us to
              investigate the correlation between immediate cytotoxic activity
              and short-term cytokine secretion. The majority of in vivo
              primed, circulating HIV-specific CD8+ T cells were discordant for
              cytolysis and cytokine secretion, notably IFN-$\gamma$, when
              encountering cognate antigen presented on defined numbers of
              cells. Our approach should facilitate determination of signatures
              of functional variance among individual effector CD8+ T cells,
              including those from mucosal samples and those induced by
              vaccines.",
  journal  = "J. Clin. Invest.",
  volume   =  121,
  number   =  11,
  pages    = "4322--4331",
  month    =  nov,
  year     =  2011,
  language = "en"
}

@ARTICLE{Xiang2015-sg,
  title    = "Targeted inhibition of tumor-specific glutaminase diminishes
              cell-autonomous tumorigenesis",
  author   = "Xiang, Yan and Stine, Zachary E and Xia, Jinsong and Lu, Yunqi
              and O'Connor, Roddy S and Altman, Brian J and Hsieh, Annie L and
              Gouw, Arvin M and Thomas, Ajit G and Gao, Ping and Sun, Linchong
              and Song, Libing and Yan, Benedict and Slusher, Barbara S and
              Zhuo, Jingli and Ooi, London L and Lee, Caroline G L and Mancuso,
              Anthony and McCallion, Andrew S and Le, Anne and Milone, Michael
              C and Rayport, Stephen and Felsher, Dean W and Dang, Chi V",
  abstract = "Glutaminase (GLS), which converts glutamine to glutamate, plays a
              key role in cancer cell metabolism, growth, and proliferation.
              GLS is being explored as a cancer therapeutic target, but whether
              GLS inhibitors affect cancer cell-autonomous growth or the host
              microenvironment or have off-target effects is unknown. Here, we
              report that loss of one copy of Gls blunted tumor progression in
              an immune-competent MYC-mediated mouse model of hepatocellular
              carcinoma. Compared with results in untreated animals with
              MYC-induced hepatocellular carcinoma, administration of the
              GLS-specific inhibitor
              bis-2-(5-phenylacetamido-1,3,4-thiadiazol-2-yl)ethyl sulfide
              (BPTES) prolonged survival without any apparent toxicities. BPTES
              also inhibited growth of a MYC-dependent human B cell lymphoma
              cell line (P493) by blocking DNA replication, leading to cell
              death and fragmentation. In mice harboring P493 tumor xenografts,
              BPTES treatment inhibited tumor cell growth; however, P493
              xenografts expressing a BPTES-resistant GLS mutant (GLS-K325A) or
              overexpressing GLS were not affected by BPTES treatment.
              Moreover, a customized Vivo-Morpholino that targets human GLS
              mRNA markedly inhibited P493 xenograft growth without affecting
              mouse Gls expression. Conversely, a Vivo-Morpholino directed at
              mouse Gls had no antitumor activity in vivo. Collectively, our
              studies demonstrate that GLS is required for tumorigenesis and
              support small molecule and genetic inhibition of GLS as potential
              approaches for targeting the tumor cell-autonomous dependence on
              GLS for cancer therapy.",
  journal  = "J. Clin. Invest.",
  volume   =  125,
  number   =  6,
  pages    = "2293--2306",
  month    =  jun,
  year     =  2015,
  language = "en"
}

@ARTICLE{Lin2018-dg,
  title    = "Host expression of {PD-L1} determines efficacy of {PD-L1} pathway
              blockade-mediated tumor regression",
  author   = "Lin, Heng and Wei, Shuang and Hurt, Elaine M and Green, Michael D
              and Zhao, Lili and Vatan, Linda and Szeliga, Wojciech and Herbst,
              Ronald and Harms, Paul W and Fecher, Leslie A and Vats, Pankaj
              and Chinnaiyan, Arul M and Lao, Christopher D and Lawrence,
              Theodore S and Wicha, Max and Hamanishi, Junzo and Mandai, Masaki
              and Kryczek, Ilona and Zou, Weiping",
  abstract = "Programmed death-1 receptor (PD-L1, B7-H1) and programmed cell
              death protein 1 (PD-1) pathway blockade is a promising therapy
              for treating cancer. However, the mechanistic contribution of
              host and tumor PD-L1 and PD-1 signaling to the therapeutic
              efficacy of PD-L1 and PD-1 blockade remains elusive. Here, we
              evaluated 3 tumor-bearing mouse models that differ in their
              sensitivity to PD-L1 blockade and demonstrated a loss of
              therapeutic efficacy of PD-L1 blockade in immunodeficient mice
              and in PD-L1- and PD-1-deficient mice. In contrast, neither
              knockout nor overexpression of PD-L1 in tumor cells had an effect
              on PD-L1 blockade efficacy. Human and murine studies showed high
              levels of functional PD-L1 expression in dendritic cells and
              macrophages in the tumor microenvironments and draining lymph
              nodes. Additionally, expression of PD-L1 on dendritic cells and
              macrophages in ovarian cancer and melanoma patients correlated
              with the efficacy of treatment with either anti-PD-1 alone or in
              combination with anti-CTLA-4. Thus, PD-L1-expressing dendritic
              cells and macrophages may mechanistically shape and
              therapeutically predict clinical efficacy of PD-L1/PD-1 blockade.",
  journal  = "J. Clin. Invest.",
  volume   =  128,
  number   =  2,
  pages    = "805--815",
  month    =  feb,
  year     =  2018,
  keywords = "Cancer immunotherapy; Immunology",
  language = "en"
}

@ARTICLE{Ghatalia2018-br,
  title    = "Approved checkpoint inhibitors in bladder cancer: which drug
              should be used when?",
  author   = "Ghatalia, Pooja and Zibelman, Matthew and Geynisman, Daniel M and
              Plimack, Elizabeth",
  abstract = "The treatment of advanced metastatic urothelial carcinoma has
              recently evolved with the approval of five checkpoint inhibitors.
              In the second-line setting, in patients who have progressed on
              cisplatin-based chemotherapy, pembrolizumab, atezolizumab,
              durvalumab, nivolumab and avelumab are United States Food and
              Drug Administration (FDA) approved. In cisplatin-ineligible
              patients, atezolizumab and pembrolizumab are the FDA-approved
              checkpoint inhibitors. Here we describe the updated clinical
              efficacy of these checkpoint inhibitors in the treatment of
              advanced urothelial carcinoma and then suggest how they can be
              sequenced in the context of available chemotherapeutic options.
              For cisplatin-eligible patients, platinum-based chemotherapy
              remains the standard first-line treatment. For patients
              progressing on platinum-based therapy, phase III trials have been
              performed comparing pembrolizumab and atezolizumab separately
              with standard chemotherapy, and results favor the use of
              pembrolizumab.",
  journal  = "Ther. Adv. Med. Oncol.",
  volume   =  10,
  pages    = "1758835918788310",
  month    =  jul,
  year     =  2018,
  keywords = "checkpoint inhibitor; chemotherapy; immunotherapy; predictive
              biomarker; urothelial carcinoma",
  language = "en"
}

@ARTICLE{Carew2007-ts,
  title    = "Targeting autophagy augments the anticancer activity of the
              histone deacetylase inhibitor {SAHA} to overcome
              {Bcr-Abl-mediated} drug resistance",
  author   = "Carew, Jennifer S and Nawrocki, Steffan T and Kahue, Charissa N
              and Zhang, Hui and Yang, Chunying and Chung, Linda and Houghton,
              Janet A and Huang, Peng and Giles, Francis J and Cleveland, John
              L",
  abstract = "Novel therapeutic strategies are needed to address the emerging
              problem of imatinib resistance. The histone deacetylase (HDAC)
              inhibitor suberoylanilide hydroxamic acid (SAHA) is being
              evaluated for imatinib-resistant chronic myelogenous leukemia
              (CML) and has multiple cellular effects, including the induction
              of autophagy and apoptosis. Considering that autophagy may
              promote cancer cell survival, we hypothesized that disrupting
              autophagy would augment the anticancer activity of SAHA. Here we
              report that drugs that disrupt the autophagy pathway dramatically
              augment the antineoplastic effects of SAHA in CML cell lines and
              primary CML cells expressing wild-type and imatinib-resistant
              mutant forms of Bcr-Abl, including T315I. This regimen has
              selectivity for malignant cells and its efficacy was not
              diminished by impairing p53 function, another contributing factor
              in imatinib resistance. Disrupting autophagy by chloroquine
              treatment enhances SAHA-induced superoxide generation, triggers
              relocalization and marked increases in the lysosomal protease
              cathepsin D, and reduces the expression of the cathepsin-D
              substrate thioredoxin. Finally, knockdown of cathepsin D
              diminishes the potency of this combination, demonstrating its
              role as a mediator of this therapeutic response. Our data suggest
              that, when combined with HDAC inhibitors, agents that disrupt
              autophagy are a promising new strategy to treat
              imatinib-refractory patients who fail conventional therapy.",
  journal  = "Blood",
  volume   =  110,
  number   =  1,
  pages    = "313--322",
  month    =  jul,
  year     =  2007,
  language = "en"
}

@ARTICLE{Louis2011-iy,
  title    = "Antitumor activity and long-term fate of chimeric antigen
              receptor-positive {T} cells in patients with neuroblastoma",
  author   = "Louis, Chrystal U and Savoldo, Barbara and Dotti, Gianpietro and
              Pule, Martin and Yvon, Eric and Myers, G Doug and Rossig, Claudia
              and Russell, Heidi V and Diouf, Oumar and Liu, Enli and Liu, Hao
              and Wu, Meng-Fen and Gee, Adrian P and Mei, Zhuyong and Rooney,
              Cliona M and Heslop, Helen E and Brenner, Malcolm K",
  abstract = "We generated MHC-independent chimeric antigen receptors (CARs)
              directed to the GD2 antigen expressed by neuroblastoma tumor
              cells and treated patients with this disease. Two distinguishable
              forms of this CAR were expressed in EBV-specific cytotoxic T
              lymphocytes (EBV-CTLs) and activated T cells (ATCs). We have
              previously shown that EBV-CTLs expressing GD2-CARs (CAR-CTLs)
              circulated at higher levels than GD2-CAR ATCs (CAR-ATCs) early
              after infusion, but by 6 weeks, both subsets became low or
              undetectable. We now report the long-term clinical and
              immunologic consequences of infusions in 19 patients with
              high-risk neuroblastoma: 8 in remission at infusion and 11 with
              active disease. Three of 11 patients with active disease achieved
              complete remission, and persistence of either CAR-ATCs or
              CAR-CTLs beyond 6 weeks was associated with superior clinical
              outcome. We observed persistence for up to 192 weeks for CAR-ATCs
              and 96 weeks for CAR-CTLs, and duration of persistence was highly
              concordant with the percentage of CD4(+) cells and central memory
              cells (CD45RO(+)CD62L(+)) in the infused product. In conclusion,
              GD2-CAR T cells can induce complete tumor responses in patients
              with active neuroblastoma; these CAR T cells may have extended,
              low-level persistence in patients, and such persistence was
              associated with longer survival. This study is registered at
              www.clinialtrials.gov as \#NCT00085930.",
  journal  = "Blood",
  volume   =  118,
  number   =  23,
  pages    = "6050--6056",
  month    =  dec,
  year     =  2011,
  language = "en"
}

@ARTICLE{Jacque2015-ad,
  title    = "Targeting glutaminolysis has antileukemic activity in acute
              myeloid leukemia and synergizes with {BCL-2} inhibition",
  author   = "Jacque, Nathalie and Ronchetti, Anne Marie and Larrue,
              Cl{\'e}ment and Meunier, Godelieve and Birsen, Rudy and Willems,
              Lise and Saland, Estelle and Decroocq, Justine and Maciel, Thiago
              Trovati and Lambert, Mireille and Poulain, Laury and Hospital,
              Marie Anne and Sujobert, Pierre and Joseph, Laure and Chapuis,
              Nicolas and Lacombe, Catherine and Moura, Ivan Cruz and Demo,
              Susan and Sarry, Jean Emmanuel and Recher, Christian and Mayeux,
              Patrick and Tamburini, J{\'e}r{\^o}me and Bouscary, Didier",
  abstract = "Cancer cells require glutamine to adapt to increased biosynthetic
              activity. The limiting step in intracellular glutamine catabolism
              involves its conversion to glutamate by glutaminase (GA).
              Different GA isoforms are encoded by the genes GLS1 and GLS2 in
              humans. Herein, we show that glutamine levels control
              mitochondrial oxidative phosphorylation (OXPHOS) in acute myeloid
              leukemia (AML) cells. Glutaminase C (GAC) is the GA isoform that
              is most abundantly expressed in AML. Both knockdown of GLS1
              expression and pharmacologic GLS1 inhibition by the drug CB-839
              can reduce OXPHOS, leading to leukemic cell proliferation arrest
              and apoptosis without causing cytotoxic activity against normal
              human CD34(+) progenitors. Strikingly, GLS1 knockdown
              dramatically inhibited AML development in NSG mice. The
              antileukemic activity of CB-839 was abrogated by both the
              expression of a hyperactive GAC(K320A) allele and the addition of
              the tricarboxyclic acid cycle product $\alpha$-ketoglutarate,
              indicating the critical function of GLS1 in AML cell survival.
              Finally, glutaminolysis inhibition activated mitochondrial
              apoptosis and synergistically sensitized leukemic cells to
              priming with the BCL-2 inhibitor ABT-199. These findings show
              that targeting glutamine addiction via GLS1 inhibition offers a
              potential novel therapeutic strategy for AML.",
  journal  = "Blood",
  volume   =  126,
  number   =  11,
  pages    = "1346--1356",
  month    =  sep,
  year     =  2015,
  language = "en"
}

@ARTICLE{Chester2018-ig,
  title    = "Immunotherapy targeting {4-1BB}: mechanistic rationale, clinical
              results, and future strategies",
  author   = "Chester, Cariad and Sanmamed, Miguel F and Wang, Jun and Melero,
              Ignacio",
  abstract = "4-1BB (CD137, tumor necrosis factor receptor superfamily 9) is an
              inducible costimulatory receptor expressed on activated T and
              natural killer (NK) cells. 4-1BB ligation on T cells triggers a
              signaling cascade that results in upregulation of antiapoptotic
              molecules, cytokine secretion, and enhanced effector function. In
              dysfunctional T cells that have a decreased cytotoxic capacity,
              4-1BB ligation demonstrates a potent ability to restore effector
              functions. On NK cells, 4-1BB signaling can increase
              antibody-dependent cell-mediated cytotoxicity. Agonistic
              monoclonal antibodies targeting 4-1BB have been developed to
              harness 4-1BB signaling for cancer immunotherapy. Preclinical
              results in a variety of induced and spontaneous tumor models
              suggest that targeting 4-1BB with agonist antibodies can lead to
              tumor clearance and durable antitumor immunity. Clinical trials
              of 2 agonist antibodies, urelumab and utomilumab, are ongoing.
              Despite initial signs of efficacy, clinical development of
              urelumab has been hampered by inflammatory liver toxicity at
              doses >1 mg/kg. Utomilumab has a superior safety profile, but is
              a less potent 4-1BB agonist relative to urelumab. Both antibodies
              have demonstrated promising results in patients with lymphoma and
              are being tested in combination therapy trials with other
              immunomodulatory agents. In an effort to optimally leverage
              4-1BB-mediated immune activation, the next generation of 4-1BB
              targeting strategies attempts to decouple the observed antitumor
              efficacy from the on-target liver toxicity. Multiple therapeutics
              that attempt to restrict 4-1BB agonism to the tumor
              microenvironment and minimize systemic exposure have emerged.
              4-1BB is a compelling target for cancer immunotherapy and future
              agents show great promise for achieving potent immune activation
              while avoiding limiting immune-related adverse events.",
  journal  = "Blood",
  volume   =  131,
  number   =  1,
  pages    = "49--57",
  month    =  jan,
  year     =  2018,
  language = "en"
}

@ARTICLE{Stein2014-br,
  title    = "{AG-221}, an Oral, Selective, {First-in-Class}, Potent Inhibitor
              of the {IDH2} Mutant Metabolic Enzyme, Induces Durable Remissions
              in a Phase {I} Study in Patients with {IDH2} Mutation Positive
              Advanced Hematologic Malignancies",
  author   = "Stein, Eytan M and Altman, Jessica K and Collins, Robert and
              DeAngelo, Daniel J and Fathi, Amir T and Flinn, Ian and Frankel,
              Arthur and Levine, Ross L and Medeiros, Bruno C and Patel, Manish
              and Pollyea, Daniel A and Roboz, Gail J and Stone, Richard M and
              Swords, Ronan T and Tallman, Martin S and Agresta, Sam and Fan,
              Bin and Yang, Hua and Yen, Katharine and de Botton, St{\'e}phane",
  abstract = "INTRODUCTION:Somatic mutations in the metabolic enzymes
              isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) confer
              gain-of-function activity in cancer cells, resulting in
              accumulation of the oncometabolite, R-2-hydroxyglutarate (2-HG).
              High levels of 2-HG result in epigenetic changes and impaired
              cellular differentiation. IDH mutations have been identified in a
              spectrum of solid tumors and hematologic malignancies. AG-221 is
              a first-in-class, oral, potent, reversible, selective inhibitor
              of the IDH2 mutant enzyme. Data from the ongoing, first-in-human,
              Phase I, open-label, dose escalation study of AG-221 are
              presented here [NCT01915498]. METHODS: Patients with advanced
              IDH2 mutation-positive hematologic malignancies are receiving
              AG-221 as a single-agent orally once daily (QD) or twice daily
              (BID) continuously, in 28-day cycles. The dose in the first
              cohort was 30 mg BID and sequentially higher dose levels are now
              ongoing at QD and BID dosing regimens; planned expansion cohorts
              will be enrolled once the recommended Phase II dose is
              identified. Bone marrow is examined on Days 15, 29, 57, and every
              56 days thereafter. The primary objectives are safety and
              determination of maximum tolerated dose (MTD) and to select a
              dose and schedule for the expansion cohorts and future Phase II
              studies. Secondary objectives include clinical activity assessed
              by investigators using International Working Group Criteria,
              pharmacokinetics (PK) and pharmacodynamics (PD). RESULTS:Since
              study start in September 2013, 48 patients have been dosed and 27
              are on study drug as of July 24, 2014. Parallel BID and QD cohort
              regimens are ongoing at doses up to 150 mg and 200 mg,
              respectively. Therapy has been well tolerated and the MTD has not
              yet been reached. The majority of adverse events reported have
              been grade 1 and 2. There have been 9 deaths and 8 within the
              first 28 days of receiving AG-221. One death reported as possibly
              related to study drug in a subject with severe pneumonia. Eight
              subjects have had 11 SAEs reported as possibly related to study
              drug. Preliminary PK analysis of the 30 mg through 75 mg BID and
              100 mg QD doses demonstrated excellent exposure to AG-221, high
              accumulation after multiple doses, and a mean plasma half-life
              >40 hours. PD evaluation demonstrated sustained plasma 2-HG
              inhibition up to 97\% in R140Q subjects and up to 50\% in R172K
              subjects after multiple doses. As of July 24, 2014, 48 subjects
              have been enrolled: 32 are evaluable for efficacy (having had a
              Day 28 bone marrow), 8 discontinued study prior to Day 28, and 8
              are on study but prior to a Day 28 bone marrow assessment.
              Investigator-assessed objective responses have been observed in
              20 subjects (8 CR, 1 CRp, 3 CRi and 8 PR).Five subjects had
              stable disease and remain on AG-221. Seven subjects have had
              progressive disease. Responses are durable, including complete
              remissions of up to 4.5 months and ongoing with subjects on study
              as long as 8 cycles (1 cycle = 28 days). Five subjects who
              achieved a CR went on to bone marrow transplantation. Additional
              and updated safety, PK/PD and efficacy data from the enrolled
              subjects will be presented. CONCLUSION: AG-221, a potent,
              selective, oral inhibitor of mutated IDH2, is well tolerated in
              patients with advanced hematologic malignancies, and triggers the
              differentiation of leukemic blast cells that ultimately leads to
              objective durable responses, including complete remissions. These
              data provide continued validation of mutant IDH2 as a therapeutic
              cancer target. Disclosures Stein:Janssen Pharmaceuticals:
              Consultancy. Altman:Astellas: Advisory board Other; Ariad:
              Advisory board, Advisory board Other; Spectrum: Advisory board,
              Advisory board Other; Teva: Advisory board, Advisory board Other;
              Novartis: Advisory board Other; BMS: Advisory board Other;
              Foundation Medicine: Advisory board Other; Ambit: Advisory board,
              Advisory board Other. Fathi:Agios Pharmaceuticals: Advisory board
              participation Other. Medeiros:Agios: Consulting - Ad board Other.
              Pollyea:Agios: Advisory board membership Other. Roboz:Agios:
              Consultation Other. Stone:Agios: Consultancy; AbbVie:
              Consultancy; Amgen: Consultancy; Celator: Consultancy; Celgene:
              Consultancy; Roche: Consultancy. Tallman:Seattle Genetics:
              Personal fee Other; Amgen: Personal fee, Personal fee Other;
              Medlogix Communications: Personal fee, Personal fee Other;
              Bioline Rx: Personal fee, Personal fee Other;
              Boehringer-Ingelheim: Personal fee Other; Celgene: Personal fee
              Other; Clavis Pharmaceuticals: Personal fee Other; Astex
              Pharmaceuticals: Personal fee, Personal fee Other; Agios
              Pharmaceuticals: Non-financial support, Non-financial support
              Other. Agresta:Agios Pharmaceuticals: Employment, Stockholder
              Other. Fan:Agios Pharmaceuticals: Employment, Stockholder Other.
              Yang:Agios Pharmaceuticals: Employment, Stockholder Other.
              Yen:Agios: Employment. de Botton:AGIOS: Grant Other.",
  journal  = "Blood",
  volume   =  124,
  number   =  21,
  pages    = "115",
  month    =  dec,
  year     =  2014
}

@ARTICLE{Durrbaum2014-gr,
  title    = "Unique features of the transcriptional response to model
              aneuploidy in human cells",
  author   = "D{\"u}rrbaum, Milena and Kuznetsova, Anastasia Yurievna and
              Passerini, Verena and Stingele, Silvia and Stoehr, Gabriele and
              Storchov{\'a}, Zuzana",
  abstract = "BACKGROUND: Aneuploidy, a karyotype deviating from multiples of a
              haploid chromosome set, affects the physiology of eukaryotes. In
              humans, aneuploidy is linked to pathological defects such as
              developmental abnormalities, mental retardation or cancer, but
              the underlying mechanisms remain elusive. There are many
              different types and origins of aneuploidy, but whether there is a
              uniform cellular response to aneuploidy in human cells has not
              been addressed so far. RESULTS: Here we evaluate the
              transcription profiles of eleven trisomic and tetrasomic cell
              lines and two cell lines with complex aneuploid karyotypes. We
              identify a characteristic aneuploidy response pattern defined by
              upregulation of genes linked to endoplasmic reticulum, Golgi
              apparatus and lysosomes, and downregulation of DNA replication,
              transcription as well as ribosomes. Strikingly, complex
              aneuploidy elicits the same transcriptional changes as trisomy.
              To uncover the triggers of the response, we compared the profiles
              with transcription changes in human cells subjected to stress
              conditions. Interestingly, we found an overlap only with the
              response to treatment with the autophagy inhibitor bafilomycin
              A1. Finally, we identified 23 genes whose expression is
              significantly altered in all aneuploids and which may thus serve
              as aneuploidy markers. CONCLUSIONS: Our analysis shows that
              despite the variability in chromosome content, aneuploidy
              triggers uniform transcriptional response in human cells. A
              common response independent of the type of aneuploidy might be
              exploited as a novel target for cancer therapy. Moreover, the
              potential aneuploidy markers identified in our analysis might
              represent novel biomarkers to assess the malignant potential of a
              tumor.",
  journal  = "BMC Genomics",
  volume   =  15,
  pages    = "139",
  month    =  feb,
  year     =  2014,
  keywords = "energetics of aneuploidy",
  language = "en"
}

@ARTICLE{Kato2013-nv,
  title    = "Acidic extracellular microenvironment and cancer",
  author   = "Kato, Yasumasa and Ozawa, Shigeyuki and Miyamoto, Chihiro and
              Maehata, Yojiro and Suzuki, Atsuko and Maeda, Toyonobu and Baba,
              Yuh",
  abstract = "Acidic extracellular pH is a major feature of tumor tissue,
              extracellular acidification being primarily considered to be due
              to lactate secretion from anaerobic glycolysis.
              Clinicopathological evidence shows that transporters and pumps
              contribute to H+ secretion, such as the Na+/H+ exchanger, the
              H+-lactate co-transporter, monocarboxylate transporters, and the
              proton pump (H+-ATPase); these may also be associated with tumor
              metastasis. An acidic extracellular pH not only activates
              secreted lysosomal enzymes that have an optimal pH in the acidic
              range, but induces the expression of certain genes of
              pro-metastatic factors through an intracellular signaling cascade
              that is different from hypoxia. In addition to lactate, CO2 from
              the pentose phosphate pathway is an alternative source of
              acidity, showing that hypoxia and extracellular acidity are,
              while being independent from each other, deeply associated with
              the cellular microenvironment. In this article, the importance of
              an acidic extracellular pH as a microenvironmental factor
              participating in tumor progression is reviewed.",
  journal  = "Cancer Cell Int.",
  volume   =  13,
  number   =  1,
  pages    = "89",
  month    =  sep,
  year     =  2013,
  language = "en"
}

@ARTICLE{Wang2013-ni,
  title    = "Multi-scale agent-based modeling on melanoma and its related
              angiogenesis analysis",
  author   = "Wang, Jun and Zhang, Le and Jing, Chenyang and Ye, Gang and Wu,
              Hulin and Miao, Hongyu and Wu, Yukun and Zhou, Xiaobo",
  abstract = "BACKGROUND: Recently, melanoma has become the most malignant and
              commonly occurring skin cancer. Melanoma is not only the major
              source (75\%) of deaths related to skin cancer, but also it is
              hard to be treated by the conventional drugs. Recent research
              indicated that angiogenesis is an important factor for tumor
              initiation, expansion, and response to therapy. Thus, we proposed
              a novel multi-scale agent-based computational model that
              integrates the angiogenesis into tumor growth to study the
              response of melanoma cancer under combined drug treatment.
              RESULTS: Our multi-scale agent-based model can simulate the
              melanoma tumor growth with angiogenesis under combined drug
              treatment. The significant synergistic effects between drug Dox
              and drug Sunitinib demonstrated the clinical potential to
              interrupt the communication between melanoma cells and its
              related vasculatures. Also, the sensitivity analysis of the model
              revealed that diffusivity related to the micro-vasculatures
              around tumor tissues closely correlated with the spread,
              oscillation and destruction of the tumor. CONCLUSIONS: Simulation
              results showed that the 3D model can represent key features of
              melanoma growth, angiogenesis, and its related micro-environment.
              The model can help cancer researchers understand the melanoma
              developmental mechanism. Drug synergism analysis suggested that
              interrupting the communications between melanoma cells and the
              related vasculatures can significantly increase the drug efficacy
              against tumor cells.",
  journal  = "Theor. Biol. Med. Model.",
  volume   =  10,
  pages    = "41",
  month    =  jun,
  year     =  2013,
  language = "en"
}

@ARTICLE{Murphy2016-an,
  title    = "Differences in predictions of {ODE} models of tumor growth: a
              cautionary example",
  author   = "Murphy, Hope and Jaafari, Hana and Dobrovolny, Hana M",
  abstract = "BACKGROUND: While mathematical models are often used to predict
              progression of cancer and treatment outcomes, there is still
              uncertainty over how to best model tumor growth. Seven ordinary
              differential equation (ODE) models of tumor growth (exponential,
              Mendelsohn, logistic, linear, surface, Gompertz, and Bertalanffy)
              have been proposed, but there is no clear guidance on how to
              choose the most appropriate model for a particular cancer.
              METHODS: We examined all seven of the previously proposed ODE
              models in the presence and absence of chemotherapy. We derived
              equations for the maximum tumor size, doubling time, and the
              minimum amount of chemotherapy needed to suppress the tumor and
              used a sample data set to compare how these quantities differ
              based on choice of growth model. RESULTS: We find that there is a
              12-fold difference in predicting doubling times and a 6-fold
              difference in the predicted amount of chemotherapy needed for
              suppression depending on which growth model was used. CONCLUSION:
              Our results highlight the need for careful consideration of model
              assumptions when developing mathematical models for use in cancer
              treatment planning.",
  journal  = "BMC Cancer",
  volume   =  16,
  pages    = "163",
  month    =  feb,
  year     =  2016,
  language = "en"
}

@ARTICLE{Bowers2022-el,
  title    = "Autophagy modulating therapeutics inhibit ovarian cancer colony
              generation by polyploid giant cancer cells ({PGCCs})",
  author   = "Bowers, Robert R and Andrade, Maya F and Jones, Christian M and
              White-Gilbertson, Shai and Voelkel-Johnson, Christina and
              Delaney, Joe R",
  abstract = "BACKGROUND: Genomic instability and chemoresistance can arise in
              cancer due to a unique form of plasticity: that of polyploid
              giant cancer cells (PGCCs). These cells form under the stress of
              chemotherapy and have higher than diploid chromosome content.
              PGCCs are able to then repopulate tumors through an asymmetric
              daughter cell budding process. PGCCs have been observed in
              ovarian cancer histology, including the deadly and common form
              high-grade serous ovarian carcinoma (HGSC). We previously
              discovered that drugs which disrupt the cellular recycling
              process of autophagy are uniquely efficacious in pre-clinical
              HGSC models. While autophagy induction has been associated with
              PGCCs, it has never been previously investigated if autophagy
              modulation interacts with the PGCC life cycle and this form of
              tumor cell plasticity. METHODS: CAOV3 and OVCAR3 ovarian cancer
              cell lines were treated with carboplatin or docetaxel to induce
              PGCC formation. Microscopy was used to characterize and quantify
              PGCCs formed by chemotherapy. Two clinically available drugs that
              inhibit autophagy, hydroxychloroquine and nelfinavir, and a
              clinically available activator of autophagy, rapamycin, were
              employed to test the effect of these autophagy modulators on PGCC
              induction and subsequent colony formation from PGCCs. Crystal
              violet-stained colony formation assays were used to quantify the
              tumor-repopulating stage of the PGCC life cycle. RESULTS:
              Autophagy inhibitors did not prevent PGCC formation in OVCAR3 or
              CAOV3 cells. Rapamycin did not induce PGCC formation on its own
              nor did it exacerbate PGCC formation by chemotherapy. However,
              hydroxychloroquine prevented efficient colony formation in CAOV3
              PGCCs induced by carboplatin (27\% inhibition) or docetaxel (41\%
              inhibition), as well as in OVCAR3 cells (95\% and 77\%,
              respectively). Nelfinavir similarly prevented colony formation in
              CAOV3 PGCCs induced by carboplatin (64\% inhibition) or docetaxel
              (94\% inhibition) as well as in OVCAR3 cells (89\% and 80\%,
              respectively). Rapamycin surprisingly also prevented PGCC colony
              outgrowth (52-84\% inhibition). CONCLUSIONS: While the autophagy
              previously observed to correlate with PGCC formation is unlikely
              necessary for PGCCs to form, autophagy modulating drugs severely
              impair the ability of HGSC PGCCs to form colonies. Clinical
              trials which utilize hydroxychloroquine, nelfinavir, and/or
              rapamycin after chemotherapy may be of future interest.",
  journal  = "BMC Cancer",
  volume   =  22,
  number   =  1,
  pages    = "410",
  month    =  apr,
  year     =  2022,
  keywords = "Aneuploidy; Autophagy; Cancer recurrence; Chemoresistance;
              Neosis; Ovarian cancer; Polyploid giant cancer cells (PGCCs);
              Senescence; Whole genome doubling",
  language = "en"
}

@ARTICLE{Larrimore2020-ax,
  title    = "Aneuploidy-induced proteotoxic stress can be effectively
              tolerated without dosage compensation, genetic mutations, or
              stress responses",
  author   = "Larrimore, Katherine E and Barattin-Voynova, Natalia S and Reid,
              David W and Ng, Davis T W",
  abstract = "BACKGROUND: The protein homeostasis (proteostasis) network
              maintains balanced protein synthesis, folding, transport, and
              degradation within a cell. Failure to maintain proteostasis is
              associated with aging and disease, leading to concerted efforts
              to study how the network responds to various proteotoxic
              stresses. This is often accomplished using ectopic overexpression
              of well-characterized, model misfolded protein substrates.
              However, how cells tolerate large-scale, diverse burden to the
              proteostasis network is not understood. Aneuploidy, the state of
              imbalanced chromosome content, adversely affects the proteostasis
              network by dysregulating the expression of hundreds of proteins
              simultaneously. Using aneuploid haploid yeast cells as a model,
              we address whether cells can tolerate large-scale, diverse
              challenges to the proteostasis network. RESULTS: Here we
              characterize several aneuploid Saccharomyces cerevisiae strains
              isolated from a collection of stable, randomly generated yeast
              aneuploid cells. These strains exhibit robust growth and
              resistance to multiple drugs which induce various forms of
              proteotoxic stress. Whole genome re-sequencing of the strains
              revealed this was not the result of genetic mutations, and
              transcriptome profiling combined with ribosome footprinting
              showed that genes are expressed and translated in accordance to
              chromosome copy number. In some strains, various facets of the
              proteostasis network are mildly upregulated without chronic
              activation of environmental stress response or heat shock
              response pathways. No severe defects were observed in the
              degradation of misfolded proteins, using model misfolded
              substrates of endoplasmic reticulum-associated degradation or
              cytosolic quality control pathways, and protein biosynthesis
              capacity was not impaired. CONCLUSIONS: We show that yeast
              strains of some karyotypes in the genetic background studied here
              can tolerate the large aneuploidy-associated burden to the
              proteostasis machinery without genetic changes, dosage
              compensation, or activation of canonical stress response
              pathways. We suggest that proteotoxic stress, while common, is
              not always an obligate consequence of aneuploidy, but rather
              certain karyotypes and genetic backgrounds may be able to
              tolerate the excess protein burden placed on the protein
              homeostasis machinery. This may help clarify how cancer cells are
              paradoxically both highly aneuploid and highly proliferative at
              the same time.",
  journal  = "BMC Biol.",
  volume   =  18,
  number   =  1,
  pages    = "117",
  month    =  sep,
  year     =  2020,
  keywords = "Aneuploidy; Protein homeostasis; Protein quality control;
              Proteostasis; Proteotoxic stress",
  language = "en"
}

@ARTICLE{Deng2021-uv,
  title    = "Measuring and modeling energy and power consumption in living
              microbial cells with a synthetic {ATP} reporter",
  author   = "Deng, Yijie and Beahm, Douglas Raymond and Ionov, Steven and
              Sarpeshkar, Rahul",
  abstract = "BACKGROUND: Adenosine triphosphate (ATP) is the main energy
              carrier in living organisms, critical for metabolism and
              essential physiological processes. In humans, abnormal regulation
              of energy levels (ATP concentration) and power consumption (ATP
              consumption flux) in cells is associated with numerous diseases
              from cancer, to viral infection and immune dysfunction, while in
              microbes it influences their responses to drugs and other
              stresses. The measurement and modeling of ATP dynamics in cells
              is therefore a critical component in understanding fundamental
              physiology and its role in pathology. Despite the importance of
              ATP, our current understanding of energy dynamics and homeostasis
              in living cells has been limited by the lack of easy-to-use ATP
              sensors and the lack of models that enable accurate estimates of
              energy and power consumption related to these ATP dynamics. Here
              we describe a dynamic model and an ATP reporter that tracks ATP
              in E. coli over different growth phases. RESULTS: The reporter is
              made by fusing an ATP-sensing rrnB P1 promoter with a
              fast-folding and fast-degrading GFP. Good correlations between
              reporter GFP and cellular ATP were obtained in E. coli growing in
              both minimal and rich media and in various strains. The ATP
              reporter can reliably monitor bacterial ATP dynamics in response
              to nutrient availability. Fitting the dynamics of experimental
              data corresponding to cell growth, glucose, acetate, dissolved
              oxygen, and ATP yielded a mathematical and circuit model. This
              model can accurately predict cellular energy and power
              consumption under various conditions. We found that cellular
              power consumption varies significantly from approximately 0.8 and
              0.2 million ATP/s for a tested strain during lag and stationary
              phases to 6.4 million ATP/s during exponential phase, indicating
              ~ 8-30-fold changes of metabolic rates among different growth
              phases. Bacteria turn over their cellular ATP pool a few times
              per second during the exponential phase and slow this rate by ~
              2-5-fold in lag and stationary phases. CONCLUSION: Our rrnB
              P1-GFP reporter and kinetic circuit model provide a fast and
              simple way to monitor and predict energy and power consumption
              dynamics in bacterial cells, which can impact fundamental
              scientific studies and applied medical treatments in the future.",
  journal  = "BMC Biol.",
  volume   =  19,
  number   =  1,
  pages    = "101",
  month    =  may,
  year     =  2021,
  keywords = "ATP biosensor; ATP dynamics; Bacterial kinetics; Cell energetics;
              Cellular power consumption; Kinetic circuit models; Metabolism",
  language = "en"
}

@ARTICLE{Farkona2016-re,
  title    = "Cancer immunotherapy: the beginning of the end of cancer?",
  author   = "Farkona, Sofia and Diamandis, Eleftherios P and Blasutig, Ivan M",
  abstract = "These are exciting times for cancer immunotherapy. After many
              years of disappointing results, the tide has finally changed and
              immunotherapy has become a clinically validated treatment for
              many cancers. Immunotherapeutic strategies include cancer
              vaccines, oncolytic viruses, adoptive transfer of ex vivo
              activated T and natural killer cells, and administration of
              antibodies or recombinant proteins that either costimulate cells
              or block the so-called immune checkpoint pathways. The recent
              success of several immunotherapeutic regimes, such as monoclonal
              antibody blocking of cytotoxic T lymphocyte-associated protein 4
              (CTLA-4) and programmed cell death protein 1 (PD1), has boosted
              the development of this treatment modality, with the consequence
              that new therapeutic targets and schemes which combine various
              immunological agents are now being described at a breathtaking
              pace. In this review, we outline some of the main strategies in
              cancer immunotherapy (cancer vaccines, adoptive cellular
              immunotherapy, immune checkpoint blockade, and oncolytic viruses)
              and discuss the progress in the synergistic design of
              immune-targeting combination therapies.",
  journal  = "BMC Med.",
  volume   =  14,
  pages    = "73",
  month    =  may,
  year     =  2016,
  keywords = "Adoptive cellular therapy; Cancer; Cytotoxic T
              lymphocyte-associated protein 4; Immune checkpoint blockade;
              Immunotherapy; Programmed cell death protein 1; T cells",
  language = "en"
}

@ARTICLE{Viner-Breuer2019-sh,
  title    = "The essentiality landscape of cell cycle related genes in human
              pluripotent and cancer cells",
  author   = "Viner-Breuer, Ruth and Yilmaz, Atilgan and Benvenisty, Nissim and
              Goldberg, Michal",
  abstract = "BACKGROUND: Cell cycle regulation is a complex system consisting
              of growth-promoting and growth-restricting mechanisms, whose
              coordinated activity is vital for proper division and
              propagation. Alterations in this regulation may lead to
              uncontrolled proliferation and genomic instability, triggering
              carcinogenesis. Here, we conducted a comprehensive bioinformatic
              analysis of cell cycle-related genes using data from CRISPR/Cas9
              loss-of-function screens performed in four cancer cell lines and
              in human embryonic stem cells (hESCs). RESULTS: Cell cycle genes,
              and in particular S phase and checkpoint genes, are highly
              essential for the growth of cancer and pluripotent cells.
              However, checkpoint genes are also found to underlie the
              differences between the cell cycle features of these cell types.
              Interestingly, while growth-promoting cell cycle genes overlap
              considerably between cancer and stem cells, growth-restricting
              cell cycle genes are completely distinct. Moreover,
              growth-restricting genes are consistently less frequent in cancer
              cells than in hESCs. Here we show that most of these genes are
              regulated by the tumor suppressor gene TP53, which is mutated in
              most cancer cells. Therefore, the growth-restriction system in
              cancer cells lacks important factors and does not function
              properly. Intriguingly, M phase genes are specifically essential
              for the growth of hESCs and are highly abundant among
              hESC-enriched genes. CONCLUSIONS: Our results highlight the
              differences in cell cycle regulation between cell types and
              emphasize the importance of conducting cell cycle studies in
              cells with intact genomes, in order to obtain an authentic
              representation of the genetic features of the cell cycle.",
  journal  = "Cell Div.",
  volume   =  14,
  pages    = "15",
  month    =  dec,
  year     =  2019,
  keywords = "Bioinformatics; CRISPR/Cas9 libraries; Cancer; Cell cycle;
              Checkpoints; Embryonic stem cells; TP53",
  language = "en"
}

@ARTICLE{Schroder2017-wi,
  title    = "A hybrid parameter estimation algorithm for beta mixtures and
              applications to methylation state classification",
  author   = "Schr{\"o}der, Christopher and Rahmann, Sven",
  abstract = "BACKGROUND: Mixtures of beta distributions are a flexible tool
              for modeling data with values on the unit interval, such as
              methylation levels. However, maximum likelihood parameter
              estimation with beta distributions suffers from problems because
              of singularities in the log-likelihood function if some
              observations take the values 0 or 1. METHODS: While ad-hoc
              corrections have been proposed to mitigate this problem, we
              propose a different approach to parameter estimation for beta
              mixtures where such problems do not arise in the first place. Our
              algorithm combines latent variables with the method of moments
              instead of maximum likelihood, which has computational advantages
              over the popular EM algorithm. RESULTS: As an application, we
              demonstrate that methylation state classification is more
              accurate when using adaptive thresholds from beta mixtures than
              non-adaptive thresholds on observed methylation levels. We also
              demonstrate that we can accurately infer the number of mixture
              components. CONCLUSIONS: The hybrid algorithm between
              likelihood-based component un-mixing and moment-based parameter
              estimation is a robust and efficient method for beta mixture
              estimation. We provide an implementation of the method
              (``betamix'') as open source software under the MIT license.",
  journal  = "Algorithms Mol. Biol.",
  volume   =  12,
  pages    = "21",
  month    =  aug,
  year     =  2017,
  keywords = "Beta distribution; Classification; Differential methylation; EM
              algorithm; Maximum likelihood; Method of moments; Mixture model",
  language = "en"
}

@ARTICLE{Rotte2019-ww,
  title    = "Combination of {CTLA-4} and {PD-1} blockers for treatment of
              cancer",
  author   = "Rotte, Anand",
  abstract = "Targeting checkpoints of immune cell activation has been
              demonstrated to be the most effective approach for activation of
              anti-tumor immune responses. Cytotoxic T-lymphocyte-associated
              protein 4 (CTLA-4) and programmed cell death protein 1 (PD-1),
              both inhibitory checkpoints commonly seen on activated T-cells
              have been found to be the most reliable targets for the treatment
              of cancer. Six drugs targeting PD-1 or its ligand PD-L1 and one
              drug targeting CTLA-4 have been approved for treatment of
              different types of cancers and several others are in advanced
              stages of development. The drugs when administered as monotherapy
              had dramatic increase in durable response rates and had
              manageable safety profile, but more than 50\% of patients failed
              to respond to treatment. Combination of CTLA-4 and PD-1 blockers
              was then evaluated to increase the response rates in patients,
              and ipilimumab (anti-CTLA-4) plus nivolumab (anti-PD-1)
              combination was shown to significantly enhance efficacy in
              metastatic melanoma patients. Subsequently, ipilimumab plus
              nivolumab was approved for treatment of metastatic melanoma,
              advanced renal cell carcinoma and metastatic colorectal cancer
              with MMR/MSI-H aberrations. The success of combination encouraged
              multiple clinical studies in other cancer types. Efficacy of the
              combination has been shown in a number of published studies and
              is under evaluation in multiple ongoing studies. This review aims
              to support future research in combination immunotherapy by
              discussing the basic details of CTLA-4 and PD-1 pathways and the
              results from clinical studies that evaluated combination of
              CTLA-4 and PD-1/PD-L1 blockers.",
  journal  = "J. Exp. Clin. Cancer Res.",
  volume   =  38,
  number   =  1,
  pages    = "255",
  month    =  jun,
  year     =  2019,
  keywords = "CTLA-4; Combination therapy; Immunotherapy; PD-1",
  language = "en"
}

@ARTICLE{Bakker2016-vq,
  title    = "Single-cell sequencing reveals karyotype heterogeneity in murine
              and human malignancies",
  author   = "Bakker, Bjorn and Taudt, Aaron and Belderbos, Mirjam E and
              Porubsky, David and Spierings, Diana C J and de Jong, Tristan V
              and Halsema, Nancy and Kazemier, Hinke G and Hoekstra-Wakker,
              Karina and Bradley, Allan and de Bont, Eveline S J M and van den
              Berg, Anke and Guryev, Victor and Lansdorp, Peter M and
              Colom{\'e}-Tatch{\'e}, Maria and Foijer, Floris",
  abstract = "BACKGROUND: Chromosome instability leads to aneuploidy, a state
              in which cells have abnormal numbers of chromosomes, and is found
              in two out of three cancers. In a chromosomal instable p53
              deficient mouse model with accelerated lymphomagenesis, we
              previously observed whole chromosome copy number changes
              affecting all lymphoma cells. This suggests that chromosome
              instability is somehow suppressed in the aneuploid lymphomas or
              that selection for frequently lost/gained chromosomes
              out-competes the CIN-imposed mis-segregation. RESULTS: To
              distinguish between these explanations and to examine karyotype
              dynamics in chromosome instable lymphoma, we use a newly
              developed single-cell whole genome sequencing (scWGS) platform
              that provides a complete and unbiased overview of copy number
              variations (CNV) in individual cells. To analyse these scWGS
              data, we develop AneuFinder, which allows annotation of copy
              number changes in a fully automated fashion and quantification of
              CNV heterogeneity between cells. Single-cell sequencing and
              AneuFinder analysis reveals high levels of copy number
              heterogeneity in chromosome instability-driven murine T-cell
              lymphoma samples, indicating ongoing chromosome instability.
              Application of this technology to human B cell leukaemias reveals
              different levels of karyotype heterogeneity in these cancers.
              CONCLUSION: Our data show that even though aneuploid tumours
              select for particular and recurring chromosome combinations,
              single-cell analysis using AneuFinder reveals copy number
              heterogeneity. This suggests ongoing chromosome instability that
              other platforms fail to detect. As chromosome instability might
              drive tumour evolution, karyotype analysis using single-cell
              sequencing technology could become an essential tool for cancer
              treatment stratification.",
  journal  = "Genome Biol.",
  volume   =  17,
  number   =  1,
  pages    = "115",
  month    =  may,
  year     =  2016,
  keywords = "Aneuploidy; Copy number detection; Karyotype heterogeneity;
              Leukaemia; Lymphoma; Single-cell sequencing",
  language = "en"
}

@ARTICLE{Mallory2020-dy,
  title    = "Methods for copy number aberration detection from single-cell
              {DNA-sequencing} data",
  author   = "Mallory, Xian F and Edrisi, Mohammadamin and Navin, Nicholas and
              Nakhleh, Luay",
  abstract = "Copy number aberrations (CNAs), which are pathogenic copy number
              variations (CNVs), play an important role in the initiation and
              progression of cancer. Single-cell DNA-sequencing (scDNAseq)
              technologies produce data that is ideal for inferring CNAs. In
              this review, we review eight methods that have been developed for
              detecting CNAs in scDNAseq data, and categorize them according to
              the steps of a seven-step pipeline that they employ. Furthermore,
              we review models and methods for evolutionary analyses of CNAs
              from scDNAseq data and highlight advances and future research
              directions for computational methods for CNA detection from
              scDNAseq data.",
  journal  = "Genome Biol.",
  volume   =  21,
  number   =  1,
  pages    = "208",
  month    =  aug,
  year     =  2020,
  keywords = "Copy number aberrations; Intra-tumor heterogeneity; Single-cell
              DNA sequencing; Tumor evolution",
  language = "en"
}

@ARTICLE{Lahnemann2020-gy,
  title    = "Eleven grand challenges in single-cell data science",
  author   = "L{\"a}hnemann, David and K{\"o}ster, Johannes and Szczurek, Ewa
              and McCarthy, Davis J and Hicks, Stephanie C and Robinson, Mark D
              and Vallejos, Catalina A and Campbell, Kieran R and Beerenwinkel,
              Niko and Mahfouz, Ahmed and Pinello, Luca and Skums, Pavel and
              Stamatakis, Alexandros and Attolini, Camille Stephan-Otto and
              Aparicio, Samuel and Baaijens, Jasmijn and Balvert, Marleen and
              Barbanson, Buys de and Cappuccio, Antonio and Corleone, Giacomo
              and Dutilh, Bas E and Florescu, Maria and Guryev, Victor and
              Holmer, Rens and Jahn, Katharina and Lobo, Thamar Jessurun and
              Keizer, Emma M and Khatri, Indu and Kielbasa, Szymon M and
              Korbel, Jan O and Kozlov, Alexey M and Kuo, Tzu-Hao and
              Lelieveldt, Boudewijn P F and Mandoiu, Ion I and Marioni, John C
              and Marschall, Tobias and M{\"o}lder, Felix and Niknejad, Amir
              and Raczkowski, Lukasz and Reinders, Marcel and Ridder, Jeroen de
              and Saliba, Antoine-Emmanuel and Somarakis, Antonios and Stegle,
              Oliver and Theis, Fabian J and Yang, Huan and Zelikovsky, Alex
              and McHardy, Alice C and Raphael, Benjamin J and Shah, Sohrab P
              and Sch{\"o}nhuth, Alexander",
  abstract = "The recent boom in microfluidics and combinatorial indexing
              strategies, combined with low sequencing costs, has empowered
              single-cell sequencing technology. Thousands-or even millions-of
              cells analyzed in a single experiment amount to a data revolution
              in single-cell biology and pose unique data science problems.
              Here, we outline eleven challenges that will be central to
              bringing this emerging field of single-cell data science forward.
              For each challenge, we highlight motivating research questions,
              review prior work, and formulate open problems. This compendium
              is for established researchers, newcomers, and students alike,
              highlighting interesting and rewarding problems for the coming
              years.",
  journal  = "Genome Biol.",
  volume   =  21,
  number   =  1,
  pages    = "31",
  month    =  feb,
  year     =  2020,
  language = "en"
}

@ARTICLE{Sazonova2021-sa,
  title    = "A link between mitotic defects and mitotic catastrophe: detection
              and cell fate",
  author   = "Sazonova, Elena V and Petrichuk, Svetlana V and Kopeina, Gelina S
              and Zhivotovsky, Boris",
  abstract = "Although the phenomenon of mitotic catastrophe was first
              described more than 80 years ago, only recently has this term
              been used to explain a mechanism of cell death linked to delayed
              mitosis. Several mechanisms have been suggested for mitotic
              catastrophe development and cell fate. Depending on molecular
              perturbations, mitotic catastrophe can end in three types of cell
              death, namely apoptosis, necrosis, or autophagy. Moreover,
              mitotic catastrophe can be associated with different types of
              cell aging, the development of which negatively affects tumor
              elimination and, consequently, reduces the therapeutic effect.
              The effective triggering of mitotic catastrophe in clinical
              practice requires induction of DNA damage as well as inhibition
              of the molecular pathways that regulate cell cycle arrest and DNA
              repair. Here we discuss various methods to detect mitotic
              catastrophe, the mechanisms of its development, and the attempts
              to use this phenomenon in cancer treatment.",
  journal  = "Biol. Direct",
  volume   =  16,
  number   =  1,
  pages    = "25",
  month    =  dec,
  year     =  2021,
  keywords = "Cancer; Cell death; DNA damage; Mitotic catastrophe; Senescence",
  language = "en"
}

@ARTICLE{Tang2018-kn,
  title    = "{Anti-CTLA-4} antibodies in cancer immunotherapy: selective
              depletion of intratumoral regulatory {T} cells or checkpoint
              blockade?",
  author   = "Tang, Fei and Du, Xuexiang and Liu, Mingyue and Zheng, Pan and
              Liu, Yang",
  abstract = "Antibodies to human CTLA-4 have been shown to induce long-lasting
              protection against melanoma. It is assumed that these antibodies
              cause tumor rejection by blocking negative signaling from the
              B7-CTLA-4 interactions to enhance priming of na{\"\i}ve T cells
              in the lymphoid organs. Recently, we reported that anti-CTLA-4
              antibody Ipilimumab effectively induces tumor rejection in vivo
              although it blocks neither B7 transendocytosis by CTLA-4 nor
              CTLA-4 binding to immobilized or cell-associated B7. Using
              genetic model in which the anti-CTLA-4 antibodies are unable to
              engage more than 50\% of CTLA-4, we demonstrated that saturating
              binding of CTLA-4 is not necessary for tumor rejection. Our
              results argue against B7-CTLA-4 blockade as the mechanism of
              action for the clinically effective Ipilimumab. Moreover,
              Ipilimumab induces tumor rejection even in the absence of de novo
              T cell priming in the lymphoid organs. Thus, our data are
              inconsistent with key provisions of the prevailing hypothesis on
              mechanism of action by anti-CTLA-4 antibodies. Furthermore,
              anti-CTLA-4 antibodies effectively induce depletion of regulatory
              T (Treg) cells in tumor microenvironment but not in the
              peripheral lymphoid organs, which is strictly dependent on Fc
              receptor on host cells. Based on these data and other recent
              publications on the subject, we propose that anti-human CTLA-4
              antibodies induce tumor rejection by selective depletion of Tregs
              in the tumors rather than blockade of B7-CTLA-4 interaction in
              lymphoid organs.",
  journal  = "Cell Biosci.",
  volume   =  8,
  pages    = "30",
  month    =  apr,
  year     =  2018,
  keywords = "B7-CTLA-4 interaction; CTLA-4; Cancer immunotherapy; Ipilimumab;
              Regulatory T cells; Tumor microenvironment;CTLs Special Forces",
  language = "en"
}

@ARTICLE{Metzcar2019-gv,
  title    = "A Review of {Cell-Based} Computational Modeling in Cancer Biology",
  author   = "Metzcar, John and Wang, Yafei and Heiland, Randy and Macklin,
              Paul",
  abstract = "Cancer biology involves complex, dynamic interactions between
              cancer cells and their tissue microenvironments. Single-cell
              effects are critical drivers of clinical progression. Chemical
              and mechanical communication between tumor and stromal cells can
              co-opt normal physiologic processes to promote growth and
              invasion. Cancer cell heterogeneity increases cancer's ability to
              test strategies to adapt to microenvironmental stresses. Hypoxia
              and treatment can select for cancer stem cells and drive invasion
              and resistance. Cell-based computational models (also known as
              discrete models, agent-based models, or individual-based models)
              simulate individual cells as they interact in virtual tissues,
              which allows us to explore how single-cell behaviors lead to the
              dynamics we observe and work to control in cancer systems. In
              this review, we introduce the broad range of techniques available
              for cell-based computational modeling. The approaches can range
              from highly detailed models of just a few cells and their
              morphologies to millions of simpler cells in three-dimensional
              tissues. Modeling individual cells allows us to directly
              translate biologic observations into simulation rules. In many
              cases, individual cell agents include molecular-scale models.
              Most models also simulate the transport of oxygen, drugs, and
              growth factors, which allow us to link cancer development to
              microenvironmental conditions. We illustrate these methods with
              examples drawn from cancer hypoxia, angiogenesis, invasion, stem
              cells, and immunosurveillance. An ecosystem of interoperable
              cell-based simulation tools is emerging at a time when cloud
              computing resources make software easier to access and
              supercomputing resources make large-scale simulation studies
              possible. As the field develops, we anticipate that
              high-throughput simulation studies will allow us to rapidly
              explore the space of biologic possibilities, prescreen new
              therapeutic strategies, and even re-engineer tumor and stromal
              cells to bring cancer systems under control.",
  journal  = "JCO Clin Cancer Inform",
  number   =  3,
  pages    = "1--13",
  month    =  feb,
  year     =  2019,
  language = "en"
}

@ARTICLE{ODwyer1984-lq,
  title    = "Acivicin: a new glutamine antagonist in clinical trials",
  author   = "O'Dwyer, P J and Alonso, M T and Leyland-Jones, B",
  journal  = "J. Clin. Oncol.",
  volume   =  2,
  number   =  9,
  pages    = "1064--1071",
  month    =  sep,
  year     =  1984,
  language = "en"
}

@ARTICLE{Izzo2004-ky,
  title    = "Pegylated arginine deiminase treatment of patients with
              unresectable hepatocellular carcinoma: results from phase {I/II}
              studies",
  author   = "Izzo, Francesco and Marra, Paolo and Beneduce, Gerardo and
              Castello, Giuseppe and Vallone, Paolo and De Rosa, Vincenzo and
              Cremona, Franco and Ensor, C Mark and Holtsberg, Frederick W and
              Bomalaski, John S and Clark, Mike A and Ng, Chaan and Curley,
              Steven A",
  abstract = "PURPOSE: Recently, we reported that a large number of human
              hepatocellular cancer (HCC) cell lines were auxotrophic for
              arginine. Here we report the results obtained with the amino
              acid-degrading enzyme arginine deiminase (ADI) conjugated to
              polyethylene glycol (ADI-SS PEG 20,000 mw) as a means of lowering
              plasma arginine to treat HCC. The study was a cohort
              dose-escalation phase I/II study. PATIENTS AND METHODS:
              Pharmacodynamic studies indicated an ADI-SS PEG 20,000 mw dose
              level of 160 U/m(2) was sufficient to lower plasma arginine from
              a resting level of approximately 130 micromol/L to below the
              level of detection ( 680 days). CONCLUSION: Elimination of all
              detectable plasma arginine in patients with HCC was well
              tolerated and seemed to be effective in the treatment of some
              patients with HCC. Further testing of ADI-SS PEG 20,000 mw in a
              larger population of individuals with HCC as well as other human
              tumors auxotrophic for arginine is warranted.",
  journal  = "J. Clin. Oncol.",
  volume   =  22,
  number   =  10,
  pages    = "1815--1822",
  month    =  may,
  year     =  2004,
  language = "en"
}

@ARTICLE{Ascierto2005-hc,
  title    = "Pegylated arginine deiminase treatment of patients with
              metastatic melanoma: results from phase {I} and {II} studies",
  author   = "Ascierto, Paolo A and Scala, Stefania and Castello, Giuseppe and
              Daponte, Antonio and Simeone, Ester and Ottaiano, Alessandro and
              Beneduce, Gerardo and De Rosa, Vincenzo and Izzo, Francesco and
              Melucci, Maria Teresa and Ensor, C Mark and Prestayko, Archie W
              and Holtsberg, Frederick W and Bomalaski, John S and Clark, Mike
              A and Savaraj, Niramol and Feun, Lynn G and Logan, Theodore F",
  abstract = "PURPOSE: Individuals with metastatic melanoma have a poor
              prognosis. Many human melanomas are auxotrophic for arginine, and
              arginine is not an essential amino acid in humans. We
              hypothesized that this auxotrophy may be therapeutically
              exploited. A novel amino acid-degrading enzyme (arginine
              deiminase) conjugated to polyethylene glycol (ADI-SS PEG 20,000
              mw) was used to lower plasma arginine in individuals with
              metastatic melanoma. PATIENTS AND METHODS: Two cohort
              dose-escalation studies were performed. A phase I study in the
              United States enrolled 15 patients, and a phase I to II study in
              Italy enrolled 24 patients. The Italian patients also received
              two subsequent cycles of treatment, each consisting of four
              once-weekly injections of 160 U/m2. The goals of these studies
              were to determine pharmacokinetics (PK), pharmacodynamics (PD),
              safety, and the antitumor activity of ADI-SS PEG 20,000 mw.
              RESULTS: PK and PD studies indicated that a dose of 160 U/m2
              lowered plasma arginine from a resting level of approximately 130
              micromol/L to less than 2 micromol/L for at least 7 days; nitric
              oxide levels also were lowered. There were no grade 3 or 4
              toxicities directly attributable to the drug. Six of 24 phase I
              to II patients responded to treatment (five partial responses and
              one complete response; 25\% response rate) and also had prolonged
              survival. CONCLUSION Elimination of all detectable plasma
              arginine in patients with metastatic melanoma was well tolerated
              and may be effective in the treatment of this cancer. Further
              testing of ADI-SS PEG 20,000 mw in a larger population of
              individuals with metastatic melanoma is warranted.",
  journal  = "J. Clin. Oncol.",
  volume   =  23,
  number   =  30,
  pages    = "7660--7668",
  month    =  oct,
  year     =  2005,
  language = "en"
}

@ARTICLE{Szlosarek2013-yv,
  title    = "Metabolic response to pegylated arginine deiminase in
              mesothelioma with promoter methylation of argininosuccinate
              synthetase",
  author   = "Szlosarek, Peter W and Luong, Phuong and Phillips, Melissa M and
              Baccarini, Marina and Stephen, Ellis and Szyszko, Teresa and
              Sheaff, Michael T and Avril, Norbert",
  journal  = "J. Clin. Oncol.",
  volume   =  31,
  number   =  7,
  pages    = "e111--3",
  month    =  mar,
  year     =  2013,
  language = "en"
}

@ARTICLE{Bochtler2013-yc,
  title    = "Clonal heterogeneity as detected by metaphase karyotyping is an
              indicator of poor prognosis in acute myeloid leukemia",
  author   = "Bochtler, Tilmann and St{\"o}lzel, Friedrich and Heilig,
              Christoph E and Kunz, Christina and Mohr, Brigitte and Jauch,
              Anna and Janssen, Johannes W G and Kramer, Michael and Benner,
              Axel and Bornh{\"a}user, Martin and Ho, Anthony D and Ehninger,
              Gerhard and Schaich, Markus and Kr{\"a}mer, Alwin",
  abstract = "PURPOSE: In acute myeloid leukemia (AML), studies based on
              whole-genome sequencing have shown genomic diversity within
              leukemic clones. The aim of this study was to address clonal
              heterogeneity in AML based on metaphase cytogenetics. PATIENTS
              AND METHODS: This analysis included all patients enrolled onto
              two consecutive, prospective, randomized multicenter trials of
              the Study Alliance Leukemia. Patients were newly diagnosed with
              non-M3 AML and were fit for intensive chemotherapy. RESULTS:
              Cytogenetic subclones were detected in 418 (15.8\%) of 2,639
              patients from the whole study population and in 418 (32.8\%) of
              1,274 patients with aberrant karyotypes. Among those, 252
              karyotypes (60.3\%) displayed a defined number of distinct
              subclones, and 166 (39.7\%) were classified as composite
              karyotypes. Subclone formation was particularly frequent in the
              cytogenetically adverse group, with subclone formation in 69.0\%,
              67.1\%, and 64.8\% of patients with complex aberrant, monosomal,
              and abnl(17p) karyotypes (P < .001 each). Two-subclone patterns
              typically followed a mother-daughter evolution, whereas for
              $\geq$ three subclones, a branched pattern prevailed. In non-core
              binding factor AML, subclone formation was associated with
              inferior event-free and overall survival and was confirmed as an
              independent predictor of poor prognosis in multivariate analysis.
              Subgroup analysis showed that subclone formation adds prognostic
              information particularly in the cytogenetic adverse-risk group.
              Allogeneic stem-cell transplantation improved the prognosis of
              patients with subclone karyotypes as shown in landmark analyses.
              CONCLUSION: Cytogenetic subclones are frequent in AML and permit
              tracing of clonal evolution and architecture. They bear
              prognostic significance with clonal heterogeneity as an
              independent adverse prognostic marker in cytogenetically
              adverse-risk AML.",
  journal  = "J. Clin. Oncol.",
  volume   =  31,
  number   =  31,
  pages    = "3898--3905",
  month    =  nov,
  year     =  2013,
  language = "en"
}

@ARTICLE{Topalian2014-te,
  title    = "Survival, durable tumor remission, and long-term safety in
              patients with advanced melanoma receiving nivolumab",
  author   = "Topalian, Suzanne L and Sznol, Mario and McDermott, David F and
              Kluger, Harriet M and Carvajal, Richard D and Sharfman, William H
              and Brahmer, Julie R and Lawrence, Donald P and Atkins, Michael B
              and Powderly, John D and Leming, Philip D and Lipson, Evan J and
              Puzanov, Igor and Smith, David C and Taube, Janis M and
              Wigginton, Jon M and Kollia, Georgia D and Gupta, Ashok and
              Pardoll, Drew M and Sosman, Jeffrey A and Hodi, F Stephen",
  abstract = "PURPOSE: Programmed cell death 1 (PD-1) is an inhibitory receptor
              expressed by activated T cells that downmodulates effector
              functions and limits the generation of immune memory. PD-1
              blockade can mediate tumor regression in a substantial proportion
              of patients with melanoma, but it is not known whether this is
              associated with extended survival or maintenance of response
              after treatment is discontinued. PATIENTS AND METHODS: Patients
              with advanced melanoma (N = 107) enrolled between 2008 and 2012
              received intravenous nivolumab in an outpatient setting every 2
              weeks for up to 96 weeks and were observed for overall survival,
              long-term safety, and response duration after treatment
              discontinuation. RESULTS: Median overall survival in
              nivolumab-treated patients (62\% with two to five prior systemic
              therapies) was 16.8 months, and 1- and 2-year survival rates were
              62\% and 43\%, respectively. Among 33 patients with objective
              tumor regressions (31\%), the Kaplan-Meier estimated median
              response duration was 2 years. Seventeen patients discontinued
              therapy for reasons other than disease progression, and 12 (71\%)
              of 17 maintained responses off-therapy for at least 16 weeks
              (range, 16 to 56+ weeks). Objective response and toxicity rates
              were similar to those reported previously; in an extended
              analysis of all 306 patients treated on this trial (including
              those with other cancer types), exposure-adjusted toxicity rates
              were not cumulative. CONCLUSION: Overall survival following
              nivolumab treatment in patients with advanced
              treatment-refractory melanoma compares favorably with that in
              literature studies of similar patient populations. Responses were
              durable and persisted after drug discontinuation. Long-term
              safety was acceptable. Ongoing randomized clinical trials will
              further assess the impact of nivolumab therapy on overall
              survival in patients with metastatic melanoma.",
  journal  = "J. Clin. Oncol.",
  volume   =  32,
  number   =  10,
  pages    = "1020--1030",
  month    =  apr,
  year     =  2014,
  language = "en"
}

@ARTICLE{Ahmed2015-me,
  title    = "Human Epidermal Growth Factor Receptor 2 ({HER2}) -Specific
              Chimeric Antigen {Receptor-Modified} {T} Cells for the
              Immunotherapy of {HER2-Positive} Sarcoma",
  author   = "Ahmed, Nabil and Brawley, Vita S and Hegde, Meenakshi and
              Robertson, Catherine and Ghazi, Alexia and Gerken, Claudia and
              Liu, Enli and Dakhova, Olga and Ashoori, Aidin and Corder, Amanda
              and Gray, Tara and Wu, Meng-Fen and Liu, Hao and Hicks, John and
              Rainusso, Nino and Dotti, Gianpietro and Mei, Zhuyong and
              Grilley, Bambi and Gee, Adrian and Rooney, Cliona M and Brenner,
              Malcolm K and Heslop, Helen E and Wels, Winfried S and Wang, Lisa
              L and Anderson, Peter and Gottschalk, Stephen",
  abstract = "PURPOSE: The outcome for patients with metastatic or recurrent
              sarcoma remains poor. Adoptive therapy with tumor-directed T
              cells is an attractive therapeutic option but has never been
              evaluated in sarcoma. PATIENTS AND METHODS: We conducted a phase
              I/II clinical study in which patients with recurrent/refractory
              human epidermal growth factor receptor 2 (HER2) -positive sarcoma
              received escalating doses (1 $\times$ 10(4)/m(2) to 1 $\times$
              10(8)/m(2)) of T cells expressing an HER2-specific chimeric
              antigen receptor with a CD28.$\zeta$ signaling domain (HER2-CAR T
              cells). RESULTS: We enrolled 19 patients with HER2-positive
              tumors (16 osteosarcomas, one Ewing sarcoma, one primitive
              neuroectodermal tumor, and one desmoplastic small round cell
              tumor). HER2-CAR T-cell infusions were well tolerated with no
              dose-limiting toxicity. At dose level 3 (1 $\times$ 10(5)/m(2))
              and above, we detected HER2-CAR T cells 3 hours after infusion by
              quantitative polymerase chain reaction in 14 of 16 patients.
              HER2-CAR T cells persisted for at least 6 weeks in seven of the
              nine evaluable patients who received greater than 1 $\times$
              10(6)/m(2) HER2-CAR T cells (P = .005). HER2-CAR T cells were
              detected at tumor sites of two of two patients examined. Of 17
              evaluable patients, four had stable disease for 12 weeks to 14
              months. Three of these patients had their tumor removed, with one
              showing $\geq$ 90\% necrosis. The median overall survival of all
              19 infused patients was 10.3 months (range, 5.1 to 29.1 months).
              CONCLUSION: This first evaluation of the safety and efficacy of
              HER2-CAR T cells in patients with cancer shows the cells can
              persist for 6 weeks without evident toxicities, setting the stage
              for studies that combine HER2-CAR T cells with other
              immunomodulatory approaches to enhance their expansion and
              persistence.",
  journal  = "J. Clin. Oncol.",
  volume   =  33,
  number   =  15,
  pages    = "1688--1696",
  month    =  may,
  year     =  2015,
  language = "en"
}

@ARTICLE{Massard2016-wn,
  title    = "Safety and Efficacy of Durvalumab ({MEDI4736)}, an
              {Anti-Programmed} Cell Death Ligand-1 Immune Checkpoint
              Inhibitor, in Patients With Advanced Urothelial Bladder Cancer",
  author   = "Massard, Christophe and Gordon, Michael S and Sharma, Sunil and
              Rafii, Saeed and Wainberg, Zev A and Luke, Jason and Curiel,
              Tyler J and Colon-Otero, Gerardo and Hamid, Omid and Sanborn,
              Rachel E and O'Donnell, Peter H and Drakaki, Alexandra and Tan,
              Winston and Kurland, John F and Rebelatto, Marlon C and Jin,
              Xiaoping and Blake-Haskins, John A and Gupta, Ashok and Segal,
              Neil H",
  abstract = "PURPOSE: To investigate the safety and efficacy of durvalumab, a
              human monoclonal antibody that binds programmed cell death
              ligand-1 (PD-L1), and the role of PD-L1 expression on clinical
              response in patients with advanced urothelial bladder cancer
              (UBC). METHODS: A phase 1/2 multicenter, open-label study is
              being conducted in patients with inoperable or metastatic solid
              tumors. We report here the results from the UBC expansion cohort.
              Durvalumab (MEDI4736, 10 mg/kg every 2 weeks) was administered
              intravenously for up to 12 months. The primary end point was
              safety, and objective response rate (ORR, confirmed) was a key
              secondary end point. An exploratory analysis of pretreatment
              tumor biopsies led to defining PD-L1-positive as $\geq$ 25\% of
              tumor cells or tumor-infiltrating immune cells expressing
              membrane PD-L1. RESULTS: A total of 61 patients (40
              PD-L1-positive, 21 PD-L1-negative), 93.4\% of whom received one
              or more prior therapies for advanced disease, were treated
              (median duration of follow-up, 4.3 months). The most common
              treatment-related adverse events (AEs) of any grade were fatigue
              (13.1\%), diarrhea (9.8\%), and decreased appetite (8.2\%). Grade
              3 treatment-related AEs occurred in three patients (4.9\%); there
              were no treatment-related grade 4 or 5 AEs. One treatment-related
              AE (acute kidney injury) resulted in treatment discontinuation.
              The ORR was 31.0\% (95\% CI, 17.6 to 47.1) in 42
              response-evaluable patients, 46.4\% (95\% CI, 27.5 to 66.1) in
              the PD-L1-positive subgroup, and 0\% (95\% CI, 0.0 to 23.2) in
              the PD-L1-negative subgroup. Responses are ongoing in 12 of 13
              responding patients, with median duration of response not yet
              reached (range, 4.1+ to 49.3+ weeks). CONCLUSION: Durvalumab
              demonstrated a manageable safety profile and evidence of
              meaningful clinical activity in PD-L1-positive patients with UBC,
              many of whom were heavily pretreated.",
  journal  = "J. Clin. Oncol.",
  volume   =  34,
  number   =  26,
  pages    = "3119--3125",
  month    =  sep,
  year     =  2016,
  language = "en"
}

@ARTICLE{Lipson2021-if,
  title     = "Relatlimab ({RELA}) plus nivolumab ({NIVO}) versus {NIVO} in
               first-line advanced melanoma: Primary phase {III} results from
               {RELATIVITY-047} ({CA224-047})",
  author    = "Lipson, Evan J and Tawbi, Hussein Abdul-Hassan and Schadendorf,
               Dirk and Ascierto, Paolo Antonio and Matamala, Luis and
               Guti{\'e}rrez, Erika Castillo and Rutkowski, Piotr and Gogas,
               Helen and Lao, Christopher D and Janoski de Menezes, Juliana and
               Dalle, St{\'e}phane and Arance, Ana Maria and Grob, Jean-Jacques
               and Srivastava, Shivani and Abaskharoun, Mena and Simonsen, Katy
               L and Li, Bin and Long, Georgina V and Hodi, F Stephen",
  abstract  = "9503Background: Immune checkpoint inhibitor therapy has
               revolutionized the treatment of patients with advanced melanoma.
               However, novel combinations are needed to optimize the
               benefit-risk profile. Lymphocyte-activation gene 3 (LAG-3)
               regulates an immune checkpoint pathway, which inhibits T-cell
               activity, and is upregulated in many tumor types including
               melanoma. Relatlimab (RELA), a human IgG4 LAG-3-blocking
               antibody, restores effector function of exhausted T cells. RELA
               in combination with nivolumab (NIVO; anti-programmed death
               [PD]-1) modulates potentially synergistic immune checkpoint
               pathways and can enhance antitumor immune responses.
               RELATIVITY-047 is a global, randomized, double-blind, phase
               II/III study evaluating a novel immune checkpoint inhibitor
               combination of RELA+NIVO as a fixed-dose combination (FDC)
               treatment in first-line advanced melanoma. Methods: Patients
               with previously untreated advanced melanoma were randomized 1:1
               to receive RELA 160 mg + NIVO 480 mg FDC intravenously (IV)
               every 4 weeks (Q4W) or NIVO monotherapy 480 mg IV Q4W,
               stratified by LAG-3 expression, programmed death ligand 1
               expression, BRAF mutation status, and AJCC (v8) M stage. The
               primary endpoint was progression-free survival (PFS) per RECIST
               v1.1 as assessed by blinded independent central review.
               Secondary endpoints were overall survival and objective response
               rate. PFS in prespecified subgroups and safety were additional
               objectives. Results: 714 patients were randomized to RELA+NIVO
               FDC (n = 355) or NIVO (n = 359). Patient characteristics were
               well balanced between treatment groups. Median follow-up was
               13.2 months. Median PFS in the RELA+NIVO FDC group (10.1 months
               [95\% CI, 6.4?15.7]) was significantly longer than in the NIVO
               group (4.6 months [95\% CI, 3.4?5.6]; hazard ratio, 0.75 [95\%
               CI, 0.6?0.9]; P = 0.0055). PFS rates at 12 months were 47.7\%
               (95\% CI, 41.8?53.2) and 36.0\% (95\% CI, 30.5?41.6) for
               RELA+NIVO FDC and NIVO, respectively. PFS favored RELA+NIVO FDC
               across key prespecified subgroups. The incidence of grade 3/4
               treatment-related adverse events (TRAEs) was higher in the
               RELA+NIVO FDC group (18.9\%) versus NIVO (9.7\%). There were 3
               treatment-related deaths with RELA+NIVO FDC and 2 with NIVO.
               TRAEs (any grade) led to treatment discontinuation in 14.6\% and
               6.7\% of patients in the RELA+NIVO FDC and NIVO groups,
               respectively. Conclusions: First-line treatment with RELA+NIVO
               FDC demonstrated a statistically significant PFS benefit
               compared to NIVO monotherapy in patients with advanced melanoma.
               RELA+NIVO FDC was well tolerated with a manageable safety
               profile and without unexpected safety signals. This is the first
               phase III study of a novel FDC to demonstrate a clinically
               meaningful benefit by dual inhibition of the LAG-3 and PD-1
               pathways. Clinical trial information: NCT03470922.",
  journal   = "J. Clin. Orthod.",
  publisher = "Wolters Kluwer",
  volume    =  39,
  number    = "15\_suppl",
  pages     = "9503--9503",
  month     =  may,
  year      =  2021
}

@ARTICLE{Perez-Garijo2015-wl,
  title    = "Spreading the word: non-autonomous effects of apoptosis during
              development, regeneration and disease",
  author   = "P{\'e}rez-Garijo, Ainhoa and Steller, Hermann",
  abstract = "Apoptosis, in contrast to other forms of cell death such as
              necrosis, was originally regarded as a 'silent' mechanism of cell
              elimination designed to degrade the contents of doomed cells.
              However, during the past decade it has become clear that
              apoptotic cells can produce diverse signals that have a profound
              impact on neighboring cells and tissues. For example, apoptotic
              cells can release factors that influence the proliferation and
              survival of adjacent tissues. Apoptosis can also affect tissue
              movement and morphogenesis by modifying tissue tension in
              surrounding cells. As we review here, these findings reveal
              unexpected roles for apoptosis in tissue remodeling during
              development, as well as in regeneration and cancer.",
  journal  = "Development",
  volume   =  142,
  number   =  19,
  pages    = "3253--3262",
  month    =  oct,
  year     =  2015,
  keywords = "Apoptosis; Morphogenesis; Signaling; Silent mechanism of cell
              elimination; Tissue remodeling",
  language = "en"
}

@ARTICLE{McKeown2019-dx,
  title    = "Nutrient restriction causes reversible {G2} arrest in Xenopus
              neural progenitors",
  author   = "McKeown, Caroline R and Cline, Hollis T",
  abstract = "Nutrient status affects brain development; however, the effects
              of nutrient availability on neural progenitor cell proliferation
              in vivo are poorly understood. Without food, Xenopus laevis
              tadpoles enter a period of stasis during which neural progenitor
              proliferation is drastically reduced, but resumes when food
              becomes available. Here, we investigate how neural progenitors
              halt cell division in response to nutrient restriction and
              subsequently re-enter the cell cycle upon feeding. We demonstrate
              that nutrient restriction causes neural progenitors to arrest in
              G2 of the cell cycle with increased DNA content, and that
              nutrient availability triggers progenitors to re-enter the cell
              cycle at M phase. Initiation of the nutrient restriction-induced
              G2 arrest is rapamycin insensitive, but cell cycle re-entry
              requires mTOR. Finally, we show that activation of insulin
              receptor signaling is sufficient to increase neural progenitor
              cell proliferation in the absence of food. A G2 arrest mechanism
              provides an adaptive strategy to control brain development in
              response to nutrient availability by triggering a synchronous
              burst of cell proliferation when nutrients become available. This
              may be a general cellular mechanism that allows developmental
              flexibility during times of limited resources.",
  journal  = "Development",
  volume   =  146,
  number   =  20,
  month    =  oct,
  year     =  2019,
  keywords = "Cell cycle; G2 arrest; Neurogenesis; Nutrition; Optic tectum;
              Stasis",
  language = "en"
}

@ARTICLE{Oromendia2014-jm,
  title    = "Aneuploidy: implications for protein homeostasis and disease",
  author   = "Oromendia, Ana B and Amon, Angelika",
  abstract = "It has long been appreciated that aneuploidy - in which cells
              possess a karyotype that is not a multiple of the haploid
              complement - has a substantial impact on human health, but its
              effects at the subcellular level have only recently become a
              focus of investigation. Here, we summarize new findings
              characterizing the impact of aneuploidy on protein quality
              control. Because aneuploidy has been associated with many
              diseases, foremost among them being cancer, and has also been
              linked to aging, we also offer our perspective on whether and how
              the effects of aneuploidy on protein quality control could
              contribute to these conditions. We argue that acquiring a deeper
              understanding of the relationship between aneuploidy, disease and
              aging could lead to the development of new anti-cancer and
              anti-aging treatments.",
  journal  = "Dis. Model. Mech.",
  volume   =  7,
  number   =  1,
  pages    = "15--20",
  month    =  jan,
  year     =  2014,
  keywords = "Aneuploidy; Disease; Protein folding",
  language = "en"
}

@ARTICLE{Storchova2008-jj,
  title    = "The consequences of tetraploidy and aneuploidy",
  author   = "Storchova, Zuzana and Kuffer, Christian",
  abstract = "Polyploidy, an increased number of chromosome sets, is a
              surprisingly common phenomenon in nature, particularly in plants
              and fungi. In humans, polyploidy often occurs in specific tissues
              as part of terminal differentiation. Changes in ploidy can also
              result from pathophysiological events that are caused by
              viral-induced cell fusion or erroneous cell division.
              Tetraploidization can initiate chromosomal instability (CIN),
              probably owing to supernumerary centrosomes and the doubled
              chromosome mass. CIN, in turn, might persist or soon give way to
              a stably propagating but aneuploid karyotype. Both CIN and stable
              aneuploidy are commonly observed in cancers. Recently, it has
              been proposed that an increased number of chromosome sets can
              promote cell transformation and give rise to an aneuploid tumor.
              Here, we review how tetraploidy can occur and describe the
              cellular responses to increased ploidy. Furthermore, we discuss
              how the specific physiological changes that are triggered by
              polyploidization might be used as novel targets for cancer
              therapy.",
  journal  = "J. Cell Sci.",
  volume   =  121,
  number   = "Pt 23",
  pages    = "3859--3866",
  month    =  dec,
  year     =  2008,
  language = "en"
}

@ARTICLE{Lambert1979-sr,
  title    = "Growth of human diploid cells (strain {MRC-5}) in defined medium;
              replacement of serum by a fraction of serum ultrafiltrate",
  author   = "Lambert, K and Pirt, S J",
  abstract = "A calf serum ultrafiltrate fraction permitted growth for at least
              3.5 generations, including one subculture, of MRC-5 cells in
              defined medium in the absence of whole serum. The active material
              has a molecular weight of 10 000 Daltons or less. This suggests
              that there may be no requirement for a large macromolecular
              component of serum. The ultrafiltrate was assayed by maximum cell
              yield from a serum-limited inoculum in a defined medium
              containing non-limiting amounts of vitamins, amino acids,
              glucose, a 68-component supplement, iron and methylcellulose. The
              levels of vitamins, amino acids and glucose were based on
              quantitative measurements of uptake and the levels of the other
              components by minimum amount required for maximum yield in
              defined medium without ultrafiltrate or serum. With excess
              ultrafiltrate maximum cell yield was limited by the defined part
              of the medium, probably the supplement. The cell doubling time in
              defined medium with ultrafiltrate fractions was 70 h compared
              with 27 h in the medium with serum. Excess ultrafiltrate did not
              inhibit growth. The lowered growth rate is attributed to a
              nutritional deficiency in the supplement.",
  journal  = "J. Cell Sci.",
  volume   =  35,
  pages    = "381--392",
  month    =  feb,
  year     =  1979,
  language = "en"
}

@ARTICLE{Dolken2008-xb,
  title    = "High-resolution gene expression profiling for simultaneous
              kinetic parameter analysis of {RNA} synthesis and decay",
  author   = "D{\"o}lken, Lars and Ruzsics, Zsolt and R{\"a}dle, Bernd and
              Friedel, Caroline C and Zimmer, Ralf and Mages, J{\"o}rg and
              Hoffmann, Reinhard and Dickinson, Paul and Forster, Thorsten and
              Ghazal, Peter and Koszinowski, Ulrich H",
  abstract = "RNA levels in a cell are determined by the relative rates of RNA
              synthesis and decay. State-of-the-art transcriptional analyses
              only employ total cellular RNA. Therefore, changes in RNA levels
              cannot be attributed to RNA synthesis or decay, and temporal
              resolution is poor. Recently, it was reported that newly
              transcribed RNA can be biosynthetically labeled for 1-2 h using
              thiolated nucleosides, purified from total cellular RNA and
              subjected to microarray analysis. However, in order to study
              signaling events at molecular level, analysis of changes
              occurring within minutes is required. We developed an improved
              approach to separate total cellular RNA into newly transcribed
              and preexisting RNA following 10-15 min of metabolic labeling.
              Employing new computational tools for array normalization and
              half-life determination we simultaneously study short-term RNA
              synthesis and decay as well as their impact on cellular
              transcript levels. As an example we studied the response of
              fibroblasts to type I and II interferons (IFN). Analysis of RNA
              transcribed within 15-30 min at different times during the first
              three hours of interferon-receptor activation resulted in a
              >10-fold increase in microarray sensitivity and provided a
              comprehensive profile of the kinetics of IFN-mediated changes in
              gene expression. We identify a previously undisclosed highly
              connected network of short-lived transcripts selectively
              down-regulated by IFNgamma in between 30 and 60 min after IFN
              treatment showing strong associations with cell cycle and
              apoptosis, indicating novel mechanisms by which IFNgamma affects
              these pathways.",
  journal  = "RNA",
  volume   =  14,
  number   =  9,
  pages    = "1959--1972",
  month    =  sep,
  year     =  2008,
  language = "en"
}

@ARTICLE{De_Saint_Basile2015-dy,
  title    = "Cytotoxic granule secretion by lymphocytes and its link to immune
              homeostasis",
  author   = "de Saint Basile, Genevi{\`e}ve and Sepulveda, Fernando E and
              Maschalidi, Sophia and Fischer, Alain",
  abstract = "The granule-dependent cytotoxic activity of T and natural killer
              lymphocytes has progressively emerged as an important effector
              pathway not only for host defence but also for immune regulation.
              The analysis of an early-onset, severe, primary immune
              dysregulatory syndrome known as hemophagocytic
              lymphohistiocytosis (HLH) has been decisive in highlighting this
              latter role and identifying key effectors on the basis of gene
              mutation analyses and mediators in the maturation and secretion
              of cytotoxic granules. Studies of cytotoxicity-deficient murine
              counterparts have helped to define primary HLH as a syndrome in
              which uncontrolled T-cell activation in response to lymphocytic
              choriomeningitis virus infection results in excessive macrophage
              activation and inflammation-associated cytopenia. Recent
              recognition of late-onset HLH, which occurs in a variety of
              settings, in association with hypomorphic, monoallelic mutations
              in genes encoding components of the granule-dependent cytotoxic
              pathway or even in the absence of such mutations has broadened
              our view about the mechanisms that underlie the perturbation of
              immune homeostasis. These findings have led to the development of
              a model in which disease occurs when a threshold is reached
              through the accumulation of genetic and environmental risk
              factors. Nevertheless, validation of this model will require
              further investigations.",
  journal  = "F1000Res.",
  volume   =  4,
  number   = "F1000 Faculty Rev",
  pages    = "930",
  month    =  sep,
  year     =  2015,
  keywords = "cytotoxic; haemophagocytic lymphohistiocytosis; natural killer
              lymphocytes;Direct Killing (Perf/Gzym/FAS)",
  language = "en"
}

@ARTICLE{Sunshine2015-hh,
  title    = "The fitness consequences of aneuploidy are driven by
              condition-dependent gene effects",
  author   = "Sunshine, Anna B and Payen, Celia and Ong, Giang T and Liachko,
              Ivan and Tan, Kean Ming and Dunham, Maitreya J",
  abstract = "Aneuploidy is a hallmark of tumor cells, and yet the precise
              relationship between aneuploidy and a cell's proliferative
              ability, or cellular fitness, has remained elusive. In this
              study, we have combined a detailed analysis of aneuploid clones
              isolated from laboratory-evolved populations of Saccharomyces
              cerevisiae with a systematic, genome-wide screen for the fitness
              effects of telomeric amplifications to address the relationship
              between aneuploidy and cellular fitness. We found that aneuploid
              clones rise to high population frequencies in nutrient-limited
              evolution experiments and show increased fitness relative to wild
              type. Direct competition experiments confirmed that three out of
              four aneuploid events isolated from evolved populations were
              themselves sufficient to improve fitness. To expand the scope
              beyond this small number of exemplars, we created a genome-wide
              collection of >1,800 diploid yeast strains, each containing a
              different telomeric amplicon (Tamp), ranging in size from 0.4 to
              1,000 kb. Using pooled competition experiments in
              nutrient-limited chemostats followed by high-throughput
              sequencing of strain-identifying barcodes, we determined the
              fitness effects of these >1,800 Tamps under three different
              conditions. Our data revealed that the fitness landscape explored
              by telomeric amplifications is much broader than that explored by
              single-gene amplifications. As also observed in the evolved
              clones, we found the fitness effects of most Tamps to be
              condition specific, with a minority showing common effects in all
              three conditions. By integrating our data with previous work that
              examined the fitness effects of single-gene amplifications
              genome-wide, we found that a small number of genes within each
              Tamp are centrally responsible for each Tamp's fitness effects.
              Our genome-wide Tamp screen confirmed that telomeric
              amplifications identified in laboratory-evolved populations
              generally increased fitness. Our results show that Tamps are
              mutations that produce large, typically condition-dependent
              changes in fitness that are important drivers of increased
              fitness in asexually evolving populations.",
  journal  = "PLoS Biol.",
  volume   =  13,
  number   =  5,
  pages    = "e1002155",
  month    =  may,
  year     =  2015,
  language = "en"
}

@ARTICLE{Graw2009-uo,
  title    = "Investigating {CTL} mediated killing with a {3D} cellular
              automaton",
  author   = "Graw, Frederik and Regoes, Roland R",
  abstract = "Cytotoxic T lymphocytes (CTLs) are important immune effectors
              against intra-cellular pathogens. These cells search for infected
              cells and kill them. Recently developed experimental methods in
              combination with mathematical models allow for the quantification
              of the efficacy of CTL killing in vivo and, hence, for the
              estimation of parameters that characterize the effect of CTL
              killing on the target cell populations. It is not known how these
              population-level parameters relate to single-cell properties. To
              address this question, we developed a three-dimensional cellular
              automaton model of the region of the spleen where CTL killing
              takes place. The cellular automaton model describes the movement
              of different cell populations and their interactions. Cell
              movement patterns in our cellular automaton model agree with
              observations from two-photon microscopy. We find that, despite
              the strong spatial nature of the kinetics in our cellular
              automaton model, the killing of target cells by CTLs can be
              described by a term which is linear in the target cell frequency
              and saturates with respect to the CTL levels. Further, we find
              that the parameters describing CTL killing on the population
              level are most strongly impacted by the time a CTL needs to kill
              a target cell. This suggests that the killing of target cells,
              rather than their localization, is the limiting step in CTL
              killing dynamics given reasonable frequencies of CTL. Our
              analysis identifies additional experimental directions which are
              of particular importance to interpret estimates of killing rates
              and could advance our quantitative understanding of CTL killing.",
  journal  = "PLoS Comput. Biol.",
  volume   =  5,
  number   =  8,
  pages    = "e1000466",
  month    =  aug,
  year     =  2009,
  language = "en"
}

@ARTICLE{Elemans2012-np,
  title    = "The efficiency of the human {CD8+} {T} cell response: how should
              we quantify it, what determines it, and does it matter?",
  author   = "Elemans, Marjet and Seich Al Basatena, Nafisa-Katrin and Asquith,
              Becca",
  abstract = "Multidisciplinary techniques, in particular the combination of
              theoretical and experimental immunology, can address questions
              about human immunity that cannot be answered by other means. From
              the turnover of virus-infected cells in vivo, to rates of thymic
              production and HLA class I epitope prediction, theoretical
              techniques provide a unique insight to supplement experimental
              approaches. Here we present our opinion, with examples, of some
              of the ways in which mathematics has contributed in our field of
              interest: the efficiency of the human CD8+ T cell response to
              persistent viruses.",
  journal  = "PLoS Comput. Biol.",
  volume   =  8,
  number   =  2,
  pages    = "e1002381",
  month    =  feb,
  year     =  2012,
  language = "en"
}

@ARTICLE{Kim2012-lf,
  title    = "Modeling protective anti-tumor immunity via preventative cancer
              vaccines using a hybrid agent-based and delay differential
              equation approach",
  author   = "Kim, Peter S and Lee, Peter P",
  abstract = "A next generation approach to cancer envisions developing
              preventative vaccinations to stimulate a person's immune cells,
              particularly cytotoxic T lymphocytes (CTLs), to eliminate
              incipient tumors before clinical detection. The purpose of our
              study is to quantitatively assess whether such an approach would
              be feasible, and if so, how many anti-cancer CTLs would have to
              be primed against tumor antigen to provide significant
              protection. To understand the relevant dynamics, we develop a
              two-compartment model of tumor-immune interactions at the tumor
              site and the draining lymph node. We model interactions at the
              tumor site using an agent-based model (ABM) and dynamics in the
              lymph node using a system of delay differential equations (DDEs).
              We combine the models into a hybrid ABM-DDE system and
              investigate dynamics over a wide range of parameters, including
              cell proliferation rates, tumor antigenicity, CTL recruitment
              times, and initial memory CTL populations. Our results indicate
              that an anti-cancer memory CTL pool of 3\% or less can
              successfully eradicate a tumor population over a wide range of
              model parameters, implying that a vaccination approach is
              feasible. In addition, sensitivity analysis of our model reveals
              conditions that will result in rapid tumor destruction,
              oscillation, and polynomial rather than exponential decline in
              the tumor population due to tumor geometry.",
  journal  = "PLoS Comput. Biol.",
  volume   =  8,
  number   =  10,
  pages    = "e1002742",
  month    =  oct,
  year     =  2012,
  language = "en"
}

@ARTICLE{Secomb2013-ft,
  title    = "Angiogenesis: an adaptive dynamic biological patterning problem",
  author   = "Secomb, Timothy W and Alberding, Jonathan P and Hsu, Richard and
              Dewhirst, Mark W and Pries, Axel R",
  abstract = "Formation of functionally adequate vascular networks by
              angiogenesis presents a problem in biological patterning.
              Generated without predetermined spatial patterns, networks must
              develop hierarchical tree-like structures for efficient
              convective transport over large distances, combined with dense
              space-filling meshes for short diffusion distances to every point
              in the tissue. Moreover, networks must be capable of
              restructuring in response to changing functional demands without
              interruption of blood flow. Here, theoretical simulations based
              on experimental data are used to demonstrate that this patterning
              problem can be solved through over-abundant stochastic generation
              of vessels in response to a growth factor generated in hypoxic
              tissue regions, in parallel with refinement by structural
              adaptation and pruning. Essential biological mechanisms for
              generation of adequate and efficient vascular patterns are
              identified and impairments in vascular properties resulting from
              defects in these mechanisms are predicted. The results provide a
              framework for understanding vascular network formation in normal
              or pathological conditions and for predicting effects of
              therapies targeting angiogenesis.",
  journal  = "PLoS Comput. Biol.",
  volume   =  9,
  number   =  3,
  pages    = "e1002983",
  month    =  mar,
  year     =  2013,
  language = "en"
}

@ARTICLE{Elemans2014-xi,
  title    = "Rates of {CTL} killing in persistent viral infection in vivo",
  author   = "Elemans, Marjet and Florins, Arnaud and Willems, Luc and Asquith,
              Becca",
  abstract = "The CD8+ cytotoxic T lymphocyte (CTL) response is an important
              defence against viral invasion. Although CTL-mediated
              cytotoxicity has been widely studied for many years, the rate at
              which virus-infected cells are killed in vivo by the CTL response
              is poorly understood. To date the rate of CTL killing in vivo has
              been estimated for three virus infections but the estimates
              differ considerably, and killing of HIV-1-infected cells was
              unexpectedly low. This raises questions about the typical
              anti-viral capability of CTL and whether CTL killing is
              abnormally low in HIV-1. We estimated the rate of killing of
              infected cells by CD8+ T cells in two distinct persistent virus
              infections: sheep infected with Bovine Leukemia Virus (BLV) and
              humans infected with Human T Lymphotropic Virus type 1 (HTLV-1)
              which together with existing data allows us to study a total of
              five viruses in parallel. Although both BLV and HTLV-1 infection
              are characterised by large expansions of chronically activated
              CTL with immediate effector function ex vivo and no evidence of
              overt immune suppression, our estimates are at the lower end of
              the reported range. This enables us to put current estimates into
              perspective and shows that CTL killing of HIV-infected cells may
              not be atypically low. The estimates at the higher end of the
              range are obtained in more manipulated systems and may thus
              represent the potential rather than the realised CTL efficiency.",
  journal  = "PLoS Comput. Biol.",
  volume   =  10,
  number   =  4,
  pages    = "e1003534",
  month    =  apr,
  year     =  2014,
  language = "en"
}

@ARTICLE{Schwarz2014-de,
  title    = "Phylogenetic quantification of intra-tumour heterogeneity",
  author   = "Schwarz, Roland F and Trinh, Anne and Sipos, Botond and Brenton,
              James D and Goldman, Nick and Markowetz, Florian",
  abstract = "Intra-tumour genetic heterogeneity is the result of ongoing
              evolutionary change within each cancer. The expansion of
              genetically distinct sub-clonal populations may explain the
              emergence of drug resistance, and if so, would have prognostic
              and predictive utility. However, methods for objectively
              quantifying tumour heterogeneity have been missing and are
              particularly difficult to establish in cancers where predominant
              copy number variation prevents accurate phylogenetic
              reconstruction owing to horizontal dependencies caused by long
              and cascading genomic rearrangements. To address these
              challenges, we present MEDICC, a method for phylogenetic
              reconstruction and heterogeneity quantification based on a
              Minimum Event Distance for Intra-tumour Copy-number Comparisons.
              Using a transducer-based pairwise comparison function, we
              determine optimal phasing of major and minor alleles, as well as
              evolutionary distances between samples, and are able to
              reconstruct ancestral genomes. Rigorous simulations and an
              extensive clinical study show the power of our method, which
              outperforms state-of-the-art competitors in reconstruction
              accuracy, and additionally allows unbiased numerical
              quantification of tumour heterogeneity. Accurate quantification
              and evolutionary inference are essential to understand the
              functional consequences of tumour heterogeneity. The MEDICC
              algorithms are independent of the experimental techniques used
              and are applicable to both next-generation sequencing and array
              CGH data.",
  journal  = "PLoS Comput. Biol.",
  volume   =  10,
  number   =  4,
  pages    = "e1003535",
  month    =  apr,
  year     =  2014,
  language = "en"
}

@ARTICLE{Benzekry2014-mx,
  title    = "Classical mathematical models for description and prediction of
              experimental tumor growth",
  author   = "Benzekry, S{\'e}bastien and Lamont, Clare and Beheshti, Afshin
              and Tracz, Amanda and Ebos, John M L and Hlatky, Lynn and
              Hahnfeldt, Philip",
  abstract = "Despite internal complexity, tumor growth kinetics follow
              relatively simple laws that can be expressed as mathematical
              models. To explore this further, quantitative analysis of the
              most classical of these were performed. The models were assessed
              against data from two in vivo experimental systems: an ectopic
              syngeneic tumor (Lewis lung carcinoma) and an orthotopically
              xenografted human breast carcinoma. The goals were threefold: 1)
              to determine a statistical model for description of the
              measurement error, 2) to establish the descriptive power of each
              model, using several goodness-of-fit metrics and a study of
              parametric identifiability, and 3) to assess the models' ability
              to forecast future tumor growth. The models included in the study
              comprised the exponential, exponential-linear, power law,
              Gompertz, logistic, generalized logistic, von Bertalanffy and a
              model with dynamic carrying capacity. For the breast data, the
              dynamics were best captured by the Gompertz and
              exponential-linear models. The latter also exhibited the highest
              predictive power, with excellent prediction scores ($\geq$80\%)
              extending out as far as 12 days in the future. For the lung data,
              the Gompertz and power law models provided the most parsimonious
              and parametrically identifiable description. However, not one of
              the models was able to achieve a substantial prediction rate
              ($\geq$70\%) beyond the next day data point. In this context,
              adjunction of a priori information on the parameter distribution
              led to considerable improvement. For instance, forecast success
              rates went from 14.9\% to 62.7\% when using the power law model
              to predict the full future tumor growth curves, using just three
              data points. These results not only have important implications
              for biological theories of tumor growth and the use of
              mathematical modeling in preclinical anti-cancer drug
              investigations, but also may assist in defining how mathematical
              models could serve as potential prognostic tools in the clinic.",
  journal  = "PLoS Comput. Biol.",
  volume   =  10,
  number   =  8,
  pages    = "e1003800",
  month    =  aug,
  year     =  2014,
  language = "en"
}

@ARTICLE{Thurley2015-tt,
  title    = "{Three-Dimensional} Gradients of Cytokine Signaling between {T}
              Cells",
  author   = "Thurley, Kevin and Gerecht, Daniel and Friedmann, Elfriede and
              H{\"o}fer, Thomas",
  abstract = "Immune responses are regulated by diffusible mediators, the
              cytokines, which act at sub-nanomolar concentrations. The spatial
              range of cytokine communication is a crucial, yet poorly
              understood, functional property. Both containment of cytokine
              action in narrow junctions between immune cells (immunological
              synapses) and global signaling throughout entire lymph nodes have
              been proposed, but the conditions under which they might occur
              are not clear. Here we analyze spatially three-dimensional
              reaction-diffusion models for the dynamics of cytokine signaling
              at two successive scales: in immunological synapses and in dense
              multicellular environments. For realistic parameter values, we
              observe local spatial gradients, with the cytokine concentration
              around secreting cells decaying sharply across only a few cell
              diameters. Focusing on the well-characterized T-cell cytokine
              interleukin-2, we show how cytokine secretion and competitive
              uptake determine this signaling range. Uptake is shaped locally
              by the geometry of the immunological synapse. However, even for
              narrow synapses, which favor intrasynaptic cytokine consumption,
              escape fluxes into the extrasynaptic space are expected to be
              substantial ($\geq$20\% of secretion). Hence paracrine signaling
              will generally extend beyond the synapse but can be limited to
              cellular microenvironments through uptake by target cells or
              strong competitors, such as regulatory T cells. By contrast,
              long-range cytokine signaling requires a high density of cytokine
              producers or weak consumption (e.g., by sparsely distributed
              target cells). Thus in a physiological setting, cytokine
              gradients between cells, and not bulk-phase concentrations, are
              crucial for cell-to-cell communication, emphasizing the need for
              spatially resolved data on cytokine signaling.",
  journal  = "PLoS Comput. Biol.",
  volume   =  11,
  number   =  4,
  pages    = "e1004206",
  month    =  apr,
  year     =  2015,
  language = "en"
}

@ARTICLE{Niculescu2015-kg,
  title    = "Crawling and Gliding: A Computational Model for {Shape-Driven}
              Cell Migration",
  author   = "Niculescu, Ioana and Textor, Johannes and de Boer, Rob J",
  abstract = "Cell migration is a complex process involving many intracellular
              and extracellular factors, with different cell types adopting
              sometimes strikingly different morphologies. Modeling
              realistically behaving cells in tissues is computationally
              challenging because it implies dealing with multiple levels of
              complexity. We extend the Cellular Potts Model with an
              actin-inspired feedback mechanism that allows small stochastic
              cell rufflings to expand to cell protrusions. This simple
              phenomenological model produces realistically crawling and
              deforming amoeboid cells, and gliding half-moon shaped
              keratocyte-like cells. Both cell types can migrate randomly or
              follow directional cues. They can squeeze in between other cells
              in densely populated environments or migrate collectively. The
              model is computationally light, which allows the study of large,
              dense and heterogeneous tissues containing cells with realistic
              shapes and migratory properties.",
  journal  = "PLoS Comput. Biol.",
  volume   =  11,
  number   =  10,
  pages    = "e1004280",
  month    =  oct,
  year     =  2015,
  language = "en"
}

@ARTICLE{Elizalde2018-de,
  title    = "A Markov chain for numerical chromosomal instability in clonally
              expanding populations",
  author   = "Elizalde, Sergi and Laughney, Ashley M and Bakhoum, Samuel F",
  abstract = "Cancer cells frequently undergo chromosome missegregation events
              during mitosis, whereby the copies of a given chromosome are not
              distributed evenly among the two daughter cells, thus creating
              cells with heterogeneous karyotypes. A stochastic model tracing
              cellular karyotypes derived from clonal populations over hundreds
              of generations was recently developed and experimentally
              validated, and it was capable of predicting favorable karyotypes
              frequently observed in cancer. Here, we construct and study a
              Markov chain that precisely describes karyotypic evolution during
              clonally expanding cancer cell populations. The Markov chain
              allows us to directly predict the distribution of karyotypes and
              the expected size of the tumor after many cell divisions without
              resorting to computationally expensive simulations. We determine
              the limiting karyotype distribution of an evolving tumor
              population, and quantify its dependency on several key parameters
              including the initial karyotype of the founder cell, the rate of
              whole chromosome missegregation, and chromosome-specific cell
              viability. Using this model, we confirm the existence of an
              optimal rate of chromosome missegregation probabilities that
              maximizes karyotypic heterogeneity, while minimizing the
              occurrence of nullisomy. Interestingly, karyotypic heterogeneity
              is significantly more dependent on chromosome missegregation
              probabilities rather than the number of cell divisions, so that
              maximal heterogeneity can be reached rapidly (within a few
              hundred generations of cell division) at chromosome
              missegregation rates commonly observed in cancer cell lines.
              Conversely, at low missegregation rates, heterogeneity is
              constrained even after thousands of cell division events. This
              leads us to conclude that chromosome copy number heterogeneity is
              primarily constrained by chromosome missegregation rates and the
              risk for nullisomy and less so by the age of the tumor. This
              model enables direct integration of karyotype information into
              existing models of tumor evolution based on somatic mutations.",
  journal  = "PLoS Comput. Biol.",
  volume   =  14,
  number   =  9,
  pages    = "e1006447",
  month    =  sep,
  year     =  2018,
  language = "en"
}

@ARTICLE{Castro2020-as,
  title    = "Testing structural identifiability by a simple scaling method",
  author   = "Castro, Mario and de Boer, Rob J",
  abstract = "Successful mathematical modeling of biological processes relies
              on the expertise of the modeler to capture the essential
              mechanisms in the process at hand and on the ability to extract
              useful information from empirical data. A model is said to be
              structurally unidentifiable, if different quantitative sets of
              parameters provide the same observable outcome. This is typical
              (but not exclusive) of partially observed problems in which only
              a few variables can be experimentally measured. Most of the
              available methods to test the structural identifiability of a
              model are either too complex mathematically for the general
              practitioner to be applied, or require involved calculations or
              numerical computation for complex non-linear models. In this
              work, we present a new analytical method to test structural
              identifiability of models based on ordinary differential
              equations, based on the invariance of the equations under the
              scaling transformation of its parameters. The method is based on
              rigorous mathematical results but it is easy and quick to apply,
              even to test the identifiability of sophisticated highly
              non-linear models. We illustrate our method by example and
              compare its performance with other existing methods in the
              literature.",
  journal  = "PLoS Comput. Biol.",
  volume   =  16,
  number   =  11,
  pages    = "e1008248",
  month    =  nov,
  year     =  2020,
  language = "en"
}

@ARTICLE{Kimmel2023-th,
  title    = "Intra-tumor heterogeneity, turnover rate and karyotype space
              shape susceptibility to missegregation-induced extinction",
  author   = "Kimmel, Gregory J and Beck, Richard J and Yu, Xiaoqing and Veith,
              Thomas and Bakhoum, Samuel and Altrock, Philipp M and Andor,
              Noemi",
  abstract = "The phenotypic efficacy of somatic copy number alterations
              (SCNAs) stems from their incidence per base pair of the genome,
              which is orders of magnitudes greater than that of point
              mutations. One mitotic event stands out in its potential to
              significantly change a cell's SCNA burden-a chromosome
              missegregation. A stochastic model of chromosome mis-segregations
              has been previously developed to describe the evolution of SCNAs
              of a single chromosome type. Building upon this work, we derive a
              general deterministic framework for modeling missegregations of
              multiple chromosome types. The framework offers flexibility to
              model intra-tumor heterogeneity in the SCNAs of all chromosomes,
              as well as in missegregation- and turnover rates. The model can
              be used to test how selection acts upon coexisting karyotypes
              over hundreds of generations. We use the model to calculate
              missegregation-induced population extinction (MIE) curves, that
              separate viable from non-viable populations as a function of
              their turnover- and missegregation rates. Turnover- and
              missegregation rates estimated from scRNA-seq data are then
              compared to theoretical predictions. We find convergence of
              theoretical and empirical results in both the location of MIE
              curves and the necessary conditions for MIE. When a dependency of
              missegregation rate on karyotype is introduced, karyotypes
              associated with low missegregation rates act as a stabilizing
              refuge, rendering MIE impossible unless turnover rates are
              exceedingly high. Intra-tumor heterogeneity, including
              heterogeneity in missegregation rates, increases as tumors
              progress, rendering MIE unlikely.",
  journal  = "PLoS Comput. Biol.",
  volume   =  19,
  number   =  1,
  pages    = "e1010815",
  month    =  jan,
  year     =  2023,
  language = "en"
}

@ARTICLE{Yates2007-cr,
  title    = "Revisiting estimates of {CTL} killing rates in vivo",
  author   = "Yates, Andrew and Graw, Frederik and Barber, Daniel L and Ahmed,
              Rafi and Regoes, Roland R and Antia, Rustom",
  abstract = "Recent experimental advances have allowed the estimation of the
              in vivo rates of killing of infected target cells by cytotoxic T
              lymphocytes (CTL). We present several refinements to a method
              applied previously to quantify killing of targets in the spleen
              using a dynamical model. We reanalyse data previously used to
              estimate killing rates of CTL specific for two epitopes of
              lymphocytic choriomeningitis virus (LCMV) in mice and show that,
              contrary to previous estimates the ``killing rate'' of effector
              CTL is approximately twice that of memory CTL. Further, our
              method allows the fits to be visualized, and reveals one
              potentially interesting discrepancy between fits and data. We
              discuss extensions to the basic CTL killing model to explain this
              discrepancy and propose experimental tests to distinguish between
              them.",
  journal  = "PLoS One",
  volume   =  2,
  number   =  12,
  pages    = "e1301",
  month    =  dec,
  year     =  2007,
  language = "en"
}

@ARTICLE{Vitale2007-us,
  title    = "Inhibition of Chk1 kills tetraploid tumor cells through a
              p53-dependent pathway",
  author   = "Vitale, Ilio and Galluzzi, Lorenzo and Vivet, Sonia and Nanty,
              Lisa and Dessen, Philippe and Senovilla, Laura and Olaussen, Ken
              A and Lazar, Vladimir and Prudhomme, Michelle and Golsteyn, Roy M
              and Castedo, Maria and Kroemer, Guido",
  abstract = "Tetraploidy constitutes an adaptation to stress and an
              intermediate step between euploidy and aneuploidy in oncogenesis.
              Tetraploid cells are particularly resistant against genotoxic
              stress including radiotherapy and chemotherapy. Here, we designed
              a strategy to preferentially kill tetraploid tumor cells.
              Depletion of checkpoint kinase-1 (Chk1) by siRNAs, transfection
              with dominant-negative Chk1 mutants or pharmacological Chk1
              inhibition killed tetraploid colon cancer cells yet had minor
              effects on their diploid counterparts. Chk1 inhibition abolished
              the spindle assembly checkpoint and caused premature and abnormal
              mitoses that led to p53 activation and cell death at a higher
              frequency in tetraploid than in diploid cells. Similarly,
              abolition of the spindle checkpoint by knockdown of Bub1, BubR1
              or Mad2 induced p53-dependent apoptosis of tetraploid cells. Chk1
              inhibition reversed the cisplatin resistance of tetraploid cells
              in vitro and in vivo, in xenografted human cancers. Chk1
              inhibition activated p53-regulated transcripts including
              Puma/BBC3 in tetraploid but not in diploid tumor cells.
              Altogether, our results demonstrate that, in tetraploid tumor
              cells, the inhibition of Chk1 sequentially triggers aberrant
              mitosis, p53 activation and Puma/BBC3-dependent mitochondrial
              apoptosis.",
  journal  = "PLoS One",
  volume   =  2,
  number   =  12,
  pages    = "e1337",
  month    =  dec,
  year     =  2007,
  language = "en"
}

@ARTICLE{Lubin2009-vd,
  title    = "Selective killing of tumors deficient in methylthioadenosine
              phosphorylase: a novel strategy",
  author   = "Lubin, Martin and Lubin, Adam",
  abstract = "BACKGROUND: The gene for methylthioadenosine phosphorylase (MTAP)
              lies on 9p21, close to the gene CDKN2A that encodes the tumor
              suppressor proteins p16 and p14ARF. MTAP and CDKN2A are
              homozygously co-deleted, with a frequency of 35 to 70\%, in lung
              and pancreatic cancer, glioblastoma, osteosarcoma, soft-tissue
              sarcoma, mesothelioma, and T-cell acute lymphoblastic leukemia.
              In normal cells, but not in tumor cells lacking MTAP, MTAP
              cleaves the natural substrate, 5'-deoxy-5'-methylthioadenosine
              (MTA), to adenine and 5-methylthioribose-1-phosphate (MTR-1-P),
              which are then converted to adenine nucleotides and methionine.
              This distinct difference between normal MTAP-positive cells and
              tumor MTAP-negative cells led to several proposals for therapy.
              We offer a novel strategy in which both MTA and a toxic adenine
              analog, such as 2,6-diaminopurine (DAP), 6-methylpurine (MeP), or
              2-fluoroadenine (F-Ade), are administered. In MTAP-positive
              cells, abundant adenine, generated from supplied MTA,
              competitively blocks the conversion of an analog, by adenine
              phosphoribosyltransferase (APRT), to its active nucleotide form.
              In MTAP-negative tumor cells, the supplied MTA cannot generate
              adenine; hence conversion of the analog is not blocked. PRINCIPAL
              FINDINGS: We show that this combination treatment--adenine analog
              plus MTA--kills MTAP-negative A549 lung tumor cells, while
              MTAP-positive human fibroblasts (HF) are protected. In
              co-cultures of the breast tumor cell line, MCF-7, and HF cells,
              MCF-7 is inhibited or killed, while HF cells proliferate
              robustly. 5-Fluorouracil (5-FU) and 6-thioguanine (6-TG) may also
              be used with our strategy. Though neither analog is activated by
              APRT, in MTAP-positive cells, adenine produced from supplied MTA
              blocks conversion of 5-FU and 6-TG to their toxic nucleotide
              forms by competing for 5-phosphoribosyl-1-pyrophosphate (PRPP).
              The combination of MTA with 5-FU or 6-TG, in the treatment of
              MTAP-negative tumors, may produce a significantly improved
              therapeutic index. CONCLUSION: We describe a selective strategy
              to kill tumor cells lacking MTAP.",
  journal  = "PLoS One",
  volume   =  4,
  number   =  5,
  pages    = "e5735",
  month    =  may,
  year     =  2009,
  language = "en"
}

@ARTICLE{Ganusov2011-xy,
  title     = "Killing of Targets by {CD8+} {T} Cells in the Mouse Spleen
               Follows the Law of Mass Action",
  author    = "Ganusov, Vitaly V and Barber, Daniel L and De Boer, Rob J",
  abstract  = "It has been difficult to correlate the quality of CD8 T cell
               responses with protection against viral infections. To
               investigate the relationship between efficacy and magnitude of T
               cell responses, we quantify the rate at which individual CD8
               effector and memory T cells kill target cells in the mouse
               spleen. Using mathematical modeling, we analyze recent data on
               the loss of target cells pulsed with three different peptides
               from the mouse lymphocytic choriomeningitis virus (LCMV) in
               mouse spleens with varying numbers of epitope-specific CD8 T
               cells. We find that the killing of targets follows the law of
               mass-action, i.e., the death rate of individual target cells
               remains proportional to the frequency (or the total number) of
               specific CD8 T cells in the spleen despite the fact that
               effector cell densities and effector to target ratios vary about
               a 1000-fold. The killing rate of LCMV-specific CD8 T cells is
               largely independent of T cell specificity and differentiation
               stage. Our results thus allow one to calculate the critical T
               cell concentration at which growth of a virus with a given
               replication rate can be prevented from the start of infection by
               memory CD8 T cell response.",
  journal   = "PLoS One",
  publisher = "Public Library of Science",
  volume    =  6,
  number    =  1,
  pages     = "e15959",
  month     =  jan,
  year      =  2011
}

@ARTICLE{Chen2012-mz,
  title    = "Serum starvation induced cell cycle synchronization facilitates
              human somatic cells reprogramming",
  author   = "Chen, Mengfei and Huang, Jingjing and Yang, Xuejiao and Liu,
              Bingqian and Zhang, Weizhong and Huang, Li and Deng, Fei and Ma,
              Jian and Bai, Yujing and Lu, Rong and Huang, Bing and Gao,
              Qianying and Zhuo, Yehong and Ge, Jian",
  abstract = "Human induced pluripotent stem cells (iPSCs) provide a valuable
              model for regenerative medicine and human disease research. To
              date, however, the reprogramming efficiency of human adult cells
              is still low. Recent studies have revealed that cell cycle is a
              key parameter driving epigenetic reprogramming to pluripotency.
              As is well known, retroviruses such as the Moloney murine
              leukemia virus (MoMLV) require cell division to integrate into
              the host genome and replicate, whereas the target primary cells
              for reprogramming are a mixture of several cell types with
              different cell cycle rhythms. Whether cell cycle synchronization
              has potential effect on retrovirus induced reprogramming has not
              been detailed. In this study, utilizing transient serum
              starvation induced synchronization, we demonstrated that
              starvation generated a reversible cell cycle arrest and
              synchronously progressed through G2/M phase after release,
              substantially improving retroviral infection efficiency.
              Interestingly, synchronized human dermal fibroblasts (HDF) and
              adipose stem cells (ASC) exhibited more homogenous epithelial
              morphology than normal FBS control after infection, and the
              expression of epithelial markers such as E-cadherin and Epcam
              were strongly activated. Futhermore, synchronization treatment
              ultimately improved Nanog positive clones, achieved a 15-20 fold
              increase. These results suggested that cell cycle synchronization
              promotes the mesenchymal to epithelial transition (MET) and
              facilitates retrovirus mediated reprogramming. Our study,
              utilization of serum starvation rather than additional chemicals,
              provide a new insight into cell cycle regulation and induced
              reprogramming of human cells.",
  journal  = "PLoS One",
  volume   =  7,
  number   =  4,
  pages    = "e28203",
  month    =  apr,
  year     =  2012,
  language = "en"
}

@ARTICLE{Soltani2013-iq,
  title    = "Numerical Modeling of Interstitial Fluid Flow Coupled with Blood
              Flow through a Remodeled Solid Tumor Microvascular Network",
  author   = "Soltani, M and Chen, P",
  abstract = "Modeling of interstitial fluid flow involves processes such as
              fluid diffusion, convective transport in extracellular matrix,
              and extravasation from blood vessels. To date, majority of
              microvascular flow modeling has been done at different levels and
              scales mostly on simple tumor shapes with their capillaries.
              However, with our proposed numerical model, more complex and
              realistic tumor shapes and capillary networks can be studied.
              Both blood flow through a capillary network, which is induced by
              a solid tumor, and fluid flow in tumor's surrounding tissue are
              formulated. First, governing equations of angiogenesis are
              implemented to specify the different domains for the network and
              interstitium. Then, governing equations for flow modeling are
              introduced for different domains. The conservation laws for mass
              and momentum (including continuity equation, Darcy's law for
              tissue, and simplified Navier-Stokes equation for blood flow
              through capillaries) are used for simulating interstitial and
              intravascular flows and Starling's law is used for closing this
              system of equations and coupling the intravascular and
              extravascular flows. This is the first study of flow modeling in
              solid tumors to naturalistically couple intravascular and
              extravascular flow through a network. This network is generated
              by sprouting angiogenesis and consisting of one parent vessel
              connected to the network while taking into account the
              non-continuous behavior of blood, adaptability of capillary
              diameter to hemodynamics and metabolic stimuli, non-Newtonian
              blood flow, and phase separation of blood flow in capillary
              bifurcation. The incorporation of the outlined components beyond
              the previous models provides a more realistic prediction of
              interstitial fluid flow pattern in solid tumors and surrounding
              tissues. Results predict higher interstitial pressure, almost two
              times, for realistic model compared to the simplified model.",
  journal  = "PLoS One",
  volume   =  8,
  number   =  6,
  pages    = "e67025",
  month    =  jun,
  year     =  2013,
  language = "en"
}

@ARTICLE{Feijo_Delgado2013-xj,
  title    = "Intracellular water exchange for measuring the dry mass, water
              mass and changes in chemical composition of living cells",
  author   = "Feij{\'o} Delgado, Francisco and Cermak, Nathan and Hecht, Vivian
              C and Son, Sungmin and Li, Yingzhong and Knudsen, Scott M and
              Olcum, Selim and Higgins, John M and Chen, Jianzhu and Grover,
              William H and Manalis, Scott R",
  abstract = "We present a method for direct non-optical quantification of dry
              mass, dry density and water mass of single living cells in
              suspension. Dry mass and dry density are obtained simultaneously
              by measuring a cell's buoyant mass sequentially in an H2O-based
              fluid and a D2O-based fluid. Rapid exchange of intracellular H2O
              for D2O renders the cell's water content neutrally buoyant in
              both measurements, and thus the paired measurements yield the
              mass and density of the cell's dry material alone. Utilizing this
              same property of rapid water exchange, we also demonstrate the
              quantification of intracellular water mass. In a population of E.
              coli, we paired these measurements to estimate the percent dry
              weight by mass and volume. We then focused on cellular dry
              density - the average density of all cellular biomolecules,
              weighted by their relative abundances. Given that densities vary
              across biomolecule types (RNA, DNA, protein), we investigated
              whether we could detect changes in biomolecular composition in
              bacteria, fungi, and mammalian cells. In E. coli, and S.
              cerevisiae, dry density increases from stationary to exponential
              phase, consistent with previously known increases in the
              RNA/protein ratio from up-regulated ribosome production. For
              mammalian cells, changes in growth conditions cause substantial
              shifts in dry density, suggesting concurrent changes in the
              protein, nucleic acid and lipid content of the cell.",
  journal  = "PLoS One",
  volume   =  8,
  number   =  7,
  pages    = "e67590",
  month    =  jul,
  year     =  2013,
  language = "en"
}

@ARTICLE{Raue2013-zr,
  title    = "Lessons learned from quantitative dynamical modeling in systems
              biology",
  author   = "Raue, Andreas and Schilling, Marcel and Bachmann, Julie and
              Matteson, Andrew and Schelker, Max and Kaschek, Daniel and Hug,
              Sabine and Kreutz, Clemens and Harms, Brian D and Theis, Fabian J
              and Klingm{\"u}ller, Ursula and Timmer, Jens",
  abstract = "Due to the high complexity of biological data it is difficult to
              disentangle cellular processes relying only on intuitive
              interpretation of measurements. A Systems Biology approach that
              combines quantitative experimental data with dynamic mathematical
              modeling promises to yield deeper insights into these processes.
              Nevertheless, with growing complexity and increasing amount of
              quantitative experimental data, building realistic and reliable
              mathematical models can become a challenging task: the quality of
              experimental data has to be assessed objectively, unknown model
              parameters need to be estimated from the experimental data, and
              numerical calculations need to be precise and efficient. Here, we
              discuss, compare and characterize the performance of
              computational methods throughout the process of quantitative
              dynamic modeling using two previously established examples, for
              which quantitative, dose- and time-resolved experimental data are
              available. In particular, we present an approach that allows to
              determine the quality of experimental data in an efficient,
              objective and automated manner. Using this approach data
              generated by different measurement techniques and even in single
              replicates can be reliably used for mathematical modeling. For
              the estimation of unknown model parameters, the performance of
              different optimization algorithms was compared systematically.
              Our results show that deterministic derivative-based optimization
              employing the sensitivity equations in combination with a
              multi-start strategy based on latin hypercube sampling
              outperforms the other methods by orders of magnitude in accuracy
              and speed. Finally, we investigated transformations that yield a
              more efficient parameterization of the model and therefore lead
              to a further enhancement in optimization performance. We provide
              a freely available open source software package that implements
              the algorithms and examples compared here.",
  journal  = "PLoS One",
  volume   =  8,
  number   =  9,
  pages    = "e74335",
  month    =  sep,
  year     =  2013,
  language = "en"
}

@ARTICLE{Hao2014-cg,
  title    = "The {LDL-HDL} profile determines the risk of atherosclerosis: a
              mathematical model",
  author   = "Hao, Wenrui and Friedman, Avner",
  abstract = "Atherosclerosis, the leading death in the United State, is a
              disease in which a plaque builds up inside the arteries. As the
              plaque continues to grow, the shear force of the blood flow
              through the decreasing cross section of the lumen increases. This
              force may eventually cause rupture of the plaque, resulting in
              the formation of thrombus, and possibly heart attack. It has long
              been recognized that the formation of a plaque relates to the
              cholesterol concentration in the blood. For example, individuals
              with LDL above 190 mg/dL and HDL below 40 mg/dL are at high risk,
              while individuals with LDL below 100 mg/dL and HDL above 50 mg/dL
              are at no risk. In this paper, we developed a mathematical model
              of the formation of a plaque, which includes the following key
              variables: LDL and HDL, free radicals and oxidized LDL, MMP and
              TIMP, cytockines: MCP-1, IFN-$\gamma$, IL-12 and PDGF, and cells:
              macrophages, foam cells, T cells and smooth muscle cells. The
              model is given by a system of partial differential equations with
              in evolving plaque. Simulations of the model show how the
              combination of the concentrations of LDL and HDL in the blood
              determine whether a plaque will grow or disappear. More
              precisely, we create a map, showing the risk of plaque
              development for any pair of values (LDL,HDL).",
  journal  = "PLoS One",
  volume   =  9,
  number   =  3,
  pages    = "e90497",
  month    =  mar,
  year     =  2014,
  language = "en"
}

% The entry below contains non-ASCII chars that could not be converted
% to a LaTeX equivalent.
@ARTICLE{Meshkat2014-vd,
  title     = "On finding and using identifiable parameter combinations in
               nonlinear dynamic systems biology models and {COMBOS}: a novel
               web implementation",
  author    = "Meshkat, Nicolette and Kuo, Christine Er-Zhen and DiStefano,
               3rd, Joseph",
  abstract  = "Parameter identifiability problems can plague biomodelers when
               they reach the quantification stage of development, even for
               relatively simple models. Structural identifiability (SI) is the
               primary question, usually understood as knowing which of P
               unknown biomodel parameters p1,, pi,, pP are-and which are
               not-quantifiable in principle from particular input-output (I-O)
               biodata. It is not widely appreciated that the same database
               also can provide quantitative information about the structurally
               unidentifiable (not quantifiable) subset, in the form of
               explicit algebraic relationships among unidentifiable pi.
               Importantly, this is a first step toward finding what else is
               needed to quantify particular unidentifiable parameters of
               interest from new I-O experiments. We further develop, implement
               and exemplify novel algorithms that address and solve the SI
               problem for a practical class of ordinary differential equation
               (ODE) systems biology models, as a user-friendly and
               universally-accessible web application (app)-COMBOS. Users
               provide the structural ODE and output measurement models in one
               of two standard forms to a remote server via their web browser.
               COMBOS provides a list of uniquely and non-uniquely SI model
               parameters, and-importantly-the combinations of parameters not
               individually SI. If non-uniquely SI, it also provides the
               maximum number of different solutions, with important practical
               implications. The behind-the-scenes symbolic differential
               algebra algorithms are based on computing Gr{\"o}bner bases of
               model attributes established after some algebraic
               transformations, using the computer-algebra system Maxima.
               COMBOS was developed for facile instructional and research use
               as well as modeling. We use it in the classroom to illustrate SI
               analysis; and have simplified complex models of tumor suppressor
               p53 and hormone regulation, based on explicit computation of
               parameter combinations. It's illustrated and validated here for
               models of moderate complexity, with and without initial
               conditions. Built-in examples include unidentifiable 2 to
               4-compartment and HIV dynamics models.",
  journal   = "PLoS One",
  publisher = "journals.plos.org",
  volume    =  9,
  number    =  10,
  pages     = "e110261",
  month     =  oct,
  year      =  2014,
  language  = "en"
}

@ARTICLE{Monteagudo2015-gu,
  title    = "Treatment Analysis in a Cancer Stem Cell Context Using a Tumor
              Growth Model Based on Cellular Automata",
  author   = "Monteagudo, {\'A}ngel and Santos, Jos{\'e}",
  abstract = "Cancer can be viewed as an emergent behavior in terms of complex
              system theory and artificial life, Cellular Automata (CA) being
              the tool most used for studying and characterizing the emergent
              behavior. Different approaches with CA models were used to model
              cancer growth. The use of the abstract model of acquired cancer
              hallmarks permits the direct modeling at cellular level, where a
              cellular automaton defines the mitotic and apoptotic behavior of
              cells, and allows for an analysis of different dynamics of the
              cellular system depending on the presence of the different
              hallmarks. A CA model based on the presence of hallmarks in the
              cells, which includes a simulation of the behavior of Cancer Stem
              Cells (CSC) and their implications for the resultant growth
              behavior of the multicellular system, was employed. This modeling
              of cancer growth, in the avascular phase, was employed to analyze
              the effect of cancer treatments in a cancer stem cell context.
              The model clearly explains why, after treatment against non-stem
              cancer cells, the regrowth capability of CSCs generates a faster
              regrowth of tumor behavior, and also shows that a continuous
              low-intensity treatment does not favor CSC proliferation and
              differentiation, thereby allowing an unproblematic control of
              future tumor regrowth. The analysis performed indicates that,
              contrary to the current attempts at CSC control, trying to make
              CSC proliferation more difficult is an important point to
              consider, especially in the immediate period after a standard
              treatment for controlling non-stem cancer cell proliferation.",
  journal  = "PLoS One",
  volume   =  10,
  number   =  7,
  pages    = "e0132306",
  month    =  jul,
  year     =  2015,
  language = "en"
}

@ARTICLE{Xu2016-fp,
  title    = "A Mathematical Model Coupling Tumor Growth and Angiogenesis",
  author   = "Xu, Jiangping and Vilanova, Guillermo and Gomez, Hector",
  abstract = "We present a mathematical model for vascular tumor growth. We use
              phase fields to model cellular growth and reaction-diffusion
              equations for the dynamics of angiogenic factors and nutrients.
              The model naturally predicts the shift from avascular to vascular
              growth at realistic scales. Our computations indicate that the
              negative regulation of the Delta-like ligand 4 signaling pathway
              slows down tumor growth by producing a larger density of
              non-functional capillaries. Our results show good quantitative
              agreement with experiments.",
  journal  = "PLoS One",
  volume   =  11,
  number   =  2,
  pages    = "e0149422",
  month    =  feb,
  year     =  2016,
  language = "en"
}

@ARTICLE{Palm2016-mk,
  title    = "Computational Screening of Tip and Stalk Cell Behavior Proposes a
              Role for Apelin Signaling in Sprout Progression",
  author   = "Palm, Margriet M and Dallinga, Marchien G and van Dijk, Erik and
              Klaassen, Ingeborg and Schlingemann, Reinier O and Merks, Roeland
              M H",
  abstract = "Angiogenesis involves the formation of new blood vessels by
              sprouting or splitting of existing blood vessels. During
              sprouting, a highly motile type of endothelial cell, called the
              tip cell, migrates from the blood vessels followed by stalk
              cells, an endothelial cell type that forms the body of the
              sprout. To get more insight into how tip cells contribute to
              angiogenesis, we extended an existing computational model of
              vascular network formation based on the cellular Potts model with
              tip and stalk differentiation, without making a priori
              assumptions about the differences between tip cells and stalk
              cells. To predict potential differences, we looked for parameter
              values that make tip cells (a) move to the sprout tip, and (b)
              change the morphology of the angiogenic networks. The screening
              predicted that if tip cells respond less effectively to an
              endothelial chemoattractant than stalk cells, they move to the
              tips of the sprouts, which impacts the morphology of the
              networks. A comparison of this model prediction with genes
              expressed differentially in tip and stalk cells revealed that the
              endothelial chemoattractant Apelin and its receptor APJ may match
              the model prediction. To test the model prediction we inhibited
              Apelin signaling in our model and in an in vitro model of
              angiogenic sprouting, and found that in both cases inhibition of
              Apelin or of its receptor APJ reduces sprouting. Based on the
              prediction of the computational model, we propose that the
              differential expression of Apelin and APJ yields a
              ``self-generated'' gradient mechanisms that accelerates the
              extension of the sprout.",
  journal  = "PLoS One",
  volume   =  11,
  number   =  11,
  pages    = "e0159478",
  month    =  nov,
  year     =  2016,
  language = "en"
}

@ARTICLE{Di_Costanzo2016-hj,
  title    = "A Macroscopic Mathematical Model for Cell Migration Assays Using
              a {Real-Time} Cell Analysis",
  author   = "Di Costanzo, Ezio and Ingangi, Vincenzo and Angelini, Claudia and
              Carfora, Maria Francesca and Carriero, Maria Vincenza and
              Natalini, Roberto",
  abstract = "Experiments of cell migration and chemotaxis assays have been
              classically performed in the so-called Boyden Chambers. A recent
              technology, xCELLigence Real Time Cell Analysis, is now allowing
              to monitor the cell migration in real time. This technology
              measures impedance changes caused by the gradual increase of
              electrode surface occupation by cells during the course of time
              and provide a Cell Index which is proportional to cellular
              morphology, spreading, ruffling and adhesion quality as well as
              cell number. In this paper we propose a macroscopic mathematical
              model, based on advection-reaction-diffusion partial differential
              equations, describing the cell migration assay using the
              real-time technology. We carried out numerical simulations to
              compare simulated model dynamics with data of observed biological
              experiments on three different cell lines and in two experimental
              settings: absence of chemotactic signals (basal migration) and
              presence of a chemoattractant. Overall we conclude that our
              minimal mathematical model is able to describe the phenomenon in
              the real time scale and numerical results show a good agreement
              with the experimental evidences.",
  journal  = "PLoS One",
  volume   =  11,
  number   =  9,
  pages    = "e0162553",
  month    =  sep,
  year     =  2016,
  language = "en"
}

@ARTICLE{Lai2017-eh,
  title    = "Combination therapy of cancer with cancer vaccine and immune
              checkpoint inhibitors: A mathematical model",
  author   = "Lai, Xiulan and Friedman, Avner",
  abstract = "In this paper we consider a combination therapy of cancer. One
              drug is a vaccine which activates dendritic cells so that they
              induce more T cells to infiltrate the tumor. The other drug is a
              checkpoint inhibitor, which enables the T cells to remain active
              against the cancer cells. The two drugs are positively correlated
              in the sense that an increase in the amount of each drug results
              in a reduction in the tumor volume. We consider the question
              whether a treatment with combination of the two drugs at certain
              levels is preferable to a treatment by one of the drugs alone at
              'roughly' twice the dosage level; if that is the case, then we
              say that there is a positive 'synergy' for this combination of
              dosages. To address this question, we develop a mathematical
              model using a system of partial differential equations. The
              variables include dendritic and cancer cells, CD4+ and CD8+ T
              cells, IL-12 and IL-2, GM-CSF produced by the vaccine, and a T
              cell checkpoint inhibitor associated with PD-1. We use the model
              to explore the efficacy of the two drugs, separately and in
              combination, and compare the simulations with data from mouse
              experiments. We next introduce the concept of synergy between the
              drugs and develop a synergy map which suggests in what proportion
              to administer the drugs in order to achieve the maximum reduction
              of tumor volume under the constraint of maximum tolerated dose.",
  journal  = "PLoS One",
  volume   =  12,
  number   =  5,
  pages    = "e0178479",
  month    =  may,
  year     =  2017,
  language = "en"
}

@ARTICLE{Potez2018-cf,
  title    = "Characterization of a {B16-F10} melanoma model locally implanted
              into the ear pinnae of {C57BL/6} mice",
  author   = "Potez, Marine and Trappetti, Verdiana and Bouchet, Audrey and
              Fernandez-Palomo, Cristian and G{\"u}{\c c}, Esra and Kilarski,
              Witold W and Hlushchuk, Ruslan and Laissue, Jean and Djonov,
              Valentin",
  abstract = "The common experimental use of B16-F10 melanoma cells focuses on
              exploring their metastatic potential following intravenous
              injection into mice. In this study, B16-F10 cells are used to
              develop a primary tumor model by implanting them directly into
              the ears of C57BL/6J mice. The model represents a reproducible
              and easily traceable tool for local tumor growth and for making
              additional in vivo observations, due to the localization of the
              tumors. This model is relatively simple and involves (i) surgical
              opening of the ear skin, (ii) removal of a square-piece of
              cartilage followed by (iii) the implantation of tumor cells with
              fibrin gel. The remodeling of the fibrin gel within the cartilage
              chamber, accompanying tumor proliferation, results in the
              formation of blood vessels, lymphatics and tissue matrix that can
              be readily distinguished from the pre-existing skin structures.
              Moreover, this method avoids the injection-enforced artificial
              spread of cells into the pre-existing lymphatic vessels. The
              tumors have a highly reproducible exponential growth pattern with
              a tumor doubling time of around 1.8 days, reaching an average
              volume of 85mm3 16 days after implantation. The melanomas are
              densely cellular with proliferative indices of between 60 and
              80\%. The induced angiogenesis and lymphangiogenesis resulted in
              the development of well-vascularized tumors. Different
              populations of immunologically active cells were also present in
              the tumor; the population of macrophages decreases with time
              while the population of T cells remained quasi constant. The
              B16-F10 tumors in the ear frequently metastasized to the cervical
              lymph nodes, reaching an incidence of 75\% by day 16. This newly
              introduced B16-F10 melanoma model in the ear is a powerful tool
              that provides a new opportunity to study the local tumor growth
              and metastasis, the associated angiogenesis, lymphangiogenesis
              and tumor immune responses. It could potentially be used to test
              different treatment strategies.",
  journal  = "PLoS One",
  volume   =  13,
  number   =  11,
  pages    = "e0206693",
  month    =  nov,
  year     =  2018,
  keywords = "B16F10\_specific",
  language = "en"
}

@ARTICLE{He2020-ay,
  title    = "Multi-panel immunofluorescence analysis of tumor infiltrating
              lymphocytes in triple negative breast cancer: Evolution of tumor
              immune profiles and patient prognosis",
  author   = "He, Ting-Fang and Yost, Susan E and Frankel, Paul H and Dagis,
              Andrew and Cao, Yu and Wang, Roger and Rosario, Anthony and Tu,
              Travis Yiwey and Solomon, Shawn and Schmolze, Daniel and
              Mortimer, Joanne and Lee, Peter and Yuan, Yuan",
  abstract = "The evolutionary changes in immune profiles of triple negative
              breast cancer (TNBC) are not well understood, although it is
              known that immune checkpoint inhibitors have diminished activity
              in heavily pre-treated TNBC patients. This study was designed to
              characterize immune profile changes of longitudinal tumor
              specimens by studying immune subsets of tumor infiltrating
              lymphocytes (TILs) in paired primary and metastatic TNBC in a
              cohort of ``poor outcome'' (relapsed within 5 years) patients.
              Immune profiles of TNBCs in a cohort of ``good outcome'' (no
              relapse within 5 years) patients were also analyzed. Immune
              subsets were characterized for CD4, CD8, FOXP3, CD20, CD33, and
              PD1 using immuno-fluorescence staining in stroma, tumor, and
              combined stroma and tumor tissue. TIL subsets in ``good outcome''
              versus ``poor outcome'' patients were also analyzed. Compared
              with primary, metastatic TNBCs had significantly lower TILs by
              hematoxylin and eosin (H\&E) staining. Stromal TILs (sTILs), but
              not tumoral TILs (tTILs) had significantly reduced cytotoxic CD8+
              T cells (CTLs), PD1+ CTLs, and total PD1+ TILs in metastatic
              compared with matched primary TNBCs. Higher PD1+ CTLs, PD1+CD4+
              helper T cells (PD1+TCONV) and all PD1+ T cells in sTILs, tTILs
              and total stromal and tumor TILS (s+tTIL) were all associated
              with better prognosis. In summary, TIL subsets decrease
              significantly in metastatic TNBCs compared with matched primary.
              Higher PD1+ TILs are associated with better prognosis in early
              stage TNBCs. This finding supports the application of immune
              checkpoint inhibitors early in the treatment of TNBCs.",
  journal  = "PLoS One",
  volume   =  15,
  number   =  3,
  pages    = "e0229955",
  month    =  mar,
  year     =  2020,
  language = "en"
}

@ARTICLE{Yang2021-xj,
  title    = "An experimental-mathematical approach to predict tumor cell
              growth as a function of glucose availability in breast cancer
              cell lines",
  author   = "Yang, Jianchen and Virostko, Jack and Hormuth, 2nd, David A and
              Liu, Junyan and Brock, Amy and Kowalski, Jeanne and Yankeelov,
              Thomas E",
  abstract = "We present the development and validation of a mathematical model
              that predicts how glucose dynamics influence metabolism and
              therefore tumor cell growth. Glucose, the starting material for
              glycolysis, has a fundamental influence on tumor cell growth. We
              employed time-resolved microscopy to track the temporal change of
              the number of live and dead tumor cells under different initial
              glucose concentrations and seeding densities. We then constructed
              a family of mathematical models (where cell death was accounted
              for differently in each member of the family) to describe overall
              tumor cell growth in response to the initial glucose and
              confluence conditions. The Akaikie Information Criteria was then
              employed to identify the most parsimonious model. The selected
              model was then trained on 75\% of the data to calibrate the
              system and identify trends in model parameters as a function of
              initial glucose concentration and confluence. The calibrated
              parameters were applied to the remaining 25\% of the data to
              predict the temporal dynamics given the known initial glucose
              concentration and confluence, and tested against the
              corresponding experimental measurements. With the selected model,
              we achieved an accuracy (defined as the fraction of measured data
              that fell within the 95\% confidence intervals of the predicted
              growth curves) of 77.2 $\pm$ 6.3\% and 87.2 $\pm$ 5.1\% for live
              BT-474 and MDA-MB-231 cells, respectively.",
  journal  = "PLoS One",
  volume   =  16,
  number   =  7,
  pages    = "e0240765",
  month    =  jul,
  year     =  2021,
  language = "en"
}

@ARTICLE{Swartz2020-gf,
  title    = "How best to interpret measures of levels of oxygen in tissues to
              make them effective clinical tools for care of patients with
              cancer and other oxygen-dependent pathologies",
  author   = "Swartz, Harold M and Flood, Ann Barry and Schaner, Philip E and
              Halpern, Howard and Williams, Benjamin B and Pogue, Brian W and
              Gallez, Bernard and Vaupel, Peter",
  abstract = "It is well understood that the level of molecular oxygen (O2 ) in
              tissue is a very important factor impacting both physiology and
              pathological processes as well as responsiveness to some
              treatments. Data on O2 in tissue could be effectively utilized to
              enhance precision medicine. However, the nature of the data that
              can be obtained using existing clinically applicable techniques
              is often misunderstood, and this can confound the effective use
              of the information. Attempts to make clinical measurements of O2
              in tissues will inevitably provide data that are aggregated over
              time and space and therefore will not fully represent the
              inherent heterogeneity of O2 in tissues. Additionally, the nature
              of existing techniques to measure O2 may result in uneven
              sampling of the volume of interest and therefore may not provide
              accurate information on the ``average'' O2 in the measured
              volume. By recognizing the potential limitations of the O2
              measurements, one can focus on the important and useful
              information that can be obtained from these techniques. The most
              valuable clinical characterizations of oxygen are likely to be
              derived from a series of measurements that provide data about
              factors that can change levels of O2 , which then can be
              exploited both diagnostically and therapeutically. The clinical
              utility of such data ultimately needs to be verified by careful
              studies of outcomes related to the measured changes in levels of
              O2 .",
  journal  = "Physiol Rep",
  volume   =  8,
  number   =  15,
  pages    = "e14541",
  month    =  aug,
  year     =  2020,
  keywords = "clinical measures of oxygen; oxygen in tissues; partial pressure",
  language = "en"
}

@ARTICLE{Meena2015-gi,
  title    = "Telomerase abrogates aneuploidy-induced telomere replication
              stress, senescence and cell depletion",
  author   = "Meena, Jitendra K and Cerutti, Aurora and Beichler, Christine and
              Morita, Yohei and Bruhn, Christopher and Kumar, Mukesh and Kraus,
              Johann M and Speicher, Michael R and Wang, Zhao-Qi and Kestler,
              Hans A and d'Adda di Fagagna, Fabrizio and G{\"u}nes, Cagatay and
              Rudolph, Karl Lenhard",
  abstract = "The causal role of aneuploidy in cancer initiation remains under
              debate since mutations of euploidy-controlling genes reduce cell
              fitness but aneuploidy strongly associates with human cancers.
              Telomerase activation allows immortal growth by stabilizing
              telomere length, but its role in aneuploidy survival has not been
              characterized. Here, we analyze the response of primary human
              cells and murine hematopoietic stem cells (HSCs) to aneuploidy
              induction and the role of telomeres and the telomerase in this
              process. The study shows that aneuploidy induces replication
              stress at telomeres leading to telomeric DNA damage and p53
              activation. This results in p53/Rb-dependent, premature
              senescence of human fibroblast, and in the depletion of
              hematopoietic cells in telomerase-deficient mice. Endogenous
              telomerase expression in HSCs and enforced expression of
              telomerase in human fibroblasts are sufficient to abrogate
              aneuploidy-induced replication stress at telomeres and the
              consequent induction of premature senescence and hematopoietic
              cell depletion. Together, these results identify telomerase as an
              aneuploidy survival factor in mammalian cells based on its
              capacity to alleviate telomere replication stress in response to
              aneuploidy induction.",
  journal  = "EMBO J.",
  volume   =  34,
  number   =  10,
  pages    = "1371--1384",
  month    =  may,
  year     =  2015,
  keywords = "aneuploidy; replication stress; senescence; telomerase; telomere",
  language = "en"
}

@ARTICLE{Gurevich2018-lu,
  title    = "Live imaging of wound angiogenesis reveals macrophage
              orchestrated vessel sprouting and regression",
  author   = "Gurevich, David B and Severn, Charlotte E and Twomey, Catherine
              and Greenhough, Alexander and Cash, Jenna and Toye, Ashley M and
              Mellor, Harry and Martin, Paul",
  abstract = "Wound angiogenesis is an integral part of tissue repair and is
              impaired in many pathologies of healing. Here, we investigate the
              cellular interactions between innate immune cells and endothelial
              cells at wounds that drive neoangiogenic sprouting in real time
              and in vivo Our studies in mouse and zebrafish wounds indicate
              that macrophages are drawn to wound blood vessels soon after
              injury and are intimately associated throughout the repair
              process and that macrophage ablation results in impaired
              neoangiogenesis. Macrophages also positively influence wound
              angiogenesis by driving resolution of anti-angiogenic wound
              neutrophils. Experimental manipulation of the wound environment
              to specifically alter macrophage activation state dramatically
              influences subsequent blood vessel sprouting, with premature
              dampening of tumour necrosis factor-$\alpha$ expression leading
              to impaired neoangiogenesis. Complementary human tissue culture
              studies indicate that inflammatory macrophages associate with
              endothelial cells and are sufficient to drive vessel sprouting
              via vascular endothelial growth factor signalling. Subsequently,
              macrophages also play a role in blood vessel regression during
              the resolution phase of wound repair, and their absence, or
              shifted activation state, impairs appropriate vessel clearance.",
  journal  = "EMBO J.",
  volume   =  37,
  number   =  13,
  month    =  jul,
  year     =  2018,
  keywords = "angiogenesis; inflammation; macrophages; neutrophils; wound",
  language = "en"
}

% The entry below contains non-ASCII chars that could not be converted
% to a LaTeX equivalent.
@ARTICLE{Chao2019-ng,
  title    = "Evidence that the human cell cycle is a series of uncoupled,
              memoryless phases",
  author   = "Chao, Hui Xiao and Fakhreddin, Randy I and Shimerov, Hristo K and
              Kedziora, Katarzyna M and Kumar, Rashmi J and Perez, Joanna and
              Limas, Juanita C and Grant, Gavin D and Cook, Jeanette Gowen and
              Gupta, Gaorav P and Purvis, Jeremy E",
  abstract = "The cell cycle is canonically described as a series of four
              consecutive phases: G1, S, G2, and M. In single cells, the
              duration of each phase varies, but the quantitative laws that
              govern phase durations are not well understood. Using time-lapse
              microscopy, we found that each phase duration follows an Erlang
              distribution and is statistically independent from other phases.
              We challenged this observation by perturbing phase durations
              through oncogene activation, inhibition of DNA synthesis, reduced
              temperature, and DNA damage. Despite large changes in durations
              in cell populations, phase durations remained uncoupled in
              individual cells. These results suggested that the independence
              of phase durations may arise from a large number of molecular
              factors that each exerts a minor influence on the rate of cell
              cycle progression. We tested this model by experimentally forcing
              phase coupling through inhibition of cyclin-dependent kinase 2
              (CDK2) or overexpression of cyclin D. Our work provides an
              explanation for the historical observation that phase durations
              are both inherited and independent and suggests how cell cycle
              progression may be altered in disease states.",
  journal  = "Mol. Syst. Biol.",
  volume   =  15,
  number   =  3,
  pages    = "e8604",
  month    =  mar,
  year     =  2019,
  keywords = "Erlang model; cell cycle; celltocell variability; computational
              systems biology; singlecell dynamics",
  language = "en"
}

@ARTICLE{Zhu2016-fu,
  title    = "Whole Genome Analysis of 132 Clinical Saccharomyces cerevisiae
              Strains Reveals Extensive Ploidy Variation",
  author   = "Zhu, Yuan O and Sherlock, Gavin and Petrov, Dmitri A",
  abstract = "Budding yeast has undergone several independent transitions from
              commercial to clinical lifestyles. The frequency of such
              transitions suggests that clinical yeast strains are derived from
              environmentally available yeast populations, including commercial
              sources. However, despite their important role in adaptive
              evolution, the prevalence of polyploidy and aneuploidy has not
              been extensively analyzed in clinical strains. In this study, we
              have looked for patterns governing the transition to clinical
              invasion in the largest screen of clinical yeast isolates to
              date. In particular, we have focused on the hypothesis that
              ploidy changes have influenced adaptive processes. We sequenced
              144 yeast strains, 132 of which are clinical isolates. We found
              pervasive large-scale genomic variation in both overall ploidy
              (34\% of strains identified as 3n/4n) and individual chromosomal
              copy numbers (36\% of strains identified as aneuploid). We also
              found evidence for the highly dynamic nature of yeast genomes,
              with 35 strains showing partial chromosomal copy number changes
              and eight strains showing multiple independent chromosomal
              events. Intriguingly, a lineage identified to be
              baker's/commercial derived with a unique damaging mutation in
              NDC80 was particularly prone to polyploidy, with 83\% of its
              members being triploid or tetraploid. Polyploidy was in turn
              associated with a >2$\times$ increase in aneuploidy rates as
              compared to other lineages. This dataset provides a rich source
              of information on the genomics of clinical yeast strains and
              highlights the potential importance of large-scale genomic copy
              variation in yeast adaptation.",
  journal  = "G3",
  volume   =  6,
  number   =  8,
  pages    = "2421--2434",
  month    =  aug,
  year     =  2016,
  keywords = "adaptation; aneuploidy; ploidy; population sequencing; population
              structure",
  language = "en"
}

@ARTICLE{Torres2008-te,
  title    = "Aneuploidy: cells losing their balance",
  author   = "Torres, Eduardo M and Williams, Bret R and Amon, Angelika",
  abstract = "A change in chromosome number that is not the exact multiple of
              the haploid karyotype is known as aneuploidy. This condition
              interferes with growth and development of an organism and is a
              common characteristic of solid tumors. Here, we review the
              history of studies on aneuploidy and summarize some of its major
              characteristics. We will then discuss the molecular basis for the
              defects caused by aneuploidy and end with speculations as to
              whether and how aneuploidy, despite its deleterious effects on
              organismal and cellular fitness, contributes to tumorigenesis.",
  journal  = "Genetics",
  volume   =  179,
  number   =  2,
  pages    = "737--746",
  month    =  jun,
  year     =  2008,
  language = "en"
}

@ARTICLE{Dayarian2014-zr,
  title    = "How to infer relative fitness from a sample of genomic sequences",
  author   = "Dayarian, Adel and Shraiman, Boris I",
  abstract = "Mounting evidence suggests that natural populations can harbor
              extensive fitness diversity with numerous genomic loci under
              selection. It is also known that genealogical trees for
              populations under selection are quantifiably different from those
              expected under neutral evolution and described statistically by
              Kingman's coalescent. While differences in the statistical
              structure of genealogies have long been used as a test for the
              presence of selection, the full extent of the information that
              they contain has not been exploited. Here we demonstrate that the
              shape of the reconstructed genealogical tree for a moderately
              large number of random genomic samples taken from a fitness
              diverse, but otherwise unstructured, asexual population can be
              used to predict the relative fitness of individuals within the
              sample. To achieve this we define a heuristic algorithm, which we
              test in silico, using simulations of a Wright-Fisher model for a
              realistic range of mutation rates and selection strength. Our
              inferred fitness ranking is based on a linear discriminator that
              identifies rapidly coalescing lineages in the reconstructed tree.
              Inferred fitness ranking correlates strongly with actual fitness,
              with a genome in the top 10\% ranked being in the top 20\%
              fittest with false discovery rate of 0.1-0.3, depending on the
              mutation/selection parameters. The ranking also enables us to
              predict the genotypes that future populations inherit from the
              present one. While the inference accuracy increases monotonically
              with sample size, samples of 200 nearly saturate the performance.
              We propose that our approach can be used for inferring relative
              fitness of genomes obtained in single-cell sequencing of tumors
              and in monitoring viral outbreaks.",
  journal  = "Genetics",
  volume   =  197,
  number   =  3,
  pages    = "913--923",
  month    =  jul,
  year     =  2014,
  keywords = "evolution; fitness inference; genealogy; population genetics",
  language = "en"
}

@ARTICLE{Zhu2016-xi,
  title    = "Fas ligand and lytic granule differentially control cytotoxic
              dynamics of natural killer cell against cancer target",
  author   = "Zhu, Yanting and Huang, Bo and Shi, Jue",
  abstract = "Interaction dynamics between Natural Killer (NK) cells and cancer
              targets have been the topic of many previous investigations, but
              the underlying rate-limiting kinetics and heterogeneity remain
              poorly understood. In this study, using quantitative single cell
              microscopy assay, we elucidate the differential dynamic control
              of NK-cancer cell interaction by multiple cytotoxic pathways. We
              found primary human NK cell, unlike NK cell line, killed adherent
              cancer target mainly by lytic granule-independent mechanism, in
              particular through Fas ligand (FasL). And the distinct kinetics
              of FasL and lytic granule pathway resulted in significant
              cell-to-cell variability. Killing by FasL occurred slowly,
              requiring transient, often multiple NK-cancer cell conjugations
              that gradually activated caspase-8, while lytic granule triggered
              rapid cytotoxicity by a switch-like induction of granzyme-B upon
              a single, prolonged conjugation. Moreover, interleukin 2 was
              observed to enhance both cytotoxic mechanisms by promoting target
              recognition by NK cell and increasing NK-cancer cell interaction
              frequency. Our results not only identify the key points of
              variation in the rate-limiting kinetics of NK-cancer cell
              cytotoxic interaction but also point to the importance of
              non-lytic granule mechanism for developing NK cell therapy.",
  journal  = "Oncotarget",
  volume   =  7,
  number   =  30,
  pages    = "47163--47172",
  month    =  jul,
  year     =  2016,
  keywords = "cytotoxic lymphocyte; immune-cancer cell interaction;
              immunotherapy; natural killer cell; single cell dynamics;Direct
              Killing (Perf/Gzym/FAS)",
  language = "en"
}

@ARTICLE{Enderling2014-og,
  title    = "Mathematical modeling of tumor growth and treatment",
  author   = "Enderling, Heiko and Chaplain, Mark A J",
  abstract = "Using mathematical models to simulate dynamic biological
              processes has a long history. Over the past couple of decades or
              so, quantitative approaches have also made their way into cancer
              research. An increasing number of mathematical, physical,
              computational and engineering techniques have been applied to
              various aspects of tumor growth, with the ultimate goal of
              understanding the response of the cancer population to clinical
              intervention. So-called in silico trials that predict
              patient-specific response to various dose schedules or treatment
              combinations and sequencing are on the way to becoming an
              invaluable tool to optimize patient care. Herein we describe
              fundamentals of mathematical modeling of tumor growth and
              tumor-host interactions, and summarize some of the seminal and
              most prominent approaches.",
  journal  = "Curr. Pharm. Des.",
  volume   =  20,
  number   =  30,
  pages    = "4934--4940",
  year     =  2014,
  language = "en"
}

@ARTICLE{Wu2014-zv,
  title    = "Metabolic reprogramming of human cells in response to oxidative
              stress: implications in the pathophysiology and therapy of
              mitochondrial diseases",
  author   = "Wu, Yu-Ting and Wu, Shi-Bei and Wei, Yau-Huei",
  abstract = "Mitochondria are the organelles producing most of the energy and
              play important roles in a variety of biochemical functions in
              human cells. Mitochondrial defects can cause ATP deficiency and
              overproduction of reactive oxygen species, which are the major
              hallmarks of mitochondrial diseases. Abundant evidence has
              suggested that mitochondrial dysfunction-elicited oxidative
              stress can play an important role in the pathogenesis and
              progression of mitochondrial diseases. Mitochondria can respond
              to energy deficiency by the retrograde signaling to trigger a
              number of molecular events to help the human cells to cope with
              physiological or environmental changes. In this article, we first
              describe oxidative stress-induced cellular responses including
              metabolic adaptation, compensatory increase of mitochondrial
              biogenesis, upregulation of antioxidant enzymes, and alteration
              of protein acetylation in human cells with mitochondrial
              dysfunction. In this regard, we review recent findings to
              elucidate the mechanisms by which human cells motivate their
              mitochondria and the antioxidant defense system to respond to
              energy deficiency and oxidative stress, which contribute to the
              adaptive metabolic reprogramming in mitochondrial diseases. In
              addition, we emphasize the critical role of the activation of
              AMPK, Sirt1 and Sirt3 in the metabolic adaptation of human cells
              harboring mitochondrial DNA mutations. Recent studies have
              revealed that AMPK and sirtuins-mediated signaling pathways are
              involved in metabolic reprogramming, which is effected by
              upregulation of antioxidant defense system and mitochondrial
              protein acetylation, in human cells with mitochondrial
              dysfunction. Finally, we discuss several potential modulators of
              bioenergetic function such as coenzyme Q10,
              mitochondria-targeting antioxidants, resveratrol, and L-carnitine
              based on recent findings from studies on human cells and animal
              models of mitochondrial diseases. Elucidation of the signaling
              pathway of this adaptive response to oxidative stress triggered
              by mitochondrial dysfunction may enable us to gain a deeper
              insight into the communication between mitochondria and the
              nucleus and guide us to develop novel therapeutic agents for
              effective treatment of mitochondrial diseases.",
  journal  = "Curr. Pharm. Des.",
  volume   =  20,
  number   =  35,
  pages    = "5510--5526",
  year     =  2014,
  language = "en"
}

@ARTICLE{Therneau1990-mh,
  title     = "{Martingale-Based} Residuals for Survival Models",
  author    = "Therneau, Terry M and Grambsch, Patricia M and Fleming, Thomas R",
  abstract  = "[Graphical methods based on the analysis of residuals are
               considered for the setting of the highly-used Cox (1972)
               regression model and for the Andersen-Gill (1982) generalization
               of that model. We start with a class of martingale-based
               residuals as proposed by Barlow \& Prentice (1988). These
               residuals and/or their transforms are useful for investigating
               the functional form of a covariate, the proportional hazards
               assumption, the leverage of each subject upon the estimates of
               $\beta$, and the lack of model fit to a given subject.]",
  journal   = "Biometrika",
  publisher = "[Oxford University Press, Biometrika Trust]",
  volume    =  77,
  number    =  1,
  pages     = "147--160",
  year      =  1990
}

@ARTICLE{Zhang2013-fv,
  title    = "Novel small-molecule {PGC-1$\alpha$} transcriptional regulator
              with beneficial effects on diabetic db/db mice",
  author   = "Zhang, Li-Na and Zhou, Hua-Yong and Fu, Yan-Yun and Li, Yuan-Yuan
              and Wu, Fang and Gu, Min and Wu, Ling-Yan and Xia, Chun-Mei and
              Dong, Tian-Cheng and Li, Jing-Ya and Shen, Jing-Kang and Li, Jia",
  abstract = "Peroxisome proliferator-activated receptor-$\gamma$
              coactivator-1$\alpha$ (PGC-1$\alpha$) has been shown to influence
              energy metabolism. Hence, we explored a strategy to target
              PGC-1$\alpha$ expression to treat metabolic syndromes. We
              developed a high-throughput screening assay that uses the human
              PGC-1$\alpha$ promoter to drive expression of luciferase. The
              effects of lead compound stimulation on PGC-1$\alpha$ expression
              in muscle cells and hepatocytes were investigated in vitro and in
              vivo. A novel small molecule, ZLN005, led to changes in
              PGC-1$\alpha$ mRNA levels, glucose uptake, and fatty acid
              oxidation in L6 myotubes. Activation of AMP-activated protein
              kinase was involved in the induction of PGC-1$\alpha$ expression.
              In diabetic db/db mice, chronic administration of ZLN005
              increased PGC-1$\alpha$ and downstream gene transcription in
              skeletal muscle, whereas hepatic PGC-1$\alpha$ and
              gluconeogenesis genes were reduced. ZLN005 increased fat
              oxidation and improved the glucose tolerance, pyruvate tolerance,
              and insulin sensitivity of diabetic db/db mice. Hyperglycemia and
              dyslipidemia also were ameliorated after treatment with ZLN005.
              Our results demonstrated that a novel small molecule selectively
              elevated the expression of PGC-1$\alpha$ in myotubes and skeletal
              muscle and exerted promising therapeutic effects for treating
              type 2 diabetes.",
  journal  = "Diabetes",
  volume   =  62,
  number   =  4,
  pages    = "1297--1307",
  month    =  apr,
  year     =  2013,
  language = "en"
}

@ARTICLE{Imanishi2019-qc,
  title    = "Reciprocal regulation of {STING} and {TCR} signaling by {mTORC1}
              for T-cell activation and function",
  author   = "Imanishi, Takayuki and Unno, Midori and Kobayashi, Wakana and
              Yoneda, Natsumi and Matsuda, Satoshi and Ikeda, Kazutaka and
              Hoshii, Takayuki and Hirao, Atsushi and Miyake, Kensuke and
              Barber, Glen N and Arita, Makoto and Ishii, Ken J and Akira,
              Shizuo and Saito, Takashi",
  abstract = "Stimulator of interferon genes (STING) plays a key role in
              detecting cytosolic DNA and induces type I interferon (IFN-I)
              responses for host defense against pathogens. Although T cells
              highly express STING, its physiological role remains unknown.
              Here, we show that costimulation of T cells with the STING ligand
              cGAMP and TCR leads to IFN-I production and strongly inhibits
              T-cell growth. TCR-mediated mTORC1 activation and sustained
              activation of IRF3 are required for cGAMP-induced IFN-I
              production, and the mTORC1 activity is partially counteracted by
              cGAMP, thereby blocking proliferation. This mTORC1 inhibition in
              response to costimulation depends on IRF3 and IRF7. Effector T
              cells produce much higher IFN-I levels than innate cells in
              response to cGAMP. Finally, we demonstrated that STING
              stimulation in T cells is effective in inducing antitumor
              responses in vivo. Our studies demonstrate that the outputs of
              STING and TCR signaling pathways are mutually regulated through
              mTORC1 to modulate T-cell functions.",
  journal  = "Life Sci Alliance",
  volume   =  2,
  number   =  1,
  month    =  feb,
  year     =  2019,
  language = "en"
}

@ARTICLE{Schukken2020-lt,
  title    = "Altering microtubule dynamics is synergistically toxic with
              spindle assembly checkpoint inhibition",
  author   = "Schukken, Klaske M and Lin, Yu-Chih and Bakker, Petra L and
              Schubert, Michael and Preuss, Stephanie F and Simon, Judith E and
              van den Bos, Hilda and Storchova, Zuzana and
              Colom{\'e}-Tatch{\'e}, Maria and Bastians, Holger and Spierings,
              Diana Cj and Foijer, Floris",
  abstract = "Chromosomal instability (CIN) and aneuploidy are hallmarks of
              cancer. As most cancers are aneuploid, targeting aneuploidy or
              CIN may be an effective way to target a broad spectrum of
              cancers. Here, we perform two small molecule compound screens to
              identify drugs that selectively target cells that are aneuploid
              or exhibit a CIN phenotype. We find that aneuploid cells are much
              more sensitive to the energy metabolism regulating drug ZLN005
              than their euploid counterparts. Furthermore, cells with an
              ongoing CIN phenotype, induced by spindle assembly checkpoint
              (SAC) alleviation, are significantly more sensitive to the Src
              kinase inhibitor SKI606. We show that inhibiting Src kinase
              increases microtubule polymerization rates and, more generally,
              that deregulating microtubule polymerization rates is
              particularly toxic to cells with a defective SAC. Our findings,
              therefore, suggest that tumors with a dysfunctional SAC are
              particularly sensitive to microtubule poisons and, vice versa,
              that compounds alleviating the SAC provide a powerful means to
              treat tumors with deregulated microtubule dynamics.",
  journal  = "Life Sci Alliance",
  volume   =  3,
  number   =  2,
  month    =  feb,
  year     =  2020,
  language = "en"
}

% The entry below contains non-ASCII chars that could not be converted
% to a LaTeX equivalent.
@ARTICLE{Fowlkes2019-ah,
  title    = "Factors Affecting Growth Kinetics and Spontaneous Metastasis in
              the {B16F10} Syngeneic Murine Melanoma Model",
  author   = "Fowlkes, Natalie and Clemons, Kelli and Rider, Paul Jf and
              Subramanian, Ramesh and Wakamatsu, Nobuko and Langohr, Ingeborg
              and Kousoulas, Konstantin G",
  abstract = "Melanoma is an immunogenic tumor that can metastasize quickly to
              proximal and distal sites, thus complicating the application of
              therapeutic modalities. Numerous mouse model systems have been
              used to gain understanding of the immunobiology and metastatic
              potential of melanoma. Here, we report the optimization of a
              syngeneic mouse melanoma model protocol using the mouse
              B16-derived melanoma cell line B16F10 that ensures the production
              of tumors on mice pinnae that are similar in size between animals
              and that enlarge in a time-dependent manner. In this model,
              B16F10 cells are first allowed to develop tumors after injection
              in the interscapular area or flank of C57BL/6J mice.
              Subsequently, the tumors are harvested, cells dissociated and
              injected into mouse pinnae. Dose-dependent studies revealed that
              injection of 2 $\times$ 105 cells allowed for slow tumor
              enlargement, producing tumors averaging 100 mm within 2 to 3 wk
              with a metastatic frequency of 100\%. This experimental protocol
              will be useful in dissecting the immunobiology of melanoma tumor
              development and metastasis and the evaluation of
              immunotherapeutic antimelanoma therapies.",
  journal  = "Comp. Med.",
  volume   =  69,
  number   =  1,
  pages    = "48--54",
  month    =  feb,
  year     =  2019,
  keywords = "B16F10\_specific",
  language = "en"
}

@ARTICLE{Wei2020-jy,
  title    = "Metabolism of Amino Acids in Cancer",
  author   = "Wei, Zhen and Liu, Xiaoyi and Cheng, Chunming and Yu, Wei and Yi,
              Ping",
  abstract = "Metabolic reprogramming has been widely recognized as a hallmark
              of malignancy. The uptake and metabolism of amino acids are
              aberrantly upregulated in many cancers that display addiction to
              particular amino acids. Amino acids facilitate the survival and
              proliferation of cancer cells under genotoxic, oxidative, and
              nutritional stress. Thus, targeting amino acid metabolism is
              becoming a potential therapeutic strategy for cancer patients. In
              this review, we will systematically summarize the recent progress
              of amino acid metabolism in malignancy and discuss their
              interconnection with mammalian target of rapamycin complex 1
              (mTORC1) signaling, epigenetic modification, tumor growth and
              immunity, and ferroptosis. Finally, we will highlight the
              potential therapeutic applications.",
  journal  = "Front Cell Dev Biol",
  volume   =  8,
  pages    = "603837",
  year     =  2020,
  keywords = "amino acids (AAs); cancer; epigenetic; ferroptosis; mTORC
              (mammalian target of rapamycin kinase complex); metabolism; tumor
              growth; tumor immunity",
  language = "en"
}

@ARTICLE{Bloomfield2023-vk,
  title    = "The fate of extra centrosomes in newly formed tetraploid cells:
              should {I} stay, or should {I} go?",
  author   = "Bloomfield, Mathew and Cimini, Daniela",
  abstract = "An increase in centrosome number is commonly observed in cancer
              cells, but the role centrosome amplification plays along with how
              and when it occurs during cancer development is unclear. One
              mechanism for generating cancer cells with extra centrosomes is
              whole genome doubling (WGD), an event that occurs in over 30\% of
              human cancers and is associated with poor survival. Newly formed
              tetraploid cells can acquire extra centrosomes during WGD, and a
              generally accepted model proposes that centrosome amplification
              in tetraploid cells promotes cancer progression by generating
              aneuploidy and chromosomal instability. Recent findings, however,
              indicate that newly formed tetraploid cells in vitro lose their
              extra centrosomes to prevent multipolar cell divisions. Rather
              than persistent centrosome amplification, this evidence raises
              the possibility that it may be advantageous for tetraploid cells
              to initially restore centrosome number homeostasis and for a
              fraction of the population to reacquire additional centrosomes in
              the later stages of cancer evolution. In this review, we explore
              the different evolutionary paths available to newly formed
              tetraploid cells, their effects on centrosome and chromosome
              number distribution in daughter cells, and their probabilities of
              long-term survival. We then discuss the mechanisms that may alter
              centrosome and chromosome numbers in tetraploid cells and their
              relevance to cancer progression following WGD.",
  journal  = "Front Cell Dev Biol",
  volume   =  11,
  pages    = "1210983",
  month    =  jul,
  year     =  2023,
  keywords = "cancer evolution; centrosome amplification; centrosomes; genomic
              instability; tetraploidy; whole genome doubling",
  language = "en"
}

@ARTICLE{Xiang2020-pf,
  title    = "A {Single-Cell} Transcriptional Roadmap of the Mouse and Human
              Lymph Node Lymphatic Vasculature",
  author   = "Xiang, Menglan and Grosso, Rub{\'e}n Adri{\'a}n and Takeda, Akira
              and Pan, Junliang and Bekkhus, Tove and Brulois, Kevin and
              Dermadi, Denis and Nordling, Sofia and Vanlandewijck, Michael and
              Jalkanen, Sirpa and Ulvmar, Maria H and Butcher, Eugene C",
  abstract = "Single-cell transcriptomics promise to revolutionize our
              understanding of the vasculature. Emerging computational methods
              applied to high-dimensional single-cell data allow integration of
              results between samples and species and illuminate the diversity
              and underlying developmental and architectural organization of
              cell populations. Here, we illustrate these methods in the
              analysis of mouse lymph node (LN) lymphatic endothelial cells
              (LEC) at single-cell resolution. Clustering identifies five
              well-delineated subsets, including two medullary sinus subsets
              not previously recognized as distinct. Nearest neighbor
              alignments in trajectory space position the major subsets in a
              sequence that recapitulates the known features and suggests novel
              features of LN lymphatic organization, providing a
              transcriptional map of the lymphatic endothelial niches and of
              the transitions between them. Differences in gene expression
              reveal specialized programs for (1) subcapsular ceiling
              endothelial interactions with the capsule connective tissue and
              cells; (2) subcapsular floor regulation of lymph borne cell entry
              into the LN parenchyma and antigen presentation; and (3) pathogen
              interactions and (4) LN remodeling in distinct medullary subsets.
              LEC of the subcapsular sinus floor and medulla, which represent
              major sites of cell entry and exit from the LN parenchyma
              respectively, respond robustly to oxazolone inflammation
              challenge with enriched signaling pathways that converge on both
              innate and adaptive immune responses. Integration of mouse and
              human single-cell profiles reveals a conserved cross-species
              pattern of lymphatic vascular niches and gene expression, as well
              as specialized human subsets and genes unique to each species.
              The examples provided demonstrate the power of single-cell
              analysis in elucidating endothelial cell heterogeneity, vascular
              organization, and endothelial cell responses. We discuss the
              findings from the perspective of LEC functions in relation to
              niche formations in the unique stromal and highly immunological
              environment of the LN.",
  journal  = "Front Cardiovasc Med",
  volume   =  7,
  pages    = "52",
  month    =  apr,
  year     =  2020,
  keywords = "computational vascular modeling; cross-species mapping;
              endothelial cell heterogeneity; lymph node; lymphatic endothelial
              cells; single-cell RNA sequencing; trajectory inference",
  language = "en"
}

@ARTICLE{Jelenic2018-ph,
  title    = "Spindle Dynamics Model Explains Chromosome Loss Rates in Yeast
              Polyploid Cells",
  author   = "Jeleni{\'c}, Ivan and Selmecki, Anna and Laan, Liedewij and
              Pavin, Nenad",
  abstract = "Faithful chromosome segregation, driven by the mitotic spindle,
              is essential for organismal survival. Neopolyploid cells from
              diverse species exhibit a significant increase in mitotic errors
              relative to their diploid progenitors, resulting in chromosome
              nondisjunction. In the model system Saccharomyces cerevisiae, the
              rate of chromosome loss in haploid and diploid cells is measured
              to be one thousand times lower than the rate of loss in isogenic
              tetraploid cells. Currently it is unknown what constrains the
              number of chromosomes that can be segregated with high fidelity
              in an organism. Here we developed a simple mathematical model to
              study how different rates of chromosome loss in cells with
              different ploidy can arise from changes in (1) spindle dynamics
              and (2) a maximum duration of mitotic arrest, after which cells
              enter anaphase. We apply this model to S. cerevisiae to show that
              this model can explain the observed rates of chromosome loss in
              S. cerevisiae cells of different ploidy. Our model describes how
              small increases in spindle assembly time can result in dramatic
              differences in the rate of chromosomes loss between cells of
              increasing ploidy and predicts the maximum duration of mitotic
              arrest.",
  journal  = "Front. Genet.",
  volume   =  9,
  pages    = "296",
  month    =  aug,
  year     =  2018,
  keywords = "cell cycle regulation; chromosome loss; chromosome segregation;
              genome instability; polyploidy; spindle assembly; theoretical
              modeling",
  language = "en"
}

@ARTICLE{Maleki2020-zf,
  title    = "Gene Set Analysis: Challenges, Opportunities, and Future Research",
  author   = "Maleki, Farhad and Ovens, Katie and Hogan, Daniel J and Kusalik,
              Anthony J",
  abstract = "Gene set analysis methods are widely used to provide insight into
              high-throughput gene expression data. There are many gene set
              analysis methods available. These methods rely on various
              assumptions and have different requirements, strengths and
              weaknesses. In this paper, we classify gene set analysis methods
              based on their components, describe the underlying requirements
              and assumptions for each class, and provide directions for future
              research in developing and evaluating gene set analysis methods.",
  journal  = "Front. Genet.",
  volume   =  11,
  pages    = "654",
  month    =  jun,
  year     =  2020,
  keywords = "gene expression; gene set analysis; gene set database; gene set
              enrichment; sensitivity; specificity",
  language = "en"
}

@ARTICLE{Dupre2015-dk,
  title    = "{T} Lymphocyte Migration: An Action Movie Starring the Actin and
              Associated Actors",
  author   = "Dupr{\'e}, Lo{\"\i}c and Houmadi, Ra{\"\i}ssa and Tang, Catherine
              and Rey-Barroso, Javier",
  abstract = "The actin cytoskeleton is composed of a dynamic filament meshwork
              that builds the architecture of the cell to sustain its
              fundamental properties. This physical structure is characterized
              by a continuous remodeling, which allows cells to accomplish
              complex motility steps such as directed migration, crossing of
              biological barriers, and interaction with other cells. T
              lymphocytes excel in these motility steps to ensure their immune
              surveillance duties. In particular, actin cytoskeleton remodeling
              is a key to facilitate the journey of T lymphocytes through
              distinct tissue environments and to tune their stop and go
              behavior during the scanning of antigen-presenting cells. The
              molecular mechanisms controlling actin cytoskeleton remodeling
              during T lymphocyte motility have been only partially unraveled,
              since the function of many actin regulators has not yet been
              assessed in these cells. Our review aims to integrate the current
              knowledge into a comprehensive picture of how the actin
              cytoskeleton drives T lymphocyte migration. We will present the
              molecular actors that control actin cytoskeleton remodeling, as
              well as their role in the different T lymphocyte motile steps. We
              will also highlight which challenges remain to be addressed
              experimentally and which approaches appear promising to tackle
              them.",
  journal  = "Front. Immunol.",
  volume   =  6,
  pages    = "586",
  month    =  nov,
  year     =  2015,
  keywords = "T lymphocytes; actin cytoskeleton; migration",
  language = "en"
}

@ARTICLE{Gadhamsetty2016-nj,
  title    = "Tissue Dimensionality Influences the Functional Response of
              Cytotoxic {T} {Lymphocyte-Mediated} Killing of Targets",
  author   = "Gadhamsetty, Saikrishna and Mar{\'e}e, Athanasius F M and de
              Boer, Rob J and Beltman, Joost B",
  abstract = "Cytotoxic T lymphocyte (CTL)-mediated killing of virus infections
              and tumors occurs over a wide range of conditions. The spatial
              environments in which CTLs encounter target cells vary from
              narrow vessels, to two-dimensional epithelial tissues, to densely
              populated 3-dimensional (3D) T cell areas within lymphoid
              tissues. How such spatial environments alter the functional
              response of CTL-mediated killing, i.e., how the killing
              efficiency depends on cell densities, is unclear. In this study,
              we perform cellular Potts model simulations in different spatial
              configurations to investigate how the dimensionality of the space
              affects the functional response of CTL-mediated killing.
              Irrespective of the spatial configuration, the function with
              separate saturation constants for CTL and for target cell
              densities that we previously proposed can in all cases describe
              the response, demonstrating its generality. However, the tissue
              dimensionality determines at which cell densities the killing
              rate starts to saturate. We show that saturation in a fully 3D
              environment is stronger than in a ``flat'' 3D environment, which
              is largely due to accompanying differences in the CTL-target
              encounter rates.",
  journal  = "Front. Immunol.",
  volume   =  7,
  pages    = "668",
  year     =  2016,
  keywords = "CTL; cellular Potts model; functional response; killing rate;
              tissue dimensionality",
  language = "en"
}

@ARTICLE{Kouidhi2017-zn,
  title    = "Impact of Metabolism on {T-Cell} Differentiation and Function and
              Cross Talk with Tumor Microenvironment",
  author   = "Kouidhi, Soumaya and Elgaaied, Amel Benammar and Chouaib, Salem",
  abstract = "The immune system and metabolism are highly integrated and
              multilevel interactions between metabolic system and T lymphocyte
              signaling and fate exist. Accumulating evidence indicates that
              the regulation of nutrient uptake and utilization in T cells is
              critically important for the control of their differentiation and
              manipulating metabolic pathways in these cells can shape their
              function and survival. This review will discuss some potential
              cell metabolism pathways involved in shaping T lymphocyte
              function and differentiation. It will also describe show subsets
              of T cells have specific metabolic requirements and signaling
              pathways that contribute to their respective function. Examples
              showing the apparent similarity between cancer cell metabolism
              and T cells during activation are illustrated and finally some
              mechanisms being used by tumor microenvironment to orchestrate
              T-cell metabolic dysregulation and the subsequent emergence of
              immune suppression are discussed. We believe that targeting
              T-cell metabolism may provide an additional opportunity to
              manipulate T-cell function in the development of novel
              therapeutics.",
  journal  = "Front. Immunol.",
  volume   =  8,
  pages    = "270",
  month    =  mar,
  year     =  2017,
  keywords = "T-lymphocytes; cancer; hypoxia; immune system; tumor cell
              metabolism; tumor microenvironment",
  language = "en"
}

@ARTICLE{Gordon2018-ty,
  title    = "Macrophage Clearance of Apoptotic Cells: A Critical Assessment",
  author   = "Gordon, Siamon and Pl{\"u}ddemann, Annette",
  abstract = "As the body continues to grow and age, it becomes essential to
              maintain a balance between living and dying cells. Macrophages
              and dendritic cells play a central role in discriminating among
              viable, apoptotic, and necrotic cells, as selective and efficient
              phagocytes, without inducing inappropriate inflammation or immune
              responses. A great deal has been learnt concerning clearance
              receptors for modified and non-self-ligands on potential targets,
              mediating their eventual uptake, disposal, and replacement. In
              this essay, we assess current understanding of the phagocytic
              recognition of apoptotic cells within their tissue environment;
              we conclude that efferocytosis constitutes a more complex process
              than simply removal of corpses, with regulatory interactions
              between the target and effector cells, which determine the
              outcome of this homeostatic process.",
  journal  = "Front. Immunol.",
  volume   =  9,
  pages    = "127",
  month    =  jan,
  year     =  2018,
  keywords = "apoptosis; apoptotic cells; clearance of apoptotic cells;
              macrophages; phagocytosis",
  language = "en"
}

@ARTICLE{Khair2019-sy,
  title    = "Combining Immune Checkpoint Inhibitors: Established and Emerging
              Targets and Strategies to Improve Outcomes in Melanoma",
  author   = "Khair, Duaa O and Bax, Heather J and Mele, Silvia and Crescioli,
              Silvia and Pellizzari, Giulia and Khiabany, Atousa and Nakamura,
              Mano and Harris, Robert J and French, Elise and Hoffmann, Ricarda
              M and Williams, Iwan P and Cheung, Anthony and Thair, Benjamin
              and Beales, Charlie T and Touizer, Emma and Signell, Adrian W and
              Tasnova, Nahrin L and Spicer, James F and Josephs, Debra H and
              Geh, Jenny L and MacKenzie Ross, Alastair and Healy, Ciaran and
              Papa, Sophie and Lacy, Katie E and Karagiannis, Sophia N",
  abstract = "The immune system employs several checkpoint pathways to regulate
              responses, maintain homeostasis and prevent self-reactivity and
              autoimmunity. Tumor cells can hijack these protective mechanisms
              to enable immune escape, cancer survival and proliferation.
              Blocking antibodies, designed to interfere with checkpoint
              molecules CTLA-4 and PD-1/PD-L1 and counteract these immune
              suppressive mechanisms, have shown significant success in
              promoting immune responses against cancer and can result in tumor
              regression in many patients. While inhibitors to CTLA-4 and the
              PD-1/PD-L1 axis are well-established for the clinical management
              of melanoma, many patients do not respond or develop resistance
              to these interventions. Concerted efforts have focused on
              combinations of approved therapies aiming to further augment
              positive outcomes and survival. While CTLA-4 and PD-1 are the
              most-extensively researched targets, results from pre-clinical
              studies and clinical trials indicate that novel agents, specific
              for checkpoints such as A2AR, LAG-3, IDO and others, may further
              contribute to the improvement of patient outcomes, most likely in
              combinations with anti-CTLA-4 or anti-PD-1 blockade. This review
              discusses the rationale for, and results to date of, the
              development of inhibitory immune checkpoint blockade combination
              therapies in melanoma. The clinical potential of new pipeline
              therapeutics, and possible future therapy design and directions
              that hold promise to significantly improve clinical prognosis
              compared with monotherapy, are discussed.",
  journal  = "Front. Immunol.",
  volume   =  10,
  pages    = "453",
  month    =  mar,
  year     =  2019,
  keywords = "CTLA-4; PD-1; PD-L1; antibody engineering; checkpoint inhibitors;
              combination immunotherapy; immunooncology therapeutics; melanoma",
  language = "en"
}

@ARTICLE{Jackson2019-pb,
  title    = "Leucocyte Trafficking via the Lymphatic Vasculature- Mechanisms
              and Consequences",
  author   = "Jackson, David G",
  abstract = "The lymphatics fulfill a vital physiological function as the
              conduits through which leucocytes traffic between the tissues and
              draining lymph nodes for the initiation and modulation of immune
              responses. However, until recently many of the molecular
              mechanisms controlling such migration have been unclear. As a
              result of careful research, it is now apparent that the process
              is regulated at multiple stages from initial leucocyte entry and
              intraluminal crawling in peripheral tissue lymphatics, through to
              leucocyte exit in draining lymph nodes where the migrating cells
              either participate in immune responses or return to the
              circulation via efferent lymph. Furthermore, it is increasingly
              evident that most if not all leucocyte populations migrate in
              lymph and that such migration is not only important for immune
              modulation, but also for the timely repair and resolution of
              tissue inflammation. In this article, I review the latest
              research findings in these areas, arising from new insights into
              the distinctive ultrastructure of lymphatic capillaries and lymph
              node sinuses. Accordingly, I highlight the emerging importance of
              the leucocyte glycocalyx and its novel interactions with the
              endothelial receptor LYVE-1, the intricacies of endothelial
              chemokine secretion and sequestration that direct leucocyte
              trafficking and the significance of the process for normal immune
              function and pathology.",
  journal  = "Front. Immunol.",
  volume   =  10,
  pages    = "471",
  month    =  mar,
  year     =  2019,
  keywords = "LYVE-1; chemokine; dendritic cell; endothelium; hyaluronan;
              lymphatic; trafficking; transmigration",
  language = "en"
}

@ARTICLE{Szabo2013-qr,
  title    = "Cellular potts modeling of tumor growth, tumor invasion, and
              tumor evolution",
  author   = "Szab{\'o}, Andr{\'a}s and Merks, Roeland M H",
  abstract = "Despite a growing wealth of available molecular data, the growth
              of tumors, invasion of tumors into healthy tissue, and response
              of tumors to therapies are still poorly understood. Although
              genetic mutations are in general the first step in the
              development of a cancer, for the mutated cell to persist in a
              tissue, it must compete against the other, healthy or diseased
              cells, for example by becoming more motile, adhesive, or
              multiplying faster. Thus, the cellular phenotype determines the
              success of a cancer cell in competition with its neighbors,
              irrespective of the genetic mutations or physiological
              alterations that gave rise to the altered phenotype. What
              phenotypes can make a cell ``successful'' in an environment of
              healthy and cancerous cells, and how? A widely used tool for
              getting more insight into that question is cell-based modeling.
              Cell-based models constitute a class of computational,
              agent-based models that mimic biophysical and molecular
              interactions between cells. One of the most widely used
              cell-based modeling formalisms is the cellular Potts model (CPM),
              a lattice-based, multi particle cell-based modeling approach. The
              CPM has become a popular and accessible method for modeling
              mechanisms of multicellular processes including cell sorting,
              gastrulation, or angiogenesis. The CPM accounts for biophysical
              cellular properties, including cell proliferation, cell motility,
              and cell adhesion, which play a key role in cancer. Multiscale
              models are constructed by extending the agents with intracellular
              processes including metabolism, growth, and signaling. Here we
              review the use of the CPM for modeling tumor growth, tumor
              invasion, and tumor progression. We argue that the accessibility
              and flexibility of the CPM, and its accurate, yet coarse-grained
              and computationally efficient representation of cell and tissue
              biophysics, make the CPM the method of choice for modeling
              cellular processes in tumor development.",
  journal  = "Front. Oncol.",
  volume   =  3,
  pages    = "87",
  month    =  apr,
  year     =  2013,
  keywords = "cell-based modeling; cellular Potts model; evolutionary tumor
              model; multiscale modeling; tumor growth model; tumor invasion
              model; tumor metastasis model",
  language = "en"
}

@ARTICLE{Coward2014-yb,
  title    = "Size Does Matter: Why Polyploid Tumor Cells are Critical Drug
              Targets in the War on Cancer",
  author   = "Coward, Jermaine and Harding, Angus",
  abstract = "Tumor evolution presents a formidable obstacle that currently
              prevents the development of truly curative treatments for cancer.
              In this perspective, we advocate for the hypothesis that tumor
              cells with significantly elevated genomic content (polyploid
              tumor cells) facilitate rapid tumor evolution and the acquisition
              of therapy resistance in multiple incurable cancers. We appeal to
              studies conducted in yeast, cancer models, and cancer patients,
              which all converge on the hypothesis that polyploidy enables
              large phenotypic leaps, providing access to many different
              therapy-resistant phenotypes. We develop a flow-cytometry based
              method for quantifying the prevalence of polyploid tumor cells,
              and show the frequency of these cells in patient tumors may be
              higher than is generally appreciated. We then present recent
              studies identifying promising new therapeutic strategies that
              could be used to specifically target polyploid tumor cells in
              cancer patients. We argue that these therapeutic approaches
              should be incorporated into new treatment strategies aimed at
              blocking tumor evolution by killing the highly evolvable,
              therapy-resistant polyploid cell subpopulations, thus helping to
              maintain patient tumors in a drug sensitive state.",
  journal  = "Front. Oncol.",
  volume   =  4,
  pages    = "123",
  month    =  may,
  year     =  2014,
  keywords = "aneuploidy; cancer stem cell; chromosomal instability;
              hyperdiploidy; polyploidy; therapy resistance; tumor evolution;
              tumor initiation",
  language = "en"
}

@ARTICLE{Swart2016-xu,
  title    = "Combination Approaches with {Immune-Checkpoint} Blockade in
              Cancer Therapy",
  author   = "Swart, Maarten and Verbrugge, Inge and Beltman, Joost B",
  abstract = "In healthy individuals, immune-checkpoint molecules prevent
              autoimmune responses and limit immune cell-mediated tissue
              damage. Tumors frequently exploit these molecules to evade
              eradication by the immune system. Over the past years,
              immune-checkpoint blockade of cytotoxic T lymphocyte antigen-4
              and programed death-1 emerged as promising strategies to activate
              antitumor cytotoxic T cell responses. Although complete
              regression and long-term survival is achieved in some patients,
              not all patients respond. This review describes promising, novel
              combination approaches involving immune-checkpoint blockade in
              the context of the cancer-immunity cycle, aimed at increasing
              response rates to the single treatments. Specifically, we discuss
              combinations that promote antigen release and presentation, that
              further amplify T cell activation, that inhibit trafficking of
              regulatory T cells or MSDCs, that stimulate intratumoral T cell
              infiltration, that increase cancer recognition by T cells, and
              that stimulate tumor killing.",
  journal  = "Front. Oncol.",
  volume   =  6,
  pages    = "233",
  month    =  nov,
  year     =  2016,
  keywords = "CTLA-4; PD-1; cancer immunotherapy; checkpoint blockade",
  language = "en"
}

@ARTICLE{Turgeon2018-bg,
  title    = "{DNA} Damage, Repair, and Cancer Metabolism",
  author   = "Turgeon, Marc-Olivier and Perry, Nicholas J S and Poulogiannis,
              George",
  abstract = "Although there has been a renewed interest in the field of cancer
              metabolism in the last decade, the link between metabolism and
              DNA damage/DNA repair in cancer has yet to be appreciably
              explored. In this review, we examine the evidence connecting DNA
              damage and repair mechanisms with cell metabolism through three
              principal links. (1) Regulation of methyl- and acetyl-group
              donors through different metabolic pathways can impact DNA
              folding and remodeling, an essential part of accurate double
              strand break repair. (2) Glutamine, aspartate, and other
              nutrients are essential for de novo nucleotide synthesis, which
              dictates the availability of the nucleotide pool, and thereby
              influences DNA repair and replication. (3) Reactive oxygen
              species, which can increase oxidative DNA damage and hence the
              load of the DNA-repair machinery, are regulated through different
              metabolic pathways. Interestingly, while metabolism affects DNA
              repair, DNA damage can also induce metabolic rewiring. Activation
              of the DNA damage response (DDR) triggers an increase in
              nucleotide synthesis and anabolic glucose metabolism, while also
              reducing glutamine anaplerosis. Furthermore, mutations in genes
              involved in the DDR and DNA repair also lead to metabolic
              rewiring. Links between cancer metabolism and DNA damage/DNA
              repair are increasingly apparent, yielding opportunities to
              investigate the mechanistic basis behind potential metabolic
              vulnerabilities of a substantial fraction of tumors.",
  journal  = "Front. Oncol.",
  volume   =  8,
  pages    = "15",
  month    =  feb,
  year     =  2018,
  keywords = "DNA damage; DNA repair; cancer; metabolism; reactive oxygen
              species",
  language = "en"
}

@ARTICLE{Seekhao2018-wh,
  title    = "{High-Performance} {Agent-Based} Modeling Applied to Vocal Fold
              Inflammation and Repair",
  author   = "Seekhao, Nuttiiya and Shung, Caroline and JaJa, Joseph and
              Mongeau, Luc and Li-Jessen, Nicole Y K",
  abstract = "Fast and accurate computational biology models offer the prospect
              of accelerating the development of personalized medicine. A tool
              capable of estimating treatment success can help prevent
              unnecessary and costly treatments and potential harmful side
              effects. A novel high-performance Agent-Based Model (ABM) was
              adopted to simulate and visualize multi-scale complex biological
              processes arising in vocal fold inflammation and repair. The
              computational scheme was designed to organize the 3D ABM
              sub-tasks to fully utilize the resources available on current
              heterogeneous platforms consisting of multi-core CPUs and
              many-core GPUs. Subtasks are further parallelized and
              convolution-based diffusion is used to enhance the performance of
              the ABM simulation. The scheme was implemented using a
              client-server protocol allowing the results of each iteration to
              be analyzed and visualized on the server (i.e., in-situ) while
              the simulation is running on the same server. The resulting
              simulation and visualization software enables users to interact
              with and steer the course of the simulation in real-time as
              needed. This high-resolution 3D ABM framework was used for a case
              study of surgical vocal fold injury and repair. The new framework
              is capable of completing the simulation, visualization and remote
              result delivery in under 7 s per iteration, where each iteration
              of the simulation represents 30 min in the real world. The case
              study model was simulated at the physiological scale of a human
              vocal fold. This simulation tracks 17 million biological cells as
              well as a total of 1.7 billion signaling chemical and structural
              protein data points. The visualization component processes and
              renders all simulated biological cells and 154 million signaling
              chemical data points. The proposed high-performance 3D ABM was
              verified through comparisons with empirical vocal fold data.
              Representative trends of biomarker predictions in surgically
              injured vocal folds were observed.",
  journal  = "Front. Physiol.",
  volume   =  9,
  pages    = "304",
  month    =  apr,
  year     =  2018,
  keywords = "agent-based modeling; biosimulation; high-performance computing;
              in situ visualization; inflammation; vocal fold; wound healing",
  language = "en"
}

@ARTICLE{Herculano-Houzel2009-la,
  title    = "The human brain in numbers: a linearly scaled-up primate brain",
  author   = "Herculano-Houzel, Suzana",
  abstract = "The human brain has often been viewed as outstanding among
              mammalian brains: the most cognitively able, the
              largest-than-expected from body size, endowed with an
              overdeveloped cerebral cortex that represents over 80\% of brain
              mass, and purportedly containing 100 billion neurons and 10x more
              glial cells. Such uniqueness was seemingly necessary to justify
              the superior cognitive abilities of humans over larger-brained
              mammals such as elephants and whales. However, our recent studies
              using a novel method to determine the cellular composition of the
              brain of humans and other primates as well as of rodents and
              insectivores show that, since different cellular scaling rules
              apply to the brains within these orders, brain size can no longer
              be considered a proxy for the number of neurons in the brain.
              These studies also showed that the human brain is not exceptional
              in its cellular composition, as it was found to contain as many
              neuronal and non-neuronal cells as would be expected of a primate
              brain of its size. Additionally, the so-called overdeveloped
              human cerebral cortex holds only 19\% of all brain neurons, a
              fraction that is similar to that found in other mammals. In what
              regards absolute numbers of neurons, however, the human brain
              does have two advantages compared to other mammalian brains:
              compared to rodents, and probably to whales and elephants as
              well, it is built according to the very economical, space-saving
              scaling rules that apply to other primates; and, among
              economically built primate brains, it is the largest, hence
              containing the most neurons. These findings argue in favor of a
              view of cognitive abilities that is centered on absolute numbers
              of neurons, rather than on body size or encephalization, and call
              for a re-examination of several concepts related to the
              exceptionality of the human brain.",
  journal  = "Front. Hum. Neurosci.",
  volume   =  3,
  pages    = "31",
  month    =  nov,
  year     =  2009,
  keywords = "brain scaling; encephalization; human; number of neurons",
  language = "en"
}

@ARTICLE{Vargas-Rondon2017-ue,
  title    = "The Role of Chromosomal Instability in Cancer and Therapeutic
              Responses",
  author   = "Vargas-Rond{\'o}n, Natalia and Villegas, Victoria E and
              Rond{\'o}n-Lagos, Milena",
  abstract = "Cancer is one of the leading causes of death, and despite
              increased research in recent years, control of advanced-stage
              disease and optimal therapeutic responses remain elusive. Recent
              technological improvements have increased our understanding of
              human cancer as a heterogeneous disease. For instance, four
              hallmarks of cancer have recently been included, which in
              addition to being involved in cancer development, could be
              involved in therapeutic responses and resistance. One of these
              hallmarks is chromosome instability (CIN), a source of genetic
              variation in either altered chromosome number or structure. CIN
              has become a hot topic in recent years, not only for its
              implications in cancer diagnostics and prognostics, but also for
              its role in therapeutic responses. Chromosomal alterations are
              mainly used to determine genetic heterogeneity in tumors, but CIN
              could also reveal treatment efficacy, as many therapies are based
              on increasing CIN, which causes aberrant cells to undergo
              apoptosis. However, it should be noted that contradictory
              findings on the implications of CIN for the therapeutic response
              have been reported, with some studies associating high CIN with a
              better therapeutic response and others associating it with
              therapeutic resistance. Considering these observations, it is
              necessary to increase our understanding of the role CIN plays not
              only in tumor development, but also in therapeutic responses.
              This review focuses on recent studies that suggest possible
              mechanisms and consequences of CIN in different disease types,
              with a primary focus on cancer outcomes and therapeutic
              responses.",
  journal  = "Cancers",
  volume   =  10,
  number   =  1,
  month    =  dec,
  year     =  2017,
  keywords = "cancer outcomes; cancer prognosis; chromosomal instability;
              predictive markers; therapeutic resistance",
  language = "en"
}

@ARTICLE{Guang2019-fv,
  title    = "Targeting Proteotoxic Stress in Cancer: A Review of the Role that
              Protein Quality Control Pathways Play in Oncogenesis",
  author   = "Guang, Matthew Ho Zhi and Kavanagh, Emma L and Dunne, Luke Paul
              and Dowling, Paul and Zhang, Li and Lindsay, Sin{\'e}ad and
              Bazou, Despina and Goh, Chia Yin and Hanley, Cathal and Bianchi,
              Giada and Anderson, Kenneth C and O'Gorman, Peter and McCann,
              Amanda",
  abstract = "Despite significant advances in cancer diagnostics and
              therapeutics the majority of cancer unfortunately remains
              incurable, which has led to continued research to better
              understand its exceptionally diverse biology. As a result of
              genomic instability, cancer cells typically have elevated
              proteotoxic stress. Recent appreciation of this functional link
              between the two secondary hallmarks of cancer: aneuploidy
              (oxidative stress) and proteotoxic stress, has therefore led to
              the development of new anticancer therapies targeting this
              emerging ``Achilles heel'' of malignancy. This review highlights
              the importance of managing proteotoxic stress for cancer cell
              survival and provides an overview of the integral role
              proteostasis pathways play in the maintenance of protein
              homeostasis. We further review the efforts undertaken to exploit
              proteotoxic stress in multiple myeloma (as an example of a
              hematologic malignancy) and triple negative breast cancer (as an
              example of a solid tumor), and give examples of: (1) FDA-approved
              therapies in routine clinical use; and (2) promising therapies
              currently in clinical trials. Finally, we provide new insights
              gleaned from the use of emerging technologies to disrupt the
              protein secretory pathway and repurpose E3 ligases to achieve
              targeted protein degradation.",
  journal  = "Cancers",
  volume   =  11,
  number   =  1,
  month    =  jan,
  year     =  2019,
  keywords = "autophagy; chemoresistance; multiple myeloma; proteasome; protein
              quality control; proteotoxic stress; triple negative breast
              cancer; unfolded protein response",
  language = "en"
}

@ARTICLE{Beck2021-ku,
  title    = "Mathematical Modelling Based on In Vivo Imaging Suggests
              {CD137-Stimulated} Cytotoxic {T} Lymphocytes Exert Superior
              Tumour Control Due to an Enhanced Antimitotic Effect on Tumour
              Cells",
  author   = "Beck, Richard J and Weigelin, Bettina and Beltman, Joost B",
  abstract = "Several immunotherapeutic strategies for the treatment of cancer
              are under development. Two prominent strategies are adoptive cell
              transfer (ACT) of CTLs and modulation of CTL function with immune
              checkpoint inhibitors or with costimulatory antibodies. Despite
              some success with these approaches, there remains a lack of
              detailed and quantitative descriptions of the events following
              CTL transfer and the impact of immunomodulation. Here, we have
              applied ordinary differential equation models to two photon
              imaging data derived from a B16F10 murine melanoma. Models were
              parameterised with data from two different treatment conditions:
              either ACT-only, or ACT with intratumoural costimulation using a
              CD137 targeted antibody. Model dynamics and best fitting
              parameters were compared, in order to assess the mode of action
              of the CTLs and examine how the CD137 antibody influenced their
              activities. We found that the cytolytic activity of the
              transferred CTLs was minimal without CD137 costimulation, and
              that the CD137 targeted antibody did not enhance the per-capita
              killing ability of the transferred CTLs. Instead, the results of
              our modelling study suggest that an antiproliferative effect of
              CTLs exerted upon the tumour likely accounted for the majority of
              the reduction in tumour growth after CTL transfer. Moreover, we
              found that CD137 most likely improved tumour control via
              enhancement of this antiproliferative effect, as well as
              prolonging the period in which CTLs were inside the tumour,
              leading to a sustained duration of their antitumour effects
              following CD137 stimulation.",
  journal  = "Cancers",
  volume   =  13,
  number   =  11,
  month    =  may,
  year     =  2021,
  keywords = "CD137; T cells; cytotoxic T lymphocytes; immunotherapy;
              mathematical modelling; ordinary differential equations; tumour",
  language = "en"
}

@ARTICLE{Tseng2011-pe,
  title    = "Metastatic tumor dormancy in cutaneous melanoma: does surgery
              induce escape?",
  author   = "Tseng, William W and Fadaki, Niloofar and Leong, Stanley P",
  abstract = "According to the concept of tumor dormancy, tumor cells may exist
              as single cells or microscopic clusters of cells that are
              clinically undetectable, but remain viable and have the potential
              for malignant outgrowth. At metastatic sites, escape from tumor
              dormancy under more favorable local microenvironmental conditions
              or through other, yet undefined stimuli, may account for distant
              recurrence after supposed ``cure'' following surgical treatment
              of the primary tumor. The vast majority of evidence to date in
              support of the concept of tumor dormancy originates from animal
              studies; however, extensive epidemiologic data from breast cancer
              strongly suggests that this process does occur in human disease.
              In this review, we aim to demonstrate that metastatic tumor
              dormancy does exist in cutaneous melanoma based on evidence from
              mouse models and clinical observations of late recurrence and
              occult transmission by organ transplantation. Experimental data
              underscores the critical role of impaired angiogenesis and immune
              regulation as major mechanisms for maintenance of tumor dormancy.
              Finally, we examine evidence for the role of surgery in promoting
              escape from tumor dormancy at metastatic sites in cutaneous
              melanoma.",
  journal  = "Cancers",
  volume   =  3,
  number   =  1,
  pages    = "730--746",
  month    =  feb,
  year     =  2011,
  language = "en"
}

@ARTICLE{Baudoin2021-pp,
  title    = "Karyotype Aberrations in Action: The Evolution of Cancer Genomes
              and the Tumor Microenvironment",
  author   = "Baudoin, Nicolaas C and Bloomfield, Mathew",
  abstract = "Cancer is a disease of cellular evolution. For this cellular
              evolution to take place, a population of cells must contain
              functional heterogeneity and an assessment of this heterogeneity
              in the form of natural selection. Cancer cells from advanced
              malignancies are genomically and functionally very different
              compared to the healthy cells from which they evolved. Genomic
              alterations include aneuploidy (numerical and structural changes
              in chromosome content) and polyploidy (e.g., whole genome
              doubling), which can have considerable effects on cell physiology
              and phenotype. Likewise, conditions in the tumor microenvironment
              are spatially heterogeneous and vastly different than in healthy
              tissues, resulting in a number of environmental niches that play
              important roles in driving the evolution of tumor cells. While a
              number of studies have documented abnormal conditions of the
              tumor microenvironment and the cellular consequences of
              aneuploidy and polyploidy, a thorough overview of the interplay
              between karyotypically abnormal cells and the tissue and tumor
              microenvironments is not available. Here, we examine the evidence
              for how this interaction may unfold during tumor evolution. We
              describe a bidirectional interplay in which aneuploid and
              polyploid cells alter and shape the microenvironment in which
              they and their progeny reside; in turn, this microenvironment
              modulates the rate of genesis for new karyotype aberrations and
              selects for cells that are most fit under a given condition. We
              conclude by discussing the importance of this interaction for
              tumor evolution and the possibility of leveraging our
              understanding of this interplay for cancer therapy.",
  journal  = "Genes",
  volume   =  12,
  number   =  4,
  month    =  apr,
  year     =  2021,
  keywords = "aneuploidy; cancer; karyotype aberrations; niche construction;
              polyploidy; tetraploidy; tumor ecology; tumor evolution; tumor
              microenvironment",
  language = "en"
}

@ARTICLE{Lindsay2019-br,
  title     = "{Scale-Optimized} Surface Roughness for Topographic Analysis",
  author    = "Lindsay, John B and Newman, Daniel R and Francioni, Anthony",
  abstract  = "Surface roughness is a terrain parameter that has been widely
               applied to the study of geomorphological processes. One of the
               main challenges in studying roughness is its highly
               scale-dependent nature. Determining appropriate mapping scales
               in topographically heterogenous landscapes can be difficult. A
               method is presented for estimating multiscale surface roughness
               based on the standard deviation of surface normals. This method
               utilizes scale partitioning and integral image processing to
               isolate scales of surface complexity. The computational
               efficiency of the method enables high scale sampling density and
               identification of maximum roughness for each grid cell in a
               digital elevation model (DEM). The approach was applied to a 0.5
               m resolution LiDAR DEM of a 210 km2 area near Brantford, Canada.
               The case study demonstrated substantial heterogeneity in
               roughness properties. At shorter scales, tillage patterns and
               other micro-topography associated with ground beneath forest
               cover dominated roughness scale signatures. Extensive
               agricultural land-use resulted in 35.6\% of the site exhibiting
               maximum roughness at micro-topographic scales. At larger spatial
               scales, rolling morainal topography and fluvial landforms,
               including incised channels and meander cut banks, were
               associated with maximum surface roughness. This method allowed
               for roughness mapping at spatial scales that are locally adapted
               to the topographic context of each individual grid cell within a
               DEM. Furthermore, the analysis revealed significant differences
               in roughness characteristics among soil texture categories,
               demonstrating the practical utility of locally adaptive,
               scale-optimized roughness.",
  journal   = "Geosci. J.",
  publisher = "Multidisciplinary Digital Publishing Institute",
  volume    =  9,
  number    =  7,
  pages     = "322",
  month     =  jul,
  year      =  2019,
  language  = "en"
}

@ARTICLE{Harada2017-ux,
  title    = "Quinacrine Inhibits {ICAM-1} Transcription by Blocking {DNA}
              Binding of the {NF-$\kappa$B} Subunit p65 and Sensitizes Human
              Lung Adenocarcinoma {A549} Cells to {TNF-$\alpha$} and the Fas
              Ligand",
  author   = "Harada, Misuzu and Morimoto, Kyoko and Kondo, Tetsuya and
              Hiramatsu, Reiko and Okina, Yuji and Muko, Ryo and Matsuda, Iyo
              and Kataoka, Takao",
  abstract = "Quinacrine has been used for therapeutic drugs in some clinical
              settings. In the present study, we demonstrated that quinacrine
              decreased the expression of intercellular adhesion molecule-1
              (ICAM-1) induced by tumor necrosis factor (TNF)-$\alpha$ and
              interleukin-1 (IL-1) $\alpha$ in human lung adenocarcinoma A549
              cells. Quinacrine inhibited ICAM-1 mRNA expression and nuclear
              factor $\kappa$B (NF-$\kappa$B)-responsive luciferase reporter
              activity following a treatment with TNF-$\alpha$ and
              IL-1$\alpha$. In the NF-$\kappa$B signaling pathway, quinacrine
              did not markedly affect the TNF-$\alpha$-induced degradation of
              the inhibitor of NF-$\kappa$B or the TNF-$\alpha$-induced
              phosphorylation of the NF-$\kappa$B subunit, p65, at Ser-536 and
              its subsequent translocation to the nucleus. In contrast, a
              chromatin immunoprecipitation assay showed that quinacrine
              prevented the binding of p65 to the ICAM-1 promoter following
              TNF-$\alpha$ stimulation. Moreover, TNF-$\alpha$ and the Fas
              ligand effectively reduced the viability of A549 cells in the
              presence of quinacrine only. Quinacrine down-regulated the
              constitutive and TNF-$\alpha$-induced expression of c-FLIP and
              Mcl-1 in A549 cells. These results revealed that quinacrine
              inhibits ICAM-1 transcription by blocking the DNA binding of p65
              and sensitizes A549 cells to TNF-$\alpha$ and the Fas ligand.",
  journal  = "Int. J. Mol. Sci.",
  volume   =  18,
  number   =  12,
  month    =  dec,
  year     =  2017,
  keywords = "intercellular adhesion molecule-1 (ICAM-1); nuclear factor
              $\kappa$B (NF-$\kappa$B); quinacrine; the Fas ligand; tumor
              necrosis-$\alpha$ (TNF-$\alpha$)",
  language = "en"
}

@ARTICLE{Lee2019-mp,
  title    = "{ER} Stress Induces Cell Cycle Arrest at the {G2/M} Phase Through
              {eIF2$\alpha$} Phosphorylation and {GADD45$\alpha$}",
  author   = "Lee, Duckgue and Hokinson, Daniel and Park, Soyoung and Elvira,
              Rosalie and Kusuma, Fedho and Lee, Ji-Min and Yun, Miyong and
              Lee, Seok-Geun and Han, Jaeseok",
  abstract = "Endoplasmic reticulum (ER) stress is known to influence various
              cellular functions, including cell cycle progression. Although it
              is well known how ER stress inhibits cell cycle progression at
              the G1 phase, the molecular mechanism underlying how ER stress
              induces G2/M cell cycle arrest remains largely unknown. In this
              study, we found that ER stress and subsequent induction of the
              UPR led to cell cycle arrest at the G2/M phase by reducing the
              amount of cyclin B1. Pharmacological inhibition of the
              IRE1$\alpha$ or ATF6$\alpha$ signaling did not affect ER
              stress-induced cell cycle arrest at the G2/M phase. However, when
              the alpha subunit of eukaryotic translation initiation factor 2
              (eIF2$\alpha$) phosphorylation was genetically abrogated, the
              cell cycle progressed without arresting at the G2/M phase after
              ER stress. GEO database analysis showed that growth arrest and
              DNA-damage-inducible protein $\alpha$ (Gadd45$\alpha$) were
              induced in an eIF2a phosphorylation-dependent manner, which was
              confirmed in this study. Knockdown of GADD45$\alpha$ abrogated
              cell cycle arrest at the G2/M phase upon ER stress. Finally, the
              cell death caused by ER stress significantly reduced when
              GADD45$\alpha$ expression was knocked down. In conclusion,
              GADD45$\alpha$ is a key mediator of ER stress-induced growth
              arrest via regulation of the G2/M transition and cell death
              through the eIF2$\alpha$ signaling pathway.",
  journal  = "Int. J. Mol. Sci.",
  volume   =  20,
  number   =  24,
  month    =  dec,
  year     =  2019,
  keywords = "ER stress; G2-M cell cycle arrest; GADD45$\alpha$; cell death;
              eIF2$\alpha$ phosphorylation",
  language = "en"
}

@ARTICLE{Nakayama2016-gv,
  title    = "Antiproliferative Fate of the Tetraploid Formed after Mitotic
              Slippage and Its Promotion; A Novel Target for Cancer Therapy
              Based on Microtubule Poisons",
  author   = "Nakayama, Yuji and Inoue, Toshiaki",
  abstract = "Microtubule poisons inhibit spindle function, leading to
              activation of spindle assembly checkpoint (SAC) and mitotic
              arrest. Cell death occurring in prolonged mitosis is the first
              target of microtubule poisons in cancer therapies. However, even
              in the presence of microtubule poisons, SAC and mitotic arrest
              are not permanent, and the surviving cells exit the mitosis
              without cytokinesis (mitotic slippage), becoming tetraploid.
              Another target of microtubule poisons-based cancer therapy is
              antiproliferative fate after mitotic slippage. The ultimate goal
              of both the microtubule poisons-based cancer therapies involves
              the induction of a mechanism defined as mitotic catastrophe,
              which is a bona fide intrinsic oncosuppressive mechanism that
              senses mitotic failure and responds by driving a cell to an
              irreversible antiproliferative fate of death or senescence. This
              mechanism of antiproliferative fate after mitotic slippage is not
              as well understood. We provide an overview of mitotic
              catastrophe, and explain new insights underscoring a causal
              association between basal autophagy levels and antiproliferative
              fate after mitotic slippage, and propose possible improved
              strategies. Additionally, we discuss nuclear alterations
              characterizing the mitotic catastrophe (micronuclei, multinuclei)
              after mitotic slippage, and a possible new type of nuclear
              alteration (clustered micronuclei).",
  journal  = "Molecules",
  volume   =  21,
  number   =  5,
  month    =  may,
  year     =  2016,
  keywords = "antiproliferative fate; basal autophagy; cell death during
              mitotic arrest; chemoresistance; clustered micronuclei;
              micronuclei; mitotic catastrophe; mitotic slippage; spindle
              assembly checkpoint; tetraploid",
  language = "en"
}

@ARTICLE{Nixon2018-fw,
  title    = "Current landscape of immunotherapy in the treatment of solid
              tumours, with future opportunities and challenges",
  author   = "Nixon, N A and Blais, N and Ernst, S and Kollmannsberger, C and
              Bebb, G and Butler, M and Smylie, M and Verma, S",
  abstract = "Immunotherapy has emerged as a new standard of care, showing
              survival benefit for solid tumours in multiple disease sites and
              indications. The survival improvements seen in diseases that were
              highly resistant to traditional therapies, with a poor prognosis,
              are unprecedented. Although the benefits observed in clinical
              trials are undeniable, not all patients derive those benefits,
              leading to emerging combination strategies and an ongoing quest
              for biomarker selection. Here, we summarize the current evidence
              for immunotherapy in the treatment of solid tumours, and we
              discuss emerging strategies at the forefront of research. We
              discuss future challenges that will be encountered as experience
              and knowledge continue to expand in this rapidly emerging field.",
  journal  = "Curr. Oncol.",
  volume   =  25,
  number   =  5,
  pages    = "e373--e384",
  month    =  oct,
  year     =  2018,
  keywords = "Immuno-oncology",
  language = "en"
}

@ARTICLE{Savage2013-hl,
  title    = "Using Fractal Geometry and Universal Growth Curves as Diagnostics
              for Comparing Tumor Vasculature and Metabolic Rate With Healthy
              Tissue and for Predicting Responses to Drug Therapies",
  author   = "Savage, Van M and Herman, Alexander B and West, Geoffrey B and
              Leu, Kevin",
  abstract = "Healthy vasculature exhibits a hierarchical branching structure
              in which, on average, vessel radius and length change
              systematically with branching order. In contrast, tumor
              vasculature exhibits less hierarchy and more variability in its
              branching patterns. Although differences in vasculature have been
              highlighted in the literature, there has been very little
              quantification of these differences. Fractal analysis is a
              natural tool for comparing tumor and healthy vasculature,
              especially because it has already been used extensively to model
              healthy tissue. In this paper, we provide a fractal analysis of
              existing vascular data, and we present a new mathematical
              framework for predicting tumor growth trajectories by coupling:
              (1) the fractal geometric properties of tumor vascular networks,
              (2) metabolic properties of tumor cells and host vascular
              systems, and (3) spatial gradients in resources and metabolic
              states within the tumor. First, we provide a new analysis for how
              the mean and variation of scaling exponents for ratios of vessel
              radii and lengths in tumors differ from healthy tissue. Next, we
              use these characteristic exponents to predict metabolic rates for
              tumors. Finally, by combining this analysis with general growth
              equations based on energetics, we derive universal growth curves
              that enable us to compare tumor and ontogenetic growth. We also
              extend these growth equations to include necrotic, quiescent, and
              proliferative cell states and to predict novel growth dynamics
              that arise when tumors are treated with drugs. Taken together,
              this mathematical framework will help to anticipate and
              understand growth trajectories across tumor types and drug
              treatments.",
  journal  = "Discrete Continuous Dyn. Syst. Ser. B",
  volume   =  18,
  number   =  4,
  month    =  jun,
  year     =  2013,
  language = "en"
}

@ARTICLE{Feng2014-ck,
  title     = "Log-transformation and its implications for data analysis",
  author    = "Feng, Changyong and Wang, Hongyue and Lu, Naiji and Chen, Tian
               and He, Hua and Lu, Ying and Tu, Xin M",
  abstract  = "SUMMARY: The log-transformation is widely used in biomedical and
               psychosocial research to deal with skewed data. This paper
               highlights serious problems in this classic approach for dealing
               with skewed data. Despite the common belief that the log
               transformation can decrease the variability of data and make
               data conform more closely to the normal distribution, this is
               usually not the case. Moreover, the results of standard
               statistical tests performed on log-transformed data are often
               not relevant for the original, non-transformed data.We
               demonstrate these problems by presenting examples that use
               simulated data. We conclude that if used at all, data
               transformations must be applied very cautiously. We recommend
               that in most circumstances researchers abandon these traditional
               methods of dealing with skewed data and, instead, use newer
               analytic methods that are not dependent on the distribution the
               data, such as generalized estimating equations (GEE).",
  journal   = "Shanghai Arch Psychiatry",
  publisher = "ncbi.nlm.nih.gov",
  volume    =  26,
  number    =  2,
  pages     = "105--109",
  month     =  apr,
  year      =  2014,
  keywords  = "hypothesis testing; lon-normal distribution; normal
               distribution; outliners; skewness",
  language  = "en"
}

@ARTICLE{Hemon2011-rb,
  title    = "{MHC} class {II} engagement by its ligand {LAG-3} ({CD223})
              contributes to melanoma resistance to apoptosis",
  author   = "Hemon, Patrice and Jean-Louis, Francette and Ramgolam, Kiran and
              Brignone, Chrystelle and Viguier, Manuelle and Bachelez,
              Herv{\'e} and Triebel, Fr{\'e}d{\'e}ric and Charron, Dominique
              and Aoudjit, Fawzi and Al-Daccak, Reem and Michel, Laurence",
  abstract = "Melanoma is the most aggressive skin cancer in humans that often
              expresses MHC class II (MHC II) molecules, which could make these
              tumors eliminable by the immune system. However, this MHC II
              expression has been associated with poor prognosis, and there is
              a lack of immune-mediated eradication. The lymphocyte activation
              gene-3 (LAG-3) is a natural ligand for MHC II that is
              substantially expressed on melanoma-infiltrating T cells
              including those endowed with potent immune-suppressive activity.
              Based on our previous data showing the signaling capacity of MHC
              II in melanoma cells, we hypothesized that LAG-3 could contribute
              to melanoma survival through its MHC II signaling capacity in
              melanoma cells. In this study, we demonstrate that both soluble
              LAG-3 and LAG-3-transfected cells can protect MHC II-positive
              melanoma cells, but not MHC II-negative cells, from FAS-mediated
              and drug-induced apoptosis. Interaction of LAG-3 with MHC II
              expressed on melanoma cells upregulates both MAPK/Erk and
              PI3K/Akt pathways, albeit with different kinetics. Inhibition
              studies using specific inhibitors of both pathways provided
              evidence of their involvement in the LAG-3-induced protection
              from apoptosis. Altogether, our data suggest that the LAG-3-MHC
              II interaction could be viewed as a bidirectional immune escape
              pathway in melanoma, with direct consequences shared by both
              melanoma and immune cells. In the future, compounds that
              efficiently hinder LAG-3-MHC II interaction might be used as an
              adjuvant to current therapy for MHC II-positive melanoma.",
  journal  = "J. Immunol.",
  volume   =  186,
  number   =  9,
  pages    = "5173--5183",
  month    =  may,
  year     =  2011,
  language = "en"
}

@ARTICLE{Qu2011-mz,
  title    = "Docking of lytic granules at the immunological synapse in human
              {CTL} requires Vti1b-dependent pairing with {CD3} endosomes",
  author   = "Qu, Bin and Pattu, Varsha and Junker, Christian and Schwarz, Eva
              C and Bhat, Shruthi S and Kummerow, Carsten and Marshall, Misty
              and Matti, Ulf and Neumann, Frank and Pfreundschuh, Michael and
              Becherer, Ute and Rieger, Heiko and Rettig, Jens and Hoth, Markus",
  abstract = "Lytic granule (LG)-mediated apoptosis is the main mechanism by
              which CTL kill virus-infected and tumorigenic target cells. CTL
              form a tight junction with the target cells, which is called the
              immunological synapse (IS). To avoid unwanted killing of
              neighboring cells, exocytosis of lytic granules (LG) is tightly
              controlled and restricted to the IS. In this study, we show that
              in activated human primary CD8(+) T cells, docking of LG at the
              IS requires tethering LG with CD3-containing endosomes
              (CD3-endo). Combining total internal reflection fluorescence
              microscopy and fast deconvolution microscopy (both in living
              cells) with confocal microscopy (in fixed cells), we found that
              LG and CD3-endo tether and are cotransported to the IS. Paired
              but not single LG are accumulated at the IS. The dwell time of LG
              at the IS is substantially enhanced by tethering with CD3-endo,
              resulting in a preferential release of paired LG over single LG.
              The SNARE protein Vti1b is required for tethering of LG and
              CD3-endo. Downregulation of Vti1b reduces tethering of LG with
              CD3-endo. This leads to an impaired accumulation and docking of
              LG at the IS and a reduction of target cell killing. Therefore,
              Vti1b-dependent tethering of LG and CD3-endo determines
              accumulation, docking, and efficient lytic granule secretion at
              the IS.",
  journal  = "J. Immunol.",
  volume   =  186,
  number   =  12,
  pages    = "6894--6904",
  month    =  jun,
  year     =  2011,
  language = "en"
}

@ARTICLE{Goding2013-mz,
  title    = "Restoring immune function of tumor-specific {CD4+} {T} cells
              during recurrence of melanoma",
  author   = "Goding, Stephen R and Wilson, Kyle A and Xie, Ying and Harris,
              Kristina M and Baxi, Aparna and Akpinarli, Akgul and Fulton, Amy
              and Tamada, Koji and Strome, Scott E and Antony, Paul Andrew",
  abstract = "Recurrent solid malignancies are often refractory to standard
              therapies. Although adoptive T cell transfer may benefit select
              individuals, the majority of patients succumb to their disease.
              To address this important clinical dilemma, we developed a mouse
              melanoma model in which initial regression of advanced disease
              was followed by tumor recurrence. During recurrence, Foxp3(+)
              tumor-specific CD4(+) T cells became PD-1(+) and represented
              >60\% of the tumor-specific CD4(+) T cells in the host.
              Concomitantly, tumor-specific CD4(+) T effector cells showed
              traits of chronic exhaustion, as evidenced by their high
              expression of the PD-1, TIM-3, 2B4, TIGIT, and LAG-3 inhibitory
              molecules. Although blockade of the PD-1/PD-L1 pathway with
              anti-PD-L1 Abs or depletion of tumor-specific regulatory T cells
              (Tregs) alone failed to reverse tumor recurrence, the combination
              of PD-L1 blockade with tumor-specific Treg depletion effectively
              mediated disease regression. Furthermore, blockade with a
              combination of anti-PD-L1 and anti-LAG-3 Abs overcame the
              requirement to deplete tumor-specific Tregs. In contrast,
              successful treatment of primary melanoma with adoptive cell
              therapy required only Treg depletion or Ab therapy, underscoring
              the differences in the characteristics of treatment between
              primary and relapsing cancer. These data highlight the need for
              preclinical development of combined immunotherapy approaches
              specifically targeting recurrent disease.",
  journal  = "J. Immunol.",
  volume   =  190,
  number   =  9,
  pages    = "4899--4909",
  month    =  may,
  year     =  2013,
  language = "en"
}

@ARTICLE{Li2014-yx,
  title    = "Real-time detection of {CTL} function reveals distinct patterns
              of caspase activation mediated by Fas versus granzyme {B}",
  author   = "Li, Jinzhu and Figueira, Sarah K and Vrazo, Alexandra C A and
              Binkowski, Brock F and Butler, Braeden L and Tabata, Yasuhiro and
              Filipovich, Alexandra and Jordan, Michael B and Risma, Kimberly A",
  abstract = "Activation of caspase-mediated apoptosis is reported to be a
              hallmark of both granzyme B- and Fas-mediated pathways of killing
              by CTLs; however, the kinetics of caspase activation remain
              undefined owing to an inability to monitor target cell-specific
              apoptosis in real time. We have overcome this limitation by
              developing a novel biosensor assay that detects continuous,
              protease-specific activity in target cells. Biosensors were
              engineered from a circularly permuted luciferase, linked
              internally by either caspase 3/7 or granzyme B/caspase 8 cleavage
              sites, thus allowing activation upon proteolytic cleavage by the
              respective proteases. Coincubation of murine CTLs with target
              cells expressing either type of biosensor led to a robust
              luminescent signal within minutes of cell contact. The signal was
              modulated by the strength of TCR signaling, the ratio of
              CTL/target cells, and the type of biosensor used. Additionally,
              the luciferase signal at 30 min correlated with target cell
              death, as measured by a (51)Cr-release assay. The rate of caspase
              3/7 biosensor activation was unexpectedly rapid following
              granzyme B- compared with Fas-mediated signal induction in murine
              CTLs; the latter appeared gradually after a 90-min delay in
              perforin- or granzyme B-deficient CTLs. Remarkably, the
              Fas-dependent, caspase 3/7 biosensor signal induced by
              perforin-deficient human CTLs was also detectable after a 90-min
              delay when measured by redirected killing. Thus, we have used a
              novel, real-time assay to demonstrate the distinct pattern of
              caspase activation induced by granzyme B versus Fas in human and
              murine CTLs.",
  journal  = "J. Immunol.",
  volume   =  193,
  number   =  2,
  pages    = "519--528",
  month    =  jul,
  year     =  2014,
  language = "en"
}

@ARTICLE{Metz2015-ka,
  title    = "Regulation of asymmetric division and {CD8+} {T} lymphocyte fate
              specification by protein kinase {C$\zeta$} and protein kinase
              {C$\lambda$/$\iota$}",
  author   = "Metz, Patrick J and Arsenio, Janilyn and Kakaradov, Boyko and
              Kim, Stephanie H and Remedios, Kelly A and Oakley, Katherine and
              Akimoto, Kazunori and Ohno, Shigeo and Yeo, Gene W and Chang,
              John T",
  abstract = "During an immune response against a microbial pathogen, activated
              naive T lymphocytes give rise to effector cells that provide
              acute host defense and memory cells that provide long-lived
              immunity. It has been shown that T lymphocytes can undergo
              asymmetric division, enabling the daughter cells to inherit
              unequal amounts of fate-determining proteins and thereby acquire
              distinct fates from their inception. In this study, we show that
              the absence of the atypical protein kinase C (PKC) isoforms,
              PKC$\zeta$ and PKC$\lambda$/$\iota$, disrupts asymmetric CD8(+) T
              lymphocyte division. These alterations were associated with
              aberrant acquisition of a pre-effector transcriptional program,
              detected by single-cell gene expression analyses, in lymphocytes
              that had undergone their first division in vivo and enhanced
              differentiation toward effector fates at the expense of memory
              fates. Together, these results demonstrate a role for atypical
              PKC in regulating asymmetric division and the specification of
              divergent CD8(+) T lymphocyte fates early during an immune
              response.",
  journal  = "J. Immunol.",
  volume   =  194,
  number   =  5,
  pages    = "2249--2259",
  month    =  mar,
  year     =  2015,
  language = "en"
}

@ARTICLE{Tian2015-wp,
  title    = "The upregulation of {LAG-3} on {T} cells defines a subpopulation
              with functional exhaustion and correlates with disease
              progression in {HIV-infected} subjects",
  author   = "Tian, Xiaoling and Zhang, Anli and Qiu, Chao and Wang, Wei and
              Yang, Yu and Qiu, Chenli and Liu, Aiping and Zhu, Lingyan and
              Yuan, Songhua and Hu, Huiliang and Wang, Wanhai and Wei, Qiang
              and Zhang, Xiaoyan and Xu, Jianqing",
  abstract = "T cells develop functional defects during HIV-1 infection,
              partially due to the upregulation of inhibitory receptors such as
              programmed death-1 (PD-1) and CTLA-4. However, the role of
              lymphocyte activation gene-3 (LAG-3; CD223), also known as an
              inhibitory receptor, in HIV infection remains to be determined.
              In this study, we revealed that LAG-3 on T cells delivers an
              inhibitory signal to downregulate T cell functionality, thereby
              playing an immunoregulatory role during persistent HIV-1
              infection. We observed that HIV-1 infection results in a
              significant increase in LAG-3 expression in both the peripheral
              blood and the lymph nodes. The upregulation of LAG-3 is
              dramatically manifested on both CD4(+) and CD8(+) T cells and is
              correlated with disease progression. As expected, prolonged
              antiretroviral therapy reduces the expression of LAG-3 on both
              CD4(+) and CD8(+) T cells. The ex vivo blockade of LAG-3
              significantly augments HIV-specific CD4(+) and CD8(+) T cell
              responses, whereas the overexpression of LAG-3 in T cells or the
              stimulation of LAG-3 on T cells leads to the reduction of T cell
              responses. Furthermore, most LAG-3 and PD-1 are expressed in
              different T cell subsets. Taken together, these data demonstrate
              that the LAG-3/MHC class II pathway plays an immunoregulatory
              role, thereby providing an important target for enhancing immune
              reconstitution in HIV-infected patients. Additionally, the
              LAG-3/MHC class II pathway may synergize with PD-1/PD ligand to
              enhance T cell-mediated immune responses.",
  journal  = "J. Immunol.",
  volume   =  194,
  number   =  8,
  pages    = "3873--3882",
  month    =  apr,
  year     =  2015,
  language = "en"
}

@ARTICLE{Peng2000-lb,
  title    = "{T} cell-mediated tumor rejection displays diverse dependence
              upon perforin and {IFN-gamma} mechanisms that cannot be predicted
              from in vitro {T} cell characteristics",
  author   = "Peng, L and Krauss, J C and Plautz, G E and Mukai, S and Shu, S
              and Cohen, P A",
  abstract = "Experimental pulmonary metastases have been successfully treated
              by adoptive transfer of tumor-sensitized T cells from perforin
              knockout (KO) or Fas/APO-1 ligand(KO) mice, suggesting a
              prominent role for secretion of cytokines such as IFN-gamma. In
              the present study we confirmed that rejection of established
              methylcholanthrene-205 (MCA-205) pulmonary metastases displayed a
              requirement for T cell IFN-gamma expression. However, this
              requirement could be obviated by transferring larger numbers of
              tumor-sensitized IFN-gamma (KO) T cells or by immunosensitizing
              sublethal irradiation (500 rad) of the host before adoptive
              therapy. Extrapulmonary tumors (MCA-205 s.c. and intracranial)
              that required adjunct sublethal irradiation for treatment
              efficacy also displayed no requirement for host or T cell
              expression of IFN-gamma. Nonetheless, rejection of MCA-205 s.c.
              tumors and i.p. EL-4 tumors, but not MCA-205 pulmonary or
              intracranial tumors, displayed a significant requirement for T
              cell perforin expression (i.e., CTL participation). The capacity
              of T cells to lyse tumor targets and secrete IFN-gamma in vitro
              before adoptive transfer was nonpredictive of the roles of these
              activities in subsequent tumor rejection. Adoptive therapy
              studies employing KO mice are therefore indispensable for
              revealing a diversity of tumor rejection mechanisms that may lack
              in vitro correlation due to delays in their induction. Seemingly
              contradictory KO data from different studies are reconciled by
              the capacity of anti-tumor T cells to rely on alternative
              mechanisms when treated in larger numbers, the variable
              participation of CTL at different anatomic locations of tumor,
              and the apparent capacity of sublethal irradiation to provide a
              therapeutic alternative to host or T cell IFN-gamma production.",
  journal  = "J. Immunol.",
  volume   =  165,
  number   =  12,
  pages    = "7116--7124",
  month    =  dec,
  year     =  2000,
  language = "en"
}

@ARTICLE{Lee2002-rf,
  title    = "{4-1BB} promotes the survival of {CD8+} {T} lymphocytes by
              increasing expression of {Bcl-xL} and Bfl-1",
  author   = "Lee, Hyeon-Woo and Park, Su-Jung and Choi, Beom K and Kim, Hyun
              Hwa and Nam, Kyung-Ok and Kwon, Byoung S",
  abstract = "4-1BB, a T cell costimulatory receptor, prolongs CD8(+) T cell
              survival. In these studies, 4-1BB stimulation was shown to
              increase expression of the antiapoptotic genes bcl-x(L) and bfl-1
              via 4-1BB-mediated NF-kappaB activation. This signaling pathway
              was specifically inhibited by PDTC and was different from the
              pathways that enhanced CD8(+) T cell proliferation. The results
              suggest a role for the antiapoptotic activities of Bcl-x(L) and
              Bfl-1 proteins in 4-1BB-mediated CD8(+) T cell survival in vivo.",
  journal  = "J. Immunol.",
  volume   =  169,
  number   =  9,
  pages    = "4882--4888",
  month    =  nov,
  year     =  2002,
  language = "en"
}

@ARTICLE{Gorris2018-fl,
  title    = "{Eight-Color} Multiplex Immunohistochemistry for Simultaneous
              Detection of Multiple Immune Checkpoint Molecules within the
              Tumor Microenvironment",
  author   = "Gorris, Mark A J and Halilovic, Altuna and Rabold, Katrin and van
              Duffelen, Anne and Wickramasinghe, Iresha N and Verweij, Dagmar
              and Wortel, Inge M N and Textor, Johannes C and de Vries, I
              Jolanda M and Figdor, Carl G",
  abstract = "Therapies targeting immune checkpoint molecules CTLA-4 and
              PD-1/PD-L1 have advanced the field of cancer immunotherapy. New
              mAbs targeting different immune checkpoint molecules, such as
              TIM3, CD27, and OX40, are being developed and tested in clinical
              trials. To make educated decisions and design new combination
              treatment strategies, it is vital to learn more about
              coexpression of both inhibitory and stimulatory immune
              checkpoints on individual cells within the tumor
              microenvironment. Recent advances in multiple immunolabeling and
              multispectral imaging have enabled simultaneous analysis of more
              than three markers within a single formalin-fixed
              paraffin-embedded tissue section, with accurate cell
              discrimination and spatial information. However, multiplex
              immunohistochemistry with a maximized number of markers presents
              multiple difficulties. These include the primary Ab
              concentrations and order within the multiplex panel, which are of
              major importance for the staining result. In this article, we
              report on the development, optimization, and application of an
              eight-color multiplex immunohistochemistry panel, consisting of
              PD-1, PD-L1, OX40, CD27, TIM3, CD3, a tumor marker, and DAPI.
              This multiplex panel allows for simultaneous quantification of
              five different immune checkpoint molecules on individual cells
              within different tumor types. This analysis revealed major
              differences in the immune checkpoint expression patterns across
              tumor types and individual tumor samples. This method could
              ultimately, by characterizing the tumor microenvironment of
              patients who have been treated with different immune checkpoint
              modulators, form the rationale for the design of immune
              checkpoint-based immunotherapy in the future.",
  journal  = "J. Immunol.",
  volume   =  200,
  number   =  1,
  pages    = "347--354",
  month    =  jan,
  year     =  2018,
  language = "en"
}

@ARTICLE{Barber2003-pd,
  title    = "Cutting edge: rapid in vivo killing by memory {CD8} {T} cells",
  author   = "Barber, Daniel L and Wherry, E John and Ahmed, Rafi",
  abstract = "In this study, we examined the cytotoxic activity of effector and
              memory CD8 T cells in vivo. At the peak of the CTL response
              following an acute lymphocytic choriomeningitis virus infection,
              effector CD8 T cells exhibited extremely rapid killing and
              started to eliminate adoptively transferred target cells within
              15 min by a perforin-dependent mechanism. Although resting memory
              CD8 T cells are poorly cytolytic by in vitro (51)Cr release
              assays, there was rapid elimination (within 1-4 h) of target
              cells after transfer into immune mice, and both CD62L(high) and
              CD62L(low) memory CD8 T cells were able to kill rapidly in vivo.
              Strikingly, when directly compared on a per cell basis, memory
              CD8 T cells were only slightly slower than effector cells in
              eliminating target cells. These data indicate that virus specific
              memory CD8 T cells can rapidly acquire cytotoxic function upon
              re-exposure to Ag and are much more efficient killers in vivo
              than previously appreciated.",
  journal  = "J. Immunol.",
  volume   =  171,
  number   =  1,
  pages    = "27--31",
  month    =  jul,
  year     =  2003,
  language = "en"
}

@ARTICLE{Caldwell2003-kx,
  title    = "The {Fas/Fas} ligand pathway is important for optimal tumor
              regression in a mouse model of {CTL} adoptive immunotherapy of
              experimental {CMS4} lung metastases",
  author   = "Caldwell, Sheila A and Ryan, Mary H and McDuffie, Elwood and
              Abrams, Scott I",
  abstract = "The mechanisms of CTL-mediated tumor regression in vivo remain to
              be fully understood. If CTL do mediate tumor regression in vivo
              by direct cytotoxicity, this may occur via two major effector
              mechanisms involving the secretion of perforin/granzymes and/or
              engagement of Fas by Fas ligand (FasL) expressed by the activated
              CTL. Although the perforin pathway has been considered the
              dominant player, it is unclear whether Fas-mediated cytotoxicity
              is additionally required for optimal tumor rejection. Previously,
              we produced H-2L(d)-restricted CTL reactive against the CMS4
              sarcoma, which expresses a naturally occurring rejection Ag
              recognized by these CTL and harbors a cytokine (IFN-gamma plus
              TNF)-inducible, Fas-responsive phenotype. The adoptive transfer
              of these CTL to syngeneic BALB/c mice with minimal (day 3
              established) or extensive (day 10 established) experimental
              pulmonary metastases resulted in strong antitumor responses. Here
              we investigated whether a FasL-dependent CTL effector mechanism
              was important for optimal tumor regression in this adoptive
              immunotherapy model. The approach taken was to compare the
              therapeutic efficacy of wild-type to FasL-deficient (gld) CTL
              clones by adoptive transfer. In comparison with wild-type CTL,
              gld-CTL efficiently mediated tumor cytolysis and produced
              comparable amounts of IFN-gamma, after tumor-specific
              stimulation, as in vitro assessments of Ag recognition. Moreover,
              gld-CTL mediated comparably potent antitumor effects in a minimal
              disease setting, but were significantly less effective under
              conditions of an extensive tumor burden. Overall, under
              conditions of extensive lung metastases, these data revealed for
              the first time an important role for a FasL-dependent CTL
              effector mechanism in optimal tumor regression.",
  journal  = "J. Immunol.",
  volume   =  171,
  number   =  5,
  pages    = "2402--2412",
  month    =  sep,
  year     =  2003,
  language = "en"
}

@ARTICLE{De_Boer2003-oz,
  title    = "Different dynamics of {CD4+} and {CD8+} {T} cell responses during
              and after acute lymphocytic choriomeningitis virus infection",
  author   = "De Boer, Rob J and Homann, Dirk and Perelson, Alan S",
  abstract = "We fit a mathematical model to data characterizing the primary
              cellular immune response to lymphocytic choriomeningitis virus.
              The data enumerate the specific CD8(+) T cell response to six MHC
              class I-restricted epitopes and the specific CD4(+) T cell
              responses to two MHC class II-restricted epitopes. The peak of
              the response occurs around day 8 for CD8(+) T cells and around
              day 9 for CD4(+) T cells. By fitting a model to the data, we
              characterize the kinetic differences between CD4(+) and CD8(+) T
              cell responses and among the immunodominant and subdominant
              responses to the various epitopes. CD8(+) T cell responses have
              faster kinetics in almost every aspect of the response. For
              CD8(+) and CD4(+) T cells, the doubling time during the initial
              expansion phase is 8 and 11 h, respectively. The half-life during
              the contraction phase following the peak of the response is 41 h
              and 3 days, respectively. CD4(+) responses are even slower
              because their contraction phase appears to be biphasic,
              approaching a 35-day half-life 8 days after the peak of the
              response. The half-life during the memory phase is 500 days for
              the CD4(+) T cell responses and appears to be lifelong for the
              six CD8(+) T cell responses. Comparing the responses between the
              various epitopes, we find that immunodominant responses have an
              earlier and/or larger recruitment of precursors cells before the
              expansion phase and/or have a faster proliferation rate during
              the expansion phase.",
  journal  = "J. Immunol.",
  volume   =  171,
  number   =  8,
  pages    = "3928--3935",
  month    =  oct,
  year     =  2003,
  language = "en"
}

@ARTICLE{Hollenbaugh2004-ho,
  title    = "The rate of the {CD8-dependent} initial reduction in tumor volume
              is not limited by contact-dependent perforin, Fas ligand, or
              {TNF-mediated} cytolysis",
  author   = "Hollenbaugh, Joseph A and Reome, Joyce and Dobrzanski, Mark and
              Dutton, Richard W",
  abstract = "Established EG7 tumors expressing OVA and growing at an
              intradermal site become rapidly reduced in size following
              adoptive therapy with in vitro-generated type I CD8 T cell (Tc1)
              effectors generated from naive CD8 T cells from transgenic TCR
              OVA-specific mice. Tc1 effectors kill EG7 target cells in vitro
              by a perforin-dependent mechanism. However, we show that there is
              no quantitative diminution of the initial phase of antitumor
              activity in vivo, whether the Tc1 effectors are derived from
              perforin-, Fas ligand-, or TNF-deficient transgenic TCR mice or
              whether the recipients are perforin deficient. Tumors are also
              equally well controlled whether the Tc1 effectors come from mice
              deficient in perforin plus Fas ligand or perforin plus TNF.
              Control of tumor growth is diminished when Tc1 effectors
              generated from IFN-gamma-deficient mice are used. We conclude
              that control of tumor growth is not in any way affected by loss
              of contact-mediated lytic mechanisms, and conclude that the CD8
              effectors must act by recruiting host effector mechanisms to
              control tumor growth.",
  journal  = "J. Immunol.",
  volume   =  173,
  number   =  3,
  pages    = "1738--1743",
  month    =  aug,
  year     =  2004,
  language = "en"
}

@ARTICLE{Hollenbaugh2006-wn,
  title     = "{IFN-$\gamma$} Regulates Donor {CD8} {T} Cell Expansion,
               Migration, and Leads to Apoptosis of Cells of a Solid Tumor",
  author    = "Hollenbaugh, Joseph A and Dutton, Richard W",
  abstract  = "We previously reported that IFN-$\gamma$ secreted by donor
               cytotoxic T cell 1 (Tc1) cells was the most important factor in
               promoting EG7 (an OVA transfection the EL4 thymoma) rejection in
               mice. In this study, we show that the ability of the host to
               respond to Tc1-secreted IFN-$\gamma$ is critical for promoting
               acute tumor rejection, while host production of IFN-$\gamma$ is
               not important. CFSE-labeled wild-type and IFN-$\gamma$-deficient
               Tc1 cells divide rapidly in secondary lymphoid organs,
               indicating no defect in rate of cell division. However,
               wild-type Tc1 cells accumulate to significantly greater numbers
               in the tumor than deficient Tc1 cells. Hosts injected with
               wild-type Tc1 effectors had more T cells within the tumor at day
               4, had higher levels of MCP-1, IFN-$\gamma$-inducible
               protein-10, MIP-1$\alpha$, and MIP-1$\beta$ mRNA transcripts,
               had greater numbers of CD11b+ and Gr-1+ cells within the tumor,
               and had massive regions of tumor cell apoptosis as compared with
               IFN-$\gamma$ knockout Tc1 cell-treated hosts. NO has a
               cytostatic effect on EG7 growth in vitro, and NO is important
               for tumor eradication by day 22. These observations are
               compatible with a model in which the donor CD8 Tc1 effectors
               expand rapidly in the host, migrate to the tumor site, and
               induce the secretion of a number of chemokines that in turn
               recruit host cells that then attack the tumor.",
  journal   = "The Journal of Immunology",
  publisher = "American Association of Immunologists",
  volume    =  177,
  number    =  5,
  pages     = "3004--3011",
  month     =  sep,
  year      =  2006,
  language  = "en"
}

@ARTICLE{Marxer2012-zn,
  title    = "Tetraploidization increases sensitivity to Aurora {B} kinase
              inhibition",
  author   = "Marxer, Miriam and Foucar, Charles E and Man, Wing Yu and Chen,
              Yu and Ma, Hoi Tang and Poon, Randy Y C",
  abstract = "Aurora kinases are overexpressed in many cancers and are targets
              for anticancer drugs. The yeast homolog of Aurora B kinase, IPL1,
              was found to be a ploidy-specific lethality gene. Given that
              polyploidization is a common feature of many cancers, we
              hypothesized polyploidization also sensitizes mammalian cells to
              inhibition of Aurora kinases. Using two models of apparent
              diploid vs. tetraploid cell lines (one based on the
              hepatocellular carcinoma cell line Hep3B and another on
              untransformed mouse fibroblasts), we found that tetraploid cells
              were more sensitive to Aurora B inhibition than their diploid
              counterparts. Apoptosis could be induced in tetraploid cells by
              two different Aurora B inhibitors. Furthermore, tetraploid cells
              were sensitive to Aurora B inhibition but were not affected by
              Aurora A inhibition. Interestingly, the underlying mechanism was
              due to mitotic slippage and the subsequent excessive genome
              reduplication. In support of this, abolition of cytokinesis with
              dihydrocytochalasin B resulted in similar effects on tetraploid
              cells as Aurora B inhibition. These results indicate that
              inhibition of Aurora B or cytokinesis can promote apoptosis
              effectively in polyploid cancer cells.",
  journal  = "Cell Cycle",
  volume   =  11,
  number   =  13,
  pages    = "2567--2577",
  month    =  jul,
  year     =  2012,
  language = "en"
}

@ARTICLE{Rello-Varona2009-cp,
  title    = "Preferential killing of tetraploid tumor cells by targeting the
              mitotic kinesin Eg5",
  author   = "Rello-Varona, Santiago and Vitale, Ilio and Kepp, Oliver and
              Senovilla, Laura and Jema{\'a}, Mohamed and M{\'e}tivier, Didier
              and Castedo, Maria and Kroemer, Guido",
  abstract = "Tetraploid cells may constitute a metastable intermediate between
              normal euploidy and cancer-associated aneuploidy. Tetraploid
              cells are relatively more resistant against DNA damaging agents
              and are genetically unstable, due to their tendency towards
              multipolar, asymmetric division. Therefore, it is important to
              develop strategies for the selective removal of tetraploid cells.
              Here, we show that targeting the mitotic kinesin Eg5 (also known
              as kinesin spindle protein, KSP) by a small interfering RNA
              (siRNA) or by the pharmacological inhibitor dimethylenastron
              (DIMEN) kills tetraploid tumor cells more efficiently than their
              diploid precursors. Cell death occurs after an attempt of
              monoastral mitosis that, in diploid cells, is followed by a
              prolonged mitotic arrest and morphological reversion to the
              interphase, with a 4n DNA content. In contrast, DIMEN-treated
              tetraploid cells exhibit a shorter mitotic arrest, bipolar or
              multipolar karyokinesis, followed by apoptosis of the daughter
              cells, as assessed by fluorescence videomicroscopy of cells that
              express a histone 2B-GFP fusion construct to monitor their
              chromosomes. Cell death occurred with hallmarks of apoptosis,
              namely loss of the mitochondrial transmembrane potential and
              terminal chromatin compaction. In conclusion, tetraploid cells
              are particular vulnerable to undergo mitotic catastrophe after
              genetic or pharmacological inhibition of Eg5.",
  journal  = "Cell Cycle",
  volume   =  8,
  number   =  7,
  pages    = "1030--1035",
  month    =  apr,
  year     =  2009,
  language = "en"
}

@ARTICLE{Martinez-Outschoorn2010-nc,
  title    = "Oxidative stress in cancer associated fibroblasts drives
              tumor-stroma co-evolution: A new paradigm for understanding tumor
              metabolism, the field effect and genomic instability in cancer
              cells",
  author   = "Martinez-Outschoorn, Ubaldo E and Balliet, Renee M and
              Rivadeneira, Dayana B and Chiavarina, Barbara and Pavlides,
              Stephanos and Wang, Chenguang and Whitaker-Menezes, Diana and
              Daumer, Kristin M and Lin, Zhao and Witkiewicz, Agnieszka K and
              Flomenberg, Neal and Howell, Anthony and Pestell, Richard G and
              Knudsen, Erik S and Sotgia, Federica and Lisanti, Michael P",
  abstract = "Loss of stromal fibroblast caveolin-1 (Cav-1) is a powerful
              single independent predictor of poor prognosis in human breast
              cancer patients, and is associated with early tumor recurrence,
              lymph node metastasis and tamoxifen-resistance. We developed a
              novel co-culture system to understand the mechanism(s) by which a
              loss of stromal fibroblast Cav-1 induces a ``lethal tumor
              micro-environment.'' Here, we propose a new paradigm to explain
              the powerful prognostic value of stromal Cav-1. In this model,
              cancer cells induce oxidative stress in cancer-associated
              fibroblasts, which then acts as a ``metabolic'' and ``mutagenic''
              motor to drive tumor-stroma co-evolution, DNA damage and
              aneuploidy in cancer cells. More specifically, we show that an
              acute loss of Cav-1 expression leads to mitochondrial
              dysfunction, oxidative stress and aerobic glycolysis in cancer
              associated fibroblasts. Also, we propose that defective
              mitochondria are removed from cancer-associated fibroblasts by
              autophagy/mitophagy that is induced by oxidative stress. As a
              consequence, cancer associated fibroblasts provide nutrients
              (such as lactate) to stimulate mitochondrial biogenesis and
              oxidative metabolism in adjacent cancer cells (the ``Reverse
              Warburg Effect''). We provide evidence that oxidative stress in
              cancer-associated fibroblasts is sufficient to induce genomic
              instability in adjacent cancer cells, via a bystander effect,
              potentially increasing their aggressive behavior. Finally, we
              directly demonstrate that nitric oxide (NO) over-production,
              secondary to Cav-1 loss, is the root cause for mitochondrial
              dysfunction in cancer associated fibroblasts. In support of this
              notion, treatment with anti-oxidants (such as N-acetyl-cysteine,
              metformin and quercetin) or NO inhibitors (L-NAME) was sufficient
              to reverse many of the cancer-associated fibroblast phenotypes
              that we describe. Thus, cancer cells use ``oxidative stress'' in
              adjacent fibroblasts (i) as an ``engine'' to fuel their own
              survival via the stromal production of nutrients and (ii) to
              drive their own mutagenic evolution towards a more aggressive
              phenotype, by promoting genomic instability. We also present
              evidence that the ``field effect'' in cancer biology could also
              be related to the stromal production of ROS and NO species.
              eNOS-expressing fibroblasts have the ability to downregulate
              Cav-1 and induce mitochondrial dysfunction in adjacent
              fibroblasts that do not express eNOS. As such, the effects of
              stromal oxidative stress can be laterally propagated, amplified
              and are effectively ``contagious''--spread from cell-to-cell like
              a virus--creating an ``oncogenic/mutagenic'' field promoting
              widespread DNA damage.",
  journal  = "Cell Cycle",
  volume   =  9,
  number   =  16,
  pages    = "3256--3276",
  month    =  aug,
  year     =  2010,
  language = "en"
}

% The entry below contains non-ASCII chars that could not be converted
% to a LaTeX equivalent.
@ARTICLE{Weigelin2012-wt,
  title    = "Intravital third harmonic generation microscopy of collective
              melanoma cell invasion: Principles of interface guidance and
              microvesicle dynamics",
  author   = "Weigelin, Bettina and Bakker, Gert-Jan and Friedl, Peter",
  abstract = "Cancer cell invasion is an adaptive process based on
              cell-intrinsic properties to migrate individually or
              collectively, and their adaptation to encountered tissue
              structure acting as barrier or providing guidance. Whereas
              molecular and physical mechanisms of cancer invasion are
              well-studied in 3D in vitro models, their topographic relevance,
              classification and validation toward interstitial tissue
              organization in vivo remain incomplete. Using combined intravital
              third and second harmonic generation (THG, SHG), and
              three-channel fluorescence microscopy in live tumors, we here map
              B16F10 melanoma invasion into the dermis with up to 600 m
              penetration depth and reconstruct both invasion mode and tissue
              tracks to establish invasion routes and outcome. B16F10 cells
              preferentially develop adaptive invasion patterns along preformed
              tracks of complex, multi-interface topography, combining
              single-cell and collective migration modes, without immediate
              anatomic tissue remodeling or destruction. The data suggest that
              the dimensionality (1D, 2D, 3D) of tissue interfaces determines
              the microanatomy exploited by invading tumor cells, emphasizing
              non-destructive migration along microchannels coupled to contact
              guidance as key invasion mechanisms. THG imaging further detected
              the presence and interstitial dynamics of tumor-associated
              microparticles with submicron resolution, revealing tumor-imposed
              conditioning of the microenvironment. These topographic findings
              establish combined THG, SHG and fluorescence microscopy in
              intravital tumor biology and provide a template for rational in
              vitro model development and context-dependent molecular
              classification of invasion modes and routes.",
  journal  = "Intravital",
  volume   =  1,
  number   =  1,
  pages    = "32--43",
  month    =  jul,
  year     =  2012,
  keywords = "adipocyte; intravital multiphoton microscopy; melanoma;
              microparticles; myofiber; second harmonic generation; third
              harmonic generation; tumor invasion; tumor
              microenvironment;B16F10\_specific",
  language = "en"
}

@ARTICLE{Bellone2013-nd,
  title    = "The acidity of the tumor microenvironment is a mechanism of
              immune escape that can be overcome by proton pump inhibitors",
  author   = "Bellone, Matteo and Calcinotto, Arianna and Filipazzi, Paola and
              De Milito, Angelo and Fais, Stefano and Rivoltini, Licia",
  abstract = "We have recently reported that lowering the pH to values that are
              frequently detected in tumors causes reversible anergy in both
              human and mouse CD8+ T lymphocytes in vitro. The same occurs in
              vivo, in the tumor microenvironment and the administration of
              proton pump inhibitors, which buffer tumor acidity, can revert
              T-cell anergy and increase the efficacy of immunotherapy.",
  journal  = "Oncoimmunology",
  volume   =  2,
  number   =  1,
  pages    = "e22058",
  month    =  jan,
  year     =  2013,
  keywords = "T cell; active immunotherapy; adoptive immunotherapy; anergy;
              melanoma; prostate cancer",
  language = "en"
}

@ARTICLE{Schietinger2013-dw,
  title    = "Longitudinal confocal microscopy imaging of solid tumor
              destruction following adoptive {T} cell transfer",
  author   = "Schietinger, Andrea and Arina, Ainhoa and Liu, Rebecca B and
              Wells, Sam and Huang, Jianhua and Engels, Boris and Bindokas,
              Vytas and Bartkowiak, Todd and Lee, David and Herrmann, Andreas
              and Piston, David W and Pittet, Mikael J and Lin, P Charles and
              Zal, Tomasz and Schreiber, Hans",
  abstract = "A fluorescence-based, high-resolution imaging approach was used
              to visualize longitudinally the cellular events unfolding during
              T cell-mediated tumor destruction. The dynamic interplay of T
              cells, cancer cells, cancer antigen loss variants, and stromal
              cells-all color-coded in vivo-was analyzed in established, solid
              tumors that had developed behind windows implanted on the backs
              of mice. Events could be followed repeatedly within precisely the
              same tumor region-before, during and after adoptive T cell
              therapy-thereby enabling for the first time a longitudinal in
              vivo evaluation of protracted events, an analysis not possible
              with terminal imaging of surgically exposed tumors. T cell
              infiltration, stromal interactions, and vessel destruction, as
              well as the functional consequences thereof, including the
              elimination of cancer cells and cancer cell variants were
              studied. Minimal perivascular T cell infiltrates initiated
              vascular destruction inside the tumor mass eventually leading to
              macroscopic central tumor necrosis. Prolonged engagement of T
              cells with tumor antigen-crosspresenting stromal cells correlated
              with high IFN$\gamma$ cytokine release and bystander elimination
              of antigen-negative cancer cells. The high-resolution,
              longitudinal, in vivo imaging approach described here will help
              to further a better mechanistic understanding of tumor
              eradication by T cells and other anti-cancer therapies.",
  journal  = "Oncoimmunology",
  volume   =  2,
  number   =  11,
  pages    = "e26677",
  month    =  nov,
  year     =  2013,
  keywords = "CD8 T cell; cancer; imaging; stroma; tumor immunology; tumor
              microenvironment",
  language = "en"
}

@ARTICLE{Liu2021-sw,
  title    = "Intravital molecular imaging reveals the restrained capacity of
              {CTLs} in the killing of tumor cells in the liver",
  author   = "Liu, Lei and Dai, Bolei and Li, Ruixue and Liu, Zheng and Zhang,
              Zhihong",
  abstract = "Cytotoxic T lymphocytes (CTLs) and their gene-engineered cells
              display great application prospects in tumor immunotherapy. The
              timing of CTL-induced molecular events in tumor cells is unclear,
              and we also unknow whether the killing efficiency of CTLs is
              restrained in the liver, an immunotolerant organ with a high
              tumor incidence. Methods: We used intravital imaging to
              dynamically monitor the fluorescence resonance energy transfer
              (FRET) signals of caspase-3 and calcium sensor in tumor cells
              after transferring CTLs into tumor-bearing mice. Results: Our
              data show that several CTLs attacked on one tumor cell, and on
              average each CTL killed 1.24 $\pm$ 0.11 tumor cells per day in
              the liver, which was much less efficient than that in the spleen
              (3.18 $\pm$ 0.26 tumor cells/CTL/day). The killing efficiency of
              CTLs is restrained in the liver and can be reversed by blocking
              immunosuppressive cytokine. Tumor cells exposed to CTLs appeared
              to have prolonged calcium influx, which occurred dozens of
              minutes before caspase-3 activity. Conclusion: The quantitative
              characterization of these molecular and cellular events provides
              accurate information to evaluate the efficiency of cellular
              immunotherapy against tumors and understand the impact of an
              organ's immune status.",
  journal  = "Theranostics",
  volume   =  11,
  number   =  1,
  pages    = "194--208",
  month    =  jan,
  year     =  2021,
  keywords = "CTL; apoptosis; calcium signaling; liver tumor; molecular imaging",
  language = "en"
}

@ARTICLE{Dephoure2014-zw,
  title    = "Quantitative proteomic analysis reveals posttranslational
              responses to aneuploidy in yeast",
  author   = "Dephoure, Noah and Hwang, Sunyoung and O'Sullivan, Ciara and
              Dodgson, Stacie E and Gygi, Steven P and Amon, Angelika and
              Torres, Eduardo M",
  abstract = "Aneuploidy causes severe developmental defects and is a near
              universal feature of tumor cells. Despite its profound effects,
              the cellular processes affected by aneuploidy are not well
              characterized. Here, we examined the consequences of aneuploidy
              on the proteome of aneuploid budding yeast strains. We show that
              although protein levels largely scale with gene copy number,
              subunits of multi-protein complexes are notable exceptions.
              Posttranslational mechanisms attenuate their expression when
              their encoding genes are in excess. Our proteomic analyses
              further revealed a novel aneuploidy-associated protein expression
              signature characteristic of altered metabolism and redox
              homeostasis. Indeed aneuploid cells harbor increased levels of
              reactive oxygen species (ROS). Interestingly, increased protein
              turnover attenuates ROS levels and this novel
              aneuploidy-associated signature and improves the fitness of most
              aneuploid strains. Our results show that aneuploidy causes
              alterations in metabolism and redox homeostasis. Cells respond to
              these alterations through both transcriptional and
              posttranscriptional mechanisms.",
  journal  = "Elife",
  volume   =  3,
  pages    = "e03023",
  month    =  jul,
  year     =  2014,
  keywords = "aneuploidy; posttranscriptional mechanisms; posttranslational
              mechanisms; proteomics",
  language = "en"
}

@ARTICLE{Metzl-Raz2017-vz,
  title    = "Principles of cellular resource allocation revealed by
              condition-dependent proteome profiling",
  author   = "Metzl-Raz, Eyal and Kafri, Moshe and Yaakov, Gilad and Soifer,
              Ilya and Gurvich, Yonat and Barkai, Naama",
  abstract = "Growing cells coordinate protein translation with metabolic
              rates. Central to this coordination is ribosome production.
              Ribosomes drive cell growth, but translation of ribosomal
              proteins competes with production of non-ribosomal proteins.
              Theory shows that cell growth is maximized when all expressed
              ribosomes are constantly translating. To examine whether budding
              yeast function at this limit of full ribosomal usage, we profiled
              the proteomes of cells growing in different environments. We find
              that cells produce excess ribosomal proteins, amounting to a
              constant $\approx$8\% of the proteome. Accordingly, $\approx$25\%
              of ribosomal proteins expressed in rapidly growing cells does not
              contribute to translation. Further, this fraction increases as
              growth rate decreases and these excess ribosomal proteins are
              employed when translation demands unexpectedly increase. We
              suggest that steadily growing cells prepare for conditions that
              demand increased translation by producing excess ribosomes, at
              the expense of lower steady-state growth rate.",
  journal  = "Elife",
  volume   =  6,
  month    =  aug,
  year     =  2017,
  keywords = "S. cerevisiae; cell biology; computational biology; proteome;
              resource allocation; ribosomes; systems biology; transcription;
              translation",
  language = "en"
}

@ARTICLE{Hose2020-fn,
  title    = "The genetic basis of aneuploidy tolerance in wild yeast",
  author   = "Hose, James and Escalante, Leah E and Clowers, Katie J and
              Dutcher, H Auguste and Robinson, Deelegant and Bouriakov, Venera
              and Coon, Joshua J and Shishkova, Evgenia and Gasch, Audrey P",
  abstract = "Aneuploidy is highly detrimental during development yet common in
              cancers and pathogenic fungi - what gives rise to differences in
              aneuploidy tolerance remains unclear. We previously showed that
              wild isolates of Saccharomyces cerevisiae tolerate chromosome
              amplification while laboratory strains used as a model for
              aneuploid syndromes do not. Here, we mapped the genetic basis to
              Ssd1, an RNA-binding translational regulator that is functional
              in wild aneuploids but defective in laboratory strain W303. Loss
              of SSD1 recapitulates myriad aneuploidy signatures previously
              taken as eukaryotic responses. We show that aneuploidy tolerance
              is enabled via a role for Ssd1 in mitochondrial physiology,
              including binding and regulating nuclear-encoded mitochondrial
              mRNAs, coupled with a role in mitigating proteostasis stress.
              Recapitulating ssd1$\Delta$ defects with combinatorial drug
              treatment selectively blocked proliferation of wild-type
              aneuploids compared to euploids. Our work adds to elegant studies
              in the sensitized laboratory strain to present a mechanistic
              understanding of eukaryotic aneuploidy tolerance.",
  journal  = "Elife",
  volume   =  9,
  month    =  jan,
  year     =  2020,
  keywords = "S. cerevisiae; aneuploidy; chromosomes; gene expression; natural
              variation; proteotoxicity; wild strains",
  language = "en"
}

@ARTICLE{Lynch2022-th,
  title    = "Quantifying chromosomal instability from intratumoral karyotype
              diversity using agent-based modeling and Bayesian inference",
  author   = "Lynch, Andrew R and Arp, Nicholas L and Zhou, Amber S and Weaver,
              Beth A and Burkard, Mark E",
  abstract = "Chromosomal instability (CIN)-persistent chromosome gain or loss
              through abnormal mitotic segregation-is a hallmark of cancer that
              drives aneuploidy. Intrinsic chromosome mis-segregation rate, a
              measure of CIN, can inform prognosis and is a promising biomarker
              for response to anti-microtubule agents. However, existing
              methodologies to measure this rate are labor intensive, indirect,
              and confounded by selection against aneuploid cells, which
              reduces observable diversity. We developed a framework to measure
              CIN, accounting for karyotype selection, using simulations with
              various levels of CIN and models of selection. To identify the
              model parameters that best fit karyotype data from single-cell
              sequencing, we used approximate Bayesian computation to infer
              mis-segregation rates and karyotype selection. Experimental
              validation confirmed the extensive chromosome mis-segregation
              rates caused by the chemotherapy paclitaxel (18.5 $\pm$
              0.5/division). Extending this approach to clinical samples
              revealed that inferred rates fell within direct observations of
              cancer cell lines. This work provides the necessary framework to
              quantify CIN in human tumors and develop it as a predictive
              biomarker.",
  journal  = "Elife",
  volume   =  11,
  month    =  apr,
  year     =  2022,
  keywords = "agent-based modeling; aneuploidy; approximate Bayesian
              computation; cancer biology; computational biology; human;
              mitosis; single-cell sequencing; systems biology",
  language = "en"
}

@ARTICLE{Zhang2022-ky,
  title    = "Evolution-based mathematical models significantly prolong
              response to abiraterone in metastatic castrate-resistant prostate
              cancer and identify strategies to further improve outcomes",
  author   = "Zhang, Jingsong and Cunningham, Jessica and Brown, Joel and
              Gatenby, Robert",
  abstract = "BACKGROUND: Abiraterone acetate is an effective treatment for
              metastatic castrate-resistant prostate cancer (mCRPC), but
              evolution of resistance inevitably leads to progression. We
              present a pilot study in which abiraterone dosing is guided by
              evolution-informed mathematical models to delay onset of
              resistance. METHODS: In the study cohort, abiraterone was stopped
              when PSA was 50\% PSA decline after initial abiraterone
              administration and met trial eligibility requirements but chose
              standard of care (SOC) dosing. RESULTS: 17 subjects were enrolled
              in the adaptive therapy group and 16 in the SOC group. All SOC
              subjects have progressed, but four patients in the study cohort
              remain stably cycling (range 53-70 months). The study cohort had
              significantly improved median time to progression (TTP; 33.5
              months; p<0.001) and median overall survival (OS; 58.5 months;
              hazard ratio, 0.41, 95\% confidence interval (CI), 0.20-0.83,
              p<0.001) compared to 14.3 and 31.3 months in the SOC cohort. On
              average, study subjects received no abiraterone during 46\% of
              time on trial. Longitudinal trial data demonstrated the
              competition coefficient ratio ($\alpha$RS/$\alpha$SR) of
              sensitive and resistant populations, a critical factor in
              intratumoral evolution, was two- to threefold higher than
              pre-trial estimates. Computer simulations of intratumoral
              evolutionary dynamics in the four long-term survivors found that,
              due to the larger value for $\alpha$RS/$\alpha$SR, cycled therapy
              significantly decreased the resistant population. Simulations in
              subjects who progressed predicted further increases in OS could
              be achieved with prompt abiraterone withdrawal after achieving
              50\% PSA reduction. CONCLUSIONS: Incorporation of evolution-based
              mathematical models into abiraterone monotherapy for mCRPC
              significantly increases TTP and OS. Computer simulations with
              updated parameters from longitudinal trial data can estimate
              intratumoral evolutionary dynamics in each subject and identify
              strategies to improve outcomes. FUNDING: Moffitt internal grants
              and NIH/NCI U54CA143970-05 (Physical Science Oncology Network).",
  journal  = "Elife",
  volume   =  11,
  month    =  jun,
  year     =  2022,
  keywords = "adaptive therapy; cancer evolution; evolutionary biology; human;
              mathematical models; medicine; metastatic prostate cancer",
  language = "en"
}

@ARTICLE{Borodin_undated-ph,
  title  = "Adversarial Queueing Theory",
  author = "Borodin, Allan and Kleinberg, Jon and Raghavan, Prabhakar and
            Sudan, Madhu and Williamson, David P"
}

@MISC{Adan2002-di,
  title     = "Queueing theory",
  author    = "Adan, Ivo and Resing, Jacques",
  publisher = "Eindhoven University of Technology Eindhoven",
  year      =  2002
}

@ARTICLE{Zybina1976-zi,
  title    = "A study of the polyploid nuclei of the giant trophoblast cells of
              several species of rodents using phase contrast microscopy",
  author   = "Zybina, E V and Chernogriadakaia, N A",
  abstract = "Patterns of chromosome morphology in high polyploid trophoblast
              nuclei of placenta were compared in the rat, rabbit and Microtus
              arvalis. In the rat and rabbit placenta two types of nuclei were
              recognized. Some nuclei have ribbon-like chromosomes, while
              others display thin oligotene fibrils with paired chromomers
              evenly distributed throughout all karyoplasm. In the latter case,
              the polytenic structure of chromosomes is seen preserved only
              near the nucleoli. In the rat and rabbit trophoblast nuclei, the
              ribbon-like polytene chromosomes could be distinguished only with
              phase contrast microscopy. In the trophoblast nuclei of Microtus
              arvalis polytene chromosomes were found only at early stages of
              embryonic development (9 day old embryo). On later stages of cell
              differentiation, the chromosomes or chromosome rosetts are seen.
              Similarities in mechanisms of polyploidization in the high
              polyploid nuclei of Diptera and in trophoblast nuclei of rodents
              are discussed.",
  journal  = "Tsitologiia",
  volume   =  18,
  number   =  2,
  pages    = "161--165",
  month    =  feb,
  year     =  1976,
  language = "ru"
}

@ARTICLE{Gross1943-cn,
  title     = "Intradermal Immunization of {C3H} Mice against a Sarcoma That
               Originated in an Animal of the Same Line",
  author    = "Gross, Ludwik",
  journal   = "Cancer Res.",
  publisher = "American Association for Cancer Research",
  volume    =  3,
  number    =  5,
  pages     = "326--333",
  month     =  may,
  year      =  1943,
  language  = "en"
}

@BOOK{Thomson2003-ds,
  title     = "The Cytokine Handbook, {Two-Volume} Set",
  author    = "Thomson, Angus W and Lotze, Michael T",
  abstract  = "The fourth edition of The Cytokine Handbook provides an
               encyclopedic coverage of the molecules that induce and regulate
               immune responses. Now expanded to two volumes, co-edited by
               Michael T Lotze, and written by over 120 international experts,
               the scope of the book has been broadened to include a major
               emphasis on the clinical applications of cytokines. The early
               chapters discuss individual cytokines, chemokines and receptors.
               Additional chapters discuss the clinical implications and
               applications of cytokines, including cytokine gene transfer,
               antisense therapy and assay systems. This book is essential for
               researchers and clinicians interested in cytokines, including
               anyone working in cancer biology, transplantation, infectious
               diseases, autoimmunity or bioinformatics.Key Features* Covers
               all main cytokines and chemokines * Written by experts*
               Up-to-date- includes detailed referencing accessing current,
               modern literature and reflects the newest findings from the
               human genome * The new edition has been thoroughly revised and
               extended (now 2 volumes) as compared to the last edition,
               including new co-editor (MTL), new authors, new hot topics and
               new chapters* Includes major emphasis on clinical applications*
               Extensively illustrated with tables and figures",
  publisher = "Elsevier",
  month     =  apr,
  year      =  2003,
  language  = "en"
}

@ARTICLE{Bost2019-gr,
  title    = "The metabolic modulator {PGC-1$\alpha$} in cancer",
  author   = "Bost, Frederic and Kaminski, Lisa",
  abstract = "The peroxisome proliferator-activated receptor gamma coactivator
              1 alpha (PGC-1$\alpha$) is a central modulator of cell
              metabolism. It regulates mitochondrial biogenesis and oxidative
              metabolism. Modifications and adaptations in cellular metabolism
              are hallmarks of cancer cells, thus, it is not surprising that
              PGC-1$\alpha$ plays a role in cancer. Several recent articles
              have shown that PGC-1$\alpha$ expression is altered in tumors and
              metastasis in relation to modifications in cellular metabolism.
              The potential uses of PGC-1$\alpha$ as a therapeutic target and a
              biomarker of the advanced form of cancer will be summarized in
              this review.",
  journal  = "Am. J. Cancer Res.",
  volume   =  9,
  number   =  2,
  pages    = "198--211",
  month    =  feb,
  year     =  2019,
  keywords = "PGC1 alpha; breast cancer; melanoma; metabolism; mitochondria;
              pancreatic cancer; prostate cancer",
  language = "en"
}

@ARTICLE{Prehn1957-kg,
  title    = "Immunity to methylcholanthrene-induced sarcomas",
  author   = "Prehn, R T and Main, J M",
  journal  = "J. Natl. Cancer Inst.",
  volume   =  18,
  number   =  6,
  pages    = "769--778",
  month    =  jun,
  year     =  1957,
  keywords = "METHYLCHOLANTHRENE; NEOPLASMS/immunology",
  language = "en"
}

@MISC{Mikko_Ronkko2019-km,
  title     = "Nested model comparison with likelihood ratio test",
  author    = "{Mikko R{\"o}nkk{\"o}}",
  abstract  = "Enjoy the videos and music you love, upload original content,
               and share it all with friends, family, and the world on YouTube.",
  publisher = "Youtube",
  month     =  aug,
  year      =  2019,
  keywords  = "research methods; statistical analysis; organizational research"
}

@ARTICLE{Wick1957-ct,
  title    = "Localization of the primary metabolic block produced by
              2-deoxyglucose",
  author   = "Wick, A N and Drury, D R and Nakada, H I and Wolfe, J B",
  journal  = "J. Biol. Chem.",
  volume   =  224,
  number   =  2,
  pages    = "963--969",
  month    =  feb,
  year     =  1957,
  keywords = "GLUCOSE/antagonists",
  language = "en"
}

@ARTICLE{Lawler2010-ic,
  title   = "Stochastic Calculus: An Introduction with Applications",
  author  = "Lawler, Gregory F",
  journal = "American Mathematical Society",
  year    =  2010
}

@ARTICLE{Perelson1984-un,
  title    = "Kinetics of {Cell-Mediated} Cytotoxicity: Stochastic and
              Deterministic Multistage Models",
  author   = "Perelson, Alan S and Macken+, A",
  journal  = "Math. Biosci.",
  volume   =  70,
  pages    = "161--194",
  year     =  1984,
  keywords = "Direct Killing (Perf/Gzym/FAS)"
}

@ARTICLE{Hori1996-dq,
  title    = "Methylthioadenosine phosphorylase {cDNA} transfection alters
              sensitivity to depletion of purine and methionine in {A549} lung
              cancer cells",
  author   = "Hori, H and Tran, P and Carrera, C J and Hori, Y and Rosenbach, M
              D and Carson, D A and Nobori, T",
  abstract = "Methylthioadenosine phosphorylase (MTAP), an enzyme involved in
              purine and methionine metabolism, is present in all normal
              tissues but is frequently deficient in a variety of cancers. It
              has been suggested that this metabolic difference between normal
              and cancer cells may be exploited to selectively treat
              MTAP-negative cancers by inhibiting de novo purine synthesis and
              by depleting L-methionine. However, these therapeutic strategies
              have only been tested in naturally occurring MTAP-positive and
              -negative cell lines, which might have additional genetic
              alterations that affect chemotherapeutic sensitivity. Therefore,
              it is of importance to examine the feasibility of
              enzyme-selective treatment using paired cell lines that have an
              identical genotype except for MTAP status. MTAP-negative A549
              lung cancer cells were transfected with eukaryotic expression
              vectors encoding MTAP cDNA in sense and antisense orientations.
              The resultant stable transfectomas were treated with inhibitors
              of de novo purine synthesis such as methotrexate,
              5,10-dideazatetrahydrofolate, and L-alanosine and by methionine
              depletion. The A549 cells transfected with an antisense construct
              (antisense transfectoma) expressed no MTAP protein and were more
              sensitive to both purine and methionine depletion than were cells
              expressing MTAP protein (sense transfectoma). Methylthioadenosine
              was able to completely rescue the sense transfectoma but not the
              antisense transfectoma from growth inhibition by depletion of
              purine and methionine. These results prove that MTAP deficiency
              contributes directly to the sensitivity of cancer cells to purine
              or methionine depletion. Inhibition of de novo purine synthesis,
              combined with methionine depletion in the presence of
              methylthioadenosine, is a highly selective treatment for
              MTAP-negative cancers.",
  journal  = "Cancer Res.",
  volume   =  56,
  number   =  24,
  pages    = "5653--5658",
  month    =  dec,
  year     =  1996,
  language = "en"
}

@BOOK{Kimura1983-ut,
  title     = "The Neutral Theory of Molecular Evolution",
  author    = "Kimura, Motoo",
  abstract  = "Motoo Kimura, as founder of the neutral theory, is uniquely
               placed to write this book. He first proposed the theory in 1968
               to explain the unexpectedly high rate of evolutionary change and
               very large amount of intraspecific variability at the molecular
               level that had been uncovered by new techniques in molecular
               biology. The theory - which asserts that the great majority of
               evolutionary changes at the molecular level are caused not by
               Darwinian selection but by random drift of selectively neutral
               mutants - has caused controversy ever since. This book is the
               first comprehensive treatment of this subject and the author
               synthesises a wealth of material - ranging from a historical
               perspective, through recent molecular discoveries, to
               sophisticated mathematical arguments - all presented in a most
               lucid manner.",
  publisher = "Cambridge University Press",
  year      =  1983,
  language  = "en"
}

@ARTICLE{Nagoshi1999-bl,
  title    = "Tumor-specific cytokine release by donor {T} cells induces an
              effective host anti-tumor response through recruitment of host
              naive antigen presenting cells",
  author   = "Nagoshi, M and Sadanaga, N and Joo, H G and Goedegebuure, P S and
              Eberlein, T J",
  abstract = "We recently reported that tumor eradication induced by
              immunotherapy (IT) in a congenic mouse model using tumor
              infiltrating lymphocytes (TIL) + recombinant interleukin-2
              (rIL-2) is dependent on recruitment of naive host immune cells at
              the tumor sites. The recruitment of host immune cells was induced
              mainly through a local secretion of interferon-gamma (IFN-gamma)
              produced by donor T cells. We now further investigated how a
              non-specific inflammatory response progresses to a host
              T-cell-mediated tumor-specific response. In cross-over
              experiments using MCA-105 and MCA-205 sarcoma tumors, pulmonary
              metastatic disease was eradicated only in mice treated with
              tumor-matched TIL + rIL-2. In vitro, TIL stimulated with the
              tumor of origin secreted relatively high levels of IFN-gamma and
              granulocyte-macrophage colony stimulating factor (GM-CSF)
              compared to TIL stimulated with mismatched tumor cells. In lungs
              of tumor-bearing mice treated with matched TIL + rIL-2,
              significant increases in the percentages of IFN-gamma, GM-CSF and
              tumor necrosis factor-alpha (TNF-alpha) positive cells were
              detected, as well as of macrophages, natural killer (NK) cells
              and dendritic cells. Depletion of macrophages or NK cells did not
              inhibit the efficacy. In contrast, depletion of dendritic cells
              partially inhibited the efficacy of the treatment. Combined
              depletion of dendritic cells and macrophages abrogated more than
              80\% of the efficacy. Our data suggest that successful IT may
              require 3 steps: (1) release of inflammatory cytokines by donor
              TIL after restimulation by tumor cells; (2) infiltration of host
              immune cells in response to local cytokine production; and (3)
              activation of tumor-specific host immune cells by dendritic cells
              and to a lesser extent by macrophages.",
  journal  = "Int. J. Cancer",
  volume   =  80,
  number   =  2,
  pages    = "308--314",
  month    =  jan,
  year     =  1999,
  language = "en"
}

@ARTICLE{Shin2008-sd,
  title    = "Serum starvation induces {G1} arrest through suppression of
              {Skp2-CDK2} and {CDK4} in {SK-OV-3} cells",
  author   = "Shin, Jae-Sik and Hong, Seung-Woo and Lee, Sae-Lo Oom and Kim,
              Tae-Hee and Park, In-Chul and An, Sung-Kwan and Lee, Won-Keun and
              Lim, Jong-Seok and Kim, Keun-Il and Yang, Young and Lee, Soo-Suk
              and Jin, Dong-Hoon and Lee, Myeong-Sok",
  abstract = "Recent studies have suggested that Skp2, an SCF-type ubiquitin
              ligase, positively regulates cell cycle through degradation of
              p27, which is an inhibitor of cyclin-dependent kinase 2 (CDK2),
              which drives cells from the G1 to S phase of cell cycles. In the
              present study, we examined key regulatory proteins involved in
              serum starvation-induced cell cycle arrest in human ovarian
              cancer cells, SK-OV-3. Cell cycle analysis showed that cells were
              arrested at the G1 phase after serum starvation. Western blot
              analysis showed that the protein levels of CDK4 and CDK2 were
              significantly decreased in SK-OV-3 cells. Consistently,
              Roscovitine, an inhibitor of CDK2, induced cell cycle arrest in
              normally proliferating cells and a chemical inhibitor of CDK4,
              3-ATA [3-Amino-9-thio(10H)-acridone], was found to induce growth
              arrest. We also found that the protein level of Skp2 was
              dramatically decreased in response to serum starvation. Moreover,
              CDK2 protein, which allows cell cycle transit from the G1 to the
              S phase, was decreased when the Skp2 expression was inhibited by
              specific siRNA of Skp2, but CDK4 was not decreased. Therefore,
              these results suggest that serum starvation induces G1 arrest
              through suppression of Skp2-dependent CDK2 activity and
              Skp2-independent CDK4 activity in human SK-OV-3 ovarian cancer
              cells.",
  journal  = "Int. J. Oncol.",
  volume   =  32,
  number   =  2,
  pages    = "435--439",
  month    =  feb,
  year     =  2008,
  language = "en"
}

@BOOK{Sprott2008-rp,
  title     = "Statistical Inference in Science",
  author    = "Sprott, D A",
  abstract  = "The aim of this book is to develop an understanding and
               treatment of the problems of inference associated with
               experiments in science. Many textbooks treat inference as
               principally the reduction of the sample information to estimates
               and their marginal distribution and supposedly optimal
               properties. In contrast, this book emphasizes techniques for
               dividing the sample information into various parts addressing
               the diverse problems of inference that arise from repeatable
               experiments. An unusually valuable feature of the book is the
               large number of practical examples, many of which use data taken
               from experiments published in various scientific journals. This
               book has evolved from the author's courses on statistical
               inference. It would be a suitable text book for advanced
               undergraduate, Masters, and Ph.D. statistics students. It can
               also be used as a reference book. A background knowledge of an
               introductory course in probability is assumed, including the
               calculation and manipulation of probability functions and
               density functions, transformation of variables and the use of
               Jacobians. The author is a Distinguished Professor Emeritus of
               Statistics, University of Waterloo, and Professor of Statistics,
               Centro de Investigaci=F3n en Matem{\'a}ticas, Guanajuato,
               Mexico. He is an Honorary member of the Statistical Society of
               Canada and a recipient of the Society's Gold Medal for Research.
               He is also an elected member of the International Statistical
               Institute and a Fellow of the American Statistical Association,
               of the Institute of Mathematical Statistics, and of the Royal
               Society of Canada.",
  publisher = "Springer Science \& Business Media",
  month     =  jan,
  year      =  2008,
  language  = "en"
}

@ARTICLE{Tozawa2008-zl,
  title    = "Oxaliplatin in treatment of the cisplatin-resistant {MKN45} cell
              line of gastric cancer",
  author   = "Tozawa, Katsuyuki and Oshima, Tadayuki and Kobayashi, Takehiko
              and Yamamoto, Noriyasu and Hayashi, Chizuko and Matsumoto,
              Takayuki and Miwa, Hiroto",
  abstract = "BACKGROUND AND AIM: The clinical efficiency of cisplatin (CDDP)
              against gastric cancer is often limited by the development of
              resistance. A third-generation platinum-containing agent,
              oxaliplatin (L-OHP), has been introduced for treating gastric
              cancer. Here, we studied oxaliplatin in vitro to reveal the
              mechanism of acquiring drug resistance and whether a
              cisplatin-resistant gastric cancer cell line has susceptibility
              to oxaliplatin. MATERIALS AND METHODS: A cisplatin-resistant
              gastric cancer cell line (MKN45/CDDP/ R1) was established by
              continuous exposure of MKN45 cells to cisplatin. The amount of
              excision repair cross-complementation group 1 (ERCC1) and
              glutathione-S-transferase (GST)-pi mRNA was measured by real-time
              polymerase chain reaction (PCR). To examine the chemosensitivity
              to CDDP and L-OHP in MKN45 and MKN45/CDDP/R1 cells, a collagen
              gel droplet-embedded culture drug sensitivity test (CD-DST) was
              performed. The intracellular concentration of CDDP and L-OHP were
              also measured to see if the drugs would be taken up by these cell
              lines. RESULTS: The MKN45/CDDP/R1 cell line was resistant to
              CDDP. The ERCC1 and GST-pi mRNA was significantly increased in
              MKN45/CDDP/R1 cells, indicating that the cells acquired
              resistance to CDDP. Intracellular CDDP was not detected in
              MKN45/CDDP/R1 cells up to 48 h after incubation, indicating that
              uptake and efflux processes of CDDP were altered in these cells.
              MKN45/CDDP/R1 cells were still susceptible to L-OHP. The
              intracellular concentration of CDDP but not L-OHP was
              significantly reduced in MKN45/CDDP/R1 cells. CONCLUSION: We
              established a CDDP-resistant cell line using MKN45 cells, in
              which ERCC1 and GST-pi were increased. This cell line showed
              susceptibility to the new generation platinum agent L-OHP,
              suggesting this anticancer agent could be used in second-line
              treatment of patients with CDDP-resistant gastric neoplasms.",
  journal  = "Anticancer Res.",
  volume   =  28,
  number   = "4B",
  pages    = "2087--2092",
  year     =  2008,
  language = "en"
}

@BOOK{Litwack2017-pt,
  title     = "Human Biochemistry",
  author    = "Litwack, Gerald",
  abstract  = "Human Biochemistry includes clinical case studies and
               applications that are useful to medical, dentistry and pharmacy
               students. It enables users to practice for future careers as
               both clinicians and researchers. Offering immediate application
               of biochemical principles into clinical terms in an updated way,
               this book is the unparalleled textbook for medical biochemistry
               courses in medical, dental and pharmacy programs. Winner of a
               2018 Most Promising New Textbook (College) Award (Texty) from
               the Textbook and Academic Authors Association 2019 PROSE Awards
               - Winner: Category: Textbook/Biological and Life Science:
               Association of American Publishers Offers immediate application
               of biochemical principles into clinical terms in an updated way
               Contains coverage of the most current research in medical
               biochemistry Presents the first solution designed to reflect the
               needs of both research oriented and clinically oriented medical
               students",
  publisher = "Academic Press",
  month     =  nov,
  year      =  2017,
  language  = "en"
}

% The entry below contains non-ASCII chars that could not be converted
% to a LaTeX equivalent.
@ARTICLE{Dong2014-wy,
  title     = "Mathematical modeling on helper {T} cells in a tumor immune
               system",
  author    = "Dong, Yueping and Miyazaki, Rinko and Takeuchi, Yasuhiro",
  abstract  = "Activation of CD8+ cytotoxic T lymphocytes (CTLs) is naturally
               regarded as a major antitumor mechanism of the immune system. In
               contrast, CD4+ T cells are commonly classified as helper T cells
               (HTCs) on the basis of their roles in providing help to the
               generation and maintenance of effective CD8+ cytotoxic and
               memory T cells. In order to get a better insight on the role of
               HTCs in a tumor immune system, we incorporate the third
               population of HTCs into a previous two dimensional ordinary
               differential equations (ODEs) ",
  journal   = "Discrete Continuous Dyn. Syst. Ser. B",
  publisher = "researchgate.net",
  volume    =  19,
  number    =  1,
  pages     = "55--72",
  year      =  2014
}

% The entry below contains non-ASCII chars that could not be converted
% to a LaTeX equivalent.
@ARTICLE{Havel2019-zt,
  title     = "The evolving landscape of biomarkers for checkpoint inhibitor
               immunotherapy",
  author    = "Havel, J J and Chowell, D and Chan, T A",
  abstract  = "Checkpoint inhibitor-based immunotherapies that target cytotoxic
               T lymphocyte antigen 4 (CTLA4) or the programmed cell death 1
               (PD1) pathway have achieved impressive success in the treatment
               of different cancer types. Yet, only a subset of patients derive
               clinical benefit ",
  journal   = "Nat. Rev. Cancer",
  publisher = "nature.com",
  year      =  2019
}

@ARTICLE{Landau1958-zh,
  title    = "Certain metabolic and pharmacologic effects in cancer patients
              given infusions of 2-deoxy-D-glucose",
  author   = "Landau, B R and Laszlo, J and Stengle, J and Burk, D",
  journal  = "J. Natl. Cancer Inst.",
  volume   =  21,
  number   =  3,
  pages    = "485--494",
  month    =  sep,
  year     =  1958,
  keywords = "ENCEPHALOMYELITIS/diagnosis; GLUCOSE/related compounds;
              NEOPLASMS/metabolism",
  language = "en"
}

@ARTICLE{Zybina1983-ya,
  title    = "Different modes of cell reproduction in the placental
              differentiation of mammals",
  author   = "Zybina, E V",
  abstract = "Summarized is the total evidence on the role of various modes of
              cell reproduction in the course of differentiation of various
              trophoblast population cells. The giant trophoblast cells,
              reaching a tremendously high (for mammals) degree of ploidy
              (512-4096c), blast cells, reaching a tremendously high for
              (mammals) degree of ploidy (512-4096c), give an example of cells
              that display a ``non-classical'' form of polyteny with not
              regular polyteny in chromosomes. For the trophoblast cells, a
              period of easy recognition with not regular, polyteny in
              chromosomes. For display a ``non-classical form of polyteny with
              not regular polyteny in chromosomes. For the trophoblast cells, a
              period of easy recognition polytene chromosome has been
              established timed to definite stages of cell differentiation and
              of the polytene nucleus cycle. The start of phagocytic activity
              in trophoblast cells coincides in time with their transition to
              endoreduplication, both the processes terminating also
              simultaneously. It does not seem unlikely that such that each a
              correlation may appear due to a strict programmed appearance of
              numerous features of trophoblast cells, including their lifespan
              both in situ and under condition of -transplantation to different
              organs. Biological importance of various ways of reproduction in
              trophoblast cells (mitosis, non-completed polyploidizing mitosis,
              endoreduplication) in various parts of placenta is discussed in
              relation to their roles in development and functioning of this
              organo.",
  journal  = "Tsitologiia",
  volume   =  25,
  number   =  10,
  pages    = "1103--1119",
  month    =  oct,
  year     =  1983,
  language = "ru"
}

@BOOK{Levin2017-uy,
  title     = "Markov Chains and Mixing Times",
  author    = "Levin, David A and Peres, Yuval",
  abstract  = "This book is an introduction to the modern theory of Markov
               chains, whose goal is to determine the rate of convergence to
               the stationary distribution, as a function of state space size
               and geometry. This topic has important connections to
               combinatorics, statistical physics, and theoretical computer
               science. Many of the techniques presented originate in these
               disciplines. The central tools for estimating convergence times,
               including coupling, strong stationary times, and spectral
               methods, are developed. The authors discuss many examples,
               including card shuffling and the Ising model, from statistical
               mechanics, and present the connection of random walks to
               electrical networks and apply it to estimate hitting and cover
               times. The first edition has been used in courses in mathematics
               and computer science departments of numerous universities. The
               second edition features three new chapters (on monotone chains,
               the exclusion process, and stationary times) and also includes
               smaller additions and corrections throughout. Updated notes at
               the end of each chapter inform the reader of recent research
               developments.",
  publisher = "American Mathematical Soc.",
  month     =  oct,
  year      =  2017,
  language  = "en"
}

@UNPUBLISHED{Mullen2009-nv,
  title    = "{DEoptim}: An {R} Package for Global Optimization by Differential
              Evolution",
  author   = "Mullen, Katharine and Ardia, David and Gil, David L and Windover,
              Donald and Cline, James",
  abstract = "This article describes the R package DEoptim, which implements
              the Differential Evolution algorithm for global optimization of a
              real-valued function of a real-valued parameter vector. The
              implementation of Differential Evolution in DEoptim interfaces
              with C code for efficiency. The utility of the package is
              illustrated by case studies in fitting a Parratt model for X-ray
              reflectometry data and a Markov-Switching Generalized
              AutoRegressive Conditional Heteroskedasticity model for the
              returns of the Swiss Market Index.",
  month    =  dec,
  year     =  2009,
  keywords = "global optimization, evolutionary algorithm, differential
              evolution, R software"
}

@ARTICLE{Lewontin2011-gk,
  title   = "The genotype/phenotype distinction",
  author  = "Lewontin, Richard",
  journal = "Stanford Encyclopedia of Philosophy",
  year    =  2011
}

@ARTICLE{Thorn1976-of,
  title    = "Studies on the mechanism of lymphocyte-mediated cytolysis. {VI}.
              A reappraisal of the requirement for protein synthesis during {T}
              cell-mediated lysis",
  author   = "Thorn, R M and Henney, C S",
  abstract = "The role of protein synthesis in the mechanism of T cell-mediated
              cytolysis has been re-investigated. Cytolytically active (C57BL/L
              anti-DBA/2) spleen cells treated with pactamycin (10-7 M to 10-6
              M) exhibited suppressed protein synthesis (100 +/- 5\%), but
              unimpeded lytic activity. Drug-treated effector cells, incubated
              for prolonged (up to 24 hr) periods of time in the presence and
              absence of antigen, showed no siginificant diminution of lytic
              activity although the incorporation of 3H-leucine into protein
              was totally ablated. Studies with emetine, another irreversible
              inhibitor of protein synthesis, gave identical results. These
              findings are difficult to reconcile with the hypothesis that
              effector T cells lysis via a soluble protein mediator.",
  journal  = "J. Immunol.",
  volume   =  116,
  number   =  1,
  pages    = "146--149",
  month    =  jan,
  year     =  1976,
  language = "en"
}

@ARTICLE{Buttgereit1991-qg,
  title    = "Quantification of {ATP-producing} and consuming processes in
              quiescent pig spleen lymphocytes",
  author   = "Buttgereit, F and M{\"u}ller, M and Rapoport, S M",
  abstract = "ATP production in quiescent pig spleen lymphocytes was estimated
              on the basis of their coupled respiration. ATP-consuming
              processes were assessed from the effects of inhibitors of protein
              synthesis, proteolysis, RNA synthesis, Na+ K(+)-ATPase and
              Ca(2+)-ATPase on respiration. About 95\% of the total ATP
              consumption could be assigned to specific processes. More than
              50\% of the ATP produced appear to be consumed by the cation
              transport ATPases.",
  journal  = "Biochem. Int.",
  volume   =  24,
  number   =  1,
  pages    = "59--67",
  month    =  may,
  year     =  1991,
  language = "en"
}

@ARTICLE{Schmidt1989-xj,
  title    = "Balancing of mitochondrial and glycolytic {ATP} production and of
              the {ATP-consuming} processes of Ehrlich mouse ascites tumour
              cells in a high phosphate medium",
  author   = "Schmidt, H and Siems, W and M{\"u}ller, M and Dumdey, R and
              Jakstadt, M and Rapoport, S M",
  abstract = "A balance of energy budgeting of Ehrlich mouse ascites tumour
              cells including mitochondrial and glycolytic ATP production and
              about 80\% of ATP consumption in a high phosphate medium is
              presented. In the share of glycolysis was about one-third of the
              total ATP production, more than twice that found in a low
              phosphate medium. The extent of a single energy reaction was
              assessed from the decrease of coupled oxygen consumption and
              lactate formation following the specific inhibition of this
              process. The inhibitory effects on coupled respiration and
              glycolysis were identical for the energy consuming processes
              measured: protein turnover, Na+/K(+)-ATPase, Ca2(+)-transport and
              RNA synthesis.",
  journal  = "Biochem. Int.",
  volume   =  19,
  number   =  5,
  pages    = "985--992",
  month    =  nov,
  year     =  1989,
  language = "en"
}

@MISC{Bob_Rudis2018-yg,
  title        = "The viridis color palettes",
  author       = "Bob Rudis, Noam Ross and Garnier, Simon",
  month        =  mar,
  year         =  2018,
  howpublished = "\url{https://cran.r-project.org/web/packages/viridis/vignettes/intro-to-viridis.html}",
  note         = "Accessed: 2019-3-27"
}

@ARTICLE{Sutton2003-hk,
  title    = "Caspase activation by granzyme {B} is indirect, and caspase
              autoprocessing requires the release of proapoptotic mitochondrial
              factors",
  author   = "Sutton, Vivien R and Wowk, Michelle E and Cancilla, Michael and
              Trapani, Joseph A",
  abstract = "Apoptosis in response to granzyme B involves activation of
              caspase-dependent target cell death pathways. Herein, we show
              that granzyme B initiates caspase processing but cannot fully
              process procaspase-3 in intact Jurkat T leukemia or NT2 neuronal
              cells. Rather, the release from mitochondria of proapoptotic
              mediators cytochrome c, Smac/Diablo, and HtrA2/Omi facilitates
              full activation of caspases that results from autoprocessing.
              Bcl-2 overexpression in mitochondria suppresses the release of
              these proapoptotic molecules, resulting in cell survival despite
              partial procaspase processing by granzyme B. We propose that
              binding of inhibitor of apoptosis (IAP) proteins to partially
              processed procaspases inhibits cell death unless mitochondrial
              disruption also occurs in response to granzyme B or activated
              BH3-domain proteins such as truncated Bid.",
  journal  = "Immunity",
  volume   =  18,
  number   =  3,
  pages    = "319--329",
  month    =  mar,
  year     =  2003,
  language = "en"
}

@ARTICLE{Moore1988-rv,
  title    = "Introduction of soluble protein into the class {I} pathway of
              antigen processing and presentation",
  author   = "Moore, M W and Carbone, F R and Bevan, M J",
  abstract = "In order to investigate how peptides associate with class I major
              histocompatibility complex (MHC) glycoproteins intracellularly,
              we generated cytotoxic T lymphocytes (CTL) specific for a readily
              available soluble protein in association with class I. C57BL/6
              (H-2b) mice immunized against a syngeneic tumor cell transfected
              with chicken ovalbumin (OVA) cDNA gave rise to H-2Kb-restricted
              CTL specific for the OVA258-276 peptide. This synthetic peptide
              and CNBr fragments of OVA (242-285 and 242-273) were able to
              target H-2b cells for lysis by the CTL in a 3 hr assay. Cells
              incubated with native OVA for up to 24 hr did not become
              sensitized for recognition and lysis. However, when OVA was
              introduced directly into the cytoplasm of cells by the osmotic
              lysis of pinosomes, the Kb restricted determinant formed readily.",
  journal  = "Cell",
  volume   =  54,
  number   =  6,
  pages    = "777--785",
  month    =  sep,
  year     =  1988,
  language = "en"
}

@ARTICLE{Fehrenbach2001-ao,
  title    = "Free radicals, exercise, apoptosis, and heat shock proteins",
  author   = "Fehrenbach, E and Northoff, H",
  abstract = "Free radicals are an integral part of metabolism and are formed
              continuously in the body. Many sources of stress heat,
              irradiation, hyperoxia, inflammation and any increases in
              metabolism including exercise, injury, and even repair processes
              lead to increased production of free radicals and associated
              reactive oxygen or nitrogen species (ROS/RNS). Evidence is
              accumulating that free radicals have important functions in the
              signal network of cells, including induction of growth and
              apoptosis and as killing tools of immunocompetent cells.
              Endogenous and nutritional antioxidant systems have to be
              adjusted to ensure adequate removal of radicals during stress to
              prevent damage to membranes, proteins, or nucleic acids.
              Excessive stress will induce DNA damage in the form of oxidized
              nucleosides, strand breaks, or DNA-protein crosslinks. Possible
              consequences of DNA damage are repair, apoptosis/necrosis, or
              defective repair leading to DNA sequence alterations and possibly
              to the development of cancer or, in case of mitochondrial DNA, to
              metabolic dysfunction. Excessive exercise will also induce DNA
              damage in peripheral leukocytes. The good message is that
              moderate stress in form of regular exercise/training may have
              protective effects against exercise-induced DNA damage.
              Up-regulation of endogenous antioxidant defense systems and
              complex regulation of repair systems such as heat shock proteins
              (HSP 70, HSP 27, HO 1) are seen in response to training and
              exercise. Up-regulation of antioxidants and modulation of the
              repair response may be mechanisms by which exercise can
              beneficially influence our health. Massive intervention into the
              redox state by pharmaceutical doses of exogenous antioxidants
              should be regarded with caution due to the ambiguous role of free
              radicals in regulation of growth, apoptosis, and cytotoxicity by
              immunocompetent cells.",
  journal  = "Exerc. Immunol. Rev.",
  volume   =  7,
  pages    = "66--89",
  year     =  2001,
  language = "en"
}

@ARTICLE{Barth1991-yr,
  title    = "Interferon gamma and tumor necrosis factor have a role in tumor
              regressions mediated by murine {CD8+} tumor-infiltrating
              lymphocytes",
  author   = "Barth, Jr, R J and Mul{\'e}, J J and Spiess, P J and Rosenberg, S
              A",
  abstract = "We have investigated the mechanisms whereby adoptively
              transferred murine CD8+ lymphocytes mediate tumor regressions.
              Noncytolytic, CD8+ tumor-infiltrating lymphocytes (TIL)
              eradicated established lung tumors in irradiated mice. Many
              cytolytic and noncytolytic CD8+ TIL cultures specifically
              secreted interferon gamma (IFN-gamma) and tumor necrosis factor
              when stimulated with tumor cells in vitro. The effectiveness of
              TIL when adoptively transferred to mice bearing micrometastases
              correlated better with their ability to specifically secrete
              lymphokines than with their cytotoxicity in vitro. In 14 of 15
              tests, therapeutically effective TIL specifically secreted
              IFN-gamma in vitro, whereas only 1 of 11 ineffective TIL
              specifically secreted IFN-gamma. In contrast, only 8 of 15
              therapeutically effective TIL were cytolytic. Antibodies to TNF
              inhibited the effectiveness of two adoptively transferred TIL
              cultures. In five experiments, antibodies to IFN-gamma abrogated
              the ability of four different CD8+ TIL cultures to mediate tumor
              regressions, indicating that secretion of IFN-gamma is an
              essential part of the mechanism of action of TIL.",
  journal  = "J. Exp. Med.",
  volume   =  173,
  number   =  3,
  pages    = "647--658",
  month    =  mar,
  year     =  1991,
  language = "en"
}

@BOOK{Nelson2008-zk,
  title     = "Lehninger Principles of Biochemistry",
  author    = "Nelson, David L and Lehninger, Albert L and Cox, Michael M",
  abstract  = "In the Fifth Edition, authors Dave Nelson and Mike Cox combine
               the best of the laboratory and best of the classroom,
               introducing exciting new developments while communicating basic
               principles through a variety of new learning tools--from new
               in-text worked examples and data analysis problems to the
               breakthrough eBook, which seamlessly integrates the complete
               text and its media components.",
  publisher = "Macmillan",
  month     =  feb,
  year      =  2008,
  language  = "en"
}

@ARTICLE{Foley1953-ty,
  title    = "Antigenic properties of methylcholanthrene-induced tumors in mice
              of the strain of origin",
  author   = "Foley, E J",
  journal  = "Cancer Res.",
  volume   =  13,
  number   =  12,
  pages    = "835--837",
  month    =  dec,
  year     =  1953,
  keywords = "ANTIGENS AND ANTIBODIES; METHYLCHOLANTHRENE/effects;
              NEOPLASMS/experimental",
  language = "en"
}

% The entry below contains non-ASCII chars that could not be converted
% to a LaTeX equivalent.
@ARTICLE{Matsushita2015-lw,
  title     = "Cytotoxic {T} lymphocytes block tumor growth both by lytic
               activity and {IFN$\gamma$-dependent} cell-cycle arrest. Cancer
               Immunol. Res. 3, 26--36. doi: 10.1158/2326 ",
  author    = "Matsushita, H and Hosoi, A and Ueha, S and Abe, J and Fujieda, N
               and {others}",
  publisher = "CIR-14-0098",
  year      =  2015
}

@ARTICLE{Geyer1991-gs,
  title     = "Markov chain Monte Carlo maximum likelihood",
  author    = "Geyer, Charles J",
  publisher = "Interface Foundation of North America",
  year      =  1991
}

@ARTICLE{Muul1987-nj,
  title    = "Identification of specific cytolytic immune responses against
              autologous tumor in humans bearing malignant melanoma",
  author   = "Muul, L M and Spiess, P J and Director, E P and Rosenberg, S A",
  abstract = "Tumor-infiltrating lymphocytes from six patients with metastatic
              malignant melanoma were expanded by culture in recombinant
              interleukin 2. Three of the preparations were highly cytotoxic
              against autologous fresh melanoma tumor cells, but not against
              autologous fresh normal cells or allogeneic fresh tumor targets.
              The other three were highly cytotoxic against autologous fresh
              melanoma tumor cells and also had a limited capacity to kill
              allogeneic fresh tumor targets. The tumor-associated specific
              killer cells could be expanded from threefold to 95,652-fold with
              maintenance of specific antitumor lysis. The expanded
              tumor-infiltrating cells were Leu-4+ T cells, and in five of six
              patients the majority were Leu-3+. These studies demonstrate that
              the melanoma-bearing patient raises an immune response against
              autologous tumor and presents a method for the generation of
              human lymphocytes with antitumor reactivity that may be useful in
              the adoptive immunotherapy of tumors.",
  journal  = "J. Immunol.",
  volume   =  138,
  number   =  3,
  pages    = "989--995",
  month    =  feb,
  year     =  1987,
  language = "en"
}

@ARTICLE{Sundberg1974-kp,
  title     = "Maximum Likelihood Theory for Incomplete Data from an
               Exponential Family",
  author    = "Sundberg, Rolf",
  abstract  = "[In this paper we study such classes of distributions which are
               generated from exponential families by loss of information due
               to the fact that only some function of the exponential family
               variable is observable. Examples of such classes are mixtures
               and convolutions of exponential type distributions as well as
               grouped, censored and folded distributions. Their common
               structure is analysed. The existence is demonstrated of a
               n1/2-consistent, asymptotically normally distributed and
               asymptotically efficient root of the likelihood equation which
               asymptotically maximizes the likelihood in every compact subset
               of the parameter space, imposing only the natural requirement
               that the information matrix is positive definite. It is further
               shown that even the weaker requirement of local parameter
               identifiability, which admits of application to non-regular
               cases, is sufficient for the existence of consistent maximum
               likelihood estimates. Finally the subject of large sample tests
               based on maximum likelihood estimates is touched upon.]",
  journal   = "Scand. Stat. Theory Appl.",
  publisher = "[Board of the Foundation of the Scandinavian Journal of
               Statistics, Wiley]",
  volume    =  1,
  number    =  2,
  pages     = "49--58",
  year      =  1974
}

% The entry below contains non-ASCII chars that could not be converted
% to a LaTeX equivalent.
@ARTICLE{Cai2007-uq,
  title     = "Exact stochastic simulation of coupled chemical reactions with
               delays",
  author    = "Cai, X",
  abstract  = " Home >; The Journal of Chemical Physics >; Volume 126, Issue
               12 >; 10.1063/1.2710253. Prev  biochemical reaction networks
               Alexander Slepoy, Aidan P. Thompson, and Steven J . Plimpton 
               accelerated stochastic simulation of chemically reacting systems
               Daniel T. Gillespie . more ",
  journal   = "J. Chem. Phys.",
  publisher = "aip.scitation.org",
  year      =  2007
}

@ARTICLE{Parnaik2000-vn,
  title    = "Differences between the clearance of apoptotic cells by
              professional and non-professional phagocytes",
  author   = "Parnaik, R and Raff, M C and Scholes, J",
  abstract = "Both professional and non-professional phagocytes [1] participate
              in clearing the massive numbers of cells that undergo apoptosis
              during animal development [2], but it is not known how they
              divide this task. Using time-lapse recordings of cells in
              culture, we show that professional phagocytes (brain macrophages
              or microglia) are highly motile, ingest apoptotic cells
              immediately, and digest them quickly. Non-professionals such as
              BHK and lens epithelial cells are sessile, often recognize
              apoptotic cells as soon as they die by showing characteristic
              palpating movements, but delay ingestion until several hours
              later. By pre-ageing apoptotic cells, we show that this delay is
              because the apoptotic cells must undergo further changes before
              non-professionals can ingest them. The difference was also
              apparent in vivo, using immunofluorescence and electron
              microscopy of the developing central nervous system. This
              arrangement favours prompt clearance by professionals if present
              in adequate numbers; if they are scarce, however,
              non-professional bystanders will reluctantly clear the apoptotic
              cells.",
  journal  = "Curr. Biol.",
  volume   =  10,
  number   =  14,
  pages    = "857--860",
  month    =  jul,
  year     =  2000,
  language = "en"
}

@ARTICLE{Anderson1983-kk,
  title   = "Human Interferon-y Is Internalized and Degraded by Cultured
             Fibroblasts",
  author  = "Anderson\$, Paul and Yip, Yum K and Eek, Jan Vil",
  journal = "Plan. Perspect.",
  volume  =  6497,
  pages   = "6502",
  year    =  1983
}

@ARTICLE{Batova1999-fq,
  title    = "Use of alanosine as a methylthioadenosine phosphorylase-selective
              therapy for T-cell acute lymphoblastic leukemia in vitro",
  author   = "Batova, A and Diccianni, M B and Omura-Minamisawa, M and Yu, J
              and Carrera, C J and Bridgeman, L J and Kung, F H and Pullen, J
              and Amylon, M D and Yu, A L",
  abstract = "Methylthioadenosine phosphorylase (MTAP) is an important enzyme
              for the salvage of adenine and methionine and is deficient in a
              variety of cancers including T-cell acute lymphocytic leukemia
              (T-ALL). Previously, we reported that the MTAP gene was deleted
              in over 30\% of T-ALL patients at both diagnosis and relapse. We
              now report that MTAP-primary T-ALL cells are more sensitive to
              the toxicity of L-alanosine, an inhibitor of de novo AMP
              synthesis, than are MTAP+ primary T-ALL cells. As measured by
              [3H]thymidine incorporation, DNA synthesis in all seven
              MTAP-primary T-ALL cells was inhibited by L-alanosine with a mean
              IC50 of 4.8+/-5.3 ILM (range, 0.3-11.3 microM). On the other
              hand, the IC50 for 60\% (12 of 20) of MTAP+ primary T-ALL was
              19+/-18 microM (range, 1.7-67 microM; P = 0.02), whereas the
              remaining 40\% (8 of 20) had an IC50 of >80 microM4. Furthermore,
              normal lymphocytes and MTAP+ primary T-ALL cells were rescued
              from L-alanosine toxicity by the MTAP substrate
              5'-deoxyadenosine, but MTAP-T-ALL cells were not. These results
              indicate that normal cells, which are intrinsically MTAP+, would
              be protected from L.-alanosine toxicity, whereas MTAP-tumor cells
              would be killed. Thus, our results support the use of L-alanosine
              alone or in combination with a salvage agent as a MTAP-selective
              therapy and therefore lay the foundation for the initiation of
              clinical trials for the treatment of T-ALL and other
              MTAP-deficient malignancies with L-alanosine.",
  journal  = "Cancer Res.",
  volume   =  59,
  number   =  7,
  pages    = "1492--1497",
  month    =  apr,
  year     =  1999,
  language = "en"
}

@ARTICLE{Jewell1982-ps,
  title     = "Mixtures of Exponential Distributions",
  author    = "Jewell, Nicholas P",
  abstract  = "[Arbitrary nonparametric mixtures of exponential and Weibull
               (fixed shape) distributions are considered as possible models
               for a lifetime distribution. A characterization of such
               distributions is given by the well-known characterization of
               Laplace transforms. The maximum likelihood estimate of the
               mixing distribution is investigated and found to be supported on
               a finite number of points. It is shown to be unique and weakly
               convergent to the true mixing measure with probability one. A
               practical algorithm for computing the maximum likelihood
               estimate is described. Its performance is briefly discussed and
               some illustrative examples given.]",
  journal   = "Ann. Stat.",
  publisher = "Institute of Mathematical Statistics",
  volume    =  10,
  number    =  2,
  pages     = "479--484",
  year      =  1982
}

% The entry below contains non-ASCII chars that could not be converted
% to a LaTeX equivalent.
@ARTICLE{Einstein_undated-vu,
  title  = "On the Motion of Small Particles Suspended in Liquids at Rest
            Required by the {Molecular-Kinetic} Theory of Heat",
  author = "Einstein, Albert"
}

% The entry below contains non-ASCII chars that could not be converted
% to a LaTeX equivalent.
@ARTICLE{Kirschner1998-mq,
  title     = "Modeling immunotherapy of the tumor--immune interaction",
  author    = "Kirschner, Denise and Panetta, John Carl",
  abstract  = "A number of lines of evidence suggest that immunotherapy with
               the cytokine interleukin-2 (IL- 2) may boost the immune system
               to fight tumors. CD4+ T cells, the cells that orchestrate the
               immune response, use these cytokines as signaling mechanisms for
               immune-response stimulation as well as lymphocyte stimulation,
               growth, and differentiation. Because tumor cells begin as
               'self', the immune system may not respond in an effective way to
               eradicate them. Adoptive cellular immunotherapy can potentially
               restore or enhance these effects. We ",
  journal   = "J. Math. Biol.",
  publisher = "Springer",
  volume    =  37,
  number    =  3,
  pages     = "235--252",
  year      =  1998
}

@ARTICLE{Selleck2003-tp,
  title    = "{IFN-gamma} sensitization of prostate cancer cells to
              Fas-mediated death: a gene therapy approach",
  author   = "Selleck, William A and Canfield, Steven E and Hassen, Waleed A
              and Meseck, Marcia and Kuzmin, Alexei I and Eisensmith, Randy C
              and Chen, Shu-Hsia and Hall, Simon J",
  abstract = "While human prostate cancers and cell lines express Fas, most of
              these cell lines are resistant to Fas-mediated death. In the
              present studies we addressed the ability of IFN-gamma to
              influence Fas-mediated cell death in prostate cancer cells. In
              vitro exposure of the human cell lines LNCaP and PC3 and the
              mouse cell line RM-1 to agonist anti-Fas antibody and/or soluble
              Fas ligand resulted in killing of only PC3 cells. However,
              preincubation with IFN-gamma resulted in synergistic killing in
              all three cell lines. In vitro treatment of RM-1 with a
              replication-incompetent adenovirus expressing mouse FasL
              (Ad.FasL) resulted in maximal cell kill near 40\%, which
              correlated with baseline Fas expression. The addition of
              IFN-gamma enhanced cell kill to a degree consistent with the
              resulting higher levels of Fas and maintained synergistic killing
              at very low doses of vector. Co-inoculation of orthotopic RM-1
              primary tumors with Ad.mFasL and an adenovirus expressing mouse
              IL-12 (Ad.mIL-12) to drive host production of IFN-gamma negated
              the survival advantage of Ad.mIL-12 alone. However, the staggered
              injection of Ad.mIL-12 and Ad.FasL achieved almost threefold
              higher levels of apoptosis in primary tumor tissue and doubled
              median survival. Therefore, IFN-gamma is capable of bestowing
              increased sensitivity to Fas-mediated cell death in prostate
              cancer cells and, in a gene therapy approach, may define a
              powerful tool to treat prostate cancers.",
  journal  = "Mol. Ther.",
  volume   =  7,
  number   =  2,
  pages    = "185--192",
  month    =  feb,
  year     =  2003,
  language = "en"
}

@ARTICLE{Zagury1979-tx,
  title    = "Studies on the mechanism of {T} cell-mediated lysis at the single
              effector cell level. I. Kinetic analysis of lethal hits and
              target cell lysis in multicellular conjugates",
  author   = "Zagury, D and Bernard, J and Jeannesson, P and Thiernesse, N and
              Cerottini, J C",
  journal  = "J. Immunol.",
  volume   =  123,
  number   =  4,
  pages    = "1604--1609",
  month    =  oct,
  year     =  1979,
  keywords = "Direct Killing (Perf/Gzym/FAS)",
  language = "en"
}

@ARTICLE{Hurtado1997-ob,
  title    = "Signals through {4-1BB} are costimulatory to previously activated
              splenic {T} cells and inhibit activation-induced cell death",
  author   = "Hurtado, J C and Kim, Y J and Kwon, B S",
  abstract = "Previously, we and others showed that signals relayed through the
              murine T cell Ag 4-1BB enhance primary T cell responses, and that
              blocking the interaction of 4-1BB with its ligand results in
              decreased responses to polyclonal activators and to alloantigens.
              Because 4-1BB expression is induced following primary
              stimulation, we investigated the role of signaling through this
              molecule in the reactivation of proliferating T cells. To this
              end, preactivated, 4-1BB-expressing T cells were restimulated in
              the presence of plate-immobilized mAbs directed against 4-1BB or
              the prototypic costimulatory molecule CD28. In this work, we show
              that in the presence of either signal, T cells respond to TCR
              cross-linking with strong proliferative responses and cytokine
              production; moreover, our findings indicate that T cell
              proliferation partially correlates with surface 4-1BB expression.
              In addition, our results suggest that Ab-mediated costimulatory
              signals can act independently of potential accessory
              B7-CD28/CTLA-4 (cytotoxic T lymphocyte Ag-4) interactions.
              Importantly, the characteristic DNA fragmentation and apoptotic
              cell death observed after TCR re-engagement are inhibited
              comparably in the presence of either 4-1BB or CD28 signaling.",
  journal  = "J. Immunol.",
  volume   =  158,
  number   =  6,
  pages    = "2600--2609",
  month    =  mar,
  year     =  1997,
  language = "en"
}

% The entry below contains non-ASCII chars that could not be converted
% to a LaTeX equivalent.
@ARTICLE{Zeijlemaker1977-nj,
  title     = "Cytotoxic Activity of Human Lymphocytes: Quantitative Analysis
               of {T} Cell and {K} Cell Cytotoxicity, Revealing {Enzyme-Like}
               Kinetics",
  author    = "Zeijlemaker, Wim P and van Oers, Rien H J and de Goede, Ruud E Y
               and Schellekens, Peter Th A",
  abstract  = "The mechanism of action of human cytotoxic lymphocytes was
               studied in two systems: T cell cytotoxicity in cell-mediated
               lympholysis (CML) and K cell cytotoxicity in antibody-dependent
               lymphocytotoxicity (ADL). The mechanisms resemble that of an
               enzyme, if the effector cells are regarded as enzyme and the
               target cells as substrate. On the basis of a kinetic analysis it
               was shown that the experimental data are compatible with a
               simple rate equation, which allows the definition of three
               constants: p, representing the maximal killing rate of the
               effector cell suspension (at target $\rightarrow$$\infty$); q,
               representing the maximal lysis of the target cells (at effector
               $\rightarrow$$\infty$); K which represents the Michaelis
               constant (i.e, the target cell number giving  Vmax), when
               extrapolated to effector = 0. The constant K may be taken to
               reflect the affinity between effector and target
               cells.Furthermore, for the ADL system the influence of the
               effector cell concentration on Km was due not to the addition of
               inert cells but rather to the presence of cells that can bind
               but not kill. Finally, it was shown that in the ADL a K cell can
               recycle, i.e., kill more than one target cell.On the basis of
               these results, experimental conditions are proposed for optimal
               measurement of cellular cytotoxicity.",
  journal   = "The Journal of Immunology",
  publisher = "American Association of Immunologists",
  volume    =  119,
  number    =  4,
  pages     = "1507--1514",
  month     =  oct,
  year      =  1977,
  language  = "en"
}

% The entry below contains non-ASCII chars that could not be converted
% to a LaTeX equivalent.
@MISC{Wikipedia_contributors2020-yw,
  title        = "Normal distribution",
  booktitle    = "Wikipedia, The Free Encyclopedia",
  author       = "{Wikipedia contributors}",
  abstract     = "Normal distribution Probability density functionThe red curve
                  is the standard normal distribution Cumulative distribution
                  functionNotation N ( $\mu$ , $\sigma$ 2 )
                  \{\textbackslashdisplaystyle \{\textbackslashmathcal
                  \{N\}\}(\textbackslashmu ,\textbackslashsigma ^\{2\})\}
                  Parameters $\mu$ $\in$ R \{\textbackslashdisplaystyle
                  \textbackslashmu \textbackslashin \textbackslashmathbb \{R\}
                  \} = mean (location) $\sigma$ 2 > 0
                  \{\textbackslashdisplaystyle \textbackslashsigma ^\{2\}>0\} =
                  variance (squared scale)Support x $\in$ R
                  \{\textbackslashdisplaystyle x\textbackslashin
                  \textbackslashmathbb \{R\} \} PDF 1 $\sigma$ 2 $\pi$ e  1 2
                  ( x  $\mu$ $\sigma$ ) 2 \{\textbackslashdisplaystyle
                  \{\textbackslashfrac \{1\}\{\textbackslashsigma
                  \{\textbackslashsqrt \{2\textbackslashpi
                  \}\}\}\}e^\{-\{\textbackslashfrac
                  \{1\}\{2\}\}\textbackslashleft(\{\textbackslashfrac
                  \{x-\textbackslashmu \}\{\textbackslashsigma
                  \}\}\textbackslashright)^\{2\}\}\} CDF 1 2 [ 1 + erf  ( x 
                  $\mu$ $\sigma$ 2 ) ] \{\textbackslashdisplaystyle
                  \{\textbackslashfrac
                  \{1\}\{2\}\}\textbackslashleft[1+\textbackslashoperatorname
                  \{erf\} \textbackslashleft(\{\textbackslashfrac
                  \{x-\textbackslashmu \}\{\textbackslashsigma
                  \{\textbackslashsqrt
                  \{2\}\}\}\}\textbackslashright)\textbackslashright]\}
                  Quantile $\mu$ + $\sigma$ 2 erf  1  ( 2 p  1 )
                  \{\textbackslashdisplaystyle \textbackslashmu
                  +\textbackslashsigma \{\textbackslashsqrt
                  \{2\}\}\textbackslashoperatorname \{erf\} ^\{-1\}(2p-1)\}
                  Mean $\mu$ \{\textbackslashdisplaystyle \textbackslashmu \}
                  Median $\mu$ \{\textbackslashdisplaystyle \textbackslashmu \}
                  Mode $\mu$ \{\textbackslashdisplaystyle \textbackslashmu \}
                  Variance $\sigma$ 2 \{\textbackslashdisplaystyle
                  \textbackslashsigma ^\{2\}\} MAD $\sigma$ 2 / $\pi$
                  \{\textbackslashdisplaystyle \textbackslashsigma
                  \{\textbackslashsqrt \{2/\textbackslashpi \}\}\} Skewness 0
                  \{\textbackslashdisplaystyle 0\} Ex. kurtosis 0
                  \{\textbackslashdisplaystyle 0\} Entropy 1 2 log  ( 2 $\pi$
                  e $\sigma$ 2 ) \{\textbackslashdisplaystyle
                  \{\textbackslashfrac
                  \{1\}\{2\}\}\textbackslashlog(2\textbackslashpi
                  e\textbackslashsigma ^\{2\})\} MGF exp  ( $\mu$ t + $\sigma$
                  2 t 2 / 2 ) \{\textbackslashdisplaystyle
                  \textbackslashexp(\textbackslashmu t+\textbackslashsigma
                  ^\{2\}t^\{2\}/2)\} CF exp  ( i $\mu$ t  $\sigma$ 2 t 2 / 2
                  ) \{\textbackslashdisplaystyle
                  \textbackslashexp(i\textbackslashmu t-\textbackslashsigma
                  ^\{2\}t^\{2\}/2)\} Fisher information I ( $\mu$ , $\sigma$ )
                  = ( 1 / $\sigma$ 2 0 0 2 / $\sigma$ 2 )
                  \{\textbackslashdisplaystyle \{\textbackslashmathcal
                  \{I\}\}(\textbackslashmu ,\textbackslashsigma
                  )=\{\textbackslashbegin\{pmatrix\}1/\textbackslashsigma
                  ^\{2\}\&0\textbackslash\textbackslash0\&2/\textbackslashsigma
                  ^\{2\}\textbackslashend\{pmatrix\}\}\} I ( $\mu$ , $\sigma$ 2
                  ) = ( 1 / $\sigma$ 2 0 0 1 / ( 2 $\sigma$ 4 ) )
                  \{\textbackslashdisplaystyle \{\textbackslashmathcal
                  \{I\}\}(\textbackslashmu ,\textbackslashsigma
                  ^\{2\})=\{\textbackslashbegin\{pmatrix\}1/\textbackslashsigma
                  ^\{2\}\&0\textbackslash\textbackslash0\&1/(2\textbackslashsigma
                  ^\{4\})\textbackslashend\{pmatrix\}\}\} Kullback-Leibler
                  divergence D KL ( N 0  N 1 ) = 1 2 \{ ( $\sigma$ 0 $\sigma$
                  1 ) 2 + ( $\mu$ 1  $\mu$ 0 ) 2 $\sigma$ 1 2  1 + 2 ln 
                  $\sigma$ 1 $\sigma$ 0 \} \{\textbackslashdisplaystyle
                  D\_\{\textbackslashtext\{KL\}\}(\{\textbackslashmathcal
                  \{N\}\}\_\{0\}\textbackslashparallel \{\textbackslashmathcal
                  \{N\}\}\_\{1\})=\{1 \textbackslashover
                  2\}\textbackslashleft\{\textbackslashleft(\{\textbackslashfrac
                  \{\textbackslashsigma \_\{0\}\}\{\textbackslashsigma
                  \_\{1\}\}\}\textbackslashright)^\{2\}+\{\textbackslashfrac
                  \{(\textbackslashmu \_\{1\}-\textbackslashmu
                  \_\{0\})^\{2\}\}\{\textbackslashsigma
                  \_\{1\}^\{2\}\}\}-1+2\textbackslashln \{\textbackslashsigma
                  \_\{1\} \textbackslashover \textbackslashsigma
                  \_\{0\}\}\textbackslashright\}\}",
  month        =  may,
  year         =  2020,
  howpublished = "\url{https://en.wikipedia.org/w/index.php?title=Normal_distribution&oldid=956322105}",
  note         = "Accessed: 2020-5-13"
}

@ARTICLE{Stokes1991-kq,
  title    = "Migration of individual microvessel endothelial cells: stochastic
              model and parameter measurement",
  author   = "Stokes, C L and Lauffenburger, D A and Williams, S K",
  abstract = "Analysis of cell motility effects in physiological processes can
              be facilitated by a mathematical model capable of simulating
              individual cell movement paths. A quantitative description of
              motility of individual cells would be useful, for example, in the
              study of the formation of new blood vessel networks in
              angiogenesis by microvessel endothelial cell (MEC) migration. In
              this paper we propose a stochastic mathematical model for the
              random motility and chemotaxis of single cells, and evaluate
              migration paths of MEC in terms of this model. In our model, cell
              velocity under random motility conditions is described as a
              persistent random walk using the Ornstein-Uhlenbeck (O-U)
              process. Two parameters quantify this process: the magnitude of
              random movement accelerations, alpha, and a decay rate constant
              for movement velocity, beta. Two other quantities often used in
              measurements of individual cell random motility properties--cell
              speed, S, and persistence time in velocity, Pv--can be defined in
              terms of the fundamental stochastic parameters alpha and beta by:
              S =square root (alpha/beta) and Pv = 1/beta. We account for
              chemotactic cell movement in chemoattractant gradients by adding
              a directional bias term to the O-U process. The magnitude of the
              directional bias is characterized by the chemotactic
              responsiveness, kappa. A critical advantage of the proposed model
              is that it can generate, using experimentally measured values of
              alpha, beta and kappa, computer simulations of theoretical
              individual cell paths for use in evaluating the role of cell
              migration in specific physiological processes. We have used the
              model to assess MEC migration in the presence of absence of the
              angiogenic stimulus acidic fibroblast growth factor (aFGF).
              Time-lapse video was used to observe and track the paths of cells
              moving in various media, and the mean square displacement was
              measured from these paths. To test the validity of the model, we
              compared the mean square displacement measurements of each cell
              with model predictions of that displacement. The comparison
              indicates that the O-U process provides a satisfactory
              description of the random migration at this level of comparison.
              Using nonlinear regression in these comparisons, we measured the
              magnitude of random accelerations, alpha, and the velocity decay
              rate constant, beta, for each cell path. We consequently obtained
              values for the derived quantities, speed and persistence time. In
              control medium, we find that alpha = 250 +/- 100 microns 2h-3 and
              beta = 0.22 +/- 0.03h-1, while in stimulus medium (control plus
              unpurified aFGF) alpha = 1900 +/- 720 microns 2h-3 and beta =
              0.99 +/- 0.37h-1.(ABSTRACT TRUNCATED AT 400 WORDS)",
  journal  = "J. Cell Sci.",
  volume   = "99 ( Pt 2)",
  pages    = "419--430",
  month    =  jun,
  year     =  1991,
  language = "en"
}

@ARTICLE{Geyer_undated-bw,
  title    = "Monte Carlo Maximum Likelihood (One Long Run)",
  author   = "{Geyer}",
  keywords = "Stochasticity"
}

@ARTICLE{Thomas1959-fx,
  title   = "Cellular and humoral aspects of the hypersensitive states",
  author  = "Thomas, Lewis and Lawrence, H S",
  journal = "New York: Hoeber-Harper",
  pages   = "529--532",
  year    =  1959
}

@ARTICLE{Kapnick2017-tg,
  title     = "Dynamic modulation of cortical actin at the immunological
               synapse controls lytic granule secretion in cytotoxic {T}
               lymphocytes",
  author    = "Kapnick, Senta and Ritter, Alex and Griffiths, Gillian and
               Lippincott-Schwartz, Jennifer and Schwartzberg, Pamela",
  abstract  = "CD8+ cytotoxic T lymphocytes (CTLs) are critical for eliminating
               virally infected cells. Upon target recognition, CTLs reorganize
               their actin cytoskeleton to facilitate the polarized secretion
               of specialized granules containing lytic proteins that kill
               cells. Because a single CTL can kill multiple targets, granule
               secretion must be tightly regulated, ensuring only appropriate
               cells are killed, and preserving granules for serial killing.
               However, how CTLs regulate secretion remains unclear. Here, we
               used live confocal and TIRF microscopy to evaluate how cortical
               actin affects granule secretion at the membrane. While previous
               work has shown that clearance of actin at the synapse precedes
               granule secretion, we find that after granule fusion, cortical
               actin recovers and no further secretion is observed.
               Depolymerization of recovered actin led to resumed granule
               fusion, suggesting that recovered actin acts as a barrier to
               prevent further lytic granule secretion. We further show that
               CTLs from mice unable to secrete granules due to a Rab27a
               mutation that prevents granule fusion, failed to recover
               cortical actin at the synapse. This suggests that granule fusion
               itself triggers actin recovery in CTLs. Thus, cortical actin
               both regulates, and is regulated by, secretion. Finally, using
               fluorescent reporters, we correlated the clearance and recovery
               of actin with PIP2. PIP2 binds numerous actin regulatory
               proteins, suggesting phosphatidylinositol distribution in the
               membrane as a potential mechanism through which CTLs regulate
               the density of cortical actin during killing. Our work provides
               insight into actin-related mechanisms regulating CTL secretion
               that may serial killing capacity during immune responses.",
  journal   = "The Journal of Immunology",
  publisher = "American Association of Immunologists",
  volume    =  198,
  number    = "1 Supplement",
  pages     = "151.4--151.4",
  month     =  may,
  year      =  2017,
  language  = "en"
}

@BOOK{National_Institute_of_Diabetes_and_Digestive_and_Kidney_Diseases_US2012-yf,
  title     = "{LiverTox}: Clinical and Research Information on Drug-induced
               Liver Injury",
  author    = "{National Institute of Diabetes and Digestive and Kidney
               Diseases (U.S.)}",
  publisher = "National Institute of Diabetes and Digestive and Kidney Diseases",
  year      =  2012,
  language  = "en"
}

@ARTICLE{Agresti2005-ow,
  title    = "Statistics: The Art and Science of Learning from Data",
  author   = "Agresti, Alan and Franklin, Christine Ladd",
  abstract = "Part 1: Gathering and Exploring Data 1. Statistics: The Art and
              Science of Learning from Data 1.1 Using Data to Answer
              Statistical Questions 1.2 Sample Versus Population 1.3 Using
              Calculators and Computers Chapter Summary Chapter Problems 2.
              Exploring Data with Graphs and Numerical Summaries 2.1 Different
              Types of Data 2.2 Graphical Summaries of Data 2.3 Measuring the
              Center of Quantitative Data 2.4 Measuring the Variability of
              Quantitative Data 2.5 Using Measures of Position to Describe
              Variability 2.6 Recognizing and Avoiding Misuses of Graphical
              Summaries Chapter Summary Chapter Problems 3. Association:
              Contingency, Correlation, and Regression 3.1 The Association
              Between Two Categorical Variables 3.2 The Association Between Two
              Quantitative Variables 3.3 Predicting the Outcome of a Variable
              3.4 Cautions in Analyzing Associations Chapter Summary Chapter
              Problems 4. Gathering Data 4.1 Experimental and Observational
              Studies 4.2 Good and Poor Ways to Sample 4.3 Good and Poor Ways
              to Experiment 4.4 Other Ways to Conduct Experimental and
              Nonexperimental Studies Chapter Summary Chapter Problems Part 1
              Review Part 1 Questions Part 1 Exercises Part 2: Probability,
              Probability Distributions, and Sampling Distributions 5.
              Probability in Our Daily Lives 5.1 How Probability Quantifies
              Randomness 5.2 Finding Probabilities 5.3 Conditional Probability:
              The Probability of A Given B 5.4 Applying the Probability Rules
              Chapter Summary Chapter Problems 6. Probability Distributions 6.1
              Summarizing Possible Outcomes and Their Probabilities 6.2
              Probabilities for Bell-Shaped Distributions 6.3 Probabilities
              When Each Observation Has Two Possible Outcomes Chapter Summary
              Chapter Problems 7. Sampling Distributions 7.1 How Sample
              Proportions Vary Around the Population Proportion 7.2 How Sample
              Means Vary Around the Population Mean 7.3 The Binomial
              Distribution Is a Sampling Distribution (Optional) Chapter
              Summary Chapter Problems Part 2 Review Part 2 Questions Part 2
              Exercises Part 3: Inferential Statistics 8. Statistical
              Inference: Confidence Intervals 8.1 Point and Interval Estimates
              of Population Parameters 8.2 Constructing a Confidence Interval
              to Estimate a Population Proportion 8.3 Constructing a Confidence
              Interval to Estimate a Population Mean 8.4 Choosing the Sample
              Size for a Study 8.5 Using Computers to Make New Estimation
              Methods Possible Chapter Summary Chapter Problems 9. Statistical
              Inference: Significance Tests about Hypotheses 9.1 Steps for
              Performing a Significance Test 9.2 Significance Tests about
              Proportions 9.3 Significance Tests about Means 9.4 Decisions and
              Types of Errors in Significance Tests 9.5 Limitations of
              Significance Tests 9.6 The Likelihood of a Type II Error (Not
              Rejecting H0, Even Though It's False) Chapter Summary Chapter
              Problems 10. Comparing Two Groups 10.1 Categorical Response:
              Comparing Two Proportions 10.2 Quantitative Response: Comparing
              Two Means 10.3 Other Ways of Comparing Means and Comparing
              Proportions 10.4 Analyzing Dependent Samples 10.5 Adjusting for
              the Effects of Other Variables Chapter Summary Chapter Problems
              Part 3 Review Part 3 Questions Part 3 Exercises Part 4: Analyzing
              Association and Extended Statistical Methods 11. Analyzing the
              Association Between Categorical Variables 11.1 Independence and
              Association 11.2 Testing Categorical Variables for Independence
              11.3 Determining the Strength of the Association 11.4 Using
              Residuals to Reveal the Pattern of Association 11.5 Small Sample
              Sizes: Fisher's Exact Test Chapter Summary Chapter Problems 12.
              Analyzing the Association Between Quantitative Variables:
              Regression Analysis 12.1 Model How Two Variables Are Related 12.2
              Describe Strength of Association 12.3 Make Inference About the
              Association 12.4How the Data Vary Around the Regression Line 12.5
              Exponential Regression: A Model for Nonlinearity Chapter Summary
              Chapter Problems 13. Multiple Regression 13.1 Using Several
              Variables to Predict a Response 13.2 Extending the Correlation
              and R-squared for Multiple Regression 13.3 Using Multiple
              Regression to Make Inferences 13.4 Checking a Regression Model
              Using Residual Plots 13.5 Regression and Categorical Predictors
              13.6 Modeling a Categorical Response Chapter Summary Chapter
              Problems 14. Comparing Groups: Analysis of Variance Methods 14.1
              One-Way ANOVA: Comparing Several Means 14.2 Estimating
              Differences in Groups for a Single Factor 14.3 Two-Way ANOVA
              Chapter Summary Chapter Problems 15. Nonparametric Statistics
              15.1 Compare Two Groups by Ranking 15.2 Nonparametric Methods For
              Several Groups and for Matched Pairs Chapter Summary Chapter
              Problems PART 4 Review Part 4 Questions Part 4 Exercises Tables
              Answers Index Index of Applications Photo Credits",
  journal  = "undefined",
  year     =  2005
}

@ARTICLE{Smyth1998-yh,
  title    = "Adoptive transfer: the role of perforin in mouse cytotoxic {T}
              lymphocyte rejection of human tumor xenografts in vivo",
  author   = "Smyth, M J and Kershaw, M H and Darcy, P K and Trapani, J A",
  abstract = "The popliteal lymph node cells of immunocompetent mice generated
              a strong in vitro cytotoxic response to footpad injection of
              several human tumor cell lines and the resulting mouse effector
              cells predominantly used a perforin-mediated cytotoxic mechanism.
              A relatively minor FasL-dependent cytotoxic response to CEM-CCRF
              and Jurkat leukemias, but not colon carcinoma COLO 205 cells, was
              also detected in immunized perforin-deficient mice. In vitro
              depletion of CD3+ CD8+ T cells, but not CD4+ T or NK1.1+ cells,
              completely inhibited lysis of human tumor cells, suggesting that
              CD3+ CD8+ T cells were effectors of perforin-mediated
              xenospecific cytotoxicity. Xenospecific cytotoxic T cells from
              wild-type mice were extremely efficient at rejecting tumor when
              adoptively transferred into scid mice bearing established COLO
              205, CEM-CCRF, or Jurkat tumor xenografts. By contrast, cytotoxic
              T lymphocytes of perforin-deficient mice had no effect on the
              growth of established tumor xenografts. These data indicate that
              perforin, and hence direct cytotoxicity, plays a key role in the
              ability of adoptively transferred CD8+ cytotoxic T lymphocytes to
              eradicate established xenografts.",
  journal  = "Xenotransplantation",
  volume   =  5,
  number   =  2,
  pages    = "146--153",
  month    =  may,
  year     =  1998,
  language = "en"
}

@ARTICLE{noauthor_undated-vi,

}

@ARTICLE{noauthor_undated-nx,
  title    = "Granzyme {B} ({GraB}) autonomously crosses the cell membrane and
              perforin initiates apoptosis and {GraB} nuclear localization",
  author   = "Shi, L and Mai, S and Israels, S and Browne, K and Trapani, J A
              and Greenberg, A H",
  abstract = "Granzyme B (GraB) induces apoptosis in the presence of perforin.
              Perforin polymerizes in the cell membrane to form a nonspecific
              ion pore, but it is not known where GraB acts to initiate the
              events that ultimately lead to apoptosis. It has been
              hypothesized that GraB enters the target cell through a perforin
              channel and then initiates apoptosis by cleaving and activating
              members of the ICE/Ced-3 family of cell death proteases. To
              determine if GraB can enter the cell, we treated YAC-1 or HeLa
              cells with FITC-labeled GraB and measured intracellular
              fluorescence with a high sensitivity CCD camera and image
              analyzer. GraB was internalized and found diffusely dispersed in
              the cell cytoplasm within 10 min. Uptake was inhibited at low
              temperature (4 degrees C) and by pretreatment with metabolic
              inhibitors, NaF and DNP, or cytochalasin B, a drug that both
              blocks microfilament formation, and FITC-GraB remained on the
              cell membrane localized in patches. With the simultaneous
              addition of perforin and FITC-GraB, no significant increase in
              cytoplasmic fluorescence was observed over that found in cells
              treated only with FITC-GraB. However, FITC-GraB was now detected
              in the nucleus of apoptotic cells labeling apoptotic bodies and
              localized areas within and along the nuclear membrane. The
              ability of GraB to enter cells in the absence of perforin was
              reexamined using anti-GraB antibody immunogold staining of
              ultrathin cryosections of cells incubated with GraB. Within 15
              min, gold particles were detected both on the plasma membrane and
              in the cytoplasm of cells with some gold staining adjacent to the
              nuclear envelope but not in the nucleus. Cells internalizing GraB
              in the absence of perforin appeared morphologically normal by
              Hoechst staining and electron microscopy. GraB directly
              microinjected into the cytoplasm of B16 melanoma cells induced
              transient plasma membrane blebbing and nuclear coarsening but the
              cells did not become frankly apoptotic unless perforin was added.
              We conclude that GraB can enter cells autonomously but that
              perforin initiates the apoptotic process and the entry of GraB
              into the nucleus.",
  journal  = "J. Exp. Med.",
  volume   =  185,
  number   =  5,
  pages    = "855--866",
  month    =  mar,
  year     =  1997,
  keywords = "Direct Killing (Perf/Gzym/FAS);B16F10\_specific",
  language = "en"
}

@ARTICLE{noauthor_undated-kk,
  title = "{KennedyJ1996a.pdf}"
}

@ARTICLE{noauthor_undated-rp,
  title = "{ANGELchpt05.pdf}"
}

@ARTICLE{noauthor_undated-xz,

}

@ARTICLE{noauthor_1976-yy,
  title   = "146.full.pdf",
  journal = "J. Immunol.",
  volume  =  116,
  pages   = "146--149",
  year    =  1976
}

@ARTICLE{noauthor_undated-yd,

}

@ARTICLE{noauthor_undated-uz,

}

@ARTICLE{noauthor_undated-al,

}

@ARTICLE{noauthor_undated-yt,

}

@ARTICLE{noauthor_undated-ad,

}

@ARTICLE{noauthor_undated-kl,
  title = "{PhysRevLett.69.2013}"
}

@ARTICLE{noauthor_undated-gq,
  title = "10.1007\%2F978-3-540-78725-9.pdf"
}

@ARTICLE{noauthor_undated-sk,
  title    = "{LNCS} 7953 - {Similarity-Based} Pattern Recognition",
  abstract = "Similarity-Based Pattern Recognition"
}

@ARTICLE{noauthor_undated-vx,

}

@ARTICLE{noauthor_undated-kl,

}

@ARTICLE{noauthor_undated-gq,
  title = "{MIT18\_05S14\_Reading15a.pdf}"
}

@ARTICLE{noauthor_undated-lt,

}

@ARTICLE{noauthor_undated-td,

}

@ARTICLE{noauthor_undated-mr,

}

@ARTICLE{noauthor_undated-gr,

}

@ARTICLE{noauthor_undated-xk,

}

@ARTICLE{noauthor_undated-ae,
  title    = "Reduction and Functional Exhaustion of {T} Cells in Patients With
              Coronavirus Disease 2019 ({COVID-19})",
  author   = "Diao, Bo and Wang, Chenhui and Tan, Yingjun and Chen, Xiewan and
              Liu, Ying and Ning, Lifen and Chen, Li and Li, Min and Liu,
              Yueping and Wang, Gang and Yuan, Zilin and Feng, Zeqing and
              Zhang, Yi and Wu, Yuzhang and Chen, Yongwen",
  abstract = "Background: The outbreak of coronavirus disease 2019 (COVID-19)
              caused by severe acute respiratory syndrome coronavirus 2
              (SARS-CoV-2) has posed great threat to human health. T cells play
              a critical role in antiviral immunity but their numbers and
              functional state in COVID-19 patients remain largely unclear.
              Methods: We retrospectively reviewed the counts of T cells and
              serum cytokine concentration from data of 522 patients with
              laboratory-confirmed COVID-19 and 40 healthy controls. In
              addition, the expression of T cell exhaustion markers were
              measured in 14 COVID-19 cases. Results: The number of total T
              cells, CD4+ and CD8+ T cells were dramatically reduced in
              COVID-19 patients, especially in patients requiring Intensive
              Care Unit (ICU) care. Counts of total T cells, CD8+ T cells or
              CD4+ T cells lower than 800, 300, or 400/$\mu$L, respectively,
              were negatively correlated with patient survival. T cell numbers
              were negatively correlated to serum IL-6, IL-10, and TNF-$\alpha$
              concentration, with patients in the disease resolution period
              showing reduced IL-6, IL-10, and TNF-$\alpha$ concentrations and
              restored T cell counts. T cells from COVID-19 patients had
              significantly higher levels of the exhausted marker PD-1.
              Increasing PD-1 and Tim-3 expression on T cells was seen as
              patients progressed from prodromal to overtly symptomatic stages.
              Conclusions: T cell counts are reduced significantly in COVID-19
              patients, and the surviving T cells appear functionally
              exhausted. Non-ICU patients with total T cells counts lower than
              800/$\mu$L may still require urgent intervention, even in the
              immediate absence of more severe symptoms due to a high risk for
              further deterioration in condition.",
  journal  = "Front. Immunol.",
  volume   =  11,
  pages    = "827",
  month    =  may,
  year     =  2020,
  keywords = "COVID-19; SARS- CoV-2; T cell exhaustion; T cell reduction;
              cytokine strom",
  language = "en"
}

@ARTICLE{noauthor_undated-qr,

}

@ARTICLE{noauthor_undated-oh,

}

@ARTICLE{noauthor_undated-il,

}

@ARTICLE{noauthor_undated-ns,

}
